<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>267754</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/content/vol112/24_suppl/#_____AMERICAN_HEART_ASSOCIATION_GUIDELINES_FOR_CARDIOPULMONARY_RESUSCITATION_AND_EMERGENCY_CARDIOVASCULAR_CARE]]&gt;</url>
    <title>2005 AHA guidelines for cardiopulmonary resuscitation and emergency cardiovascular care</title>
    <publicationDate>2005-12-13T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,UNSTABLE ANGINA,ACUTE CORONARY SYNDROMES,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,DIAGNOSIS,CARDIOVASCULAR DISEASES,CONDITIONS,CARDIOPULMONARY ARREST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;Updates the 2000 guidelines&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;How to improve survival from sudden cardiac arrest and acute life-threatening cardiopulmonary problems&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Based on the most extensive review of cardiopulmonary resuscitation (CPR) published&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Streamlined to reduce the amount of information rescuers need to learn and to clarify the most important skills needed&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Main recommendations:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Increased number of chest compressions a minute&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Reduced interruptions in chest compressions during CPR&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;The "recommendations do not imply that care involving the use of earlier guidelines is unsafe". They confirm the safety and effectiveness of many approaches, acknowledge that other approaches may not be optimal and recommend new treatments that have undergone evidence evaluation.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282085</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/116/23/2762#FIG1187930]]&gt;</url>
    <title>2007 Chronic angina focused update of the ACC / AHA 2002 guidelines for the management of patients with chronic stable angina : a report of the American College of Cardiology / American Heart  Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina</title>
    <publicationDate>2007-11-12T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,PREVENTION,GENERAL/OTHER,STABLE ANGINA,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,CONDITIONS,CHEST PAIN,PREVENTION,GENERAL,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To update the 2002 ACC/AHA guidelines for the management of patients with chronic stable angina.&amp;nbsp; Clinical trials presented at the 2005 and 2006 annual scientific meetings of the American College of Cardiology, American Heart Association and the European Society of Cardiology and other data, were reviewed to identify trials and key data that might impact on exisiting guideline recommendations. New or modified recommendations relating to cardiovascular risk reductions for patients with chronic angina are presented in this update. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281794</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188208]]&gt;</url>
    <title>2007 Focused update of the ACC / AHA / SCAI 2005 guideline update for percutaneous coronary intervention : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines : 2007 Writing Group to review new evidence and update the ACC / AHA / SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,SURGICAL PROCEDURES,INTERVENTIONS / PROCEDURES,REVASCULARISATION,GENERAL/OTHER,SECONDARY PREVENTION,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,RESCUE PCI,REPERFUSION,CARDIOVASCULAR DISEASES,ANTI-PLATELET DRUGS,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;To update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Clinical trials presented at the 2005 and 2006 annual scientific meetings of the American College of Cardiology, American Heart Association and the European Society of Cardiology and other data, were reviewed to identify trials and key data that might impact on exisiting guideline recommendations. Relevant information and the impact on exisiting guidance is presented here. &lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;The document is divided into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Introduction including 'evidence review'&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Patients with unstable angina/non-ST elevation myocardial infarction&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Facilitated percutaneous coronary intervention (PCI)&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Rescue PCI&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;PCI after fibrinolysis or for patients not undergoing primary reperfusion&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Ancillary therapy for patients undergoing PCI for segment elevation myocardial infarction (STEMI)&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Antiplatelet therapy&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Bare-metal and drug-eluting stents&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Secondary prevention&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281986</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/117/2/296]]&gt;</url>
    <title>2007 Focused update of the ACC / AHA 2004 guidelines for the management of patients with ST- elevation myocardial infarction : a report of the American College of Cardiology / American Heart Association Task Force on practice guidelines : developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians : 2007 Writing Group to review new evidence and update the ACC / AHA 2004 guidelines for the management of patients with ST- elevation myocardial infarction, writing on behalf of the 2004 Writing Committee</title>
    <publicationDate>2007-12-10T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ THROMBOLYTICS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY ARTERY BYPASS GRAFTS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,ACUTE CORONARY SYNDROMES,SECONDARY PREVENTION,OTHER,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,RESCUE PCI,REPERFUSION,CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,ANTI-PLATELET DRUGS,ANTI-COAGULANTS,BETA BLOCKERS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;To update the 2004 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Clinical trials presented at the 2005 and 2006 annual scientific meetings of the American College of Cardiology, American Heart Association and the European Society of Cardiology and other data, were reviewed to identify trials and key data that might impact on exisiting guideline recommendations. Relevant information and the impact on exisiting guidance is presented here. &lt;/P&gt;
&lt;P&gt;The document is divided into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction including 'evidence review'&lt;BR&gt;
&lt;LI&gt;Analgesia &lt;BR&gt;
&lt;LI&gt;Beta Blockers &lt;BR&gt;
&lt;LI&gt;Reperfusion&lt;BR&gt;
&lt;LI&gt;Facilitated percutaneous coronary intervention (PCI) &lt;BR&gt;
&lt;LI&gt;Immediate or emergency invasive strategy and rescue PCI &lt;BR&gt;
&lt;LI&gt;PCI after fibrinolysis or for patients not undergoing primary reperfusion &lt;BR&gt;
&lt;LI&gt;Ancillary therapy &lt;BR&gt;
&lt;LI&gt;Thienopyridines &lt;BR&gt;
&lt;LI&gt;Anticoagulants &lt;BR&gt;
&lt;LI&gt;Invasive evaluation&lt;BR&gt;
&lt;LI&gt;Secondary prevention &lt;BR&gt;
&lt;LI&gt;Antiplatelet therapy &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298956</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/118/15/e523]]&gt;</url>
    <title>2008 Focused update incorporated into the ACC / AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the management of patients with valvular heart disease) : endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</title>
    <publicationDate>2008-09-26T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ VALVE DISORDERS,GENERAL  / OVERVIEWS,GENERAL/OTHER,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This document is a revision of the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. These guidelines cover general issues of treatment of patients with heart valve disorders as well as dealing with more specialised issues relating to valve lesions. They also incorporate a 2008 focused update which highlights the 2007 AHA guidelines for infective endocarditis prophylaxis. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315308</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315308]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Cardioversion</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,ARRHYTHMIA,GENERAL,DISEASE MANAGEMENT,PREVENTION,GENERAL/OTHER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Cardioversion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;C A R D I O V E R S I O N&lt;/STRONG&gt; 
&lt;P&gt;&lt;STRONG&gt;Jayne Mudd&lt;/STRONG&gt; 
&lt;P&gt;Specialist Arrythmia Nurse, James Cook University Hospital, Middlesbough&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Use&amp;nbsp;back arrow&amp;nbsp;on browser or return to the index or &lt;A href="nelh:314789:0" name=internalLink&gt;click here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 122px; HEIGHT: 82px" height=85 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315308/nelhImp_0004_paddles.jpg" width=120 border=1 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&amp;nbsp; 
&lt;H2&gt;Expert Reviews&lt;/H2&gt;
&lt;P&gt;Sixteen reviews were identified between 2005 and 2008.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002903/frame.html" target="_blank"&gt;Cordina et al&lt;/A&gt; (2005) assessed the effects of pharmacological cardioversion of atrial fibrillation (AF) in adults on the annual risk of stroke, peripheral embolism and mortality from two completed studies (AFFIRM and PIAF) . No mortality difference was found between rhythm control and rate control. Both studies showed significantly higher rates of hospitalisation and adverse events in the rhythm control group and no difference in quality of life between the two groups. In AFFIRM, incidence of ischaemic stroke, bleeding and systemic embolism was similar in the two groups, but certain malignant dysrhythmias were significantly more likely to occur in the rhythm control group. There were similar scores of cognitive assessment. In PIAF, cardioverted patients enjoyed an improved exercise tolerance but there was no overall benefit in terms of symptom control or quality of life. Cordina et al (2005) conclude that there was no evidence that pharmacological cardioversion of AF to sinus rhythm is superior to rate control, and it does not reduce the risk of stroke. However the findings cannot be generalised to all people with AF: most of the patients included in the studies were over 60 years of age with significant cardiovascular risk factors.&lt;/P&gt;
&lt;P&gt;A meta anlaysis by &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=243300&amp;amp;tabID=289" target="_blank"&gt;Sanoski et al&lt;/A&gt; (2005 ) reviewed five RCTs to compare the effect of strategies for the management of AF on mortality and stroke. Studies of pharmacologic rhythm and rate control as first line strategies were eligible for inclusion. No statistically significant difference in all cause mortality or stroke between the rate and rhythm control groups was found. Ventricular rate control in combination with anticoagulation in appropriate patients was found to be at least equivalent -possibly superior- for patients with persistent AF or at risk of AF recurrence. &lt;/P&gt;
&lt;P&gt;Meta analysis of five RCTs by &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=243850&amp;amp;tabID=289" target="_blank"&gt;Kumana et al&lt;/A&gt; (2005) compared the effects of rate control versus rhythm control in patients with persistent or recurrent AF. They concluded that the only significant reduction between the rate and rhythm groups related to hospitalisation which was lower in the rate control group. No significant differences were found regarding treatment strategies for death, non CNS bleeding or ischaemic stroke. Quality of life scores were similar in both groups. Therefore they recommended that rate control, as the less costly strategy, should be favoured. &lt;/P&gt;
&lt;P&gt;Meta anlaysis of five RCTs by &lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=12005001803" target="_blank"&gt;Testa et al&lt;/A&gt; (2005) assessed the effects of a rhythm control strategy versus a rate control strategy, reporting a significantly lower risk with the rate control strategy for combined outcome of death or thromboembolic stroke, and a non- significant reduction in death and thromboembolic stroke. Both strategies resulted in similar rates of major bleeds and systemic embolism. An initial rate control strategy was found to be associated with a better prognosis than a rhythm control strategy. &lt;/P&gt;
&lt;P&gt;A systematic review by &lt;A href="http://www.ccmjournal.com/pt/re/ccm/abstract.00003246-200805000-00035.htm;jsessionid=Kb2K8FHW5gtdLLzn4YxQkJ25GLLgrL4hKHFxGmhgLfgfZy8vSJKy!-701738752!181195629!8091!-1" target="_blank"&gt;Kanji et al&lt;/A&gt; (2008 ) evaluated the efficacy of pharmacologic rhythm control of new onset AF in in non cardiac, critically ill adults. Four trials were reviewed which showed that no standard treatment could be recommended for this group of patients and that further research was required.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A systematic review by &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=237914&amp;amp;tabID=289" target="_blank"&gt;Mead et al&lt;/A&gt; (2005) assessed the effects of electrical cardioversion of AF or flutter on the risk of thromboembolic events, strokes and mortality, rate of cognitive decline, quality of life, use of anticoagulants and risk of re- hospitalisation. Three trials were reviewed; they concluded that electrical cardioversion (EC, rhythm control) led to a non-significant increase in stroke risk but improved three domains of quality of life.&lt;/P&gt;
&lt;P&gt;Medication use for maintenance of sinus rhythm following successful EC , and for increasing the chances of success at restoring sinus rhythm at initial EC has also been widely investigated. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://journals.indexcopernicus.com/abstracted.php?icid=875780" target="_blank"&gt;Tang et al&lt;/A&gt;(2008) meta analysis of seven studies examined the relationship between brain natriuretic peptide (BNP) and AF recurrence after successful EC. A higher BNP level after successful EC was associated with greater risk of AF recurrence. BNP may thus serve as an indicator for AF recurrence after successful EC.&lt;/P&gt;
&lt;P&gt;With respect to maintaining sinus rhythm with the use of anti arrhythmic (AA) drugs following cardioversion of AF a systematic review by &lt;A href="http://archinte.ama-assn.org/cgi/reprint/166/7/719" target="_blank"&gt;Lafuente et al&lt;/A&gt; (2006) examined the effect of long term treatment with AAs on death, embolisms, adverse effects and AF recurrence. Forty four trials were reviewed which revealed that class IA, IC and III drugs are effective in maintaining sinus rhythm but increased adverse effects, and class IA drugs may increase mortality. This was reinforced by &lt;A href="http://www.cochrane.org/reviews/en/ab005049.html" target="_blank"&gt;Lafuente et al&lt;/A&gt; (2007) in a meta analysis which focused on the effect of long term treatment with AA drugs after conversion to sinus rhythm ,suggesting that final risk- benefit ratio of AA drugs on clinically relevant outcomes is still unclear. Further systematic review by Lafuent et al (2007) revealed similar outcomes and identified that quinidine and disopyramide are associated with increased mortality. Benefit on clinically relevant outcomes (embolisms, heart failure, and mortality) remains to be established.&lt;/P&gt;
&lt;P&gt;There is evidence that links AF to the inflammatory state and that increased C-reactive protein (CRP) levels have been associated with greater risk of recurrence of AF following successful cardioversion. Meta analysis by &lt;A href="http://www.journals.elsevierhealth.com/periodicals/jac/article/PIIS0735109707004299/abstract" target="_blank"&gt;Liu et al&lt;/A&gt; (2007) examined the association of CRP and immediate success of EC in persistent AF. In a second meta analysis in 2008 they examined the association between CRP and recurrence of AF following successful EC.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;The thirteen studies that were examined during both reviews revealed that CRP levels increase the risk of EC failure and are associated with a greater risk of AF recurrence. Therefore CRP assessment before EC may provide prognostic information regarding the success of the procedure. The use of CRP levels in predicting sinus rhythm maintenance appears promising but requires further study.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=300256&amp;amp;tabID=289" target="_blank"&gt;Sheriden et al&lt;/A&gt; (2007) reviewed 10 RCTs to determine the effectiveness of IV magnesium in the conversion of acute onset AF to sinus rhythm and in reducing ventricular response and risk of bradycardia. They concluded that IV magnesium is not effective in converting acute onset AF to sinus rhythm in patients with a normal serum magnesium concentration but is a safe adjunct to digoxin for controlling the ventricular response in AF. In comparison another meta analysis by &lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T10-4NKB0FM-3&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=72fe6220c91e3c816ef29c9b55d191e2" target="_blank"&gt;Onalan et al&lt;/A&gt; (2007) examined the efficacy of magnesium administration in the acute treatment of rapid AF. Twelve trials were reviewed and they concluded that IV magnesium is an effective and safe strategy for the acute management of rapid AF. Thus there is ongoing uncertainty about the role of magnesium.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;References&lt;/STRONG&gt; 
&lt;P&gt;
&lt;P&gt;Cordina et al. &lt;A href="http://www.cochrane.org/reviews/en/ab003713.html" target="_blank"&gt;Pharmacological cardioversion for atrial fibrillation and flutter. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;de Denus&amp;nbsp;S,&amp;nbsp;et al. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;amp;ID=12005008116" target="_blank"&gt;Rate vs. rhythm control in patients with atrial fibrillation: a meta-analysis. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Sheridan DJ, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17449500" target="_blank"&gt;Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Kanji S, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18434899" target="_blank"&gt;Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Kumana C.R, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16187966" target="_blank"&gt;Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Testa L, et al. &lt;A href="http://eurheartj.oxfordjournals.org/cgi/content/abstract/26/19/2000" target="_blank"&gt;Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Lafuente-Lafuente C, et al. &lt;A href="http://archinte.ama-assn.org/cgi/reprint/166/7/719" target="_blank"&gt;Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trial. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Lafuente-Lafuente C, et al. &lt;A href="http://www.cochrane.org/reviews/en/ab005049.html" target="_blank"&gt;Maintaining sinus rhythm after cardioversion of atrial fibrillation.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mead GE, et al. &lt;A href="http://www.cochrane.org/reviews/en/ab002903.html" target="_blank"&gt;Electrical cardioversion for atrial fibrillation and flutter. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Onalan O, et al. &lt;A href="http://www.cochrane.org/reviews/en/ab002903.html" target="_blank"&gt;Meta-anAnalysis of magnesium therapy for the acute management of rapid atrial fibrillation. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Tang Y-Q, et al. &lt;A href="http://journals.indexcopernicus.com/abstracted.php?icid=875780" target="_blank"&gt;Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: A meta analysis.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Liu T,&lt;/SPAN&gt; et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18549852" target="_blank"&gt;Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Carmelo Lafuente-Lafuente, Stephane Mouly, Miguel Angel Longas-Tejero, Jean-François Bergmann (2007). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005049/frame.html" target="_blank"&gt;Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Khalid A Khalaiwi, Faiz Al-Harbi, Saleh Altamimi, Sami Qashqari, Christian Vaillancourt (2007). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006326/pdf_fs.html" target="_blank"&gt;Anaesthesia for cardioversion.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NHS Economic Evaluations&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Schadlich P K, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht J G (2008). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007001655" target="_blank"&gt;Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Thomas L, Veltman M, Levett K, Hoy M, Ross D L (2008). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008100688" target="_blank"&gt;Transoesophageal echocardiography and cardioversion: feasibility of a combined approach in clinical practice&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Zhao L, Zhang Z, Kolm P, Jasper S, Lewis C, Klein A, Weintraub W (2008). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008000445" target="_blank"&gt;Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II randomized multicenter study)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other relevant information&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;British Heart Foundation (2008). &lt;A href="http://www.bhf.org.uk/living_with_a_heart_condition/treatment/cardioversion.aspx" target="_blank"&gt;Cardioversion&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NHS Institute for Innovation and Improvement (2009). &lt;A href="http://www.institute.nhs.uk/nhs_live/case_studies/redesigning_cardioversion_services.html" target="_blank"&gt;Redesigning Cardioversion Services&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NHS Heart Improvement (2008). &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/definitive_treatment/cardioversion.html" target="_blank"&gt;Definitive Treatment: Cardioversion&amp;nbsp;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315027</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315027]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Catheter Ablation</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Catheter Ablation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;H3&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;C A T H E T E R&amp;nbsp;&amp;nbsp; &amp;nbsp;A B L A T I O N&lt;/SPAN&gt;&lt;/H3&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;STRONG&gt;Dr Richard Schilling&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;BR&gt;Consultant Cardiologist and reader, Queen Mary University of London&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here. &lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=100 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315027/nelhImp_0000_ablation1.jpg" width=120 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Four reviews were identified. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Palliative ablation&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Shen&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;et al (2007) reviewed the question as to whether biventricular pacing after AV node ablation is preferable to RV pacing alone. The studies examined did not show significant differences in outcome between the two pacing modes but on meta-analysis there was an insignificant trend towards reduced all-cause mortality in the biventricular pacing group. At the present time there is insufficient evidence to recommend biventricular pacing for all patients undergoing AV node ablation but it is probably reasonable to recommend biventricular pacing for patients who have pre-existing impairment of LV function and heart failure symptoms. &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Rhythm control&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;McKenna et al (2008) examined the cost efficacy of catheter ablation of AF. They conclude that ablation is cost effective if the benefits are maintained for &amp;gt;5 years. One of the limitations of the study is that there have never been large randomised trials examining the efficacy of antiarrhythmic drug use in paroxysmal AF and there are no long term outcome data for catheter ablation of AF. &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Ablation vs drug treatment&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Two reviews have looked at the results of catheter ablation compared to antiarrhythmic drugs. &lt;/P&gt;
&lt;P class=MsoNormal&gt;Nair et al (2008)&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;performed a meta-analysis of six randomised trials and concluded that catheter ablation reduces AF recurrence by 65% at 1 year compared to antiarrhythmic drugs. &lt;/P&gt;
&lt;P class=MsoNormal&gt;Noheria et&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;al (2008) analysed four trials and demonstrated that catheter ablation has a 75% arrhythmia survival at 1 year compared to 18.8% in antiarrhythmic drugs. &lt;/P&gt;
&lt;P class=MsoNormal&gt;One of the problems with these studies is that patients are only recruited after having failed antiarrhythmic drug therapy and this is therefore not a demonstration that catheter ablation is a superior first line therapy. It is reasonable to conclude that catheter ablation is a highly effective therapy and should be considered for patients who remain symptomatic despite antiarrhythmic drug therapy.&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Bradley DJ, Shen WK. Heart Rhythm.&lt;/SPAN&gt;&lt;/SPAN&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials.&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17275763?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Arial"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;McKenna C, Palmer S, Rodgers M et al &lt;I&gt;Heart.&lt;/I&gt; 2008.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the UK.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19095714?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A &lt;I&gt;J Cardiovasc Electrophysiol.&lt;/I&gt; 2008.&lt;/SPAN&gt;Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18775040" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Noheria A, Kumar A, Wylie J, V, Josephson ME.&lt;/SPAN&gt; Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18362249?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Gjesdal K, Vist GE, Bugge E et al.&lt;/SPAN&gt; Curative ablation for atrial fibrillation: a systematic review.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18362249?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place w:st="on"&gt;&lt;st1:City w:st="on"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Barnett&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt; &lt;st1:State w:st="on"&gt;SD&lt;/st1:State&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;, Ad N.&amp;nbsp;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16678586?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed Abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Gjesdal K, Vist GE, Bugge E et al.&amp;nbsp;&lt;/SPAN&gt;Curative ablation for atrial fibrillation: a systematic reviews. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18273730?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed&amp;nbsp;Abstract &lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrc.org/" target="_blank"&gt;UK&amp;nbsp;Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314695</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=314695]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Contributors</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,APR-JUN 09,CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C O N T R I B U T O R S&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308813/nelhImp_0000_contributors.gif" name=nelh_tempImage0&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN; mso-bidi-font-weight: bold"&gt;The following individuals participated in the 2009&amp;nbsp;Annual Evidence Update on Atrial Fibrillation:&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; LETTER-SPACING: 2pt; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; LETTER-SPACING: 2pt; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; LETTER-SPACING: 2pt; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;STRONG&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp; Jayne Mudd&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=Normal1&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Specialist&amp;nbsp;Arrhythmia&amp;nbsp;Nurse,James&amp;nbsp;&amp;nbsp;Cook&amp;nbsp;University&amp;nbsp;Hospital,&amp;nbsp;Middlesborough.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P class=Normal1&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;STRONG&gt;v&lt;/STRONG&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;Dr Richard Schilling &lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Consultant Cardiologist &amp;amp; Reader, Barts and the London NHS Trust&amp;nbsp;and&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&amp;nbsp;Queen Mary, University of London.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp; Dr Matthew Fay &lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Westfield Medical Practice, Shipley&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp; Mr Norman Briffa&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/H2&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Consultant in Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Trust; Honorary Clinical Senior Lecturer, University of Sheffield.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&amp;nbsp;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp; Mr Antonios Kourliouros&lt;/H2&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Specialist Registrar in Cardiothoracic Surgery St George's&amp;nbsp; Hospital, London.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&amp;nbsp;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; LETTER-SPACING: 2pt; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;NHS Evidence – cardiovascular team&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; LETTER-SPACING: 2pt; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;Professor Tom Quinn &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;Professor of Clinical Practice, University of Surrey&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;Rusell Dube&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial"&gt;Information Specialist&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;FONT color=#000066&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314789</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=314789]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Homepage</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PREVENTION,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,ARRYTHMIA,APR-JUN 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;Published on the&amp;nbsp;1st&amp;nbsp;of&amp;nbsp;June&amp;nbsp;2009: &lt;/STRONG&gt;An update for health professionals and patients on significant advances in knowledge about&amp;nbsp;Atrial Fibrillation&amp;nbsp;since NICE Published a &lt;A href="http://www.nice.org.uk/Guidance/CG36" target="_blank"&gt;guideline &lt;/A&gt;in 2006.&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;Please send us your feedback on this update.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;
&lt;TABLE border=1&gt;
&lt;TBODY&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;TABLE border=0 cellSpacing=5 cellPadding=5&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage7 name="nelh_tempImage7&lt;/TD" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0000_HFKNWwelcome.jpg"&gt; 
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0012_methodology.jpg" width=120 height=85&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0001_contributors.gif"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID314789/nelhImp_0004_Preventingstroke.gif"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315564&amp;amp;code=b3be86f5192cabe3efb037cd8ad90e10" target="_blank"&gt;Introduction&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314838&amp;amp;code=e991544caa942b9e0ed95f44783ac5e5" target="_blank"&gt;Methodology&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314695&amp;amp;code=2f13d7047f93035a5e6886ce64483af5" target="_blank"&gt;Contributors&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315601&amp;amp;code=42cb8bd75cd686a7020aea3908073d56" target="_blank"&gt;&lt;STRONG&gt;&lt;STRONG&gt;Preventing&lt;/STRONG&gt;&lt;/STRONG&gt; Stroke&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;TABLE cellSpacing=5 cellPadding=5&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 border=1 name=nelh_tempImage0 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID314789/nelhImp_0000_paddles.jpg" width=120 height=85&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 border=1 name=nelh_tempImage0 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID314789/nelhImp_0001_ablation1.jpg" width=120 height=85&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 border=1 name=nelh_tempImage0 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID314789/nelhImp_0005_surgery.jpg" width=120 height=85&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 border=1 name=nelh_tempImage0 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID314789/nelhImp_0006_KEYDOCUMENTS2.jpg" width=120 height=85&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315308&amp;amp;code=de0ebc78b8f22e0de97cb79aefbf82e8" target="_blank"&gt;Cardioversion&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315027&amp;amp;code=f0a7ce1804db157f8faace98b1d09f0b" target="_blank"&gt;&lt;STRONG&gt;&lt;STRONG&gt;Catheter&lt;/STRONG&gt;&lt;/STRONG&gt; Ablation&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315451&amp;amp;code=c99bef9c97b369af69190c1d0054168b" target="_blank"&gt;&lt;STRONG&gt;&lt;STRONG&gt;Surgi&lt;/STRONG&gt;&lt;/STRONG&gt;cal Treatment&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=315609&amp;amp;code=0198b751cbebfb8d0df3fd3e25393930" target="_blank"&gt;Key Documents&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TABLE&gt;
&lt;P&gt;A flyer is available &amp;nbsp;to promote the 2009 Annual Evidence Update on Atrial Fibrillation.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315564</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315564]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Introduction</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,APR-JUN 09,ARRHYTHMIA,CONDITIONS,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;I N T R O D U C T I O N&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;University of Surrey.&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315564/nelhImp_0002_AEUIntroduction.jpg" name=nelh_tempImage0&gt;&lt;A href="http://images.google.co.uk/imgres?imgurl=http://www.sscn.nhs.uk/Team/Images/DSC00805.JPG&amp;amp;imgrefurl=http://www.sscn.nhs.uk/Team/Board.htm&amp;amp;usg=__3awqcB8sg_VtAD0eYeo3s4-Xa5w=&amp;amp;h=1224&amp;amp;w=1632&amp;amp;sz=310&amp;amp;hl=en&amp;amp;start=1&amp;amp;tbnid=aT7GWqb115jfCM:&amp;amp;tbnh=113&amp;amp;tbnw=150&amp;amp;prev=/images%3Fq%3Dproffesor%2BTom%2Bquinn%26gbv%3D2%26hl%3Den%26rlz%3D1W1SNYW%26sa%3DG" target="_blank"&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice and accounts for up to a third of hospitalisations with rhythm disorders. According to the &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=270445&amp;amp;tabID=288" target="_blank"&gt;International guidelines &lt;/A&gt;published jointly by the American Heart Association and European Society of Cardiology,&amp;nbsp; AF affects more than 4 million people across the European Union and treatment of AF and its consequences costs over 13 billion Euros per annum. Admissions appear to be rising, perhaps explained by an ageing population and better detection. The longer term risk of stroke, heart failure and death is increased in people -especially women- in AF compared to those in normal sinus rhythm (NSR): the death rate is around double in people with AF compared to those in NSR. The importance of improving care of people with AF was recognised by the Department of Health, resulting in a new chapter for the &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=82452&amp;amp;tabID=288&amp;amp;catID=6863" target="_blank"&gt;coronary heart disease National Service Framework&lt;/A&gt;&amp;nbsp; and by NICE who have published a &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=144065&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLISHER" target="_blank"&gt;clinical guideline&lt;/A&gt; in 2006 &lt;BR&gt;AF is an extremely important subject and it is timely that we launch this first Annual Evidence Update on AF to coincide with the British Cardiovascular Society annual scientific conference.&lt;BR&gt;&lt;BR&gt;I am grateful to our panel of experts who have given of their free time to write short reviews summarising the latest evidence, and to Trudie Loban of the Arrhythmia Alliance and the new &lt;A href="http://www.atrialfibrillation.org.uk/" target="_blank"&gt;Atrial Fibrillation Association&lt;/A&gt;. Steve Sharp undertook with his usual expertise the initial, complex and robust search of the literature to inform those reviews.&amp;nbsp; Rusell Dube, who has shouldered much of the burden of bringing this Annual Evidence Update to fruition on deadline with considerable care, deserves particular thanks.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315609</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315609]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Key Documents</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Key Documents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE style="WIDTH: 486px; HEIGHT: 99px" width=486 border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;K E Y&amp;nbsp;&amp;nbsp; D O C U M E N T S&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click&amp;nbsp;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=85 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315609/nelhImp_0000_KEYDOCUMENTS2.jpg" width=120 border=1 name=nelh_tempImage0&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=5276" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;NICE commissioning guide – anticoagulant services&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/anticoagulationtherapyservice/anticoagulation_therapy_service.jsp" target="_blank"&gt;http://www.nice.org.uk/usingguidance/commissioningguides/anticoagulationtherapyservice/anticoagulation_therapy_service.jsp&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;
&lt;P&gt;Patient Alert Safety&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=5276" target="_blank"&gt;http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=5276&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;DH Chapter 8 of CHD NSF&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=82452&amp;amp;tabID=288&amp;amp;catID=6863" target="_blank"&gt;http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=82452&amp;amp;tabID=288&amp;amp;catID=6863&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;CKS resources on AF&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=272684&amp;amp;tabID=288" target="_blank"&gt;
&lt;TABLE style="WIDTH: 262pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width=349 border=0 x:str&gt;
&lt;COLGROUP&gt;
&lt;COL style="WIDTH: 262pt; mso-width-source: userset; mso-width-alt: 12763" width=349&gt;
&lt;TBODY&gt;
&lt;TR style="HEIGHT: 12.75pt" height=17&gt;
&lt;TD style="BORDER-RIGHT: #ece9d8; BORDER-TOP: #ece9d8; BORDER-LEFT: #ece9d8; WIDTH: 262pt; BORDER-BOTTOM: #ece9d8; HEIGHT: 12.75pt; BACKGROUND-COLOR: transparent" width=349 height=17&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=272684&amp;amp;tabID=288" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=272684&amp;amp;tabID=288&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;ACC/AHA/ESC guidelines on AF &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=270445&amp;amp;tabID=288" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=270445&amp;amp;tabID=288&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;ACC/AHA performance measures&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=281530&amp;amp;tabID=290" target="_blank"&gt;http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=281530&amp;amp;tabID=290&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;HRS/EHRA/ECAS Expert consensus statement&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=277982&amp;amp;tabID=288" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=277982&amp;amp;tabID=288&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;Cochrane protocols on AF topics&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_2A98EACA82E26AA2008978C766E71854" target="_blank"&gt;http://www.cochrane.org/reviews/en/protocol_2A98EACA82E26AA2008978C766E71854&lt;/A&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_2A98EACA82E26AA2008978C766E71854.html" target="_blank"&gt;.html&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_680902051013042636.html" target="_blank"&gt;http://www.cochrane.org/reviews/en/protocol_680902051013042636.html&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_2A98EACA82E26AA2008978C766E71854.html" target="_blank"&gt;http://www.cochrane.org/reviews/en/protocol_2A98EACA82E26AA2008978C766E71854.html&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_9C258AB282E26AA20133FE5DDB150C09.html" target="_blank"&gt;http://www.cochrane.org/reviews/en/protocol_9C258AB282E26AA20133FE5DDB150C09.html&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.cochrane.org/reviews/en/protocol_0509FA5382E26AA2017127F4F77BA25C.html" target="_blank"&gt;http://www.cochrane.org/reviews/en/protocol_0509FA5382E26AA2017127F4F77BA25C.html&lt;/A&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/H2&gt;
&lt;H2 class=MsoNormal&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 class=MsoNormal&gt;Heart Improvement Programme&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.heart.nhs.uk/priority_projects/atrial_fibrilation_in_primary_care/fibrillation.html" target="_blank"&gt;http://www.heart.nhs.uk/priority_projects/atrial_fibrilation_in_primary_care/fibrillation.html&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Stroke Association – AF and the risk of stroke&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=308541&amp;amp;tabID=290" target="_blank"&gt;http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=308541&amp;amp;tabID=290&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;NHS Choices&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=123253&amp;amp;tabID=292" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=123253&amp;amp;tabID=292&lt;/A&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;NPSA Safety alert on anticoagulation&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814" target="_blank"&gt;http://www.nrls.npsa.nhs.uk/resources/?entryid45=59814&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Links to key organisations:&lt;/H2&gt;
&lt;H2&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;Arrhythmia Alliance&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=56410&amp;amp;tabID=292&amp;amp;catID=679" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=56410&amp;amp;tabID=292&amp;amp;catID=679&lt;/A&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/H2&gt;
&lt;P class=MsoNormal&gt;Atrial Fibrillation Association&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=278780&amp;amp;tabID=292" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=278780&amp;amp;tabID=292&lt;/A&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/H2&gt;
&lt;P class=MsoNormal&gt;British Cardiovascular Society&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3557&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3557&amp;amp;tabID=290&amp;amp;catID=679&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;British Heart Foundation&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3560&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3560&amp;amp;tabID=290&amp;amp;catID=679&lt;/A&gt;&lt;/P&gt;
&lt;H2 class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/H2&gt;
&lt;P class=MsoNormal&gt;Stroke Association&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=269753&amp;amp;tabID=290&amp;amp;catID=13305" target="_blank"&gt;http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=269753&amp;amp;tabID=290&amp;amp;catID=13305&lt;/A&gt;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314838</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=314838]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Methodology</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;M E T H O D O L O G Y&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308812/nelhImp_0000_methodology.jpg" name=nelh_tempImage1&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;Introduction&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;This&amp;nbsp;page provides details of the literature search strategy for the 2009 Annual Evidence Update on Atrial Fibrillation. It also provides information on the number of references retrieved from individual databases, the sifting process, and into which category of&amp;nbsp;Atrial Fibrillation&amp;nbsp;each of the references ended. The period of the literature search is&amp;nbsp;&lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:date Year="2008" Day="2" Month="3"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;1 January 2005&lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;&amp;nbsp;to&amp;nbsp;18 February 2009&lt;/SPAN&gt;&lt;st1:date Year="2009" Day="20" Month="2"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;.&lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;The sources searched for systematic reviews and meta-analyses were:&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Cochrane&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;DARE&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Medline (via the NLH database)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Embase (via the NLH database)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Cinahl (via the NLH database)&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=314838" target="_blank"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;DARE, Pubmed, Medline, Embase, Cinahl search&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;Total references retrieved&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;/STRONG&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" align=left&gt;
&lt;TABLE class=MsoNormalTable style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none; BORDER-COLLAPSE: collapse; mso-border-alt: solid windowtext .5pt; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-border-insideh: .5pt solid windowtext; mso-border-insidev: .5pt solid windowtext" cellSpacing=0 cellPadding=0 border=1&gt;
&lt;TBODY&gt;
&lt;TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt" vAlign=top width=162&gt;
&lt;H3&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Database&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/H3&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;H2&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&amp;nbsp; &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;No. of references retrieved&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/H2&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;
&lt;TR style="mso-yfti-irow: 1"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Cochrane&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/STRONG&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;12&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;
&lt;TR style="mso-yfti-irow: 2"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;DARE&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;&lt;FONT face=Arial&gt;34&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 3"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Pubmed&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;188&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 4"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Medline&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;1468&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 5"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Embase&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;2355&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 6"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Cinahl &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;388&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 7; mso-yfti-lastrow: yes"&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt solid; WIDTH: 121.25pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=162&gt;
&lt;H1&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;Total&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/H1&gt;&lt;/TD&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/B&gt;&lt;/STRONG&gt;
&lt;TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: medium none; WIDTH: 122.55pt; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt solid; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=163&gt;
&lt;H3 class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;4445 ( -1148 duplicates = 3508&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/H3&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;DIV align=left&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV align=left&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;Sifting for relevance&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/DIV&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana"&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;/SPAN&gt;The Information Specialist sifted 457 references and categorised them as:&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Relevant&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;142&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; v&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Not relevant&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;3297&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN-RIGHT: 0px; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;v&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Unsure&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;69&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;The Clinical Lead conducted a further sift and categorised as:&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Relevant&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;42&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Not relevant&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;29&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;Classifying the references&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;The final&amp;nbsp;references were classified as: &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 7pt; COLOR: red; FONT-FAMILY: 'Times New Roman'; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Catheter Ablation&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Perioperative&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;AF&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Surgical&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;Preventing Stroke&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #99cc00; FONT-FAMILY: Wingdings; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp; Cardioversion&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" align=left&gt;&lt;SPAN style="FONT-SIZE: 8pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315601</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315601]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Preventing Stroke</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,APR-JUN 09,CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Preventing Stroke&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;PREVENTING STROKE &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Matthew Fay&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;STRONG&gt;Westcliffe Medical Practice, Shipley&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 height=100 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315601/nelhImp_0000_preventingstroke2.jpg" width=120 border=1 name=nelh_tempImage0&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN lang=EN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;14 reviews were identified.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;Atrial fibrillation&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;(AF) is an important risk factor in the aetiology of stroke. In patients over 65 who have AF without other cardiovascular problems have a five fold increase in prevalence of ischaemic stroke. The risk increasing with age and cardiovascular co-morbidities. The Stroke Prevention in Atrial Fibrillation (SPAF) study showed that the risks were the same in the Paroxysmal and Persistent AF groups.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;Aspirin, warfarin, or both?&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;A systematic review by Aguliar et al (2005) in patients with non-valvular AF (NVAF) demonstrated that aspirin reduced stroke rates in NVAF at a similar level to other high risk groups (about 25%).&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;A meta-analysis of warfarin in the prevention of systemic emboli in NVAF by Andersen et al demonstrated that formal anti-coagulation with monitored warfarin was superior to placebo and anti-platelet agents. This was associated with an increased risk of haemorrhage compared to placebo but not to the anti-platelet agents.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;The Atrial Fibrillation, Aspirin Anticoagulation Study (AFASAK) demonstrated a reduction of strokes by 64% per year with warfarin (INR 2.8-4.2), compared with placebo, a 3.5% per year reduction. A non-significant reduction in stroke was seen with aspirin 75mg.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;Combined therapy&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Dentali et al performed a meta-analysis of interventions combining oral anti-coagulants and aspirin in comparison to oral anticoagulants alone. No significant benefit was seen from combined therapy, with an increased risk of significant haemorrhage. In the ACTIVE A trial comparing aspirin alone with an aspirin/clopidogrel combination there was an 11% endpoint reduction of stroke, MI and systemic emboli compared with aspirin alone, at the expense of an increase in major haemorrhage from aspirin alone of 1.27% to 2% (an increase of 58%)&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;Balancing risk and benefit – elderly patients&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;With the evidence suggesting that formal anti-coagulation is more effective than anti-platelet agents, patient safety needs to be assured. A concern often given about a choice to formally anti-coagulate is that the population to be treated is elderly and at risk of falls. This was reviewed by Garwood et al, who concluded that the risk of falls should not automatically disqualify a person from being treated with warfarin. Man-Son-Hing et al calculated risk of intracranial bleeding from falls fin a meta-analysis of 5 randomised control studies. In a patient with a 5% annual stroke risk (CHADS&lt;SUB&gt;2 &lt;/SUB&gt;of 2-3, see below), the person would need to fall 295 times in a year for the risk from the falls to exceed the benefits from anticoagulation. &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Hughes, Lipp et al performed a systematic review of stroke risk factors, risk stratification and cost effectiveness data. They concluded that few models had addressed the cumulative nature of risk factors where a combination of risk factors would confer a greater risk than either factor alone. In patients at high risk of stroke, anticoagulation is most cost effective, but not for those at low risk of stroke. The Stroke Risk in Atrial fibrillation Working Group state that 4 features, (previous stroke event, advancing age, hypertension and diabetes) are consistent independent risk factors. Prior stroke/TIA are the most powerful . &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;The CHADS&lt;SUB&gt;2 &lt;/SUB&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;Schema is based on two previous schema, the Atrial Fibrillation Investigators and Stroke Prevention in Atrial Fibrillation. It was shown to be superior to these by Gage et al. Its simple structure - giving an individual point for Age over 75, hypertension, congestive heart failure and diabetes and 2 points for previous stroke or TIA - makes it an appealing tool in general practice. A score of 2 or greater would suggest benefit from formal anticoagulation. Using simple, generally coded, information in the clinical computer systems of primary care makes population data easily extractable to develop flags within the system or patient lists for consideration of formal anti-coagulation.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Through this the importance of establishing the nature of the patient's rhythm that presents with TIA or stroke is of paramount importance to inform future management of risk. 15% of all people presenting with stroke however its as yet unknown how many people may be suffering from atrial fibrillation of a paroxysmal nature.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;Emerging agents&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Ximelagatran, a direct thrombin inhibitor, has shown early promise in the prevention of venous thromboembolism in patients undergoing orthopaedic procedures. The METHRO and EXPRESS studies had shown non-inferiority to low molecular weight heparin. The SPORTIF III trial demonstrated an event end point of 2.3% per year for warfarin compared to a 1.6% per year for Ximelagatran. The rate of major and minor haemorrhages were also lower (relative risk reduction of 14%). However liver function disturbance was noted. Testa et al performed a meta-analysis of Ximelagatran compared with conventional oral anticoagulants. There were no differences between primary end points such as Stoke, systemic emboli and myocardial infarction, nor were there differences in major bleeds. However the hepatotoxicity precludes its use. &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;New anti-coagulants are now entering the market. Dabigatran etexilate is a pro-drug metabolised to dabigatran, which is a reversible direct thrombin inhibitor. This inhibits thrombin in its free and clot bound form. In a series of studies Dabigatran has been compared with low molecular weight heparin and has been shown to be non-inferior; it currently has a licence for primary prevention of venous thromboembolism in patients post-hip replacement. Evidence for its use in AF is yet to be established. Currently there is not a method for the rapid reversal of its anti-coagulant effects.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Rivaroxaban inhibits activated factor Xa. Eriksson et al in the RECORD studies have established its superior activity in reducing deep vein thrombosis, non fatal pulmonary embolism and all cause mortality following orthopaedic procedures compared with low molecular weight heparin. It is yet to gain FDA approval ,however a phase 3 trial is assessing its performance compared to warfarin in patients with paroxysmal or permanent AF.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Aguilar M, Hart R.&lt;/SPAN&gt; &lt;A href="http://www.cochrane.org/reviews/en/ab001925.html" target="_blank"&gt;Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Andersen LV, et al. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18208828" target="_blank"&gt;Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.&amp;nbsp;&lt;/A&gt;&lt;/SPAN&gt;&lt;o:p&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18208828" target="_blank"&gt;&amp;nbsp;&lt;/A&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Cooper NJ, &lt;/SPAN&gt;et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16801509" target="_blank"&gt;Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Dentali F,&lt;/SPAN&gt; et al. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17242311" target="_blank"&gt;Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;Dolan G, et al. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18402715" target="_blank"&gt;Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Garwood CL, et al.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18334606" target="_blank"&gt;Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Ghali WA, et al.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15694889" target="_blank"&gt;Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Hart RG, et al. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17577005" target="_blank"&gt;Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;A href="http://qjmed.oxfordjournals.org/cgi/content/abstract/100/10/599" target="_blank"&gt;Hughes M, Lip GY.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://qjmed.oxfordjournals.org/cgi/content/abstract/100/10/599" target="_blank"&gt;Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Hughes M, Lip GY.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18278178" target="_blank"&gt;Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Molckovsky D, Boucher M. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16614732" target="_blank"&gt;Ximelagatran: a new type of oral anticoagulant.&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-BOTTOM: 6pt; TEXT-AUTOSPACE: ideograph-numeric; mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Lip GYH, Edwards SJ. &lt;/SPAN&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T1C-4H6XKTD-1&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=45b4178cf692574795edfe588ae14083" target="_blank"&gt;Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-BOTTOM: 6pt; TEXT-AUTOSPACE: ideograph-numeric; mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Stroke Risk in Atrial Fibrillation Working Group.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17679673" target="_blank"&gt;Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN-BOTTOM: 6pt; TEXT-AUTOSPACE: ideograph-numeric; mso-list: l0 level1 lfo1; tab-stops: 36.0pt"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Testa L,&lt;/SPAN&gt; et al. &lt;A href="http://www.internationaljournalofcardiology.com/article/S0167-5273(06)01449-5/abstract" target="_blank"&gt;Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. &lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 6pt 36pt; TEXT-AUTOSPACE: ideograph-numeric; tab-stops: right 27.0pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Normal1&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315451</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315451]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Surgical Treatment</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,SURGERY,SURGERY,ISCHAEMIC HEART DISEASE,HEART,REVASCULARISATION,APR-JUN 09,CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,ARRHYTHMIA,GENERAL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Surgical Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;S u r g i c a l&amp;nbsp;&amp;nbsp; T r e a t m e n t &lt;/SPAN&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;STRONG&gt;Antonios Kourliouros&lt;/STRONG&gt;&lt;BR&gt;Specialist Registrar in Cardiothoracic Surgery St George's Hospital, London&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here.&lt;/A&gt;&amp;nbsp;&lt;/EM&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=85 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID315451/nelhImp_0000_surgery.jpg" width=120 border=1 name=nelh_tempImage1&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt; &lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Arial"&gt;&lt;SPAN style="mso-list: Ignore"&gt;1.&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Surgical treatment of atrial fibrillation: a systematic&amp;nbsp;&amp;nbsp; review.&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Khargi K, Keyhan-Falsafi A, Hutten BA, Ramanna H, Lemke B, Deneke T. &lt;I&gt;Herzschrittmacherther Elektrophysiol.&lt;/I&gt; 2007;18:68-76.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;OBJECTIVES:&lt;/B&gt; In this review the efficacy of the alternative sources of Energy (radiofrequency-microwave and cryoablation; (group I) and the classical "cut and sew" Cox-Maze III (group II), which claims a 97-99% sinus rhythm (SR) success rate, were evaluated in the surgical treatment of atrial fibrillation (AF). &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;BOTTOM LINE CONCLUSIONS&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;: The authors could not&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;identify any significant difference in the postoperative SR conversion rates between the classical 'cut and sew' and the alternative sources of energy, which were used to treat AF&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Arial"&gt;&lt;SPAN style="mso-list: Ignore"&gt;2.&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Meta-analysis of clinical outcomes of maze-related surgical procedures for medically refractory atrial fibrillation. &lt;/B&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Reston JT, Shuhaiber JH. Meta-analysis of clinical outcomes of maze-related surgical procedures for medically refractory atrial fibrillation. &lt;I&gt;European Journal of Cardio-Thoracic Surgery.&lt;/I&gt; 2005;28(5):724-730.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;To assess whether a simultaneous maze procedure reduces the risk of stroke, death, post-operative bleeding or need for pacemaker in patients with chronic or paroxysmal atrial fibrillation (AF) who receive mitral valve surgery. Studies that compared the maze procedure (including variants with different incision patterns and energy sources) combined with mitral valve surgery to mitral valve surgery alone were eligible for inclusion. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;BOTTOM LINE CONCLUSION:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt; There was weak evidence to support a reduction in stroke rates, but an increase in need for pacemakers, amongst patients receiving the maze procedure over mitral valve surgery alone. Radiofrequency maze may avoid an excess risk of post-operative bleeding associated with maze incisions. The authors stated that experienced heart surgeons should continue treating medically refractory AF when feasible simultaneously with mitral valve surgery. Research: The authors stated that larger, longer term RCTs are required to confirm their findings and to investigate survival and quality of life. They also stated that the results should be adjusted for patient risks and surgeon protocol for anticoagulation and anti-arrhythmic medication.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Arial"&gt;&lt;SPAN style="mso-list: Ignore"&gt;3.&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Impact of maze and concomitant mitral valve surgery on clinical outcomes.&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;Wong JW, Mak KH. &lt;I&gt;Annals of Thoracic Surgery.&lt;/I&gt; 2006; 82(5):1938-1947.&lt;BR style="mso-special-character: line-break"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;To evaluate the effects of treating atrial fibrillation (AF) by the surgical maze procedure in patients with AF; undergoing mitral valve surgery.&lt;BR&gt;The authors stated that larger RCTs or propensity-matched studies with adequate follow-up are needed to determine the effect of concomitant maze surgery on clinical outcomes in patients with AF undergoing mitral valve surgery.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;STRONG&gt;References&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;1. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. &lt;A href="http://www.hrsonline.org/News/Media/press-releases/upload/HR-and-Euro-Copy-for-Print.pdf" target="_blank"&gt;HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;2. &lt;/SPAN&gt;&lt;SPAN lang=EL style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'"&gt;Kourliouros A. &lt;A href="http://www.library.nhs.uk/theatres/ViewResource.aspx?resID=262329&amp;amp;tabID=290" target="_blank"&gt;Surgical management of atrial fibrillation - a mini topic review.&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN lang=EL style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN lang=EL style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;3. Khargi K, Keyhan-Falsafi A, Hutten BA, Ramanna H, Lemke B, Deneke T. &lt;A href="http://ejcts.ctsnetjournals.org/cgi/reprint/27/2/258" target="_blank"&gt;Surgical treatment of atrial fibrillation : a systematic review. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;4.&amp;nbsp;NICE. &lt;A href="http://www.nice.org.uk/nicemedia/pdf/IPG286Guidance.pdf" target="_blank"&gt;Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation.&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="LINE-HEIGHT: 150%; TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 12pt; LINE-HEIGHT: 150%; FONT-FAMILY: 'Times New Roman','serif'; mso-ansi-language: EN-GB"&gt;5. Henry L, Ad N. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18992626" target="_blank"&gt;The Maze procedure: a surgical intervention for ablation of atrial fibrillation. Heart Lung &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314832</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=314832]]&gt;</url>
    <title>2009 Annual Evidence Update on Atrial Fibrillation : Uncertainities</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PREVENTION,APR-JUN 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Atrial Fibrillation : Uncertainities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;U&amp;nbsp;N C E R T A I N T I E S&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Use backarrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;click here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305787/nelhImp_0000_DUETs.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;In completing this annual evidence update on&amp;nbsp;Atrial Fibrillation&amp;nbsp;we identified&amp;nbsp;the following&amp;nbsp;uncertainties of treatment:&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=308584&amp;amp;tabID=296" target="_blank"&gt;Is Disease Management more effective than good quality usual care for heart failure?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T10-4NKB0FM-3&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=72fe6220c91e3c816ef29c9b55d191e2" target="_blank"&gt;Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;A href="http://www.cardiologyreviewonline.com/issues/articles/2006-11_09.asp" target="_blank"&gt;Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;A href="http://www.cardiologyreviewonline.com/issues/articles/2006-11_09.asp" target="_blank"&gt;.&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=237914&amp;amp;tabID=289" target="_blank"&gt;Electrical cardioversion for atrial fibrillation and flutter. &lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN&gt;&lt;A href="http://www.ccmjournal.com/pt/re/ccm/abstract.00003246-200805000-00035.htm;jsessionid=Kb2K8FHW5gtdLLzn4YxQkJ25GLLgrL4hKHFxGmhgLfgfZy8vSJKy!-701738752!181195629!8091!-1" target="_blank"&gt;Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials.&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN&gt;&lt;SPAN&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;A href="http://www.journals.elsevierhealth.com/periodicals/jac/article/PIIS0735109707004299/abstract" target="_blank"&gt;Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation.&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308805</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308805]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Access</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Access&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;A C C E S S&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Professor of Cardiovascular Nursing, University of Leicester.&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/admin/images/scratch/50322943/nelhImp_0002_access.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P style="mso-layout-grid-align: none; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;We identified one meta-analysis relating to access published since the &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;2008 Annual Evidence Update on Cardiac Rehabilitation. &lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 8pt; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 8pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Expert summary&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P class=normal1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;It is apparent that many eligible patients are either not referred to, enrolled in or attend cardiac rehabilitation programmes. Many factors appear to be associated with cardiac rehabilitation access including active referral, younger age, higher income, better education and lower deprivation.&lt;/SPAN&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18800004?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Molloy GJ et al (2008)&lt;/A&gt;&lt;/SPAN&gt; examined the association between marital status and cardiac rehabilitation and concluded that coronary heart disease patients who are married or have a partner are between 1.5-2 times more likely to attend cardiac rehabilitation and that associations between marital status and cardiac rehabilitation attendance may partly explain coronary heart disease outcomes. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=normal1&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=normal1&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Meta-analysis&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Molloy GJ, Hamer M, Randall G, Chida Y (2008). &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Marital status and cardiac rehabilitation attendance: a meta-analysis.&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: ES" lang=ES&gt; European Journal of Cardiovascular Prevention and Rehabilitation 2008;15(5):557-561.&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Results:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; Eleven studies were identified which incorporated 6,984 CHD patients. Being married/partnered was associated with significantly higher odds of attending CR. Using a fixed effects model, the pooled odds ratio of CR attendance was 1.72 [95% confidence interval (CI) 1.50-1.97] for those who were married/partnered. There was no evidence of heterogeneity of effects (P=0.42) or publication bias (P=0.12). &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; CHD patients who are married or have a partner are between 1.5-2 times more likely to attend CR. Associations between marital status and CR attendance may partly explain CHD outcomes. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18800004?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;PubMed Abstract.&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: ES" lang=ES&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=normal1&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=ES&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-WEIGHT: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=normal1&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Randomised Controlled Trials&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=normal1&gt;&lt;SPAN class=MsoHyperlink&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=normal11&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;* &lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=3" target="_blank"&gt;Randomised controlled trials published between 2 March 2008 and 20 February 2009 listed in PubMed on the topic of cardiac rehabilitation.&lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;/SPAN&gt;&lt;SPAN class=MsoHyperlink&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp;&lt;EM&gt;&lt;SPAN style="FONT-FAMILY: Verdana"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Cochrane Protocols&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;Davies P, Taylor F, Beswick A, Harris - Wise F, Moxham T, &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;Taylor&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt; RS (2009)&lt;/SPAN&gt;&lt;SPAN&gt;. &lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007131/pdf_fs.html" target="_blank"&gt;Promoting patient uptake and adherence in cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="COLOR: red"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;Taylor&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt; RS, Dalal H, Jolly K, Moxham T, Zawada A (2008). &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Home-based versus centre-based cardiac rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 12pt; mso-bidi-font-size: 8.0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Economic Evaluations&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;Bond C (2008). &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007001791" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-weight: normal"&gt;The MEDMAN study : a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Latour CH, Bosmans JE, van Tulder MW, de Vos R, Huyse FJ, de Jonge P, van Gemert LA, &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Stalman&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;st1:State&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;WA&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:State&gt;&lt;/st1:place&gt;&lt;SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; (2008). &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; mso-bidi-font-weight: normal"&gt;Cost-effectiveness of a nurse-led case management intervention in general medical outpatients compared with usual care : an economic evaluation alongside a randomized controlled trial&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;/A&gt;&lt;SPAN class=source-copyright1&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;Other relevant information&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: 'Times New Roman'; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;British Association for Cardiac Rehabilitation Website&lt;/SPAN&gt;&lt;/A&gt; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;British Association for Cardiac Rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #444444; mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt; Phase IV Exercise Instructor Training Website&lt;/A&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;British Heart Foundation (2008). &lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1000617" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;National Audit for Cardiac Rehabilitation 2008 Annual Report&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;A href="http://www.heartstats.org/homepage.asp?id=6" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;British Heart Foundation Statistics Website&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN-US; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;British Heart Foundation Cardiac Care and Education Research Group (2009). &lt;A href="http://www.cardiacrehabilitation.org.uk/dataset.htm" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;The National Cardiac Rehabilitation Audit Project&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN-US; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%" class=MsoBodyText&gt;&lt;SPAN class=bodytext1char&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;CKS (2008).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;A href="http://cks.library.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation" target="_blank"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Myocardial infarction secondary prevention : evidence on rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;Department of Health (2009). &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;The NHS in England : The operating framework for 2009/10&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Recovering from a heart attack&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Recovering from heart disease&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN-US; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%" class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Heart Improvement (2009). &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Cardiac rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Information Centre (2008). &lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/heart-disease/cardiac-rehabilitation" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;The National Audit of Cardiac Rehabilitation&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NHS Institute for Innovation and Improvement (2009). &lt;A href="http://www.institute.nhs.uk/scenariogenerator/tools/reduce_readmissions.html" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Reduce readmissions&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;NICE (2008). &lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CommissioningCardiacRehabilitationService.jsp" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;Commissioning a cardiac rehabilitation service&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN-US; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="mso-ansi-language: EN-US; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN-US&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%" class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: FR; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=FR&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Verdana; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: FR; mso-bidi-font-weight: bold; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=FR&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-SIZE: 8pt"&gt;UK Clinical Research Network&lt;/SPAN&gt;&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-SIZE: 8pt"&gt;Current Controlled Trials&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Verdana; COLOR: black; FONT-SIZE: 9pt; mso-ansi-language: FR; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=FR&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%" class=MsoBodyText&gt;&lt;SPAN style="mso-ansi-language: FR; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=FR&gt;&amp;nbsp; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 115%" class=normalweb21&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-SIZE: 7.5pt; mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-SIZE: 9pt; mso-ansi-language: EN; mso-bidi-font-family: Arial; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308813</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308813]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Contributors</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C O N T R I B U T O R S&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308813/nelhImp_0000_contributors.gif"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-ansi-language: EN; mso-bidi-font-weight: bold" lang=EN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-ansi-language: EN; mso-bidi-font-weight: bold" lang=EN&gt;The following individuals participated in the 2009&amp;nbsp;Annual Evidence Update on Cardiac Rehabilitation:&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;B&gt;&lt;SPAN style="LETTER-SPACING: 2pt; COLOR: black; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;B&gt;&lt;SPAN style="LETTER-SPACING: 2pt; COLOR: black; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial; mso-fareast-language: EN-US"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Professor David Thompson &lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Professor of Cardiovascular Nursing, &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;University&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; of &lt;/SPAN&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Leicester&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&lt;U&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;o:p&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="LETTER-SPACING: 2pt; COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;NHS Evidence – cardiovascular team&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings" lang=EN&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;Professor Tom Quinn &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: 18pt; MARGIN-LEFT: 18pt" class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;Professor of Clinical Practice, University of Surrey &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings" lang=EN&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;Ann Daly &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: 18pt; MARGIN-LEFT: 18pt" class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;Information Specialist&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308808</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308808]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Exercise</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Exercise&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;E X E R C I S E&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/admin/images/scratch/50322943/nelhImp_0011_exercise.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-layout-grid-align: none" class=MsoNormal&gt;
&lt;P class=MsoNormal&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;We identified three systematic reviews and two meta-analyses relating to exercise published since the &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;2008 Annual Evidence Update on Cardiac Rehabilitation.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; mso-ansi-language: EN; mso-bidi-font-family: Arial" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Systematic Reviews&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Le Grande MR, Elliott PC, &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Worcester&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; MU, Murphy BM, Goble AJ (2008). An evaluation of self-report physical activity instruments used in studies involving cardiac patients. Journal of Cardiopulmonary Rehabilitation and Prevention 2008;28(6):358-369. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Some instruments are more suited to epidemiologic research than to clinical interventions where responsiveness to interventions is crucial. Recommendations for the constituents of an acceptable self-report physical activity instrument for cardiac patients are presented and the most suitable existing instruments are identified. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19008689" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN class=name1&gt;&lt;SPAN style="FONT-SIZE: 9pt"&gt;Oliveira JLM, Galvao CM, Rocha SMM (2008). &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Resistance exercises for health promotion in coronary patients: evidence of benefits and risks. International Journal of Evidence-Based Healthcare 2008 6 (4) 431-439. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; The resistance exercises can be used as a safe and effective strategy in health promotion programmes for coronary patients, making social, physical and psychological rehabilitation easier for those people. &lt;A href="http://www3.interscience.wiley.com/journal/121502577/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Nolan RP, Jong P, Barry-Bianchi SM, Tanaka TH, Floras JS (2008). Effects of drug, biobehavioral and exercise therapies on heart rate variability in coronary heart disease: a systematic review. European Journal of Cardiovascular Prevention and Rehabilitation 2008; 15: 386-396. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Pharmacologic biobehavioral and exercise strategies for secondary prevention of coronary artery disease significantly increase heart rate variability. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=%22European%20journal%20of%20cardiovascular%20prevention%20and%20rehabilitation%20%3A%20official%20journal%20of%20the%20European%20Society%20of%20Cardiology%2C%20Working%20Groups%20on%20Epidemiology%20%26%20Prevention%20and%20Cardiac%20Rehabilitation%20and%20Exercise%20Physiology%22%5BJour%5D%20AND%2015%5Bvolume%5D%20AND%202008%5Bpdat%5D%20AND%20effects%20of%20drug" target="_blank"&gt;PubMed abstract&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Meta - analyses&lt;/SPAN&gt;&lt;/B&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Kelley GA, Kelley KS, Franklin B (2008). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006008515" target="_blank"&gt;Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.&lt;/A&gt; DARE 2008. &lt;B style="mso-bidi-font-weight: normal"&gt;Authors’ conclusions:&lt;/B&gt; In adults with CVD, particularly men, chronic aerobic exercise increases high-density lipoprotein cholesterol and decreases triglycerides. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; The review addressed a clear question and undertook a comprehensive search for published trials, although no search terms were provided. The authors restricted the inclusion criteria to English language publications, thus potentially introducing language and publication bias. They did, however, assess publication bias in their analyses. Steps were also taken to minimise reviewer bias and errors in the study selection and data extraction processes. Quality was assessed and appears to have been considered in the sensitivity analyses. Although some details of the included studies were provided, the quality of each study was not reported. Standard statistical methods were used to pool the data and potential sources of heterogeneity were explored. The conclusions seem reliable, but should have been more cautiously made given that the quality of the included studies appears to be poor.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: PT-BR" lang=PT-BR&gt;Sofi F, Capalbo A, Cesari F, Abbate R, Gensini GF (2008). &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. European Journal of Cardiovascular Prevention &amp;amp; Rehabilitation 2008 ;15(3):247-257. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; The current meta-analysis reports significant protection against the occurrence of CHD resulting from moderate-to-high levels of physical activity. These results strengthen the recommendations of guidelines that indicate the protective effect against cardiovascular disease of physical activity profiles that are attainable by ordinary people. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18525378?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed Abstract.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;STRONG&gt;Randomised Controlled Trials&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=normal11&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;* &lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=3" target="_blank"&gt;Randomised controlled trials published between 2 March 2008 and 20 February 2009 listed in PubMed on the topic of cardiac rehabilitation.&lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;/SPAN&gt;&lt;SPAN class=MsoHyperlink&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Cochrane Protocols&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-font-weight: bold"&gt;Davies P, Taylor F, Beswick A, Harris - Wise F, Moxham T, &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-font-weight: bold"&gt;Taylor&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-font-weight: bold"&gt; RS (2009)&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;.&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007131/pdf_fs.html" target="_blank"&gt;Promoting patient uptake and adherence in cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="COLOR: red"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;Taylor&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt; RS, Dalal H, Jolly K, Moxham T, Zawada A (2008). &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;Home-based versus centre-based cardiac rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; COLOR: #444444"&gt;NHS Economic Evaluations&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt"&gt;Bond C (2008). &lt;/SPAN&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007001791" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;The MEDMAN study : a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Latour CH, Bosmans JE, van Tulder MW, de Vos R, Huyse FJ, de Jonge P, van Gemert LA, &lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Stalman&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; &lt;/SPAN&gt;&lt;st1:State&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;WA&lt;/SPAN&gt;&lt;/st1:State&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; (2008). &lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Cost-effectiveness of a nurse-led case management intervention in general medical outpatients compared with usual care : an economic evaluation alongside a randomized controlled trial&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Other relevant information&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;British Association for Cardiac Rehabilitation Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;British Association for Cardiac Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt; Phase IV Exercise Instructor Training Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation (2008). &lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1000617" target="_blank"&gt;National Audit for Cardiac Rehabilitation 2008 Annual Report&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.heartstats.org/homepage.asp?id=6" target="_blank"&gt;British Heart Foundation Statistics Website&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation Cardiac Care and Education Research Group (2009). &lt;A href="http://www.cardiacrehabilitation.org.uk/dataset.htm" target="_blank"&gt;The National Cardiac Rehabilitation Audit Project&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN class=BodyText1Char&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-fareast-font-family: Calibri"&gt;CKS (2008).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://cks.library.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Myocardial infarction secondary prevention : evidence on rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Department of Health (2009). &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445" target="_blank"&gt;The NHS in England : The operating framework for 2009/10&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from a heart attack&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from heart disease&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Heart Improvement (2009). &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;Cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Information Centre (2008). &lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/heart-disease/cardiac-rehabilitation" target="_blank"&gt;The National Audit of Cardiac Rehabilitation&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Institute for Innovation and Improvement (2009). &lt;A href="http://www.institute.nhs.uk/scenariogenerator/tools/reduce_readmissions.html" target="_blank"&gt;Reduce readmissions&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NICE (2008). &lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CommissioningCardiacRehabilitationService.jsp" target="_blank"&gt;Commissioning a cardiac rehabilitation service&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: FR" lang=FR&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=normalweb21&gt;&lt;SPAN style="FONT-SIZE: 7.5pt; mso-ansi-language: EN" lang=EN&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>305805</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=305805]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Homepage</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;Published on the 14th&amp;nbsp;April 2009: &lt;/STRONG&gt;An update for health professionals and patients on significant advances in knowledge about cardiac rehabilitation&amp;nbsp;since our &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;last update&lt;/A&gt;&amp;nbsp;in 2008. &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;Please send us your feedback on this update.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;
&lt;TABLE border=1&gt;
&lt;TBODY&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;TABLE border=0 cellSpacing=5 cellPadding=5&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage7 name="nelh_tempImage7&lt;/TD" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0000_HFKNWwelcome.jpg"&gt; 
&lt;TD width=130&gt;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0017_AEUaccess.jpg"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;A href="nelh:308806:0" name=internalLink&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308805" target="_blank"&gt;Access&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308807" target="_blank"&gt;Psychosocial&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=308808&amp;amp;code=9ac122c50320d1431a393cc4a43908af" target="_blank"&gt;Exercise&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&amp;nbsp; 
&lt;TABLE cellSpacing=5 cellPadding=5&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=130&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0005_secondary.jpg"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0019_AEUmethodology.jpg"&gt;&lt;/TD&gt;
&lt;TD width=130&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0021_AEUcontributors.gif"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="nelh:308809:0" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;Secondary Prevention&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=308810&amp;amp;code=9136aeea20ac61d73727e64e51de1881" target="_blank"&gt;Uncertainities&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308812" target="_blank"&gt;Methodology&amp;nbsp;&lt;/A&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD width=130 align=middle&gt;&lt;STRONG&gt;&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=308813&amp;amp;code=1d63a3a13af8d16d8ba3b4eac8b7a595" target="_blank"&gt;Contributors&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TABLE&gt;
&lt;P&gt;A &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=305805" target="_blank"&gt;flyer is available &lt;/A&gt;to promote the 2009 Annual Evidence Update on Chest Pain.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308806</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308806]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Introduction</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;I N T R O D U C T I O N&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;University of Surrey.&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308806/nelhImp_0000_welcome.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;Welcome to this, our second Annual Evidence Update on cardiac rehabilitation.&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 5pt 0cm; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;Rehabilitation is recognised as an important component of high quality care. Yet we know that, for all the major improvements made in the care of cardiac patients since publication of the National Service Framework almost a decade ago, there remains much to do to ensure that every patient who needs cardiac rehabilitation (CR) can obtain access to a high quality service; see &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445" target="_blank"&gt;The operating framework for 2009/10.&lt;/A&gt; NICE have produced a helpful commissioning guide, &lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CommissioningCardiacRehabilitationService.jsp" target="_blank"&gt;Commissioning a cardiac rehabilitation service&lt;/A&gt; setting out the benefits of CR, and a &lt;A href="http://www.cardiacrehabilitation.org.uk/dataset.htm" target="_blank"&gt;national audit,&lt;/A&gt; funded by the British Heart Foundation, is helping to drive further improvement for our patients. The &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;NHS Improvement Programme&lt;/A&gt; have made CR one of their national priorities and have galvanised colleagues across the country to increase access, equity of provision and uptake of CR for those who have had a heart attack, angioplasty or coronary surgery.&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;We identified six systematic reviews and&amp;nbsp;four meta-analyses published since the &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;2008 Annual Evidence Update on cardiac rehabilitation,&lt;/A&gt; which we categorised as:&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=Normal1&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-SIZE: 8pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308805" target="_blank"&gt;Access&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308807" target="_blank"&gt;Psychosocial&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=308808" target="_blank"&gt;Exercise&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=308809" target="_blank"&gt;Secondary prevention&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 5pt 0cm; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 5pt 0cm; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Within this new evidence we identified no uncertainties of treatment.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 5pt 0cm; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial"&gt;I am grateful to Professor David Thompson for his expert commentary, and particular thanks go to Ann Daly who has shouldered the substantial burden of developing what I hope will be an informative update for all those interested in improving cardiac rehabilitation. &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308812</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308812]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Methodology</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;M E T H O D O L O G Y&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308812/nelhImp_0000_methodology.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Introduction&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;This&amp;nbsp;page provides details of the literature search strategy for the 2009 Annual Evidence Update on Cardiac Rehabilitation. It also provides information on the number of references retrieved from individual databases, the sifting process, and into which category of cardiac rehabilitation each of the references ended. The period of the literature search is &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:date Month="3" Day="2" Year="2008"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;2 March 2008&lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt; to &lt;/SPAN&gt;&lt;st1:date Month="2" Day="20" Year="2009"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;20 February 2009&lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;; the start date reflects the end literature search date of the &lt;A href="http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;amp;pagename=CRAEU08" target="_blank"&gt;&lt;SPAN style="FONT-SIZE: 8pt; mso-bidi-font-size: 12.0pt"&gt;2008 Annual Evidence Update on Cardiac Rehabilitation.&lt;/SPAN&gt;&lt;/A&gt; The sources searched for systematic reviews and meta-analyses were:&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Cochrane&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;DARE&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Medline (via the NLH database)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Embase (via the NLH database)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Cinahl (via the NLH database)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Cochrane search&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Type of search&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Advanced / free text&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -108pt; MARGIN-LEFT: 108pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Search terms&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;(&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;myocardial infarction OR coronary artery bypass OR angioplasty OR angina OR heart failure OR cardiac transplants OR coronary disease OR cardiac OR heart OR vascular OR coronary OR cardiovascular) &lt;B&gt;AND&lt;/B&gt; (rehab* OR physiotherapy OR occupational therapy OR exercise therapy OR cognitive therapy OR counselling OR diet therapy OR patient care team)&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Limits&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Title, abstract or keyword&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Results&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;39&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Type of search&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;MeSH / Explode option&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -108pt; MARGIN-LEFT: 108pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Search terms&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;rehabilitation (cardiac rehabilitation not listed as a MeSH term)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Limit&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;2008 – 2009&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -108pt; MARGIN-LEFT: 108pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Results &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;26 (24 listed in the free text search, therefore just &lt;B style="mso-bidi-font-weight: normal"&gt;2&lt;/B&gt; exported to Ref Mgr)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;39 + 2 =&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;41&lt;/B&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;DARE search&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Type of search&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;All of the words&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -108pt; MARGIN-LEFT: 108pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Search terms&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;(&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;myocardial infarction OR coronary artery bypass OR angioplasty OR angina OR heart failure OR cardiac transplants OR coronary disease OR cardiac OR heart OR vascular OR coronary OR cardiovascular) AND (rehab* OR physiotherapy OR occupational therapy OR exercise therapy OR cognitive therapy OR counselling OR diet therapy OR patient care team)&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Limits&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Published date &lt;/SPAN&gt;&lt;st1:date Month="3" Day="2" Year="2008"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;02/3/2008 - &lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;20/2/2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Results&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;15&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Type of search&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;MeSH&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Search terms&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;rehabilitation AND recovery of function&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Limits&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Published date &lt;/SPAN&gt;&lt;st1:date Month="3" Day="2" Year="2008"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;02/03/08&lt;/SPAN&gt;&lt;/st1:date&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt; – 20/02/2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Saved to &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;DARE database&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Results &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;9&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;15 + 9 = 24&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;A href="http://www.library.nhs.uk/specialistlibrarysearch/Download.aspx?resID=308812" target="_blank"&gt;Medline, Embase and Cinahl search&lt;/A&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Total references retrieved&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 85.2pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-border-alt: solid windowtext .5pt; mso-yfti-tbllook: 480; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-border-insideh: .5pt solid windowtext; mso-border-insidev: .5pt solid windowtext" class=MsoNormalTable border=1 cellSpacing=0 cellPadding=0&gt;
&lt;TBODY&gt;
&lt;TR style="mso-yfti-irow: 0"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Database&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;No. of references retrieved&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 1"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Cochrane&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;41&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 2"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;DARE&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;24&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 3"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Medline&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;192&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 4"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Cinahl &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;150 &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 5"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Embase&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;117&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 6; mso-yfti-lastrow: yes"&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 148.2pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=198&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;Total&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 179.55pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt" vAlign=top width=239&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;524 ( - 67 duplicates = 457)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Sifting for relevance&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;The Information Specialist sifted 457 references and categorised them as:&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo3; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Relevant&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 31&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo3; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Not relevant&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;403&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo3; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Unsure &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;23&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;The Clinical Lead conducted a further sift and categorised as:&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l3 level1 lfo2; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Relevant &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;10&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l3 level1 lfo2; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Not relevant&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;447 &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Of the 447 not relevant references, nine were systematic reviews of a generic rehabilitation nature. On consultation with the Cardiac Rehabilitation AEU expert panel it was decided not to include these in this AEU.&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Classifying the references&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;o:p&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt"&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;The final&amp;nbsp;references were classified as: &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Access&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 3"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;1&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Exercise&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;5&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Psychosocial&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 2"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;3&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 54pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo1; tab-stops: list 54.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Wingdings; COLOR: #99cc00; FONT-SIZE: 10pt; mso-bidi-font-family: Wingdings; mso-fareast-font-family: Wingdings"&gt;&lt;SPAN style="mso-list: Ignore"&gt;v&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: red; FONT-SIZE: 7pt; mso-fareast-font-family: Wingdings"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Secondary prevention&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 8pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Verdana; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;1&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308807</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308807]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Psychosocial</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,OCT-DEC 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Psychosocial&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;P S Y C H O S O C I A L&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Professor of Cardiovascular Nursing, University of Leicester.&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/admin/images/scratch/50322943/nelhImp_0010_education.jpg"&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;We identified two systematic reviews and one meta-analysis relating to psychosocial published since the &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;2008 Annual Evidence Update on Cardiac Rehabilitation.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Expert summary&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Comprehensive cardiac rehabilitation can alleviate psychological distress and enhance quality of life as well as improve physical health status &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18924386?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;(Peck MD, et al 2008)&lt;/A&gt;, though a recent review concludes that the setting for optimal inpatient rehabilitation remains unclear &lt;A href="http://dl.begellhouse.com/journals/757fcb0219d89390,54883b73768ea435,1a6f801e41f996cb.html" target="_blank"&gt;(Vincent HK, et al 2008).&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;A meta-analysis of psychological treatment alone of cardiac patients found a significant reduction in risk of all-cause mortality at two years but only in men &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008000023" target="_blank"&gt;(Linden W, et al. 2008). &lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;The beneficial effect of psychological treatment was stronger in studies that initiated treatment more than two months after the event.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Psychological treatment was associated with a significant reduction in heart rate and improvements in social support and quality of life. This suggests that there is a need to assess psychological distress and depression repeatedly throughout the cardiac rehabilitation process, that the psychological treatment continues until distress is reduced and that appropriate gender-specific interventions are needed.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Systematic Reviews&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Peck MD, Ai &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:State&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;AL&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:State&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; (2008). Cardiac conditions. Journal of Gerontological Social Work &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;2008;50 (Suppl.1):13-44. &lt;B style="mso-bidi-font-weight: normal"&gt;Abstract:&lt;/B&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Cardiovascular disease (CVD) is the leading cause of death in the &lt;/SPAN&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;US&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;. The growth of the older population in coming decades will inevitably increase the incidence of age-related cardiac disease. Increasing evidence has shown the prevalence of co-morbid mental health conditions in CVD patients. Specifically, depression and anxiety have been linked with CVD mortality. Due to the risk of psychosocial conditions with cardiac patients, mental health practitioners in health and gerontology need to be well-informed about CVD-related mental health comorbidity and current research developments. Accordingly, this article provides a systematic review of the clinical evidence about the efficacy, cost-effectiveness, and any potential risk of psychosocial intervention with cardiac patients. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18924386?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed Abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Vincent HK, Stephenson ML, Omli MR, Vincent KR (2008). Clinical outcomes following postacute comprehensive rehabilitative care in patients with cardiopulmonary disease. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Critical Reviews in Physical and Rehabilitation Medicine 2008&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;;20(2):127-158. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; The limited data on the outcomes following comprehensive inpatient rehabilitation in cardiopulmonary patients indicate that consistent improvements can be expected in physical function, mobility, and disease symptoms by discharge. Additional benefits of rehabilitation include the alleviation of depression and increased quality of life. The setting for optimal inpatient rehabilitation, however, is still unclear, but preliminary data suggest that higher volumes of therapy likely generate more favorable outcomes such as discharge to home and independent mobility. &lt;A href="http://dl.begellhouse.com/journals/757fcb0219d89390,54883b73768ea435,1a6f801e41f996cb.html" target="_blank"&gt;Abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Meta-analysis&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Linden&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; W, Phillips MJ, Leclerc J (2008). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008000023" target="_blank"&gt;Psychological treatment of cardiac patients: a meta-analysis.&lt;/A&gt; DARE 2008. &lt;B style="mso-bidi-font-weight: normal"&gt;Authors’ conclusion:&lt;/B&gt; Treatment of cardiac patients with psychological interventions reduces mortality and morbidity in men but not women. PT was more effective if initiated 2 months after the cardiac event rather than immediately. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary: &lt;/B&gt;This review answered a clearly stated research question. The search strategy was comprehensive and unlikely to have missed relevant evidence. Attempts were made to reduce the potential for language bias by including studies from a range of languages, and to reduce publication bias by&amp;nbsp;asking key researchers for&amp;nbsp;unpublished data. However,&amp;nbsp;publication&amp;nbsp;bias was not formally assessed.&amp;nbsp;The methodology&amp;nbsp;used to select the studies and extract the data was not adequately described to exclude the possibility of error or bias during these parts of the review process. No quality assessment was reported, although the authors noted that the quality of non-English language studies tended to be poorer than those reported in English. The methods used to synthesise the data, including the use of subgroup analyses to&amp;nbsp;investigate heterogeneity,&amp;nbsp;were appropriate. The reliability of the authors’ conclusions is uncertain given the lack of a validity assessment and the poor reporting of the review process.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;STRONG&gt;Randomised Controlled Trials&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;* &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=3" target="_blank"&gt;Randomised controlled trials published between 2 March 2008 and 20 February 2009 listed in PubMed on the topic of cardiac rehabilitation.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN class=MsoHyperlink&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Cochrane Protocols&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Davies P, Taylor F, Beswick A, Harris - Wise F, Moxham T, &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Taylor&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-weight: bold; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt; RS (2009)&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;.&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007131/pdf_fs.html" target="_blank"&gt;Promoting patient uptake and adherence in cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="COLOR: red"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;Taylor&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt; RS, Dalal H, Jolly K, Moxham T, Zawada A (2008). &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;Home-based versus centre-based cardiac rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; COLOR: #444444"&gt;NHS Economic Evaluations&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt"&gt;Bond C (2008). &lt;/SPAN&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007001791" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;The MEDMAN study : a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Latour CH, Bosmans JE, van Tulder MW, de Vos R, Huyse FJ, de Jonge P, van Gemert LA, &lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Stalman&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; &lt;/SPAN&gt;&lt;st1:State&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;WA&lt;/SPAN&gt;&lt;/st1:State&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; (2008). &lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Cost-effectiveness of a nurse-led case management intervention in general medical outpatients compared with usual care : an economic evaluation alongside a randomized controlled trial&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; COLOR: #444444"&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;FONT color=#444444&gt;&lt;/FONT&gt;Other relevant information&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;British Association for Cardiac Rehabilitation Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;British Association for Cardiac Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt; Phase IV Exercise Instructor Training Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation (2008). &lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1000617" target="_blank"&gt;National Audit for Cardiac Rehabilitation 2008 Annual Report&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.heartstats.org/homepage.asp?id=6" target="_blank"&gt;British Heart Foundation Statistics Website&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation Cardiac Care and Education Research Group (2009). &lt;A href="http://www.cardiacrehabilitation.org.uk/dataset.htm" target="_blank"&gt;The National Cardiac Rehabilitation Audit Project&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN class=BodyText1Char&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-fareast-font-family: Calibri"&gt;CKS (2008).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://cks.library.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Myocardial infarction secondary prevention : evidence on rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Department of Health (2009). &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445" target="_blank"&gt;The NHS in England : The operating framework for 2009/10&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from a heart attack&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from heart disease&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Heart Improvement (2009). &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;Cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Information Centre (2008). &lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/heart-disease/cardiac-rehabilitation" target="_blank"&gt;The National Audit of Cardiac Rehabilitation&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Institute for Innovation and Improvement (2009). &lt;A href="http://www.institute.nhs.uk/scenariogenerator/tools/reduce_readmissions.html" target="_blank"&gt;Reduce readmissions&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NICE (2008). &lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CommissioningCardiacRehabilitationService.jsp" target="_blank"&gt;Commissioning a cardiac rehabilitation service&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: FR" lang=FR&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=normalweb21&gt;&lt;SPAN style="FONT-SIZE: 7.5pt; mso-ansi-language: EN" lang=EN&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308809</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308809]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Secondary Prevention</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Secondary Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;S E C O N D A R Y&amp;nbsp;&amp;nbsp; P R E V E N T I O N&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308809/nelhImp_0000_AEUsecondaryPrevention.jpg"&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;We identified one systematic review relating to secondary prevention published since the &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;2008 Annual Evidence Update on Cardiac Rehabilitation. &lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 8pt; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 2pt; mso-bidi-font-family: Arial"&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;STRONG&gt;Systematic Review&amp;nbsp;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: PT-BR" lang=PT-BR&gt;Auer R, Gaume J, Rodondi N, Cornuz J, Ghali WA (2008). &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. Circulation 2008 ;117(24):3109-3118. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; The evidence for in-hospital, patient-level interventions for secondary prevention is promising but not definitive because only before-after studies suggest a significant reduction in mortality. Future research should formally test which components of interventions provide the greatest benefit. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18541742?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;PubMed abstract &lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;STRONG&gt;Randomised Controlled Trials&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=Normal1&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;* &lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=3" target="_blank"&gt;Randomised controlled trials published between 2 March 2008 and 20 February 2009 listed in PubMed on the topic of cardiac rehabilitation.&lt;/A&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=4" target="_blank"&gt;&lt;/SPAN&gt;&lt;SPAN class=MsoHyperlink&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;Cochrane Protocols&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Davies P, Taylor F, Beswick A, Harris - Wise F, Moxham T, &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Taylor&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt; RS (2009)&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;.&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007131/pdf_fs.html" target="_blank"&gt;Promoting patient uptake and adherence in cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="COLOR: red"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;Taylor&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt; RS, Dalal H, Jolly K, Moxham T, Zawada A (2008). &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;Home-based versus centre-based cardiac rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; COLOR: #444444"&gt;NHS Economic Evaluations&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt"&gt;Bond C (2008). &lt;/SPAN&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007001791" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;The MEDMAN study : a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Latour CH, Bosmans JE, van Tulder MW, de Vos R, Huyse FJ, de Jonge P, van Gemert LA, &lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Stalman&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; &lt;/SPAN&gt;&lt;st1:State&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;WA&lt;/SPAN&gt;&lt;/st1:State&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt; (2008). &lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Cost-effectiveness of a nurse-led case management intervention in general medical outpatients compared with usual care : an economic evaluation alongside a randomized controlled trial&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 2pt; COLOR: #444444"&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000656" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=source-copyright1&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-US; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN-US&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; LETTER-SPACING: 2pt; FONT-SIZE: 12pt; mso-ansi-language: EN" lang=EN&gt;&lt;FONT color=#444444&gt;&lt;/FONT&gt;Other relevant information&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;British Association for Cardiac Rehabilitation Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;British Association for Cardiac Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt; Phase IV Exercise Instructor Training Website&lt;/A&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: #444444; FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;SPAN lang=EN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation (2008). &lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1000617" target="_blank"&gt;National Audit for Cardiac Rehabilitation 2008 Annual Report&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.heartstats.org/homepage.asp?id=6" target="_blank"&gt;British Heart Foundation Statistics Website&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;British Heart Foundation Cardiac Care and Education Research Group (2009). &lt;A href="http://www.cardiacrehabilitation.org.uk/dataset.htm" target="_blank"&gt;The National Cardiac Rehabilitation Audit Project&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN class=BodyText1Char&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-fareast-font-family: Calibri"&gt;CKS (2008).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US"&gt; &lt;SPAN lang=EN&gt;&lt;A href="http://cks.library.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-size: 10.0pt; mso-ansi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Myocardial infarction secondary prevention : evidence on rehabilitation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Department of Health (2009). &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_091445" target="_blank"&gt;The NHS in England : The operating framework for 2009/10&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from a heart attack&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Choices (2009). &lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;Recovering from heart disease&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Heart Improvement (2009). &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;Cardiac rehabilitation&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Information Centre (2008). &lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/heart-disease/cardiac-rehabilitation" target="_blank"&gt;The National Audit of Cardiac Rehabilitation&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Institute for Innovation and Improvement (2009). &lt;A href="http://www.institute.nhs.uk/scenariogenerator/tools/reduce_readmissions.html" target="_blank"&gt;Reduce readmissions&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NICE (2008). &lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CommissioningCardiacRehabilitationService.jsp" target="_blank"&gt;Commissioning a cardiac rehabilitation service&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: FR" lang=FR&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoBodyText&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=normalweb21&gt;&lt;SPAN style="FONT-SIZE: 7.5pt; mso-ansi-language: EN" lang=EN&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308810</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=308810]]&gt;</url>
    <title>2009 Annual Evidence Update on Cardiac Rehabilitation : Uncertainties</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cardiac Rehabilitation : Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;U N C E R T A I N T I E S&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=305805" target="_blank"&gt;click here&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID308810/nelhImp_0000_DUETs.gif"&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;No uncertainties of treatment were identified in the 2009 Annual Evidence Update on Cardiac Rehabilitation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;For information relating to&amp;nbsp;the UK Database of Uncertainties about the Effects of Treatment (DUETs) &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;click here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304796</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304796]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest pain : Acute Coronary Syndromes</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CHEST PAIN,CONDITIONS,GENERAL  / OVERVIEWS,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CARDIOVASCULAR,CHEST PAIN (ISCHAEMIC),MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,CHEST,MYOCARDIAL INFARCTION,GENERAL / OVERVIEWS,GENERAL / OVERVIEWS,UNSTABLE ANGINA,ACUTE CORONARY SYNDROMES,OTHER,UNSTABLE ANGINA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest pain : Acute Coronary Syndromes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;A C U T E&amp;nbsp; C O R O N A R Y&amp;nbsp; S Y N D R O M E&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Dr Ian Jones&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Senior Lecturer in Cardiac Nursing, University of Salford &lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD align=middle&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304796/nelhImp_0000_acs.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;We identified 19 reviews related to the management of acute coronary syndromes (ACS) published since the last AEU. Most of these focus on efficacy of drug therapy or intervention.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Anti-thrombotic therapy&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003462/frame.html" target="_blank"&gt;Magee and colleagues &lt;/A&gt;reviewed 8 Randomised Controlled Trials (RCTs) comparing use of low molecular weight heparin (LMWH) or unfractionated heparin (UFH) with placebo in high-risk unstable angina or NSTEMI. When given in the acute phase in addition to standard therapy with aspirin, LMWH and UFH prevented more heart attacks than placebo but do not reduce mortality, the need for revascularization procedures or recurrent angina. Although there was limited reporting of side effects, heparins caused more cases of minor bleeding. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007003523" target="_blank"&gt;Murphy et al &lt;/A&gt;undertook a meta analysis of 12 RCTs (n =49,076) comparing Enoxaparin with UFH in patients with acute coronary syndromes (ACS). Enoxaparin had a significant net benefit, particularly for STEMI, demonstrated by reductions in deaths and recurrent MI but with increased risk of bleeding. These benefits were not seen in patients with NSTEMI. Methods to minimise bias and error in the selection of studies or in the extraction of data were not described, neither did the authors report how study validity was assessed, therefore it is difficult to be certain of the reliability of these conclusions. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18172222?dopt=Citation" target="_blank"&gt;Singh, Molnar and Arora &lt;/A&gt;undertook a meta analysis to compare efficacy of heparin with that of Bivalirudin. They pooled the results of 5 RCTs (n =25,457). Rates of MI, death, revascularisation and composite ischaemic end points were similar for both groups. However, major bleeding was significantly lower in the Bivalirudin group. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006001521" target="_blank"&gt;Andreotti, Biondi-Zoccai and Crea&lt;/A&gt; reviewed 14 RCTs (n =25,037) studying the effects of aspirin (ASA) combined with warfarin when compared with ASA alone in patients recovering from ACS. The combination of ASA and warfarin had no effect on major adverse effects but increased risk of major bleed and extra cranial bleed (no effect was observed on rates of &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;intracranial bleeding), and significantly reduced risk of non fatal thromboembolic stroke. There was significant heterogeneity and the authors restricted further analysis to patients with INR between 2 – 3. In this latter analysis the combination of ASA and warfarin was associated with a significant reduction in major adverse effects at the expense of an increase in the risk of major bleeds. There was no reduction in all cause mortality but a 57% reduction in non fatal thromboembolic stroke.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://jama.ama-assn.org/cgi/content/full/298/7/765" target="_blank"&gt;Donahoe et al&lt;/A&gt; reviewed subgroups of diabetic patients recruited to 11 RCTs in the TIMI trials between 1997 and 2006. 30-day mortality was significantly higher in ACS patients with diabetes than in those without diabetes, even after confounding variables were controlled. Despite modern therapies for ACS, diabetes confers a significant adverse prognosis, highlighting the need for aggressive strategies (and more research) to manage this high risk group.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Gender differences &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18071161?dopt=Citation" target="_blank"&gt;Canto et al&lt;/A&gt; reviewed 69 studies published between 1970 - 2005, with a particular interest in gender differences in symptoms, finding a lack of standardisation in characterising ACS presentation and reporting of symptoms. Between a quarter and a third of patients presented without chest pain, with women less likely to report pain. However these differences did not, according to the authors, warrant gender specific health messages. There is clearly a need for more research in this area.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18482629" target="_blank"&gt;Stephen, Darney and Rosenfield&lt;/A&gt; also explored the needs of women with ACS but in this integrative review of eight studies focussed specifically on symptoms of women suffering ACS in the presence of diabetes. The evidence on ACS presentation in diabetic women was conflicting. There is a need for future research into the full range of ACS symptoms, involving multi ethnic samples of women with diabetes&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Statins&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007002198" target="_blank"&gt;Bavry et al&lt;/A&gt; reviewed seven RCTs comparing statins with placebo or less intensive lipid lowering therapy in ACS. All cause mortality and cardiovascular mortality were reduced at 24 months (no statistical difference at 6 or 12 months), together with a reduced risk of MI, unstable angina and revascularisation in the statin group compared to less intensive lipid therapy.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006008203" target="_blank"&gt;Briel et al&lt;/A&gt; reviewed the effects of starting statin therapy within 14 days of the onset of ACS, in 12 RCTs (n =13,024). Statin therapy did not reduce death but may reduce the risk of unstable angina. Hulten et al also reviewed the effects of early intensive statin therapy for ACS in 13 RCTs (n =17,963). Early intensive statin therapy decreased the rate of cardiovascular events over 2 years follow up. Benefits of therapy were not observed until six months, when a significant reduction in cardiovascular events was seen. The pooled results should be treated with caution due to a number of methodological concerns. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Intervention&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008008085" target="_blank"&gt;Qayyum et al&lt;/A&gt; undertook a reasonably good quality review of 10 RCTs (n =10,648) NSTEMI patients allocated to either routine or selective intervention. The authors concluded that there was no evidence to support routine intervention in this patient group. However there is still an argument for selective intervention based on risk. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;Another study that has reviewed the efficacy of a novel therapy was conducted by &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008103020" target="_blank"&gt;Hongcai and colleagues &lt;/A&gt;who explored the efficacy of Compound Salvia droplet pil, a traditional Chinese medicine for the management of unstable angina. These authors undertook a review of 17 RCTs or quasi RCT involving 1, 462 patients. The authors considered all studies that had either compared CSDP with placebo, had made comparisons with traditional western drugs or had been combined with a western drug and compared to western drug alone. Ultimately the review only considered the latter. Based on the results of the review the authors comment that CSDP has a significant effect on improving angina symptoms, ECG and lipid levels in patients with unstable angina. However the evidence is low quality due to the poor quality of the studies reviewed. This was a well conducted study and the results are likely to be reliable.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Hyperbaric oxygen&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Normal pressure oxygen therapy is beginning to receive more scrutiny as evidence grows suggestive of harm in MI patients. Hyperbaric oxygen therapy has been suggested as a treatment option for patients with ACS. &lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/search.aspx?ItemSubCollection=bnj.ovi.emez&amp;amp;ItemId=ovid.com:/bib/embase/2007077046&amp;amp;Id=1" target="_blank"&gt;Bennet, Jepson and Lehm &lt;/A&gt;&amp;nbsp;(NHS Athens password required) found that whilst the hyperbaric oxygen reduced the risk of major cardiac events it did not improve overall mortality. However studies were small and had some methodological shortcoming. The authors therefore conclude that the routine use of hyperbaric oxygen therapy in ACS patients can not be justified.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Changing behaviour&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Behaviour modification forms part of the cardiac rehabilitation service and is routine in many post ACS protocols. &lt;A href="http://www.circ.ahajournals.org/cgi/content/abstract/117/24/3109" target="_blank"&gt;Auer et al&lt;/A&gt; undertook a systematic review and meta analysis to investigate the efficacy of in-hospital risk factor targeting strategies. The authors reviewed 26 studies that were either clinical trials or pre and post test studies that included some element of education or counselling. The authors conclude that the evidence for in-hospital patient level interventions for secondary prevention is promising but not definitive because only before-after studies suggest a significant reduction in mortality. Future research is required to formally assess which components of intervention provide greatest benefit. Interventions are frequently inter-related and as such the whole benefit may be equal to more than the sum of individual interventions.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="TEXT-ALIGN: justify"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;STRONG&gt;ANDREOTTI F, TESTA L, BIONDI-ZOCCAI GG, CREA F (2007). &lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006001521" target="_blank"&gt;&lt;STRONG&gt;Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp; Bottom-line conclusion: &lt;/STRONG&gt;In patients recovering from ACS at INR of 2-3, a combination of A+W is superior to aspirin alone in preventing MAEs, although it doubles the risk of MB. Whether this combined regimen is also superior to a double antiplatelet strategy or to newer evolving treatments warrants further investigation. &lt;STRONG&gt;CRD commentary:&lt;/STRONG&gt; The review question and inclusion criteria were clear and the search was reasonable, but the authors did not adequately describe how they selected the studies. Study quality was assessed, but only some components of the assessment were reported and the authors did not state how they performed the quality assessment; the potential for reviewer error or bias could not, therefore, be assessed. There was significant heterogeneity in the overall analysis of all studies, although the authors discussed the possible reasons for this heterogeneity and addressed the issue by restricting the analyses to studies with INRs of between 2 and 3. Overall, the authors' conclusion appears to be supported by the evidence presented.&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;AUER R, GAUME J, RODONDI N, CORNUZ J, GHALI WA (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; The evidence for in-hospital, patient-level interventions for secondary prevention is promising but not definitive because only before-after studies suggest a significant reduction in mortality. Future research should formally test which components of interventions provide the greatest benefit. &lt;A href="http://www.circ.ahajournals.org/cgi/content/abstract/117/24/3109" target="_blank"&gt;Abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;BAVRY AA, MOOD GR, KUMBHANI DJ, BOREK PP, ASKARI AT, BHATT DL (2007). &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007002198" target="_blank"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials&lt;/SPAN&gt;&lt;/A&gt;. &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; Initiation of statin therapy during ACS slowly produces benefit, such that all-cause mortality, cardiovascular mortality, unstable angina and revascularisation are all reduced at around 24 months.&lt;/SPAN&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;CRD commentary:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; This review had clearly stated inclusion criteria with respect to the study design, participants and intervention, but not outcomes. Several relevant sources were searched and the potential influence of publication bias was evaluated through appropriate methods, with no evidence of publication bias detected. It was unclear whether language restrictions were applied, therefore language bias may have been introduced.&amp;nbsp; The data extraction was conducted in duplicate, but it was unclear whether similar methods were used to reduce reviewer error and bias during the study selection and validity assessment processes. Validity was assessed according to published criteria. Details presented on the included studies suggest that the decision to combine some of the studies statistically was appropriate. However, the main analyses were for a weighted mean follow-up of 23 months, combining two studies with 6 months, two with 12 months, and three with 24 months’ follow-up; separate analyses were given for combining the three studies with 24 months’ follow-up. Statistical heterogeneity was assessed. Despite the lack of reporting of some parts of the review process, the review appears generally well conducted. The authors’ conclusions seem reliable based on the evidence presented.&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt;BENNETT MH, JEPSON N, LEHM J (2006).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Herperbaric oxygen therapy for acute coronary syndrome: A systematic review of randomised controlled trials. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; For people with ACS, the addition of HBOT reduced the risk of MACE and some dysrhythmias, and reduced the time to relief from ischaemic pain, but did not significantly reduce mortality. The review was hampered by modest numbers of patients, methodological shortcomings and poor reporting. More research is needed. The routine application of HBOT to these patients cannot be justified from this review. &lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/search.aspx?ItemSubCollection=bnj.ovi.emez&amp;amp;ItemId=ovid.com:/bib/embase/2007077046&amp;amp;Id=1" target="_blank"&gt;Embase abstract.&lt;/A&gt;&amp;nbsp;(NHS Athens password required).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;BRIEL M, SCHWARTZ GG, THOMPSON PL, DE LEMOS JA, BLAZING MA, VAN ES GA, KAYIKCIOGLU M, ARNTZ HR, DEN HARTOG FR, VEEGER NJ, COLIVICCHI F, DUPUIS J, OKAZAKI S, WRIGHT RS, BUCHER HC, NORDMANN AJ (2006). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006008203" target="_blank"&gt;Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Starting statin treatment within 14 days of the onset of ACS does not reduce death, MI or stroke up to 4 months, but it may reduce the risk of unstable angina. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary: &lt;/B&gt;The review addressed a clear question that was defined in terms of the participants, intervention, outcomes and study design. Several relevant sources were searched without language restrictions and attempts were made to locate unpublished data, thus minimising the possibility of language and publication bias. The potential for publication bias was tested and no evidence of its presence was found. Two reviewers independently selected studies for inclusion, assessed validity and extracted the data, thus reducing the potential for reviewer bias and errors. Validity was assessed using established criteria and the results of the assessment were reported. Adequate details of each included study were presented and statistical heterogeneity was assessed. The decision to statistically combine the studies appeared appropriate, as was the meta-analysis technique used. The influence of various factors including quality criteria was examined. In addition, the authors calculated the power of the meta-analysis to detect a treatment difference. This was a well-conducted and clearly reported review and the authors' conclusions are likely to be reliable.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;CANTO JG, GOLDBERG RJ, HAND MM, BONOW RO, SOPKO G, PEPINE CJ, LONG T (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Symptom presentation of women with acute coronary syndromes: myth vs reality. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Women are significantly less likely to report chest pain or discomfort compared with men. These differences, however, are not likely large enough to warrant sex-specific public health messages regarding the symptoms of ACS at the present time. Further research must systematically investigate sex differences in the clinical presentation of ACS symptoms and must include standardized data collection efforts. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18071161?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;DONAHOE SM, STEWART GC, MCCABE CH, MOHANAVELU S, MURPHY SA, CANNON CP, ANTMAN EM (2007). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Diabetes and mortality following acute coronary syndromes. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Despite modern therapies for ACS, diabetes confers a significant adverse prognosis, which highlights the importance of aggressive strategies to manage this high-risk population with unstable ischemic heart disease. &lt;A href="http://jama.ama-assn.org/cgi/content/full/298/7/765" target="_blank"&gt;Full-text. &lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;HULTEN E, JACKSON JL, DOUGLAS K, GEORGE S, VILLINES TC (2007). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006008386" target="_blank"&gt;The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials.&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;BR&gt;Bottom-line conclusion:&lt;/B&gt; Early intensive statin therapy reduced death and cardiovascular events after 4 months of treatment, but a meta-analysis using individual patient data would strengthen the validity of this finding. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; This review addressed a clear question and stated clear inclusion criteria. The search was not restricted to English language publications, which helps prevent language bias. Studies published only as abstracts were excluded, but the authors assessed publication bias and concluded that there was no evidence of any. Steps were taken throughout the review process to reduce errors and bias by having two reviewers independently screen articles and perform the quality assessment and data extraction. The quality of the studies was assessed, although full details were not reported; this makes it difficult for readers of the review to assess study quality. The assessment also did not seem to follow the usual scoring of the Jadad scale, and it was unclear whether the quality assessment encompassed issues relevant to RCTs such as allocation concealment. The analyses were based on HRs but were performed using estimated values, rather than actual values as reported in the studies. There was also considerable statistical heterogeneity that could not be fully explained. Therefore, the pooled results may be unreliable, a fact which the authors acknowledge as a limitation of this meta-analysis. The evidence presented supports the authors' conclusions but the pooled results should be treated with some caution.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;JUNHUA Z, HONGCAI S, XIUMEI G, BOLI Z, YAOZU X, HONGBO C, MING R, HUI W (2008). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008103020" target="_blank"&gt;Compound salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review.&lt;/A&gt;&amp;nbsp;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion: &lt;/B&gt;CSDP has a significant effect on improving angina symptoms, ECG and level of blood lipids in patients with UA, with few side-effects. However, the evidence is unreliable because of the low quality of the included trials. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; The review addressed a well-defined question and inclusion criteria for the intervention, participants, outcomes and study design were stated clearly. Several relevant databases were searched for studies in any language, thus minimising the risk of language bias. Attempts were made to identify unpublished material and publication bias was assessed in the analyses. The study selection, validity assessment and data extraction processes were conducted independently by more than one reviewer, thereby minimising the risk of reviewer error and bias. The decision to combine the studies in an meta-analysis was appropriate, and statistical heterogeneity was assessed and taken into account in the analysis. This was a well-conducted review and the conclusions are likely to be reliable.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;MAGEE KD, &lt;/SPAN&gt;&lt;/B&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;CAMPBELL&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; SG, MOHER D, ROWE BH (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003462/frame.html" target="_blank"&gt;Heparin versus placebo for acute coronary syndromes.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Compared to placebo, patients treated with heparins had similar risk of mortality, revascularization, recurrent angina, major bleeding and thrombocytopenia. However, those treated with heparins had decreased risk of MI and a higher incidence of minor bleeding. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;MURPHY SA, GIBSON CM, MORROW DA, VAN DE WERF F, MENOWN IB, GOODMAN SG, MAHAFFEY KW, COHEN M, MCCABE CH, ANTMAN EM, BRAUNWALD E (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007003523" target="_blank"&gt;Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Enoxaparin was associated with superior efficacy to UFH. Although bleeding was increased, this was offset by reductions in deaths and the incidence of MI. The benefit of enoxaparin was found in patients with STEMI; there was no difference in net clinical benefit between the treatments for non-ST elevation ACS patients. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; The review question and the inclusion criteria were clear. Only one database was searched, which makes it likely that some relevant studies were not included in the review. The &lt;SPAN style="BACKGROUND: white"&gt;authors did not report&lt;/SPAN&gt; using methods designed to minimise bias and error in the selection of studies for the review or in the extraction of data. They also did not report conducting an assessment of study validity. The decision to employ meta-analysis appears appropriate and suitable subgroup and sensitivity analyses were conducted. The authors' conclusions accurately reflect the pooled results of a number of large trials but, in view of the methodological and reporting issues outlined, it is difficult to be certain of their reliability.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;QAYYUM R, KHALID MR, ADOMAITYTE J, PAPADAKOS SP, MESSINEO FC (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008008085" target="_blank"&gt;Systematic review: comparing routine and selective invasive strategies for the acute coronary syndrome.&amp;nbsp;&lt;/A&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&amp;nbsp;Bottom-line conclusion: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;The current evidence does not clearly support the superiority of a routine invasive strategy over a selective invasive strategy to reduce mortality or nonfatal MI in patients with non-ST-segment elevation ACS.&lt;FONT face=Verdana&gt; &lt;/FONT&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;The review question was supported by clear inclusion criteria. Although several sources were searched, only peer-reviewed journals published in English were included. In addition, while publication bias was assessed, this may not be reliable because of the small number of studies included. The methods &lt;SPAN style="BACKGROUND: white"&gt;used&lt;/SPAN&gt; to select studies for inclusion in the review, assess validity and extract the data were likely to have minimised the potential for error &lt;SPAN style="BACKGROUND: white"&gt;and &lt;/SPAN&gt;bias. The validity of the included studies was assessed and the results reported. Standard meta-analytical methods were used to combine the studies and the statistical heterogeneity of the studies was assessed. In addition, the authors explored possible sources of heterogeneity. However, given the variation in population, management protocols with variable use of stents and glycoprotein IIb/IIIa inhibitors, and durations of follow-up that the authors highlighted&lt;SPAN style="BACKGROUND: white"&gt;, it&lt;/SPAN&gt; might not have been reasonable to quantitatively combine these studies. O&lt;SPAN style="BACKGROUND: white"&gt;verall,&lt;/SPAN&gt; this was a reasonably well-conducted review and the &lt;SPAN style="BACKGROUND: white"&gt;authors' cautious conclusions&lt;/SPAN&gt; are likely to be reliable.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;SINGH S, MOLNAR J, ARORA R (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion: &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;The present meta-analysis suggests that bivalirudin may be noninferior to the heparins in reducing the composite of ischemic end points. Additionally, compared to the heparins, bivalirudin monotherapy may lower the rate of major bleeding. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18172222?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;STEPHEN SA, DARNEY BG, ROSENFELD AG (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Symptoms of acute coronary syndrome in women with diabetes: an integrative review of the literature. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; There is a paucity of literature on ACS symptoms in women, particularly &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Latina&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; women, with diabetes, and results are inconclusive. Future research should examine the full range of ACS symptoms in multiethnic samples of women with diabetes. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18482629" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;WU T, HARRISON RA, CHEN X, NI J, ZHOU L, QIAO J, WANG Q, WEI,J, XIN D, ZHENG J (2008). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004474/frame.html" target="_blank"&gt;Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. &lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Tongxinluo in combination with routine angina therapy appears to reduce the risk of subsequent &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;AMI&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;, PTCA or CABG, angina attacks and severity, as well as improving symptoms and ischaemic changes on the electrocardiogram (ECG). Due to the methodological limitations of the studies, the evidence is insufficient to make any conclusive recommendations about the use of this treatment for patients presenting with unstable angina. Large high quality randomised controlled trials are warranted. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;COCHRANE PROTOCOLS&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt;BRIEL M, NORDMANN AJ, SCHWARTZ GG, DE LEMOS JA, COLIVICCHI F, DEN HARTOG F, BUCHER HC (2008). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006870/frame.html" target="_blank"&gt;Statins for acute coronary syndrome.&lt;/A&gt; The objectives of this review are: To assess the effects, both harms and benefits, of early administered statins in patients with acute coronary syndrome, in terms of mortality and cardiovascular events. &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;BRITO V, CIAPPONI A, LERMAN J (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007038/frame.html" target="_blank"&gt;Xa inhibitors for acute coronary syndromes.&lt;/A&gt; The objectives of this review are: To evaluate the efficacy and safety of actor Xa inhibitors for the treatment of patients suffering from an acute coronary syndrome.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt;XIYANG CHEN, LEI DENG, TAIXIANG WU (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007050/frame.html" target="_blank"&gt;Beta-blockers for unstable angina.&lt;/A&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;The objectives of this review are: To assess the effect of beta-blockers for treatment of unstable angina compared with other therapy or placebo. Specific comparisons will be made between beta-blockers with or without cardioselectivity, beta-blockers with or without intrinsic sympathomimetic activity, and beta-blockers with or without alpha1-adrenoceptor blockade. In addition, lipophilic and hydrophilic beta-blockers will be compared.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;CRD PROVISIONAL RECORDS&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;TARANTINI G, RAZZOLINI R, RAMONDO A, NAPODANO M, MANICA A, FAVARETTO E, ILICETO S (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008005253" target="_blank"&gt;Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome.&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;RANDOMISED CONTROLLED TRIALS *&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black"&gt;Randomised Controlled Trials published between November 2006 and November 2008 listed in PubMed on the topic of &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28%22chest+pain%22%5BMeSH+Terms%5D+OR+%28%22chest%22%5BAll+Fields%5D+AND+%22pain%22%5BAll+Fields%5D%29+OR+%22chest+pain%22%5BAll+Fields%5D%29+AND+%28%22acute+coronary+syndrome%22%5BMeSH+Terms%5D+OR+%28%22acute%22%5BAll+Fields%5D+AND+%22coronary%22%5BAll+Fields%5D+AND+%22syndrome%22%5BAll+Fields%5D%29+OR+%22acute+coronary+syndrome%22%5BAll+Fields%5D%29+AND+%28%28%222006%2F11%2F18%22%5BPDAT%5D+%3A+%222008%2F11%2F06%22%5BPDAT%5D%29+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;chest pain and acute coronary syndrome&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;FURTHER RELEVANT DOCUMENTS&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Guidance&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;American Heart Association (2008) &lt;A href="http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188950" target="_blank"&gt;Management of Cocaine-Associated Chest Pain and Myocardial Infarction: A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;American&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;College&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; of Cardiology (2007) &lt;A href="http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.107.181940v1" target="_blank"&gt;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction.&lt;/A&gt; A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina / Non–ST-Elevation Myocardial Infarction) &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;Department of Health (2008) &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;Treatment of heart attack national guidance: final report of the National Infarct Angioplasty Project (NIAP)&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NICE (2009) &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byId&amp;amp;o=11661" target="_blank"&gt;Chest pain / discomfort of recent onset&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Guideline in progress, expected date of issue February 2010&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;General&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Healthcare Commission (2008)&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/waitingtimesforrapidaccesschestpainclinic.cfm" target="_blank"&gt;Waiting times for rapid access chest pain clinic / &lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;Indicator listings for acute and specialist trusts - existing national targets 2007/2008&lt;/SPAN&gt;&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;Healthcare Commission (2008) &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/cardiovasculardiseasemortality.cfm" target="_blank"&gt;Cardiovascular Disease Mortality / Primary care trusts overview - new national targets 2007/2008&lt;/A&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Health and Social Care Information Centre (2007)&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/Services/NCASP/Heart/reports/17040107%20IC%20NationalAngioplastyAudit.pdf" target="_blank"&gt;National Coronary Angioplasty Audit A Rapidly Evolving way to Treat Patients with Heart Disease: Report on Percutaneous Coronary Intervention in the United Kingdom 2005&lt;/A&gt;&lt;SPAN style="COLOR: #6d6e70"&gt; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/clock_scenarios.html" target="_blank"&gt;Improving cardiac patients pathways: the sustainability toolkit: chest pain pathway scenarios&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=66" target="_blank"&gt;NHS Heart Improvement: Reperfusion – emergency treatment of heart attack&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Economic Evaluations&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000867" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest pain and suspected CAD&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 7.5pt; COLOR: black"&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304797</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304797]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Angina</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,STABLE ANGINA,JAN-MAR 09,CONDITIONS,CHEST PAIN,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Angina&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;ANGINA&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Dr John W Albarran&lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-weight: bold"&gt;Reader in Critical Care, University of the West of &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-weight: bold"&gt;England&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-weight: bold"&gt;, &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-weight: bold"&gt;Bristol&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;EM&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt; &lt;/SPAN&gt;&lt;/B&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here&lt;/A&gt;. &lt;/EM&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304797/nelhImp_0000_angina.jpg"&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Three systematic reviews and one meta-analysis were identified. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Angina prevalence&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18347213?dopt=Citation" target="_blank"&gt;Hemingway et al&lt;/A&gt; identified 74 studies that used the&lt;SUP&gt; &lt;/SUP&gt;Rose angina questionnaire in population-based surveys of women&lt;SUP&gt; &lt;/SUP&gt;and men, to determine angina prevalence in countries that differ in the rate of mortality due to myocardial infarction (MI). Angina prevalence data revealed a small female excess with a pooled random-effects sex ratio&lt;SUP&gt; &lt;/SUP&gt;of 1.20 (95% CI 1.14 to 1.28, &lt;I&gt;P&lt;/I&gt;&amp;lt;0.0001). This female excess was noted in countries with widely differing MI mortality rates in women. It was higher in North American studies and among non-white ethnic groups as compared to whites. Over time and at different ages, women have a similar or slightly higher prevalence of angina when compared to men across countries with variable MI mortality rates. However, there was limited data on the selected studies for inclusion, and the authors note that the Rose angina questionnaire was developed and validated for use in men.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Chinese herbal medicine&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;The use of suxiao jiuxin wan, a Chinese herbal medicine, is used in &lt;/SPAN&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;China&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt; for angina pectoris. &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004473/frame.html" target="_blank"&gt;Duan and associates&lt;/A&gt;&lt;SPAN style="COLOR: navy"&gt; reviewed&lt;/SPAN&gt;&lt;SPAN style="COLOR: black"&gt; 15 randomised controlled trials (RCTs) of &lt;/SPAN&gt;suxiao jiuxin wan (n =1776) &lt;SPAN style="COLOR: black"&gt;to determine the effects of this herbal medicine in the treatment of angina, and in comparison to other mainstay therapies. There was weak evidence for &lt;/SPAN&gt;suxiao jiuxin wan, when compared to nitroglycerin, in terms of decreases in symptoms, diastolic pressure, frequency of angina attacks and need for supplementary nitroglycerin, or improvements in the ECG. There was no difference between suxiao jiuxin wan and isosorbide dinitrate both for symptom and ECG improvements. Overall, there is weak evidence for the use of suxiao jiuxin wan alone or in combination with other, Western therapies. Larger robust trials are needed.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Perhexiline&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004003509" target="_blank"&gt;Killalea and Krum&lt;/A&gt;&lt;SPAN style="COLOR: navy"&gt; &lt;/SPAN&gt;&lt;SPAN style="COLOR: black"&gt;examined the effects and tolerability of perhexiline in the treatment of ischaemic heart disease in 36 studies (34 cross over design and two parallel-group design). Information is lacking on quality assessment and inclusion criteria for the studies, how many reviewers were involved in this process and in &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;sample composition within individual studies apart from reporting that some had uncontrolled angina or MI. Despite the absence of well designed RCTs, there is consistency within the available studies suggesting superiority of perhexiline compared with placebo for angina sufferers. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Psychoeducational interventions&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;By contrast, &lt;A href="http://www.ingentaconnect.com/content/ben/ccr/2008/00000004/00000001/art00001;jsessionid=104qjfara3lti.alexandra?format=print&amp;amp;token=005311eef757e6f3f2f2730673f582f6b6d383a4b3b257b6e7b457a7a386f2c49675df56e8fe38e1205" target="_blank"&gt;McGillon&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: navy; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;undertook a meta-analysis to determine effectiveness of psychoeducational interventions for improving symptoms, health-related quality of life &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;(HRQL)and psychological well being among stable angina patients. Analysis of seven trials concluded that patients receiving psychoeducation experienced less episodes of angina and used sublingual nitrates less often at 3-6 months after the intervention. Significant (HQRL) improvements in physical limitation and illness perceptions were noted, although confidence intervals were broad. Estimates of psychological outcomes proved difficult due to the heterogeneity of measures used. Sample size and heterogeneity of methods limit &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt"&gt;generalisation&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;. Further, larger scale studies may determine the effectiveness of these low cost measures in improving the management of angina patients.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;SYSTEMATIC REVIEWS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;DUAN X, ZHOU L, WU T, LIU G, QIAO J, WEI J, NI J, ZHENG J, CHEN X, WANG Q (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004473/frame.html" target="_blank"&gt;Chinese herbal medicine suxiao jiuxin wan for angina pectoris.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Suxiao jiuxin wan appears to be effective in the treatment of angina pectoris and no serious side effects were identified. However, the evidence remains weak due to poor methodological quality of including studies.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;HEMINGWAY H, LANGENBERG C, DAMANT J, FROST C, PYORALA K, BARRETT-CONNOR E (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Over time and at different ages, independent of diagnostic and treatment practices, women have a similar or slightly higher prevalence of angina than men across countries with widely differing myocardial infarction mortality rates. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18347213?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;KILLALEA SM, KRUM H (2006).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; &lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004003509" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.&lt;/SPAN&gt;&lt;/A&gt; &lt;/SPAN&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Bottom-line conclusion: &lt;/SPAN&gt;&lt;/STRONG&gt;Despite a lack of well-designed trials, there is consistency in data suggesting that perhexiline, when used alone, is more effective than placebo for angina. It also gives some additional relief to those taking conventional anti-angina therapy. There is insufficient evidence on the effects of low dosages (100 to 200 mg/day). Evidence suggests that adverse effects can be minimised by keeping plasma perhexiline concentrations withing a therapeutic range of 150 to 600 microg/L. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD Commentary:&lt;/B&gt; The aims of this review were not fully stated in that inclusion criteria were not given for the participants and outcomes. The search seemed comprehensive and the authors made attempts to identify studies that might not have been available from major databases. The methods of the review (study selection, data extraction) were not described; bias may be introduced into the review at these stages. No details of any quality assessment were given. In addition, there was little information on the participants in the included studies, and it may therefore be difficult to generalise from the results of this review. The authors chose to synthesis the results in a narrative and grouped the studies appropriately for this. However, as part of the narrative synthesis, they used a simple vote counting approach to combine information from the studies. It would have been interesting to see a formal pooled analysis of those placebo-controlled studies that assessed similar outcomes. The authors also acknowledged that the included studies were small and short term. In view of this, and the comments above, the authors' conclusions should be treated with caution.&lt;B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;MCGILLION M, ARTHUR H, VICTOR JC, WATT-WATSON J, COSMAN T (2008). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Effectiveness of psychoeducational interventions for improving symptoms, health-related quality of life, and psychological well being in patients with stable angina. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Psychoeducational interventions may significantly reduce angina frequency and decrease SL nitrate use in the short-term. These encouraging results must be interpreted with caution due to heterogeneity in methods and small samples. Larger, robust trials are needed to further determine the effectiveness of psychoeducation for stable angina management. &lt;A href="http://www.ingentaconnect.com/content/ben/ccr/2008/00000004/00000001/art00001;jsessionid=104qjfara3lti.alexandra?format=print&amp;amp;token=005311eef757e6f3f2f2730673f582f6b6d383a4b3b257b6e7b457a7a386f2c49675df56e8fe38e1205" target="_blank"&gt;Abstract from Current Cardiology Reviews.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;COCHRANE PROTOCOLS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;AMIN F, AL HAJERI A, CIVELEK B, FEDOROWICZ Z, MANZER BM (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007219/frame.html" target="_blank"&gt;Enhanced external counterpulsation for chronic angina pectoris.&lt;/A&gt; The objectives of this Cochrane review are: To provide reliable evidence for the effectiveness and safety of enhanced external counterpulsation therapy in improving health outcomes for patients with chronic stable or refractory stable angina pectoris.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;CRD PROVISIONAL RECORDS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;WANG G, WANG L, XIONG ZY, MAO B, LI TQ (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006000585" target="_blank"&gt;Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis&lt;/A&gt;. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;RANDOMISED CONTROLLED TRIALS*&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt"&gt;Randomised Controlled Trials published between November 2006 and November 2008 listed in PubMed on the topic of &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=18" target="_blank"&gt;angina&lt;/A&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;FURTHER RELEVANT DOCUMENTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Guidance&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;American&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;College&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; of Cardiology / American Heart Association (2007) &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://circ.ahajournals.org/cgi/content/full/116/23/2762#FIG1187930" target="_blank"&gt;2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina.&lt;/A&gt; A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;American&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;College&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; of Cardiology (2007) &lt;A href="http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.107.181940v1" target="_blank"&gt;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction.&lt;/A&gt; A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Department of Health (2008) &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;Treatment of heart attack national guidance: final report of the National Infarct Angioplasty Project (NIAP)&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;European Society of Cardiology (2006) &lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf" target="_blank"&gt;Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NICE (2009) &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byId&amp;amp;o=11661" target="_blank"&gt;Chest pain / discomfort of recent onset&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Guideline in progress, expected date of issue&amp;nbsp;February 2010&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Scottish Intercollegiate Guidelines Network&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;(2007) &lt;A href="http://www.sign.ac.uk/pdf/sign96.pdf" target="_blank"&gt;Management of stable angina: a national clinical guideline&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&amp;nbsp;&lt;/B&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=NormalWeb2&gt;&lt;SPAN style="FONT-FAMILY: Symbol; COLOR: black; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-fareast-font-family: Symbol"&gt;&lt;SPAN style="mso-list: Ignore"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=NormalWeb2&gt;&lt;SPAN style="FONT-FAMILY: Symbol; COLOR: black; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-fareast-font-family: Symbol"&gt;&lt;SPAN style="mso-list: Ignore"&gt;·&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="COLOR: black"&gt;General&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Batista DCS,&amp;nbsp;et al&amp;nbsp;(2008). &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Pain similarities and differences in the chest syndromes: systematic literature review.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18822764" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: navy; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN&gt;Cheng&amp;nbsp;JW (2006). Ranolazine for the management of coronary artery disease. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17296457" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Healthcare Commission (2008)&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/waitingtimesforrapidaccesschestpainclinic.cfm" target="_blank"&gt;Waiting times for rapid access chest pain clinic / &lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;Indicator listings for acute and specialist trusts - existing national targets 2007/2008&lt;/SPAN&gt;&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Healthcare Commission (2008) &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/cardiovasculardiseasemortality.cfm" target="_blank"&gt;Cardiovascular Disease Mortality / Primary care trusts overview - new national targets 2007/2008&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Health and Social Care Information Centre (2007)&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/Services/NCASP/Heart/reports/17040107%20IC%20NationalAngioplastyAudit.pdf" target="_blank"&gt;National Coronary Angioplasty Audit A Rapidly Evolving way to Treat Patients with Heart Disease: Report on Percutaneous Coronary Intervention in the United Kingdom 2005&lt;/A&gt;&lt;SPAN style="COLOR: #6d6e70"&gt; &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Henry TD, et al (2007).&lt;SPAN style="mso-spacerun: yes"&gt;&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/SPAN&gt;Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17825712?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/clock_scenarios.html" target="_blank"&gt;Improving cardiac patients pathways: the sustainability toolkit: chest pain pathway scenarios&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=66" target="_blank"&gt;NHS Heart Improvement: Reperfusion – emergency treatment of heart attack&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Wenger NK, et al (2008). Coronary heart disease in women: update 2008.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18043680?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Zerumsky K, McBride BF (2006).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Ranolazine in the management of chronic stable angina. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17106005?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Economic Evaluations&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007006125" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Incremental cost-effectiveness of exercise echocardiography vs SPECT imaging for the evaluation of stable chest pain&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000602" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;The burden of angina pectoris and its complications&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007002107" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Economic considerations in managing patients with chronic stable angina&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000867" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest pain and suspected CAD&lt;/SPAN&gt;&lt;/A&gt; : &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007008064" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22006001476" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Direct hospital costs of chest pain patients attending the emergency department: a retrospective study&lt;/SPAN&gt;&lt;/A&gt; &lt;/SPAN&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000691" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain&lt;/SPAN&gt;&lt;/A&gt; &lt;/SPAN&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; FONT-WEIGHT: normal; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -18pt; MARGIN-LEFT: 36pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=NormalWeb2&gt;&lt;SPAN style="FONT-FAMILY: Symbol; COLOR: black; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-fareast-font-family: Symbol"&gt;&lt;SPAN style="mso-list: Ignore"&gt;·&lt;SPAN style="FONT: 7pt 'Times New Roman'"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="COLOR: black"&gt;Patient Information&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;FONT color=#000066&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NHS CKS (2009)&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;A href="http://www.cks.library.nhs.uk/angina/view_whole_topic" target="_blank"&gt;Primary care management of people with stable angina&lt;/A&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/SPAN&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 7.5pt"&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>305791</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=305791]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Contributors</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,PREVENTION,PREVENTION,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DIAGNOSIS,DIAGNOSIS,STABLE ANGINA,OTHER,PREVENTION,DIAGNOSIS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,UNSTABLE ANGINA,JAN-MAR 09,CONDITIONS,CHEST PAIN,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C O N T R I B U T O R S&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305791/nelhImp_0000_contributors.gif" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;The following contributors participated in the 2009&amp;nbsp;Annual Evidence Update on Chest Pain&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dr John W Albarran, Reader in Critical Care Nursing, University of the West of England, Bristol &lt;/LI&gt;
&lt;LI&gt;Professor Steve Goodacre, Professor of Emergency Medicine, School of Health and Related Research, University of Sheffield&lt;/LI&gt;
&lt;LI&gt;Dr Ian Jones, Senior Lecturer in Cardiac Nursing, University of Salford&lt;/LI&gt;
&lt;LI&gt;Dr Sunil Nadar, Specialist Registrar in Cardiology, New Cross Hospital, Wolverhampton&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Alison Pottle, Consultant Nurse in Cardiology, Royal Brompton and Harefield NHS Trust&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;T H E&amp;nbsp;&amp;nbsp; C V D S L&amp;nbsp;&amp;nbsp; P R O J E C T&amp;nbsp;&amp;nbsp; T E A M&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Professor Tom Quinn, Professor of Clinical Practice, University of Surrey&lt;/LI&gt;
&lt;LI&gt;Ann Daly, Information Specialist&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304799</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304799]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Diagnosis and risk stratification</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIAGNOSIS,CONDITIONS,CHEST PAIN,GENERAL,GENERAL,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,DIAGNOSIS,DIAGNOSIS,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,DIAGNOSIS,CAUSES AND RISK FACTORS,DIAGNOSIS,STABLE ANGINA,OTHER,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Diagnosis and risk stratification&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;D I A G N O S I S&amp;nbsp; &amp;amp;&amp;nbsp; R I S K&amp;nbsp; S T R A T I F I C A T I O N&lt;/STRONG&gt;&lt;BR&gt;&lt;SPAN&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;STRONG&gt;Dr Sunil Nadar&lt;BR&gt;&lt;/STRONG&gt;Specialist Registrar in&amp;nbsp;Cardiology,&amp;nbsp;Newcross Hospital, Wolverhampton&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; LETTER-SPACING: 1.2pt; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here&lt;/A&gt;. &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304799/nelhImp_0000_HFNKWdiagnosis.jpg"&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;STRONG&gt;&lt;U&gt;EXPERT SUMMARY&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;We identified 14 reviews on diagnosis of ischaemic heart disease (IHD).&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Clinical diagnosis&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Missed diagnosis and mis-diagnosis have serious implications. Given the time constraints, making any diagnosis in a primary care setting can be difficult.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18842618?dopt=Citation" target="_blank"&gt;Kostopoulou et al&lt;/A&gt; performed a systematic review of the difficulty and error in making any diagnosis in a primary care setting. They investigated conditions such as anaemia, malignancies and myocardial infarctions (MI). They felt that it was not usually possible to determine how to prevent delay in diagnosis and referral. Atypical presentations, the presence of comorbidity&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;and the low prevalence of some conditions contributed to the misdiagnosis. They have however not made any suggestions to help overcome the problem. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18822764?dopt=Citation" target="_blank"&gt;Batista et al&lt;/A&gt; and &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18307844?dopt=Citation" target="_blank"&gt;Bruyninckx et al&lt;/A&gt; undertook a review to determine if there were specific characteristics of chest pain that would help differentiate various causes such as dissecting aneurysm, pericarditis and acute MI. No features were characteristic of any one diagnosis except for chest wall tenderness which effectively ruled out IHD. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Non invasive testing and imaging&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18203117?dopt=Citation" target="_blank"&gt;Southard et al&lt;/A&gt;&amp;nbsp;compared exercise treadmill testing and exercise stress echocardiography. In patients with chest pain with a normal baseline ECG and able to exercise for 6 minutes, exercise testing was able to rule out significant IHD. They suggest that stress echocardiography should be reserved as the initial test for patients with an abnormal baseline ECG or with reduced exercise capacity. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18669550?dopt=Citation" target="_blank"&gt;Mowatt et al&lt;/A&gt; concluded that 64 slice computed tomography (CT) angiography had a high sensitivity (99%), high specificity (89%) and negative predictive value (NPV) (100%) and suggest that this test be used when the diagnosis remains unclear despite clinical evaluation and simple non invasive testing. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19083882" target="_blank"&gt;Raff et al&lt;/A&gt; also found high sensitivity (96%), high NPV (94%) and moderate specificity (74%) and positive predictive value (PPV) (83%) for multislice CT (MSCT). These studies support the use of this modality to rule out significant IHD. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18669550?dopt=Citation" target="_blank"&gt;Mowat et al&amp;nbsp;&lt;/A&gt; also performed a cost benefit analysis for the diagnosis of IHD using MSCT. They found this almost as good as coronary angiography in terms of detecting true positives, but it was somewhat poorer in terms of false positives. Angiography however provides other significant information, especially in patients with previous coronary grafts. The high sensitivity of MSCT avoids the costs of unnecessary angiography in those referred for investigation but who do not have IHD (i.e. in those with a low pre-test probability of the disease). Given the small but possible mortality rate with angiography, the authors suggest a small survival benefit with MSCT that might it cost effective in the long run. Avoidance of unnecessary angiography through use of MSCT also appears likely to result in overall cost savings. Only if both the cost of angiography is relatively low and the prevalence of coronary artery disease in the presenting population is relatively high (so that more people will go on to have angiography), will CT be more expensive. However it is unlikely that CT will totally replace angiography, as often angiography and angioplasty may be done in the same procedure. Also, angiography is ultimately required if the CT shows significant disease. CT still has a role where the pre-test likelihood is low and patient has a strong dislike of an invasive test. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;In the acute setting &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18093295?dopt=Citation" target="_blank"&gt;Vanboenacker et al&lt;/A&gt; found that MSCT scanning had a pooled sensitivity of 95% and specificity of 90% to rule out an acute coronary syndrome or unstable angina. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Other imaging modalities have also been studied. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18513641?dopt=Citation" target="_blank"&gt;Inaba et al&lt;/A&gt;&amp;nbsp; suggest that imaging with beta methyl-p-[123l]-iodophenyl-pentadecanoic acid (BMIPP) has moderate sensitivity (78%), and specificity (84%) and may be of value in patients who may not be candidates for exercise testing and myocardial perfusion imaging. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Laboratory tests and biomarkers&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;Laboratory tests for the diagnosis of IHD have also been evaluated. &lt;A href="http://translate.google.co.uk/translate?hl=en&amp;amp;sl=zh-CN&amp;amp;u=http://www.cjebm.org.cn/oa/DArticle.aspx%3Ftype%3Dview%26id%3D0403&amp;amp;sa=X&amp;amp;oi=translate&amp;amp;resnum=2&amp;amp;ct=result&amp;amp;prev=/search%3Fq%3DHuman%2Bheart-type%2Bfatty%2Bacid-binding%2Bprotein%2Bfor%2Bearly%2Bdetection%2Bof%2Bacute%2Bmyocardial%2Binfarction:%2BA%2Bsystematic%2Breview%26hl%3Den%26sa%3DG" target="_blank"&gt;Liu et al&lt;/A&gt; found that Human heart type fatty acid binding protein has acceptable diagnostic accuracy within 3 hours of symptoms onset, and high diagnostic efficacy within 12 hours, for diagnosis of MI (pooled sensitivity of 86% and specificity of 76% within the first 6 hours and 97% and 52% respectively for the group between 6 and 12 hours). &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB"&gt;The prognostic value of these tests has also been evaluated. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17222734?dopt=Citation" target="_blank"&gt;Metz et al&lt;/A&gt; performed a meta analysis of the prognostic value of a normal exercise myocardial perfusion imaging (MPI) and exercise echocardiography. MPI and stress echocardiogram had negative predictive values for myocardial infarction and cardiac death at 98% and 98.8% over 36 months respectively. These values were similar for men and women. &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;SYSTEMATIC REVIEWS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;/o:p&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Bruyninckx R, Aertgeerts B, Bruyninckx P, Buntinx F (2008).&lt;/STRONG&gt; Signs and symptoms in diagnosing acute myocardial infarction and acute coronary syndrome: a diagnostic meta-analysis. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on this meta-analysis it was not possible to define an important role for signs and symptoms in the diagnosis of acute myocardial infarction or acute coronary syndrome. Only chest-wall tenderness on palpation largely ruled out acute myocardial infarction or acute coronary syndrome in low-prevalence settings. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18307844?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;STRONG&gt;El-Serag H, Hill C, Jones R (2008).&amp;nbsp;&lt;/STRONG&gt;&lt;/SPAN&gt;Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care - a review of studies using the &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;UK&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; General Practice Research Database. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;The General Practice Research Database is an effective way of studying the epidemiology of gastro-oesophageal reflux disease in a large population-based primary care setting. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Aliment%20Pharmacol%20Ther%20%5BJour%5D%20AND%202008%2F11%2F25%5Bpdat%5D%20AND%20Systematic%20review%3A%20the%20epidemiology%20of%20gastro-oesophageal%20reflux%20disease%20in%20primary%20care%20-%20a%20review%20of%20studies%20using%20the%20UK%20General%20Practice%20Research%20Database" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;STRONG&gt;Inaba Y, Begmann SR (2008).&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a meta-analysis. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Imaging with BMIPP at rest exhibits a moderate sensitivity and high specificity to detect CAD in patients with a high prevalence of CAD. Thus, this tracer may be of great value for patients with acute chest pain and those with relative contraindications to exercise or pharmacologic stress myocardial perfusion imaging (MPI). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18513641?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Kostopoulou O, Delaney BC, Munro CW (2008).&lt;/STRONG&gt; Diagnostic difficulty and error in primary care, a systematic review. &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt;&lt;/SPAN&gt; &lt;SPAN style="FONT-SIZE: 10pt"&gt;Misdiagnosis in primary care covers a wide range of conditions that may be related in the manner in which they present. The challenge is to identify ways of supporting the diagnostic process in potentially difficult presentations. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18842618?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Liu J, Wang Q, Geng RW, Zeng FY, Zhang P (2007).&lt;/STRONG&gt; Human heart-type fatty acid-binding protein for early detection of acute myocardial infarction: a systematic review. &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;In this systematic review, we found that human heart-type fatty acid-binding protein (H-FABP) has an acceptable diagnostic accuracy within 3 hours after the onset of symptoms, and within 12 hours after the onset of symptoms, H-FABP has a high diagnostic efficacy. So H-FABP may be a new symbol for the early diagnosis of AMI. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://translate.google.co.uk/translate?hl=en&amp;amp;sl=zh-CN&amp;amp;u=http://www.cjebm.org.cn/oa/DArticle.aspx%3Ftype%3Dview%26id%3D0403&amp;amp;sa=X&amp;amp;oi=translate&amp;amp;resnum=2&amp;amp;ct=result&amp;amp;prev=/search%3Fq%3DHuman%2Bheart-type%2Bfatty%2Bacid-binding%2Bprotein%2Bfor%2Bearly%2Bdetection%2Bof%2Bacute%2Bmyocardial%2Binfarction:%2BA%2Bsystematic%2Breview%26hl%3Den%26sa%3DG" target="_blank"&gt;Abstract from CJEBM 2007 (4) 251-258.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: DE" lang=DE&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: DE" lang=DE&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: DE" lang=DE&gt;&lt;STRONG&gt;Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE &lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;(2007).&lt;/STRONG&gt; The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt;&lt;/SPAN&gt; &lt;SPAN style="FONT-SIZE: 10pt"&gt;Both exercise MPI and exercise echocardiography have high NPVs for primary and secondary cardiac events. The prognostic utility of both modalities is similar for both men and women. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17222734?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, Hillis GS, Fraser C (2008).&lt;/STRONG&gt; Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; The main value of 64-slice CT may at present be to rule out significant CAD. It is unlikely to replace CA in assessment for revascularisation of patients, particularly as angiography and angioplasty are often done on the same occasion. Further research is needed into the marginal advantages and costs of 256-slice machines compared with 64-slice CT, the usefulness of 64-slice CT in people with suspected acute coronary syndrome, the potential of multislice computed tomography to examine plaque morphology, the role of CT in identifying patients suitable for CABG, and the concerns raised about repetitive use, or use of 64-slice or higher CT angiography in younger individuals or women of childbearing age. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18462576" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Mowatt G, Cook JA, Hillis GS, Walker S, Fraser C, Jia X, Waugh N (2008).&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; &lt;/SPAN&gt;&lt;st1:Street&gt;&lt;st1:address&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;64-Slice CT&lt;/SPAN&gt;&lt;/st1:address&gt;&lt;/st1:Street&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; is highly sensitive for patient-based detection of CAD and has high NPV. An ability to rule out significant CAD means that it may have a role in the assessment of chest pain, particularly when the diagnosis remains uncertain despite clinical evaluation and simple non-invasive testing. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18669550?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: DE; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'" lang=DE&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Raff GL (2007).&lt;/STRONG&gt; Interpreting the evidence: How accurate is coronary computed tomography angiography? &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; Clinical studies support the effectiveness of CTA for exclusion of significant coronary disease. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19083882" target="_blank"&gt;PubMed abstract&amp;nbsp;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: DE; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'" lang=DE&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: DE; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'" lang=DE&gt;&lt;STRONG&gt;Rizkallah J, Man SF, Sin DD &lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;STRONG&gt;(2008).&lt;/STRONG&gt; Prevalence of Pulmonary Embolism in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; One out of four COPD patients who require hospitalization for an acute exacerbation may have PE. A diagnosis of PE should be considered in patients with exacerbation severe enough to warrant hospitalization, especially in those with an intermediate to high pre-test probability of PE.&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812453?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: FR" lang=FR&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: FR" lang=FR&gt;&lt;STRONG&gt;Santoro Batista DC, Pimenta CA &lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;(2008).&lt;/STRONG&gt; Pain similarities and differences in the chest syndromes, systematic literature review. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; No conclusive studies on the characterization of chest pain diagnosis were found. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18822764?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Southard J, Baker L, Schaefer S (2008).&lt;/STRONG&gt; In search of the false-negative exercise treadmill testing evidence-based use of exercise echocardiography. &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; These findings support the use of the ETT without imaging as the initial test in patients with chest pain who have a normal baseline ECG and are able to exercise 6 min. Using these criteria, false negative findings are generally seen in patients without critical large vessel epicardial disease. The ESE should be reserved as the initial test for patients with an abnormal baseline ECG or reduced functional capacity. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18203117?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;st1:Street&gt;&lt;st1:address&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/st1:address&gt;&lt;/st1:Street&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;st1:Street&gt;&lt;st1:address&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Vanhoenacker PK&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/st1:address&gt;&lt;/st1:Street&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;, Decramer I, Bladt O, Sarno G, Bevernage C, Wijns W (2007).&lt;/STRONG&gt; Detection of non-ST-elevation myocardial infarction and unstable angina in the acute setting: meta-analysis of diagnostic performance of multi-detector computed tomographic angiography. &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Multi-detector computed tomography angiography (MDCTA) of the coronary arteries performs good to excellent in the diagnosis of coronary artery disease in the acute setting and it can be used for early exclusion of NSTEMI or unstable angina pectoris in patients in the emergency department. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18093295?dopt=Citation" target="_blank"&gt;PubMed abstract&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;CRD PROVISIONAL RECORDS&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;McKeogh JR (2008).&lt;/STRONG&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007003199" target="_blank"&gt;The diagnostic role of stress echocardiography in women with coronary artery disease: evidence based review.&lt;/A&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt; mso-bidi-font-family: Arial"&gt;RANDOMISED CONTROLLED TRIALS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt"&gt;Randomised Controlled Trials published between November 2006 and November 2008 listed in PubMed on the topic of &lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=17" target="_blank"&gt;chest pain, diagnosis and risk stratification.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'"&gt;&lt;BR&gt;&amp;nbsp; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt; mso-bidi-font-family: Arial"&gt;FURTHER RELEVANT DOCUMENTS&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;B&gt;Guidance&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;American&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt; &lt;/SPAN&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;College&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt; of Cardiology / American Heart Association (2007). &lt;A href="http://circ.ahajournals.org/cgi/content/full/116/23/2762#FIG1187930" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; tab-stops: 285.75pt" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&amp;nbsp; &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;American&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt; &lt;/SPAN&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;College&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt; of Cardiology / American Heart Association (2007). &lt;A href="http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.107.181940v1" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&amp;nbsp;&lt;BR&gt;American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology (2008). &lt;A href="http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188950" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Management of Cocaine-Associated Chest Pain and Myocardial Infarction: A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;BR&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Department of Health (2008) &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;Treatment of heart attack national guidance: final report of the National Infarct Angioplasty Project (NIAP)&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;European Society of Cardiology (2006). &lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;NICE (2009). &lt;U&gt;&lt;SPAN style="COLOR: blue"&gt;Chest pain / discomfort of recent onset &lt;/SPAN&gt;&lt;/U&gt;Guideline in progress, expected date of issue Guideline in progress, expected date of issue February 2010&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;Scottish Intercollegiate Guidelines Network (2007). &lt;A href="http://www.sign.ac.uk/pdf/sign96.pdf" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Management of stable angina: a national clinical guideline&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;Economic Evaluations&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2008).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101740" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain : provisional abstract&lt;/SPAN&gt;&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2008).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007006581" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Reimbursement for chest-pain CT: estimates based on current imaging strategies / Cost study&lt;/SPAN&gt;&lt;/A&gt;&lt;BR style="mso-special-character: line-break"&gt;&lt;BR style="mso-special-character: line-break"&gt;&lt;/P&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2007).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007002068" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain: provisional abstract &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;BR&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2007).&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007006125" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Incremental cost-effectiveness of exercise echocardiography vs SPECT imaging for the evaluation of stable chest pain: provisional abstract &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;BR&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2007).&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000867" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest pain and suspected CAD: cost analysis&amp;nbsp; / Economic Evaluation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;BR&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;NHS Economic Evaluation Database (2007).&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007000867" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain / Partial Economic Evaluation&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l3 level1 lfo3; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;General&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;Healthcare Commission (2008).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/cardiovasculardiseasemortality.cfm" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Cardiovascular Disease Mortality / Primary care trusts overview - new national targets 2007/2008 &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;BR&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;Healthcare Commission (2008).&lt;/SPAN&gt; &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/waitingtimesforrapidaccesschestpainclinic.cfm" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Waiting times for rapid access chest pain clinic / Indicator listings for acute and specialist trusts - existing national targets 2007/2008&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;Health and Social Care Information Centre (2007).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.ic.nhs.uk/webfiles/Services/NCASP/Heart/reports/17040107%20IC%20NationalAngioplastyAudit.pdf" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;National Coronary Angioplasty Audit A Rapidly Evolving way to Treat Patients with Heart Disease: Report on Percutaneous Coronary Intervention in the United Kingdom 2005 (Published 2007)&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/clock_scenarios.html" target="_blank"&gt;Improving cardiac patients pathways: the sustainability toolkit: chest pain pathway scenarios&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=66" target="_blank"&gt;NHS Heart Improvement: Reperfusion – emergency treatment of heart attack&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;NIHR Health Technology Assessment Programme (2008).&lt;/SPAN&gt; &lt;A href="http://www.hta.ac.uk/1715" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Enhanced External Counterpulsation (EECP) for the treatment of stable angina and heart failure: a systematic review and economic analysis &lt;/SPAN&gt;&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;This project is at the editorial review stage, the expected date of publication is May 2009.&lt;o:p&gt;&lt;/o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="TEXT-INDENT: 36pt; MARGIN-LEFT: 18pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo4; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;Patient information&lt;/SPAN&gt;&lt;/B&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;NHS CKS (2008).&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt; &lt;A href="http://www.cks.library.nhs.uk/angina#171732001" target="_blank"&gt;&lt;SPAN style="mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;Primary care management of people with stable angina &lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 10pt; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt"&gt;UK Clinical Research Network&lt;/SPAN&gt;&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;SPAN style="FONT-FAMILY: Verdana; mso-ansi-font-size: 10.0pt; mso-bidi-font-size: 10.0pt"&gt;Current Controlled Trials&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 7.5pt"&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: black; FONT-SIZE: 9pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304802</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304802]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Emergency Care</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,GENERAL  / OVERVIEWS,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,CHEST PAIN (PLEURITIC),CHEST PAIN (ATYPICAL),ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,GENERAL / OVERVIEWS,GENERAL / OVERVIEWS,OTHER,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Emergency Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;E M E R G E N C Y&amp;nbsp; C A R E&lt;/STRONG&gt;&lt;BR&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Professor Steve Goodacre&lt;BR&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;Professor of Emergency Medicine, &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;School&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt; of &lt;/SPAN&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;Health&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt; and Related Research, &lt;/SPAN&gt;&lt;st1:place&gt;&lt;st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;University&lt;/SPAN&gt;&lt;/st1:PlaceType&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt; of &lt;/SPAN&gt;&lt;st1:PlaceName&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;Sheffield&lt;/SPAN&gt;&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;&lt;I&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here&lt;/A&gt;. &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /&gt;&lt;v:shapetype id=_x0000_t75 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"&gt;&amp;nbsp;&lt;v:stroke joinstyle="miter"&gt;&lt;/v:stroke&gt;&lt;v:formulas&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;/v:f&gt;&lt;/v:formulas&gt;&lt;v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"&gt;&lt;/v:path&gt;&lt;o:lock v:ext="edit" aspectratio="t"&gt;&lt;/o:lock&gt;&lt;/v:shapetype&gt;&lt;v:shape id=_x0000_i1025 style="WIDTH: 90pt; HEIGHT: 63.75pt" type="#_x0000_t75"&gt;&lt;v:imagedata src="file:///C:\DOCUME~1\library\LOCALS~1\Temp\msohtml1\01\clip_image001.jpg" o:title="ec"&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304802/nelhImp_0000_ec.jpg" name=nelh_tempImage0&gt;&lt;/v:imagedata&gt;&lt;/v:shape&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Two relevant systematic reviews were published in 2008. &lt;A href="http://www.accessmylibrary.com/coms2/summary_0286-34730737_ITM" target="_blank"&gt;Hess et al&lt;/A&gt; reviewed clinical prediction rules based on clinical features, electrocardiogram (ECG) and cardiac biomarkers for acute coronary syndrome (ACS) in the emergency department and identified eight studies meeting their inclusion criteria. The studies had substantial methodological limitations, such as lack of verification against an independent reference standard, lack of blinding and lack of prospective validation. The clinical prediction rules appeared to be useful for ruling out ACS when negative, as indicated by negative likelihood ratios of 0.01 to 0.17, but little value for ruling in ACS, with positive likelihood ratios of 1.1 to 2.2. These findings suggest that clinical prediction rules based on clinical assessment, ECG and cardiac biomarkers could be used to exclude ACS in the emergency department. Many would argue that unstructured assessment by an experienced clinician with access to ECG and cardiac biomarkers would achieve the same goal without requiring a clinical prediction rule.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Coronary reperfusion can provide substantial benefit in patients with myocardial infarction who present with left bundle branch block, but diagnosis presents a challenge because many patients with heart disease have pre-existing left bundle branch block. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18342992" target="_blank"&gt;Tabas et al&lt;/A&gt; reviewed studies evaluating the Sgarbossa criteria for diagnosing acute myocardial infarction in the presence of left bundle branch block and identified eleven relevant studies. A Sgarbossa score of 3 or more provides powerful but not conclusive evidence of myocardial infarction with a likelihood ratio of 7.9. This score represents either 1mm or more of ST elevation concordant with the QRS complex or 1mm or more of ST depression in leads V1, V2 or V3. Other Sgarbossa criteria were much less useful with likelihood ratios close to 1 and substantial heterogeneity between studies.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Two randomised trials published in 2008 evaluated the effect of using point-of-care, as opposed to laboratory, cardiac markers in the assessment of acute chest pain. &lt;A href="http://www3.interscience.wiley.com/journal/119413652/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Renaud et al&lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;found that point-of-care troponin testing was associated with a 45 minutes decrease in the time delay before anti-ischaemic therapy in patients with non-ST elevation acute coronary syndrome. The association between time delay and effectiveness of anti-ischaemic therapy is not well established, unlike time delays in reperfusion for ST-elevation myocardial infarction. So it is not clear whether the reduction in time delay achieved by point-of-care testing is clinically meaningful.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=Annals%20of%20emergency%20medicine%5bJour%5d%20AND%202008%5bpdat%5d%20AND%20Ryan%5bauthor%5d" target="_blank"&gt;Ryan et al&lt;/A&gt; found in a multi-centre study that using point-of-care markers had no overall effect on length of stay in the emergency department. Effects varied between centres and patient groups with point-of-care testing being associated with reduced time to admission in one hospital and increased time to discharge in another. This reflects similar findings in previous studies of chest pain assessment. Routine practice in chest pain assessment varies substantially between hospitals so it is perhaps not surprising that the effect of interventions in chest pain assessment can show similar variation. This emphasises the importance of considering the applicability of findings from research studies to the local setting. An intervention that reduces time delays or admissions in one setting may have the opposite effect in another.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;SYSTEMATIC REVIEWS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt;HESS EP, THIRUGANASAMBANDAMOORTHY V, WELLS GA, ERWIN P, JAFFE AS, HOLLANDER JE, MONTORI VM, STIELL IG (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Diagnostic accuracy of clinical prediction rules to exclude acute coronary syndrome in the emergency department setting: a systematic review. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Current prediction rules for ACS have substantial methodological limitations and have not been successfully implemented in the clinical setting. Future methodologically sound studies are needed to guide clinical practice. &lt;A href="http://www.accessmylibrary.com/coms2/summary_0286-34730737_ITM" target="_blank"&gt;Abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;LAU J, IOANNIDIS JP, BALK E, MILCH C, CHEW P, TERRIN N, LANG TA, &lt;/SPAN&gt;&lt;/B&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;SALEM&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; D, WONG JB (2006). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12001008441" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-family: Arial"&gt;Evaluation of technologies for identifying acute cardiac ischemia in emergency departments.&lt;/SPAN&gt;&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion: &lt;/B&gt;No single technology is able to identify all ACI patients whilst avoiding hospitalisation of many patients without ACI. Research was characterised by heterogeneity and poor reporting. Some technologies remain underevaluated and little research has been conducted on sequential or combination testing. The clinical impact of testing has been inadequately addressed. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; This review addressed a clearly stated question. Broad inclusion criteria were defined in respect of the technologies and study populations assessed. No inclusion criteria relating to the reference standard were specified, and a number of different definitions of disease appear to have been used in the included studies. Although a large number of studies were included, the restriction of the search to studies published in English as full papers and the searching of only one bibliographic database might have resulted in incomplete retrieval of the available data. Full details of the included studies and evidence grading were given in the report, and appropriate measures were taken to avoid the introduction of biases during the review process. Given the apparent differences in key study characteristics (e.g. reference standard) and the lack of a reported method for assessing between-study heterogeneity, the presentation of pooled accuracy estimates may be of limited value. The authors' conclusions are suitably cautious given the limitations outlined.&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-ansi-language: DE"&gt;TABAS JA, RODRIGUEZ RM, SELIGMAN HK, GOLDSCHLAGER NF (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Electrocardiographic criteria for detecting acute myocardial infarction in patients with left bundle branch block: a meta-analysis. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; A Sgarbossa ECG algorithm score of greater than or equal to 3, representing greater than or equal to 1 mm of concordant ST elevation or greater than or equal to 1 mm ST depression in leads V1 to V3, is useful for diagnosing acute myocardial infarction in patients who present with left bundle branch block on ECG. The scoring system demonstrates good to excellent overall interobserver variability. A score of 2, representing 5 mm or more of discordant ST deviation, demonstrated ineffective positive likelihood ratios. A Sgarbossa ECG algorithm score of 0 is not useful in excluding acute myocardial infarction. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18342992" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;RANDOMISED CONTROLLED TRIALS *&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;SPAN class=name1&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;BERTRAND RENAUD et al (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;SPAN class=name1&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: #333333; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;Impact of Point-of-care Testing in the Emergency Department Evaluation and Treatment of Patients with Suspected Acute Coronary Syndromes. &lt;B&gt;Bottom-line conclusion:&lt;/B&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;Point-of-care testing for cTnI measurement might be clinically relevant for ED patients with a suspicion of NSTE-ACS, particularly for high-risk patients with a low suspicion of ACS. &lt;A href="http://www3.interscience.wiley.com/journal/119413652/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Abstract&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;RYAN RJ et al (2008). &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;A Multicenter Randomized Controlled Trial Comparing Central Laboratory and Point-of-Care Cardiac Marker Testing Strategies: The Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) Trial. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;The effect of point-of-care testing on length of stay in the ED varies between settings. At one site, point-of-care testing decreased time to admission, whereas at another, point-of-care testing increased time to discharge. Potential effects of point-of-care testing on patient throughput should be considered in the full context of ED operations. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=Annals%20of%20emergency%20medicine%5bJour%5d%20AND%202008%5bpdat%5d%20AND%20Ryan%5bauthor%5d" target="_blank"&gt;Abstract&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black"&gt;Other Randomised Controlled Trials published between November 2006 and November 2008 listed on PubMed on the topic of &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;cmd=historysearch&amp;amp;querykey=20" target="_blank"&gt;chest pain and emergency care&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;FURTHER RELEVANT DOCUMENTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Guidance&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;Department of Health (2008) &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;Treatment of heart attack national guidance: final report of the National Infarct Angioplasty Project (NIAP)&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NICE (2009) &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byId&amp;amp;o=11661" target="_blank"&gt;Chest pain / discomfort of recent onset&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Guideline in progress, expected date of issue&amp;nbsp;February 2010&lt;/SPAN&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Economic Evaluations&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;NHS EED (2008) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101825" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Maryland's first inpatient chest pain short stay unit as an alternative to emergency room-based observation unit&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22006001476" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Direct hospital costs of chest pain patients attending the emergency department: a retrospective study&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;NHS EED (2007) &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007002068" target="_blank"&gt;&lt;SPAN style="mso-bidi-font-weight: normal"&gt;Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain&lt;/SPAN&gt;&lt;/A&gt;&amp;nbsp;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;&lt;SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-weight: bold"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="mso-layout-grid-align: none; tab-stops: list 36.0pt; mso-list: l0 level1 lfo1"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;General&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN&gt;Atzema CL et al&amp;nbsp;(2008). ALaRMED: adverse events in low-risk chest pain patients receiving continuous ECG monitoring in the emergency department: a survey of Canadian emergency physicians. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18826728?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN&gt;Ekelund U et al&amp;nbsp;(2008).&lt;STRONG&gt; &lt;/STRONG&gt;New methods for improved evaluation of patients with suspected acute coronary syndrome in the emergency department. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18322128?dopt=Citation" target="_blank"&gt;PubMed abstract. &lt;/A&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Healthcare Commission (2008) &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/waitingtimesforrapidaccesschestpainclinic.cfm" target="_blank"&gt;Waiting times for rapid access chest pain clinic / &lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;Indicator listings for acute and specialist trusts - existing national targets 2007/2008&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;&amp;nbsp; &lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Kontos MC et al (2008). Value of simultaneous functional assessment in association with acute rest perfusion imaging for predicting short- and long-term outcomes in emergency department patients with chest pain. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18984452?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Miller CD et al&amp;nbsp;(2008). Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18660397?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN&gt;Mukerjee D et al&amp;nbsp;(2007). The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17976502?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="mso-layout-grid-align: none"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/clock_scenarios.html" target="_blank"&gt;Improving cardiac patients pathways: the sustainability toolkit: chest pain pathway scenarios&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=66" target="_blank"&gt;NHS Heart Improvement: Reperfusion – emergency treatment of heart attack&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 7.5pt; COLOR: black"&gt;* The links provided to randomised controlled trials listed in PubMed are for information only and did not form a part of the search process for this annual evidence update. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Arial; mso-ansi-language: EN-GB; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;v:shapetype id=_x0000_t75 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"&gt;&amp;nbsp;&lt;v:stroke joinstyle="miter"&gt;&lt;/v:stroke&gt;&lt;v:formulas&gt;&lt;v:f eqn="if lineDrawn pixelLineWidth 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @0 1 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum 0 0 @1"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @2 1 2"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @3 21600 pixelWidth"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @3 21600 pixelHeight"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @0 0 1"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @6 1 2"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @7 21600 pixelWidth"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @8 21600 0"&gt;&lt;/v:f&gt;&lt;v:f eqn="prod @7 21600 pixelHeight"&gt;&lt;/v:f&gt;&lt;v:f eqn="sum @10 21600 0"&gt;&lt;/v:f&gt;&lt;/v:formulas&gt;&lt;v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"&gt;&lt;/v:path&gt;&lt;o:lock v:ext="edit" aspectratio="t"&gt;&lt;/o:lock&gt;&lt;/v:shapetype&gt;&lt;v:shape id=_x0000_i1025 style="WIDTH: 90pt; HEIGHT: 63.75pt" type="#_x0000_t75"&gt;&lt;v:imagedata src="file:///C:\DOCUME~1\library\LOCALS~1\Temp\msohtml1\01\clip_image001.jpg" o:title="ec"&gt;&lt;/v:imagedata&gt;&lt;/v:shape&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>305729</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=305729]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Homepage</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,PREVENTION,PREVENTION,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DIAGNOSIS,DIAGNOSIS,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,STABLE ANGINA,OTHER,PREVENTION,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL / OVERVIEWS,UNSTABLE ANGINA,JAN-MAR 09,CONDITIONS,CHEST PAIN,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published on the 23rd February 2009: &lt;/STRONG&gt;An update for health professionals and patients on significant advances in knowledge about chest pain since our &lt;A href="http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;amp;pagename=CHESTPAIN" target="_blank"&gt;last update&lt;/A&gt;&amp;nbsp;in 2007. &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ContactUs.aspx" target="_blank"&gt;Please send us your feedback on this update.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0000_HFKNWwelcome.jpg"&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:304763:0" name=internalLink&gt;&lt;STRONG&gt;Welcome&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0008_contributors.gif"&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="nelh:305791:0" name=internalLink&gt;Contributors&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0002_HFNKWdiagnosis.jpg"&gt;&lt;BR&gt;&lt;A href="nelh:304799:0" name=internalLink&gt;Diagnosis&amp;nbsp;&amp;amp;&amp;nbsp;Risk&lt;BR&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0003_angina.jpg"&gt;&lt;BR&gt;&lt;A href="nelh:304797:0" name=internalLink&gt;Angina&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0004_ec.jpg"&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:304802:0" name=internalLink&gt;&lt;STRONG&gt;Emergency Care&lt;BR&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0005_acs.jpg"&gt;&lt;BR&gt;&lt;A href="nelh:304796:0" name=internalLink&gt;Acute &lt;BR&gt;Coronary Syndromes&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0006_other.gif"&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="nelh:304803:0" name=internalLink&gt;Other&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0009_DUETs.gif"&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="nelh:305787:0" name=internalLink&gt;Uncertainties&lt;A href="nelh:304805:0" name=internalLink&gt;&lt;BR&gt;&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;A &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=305729" target="_blank"&gt;flier is available &lt;/A&gt;to promote the 2009 Annual Evidence Update on Chest Pain.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304763</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304763]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Introduction</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,GENERAL / OVERVIEWS,OTHER,STABLE ANGINA,JAN-MAR 09,CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;I N T R O D U C T I O N&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt; 
&lt;P&gt;University of Surrey&lt;/P&gt;
&lt;P&gt;Use back arrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here.&amp;nbsp;&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width="20%"&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304763/nelhImp_0001_HFKNWwelcome.jpg" name=nelh_tempImage0&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;WELCOME TO THE 2009 ANNUAL EVIDENCE&amp;nbsp; UPDATE ON CHEST PAIN&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Annual Evidence Updates (AEUs) provide findings from a detailed search of recent, high quality evidence – mostly systematic reviews - on a particular topic, to support clinicians, commissioners and patients in designing and delivering improved care, and making decisions with individual patients. This AEU builds on the work we published during last year’s &lt;A href="http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;amp;pagename=CHESTPAIN" target="_blank"&gt;chest pain AEU&lt;/A&gt; . We have also published AEUs on &lt;A href="http://www.library.nhs.uk/cardiovascular/Page.aspx?pagename=HFAEU08INT" target="_blank"&gt;heart failure&lt;/A&gt;, &lt;A href="http://www.library.nhs.uk/Cardiovascular/Page.aspx?pagename=CRAEU08" target="_blank"&gt;cardiac rehabilitation&lt;/A&gt; and&amp;nbsp;&lt;A href="http://www.library.nhs.uk/stroke/Page.aspx?prv=y&amp;amp;pagename=SAEUINTRO0" target="_blank"&gt;stroke rehabilitation.&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/stroke/Page.aspx?prv=y&amp;amp;pagename=SAEUINTRO0" target="_blank"&gt;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chest pain is a common reason to seek healthcare, often as an emergency. But not all chest pain is cardiac in origin, for example, the proportion of those calling for an ambulance with chest pain who have proven heart attack is low – less than 10% in some studies. Getting the diagnosis right is important – treatment may be time dependent - and a growing array of technologies are becoming available to improve diagnosis and risk stratification, and to improve outcome for patients. This AEU provides key systematic reviews and related documents to support clinicians and commissioners in identifying the best available, current evidence on this topic &amp;nbsp;(NICE are due to publish guideline on &lt;A href="http://www.nice.org.uk/Guidance/CG/Wave14/25" target="_blank"&gt;chest pain / discomfort of recent onset&lt;/A&gt; in December 2009). There is of necessity some overlap in the different sections presented – for example, diagnosis, acute coronary syndromes and ACS. Because our brief was chest pain rather than ACS or STEMI per se we have not been able to cover the recent advances in reperfusion therapy (for example) although we do provide links to the recent &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;National Infarct Angioplasty Pilot &lt;/A&gt;(NIAP) and to the excellent work being led by the &lt;A href="http://www.improvement.nhs.uk/heart/" target="_blank"&gt;Heart Improvement Programme. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;I hope that the information we provide is useful and that it will help bring about improvements in care. My thanks are due once again to our expert advisors and to &lt;A href="mailto:ann.daly@bwhct.nhs.uk" target="_blank"&gt;Ann Daly&lt;/A&gt; who has project managed this AEU with unparalleled expertise and commitment. Our team are keen to receive &lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;feedback&lt;/A&gt;.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;UNCERTAINTIES :&amp;nbsp;ACKNOWLEDGING&amp;nbsp; WHAT&amp;nbsp; WE&amp;nbsp;DON'T&amp;nbsp;KNOW ...&lt;/STRONG&gt;&lt;BR&gt;While the systematic reviews highlighted in this AEU will help to promote knowledge of what we know about the effectiveness of different elements of chest pain care, it is important to acknowledge that there are many questions that remain unanswered, or where the conclusion of a study or review is uncertain. The National Library for Health is playing a key role in helping to identify uncertainties about the effectiveness of treatments, helping to combat what Sir Iain Chalmers describes as &lt;A href="http://www.bmj.com/cgi/content/extract/337/jul16_3/a841?papetoc" target="_blank"&gt;‘therapeutic ignorance’&lt;/A&gt; To learn more visit the &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK Database of Uncertainties about the Effects of Treatments&lt;/A&gt; (DUETS). &lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;BR&gt;We brought together a small panel of experts to advise us on the scope of the AEU and to support us in summarising key evidence and commenting on the 'state of the art'. The starting point for our literature search was November 2006. Please see the complete&amp;nbsp;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=304763" target="_blank"&gt;search strategy &lt;/A&gt;for details of sources searched and search terms used. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In addition, other sources were hand-searched for relevant key documents (including guidance, statistics and reports). Sources hand-searched were: NICE, NHS Clinical Knowledge Summaries, NHS Institute for Innovation and Improvement, NHS Heart Improvement Programme, Department of Health, Information Centre for Health and Social Care, Healthcare Commission, National Co-ordinating Centre for Health Technology Assessments (HTA), European Society of Cardiology and other organisations such as the British Heart Foundation. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>304803</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=304803]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Other</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,GENERAL / OVERVIEWS,OTHER,STABLE ANGINA,MYOCARDIAL INFARCTION,UNSTABLE ANGINA,GENERAL / OVERVIEWS,JAN-MAR 09,CONDITIONS,CHEST PAIN,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 1pt"&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="LETTER-SPACING: 1pt"&gt;OTHER&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/B&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Alison Pottle&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Consultant Nurse in Cardiology, Royal Brompton and Harefield NHS Trust&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-bidi-font-style: italic"&gt;&lt;/SPAN&gt;Use back arrow on browser to return to&amp;nbsp;the index &lt;A href="nelh:305729:0" name=internalLink&gt;or click here.&amp;nbsp;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304803/nelhImp_0000_other.gif" name=nelh_tempImage1&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;EXPERT SUMMARY&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;Eight systematic reviews were identified; five looked at a variety of aspects relating to interventions for chest pain. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007000697" target="_blank"&gt;Groeneveld (2007)&lt;/A&gt; &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;assessed studies into quality of life (QoL) differences between people who did and did not experience restenosis and target vessel revascularisation (TVR) following implantation of a drug-eluting stent (DES). Various QoL measures were used in the studies including the Seattle Angina Questionnaire, the EuroQoL-5D, the Hospital Anxiety and Depression Scale and the Impact of Event Scale. Follow-up ranged from initial hospitalisation to 12-months post percutaneous coronary intervention (PCI). The author concluded that the studies were too heterogeneous for a formal meta-analysis. However, in all the studies where restenosis developed or there was a need for TVR, there was a measurable loss in QoL. Four of the randomised controlled trials also assessed cost. Unsurprisingly, DES had a higher initial cost than bare metal stents (BMS). However, because of the higher revascularisation procedures; the follow-up costs were higher in the first year with BMS than DES. There is limited information about the included studies and their participants which could affect the generalisability of the review. The author recommends that further research is needed into QoL effects of restenosis in people with DES, including longer term follow-up.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;Atherectomy is not routinely used before stenting in the &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;UK&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006007384" target="_blank"&gt;Niccoli (2008)&lt;/A&gt; carried out a review of the use of directional coronary atherectomy (DCA) versus stenting alone in PCI. DCA was associated with a statistically significant increase in acute gain, a greater final minimal lumen diameter and a significant reduction in angiographic restenosis rate compared to stenting alone. There was no statistically significant difference between the two treatments in late loss.&lt;SPAN style="COLOR: #ff6600"&gt; &lt;/SPAN&gt;Compared to stenting alone, DCA was associated with a statistically significant lower rate of late target lesion revascularisation, but a significantly higher rate of early major adverse cardiac events (MACE). Late MACE rates were similar in the two groups. The studies included in the review varied widely – three were RCTs and 9 case-control studies, and results from the two types of study design were quite different. Also, the type of stent used in the studies is not stated. It would therefore be difficult to conclude the usefulness of DCA.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007005858" target="_blank"&gt;Svilaas (2008)&lt;/A&gt; compared bare metal stenting with balloon angioplasty in patients with acute myocardial infarction (STEMI). There were few differences between the two groups except in regard to reocclusion and restenosis, which were both significantly reduced in the bare-metal stenting group. The authors stated that the results support bare-metal stent placement in STEMI. However there is a need for further studies into areas such as drug eluting stents and distal protection of the affected vessel. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;The review carried out by &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007004134" target="_blank"&gt;Ioannidis (2008)&lt;/A&gt; considered the use of PCI for late reperfusion after STEMI in stable patients. The review concluded that this intervention does not appear to be of benefit as it did not improve major clinical outcomes and involves costs and high radiation times for both physicians and patients. Further large studies on this topic are not warranted.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;There is a continuing debate regarding the best procedure, PCI or coronary bypass surgery? &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17320555?dopt=Citation" target="_blank"&gt;Bainbridge (2007)&lt;/A&gt; carried out a meta-analysis of six RCTs comparing off-pump minimally invasive coronary artery bypass surgery compared to PCI with reference to mortality, morbidity and resource utilization. The primary outcome was the need for coronary reintervention at one to five years. In single or double vessel disease, off pump coronary artery bypass improved the short and mid term clinical outcomes compared to PCI but was associated with increased length of hospital stay. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;Primary PCI is the gold standard for STEMI however there continues to be a concern about possible delays in treatment and resultant effectiveness when compared to thrombolysis. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17277350?dopt=Citation" target="_blank"&gt;Asseburg’s review (2007)&lt;/A&gt; concluded that for all outcomes including mortality, non-fatal reinfarction and non-fatal stroke, the benefit of PCI decreased with longer delay. For delays of 30-90 minutes, PCI was superior for one-month fatal and non fatal outcomes. For delays of around 90 minutes thrombolysis may be the preferred option as assessed by six-month mortality. However, there is considerable uncertainty for longer time delays. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;The differences between women’s experiences of chest pain as compared to men’s has been studied by &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18727283?dopt=Citation" target="_blank"&gt;O’Keefe and McCarthy (2008)&lt;/A&gt;. Women experience cardiac pain differently to men and that this may lead to misunderstandings of warning signs of MI and ischaemic pain. Further research and education are needed.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18727283?dopt=Citation" target="_blank"&gt;Katerndahl (2008)&lt;/A&gt; examined the association between panic disorder and coronary artery disease (CAD) among primary care patients presenting with chest pain. In primary care settings where the prevalence of CAD is low, there may be a significant association between panic disorder and CAD. This may have several implications for primary care clinicians managing patients with chest pain, and the treatment of panic disorder should be adjusted in the presence of co morbid CAD.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;SYSTEMATIC REVIEWS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt;ASSEBURG C, VERGEL YB, PALMER S, FENWICK E, DE BELDER M, ABRAMS KR, SCULPHER M (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Assessing the effectiveness of primary angioplasty compared with thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; The benefit of primary angioplasty, over thrombolysis, depends on the former's additional time delay. For delays of 30-90 minutes, angioplasty is superior for 1-month fatal and non-fatal outcomes. For delays of around 90 minutes thrombolysis may be the preferred option as assessed by 6-month mortality; there is considerable uncertainty for longer time delays. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17277350?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;BAINBRIDGE D, CHENG D, MARTIN J, NOVICK R (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Does off-pump or minimally invasive coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with percutaneous coronary intervention? A meta-analysis of randomized trials. &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; In single- or double-vessel disease, off-pump coronary artery bypass improved short-term and midterm clinical outcomes compared with percutaneous coronary intervention but was associated with an increased length of hospital stay. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17320555?dopt=Citation" target="_blank"&gt;PubMed abstract.&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;GROENEVELD PW, SUH JJ, MATTA MA (2007).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007000697" target="_blank"&gt;The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; There is agreement on the QoL benefits of avoiding revascularisation; the average QALY benefit of an avoided revascularisation is 0.04 to 0.08. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; The aims of this review were only partially stated in that no criteria were given for the study design. The review aimed, first, to assess the costs and cost-effectiveness of DES; and second, to evaluate the QoL effects of lower revascularisation and restenosis rates as a result of DES. The search was limited by language and type of publication, and it is therefore likely that studies were missed. This could result in publication and/or language bias. The methods of the review were appropriate for minimising the introduction of bias, and quality was assessed. However, little information was given about the included studies and their participants, and this could affect the generalisability of the review. The decision to combine the results in a narrative review seemed appropriate given the differences between the studies. The studies included a variety of patients, outcome measures and study designs, and none of the studies were rated as being of a high quality; the reliability of the results is therefore unclear. Although the authors' conclusions appear to be supported by the data presented, they should be interpreted with caution given the aforementioned concerns.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;IOANNIDIS JP, KATRITSIS DG (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007004134" target="_blank"&gt;Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; PCI for late revascularisation of occluded arteries after MI in stable patients does not appear to be of benefit. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;The study objectives and inclusion criteria were clear, the search was adequate, and relevant criteria were assessed for risk of bias. However, it was not reported whether steps were taken to minimise reviewer error and bias in the selection of studies and assessment of risk of bias (such as an independent assessment by more than one reviewer). The meta-analysis appears justified and potential sources of clinical, methodological and statistical heterogeneity were discussed and evaluated appropriately. Despite some limitations in the reporting of review methods, the review was well conducted and the conclusions are likely to be reliable.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;KATERNDAHL DA (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=18787675" target="_blank"&gt;The association between panic disorder and coronary artery disease among primary care patients presenting with chest pain: an updated literature review.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; The association between panic disorder and CAD has several implications for primary care physicians managing patients with chest pain. When comorbid, the panic attacks may cause the patient with coronary disease to seek care but could also provoke a cardiac event. If one condition is recognized, a search for the other may be warranted because of the potential consequences if left undetected. The treatment approach to the panic disorder should be adjusted in the presence of comorbid CAD.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;NICCOLI G, TESTA L, MONGIARDO R, RICCO A, BELLONI,F, ROMAGNOLI E, LEONE AM, BURZOTTA F, TRANI C, MAZZARI MA, REBUZZI AG, CREA F (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006007384" target="_blank"&gt;Directional atherectomy before stenting versus stenting alone in percutaneous coronary interventions: a meta-analysis.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; DCA before stenting improved acute angiographic results and target lesion revascularisation more than stenting alone, but also&amp;nbsp;increased early MACE. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; The review question was clear but broadly defined. Several relevant sources were searched and attempts were made to minimise publication and language bias. The data extraction was undertaken in duplicate, thus minimising reviewer errors and bias, but it is not clear whether similar steps were taken at the&amp;nbsp;study selection stage. Study validity was not assessed, thus the results from these studies and any synthesis may not be reliable. Data from randomised and non-randomised studies were pooled. Forest plots showed the results separately for the two types of study design, and the authors&amp;nbsp;acknowledged that the&amp;nbsp;results for the two different types of studies differed: case-control studies showed a statistically significant&amp;nbsp;benefit from the combined strategy compared with stenting alone for restenosis rate, target lesion revascularisation and early MACE, whereas&amp;nbsp;RCTs showed no significant difference between treatments for these outcomes. However, the main results were from the analyses of all studies. In view of the incomplete reporting of review methods, lack of a validity assessment, the pooling of data from studies of differing design, and differences between the studies, the authors’ conclusions may not be reliable. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;O'KEEFE-MCCARTHY S (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Women's experiences of cardiac pain: a review of the literature. &lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Bottom-line conclusion:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; Results of this review revealed that women experience cardiac pain differently than men. Different cardiac pain experienced by women leads to misunderstandings of warning signs and symptoms of myocardial infarction and ischemic cardiac pain. Moreover, women do not recognize the threat of CHD, even with significant family history, and delay seeking health care for signs of acute myocardial infarction. Further research and education are warranted. Nurses need to challenge the antiquated assumptions surrounding women's experiences of cardiac pain. Clinicians must be cognizant of the importance of a thorough patient assessment, the ability to identify women at risk, individualizing the person's CHD experience, and providing health promotion strategies that educate women to recognize the signs and symptoms of CHD. Studies that identify the educational needs specific to women and cardiac pain are necessary. Educational intervention studies promoting health-related behaviour change that targets cardiac pain recognition for women are imperative. Future research examining whether the experience of changes in cardiac pain over time and post-intervention(s) need to be conducted. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18727283?dopt=Citation" target="_blank"&gt;PubMed abstract:&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: DE"&gt;SVILAAS T, VAN DER HORST I, ZIJLSTRA F (2008).&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=DE style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-ansi-language: DE"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial"&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007005858" target="_blank"&gt;A quantitative estimate of bare-metal stenting compared with balloon angioplasty in patients with acute myocardial infarction: angiographic measures in relation to clinical outcome.&lt;/A&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;Bottom-line conclusion:&lt;/B&gt; Compared with balloon angioplastiy supported by provisional stenting, routine bare-metal stenting results in a significant benefit in terms of reocclusion and restenosis. There were no differences in sub-acute thrombosis between the groups, but there were benefits from bare-metal stenting with respect to target vessel revascularisation. However, no differences were seen in mortality or reinfarction rates, but follow-up may not have been long enough to detect relevant benefits. &lt;B style="mso-bidi-font-weight: normal"&gt;CRD commentary:&lt;/B&gt; This review had clearly stated inclusion criteria with respect to the study design, participants, interventions and outcomes. The authors searched two relevant databases and efforts were made to identify supplemental information. The study selection and data extraction processes were conducted in duplicate, thus reducing the potential for error and bias. However, as the authors considered that quality could not be reliably assessed, no validity assessment of the studies was included. Study details were tabulated. The authors cautioned that the interpretation of the data may be limited by the clinical heterogeneity between the trials. Some of the studies were designed to randomise patients after successful balloon angioplasty, and changing trends in concomitant pharmacotherapy and in stent technology may have resulted in differences between earlier and later trials. Given the limitations of the available evidence, the authors’ conservative conclusion and recommendation for further research seem appropriate and reliable. Overall, the conclusions appear to be consistent with the data presented.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;SPAN style="LETTER-SPACING: 1.2pt"&gt;FURTHER RELEVANT DOCUMENTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Guidance&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;American Heart Association (2008) &lt;A href="http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188950" target="_blank"&gt;Management of Cocaine-Associated Chest Pain and Myocardial Infarction: A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;Department of Health (2008) &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089455" target="_blank"&gt;Treatment of heart attack national guidance: final report of the National Infarct Angioplasty Project (NIAP)&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NICE (2009) &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byId&amp;amp;o=11661" target="_blank"&gt;Chest pain / discomfort of recent onset&lt;/A&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Guideline in progress, expected date of issue&amp;nbsp;February 2010&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;General&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Healthcare Commission (2008) &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/waitingtimesforrapidaccesschestpainclinic.cfm" target="_blank"&gt;Waiting times for rapid access chest pain clinic / &lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;Indicator listings for acute and specialist trusts - existing national targets 2007/2008&lt;/SPAN&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;Healthcare Commision (2008) &lt;A href="http://www.healthcarecommission.org.uk/guidanceforhealthcarestaff/nhsstaff/annualhealthcheck/annualhealthcheck2007/08/qualityofs/cardiovasculardiseasemortality.cfm" target="_blank"&gt;Cardiovascular Disease Mortality / Primary care trusts overview - new national targets 2007/2008&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold"&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/sustainability/clock_scenarios.html" target="_blank"&gt;Improving cardiac patients pathways: the sustainability toolkit: chest pain pathway scenarios&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN lang=EN style="FONT-SIZE: 10pt; mso-ansi-language: EN"&gt;NHS Improvement (2009) &lt;A href="http://www.improvement.nhs.uk/heart/?TabId=66" target="_blank"&gt;NHS Heart Improvement: Reperfusion – emergency treatment of heart attack&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=NormalWeb2&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; mso-bidi-font-weight: bold"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>305787</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=305787]]&gt;</url>
    <title>2009 Annual Evidence Update on Chest Pain : Uncertainties</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,DIAGNOSIS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,PREVENTION,PREVENTION,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,PREVENTION,GENERAL / OVERVIEWS,STABLE ANGINA,OTHER,JAN-MAR 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chest Pain : Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;U&amp;nbsp;N C E R T A I N T I E S&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Use backarrow on browser to return to&amp;nbsp;the index or &lt;A href="nelh:305729:0" name=internalLink&gt;click here&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305787/nelhImp_0000_DUETs.gif" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P id=EC_pageTitle align=left&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;In completing this annual evidence update on chest pain we identified&amp;nbsp;the following&amp;nbsp;uncertainties of treatment:&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;A href="nelh:306757:0" name=internalLink&gt;&lt;FONT size=2&gt;Bare-metal stenting compared with balloon angioplasty in patients with acute myocardial infarction&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;A href="nelh:306747:0" name=internalLink&gt;&lt;FONT size=2&gt;Routine and selective invasive strategies for acute coronary syndrome&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;FONT style="FONT-SIZE: 10pt" size=2&gt;&lt;A href="nelh:306747:0" name=internalLink&gt;&lt;/P&gt;
&lt;P id=EC_pageTitle&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325502</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325502]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure -  Key Documents</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,HEART FAILURE,STATISTICS,GENERAL  / OVERVIEWS,ECONOMIC EVALUATIONS,JUL-SEP 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 10 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure -  Key Documents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;10 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Key Documents&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Guidance documents and links to Organisations&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325502/nelhImp_0002_HF2009Keydocs.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;G U I D E L I N E S &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;National&amp;nbsp;Institute for&amp;nbsp;Health&amp;nbsp;and&amp;nbsp;Clinical Excellence (NICE)&lt;/STRONG&gt; - Chronic Heart Failure [&lt;A href="http://www.nice.org.uk/CG005" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Department of Health&lt;/STRONG&gt; - End of life care strategy [&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_086277" target="_blank"&gt;fulltext&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;NHS Clinical Knowledge Summaries&amp;nbsp;CKS&lt;/STRONG&gt;&amp;nbsp;- Heart Failure [&lt;A href="http://www.cks.nhs.uk/heart_failure_chronic" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;NHS Improvement&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;– Heart Failure: A&amp;nbsp;quick guide to&amp;nbsp; quality commissioning [&lt;A href="http://www.heart.nhs.uk/heart/Portals/0/docs_2008/HF_commissioning_guide.pdf" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;European Society of Cardiology&lt;/STRONG&gt;&amp;nbsp;- Diagnosis and treatment of acute and chronic heart failure. [&lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-HF-FT.pdf" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;American Heart Association&lt;/STRONG&gt;&amp;nbsp;- Promoting Self-Care in Persons With Heart Failure [&lt;A href="http://circ.ahajournals.org/cgi/reprint/120/12/1141" target="_blank"&gt;Fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;American Heart Association &lt;/STRONG&gt;- Diagnosis and management of heart failure in adults [&lt;A href="http://content.onlinejacc.org/cgi/reprint/53/15/1343.pdf" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;European Society of Cardiology&lt;/STRONG&gt;&amp;nbsp;- Diagnosis and treatment of acute and chronic heart failure.[&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure.[" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;British National Formulary (BNF)&amp;nbsp;&lt;/STRONG&gt; - Diuretics&amp;nbsp; [&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=121587&amp;amp;tabID=288" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;A U D I T&amp;nbsp; A N D &amp;nbsp;S T A T I S T IC S&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;FONT face=Arial&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;SPAN class=330374411-05102009&gt;NHS&lt;/SPAN&gt; Information Centre&amp;nbsp;&lt;/STRONG&gt; - National&amp;nbsp;&amp;nbsp;Heart Failure Audit [&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/Services/NCASP/18090208.NHSIC-HeartFailureFV-2008.pdf" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;fulltext&lt;/FONT&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;]&lt;/FONT&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;FONT face=Arial&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;British Heart Foundation&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;-&amp;nbsp;Coronary heart disease Statistics.[&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="http://www.heartstats.org/datapage.asp?id=7998" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;fulltext]&lt;/FONT&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt; &lt;/FONT&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;FONT face=Arial size=2&gt;&lt;STRONG&gt;U S E F U L&amp;nbsp; W E B S I T ES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;FONT face=Arial size=2&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;FONT face=Arial&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;NHS Choices&amp;nbsp;- Heart Failure&lt;/STRONG&gt; [&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="http://www.nhs.uk/Pathways/Heartfailure/Pages/Symptoms.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;fulltext&lt;/FONT&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;] &lt;/FONT&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;FONT face=Arial&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;British Heart Foundation&lt;/STRONG&gt; [&lt;A href="http://www.bhf.org.uk/living_with_a_heart_condition/understanding_heart_conditions/types_of_heart_conditions/heart_failure.aspx" target="_blank"&gt;heart failure information link]&amp;nbsp;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;British Society for Heart Failure&lt;/STRONG&gt;&amp;nbsp;&lt;A href="http://www.bsh.org.uk/" target="_blank"&gt;[weblink]&lt;/A&gt;&lt;/LI&gt;&lt;/FONT&gt;
&lt;LI&gt;&lt;SPAN class=330374411-05102009&gt;&lt;STRONG&gt;Heart Failure Matters (European Society&amp;nbsp;of Cardiology)&lt;/STRONG&gt;&amp;nbsp;&lt;A href="http://www.heartfailurematters.org/EN/Pages/index.aspx" target="_blank"&gt;[weblink]&lt;/A&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;C O C H R A N E&amp;nbsp;&amp;nbsp; P R O T O C O L S&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cleland JGF, Freemantle N, Eastaugh J, Young PJ, Harrison&amp;nbsp;J.&amp;nbsp;Beta-blockers for heart failure. The Cochrane Library 2009 [f&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002131/pdf_fs.html" target="_blank"&gt;ulltext&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cleland JGF, Freemantle N, Eastaugh J, Young PJ, Harrison&amp;nbsp;J.Angiotensin converting enzyme inhibitors for heart failure. The Cochrane Library 2009 [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002134/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;Jong P, Demers C, McKelvie RS, Liu P. &lt;/FONT&gt;Angiotensin receptor blockers for heart failure. The Cochrane Library 2009 [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003040/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;Romme JJCM, Black CN, Colman N, Scholten RJ, Reitsma JB, Wieling W, Van Dijk N. &lt;/FONT&gt;Drugs and pacemakers for neurally mediated reflex syncope. The Cochrane Library 2009. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004194/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Hood SG, Bereznicki L, Dunt D, Jackson S, Lowe A, Mackson J, Phillips S, Pirkis J, Taylor SJC. &lt;/FONT&gt;Interventions to improve evidence-based prescribing for heart failure. The Cochrane Library 2009. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006091/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;Ngo K, Kotecha D, Manzano L, Walters JAE, Flather M. &lt;/FONT&gt;Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. The Cochrane Library 2009. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007613/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;Li J, Huang P, Wu T, Chen X.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;Nitrates for acute heart failure. The Cochrane&amp;nbsp;Library 2009. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005551/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;&lt;FONT face=AGaramond-Bold&gt;
&lt;LI&gt;Van Marum R, Zwinderman AAH, Cleophas AJM.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/FONT&gt;Second generation dihydropyridine calcium channel blockers for heart failure. The Cochrane Library. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003835/pdf_fs.html" target="_blank"&gt;fulltext&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;E C O N O M I C&amp;nbsp; &amp;nbsp;E V A L U A T I O N S&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Roytman M M, Thomas S M, Jiang C S.&amp;nbsp;Comparison of practice patterns of hospitalists and community physicians in the care of patients with congestive heart failure.&amp;nbsp;Journal of Hospital Medicine&amp;nbsp;2008;&amp;nbsp;3(1):&amp;nbsp;35-41 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008000578" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Ng T M, Dasta J F, Durtschi A J, McLaughlin T P, Feldman D S.&amp;nbsp;Characteristics, drug therapy, and outcomes from a database of 500,000 hospitalized patients with a discharge diagnosis of heart failure.&amp;nbsp;Congestive Heart Failure&amp;nbsp;2008;&amp;nbsp;14(4):&amp;nbsp;202-210 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22009100316" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Miyao Y, Tanaka T, Fukushima R, Harada M, Fujimoto K.&amp;nbsp;Effectiveness of the critical path for administering carvedilol in patients with congestive heart failure.&amp;nbsp;Respiration and Circulation&amp;nbsp;2008;&amp;nbsp;56(9):&amp;nbsp;953-956&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;[&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008102146" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Gohler A, Conrads-Frank A, Worrell S S, Geisler B P, Halpern E F, Dietz R, Anker S D, Gazelle G S, Siebert U.&amp;nbsp;Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure.&amp;nbsp;European Journal of Heart Failure&amp;nbsp;2008;&amp;nbsp;10(10):&amp;nbsp;1026-1032 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008102180" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Miller G, Randolph S, Forkner E, Smith B, Galbreath A D.&amp;nbsp;Long-term cost-effectiveness of disease management in systolic heart failure.&amp;nbsp;Medical Decision Making&amp;nbsp;2009;&amp;nbsp;29(3):&amp;nbsp;325-333 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22009102176" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Scott M A, Price C P, Cowie M R, Buxton MJ.&amp;nbsp;Cost-consequences analysis of natriuretic peptide assays to refute symptomatic heart failure in primary care.&amp;nbsp;British Journal of Cardiology&amp;nbsp;2008;&amp;nbsp;15(4):&amp;nbsp;199-204 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22009100920" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Hebert P L, Sisk J E, Wang J J, Tuzzio L, Casablanca J M, Chassin M R, Horowitz C, McLaughlin M A.&amp;nbsp;Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community.&amp;nbsp;Annals of Internal Medicine&amp;nbsp;2008;&amp;nbsp;149:&amp;nbsp;540-548 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101905" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Chan D C, Heidenreich P A, Weinstein M C, Fonarow G C.&amp;nbsp;Heart failure disease management programs: a cost-effectiveness analysis.&amp;nbsp;American Heart Journal&amp;nbsp;2008;&amp;nbsp;155:&amp;nbsp;332-338[&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008000312" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Patel H, Shafazand M, Ekman I, Hojgard S, Swedberg K, Schaufelberger M.&amp;nbsp;Home care as an option in worsening chronic heart failure: a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness.&amp;nbsp;European Journal of Heart Failure&amp;nbsp;2008;&amp;nbsp;10(7):&amp;nbsp;675-681 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101450" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Swindle J, Burroughs T E, Schnitzler M A, Hauptman P J.&amp;nbsp;Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.&amp;nbsp;American Heart Journal&amp;nbsp;2008;&amp;nbsp;156(2):&amp;nbsp;322-328 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101507" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Liao L, Allen L A, Whellan D J.&amp;nbsp;Economic burden of heart failure in the elderly.&amp;nbsp;Pharmacoeconomics&amp;nbsp;2008;&amp;nbsp;26(6):&amp;nbsp;447-462 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101024" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Russo M J, Gelijns A C, Stevenson L W, Sampat B, Aaronson K D, Renlund D G, Ascheim D D, Hong K N, Oz M C, Moskowitz A J, Rose E A, Miller L W.&amp;nbsp;The cost of medical management in advanced heart failure during the final two years of life.&amp;nbsp;Journal of Cardiac Failure&amp;nbsp;2008;&amp;nbsp;14(8):&amp;nbsp;651-658 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008102048" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;de Lissovoy G, Fraeman K, Salon J, Woodward T C, Sterz R.&amp;nbsp;The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.&amp;nbsp;Journal of Medical Economics&amp;nbsp;2008;&amp;nbsp;11:&amp;nbsp;415-429 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101895" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Hutchinson J, Scott D A, Clegg A J, Loveman E, Royle P, Bryant J, Colquitt J L.&amp;nbsp;Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.&amp;nbsp;Expert Review of Cardiovascular Therapy&amp;nbsp;2008;&amp;nbsp;6(2):&amp;nbsp;175-185 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008000733" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV id=xxx&gt;Velez M, Westerfeldt B, Rahko P S.&amp;nbsp;Why it pays for hospitals to initiate a heart failure disease management program.&amp;nbsp;Disease Management and Health Outcomes&amp;nbsp;2008;&amp;nbsp;16(3):&amp;nbsp;155-173 [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008100983" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT face=Arial size=2&gt;For details of ongoing research visit the &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&amp;nbsp;Link to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>326242</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=326242]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Contributors</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,GENERAL  / OVERVIEWS,JUL-SEP 09,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Contibutors page of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;CONTRIBUTORS&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE width="100%" border=1 Valign="top"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326242/nelhImp_0000_Andrewclark2.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;H3&gt;Dr. Andrew L&amp;nbsp;Clark&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Andrew Clark was educated at Pembroke College, Cambridge, and trained in medicine at the Westminster Medical School.&amp;nbsp;He trained in cardiology at Manchester Royal Infirmary, the National Heart and Lung Institute (London) and the Western Infirmary, Glasgow. &lt;/P&gt;
&lt;P&gt;He is a founder member of the British Society for Heart Failure, and is a member of the working groups for Heart Failure and Cardiac Rehabilitation and Exercise Physiology in the European Society of Cardiology. &lt;/P&gt;
&lt;P&gt;He is presently Reader and Honorary Consultant Cardiologist at Hull University and hospitals. He is responsible for running the echocardiography service in Hull, and he plays an active role in the day-to-day provision of cardiology services to the population of the East Riding of Yorkshire.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326242/nelhImp_0001_JMant.jpg" name=nelh_tempImage3&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;H3&gt;Professor Jonathan Mant&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Jonathan Mant is Professor of Primary Care Research, University of Cambridge.&lt;/P&gt;
&lt;P&gt;He was chair of the Guideline Development Group for the 2003 NICE guideline on the diagnosis and management of chronic heart failure, and has led NHS HTA funded secondary research on the diagnosis of heart failure in primary care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326242/nelhImp_0002_DThompson2.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;H3&gt;Professor David Thompson&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;David Thompson is Professor of Cardiovascular Nursing at the University of Leicester.&amp;nbsp; Prior to this he was Professor and Director of the Nethersole School of Nursing at the Chinese University of Hong Kong, and Director of the Hong Kong Centre for Evidence-Based Nursing, from June 2002 to May 2007.&amp;nbsp; From April 1998 until May 2002 he was Foundation Professor of Nursing at the University of York. From 1994-1998 he was Professor of Nursing at the University of Hull and from 1998-2001 he was also the first Professor of Nursing Research at the Department of Health in the UK, a new post established on a part-time basis to advise the Director of Research and Development.&amp;nbsp; He is Visiting Professor at the University of London and the University of Queensland.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;He &amp;nbsp;has extensive clinical and research experience in the field of cardiac care and rehabilitation, has published 350 papers, 40 chapters and 15 books, been awarded research grants in excess of £3 million and served as a member of numerous expert committees and prestigious bodies, including the Department of Health, the Medical Research Council, the British Heart Foundation and the European Society of Cardiology.&amp;nbsp; He is editor of the European Journal of Cardiovascular Nursing.&lt;/P&gt;
&lt;P&gt;Professor Thompson has received a number of honours in recognition of his contributions to the art and science of nursing and cardiology, including being elected a Fellow of the Royal College of Nursing, in 1992, and a Fellow of the European Society of Cardiology, in 1998.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326242/nelhImp_0003_JillianRiley2.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;H3&gt;Jillian Riley&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Jillian Riley is Head of Postgraduate Education (Nursing and Allied Professions) at the Royal Brompton Hospital, course director for the MSc Cardio-respiratory Nursing at Imperial College and&amp;nbsp; works in Professor Martin Cowie’s Health Services Research Group evaluating the use of remote monitoring in chronic heart failure. Qualifying in Nursing at University College Hospital, London, Jill&amp;nbsp; is a graduate of Manchester and City Universities. She trained in cardiac intensive care at the Hammersmith Hospital and has clinical experience working in the UK and North America. &lt;/P&gt;
&lt;P&gt;Involved in the development of the National Service Framework for Coronary Heart Disease, Jill was President of BANCC until 2003. She has served on a number of expert committees at the British Cardiovascular Society and British Heart Foundation and chairs the Scientific Programme Committee of the Council of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. &lt;/P&gt;
&lt;P&gt;Jillian has co-authored a text on cardiothoracic nursing, has contributed to a number of other text books and publications, and is on the editorial board of the British Journal of Cardiac Nursing.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326242/nelhImp_0004_TomQuinn2.jpg" name=nelh_tempImage3&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;H3&gt;Professor Tom Quinn&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Professor Tom Quinn is one of the UK's leading cardiovascular nurses and has made a significant contribution to practice, policy and research both nationally and internationally. &lt;/P&gt;
&lt;P&gt;He was the UK's first Professor of Cardiac Nursing (at Coventry University), and took up post as Professor of Clinical Practice at the University of Surrey in January 2009. He has published extensively on acute cardiac and stroke care and his current responsibilities include being clinical lead for the NHS Evidence cardiovascular, stroke and vascular collections, part of the National Institute for Health and Clinical Excellence. He has been chief or co-applicant on more than £3.5m successful grant applications in the past two years, involving research into emergency cardiac and stroke care, and is on the steering group for two major clinical trials. He continues to advise the Department of Health as a member of the Emergency Cardiac Care Board, is a member of the group developing the Stroke Specific Educational Framework sponsored by the Department of Health, and chairs the steering group for development of primary angioplasty for the NHS in Surrey. He is Honorary Clinical and Research Adviser to South East Coast Ambulance Service NHS Trust.&lt;/P&gt;
&lt;P&gt;Tom Quinn is a member of the advisory committee for the European Society of Cardiology (ESC) Council of Cardiovascular Nursing and Allied Health Professions, a member of the ESC Working Group on Acute Cardiac Care, and a former Chairman of the ESC Working Group on Cardiovascular Nursing. He became a Fellow of the ESC in the mid 1990s and was awarded Fellowship of the Royal College of Nursing&amp;nbsp;for his 'outstanding contribution to cardiac care' in 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325499</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325499]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Devices and Interventions</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,GENERAL/OTHER,OCT-DEC 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 4 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Devices and Interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=3 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 name=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg"&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;4 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 12pt"&gt;&lt;B&gt;Devices and Interventions&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Clinical Lead NHS Evidence – cardiovascular.&lt;BR&gt;Professor of Clinical Practice, Faculty of Health and Medical Sciences, University of Surrey.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325499/nelhImp_0000_HF2009Devices.jpg"&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE border=0 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%"&gt;
&lt;P&gt;&lt;STRONG&gt;CRT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cardiac resynchronisation therapy (CRT) has been shown to benefit patients with heart failure and QRS widening, facilitating reverse modelling of the left ventricle (LV) and increased LV ejection fraction (LVEF), improving quality of life and exercise tolerance, as well as reducing mortality. According to the reviews we identified, the small number of trials and short follow up periods mean that uncertainties still remain about the precise long term benefits for patients, and further trials are needed. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=319459&amp;amp;tabID=289" target="_blank"&gt;Rossi&lt;/A&gt; et al undertook a meta-analysis of controlled clinical studies on CRT for symptomatic heart failure in patients with LV dysfunction and sinus rhythm with complete left bundle branch block. The search strategy included PubMed, MEDLINE and the ClinicalTrials.gov database, together with hand searches of conference abstracts from American (but not European or other regional) scientific meetings. Of 8040 ‘potentially relevant’ reports only six met the inclusion criteria. CRT significantly reduced all-cause mortality by 28% and new hospital admission for worsening heart failure by 37% in symptomatic patients. Patients with ICD alone and with CRT+ICD had significant reduction in hospital admission compared to no-CRT, no-ICD patients. Readmission rates were similar for CRT and CRT+ICD.&amp;nbsp; Differences in effect of ICD alone and CRT +ICD were attributed to the greater proportion of underlying coronary disease in the ICD studies. The relatively short follow-up period in included trials, and the small number of trials overall, means that uncertainty still remains about the long term benefits of CRT in heart failure patients.&lt;/P&gt;
&lt;P&gt;Available technology now allows separate programmability of right and left ventricular output. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18611967" target="_blank"&gt;Lim&lt;/A&gt; and colleagues undertook a systematic review of CRT focussing on the optimization of sequential (V-V delay) compared to default simultaneous biventricular pacing in heart failure patients. 18 articles (out of 70 identified from a search of MEDLINE and EMBASE only) were included. The authors conclude that data supporting ventricular optimization of biventricular pacing are limited to predominantly small, single centre, non-randomized, short term studies employing a variety of surrogate endpoints. The two randomised trials failed to demonstrate any significant improvement in functional status, LV dimensions or quality of life, but this may have been due to inadequate study power. Uncertainty remains regarding whether newer approaches to optimization such as echocardiographic techniques can improve outcome.&lt;/P&gt;
&lt;P&gt;Predicting which patients will respond to –and benefit from- CRT can be difficult. Around 30% of patients with wide QRS do not show symptomatic improvement. Baseline QRS duration alone is an imperfect predictor and the role of CRT in heart failure patients with narrow QRS and baseline mechanical asynchrony has recently been explored in a meta-analysis by &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18651415" target="_blank"&gt;Jeevanantham&lt;/A&gt; and colleagues. Only three trials (out of 80 studies identified in a search strategy limited to MEDLINE and the Cochrane Controlled Trials Register) met the inclusion criteria for the review, and these were not randomised, and there were no controls. The authors conclude that in patients with narrow QRS and baseline mechanical asynchrony, CRT (after optimal medical therapy) significantly reduced NYHA class, improved LVEF and exercise tolerance (6 minute walk test) during follow up. However, the limitations of the available evidence means that uncertainty remains about the true benefits of CRT in this group, and further, randomised studies are needed.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jeevanantham V, Zareba W, Navaneethan S, Fitzgerald D, Yu CM, Achilli A, et al. Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex. Cardiology Journal. 2008; 15(3):230-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18651415" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Lim SH, Lip GY, Sanderson JE. Ventricular optimization of biventricular pacing. A systematic review. Europace. 2008 Aug; 10 (8): 901-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18611967" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Rossi A, Rossi G, Piacenti M, Startari U, Panchetti L, Morales MA. The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients. A meta-analysis from clinical trials. Heart and Vessels. 2008 Jul; 23 (4): 217-223. &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=319459&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Device*%5BTitle%2FAbstract%5D+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;&lt;STRONG&gt;Heart Failure and Devices&amp;nbsp;&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325323</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325323]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Diagnosis and Risk Stratification</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS,GENERAL  / OVERVIEWS,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,HEART FAILURE,JUL-SEP 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 2 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Diagnosis and Risk Stratification&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE border=3 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 name=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png"&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg"&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION 2 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 12pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Diagnosis and Risk Stratification&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;STRONG&gt;Professor Jonathan Mant&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Professor of&amp;nbsp;Primary Care&amp;nbsp;Research, University of Cambridge.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325323/nelhImp_0001_HFNKWDiagnosis.png"&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp; 
&lt;TABLE border=0 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%" border="0"&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;There have been two recent systematic reviews of diagnosis of heart failure in primary care. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19691616" target="_blank"&gt;Madhok, Fahey et al&lt;/A&gt; looked at symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction (which is responsible for about 50% of heart failure). They found that the clinical sign of a displaced apex beat was very useful if present at raising suspicion of heart failure (positive likelihood ratio of 16), and confirmed previous findings that ECG and natriuretic peptide measurements have similar potential as ‘rule out’ tests. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19586584" target="_blank"&gt;Mant et al&amp;nbsp;&lt;/A&gt;&amp;nbsp; supplemented a systematic review of symptoms signs and diagnostic tests with an individual patient data analysis, and came to different conclusions. They found that natriuretic peptides were superior to ECG in diagnosing heart failure, that the natriuretic peptides BNP and NT-proBNP were of similar utility, and that simple clinical features (namely basal crepitations, previous history of myocardial infarction; ankle oedema and gender) could be used as a way of determining which patients should be referred directly for echocardiography without having any prior testing. The potential implications of this work are currently being reviewed by NICE. Practical guidance on how to interpret BNP levels is hampered by heterogeneity between studies as to what constitutes a ‘raised’ BNP. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18973463" target="_blank"&gt;Mastandrea&lt;/A&gt; reviewed this heteregoneity and found three key sources: differences in how the diagnosis of heart failure was made; differences in the clinical severity of heart failure; and differences in the frequency of heart failure in the population being studied.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Risk stratification&lt;/STRONG&gt;&lt;/SPAN&gt; &lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;There have been a number of systematic reviews published in the last year that have looked at what clinical or laboratory tests might give insights into prognosis in people with heart failure. One of the surprising observations that has been previously noted is that people with raised body mass index (BMI) in heart failure actually have longer life expectancy. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18585492" target="_blank"&gt;Oreopoulos et al&lt;/A&gt;&amp;nbsp;revisited this ‘obesity paradox’ in their systematic review and did indeed find lower mortality in overweight people (BMI 25-30kg/m2) and in obese people (BMI =30kg/m2) with heart failure as compared to people with BMI less than 25kg/m2. While it is likely that this is the result of confounding (e.g obese people have their heart failure diagnosed earlier; weight loss is a marker for more severe disease in heart failure), it is interesting that the association was still present in studies that adjusted for many potential confounders. An easier to interpret finding is the worse mortality in heart failure in people with diabetes as compared to those without diabetes that was noted by &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19398078" target="_blank"&gt;Kamalesh et al &lt;/A&gt;in their systematic review. C-Reactive Protein (CRP) is a marker of inflammation that is increasingly being used in clinical practice. The systematic review by Araujo et al explored whether CRP was of prognostic value in people who had heart failure. While they did find an association between raised CRP levels and prognosis in heart failure, the clinical implications of this are unclear, since it is difficult to define ‘cut-off’ points that differentiate normal from abnormal, and it is not certain what action should be taken in people with raised CRP. Heart failure is categorised into two main groups: heart failure due to left ventricular systolic dysfunction (Heart Failure with Reduced Ejection Fraction - HFREF) and heart failure with preserved ejection fraction (HFPEF). It has previously been reported in retrospective studies that HFPEF and HFREF have similar prognosis, but the systematic review of prospective studies by &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19307097" target="_blank"&gt;Somaratne et al (a)&lt;/A&gt; showed that people with HEFPEF have much better outcome (50% lower mortality) than people with HFREF. Prospective design is a more robust way to assess prognosis, so it is likely that there is a genuine difference in prognosis between these two groups that has perhaps been masked in the past by the fact that HFPEF patients tend to be older. Other echocardiographic parameters can also offer insights into prognosis. One such parameter is restrictive mitral filling pattern (RFP), which the MeRGE Collaborators have shown in their individual patient data analysis is associated with poorer survival, and that this effect is independent of age, left ventricular ejection fraction, and NYHA class. Another such parameter is pseudo-normal mitral filling, which has also been found to be associated with worse prognosis (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19654140" target="_blank"&gt;Somaratne et al (b)&lt;/A&gt;). &amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: Pooled analysis of 39,505 subjects. Journal of Cardiac Failure. 2009; May, 15 (4): 305-309. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19398078" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Madhok V, Falk G, Rogers A, Struthers AD, Sullivan FM, Fahey T. The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care. A diagnostic accuracy systematic review. BMC Family Practice. 2008, Oct, 9: 56. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18842141" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care.Health Technol Assessment. 2009; 13 (32): 1-207. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19586584" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Mastandrea, P. Some heterogeneity factors affecting the B-type natriuretic peptides outcomes: a meta-analysis. Clinical Chemistry &amp;amp; Laboratory Medicine. 2008;46:1687–1695. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18973463" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure. A meta-analysis. American Heart Journal. 2008; 156: 13-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18585492" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Somaratne JB, Whalley GA, Poppe KK, Gamble GD, Doughty RN. Pseudonormal mitral fillings is associated with similar poor prognosis as restrictive fillings in patients with heart failure and coronary heart disease: A systematic review and meta-analysis of prospective studies. Journal of the American Society of Echocardiography. 2009; 22 (5): 494-498. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19307097" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction. A literature-based meta-analysis. European Journal of Heart Failure. 2009; 11, 855–862. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19654140" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19691616" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional documents and weblinks&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Araújo, JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Prognostic Value of high-sensitivity C-reactive protein in heart failure. A systematic review. Journal of Cardiac Failure. 2009; 15 (3): 256-266. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19327628" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Au-Yong, A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2. C-reactive protein in the differential diagnosis of heart failure and chest infections.Emergency Medicine Journal. 2009; 26: 58-59. &lt;A href="http://emj.bmj.com/cgi/content/extract/26/1/58" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Balion CM, Robert S, McKelvie, SR, Santaguida P, Booker L, Worster A, Raina P, McQueen MJ, Hill, S. Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: Is BMP or NT-ProBNP a useful assessment tool? Clinical Biochemistry. 2008; 41 (4-5): 266-276. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17991434" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2009; Feb, 11(2):119-129. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19168509" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Landrum, L. Description of symptom severity in heart failure. Review of the literature. Home Health Care Management Practice. 2009; April, 21 (3): 158-170. &lt;A href="http://hhc.sagepub.com/cgi/content/abstract/21/3/158" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Meta-analysis Research Group in Echocardiography (MeRGE) Heart Failure Collaborators. Independence of restrictive filling patterns and LV ejection faction with mortality in heart failure: An individual patient meta-analysis. European Journal of Heart Failure. 2008; 10 (8): 786-792. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18617438" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Najafi F, Jamrozik K, Dobson AJNajafi, F, Jamrozik K. Understanding the ‘epidemic of heart failure’: A systematic review of trends in determinants of heart failure. European Journal of Heart Failure. 2009; 11 (5):472-479. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19251729" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. Journal of Hypertension. 2008; 26 (7): 1477-1486. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18551026" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;van der Avoort CJ, Filion KB, Dendukuri N, Brophy JM. Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left-ventricular dysfunction. A systematic review and meta-analysis. BMC Cardiovascular Disorders. 2009; 9: 5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19175926" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Diagnosis%5BTitle%2FAbstract%5D+OR+%28Risk%5BTitle%2FAbstract%5D+AND+Stratification%5BTitle%2FAbstract%5D%29%29+ AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;Heart Failure and Diagnosis or Risk Stratification&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325170</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325170]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Home Page</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,JUL-SEP 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>2009 Annual evidence Update on Heart Failure: Introduction and Contents page</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE border=1 width="80%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 alt="Diagnosis and Risk Stratification" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0014_HF2009diagnosis.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis and Risk&lt;BR&gt;Stratification&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 alt="Pharmacological Therapy" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0015_HF2009tablets.gif" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325498:0" name=internalLink&gt;Pharmacological&lt;BR&gt;Therapy&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0016_HF2009Devices.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices and&lt;BR&gt;Interventions&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 alt="Psychological Treatment" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0017_HF2009Psych.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychological&lt;BR&gt;Treatment&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0018_HF2009rehabilitation.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;BR&gt;.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Organisation and&lt;BR&gt;Monitoring of Care&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0020_HF2009palliative.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative&lt;BR&gt;Care&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt=Miscellany src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0021_HF2009other.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;BR&gt;.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=89&gt;&lt;BR&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key&lt;BR&gt;Documents&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 alt=Methodolgy src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0023_rubik89px.jpg" height=70&gt;&lt;BR&gt;&lt;A href="nelh:326457:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;BR&gt;.&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=1 width="100%" Valign="top"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="70%"&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION 1 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 12pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="LETTER-SPACING: 1pt; FONT-SIZE: 12pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Introduction&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Clinical Lead, NHS Evidence-cardiovascular.&lt;BR&gt;Professor of Clinical Practice, University of Surrey.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="70%"&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;WELCOME TO THE 2009 EVIDENCE UPDATE ON HEART FAILURE&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Our Evidence Updates provide findings from a detailed search of recent, high quality evidence –mostly systematic reviews- on a particular topic, to support clinicians, commissioners and patients in designing and delivering improved care, and making decisions with individual patients. I hope that the information we provide is useful to clinicians, commissioners and patients and that it will help bring about improvements in care. My thanks are due once again to our expert advisors and our project team.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;UNCERTAINTIES : ACKNOWLEDGING WHAT WE DON’T KNOW....&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;NHS Evidence - cardiovascular is playing a key role in identifying uncertainties about the effectiveness of treatments, helping to combat what Sir Iain Chalmers describes as ‘therapeutic ignorance’ &lt;A href="http://www.bmj.com/cgi/content/extract/337/jul16_3/a841?papetoc" target="_blank"&gt;[read more..]&lt;/A&gt;.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;To learn more visit the &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;Database of Uncertainties about the Effects of Treatments &lt;/A&gt;(DUETS).&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;B&gt;Expert Reviewers&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P align=center&gt;&amp;nbsp; 
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Dr Andrew L Clark&lt;/SPAN&gt; 
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Professor Jonathan Mant&lt;/SPAN&gt; 
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Professor David Thompson&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Jillian Riley&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="nelh:326242:0" name=internalLink&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;About our panel&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;EM&gt;Feedback and comment&lt;/EM&gt;&lt;/SPAN&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="70%"&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;About this Annual Evidence Update&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Our literature search was designed to add to the body of knowledge in last year's Heart Failure Evidence Update. Database searches were designed with a slight overlap period to ensure a good fit.&lt;/P&gt;
&lt;P&gt;We brought together a small panel of experts to support us by summarising key evidence and commenting on key developments in the field.&lt;/P&gt;
&lt;P&gt;In these pages you will find a concise update on the latest high quality evidence on heart failure, together with links to key guidance information and websites.&lt;/P&gt;
&lt;P&gt;View&amp;nbsp;a &lt;A href="nelh:326457:0" name=internalLink&gt;complete description of our methodolgy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;Feedback&lt;/H3&gt;
&lt;P&gt;Please tell us if this evidence update meets your needs. We would like to hear from you about how you use our site, what is useful, and what we can improve.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Contact us here&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/Page.aspx?prv=y&amp;amp;pagename=HFAEU08INT" target="_blank"&gt;Link to 2008 Heart Failure Annual Evidence Update&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>326457</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=326457]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Methodology</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,HEART FAILURE,OCT-DEC 09,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>2009 Annual evidence Update on Heart Failure: Methodology</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt; &lt;P&gt;Published 5th October 2009 &lt;/P&gt; &lt;TABLE width="100%" border=3&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt; &lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;TABLE width="100%" border=1&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD width="80%"&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;11 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Methodology &lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt; &lt;TD&gt; &lt;P align=right&gt;&lt;IMG id=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326457/nelhImp_0000_rubik89px.jpg" name=nelh_tempImage3&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P&gt; &lt;TABLE width="100%" border=0&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD width="80%" border="0"&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/P&gt; &lt;H2&gt;Methodology&lt;/H2&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Our literature search was designed to add to the body of knowledge in last year's Heart Failure Evidence Update. Searches were designed with a slight overlap period to ensure a good fit. &lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;We brought together a small panel of experts to support us by summarising key evidence and commenting on key developments in the field. &lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;We identified systematic reviews published between June 2008 and July 2009 and sifted them for relevance and quality. Material included in the last evidence update was excluded, with exceptions made for reviews amended within the search period and a small number not previously considered by an expert reviewer. Our reviewers were able to identify additional evidence relevant to any section.&lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;We were able to take into account the NICE strategy being prepared for a partial review of Heart Failure guideline which will be published next year.&lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;In addition to a wide range of databases, we hand searched other Key sources for relevant guidance, statistics and reports. We were able to include some evidence published after the main search period.&lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Download our &lt;A href="http://www.library.nhs.uk/specialistlibrarysearch/download.aspx?resid=326457" target="_blank"&gt;search strategy&lt;/A&gt; and &lt;A href="http://www.library.nhs.uk/specialistlibrarysearch/download.aspx?resid=326799" target="_blank"&gt;bibliography&lt;/A&gt;. &lt;/SPAN&gt;&lt;/P&gt; &lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Also see &lt;STRONG&gt;related files&lt;/STRONG&gt; at the foot of this page.&lt;/P&gt;&lt;/SPAN&gt; &lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt; &lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>326456</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=326456]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Miscellany</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,GENERAL  / OVERVIEWS,OCT-DEC 09,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 9 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Miscellany&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;9 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt"&gt;&lt;B&gt;Miscellany&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Clinical Lead NHS Evidence – cardiovascular.&lt;BR&gt;Professor of Clinical Practice, Faculty of Health and Medical Sciences, University of Surrey.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0000_HF2009other.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%"&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Enhanced external counterpulsation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Enhanced external counterpulsation (EECP) has been used to improve symptoms in patients with chronic stable angina and has been investigated in the setting of the patient with mild heart failure. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19409154" target="_blank"&gt;McKenna&lt;/A&gt;&amp;nbsp;et al&amp;nbsp;undertook a systematic review and economic analysis for the Health Technology Assessment (HTA) programme, to determine clinical and cost-effectiveness of this EECP compared to standard care. One randomised trial in heart failure was identified. At six months post treatment, more patients in the EECP group achieved a 60 second increase in exercise duration (RR 1.39, 95% CI 0.89-2.16) but improvement in peak VO2 was similar compared to patients receiving standard care. Patients receiving EECP had more improvement in NYHA class (RR 2.25, 95% CI 1.25-4.06) and mean exercise duration, but there were more withdrawals from the EECP arm of the study due to adverse events.&lt;BR&gt;Uncertainty remains about the role of EECP in heart failure care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Non-invasive positive pressure ventilation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005351/frame.html" target="_blank"&gt;Vital&lt;/A&gt; et al undertook a Cochrane systematic review of the safety and effectiveness of non-invasive positive pressure ventilation (NPPV) for cardiogenic pulmonary oedema. 21 studies (19 RCTs) were included from a comprehensive search of databases and bibliographies.&amp;nbsp; Compared to standard medical care, NPPV significantly reduced hospital mortality (RR 0.6, 95% CI 0.45-0.84) and need for endotracheal intubation (RR 0.53, 95% CI 0.34-0.83) with NNT of 13 and 8 respectively. There was no difference in length of stay, but ICU stay was reduced by 1 day. No significant increase in MI during NPPV was observed. NIPPV, especially CPAP, in addition to standard medical therapy, was shown to be a safe and effective intervention for the treatment of adult patients with acute cardiogenic pulmonary oedema. Further studies are required, however, to address uncertainties regarding length of hospital stay, long-term mortality, costs and the time required to manage NPPV, and to address questions about the benefits in hypercapnic versus non- hypercapnic patients, and to compare benefits of bilevel NPPV with CPAP.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;McKenna C, McDaid C, Suekarran S, Hawkins N, Claxton K, Light K, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technology Assessment. 2009; 13 (24): 1-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19409154" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Vital FMR, Saconato H, Ladeira MT, Sen A, Hawkes CA, Bernardo et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema.The Cochrane Database of Systematic Reviews. 2008 (3):CD005351. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005351/frame.html" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Additional documents and weblinks&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Anemia and mortality in heart failure patients a systematic review and meta-analysis. Journal of the American College of Cardiology. 2008;52(10). [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18755344" target="_blank"&gt;abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: A meta-analysis and systemic review. Congestive Heart Failure. 2009;15(3):123-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19522961" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Muth C, Gensichen J, Beyer M, Hutchinson A, Gerlach FM. The systematic guideline review: method, rationale, and test on chronic heart failure. BMC Health Services Research. 2009; 9:74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19426504" target="_blank"&gt;[abstract] &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325496</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325496]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Organisation and Monitoring</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,OCT-DEC 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 7 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Organisation and Monitoring&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;7 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Organisation and Monitoring of Care&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;&lt;STRONG&gt;Jillian Riley&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt"&gt;Head of Post-Graduate Education (Nursing),Royal Brompton Hospital &lt;BR&gt;Honorary Lecturer, Imperial College, London. &lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325496/nelhImp_0000_HF2009monitor.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%"&gt;
&lt;P&gt;Seven reviews were identified. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19332417" target="_blank"&gt;Maric and colleagues&lt;/A&gt; undertook a systemic review including 56 studies published before August 2007. The review included studies employing a variety of telemonitoring interventions that ranged from simple electronic weighing scales to video-consultation and a variety of study designs. Remote monitoring&amp;nbsp;was acceptable to patients, improved quality of life and decreased the risk of hospitalisation, but more randomised trials are required to establish efficacy. Moreover, it remains&amp;nbsp;important to establish the exact components of telemonitoring that provide benefit.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007228/frame.html" target="_blank"&gt;Inglis et al &lt;/A&gt;are undertaking a review of telemonitoring and telephone support programmes through the Cochrane Collaboration and are due to report their findings&amp;nbsp;later this year. When&amp;nbsp;considering the cost of remote monitoring, &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18817497" target="_blank"&gt;Seto’s review &lt;/A&gt;suggests that an initial financial investment is required but that&amp;nbsp;overall cost savings may be possible through a reduction in hospitalisation and travel costs. However only 10 telemonitoring studies that included an economic evaluation were identified and there were large differences in both the models of telemonitoring and the costs included.&lt;/P&gt;
&lt;P&gt;Finally, &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=283857&amp;amp;tabID=289" target="_blank"&gt;Koshman et al &lt;/A&gt;reviewed studies of disease management programmes, to establish to what extent the addition of a pharmacist to the multi-disciplinary team influenced patient outcome. They identified a total of 12 randomised studies and categorised them according to the level of involvement of the pharmacists; pharmacist directed care (n=7) and pharmacist collaborative care (n=5).&amp;nbsp;A meta-analysis&amp;nbsp;concluded that patient outcome is&amp;nbsp;improved with pharmacist &lt;EM&gt;collaborative&lt;/EM&gt; care&amp;nbsp;with a greater reduction in heart failure related hospitalisations associated with collaborative care (OR, 0.84; 95% CI, 0.61 – 1.15) than with pharmacist directed care alone (OR, 0.89; 95% CI, 0.68 – 1.17).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clark RA, Inglis SC, McAlister FA, Cleland JGF, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure. A systematic review and meta-analysis. Cochrane Database of Systematic Reviews. 2008. &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=283857&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Archives of Internal Medicine. 2008;168(7):687-694. &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=283857&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Maric B, Kaan A, Ignaszewski A, Lear SA. A systematic review of telemonitoring technologies in heart failure. European Journal of Heart Failure. 2009;11(5):506-17. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19332417" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Seto, E. Cost comparison between telemonitoring and usual care of heart failure: A systematic review.Telemedicine and e-Health. 2008. Sept, 14 (7): 679-686. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18817497" target="_blank"&gt;[abstract]&amp;nbsp;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Additional&amp;nbsp;documents and weblinks&lt;/STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Doyon O, Parent N. Systematic review coupled with meta-analysis regarding the clinical follow-up programs of congestive heart failure (CHF) patients. Canadian journal of cardiovascular nursing. 2008;18(4):56-67 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19093423" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Inglis SC, Clark RA, Cleland JGF, McAlister FA, Stewart S. Structured telephone support or telemonitoring programs for patients with chronic heart failure. Cochrane Database of Systematic Reviews: Protocols. 2008;Issue 3. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007228/frame.html" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, Krumholz HM. Statistical models and patient predictors of readmission for heart failure: a systematic review. Archives of Internal Medicine. 2008;168 (13): 1371-1386. [&lt;A href="http://archinte.ama-assn.org/cgi/content/abstract/168/13/1371" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray JJV, Naylor MD, et al. What Works In Chronic Care Management: The Case Of Heart Failure. Health Affairs 2009;28(1):179-189. &lt;A href="http://content.healthaffairs.org/cgi/content/abstract/28/1/179" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=(%28Telemonitor*%5BTitle%2FAbstract%5D+OR%28(Care%5BTitle%2FAbstract%5D+AND+Management%5BTitle%2FAbstract%5D)+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;Heart Failure and&amp;nbsp;Care Management or TeleMonitoring&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325500</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325500]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Palliative Care</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,GENERAL  / OVERVIEWS,OCT-DEC 09,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 8 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Palliative Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;8 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Palliative Care&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Professor of Cardiovascular Nursing, University of Leicester.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325500/nelhImp_0000_HF2009palliative.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%" border="0"&gt;The prevalence of symptoms, especially fatigue, dyspnoea and pain, is high in patients with chronic heart failure. In end-stage congestive heart failure the daily symptom burden can hamper patient management, including palliative care, and further research is warranted to develop patient-centred palliative care programmes (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18801874" target="_blank"&gt;Janssen et al. 2008&lt;/A&gt;). &lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Janssen DJA, Spruit MA, Wouters EFM, Schols JMGA. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliative Medicine 2008;22(8):938-948 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18801874" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of articles published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Palliative*%5BTitle%2FAbstract%5D+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D%29" target="_blank"&gt;Heart Failure and Palliative Care&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325498</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325498]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Pharmacological Therapy</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,EMERGENCY CARE,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,HEART FAILURE,BETA BLOCKERS,GENERAL  / OVERVIEWS,CARDIOVASCULAR,HEART FAILURE,OCT-DEC 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 3 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Pharmacological Therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;3 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt"&gt;&lt;B&gt;Pharmacological Therapy&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Dr. Andrew L Clark&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Reader and Honorary Consultant Cardiologist, Castle Hill Hospital, University of Hull.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325498/nelhImp_0000_LARGEtablets.gif" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%" border="0"&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Chronic heart failure&lt;/STRONG&gt; is one of the most rewarding long-term conditions for physicians and health workers to treat as modern pharmacological therapy has dramatically improved the outcome for most patients. Life-expectancy once the diagnosis has been made has approximately doubled over the last 20 years, largely due to combination therapy with angiotensin converting enzyme inhibitors (ACEIs) (or angiotensin receptor blockers; ARBs), beta adrenoceptor antagonists (beta-blockers) and aldosterone antagonists (AAs). &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;The success of “triple therapy” strengthens the neurohormonal hypothesis of the pathophysiology of chronic heart failure: the failing heart sets in train a series of neural and hormonal responses which cause further damage to the myocardium. Interrupting the vicious cycle is how triple therapy confers benefit. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;The success of the neurohormonal approach has led to large numbers of clinical trials designed to assess the effects of more vigorous neurohormonal blockade or blockade of different neurohormonal systems. However, despite much effort by investigators and pharmaceutical companies, further neurohormonal blockade has not been successful, perhaps suggesting that a limit has been reached. However, there is much still to be learned about the best way to use the successful treatments. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;ACEIs/ARBs&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Whether there is any substantial difference between ACEIs and ARBs in heart failure treatment continues to generate a lot of discussion, some of it expressed very forcefully! &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18793376" target="_blank"&gt;Shibata&lt;/A&gt; and colleagues find no evidence for any difference between the agents, or a benefit for combination therapy. They suggest that ARBs might reduce the risk of hospitalisation, a result driven by the CHARM study. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Beta blockers &lt;BR&gt;&lt;/STRONG&gt;How beta-blockers mediate their beneficial effects is not completely clear. The simple hypothesis that the reduction in heart rate is central is given support by the meta-analysis from &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=319495&amp;amp;tabID=289" target="_blank"&gt;McAlister&lt;/A&gt;, which suggests that for every heart rate reduction of 5 beats/min there is a nearly 20% reduction in risk: the dose of beta-blocker was not directly associated with risk reduction.&lt;BR&gt;A vital unanswered question with beta-blocker therapy is whether its use can be extended to children. The Cochrane analysis&amp;nbsp;(&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=304964&amp;amp;tabID=289" target="_blank"&gt;Frobel)&lt;/A&gt; attempts to answer the question, but there is simply not enough evidence to know. Whether a large enough trial can ever be mounted is debatable.&lt;BR&gt;Another debating point in beta-blocker therapy is the suitability or otherwise of their use as first line treatment for hypertension. Given their success in treating heart failure once it has occurred, it’s possible that beta-blockers might offer the specific benefit of reducing incident heart failure, but the finding from &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18848139" target="_blank"&gt;Bangalore&lt;/A&gt; is that the reduction in risk of heart failure is driven purely by blood pressure reduction, and that beta-blockers have no effect above what might be expected from blood pressure reduction alone. &lt;/SPAN&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Aldosterone antagonists&lt;/STRONG&gt; &lt;BR&gt;Aldosterone antagonists have only been trialled in patients with either post-infarction heart failure or with severe symptoms. The meta-analysis by &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19066207" target="_blank"&gt;Ezekowitz&lt;/A&gt; collected a substantial number of patients from small studies of aldosterone antagonists in very heterogenous patient groupings and found a beneficial effect in patients with modest symptoms and with normal left ventricular ejection fraction. The findings should encourage new randomised trials, but cannot be taken as evidence that AAs should be more widely used.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Interactions&lt;/STRONG&gt;&lt;BR&gt;Any study to have examined the effects of non-steroidal anti-inflammatory agents (NSAIDS) on heart failure show an increase in the risk, reviewed in &lt;A href="http://eurjhf.oxfordjournals.org/cgi/content/abstract/10/11/1102" target="_blank"&gt;Scott&lt;/A&gt;. Part of the reason may be the interaction between NSAIDS and ACE inhibitors &lt;FONT size=2&gt;(&lt;/FONT&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16905022" target="_blank"&gt;Dagenais&lt;/A&gt;&lt;FONT size=2&gt;).&amp;nbsp;&lt;/FONT&gt;Aspirin is, of course, an NSAID – and there is astonishingly little evidence to support the use of aspirin in patients with chronic heart failure Its use is associated with an increase in the risk of adverse events compared with warfarin (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19289640" target="_blank"&gt;Massie&lt;/A&gt;). Perhaps the time has come to stop recommending the use of aspirin in patients with chronic heart failure due to ischaemic heart disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;New fields of research&lt;BR&gt;&lt;/STRONG&gt;As targeting neurohormonal systems seems to have reached its end, much current research effort is directed at novel targets, such as the preservation of renal function with adenosine antagonists, the alleviation of hyponatraemia and the treatment of anaemia.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Acute heart failure&lt;/STRONG&gt; &lt;BR&gt;After a long period of inactivity in the field, there is much interest in acute heart failure, partly driven by the availability of potential new therapies. One of the oldest treatments for acute pulmonary oedema is opiates – undoubtedly effective at reducing anxiety, but of uncertain effect on outcome. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18973635" target="_blank"&gt;Sosnowski &lt;/A&gt;identified only five studies dealing specifically with the effects of opiates in acute cardiogenic pulmonary oedema. Although he concluded that there was no evidence to support the use of opiates, the striking feature of his analysis is the low quality of the available studies. It’s a fine example of how many therapies are accepted in current clinical use because of a “grandfather clause”; whether the studies will ever be done to demonstrate the efficacy of all the older treatments we use must be very doubtful.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width="20%"&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. Journal of the American College of Cardiology. 2008; 52(13):1062-1072. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18848139" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ezekowitz JA, McAlister, F A. Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials. European Heart Journal. 2009; 30(4):469-677. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19066207" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Frobel AK, Hulpke-Wette M, Schmidt KG, Läer S. Beta-blockers for congestive heart failure in children. Cochrane Database of Systematic Reviews. 2009. &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=304964&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009. 150 (11): 784-794. &lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=319495&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure. Meta-analyses of observational studies and randomised controlled trials. European Journal of Heart Failure 2008. Nov, 10 (11):1102-1107. &lt;A href="http://eurjhf.oxfordjournals.org/cgi/content/abstract/10/11/1102" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure. A systematic review. International Journal of Clinical Practice. 2008. Sept, 62 (9): 1397-1407. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18793376" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Sosnowski MA. Review article. Lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema. Emergency Medicine Australasia. 2008. Oct, 20: 384-390. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18973635" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Additional evidence added by reviewer&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16905022" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616-24 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19289640" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;Additional&amp;nbsp;documents and weblinks&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guo R, Pittler M, Edzard E. Hawthorn extract for treating chronic heart failure. Cochrane Database of Systematic Reviews: Reviews. 2008;Issue 1.&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=279137&amp;amp;tabID=289" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic Journal of Cardiology. 2009. Mar, 50: 105-118. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19329412" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opinion on Investigational Drugs 2008. Aug, 17 (8): 1143-50. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18616411" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ulbricht C, Basch E, Boon H, Karpa KD, Gianutsos G, Nummy K, Seamon E, Smith M, Sollars D, Tanguay-Colucci S, Varghese M, Weissner W, Woods J. An evidence-based systematic review of passion flower (Passiflora incarnata L.) by the natural standard research collaboration. Journal of Dietary Supplements. 2008. Nov, 5 (3): 310-340. &lt;A href="http://www.informaworld.com/smpp/content~content=a906952110~db=all~jumptype=rss" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Pharmacolog*%5BTitle%2FAbstract%5D+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%05+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;&lt;STRONG&gt;Heart Failure and Pharmacolog* Therapy&lt;/STRONG&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NHS Economic Evaluations Database&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Duerden M, Tabberer M. A budget impact model for a drug in heart failure: eplerenone. British Journal of Cardiology. 2008. 15 (2): 101-105. &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=319524&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;De Lissovoy G, Fraeman K, Salon J, Woodward TC, Sterz R. The costs of treating acute heart failure: An economic analysis of the SURVIVE trial. Journal of Medical Economics. 2008. 11 (3): 415-29. &lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=319537&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to Contents Page&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325497</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325497]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Psychology</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,HEART FAILURE,OCT-DEC 09,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 5 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Psychology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt"&gt;&lt;B&gt;SECTION&amp;nbsp;5 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Psychology&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Professor of&amp;nbsp;Cardiovascular Nursing, &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;University of Leicester.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325497/nelhImp_0000_HF2009Psych.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="90%" border="0"&gt;
&lt;P&gt;Depression is a significant problem in patients with heart failure and the incidence varies markedly (14-60%) according to whether it was assessed by screening instruments (21-60%) or diagnostic interviews (14-39%). Thus, depression screening instruments appear to over-estimate the incidence of depression (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18770104" target="_blank"&gt;Delville &amp;amp; McDougall 2008&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;Coping may play an important role in the management of depression. The type of coping a person uses may vary. Adaptive coping such as active coping, acceptance and planning tends to be used by more patients and is associated with less depression, whereas maladaptive coping such as denial and disengagement is likely to be associated with more depression. Thus, it is important to examine the type of coping people use and the strategies that might be used to assist them cope (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19242276" target="_blank"&gt;Allman et al. 2009&lt;/A&gt;). &lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Allman E, Berry D, Nasir L. Depression and coping in heart failure patients. A review of the literature. Journal of Cardiovascular Nursing 2009;24(2):106-117 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19242276" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Delville CL, McDoungall G. A systematic review of depression in adults with heart failure: instruments and incidence. Issues in Mental Health Nursing 2008;29(9):1002-1017 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18770104" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Psychol*%5BTitle%2FAbstract%5D+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;Heart Failure and Psychology&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325501</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=325501]]&gt;</url>
    <title>2009 Annual Evidence Update on Heart Failure - Rehabilitation</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,HEART FAILURE,OCT-DEC 09,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Section 6 of the 2009 Annual evidence Update on Heart Failure</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Heart Failure - Rehabilitation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence-cardiovascular Annual Evidence Update &lt;/P&gt;
&lt;P&gt;Published 5th October 2009 &lt;/P&gt;
&lt;TABLE width="100%" border=3&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage8 alt=Intro/Contents src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0000_Welcome.png" name=nelh_tempImage8&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0001_Diagnosis.png" name=nelh_tempImage1&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 alt=Pharmacology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0002_Pharma.png" name=nelh_tempImage5&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 alt="Devices and Interventions" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0003_Devices.png" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 alt=Psychology src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0004_Psych.png" name=nelh_tempImage6&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 alt=Rehabilitation src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0005_Rehabilitation.png" name=nelh_tempImage7&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 alt="Organisation and Monitoring of Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0006_Monitor.jpg" name=nelh_tempImage2&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage4 alt="Palliative Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0007_Palliative.png" name=nelh_tempImage4&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage3 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0008_Other.png" name=nelh_tempImage3&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID326456/nelhImp_0001_HF2009kybdsmall.jpg" name=nelh_tempImage0&gt;&lt;/A&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Intro/Contents&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325323:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt" valign="top"&gt;&lt;A href="nelh:325498:1" name=internalLink&gt;Pharmacology&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325499:0" name=internalLink&gt;Devices&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325497:0" name=internalLink&gt;Psychology&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325501:0" name=internalLink&gt;Rehabilitation&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325496:0" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325500:0" name=internalLink&gt;Palliative Care&lt;/A&gt; &lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:326456:0" name=internalLink&gt;Miscellany&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="FONT-SIZE: 8pt"&gt;&lt;A href="nelh:325502:0" name=internalLink&gt;Key Docs&lt;/A&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;SECTION&amp;nbsp;6 &lt;/B&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; LETTER-SPACING: 1pt; mso-bidi-font-family: Arial"&gt;&lt;B&gt;Rehabilitation&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;Professor of Cardiovascular Nursing, University of Leicester.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325501/nelhImp_0000_HF2009rehabilitation.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback and comment&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;Link to contents page&lt;/A&gt;&lt;/EM&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE width="100%" border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="80%" border="0"&gt;&lt;STRONG&gt;Self-management education&lt;/STRONG&gt; is a key component of rehabilitation for patients with heart failure and nurses play a central role as educator. &lt;BR&gt;&lt;BR&gt;Though beneficial, &lt;STRONG&gt;educational interventions&lt;/STRONG&gt; vary markedly and those that specify content, educators, materials used and timing/dose are needed to quantify their impact (&lt;A href="http://www.ingentaconnect.com/content/bsc/jbr/2009/00000007/00000003/art00002" target="_blank"&gt;Boren et al. 2009&lt;/A&gt;)&lt;BR&gt;&lt;BR&gt;Although &lt;STRONG&gt;exercise training&lt;/STRONG&gt; is an accepted intervention beneficial to patients with heart failure, such as having a favourable effect on brain natriuretic peptide (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19664831" target="_blank"&gt;Smart &amp;amp; Steele 2009&lt;/A&gt;), more information is needed to clarify the effects of exercise and optimise the interventions. There are undoubtedly favourable physiological responses to exercise but in most of the trials, the sample sizes are relatively small, the groups selected and the exercise programme varies widely. These need to be addressed and reliable strategies for maintaining the positive effects of exercise and extending them to daily life (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18829599" target="_blank"&gt;Tai et al. 2009&lt;/A&gt;).&lt;BR&gt;&lt;BR&gt;Many patients with chronic heart failure will experience disabling dyspnoea, fatigue and exercise intolerance and attempts to rehabilitate them with exercise training may be futile. Thus, new modalities such as &lt;STRONG&gt;neuromuscular electrical stimulation&lt;/STRONG&gt; offer appeal and trials, though limited in number, have produced promising results, including improvements in muscle strength, exercise capacity and/or health status (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19363213" target="_blank"&gt;Sillen et al. 2009&lt;/A&gt;). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Oxygen therapy&lt;/STRONG&gt; is often used to treat dyspnoea in patients with CHF, but there are few studies and the evidence is insufficient to demonstrate a consistent beneficial effect of oxygen inhalation over air inhalation (&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004769/frame.html" target="_blank"&gt;Cranston et al. 2008&lt;/A&gt;). &lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-color: blue"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Boren SA, Wakefield BJ, Gunlock TL, Wakefield DS. Heart failure self-management education: a systematic review of the evidence. International Journal of Evidence-Based Healthcare 2009; 7 (3):159-168. &lt;A href="http://www.ingentaconnect.com/content/bsc/jbr/2009/00000007/00000003/art00002" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database of Systematic Reviews 2008;CD004769 &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004769/frame.html" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Sillen MJ, Speksnijder CM, Eterman RM, Janssen PP, Wagers SS, Wouters EF, Uszko-Lencer NH, Spruit MA. Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. Chest 2009;136(1):44-61 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19363213" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Smart NA, Steele M. Systematic review of the effect of aerobic and resistance exercise training on systemic brain natriuretic peptide (BNP) and N-terminal BNP expression in heart failure patients. International Journal of Cardiology 2009: e-publication ahead&amp;nbsp;of print &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19664831" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Tai M, Meininger JC, Frazier LQ. A systematic review of evidence interventions in patients with heart failure. Biological Research for Nursing 2008;10(2):156-182 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18829599" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical&amp;nbsp;Trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;View results of randomised controlled trials published in the last 2 years (Pubmed) on the topic of&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=%28Rehabilitat*%5BTitle%2FAbstract%5D+AND+Heart%5BTitle%2FAbstract%5D+AND+Failure%5BTitle%2FAbstract%5D%29+AND+%28%222007%2F10%2F01%22%5BEDat%5D+%3A+%222009%2F09%2F29%22%5BEDat%5D+AND+%222007%2F10%2F01%22%5BPDat%5D+%3A+%222009%2F09%2F29%22%5BPDat%5D+AND+Randomized+Controlled+Trial%5Bptyp%5D%29" target="_blank"&gt;Heart Failure and Rehabilitation&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;&lt;A href="nelh:325170:0" name=internalLink&gt;link to contents page&lt;/A&gt; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344327</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/119/22/e561]]&gt;</url>
    <title>2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging</title>
    <publicationDate>2009-05-18T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CORONARY HEART DISEASE,GENERAL,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report addresses the appropriate use of cardiac RNI. Improvements&lt;SUP&gt; &lt;/SUP&gt;in cardiovascular imaging technology and its application, coupled&lt;SUP&gt; &lt;/SUP&gt;with increasing therapeutic options for cardiovascular disease,&lt;SUP&gt; &lt;/SUP&gt;have led to an increase in cardiovascular imaging. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; September 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324548</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://content.onlinejacc.org/cgi/reprint/53/15/e1.pdf]]&gt;</url>
    <title>2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults.</title>
    <publicationDate>2009-04-14T00:00:00</publicationDate>
    <publisher>American College of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DIAGNOSIS,HEART FAILURE,JUL-SEP 09,GENERAL,GENERAL,PREVENTION,CONDITIONS,DIAGNOSIS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document focuses on the prevention of heart failure (HF)&amp;nbsp;and on the diagnosis and management of chronic heart failure in the adult patient with normal or low left ventricular ejection fraction (LVEF). The guidelines exclude&amp;nbsp;HF in children, both because the underlying causes of&amp;nbsp;HF in children differ from those in adults and because none of the controlled trials of treatments for&amp;nbsp;HF have included children. The management of HF due to primary valvular disease is not considered (see &lt;EM&gt;ACC/AHA Guidelines on the management of patients with valvular heart disease&lt;/EM&gt;) nor are congenital malformations. No&amp;nbsp;recommendations are made&amp;nbsp;for the treatment of specific myocardial disorders (hemochromatosis, sarcoidosis or amyloidosis). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Cardiovascular surgeons, healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published online 26 March 2009 and later in the Journal of American College of Cardiology, 14 April 2009, Vol.53(15): e1-e90. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331093</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.109.192663v1]]&gt;</url>
    <title>2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update).</title>
    <publicationDate>2009-11-27T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL/OTHER,OCT-DEC 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;/P&gt;
&lt;P&gt;Aims:&amp;nbsp; To update the 2004 Guideline and&amp;nbsp;2007 Focused Update&amp;nbsp;ACC/AHA guidelines and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update.&lt;/P&gt;
&lt;P&gt;The document is divided into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Glycoprotein IIb/IIIa Receptor Antagonists&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Thienopyridines&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Parenteral Anticoagulants&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Triage and Transfer for PCI&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Control in STEMI&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Thrombus Aspiration&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Stent Selection for STEMI&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Angiography in Patients With Chronic&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Kidney Disease&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Fractional Flow Reserve&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;Intended audience: Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;Publication history information: Published in November 2009.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>374014</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374014]]&gt;</url>
    <title>2010  Evidence Update on Atrial Fibrillation - Miscellaneous</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,GENERAL  / OVERVIEWS,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010  Evidence Update on Atrial Fibrillation - Miscellaneous&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Miscellaneous&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;This section highlights other systematic reviews idenitfied that do not fall into any of the other catergories. There is no expert summary for this section.&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374014/nelhImp_0000_otherpic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 12pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace. 2009;11(9):1156-9. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The risk of AF is significantly higher in athletes compared with not athletes. However, this finding should be confirmed further in large-scale prospective longitudinal studies. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19633305" target="_blank"&gt;PubMed Abstract&lt;/A&gt;] &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Anselmi A, Possati G, Gaudino M. Postoperative Inflammatory Reaction and Atrial Fibrillation: Simple Correlation or Causation? Annals of Thoracic Surgery. 2009;88(1):326-33.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Among the strategies attempted, statins currently represent the most reasonable pathway in the clinical treatment-outcome balance to reduce the incidence of AF&lt;BR&gt;after cardiac surgery. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19559266" target="_blank"&gt;PubMed bstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. European Journal of Heart Failure. 2009;11(7):676-83. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;In conclusion, meta-analysis of 16 studies involving 53,969 patients suggests that the presence of AF is associated with an adverse prognosis in CHF irrespective of LV systolic function. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19553398" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;McCabe PJ. Psychological distress in patients diagnosed with atrial fibrillation: the state of the science. Journal of Cardiovascular Nursing. 2010 2010 Jan-Feb;25(1):40-51. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The presence of&amp;nbsp; psychological distress in patients diagnosed with AF has potential for stimulating physiological responses&amp;nbsp; that trigger and perpetuate AF episodes. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19935428" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. European Heart Journal. 2009;30(9):1038-45. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The bulk of evidence demonstrates that AF in patients hospitalized for AMI carries adverse prognostic implications regarding in-hospital, but also long-term mortality.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19109347" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Cochrane Protocols for Systematic Reviews&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;None identified&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="nelh:3557:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="nelh:3560:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Improvement [&lt;A href="nelh:101581:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="nelh:284666:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394565</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/122/16_suppl_2/S582]]&gt;</url>
    <title>2010 American Heart Association and American Red Cross International Consensus on First Aid Science With Treatment Recommendations</title>
    <publicationDate>2010-10-19T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,CARDIOPULMONARY ARREST,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;This statement aims to&amp;nbsp;answer 38 questions in first aid practice that had not been subjected to an evidence review process and to update those that needed to be updated since the 2005 process.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;It&amp;nbsp;Includes the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;First Aid for Medical Emergencies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chest Discomfort – Aspirin Administration &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Positioning of Breathing but Unresponsive Victim &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Oxygen Administration &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Poisoning &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anaphylaxis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394546</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/122/18_suppl_3/S640]]&gt;</url>
    <title>2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science</title>
    <publicationDate>2010-11-02T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,RECENT ADDITIONS,DECEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To analyse the sequence and priorities of the steps of CPR in light of current scientific advances to identify factors with the greatest potential impact on survival.The 2010 AHA Guidelines for CPR and ECC are based on the most current and comprehensive review of resuscitation literature ever published, the 2010 ILCOR International Consensus on CPR and ECC Science With Treatment Recommendations&lt;/P&gt;
&lt;P&gt;More detailed information is available in other parts of this publication. See related links below.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published Novemeber 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334321</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334321]]&gt;</url>
    <title>2010 Annual Evidence Update on Chest Pain : Contents page. (Published February 2010)</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,GENERAL / OVERVIEWS,GENERAL / OVERVIEWS,STABLE ANGINA,OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chest Pain : Contents page. (Published February 2010)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;DIV align=center&gt;
&lt;CENTER&gt;
&lt;TABLE border=0 cellSpacing=4 width="31%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG style="WIDTH: 120px; HEIGHT: 84px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0008_Diagnosispic.gif" width=124 height=90&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG style="WIDTH: 119px; HEIGHT: 85px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0009_anginapic.gif" width=111 height=91&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG style="WIDTH: 125px; HEIGHT: 84px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0010_acs2.gif" width=123 height=94&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;IMG id=nelh_tempImage9 name=nelh_tempImage9 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0012_whiteblock.JPG"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="20%" align=middle&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;BR&gt;&lt;BR&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;FONT size=2&gt;&lt;/A&gt;&lt;FONT size=2&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:331183:1" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Diagnosis and Risk&lt;/STRONG&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Angina&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Acute Coronary&lt;BR&gt;Syndromes&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;FONT size=2&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG"&gt;&lt;BR&gt;&lt;BR&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;&lt;A href="nelh:343143:0" name=internalLink&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG style="WIDTH: 126px; HEIGHT: 85px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0011_Surgerypic.gif" width=127 height=103&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG style="WIDTH: 123px; HEIGHT: 85px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0012_otherpic.gif" width=120 height=100&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG style="WIDTH: 120px; HEIGHT: 87px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0013_Uncertaintiespic.gif" width=126 height=100&gt;&lt;/A&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;/TD&gt;
&lt;TD align=middle&gt;&lt;IMG style="WIDTH: 58px; HEIGHT: 52px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" width=103 height=71&gt;&lt;BR&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;&lt;A href="nelh:343153:0" name=internalLink&gt;&lt;FONT size=2&gt;&lt;FONT size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Surgery or Interventions&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:341682:0" name=internalLink&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;Miscellaneous&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/stroke/Page.aspx?&amp;amp;amp;pagename=SAEUFEED08" target="_blank"&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 65px; HEIGHT: 39px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334321/nelhImp_0015_feedbackimage.gif" width=70 height=42&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; &lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;Feedback&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.srr.org.uk/" target="_blank"&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;
&lt;P&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:331177:1" name=internalLink&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:331182:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="83%"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="83%" align=middle&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/stroke/Page.aspx?&amp;amp;amp;pagename=SAEUFEED08" target="_blank"&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/CENTER&gt;&lt;/DIV&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>343143</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=343143]]&gt;</url>
    <title>2010 Annual Evidence Update on Chest Pain : Contributors</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,STABLE ANGINA,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chest Pain : Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;:&amp;nbsp; C O N T R I B U T O R S &lt;BR&gt;&lt;/STRONG&gt;&lt;U&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;&lt;U&gt;&lt;/A&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;&lt;U&gt;&lt;U&gt;&lt;U&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;&lt;U&gt;&lt;U&gt;&lt;U&gt;Go back to Chest Pain Annual Evidence Update 2010 Contents Page&lt;/U&gt;&lt;/A&gt;&lt;/U&gt;&lt;BR&gt;&lt;/U&gt;&lt;/U&gt;&lt;/U&gt;&lt;/U&gt;&lt;/A&gt;&lt;U&gt;&lt;/A&gt;&lt;/U&gt;&lt;/U&gt;&lt;/A&gt;&lt;/U&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343143/nelhImp_0000_contributorspic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=left&gt;We would like to thank the following experts for their contributions to the 2010&amp;nbsp;Evidence&amp;nbsp;Update on Chest Pain.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Professor Steve Goodacre, Professor of Emergency Medicine, School of Health and Related Research, University of Sheffield.&lt;BR&gt;&lt;/STRONG&gt;Steve Goodacre is Professor of Emergency Medicine at the University of Sheffield, UK and Consultant at the Northern General Hospital. His research interests include organisation of emergency care, economic analysis, clinical trials in emergency medicine and developing evaluation methods for emergency care. His current major research projects include RATPAC trial of point-of-care cardiac markers, the 3Mg trial of magnesium sulphate in acute asthma and the DAVROS study. He is also a Deputy Editor for the Emergency Medicine Journal and Consulting Editor for Annals of Emergency Medicine.&lt;BR&gt;&lt;EM&gt;For further details see: &lt;/EM&gt;&lt;A href="http://www.shef.ac.uk/scharr/sections/hsr/emergency/staff/stevegoodacre.html" target="_blank"&gt;&lt;EM&gt;http://www.shef.ac.uk/scharr/sections/hsr/emergency/staff/stevegoodacre.html&lt;/EM&gt;&lt;/A&gt;&lt;BR&gt;(Warning:&amp;nbsp;Requires leaving this site)&amp;nbsp;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Dr Kathryn E Griffith, GP,&amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;University Health Centre, York University, Heslington, York.&lt;/STRONG&gt; &lt;BR&gt;Dr Griffith is a GP in York and also works at York Hospital Foundation Trust within the Cardiac Research Department and the Rapid Access Chest Pain Clinic. She has completed her MSc in Postgraduate Cardiology and is now a lecturer on the course for Practitioners with a Special Interest in Cardiology. She is chair elect of the Primary Care Cardiovascular Society and a member of the Renal Advisory Group at the Department of Health.&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Dr Sunil Nadar, Consultant Interventional Cardiologist,&amp;nbsp;Heart of England NHS Trust, Birmingham.&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;Dr Nadar is a consultant Inerventional Cardiologist at the Heart of England NHS Trust, Birmingham. Besides interventional cardiology,&amp;nbsp;his other interests include thrombosis, platelet physiology and hypertension.&amp;nbsp;He has published extensively in the above topics and also frequently peer review articles for journals in the above topics. &lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Alison Pottle, Consultant Nurse in Cardiology, Royal Brompton and Harefield NHS Trust.&lt;BR&gt;&lt;/STRONG&gt;Alison Pottle trained at St Mary’s Paddington and first came to Harefield Hospital in 1985. In August 1986 she left to undertake the ENB 124 CCU course at West Middlesex. She returned to Harefield Hospital in July 1987 and initially worked as the Senior Staff Nurse on one of the Medical wards. She was promoted to Sister in June 1988 and continued in this role until 1995 when she set up the post of Resuscitation Officer for the hospital. From then until June 2000 she worked 2 days a week as Resuscitation Officer and 3 days a week as Senior Sister on the medical high dependency unit. 
&lt;P&gt;In June 2000 she was appointed as Nurse Consultant in Cardiology, one of the first posts in Cardiology in the country. She initially had 3 areas of clinical responsibility – running the Rapid Access Chest Pain Clinic, setting up and running PCI follow-up clinics and establishment of an LDL-apheresis service at Harefield. The role and responsibilities have expanded greatly in the 9 years she has been in post. She has now also set up pre-admission clinics for pre-PCI patients and is planning to extend this initiative to all elective admissions in 2010. She also oversees the nurse-led ICD/CRT service and manage a team of 10 cardiology nurse specialists. She has been published in a number of cardiac and nursing journals on a wide range of subjects. She also achieved first prize in the Cardiac Nursing Awards in 2008 for excellence in primary or secondary prevention.&lt;/P&gt;
&lt;P&gt;Her training involved the RGN and Diploma in Nursing combined. She has since obtained a BSc Hons in Nursing, 730 Teaching Certificate, ENB 124, 998, 934 and completed an MSc in Cardiology in 1999. She is an Advanced Life Support Instructor and was responsible for setting up and running the Advanced Life Support Course at Harefield. She is also a trained aromatherapist. She has completed the Nurse Prescribing Course and use this in her clinical practice.&lt;/P&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Professor Tom Quinn, Professor of Clinical Practice, University of Surrey and Clinical Lead for the Cardiovascular, Stroke and Vascular Specialist Collections.&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://portal.surrey.ac.uk/portal/page?_pageid=731,2400917&amp;amp;_dad=portal&amp;amp;_schema=PORTAL" target="_blank"&gt;Link to Professor Quinn's biography here&amp;nbsp;&lt;BR&gt;&lt;/A&gt;(Warning:&amp;nbsp;Requires leaving this site)&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;BR&gt;Special thanks also go to &lt;STRONG&gt;Rusell Dube, Information Specialist&lt;/STRONG&gt;, University of Surrey who co-ordinated this Evidence Update and undertook much of&amp;nbsp;the searching for evidence&amp;nbsp;and the rest of the Cardiovascular Specialist Collection team&lt;STRONG&gt; &lt;/STRONG&gt;who assisted in this work.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334323</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334323]]&gt;</url>
    <title>2010 Annual Evidence Update on Chest Pain : Introduction</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,CHEST PAIN (ATYPICAL),CHEST PAIN (PLEURITIC),JAN-MAR 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chest Pain : Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;: I N T R O D U C T I&amp;nbsp;O N&lt;BR&gt;Professor Tom Quinn, Professor of Clinical Practice, &lt;STRONG&gt;University of Surrey&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;and Clinical Lead for the Cardiovascular, Stroke and Vascular Specialist Collections.&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304763/nelhImp_0001_HFKNWwelcome.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;The burden of chest pain is considerable. Between 20 to 40% of people will experience chest pain or discomfort at some point, resulting in around 1% of primary care consultations, 5% of emergency department attendance, and 40% of emergency hospital admissions. Not all of these result in a diagnosis of acute coronary syndrome, angina, or even coronary disease; there are many non-cardiac causes of the symptom.&lt;/P&gt;
&lt;P&gt;Chest pain is the subject of a NICE guideline, expected to be published soon. We present here the findings, and expert commentary, from our focussed searches of the high quality evidence, from systematic reviews published since our last Evidence Update on the subject, published online in February 2009.&lt;/P&gt;
&lt;P&gt;I hope you find the information and commentaries useful and informative, and would like to thank our expert reviewers and the NHS Evidence-cardiovascular team, who have worked together so well to produce this Evidence Update.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394508</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/abstract/CIR.0b013e3181fcae66v1]]&gt;</url>
    <title>2010 Appropriate Use Criteria for Cardiac Computed Tomography</title>
    <publicationDate>2010-10-25T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CORONARY HEART DISEASE,ELECTROCARDIOGRAM,DIAGNOSIS,ARTERIOSCLEROSIS,DIAGNOSIS,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To update the original CCT/cardiac magnetic resonance appropriateness criteria published in 2006, written to reflect changes in test utilization, to incorporate new clinical data, and to clarify CCT use where omissions or lack of clarity existed in the original criteria.&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;Document provides the following Information:&lt;/P&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Improvements in cardiovascular imaging technology and their application, coupled with increasing therapeutic options for cardiovascular disease, have led to an increase in cardiovascular imaging.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;As the field of CCT continues to advance along with other imaging modalities, the healthcare community needs to understand how to best incorporate this technology into daily clinical care.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Of importance, inappropriate use of CCT may be potentially harmful to patients and generate unwarranted costs to the healthcare system, whereas appropriate procedures should likely improve patients’ clinical outcomes&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373642</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=373642]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Cardioversion</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-ARRHYTHMIC DRUGS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Cardioversion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;Cardioversion&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;No new systematic reviews or protocols&amp;nbsp;for systematic reviews&amp;nbsp;were identified under this topic area since the last evidence&amp;nbsp;update. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Visit the &lt;A href="nelh:315308:1" name=internalLink&gt;&lt;STRONG&gt;Atrial Fibrillation - Cardioversion evidence update 2009 &lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;topic for details of systematic reviews identified at that point.&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373642/nelhImp_0000_cardioversion.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clinical Knowledge Summaries (CKS) - rhythm-control treatments. [&lt;A href="http://www.cks.nhs.uk/atrial_fibrillation/management/detailed_answers/rhythm_control_treatments" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:0" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=56410&amp;amp;tabID=292&amp;amp;catID=679" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:0" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=278780&amp;amp;tabID=292" target="_blank"&gt;weblink&lt;/A&gt;&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="nelh:3557:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="nelh:3980:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Improvement [&lt;A href="http://www.improvement.nhs.uk/" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="nelh:284666:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374001</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374001]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Catheter Ablation and Devices</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Catheter Ablation and Devices&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert summary on Catheter Ablation and Devices by Dr Campbell Cowan&lt;/H2&gt;
&lt;H2&gt;Consultant Cardiologist, Leeds General Infirmary&amp;nbsp; &lt;BR&gt;&lt;BR&gt;National Clinical Lead for the Heart Improvement Programme.&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374001/nelhImp_0000_catheterablation.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;Catheter ablation for atrial fibrillation&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Trials continue to show the superiority of catheter ablation over anti-arrhythmic drugs in the management of atrial fibrillation. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Assessment of Randomised controlled trials&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The purest comparison of the two approaches is based on randomised controlled clinical trials.&amp;nbsp; &lt;A href="#Nair"&gt;Nair et al&lt;/A&gt; identified 6 such trials, five in patients who had previously failed other anti-arrhythmic drugs and one of first line drug therapy.&amp;nbsp;&amp;nbsp; These trials totalled less than 700 patients.&amp;nbsp; AF recurrence at one year was reduced by 65% by ablation in comparison with anti-arrhythmic therapy.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="#dagres"&gt;Dagres et al&lt;/A&gt; compared mortality at one year of follow-up in randomised trials.&amp;nbsp; Mortality was low and no different in ablation and anti-arrhythmic therapy arms.&amp;nbsp; There was similarly no difference in stroke or TIA between the two arms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment of non-randomised case series&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#chambers"&gt;Chambers et al&lt;/A&gt; additionally considered the value of non-randomised case series.&amp;nbsp; These studies are much more numerous and enable many more patients to be considered.&amp;nbsp; Additionally, they often have longer follow-up and contain more information on adverse events.&amp;nbsp; They concluded that the experience in case series was comparable to that of the randomised controlled trials and added to the knowledge of the ablation procedure.&lt;/P&gt;
&lt;P&gt;&lt;A href="#calkin"&gt;Calkins et al&lt;/A&gt; extended this principle, conducting two separate systematic literature reviews and meta-analyses, one for radiofrequency ablation and the other for anti-arrhythmic drug therapies enabling patient numbers to be increased to over 6000 in&amp;nbsp;each group.&amp;nbsp; The anti-arrhythmic drugs considered were amiodarone, dofetilide, sotalol, flecainide and propafenone.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Patients in the two series were not entirely comparable.&amp;nbsp; Ablation studies tended to recruit younger patients with a greater proportion of paroxysmal AF, factors which might favour ablation therapy.&amp;nbsp; By contrast, drug therapy trials recruited patients with a shorter duration of AF and fewer previous drug failures, factors which might favour drug therapy. &lt;/P&gt;
&lt;P&gt;Overall the efficacy of a single ablation procedure in preventing AF recurrence was 57%, compared with a successful outcome in 52% of patients in anti-arrhythmic drug therapy trials.&amp;nbsp; Interestingly, the benefit in favour of ablation seemed to be less than in the randomised controlled trials, suggesting differences in patient selection in the two types of study.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; While normally one would view the results from the randomised controlled trials as the more useful, in this case the sheer weight of numbers from non-randomised case series provides particularly valuable information.&lt;/P&gt;
&lt;P&gt;In the Calkins analysis, ablation was more successful if evaluated after multiple procedures (71% free of AF recurrence) or with combined drug therapy (72% free of AF) or with multiple procedures and combined drug therapy (77% free of AF).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risks, side effects and complications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Both treatment strategies carry risks of side effects or complications.&amp;nbsp; Calkins reported that as many as 30 % of patients may experience adverse events with anti-arrhythmic drug therapy, most of which are not serious.&amp;nbsp; Complications of ablation are less common but, as they are potentially serious and more immediate, are of particular concern.&amp;nbsp; The main complications were pulmonary vein narrowing (1.6%), pericardial effusion / tamponade (1.3%) and stroke/ TIA (0.5%).&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Technique of ablation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A number of studies have compared techniques of ablation, most particularly pulmonary vein isolation versus wide-area circumferential ablation.&amp;nbsp; &lt;A href="#Terasawa"&gt;Terasawa et al &lt;/A&gt;found a moderate level of evidence favouring wide-area circumferential ablation over pulmonary vein isolation.&amp;nbsp; The reviewers also considered the role of ablation lines, but&amp;nbsp; thought that evidence was insufficient to derive conclusions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The large number of patients in the Calkins meta-analysis enabled trends in success rates over time to be considered.&amp;nbsp; Perhaps surprisingly, no clear differences were observed over a decade of study reports despite advances in operator experience and techniques.&amp;nbsp;&amp;nbsp;&amp;nbsp; The authors suggested that the apparent lack of improvement may reflect changing demographics of patients undergoing ablation and an increasing complexity of patient case mix.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What is the role of ablation?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;What then is the current place of ablation in the management of AF?&amp;nbsp; It is well established as a more effective strategy than anti-arrhythmic drug therapy in patients who have already failed a number of drugs.&amp;nbsp; Its cost efficacy is also well established in this group (&lt;A href="#rodgers"&gt;Rodgers et al&lt;/A&gt;).&amp;nbsp;&amp;nbsp;&amp;nbsp; However, its role as a first line therapy for AF remains uncertain.&lt;/P&gt;
&lt;P&gt;A number of critical issues remain.&amp;nbsp; AF is predominantly a disease of older age, yet hitherto it is predominantly younger patients who have participated in ablation studies.&amp;nbsp;&amp;nbsp; It remains to be seen if ablation can prove equally successful amongst older patients.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The second critical issue is whether initial success will be maintained on longer term follow-up.&amp;nbsp;&amp;nbsp; The assumption that benefits will be maintained is particularly important in relation to cost efficacy analysis.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Finally, longer term studies addressing the issues of mortality and stroke prevention are still needed.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=calkin&gt;Calkins H&lt;/A&gt;, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. Circulation: Arrhythmia and Electrophysiology. 2009;2(4):349-61. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Studies of RFA for treatment of atrial fibrillation report higher efficacy rates than do studies of AAD therapy and a lower rate of complications&lt;BR&gt;[&lt;A href="nelh:360703:0" name=internalLink&gt;DARE commentary&lt;/A&gt;&lt;A href="nelh:360703:0" name=internalLink&gt;]&lt;/A&gt;&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19808490" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=Dagres&gt;Dagres N&lt;/A&gt;, Varounis C, Flevari P, Piorkowski C, Bode K, Rallidis LS, et al. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials. American Heart Journal. 2009;158(1):15-20. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This meta-analysis of randomized controlled trials showed similar survival of patients undergoing catheter ablation for AF compared with patients treated with AADs after 12 months of follow-up.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19540387" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=Inama&gt;Inama G&lt;/A&gt;, Pedrinazzi C, Adragao P, Alvarez M, Arribas F, Bonhorst D, et al. Five years of catheter ablation procedures in south-western europe: Meta-analysis of national registries. PACE - Pacing and Clinical Electrophysiology. 2009;32(4):506-15.&lt;BR&gt;&lt;STRONG&gt;Bottom-line&lt;/STRONG&gt; &lt;STRONG&gt;conclusion:&lt;/STRONG&gt;The progress of catheter ablation and the impetus for additional research and development of new approaches and technologic advances requires further data on clinical indications, methodologic approach, complications, and long-term success rate in the real world&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19335861" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;Lefevre F, Aronson N, Ziegler KM, Bonnell CJ, Gere MA. Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation. 2009:1-39. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Because of this high rate of repeated procedures, the results reported in these studies do not reflect the success of a single procedure. Rather, they more accurately estimate the success of an ablation strategy that includes repeated procedures for recurrences that occur within the first year of treatment.&lt;BR&gt;[&lt;A href="http://www.bcbs.com/blueresources/tec/vols/23/radiofrequency_catheter_ablation.pdf" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=nair&gt;Nair GM&lt;/A&gt;, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2009;20(2):138-44. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In selected patients with atrial fibrillation, radiofrequency ablation reduced the risk of atrial fibrillation recurrence at one year by 65 per cent in patients with paroxysmal and persistent atrial fibrillation and structurally normal hearts, compared with antiarrhythmic medications.&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;[&lt;A href="nelh:322436:0" name=internalLink&gt;PubMed abstract&lt;/A&gt;] &lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=rodgers&gt;Rodgers M&lt;/A&gt;, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: Systematic review and economic evaluation. Health Technology Assessment. 2008;12:34. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; RFCA is a relatively safe and efficacious procedure for the therapeutic treatment of AF and typical atrial flutter&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19036232" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=Terasawa&gt;Terasawa T&lt;/A&gt;, Balk EM, Chung M, Garlitski AC, Alsheikh-Ali AA, Lau J, et al. Systematic review: Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Annals of Internal Medicine. 2009 4;151(3):191-202.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Radiofrequency catheter ablation is effective for up to 12 months of rhythm control when used as a second-line therapy for atrial fibrillation in relatively young patients with near-intact cardiac function.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19581635" target="_blank"&gt;abstract&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;[&lt;A href="nelh:324279:1" name=internalLink&gt;DARE commentary&lt;/A&gt;]&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;A name=Chambers&gt;Chambers D&lt;/A&gt;, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. Journal of Clinical Epidemiology. 2009;62(12):1253-60.e4. &lt;BR&gt;&lt;STRONG&gt;Bottom line conclusion:&lt;/STRONG&gt; In the case of review of radiofrequency catheter ablation for Atrial Fibrillation, the case series make a useful contribution to the systematic review. Inclusion of case series can increase the evidence base and strengthen the credibility of a review of an emerging health technology. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19349144" target="_blank"&gt;PubMed Abstract&lt;/A&gt;] &lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;STRONG&gt;C&lt;/STRONG&gt;&lt;STRONG&gt;ochrane Protocols for Systematic Reviews&lt;BR&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Hassantash SA, Kalantarian S, Bikdeli B, Sadeghian M, Kasraii F, Haghdoost A. Surgical ablation for atrial fibrillation. The Cochrane library.[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007318/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Chen HS, JunMin W, Liu J, ShengNan W. Catheter ablation for paroxysmal and persistent atrial fibrillation. The Cochrane Library. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007101/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;McKenna C, Palmer S, Rodgers M, Chambers D, Hawkins N, Golder S, Van Hout S, Pepper C, Todd D, Woolacott N. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom.&amp;nbsp;&amp;nbsp; &lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Heart&amp;nbsp;2009;&amp;nbsp;95(7):&amp;nbsp;542-549&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;[&lt;A href="nelh:327084:1" name=internalLink&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation. [&lt;A href="http://guidance.nice.org.uk/IPG294" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. [&lt;A href="http://guidance.nice.org.uk/IPG286" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. [&lt;A href="http://www.nice.org.uk/nicemedia/live/11216/47574/47574.pdf" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="nelh:3557:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="nelh:3560:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Improvement&lt;A href="http://www.improvement.nhs.uk/" target="_blank"&gt;[weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="nelh:284666:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt"&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE rules=rows border=1&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage8 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg" name=nelh_tempImage8&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg" name=nelh_tempImage1&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage10 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg" name=nelh_tempImage10&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374119</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374119]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Contributors</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=0 cellPadding=4 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3 face=arial&gt;&lt;STRONG&gt;Contributors&lt;/STRONG&gt; &lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG style="WIDTH: 140px; HEIGHT: 94px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0008_contributors.gif" width=138 height=85&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="90%" padding="10"&gt;
&lt;TABLE border=0 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0013_tomquinn.gif"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Professor Tom Quinn &lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;Professor of Clinical Practice at the University of Surrey ;&lt;/FONT&gt;&amp;nbsp;Clinical Lead for NHS Evidence - Cardiovascular, Stroke and Vascular&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;Tom Quinn is one of the UK's leading cardiovascular nurses and has made a significant contribution to practice, policy and research both nationally and internationally. &lt;BR&gt;He was the UK's first Professor of Cardiac Nursing (at Coventry University), and took up post as Professor of Clinical Practice at the University of Surrey in January 2009. He has published extensively on acute cardiac and stroke care and his current responsibilities include being clinical lead for the NHS Evidence cardiovascular, stroke and vascular collections, part of the National Institute for Health and Clinical Excellence. He has been chief or co-applicant on more than £3.5m successful grant applications in the past two years, involving research into emergency cardiac and stroke care, and is on the steering group for two major clinical trials. He continues to advise the Department of Health as a member of the Emergency Cardiac Care Board, is a member of the group developing the Stroke Specific Educational Framework sponsored by the Department of Health, and chairs the steering group for development of primary angioplasty for the NHS in Surrey. He is Honorary Clinical and Research Adviser to South East Coast Ambulance Service NHS Trust.&lt;BR&gt;Tom Quinn is a member of the advisory committee for the European Society of Cardiology (ESC) Council of Cardiovascular Nursing and Allied Health Professions, a member of the ESC Working Group on Acute Cardiac Care, and a former Chairman of the ESC Working Group on Cardiovascular Nursing. He became a Fellow of the ESC in the mid 1990s and was awarded Fellowship of the Royal College of Nursing for his 'outstanding contribution to cardiac care' in 2006.&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Denise Williams&lt;/STRONG&gt; &lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Consultant Clinical Geneticist at Birmingham Women's Hospital ; Clinical Lead for NHS Evidence - Genetic Conditions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Denise Williams works as a Consultant Clinical Geneticist for the West Midlands Regional Genetics Service. Her clinical interests include eye genetics, for which she has established a regional ophthalmic genetics service, paediatric genetics and prenatal genetics. She has a strong commitment to genetics training and is the Clinical Genetics Training Programme Director and Regional Specialties Advisor for the West Midlands . She is a member of the Clinical Genetics Supraregional Specialist Training Committee and the Joint Royal Colleges of Physicians Training Board Specialist Advisory Committee. In January 2006 she worked with the Centre's team writing material for the Genetics in Practice section of their website. She rejoined the Centre in November 2007 as lead clinician for the NHS Evidence - Genetic Conditions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Dr Matthew Fay&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;GP Westcliffe Medical Practice, Shipley and National Clinical Lead for NHS Improvement - Stroke.&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Dr Fay is a GP at Westcliffe Medical Practice in Shipley, West Yorkshire. Dr Matthew Fay was accredited as GPwSI in Cardiology since 2002. He is also the National Clinical Lead for the Stroke Improvement Programme. Dr Fay is also a Practice manager, DGH Cardiologist and Tertiary Cardiologist. He also serves on the executive committee for the Arrhythmia Alliance.&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Cambell Cowan&lt;BR&gt;&lt;BR&gt;Consultant Cardiologist at Leeds General Infirmary; National Clinical Lead for NHS Improvement - Heart&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Dr Campbell Cowan is a Consultant Cardiologist at Leeds General Infirmary, he specialty includes heart rhythm disorders, radiofrequency ablation, implantable devices and resynchronisation and pacing for heart failure. He is also National Clinical Lead&amp;nbsp;for NHS Improvement -&amp;nbsp;&amp;nbsp;Heart. Dr Cowan is also one of the Editorial advisors with Arrhythmia Watch which is linked to the British Journal of Cardiology.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374119/nelhImp_0000_Dhiraj_Gupta.JPG"&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Dhiraj Gupta&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Consultant Cardiologist, Liverpool Heart and Chest Hospital NHS Trust&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Dr Dhiraj Gupta is a consultant cardiologist at the Liverpool Heart and Chest Hospital, and part of the largest cardiac rhythm unit in the United Kingdom.&amp;nbsp; He joined LHCH in March 2007, moving from St. Bartholomew’s Hospital in London.&lt;/P&gt;
&lt;P&gt;Professional Interests:&lt;/P&gt;
&lt;P&gt;Dr Gupta looks after patients with all kinds of heart rhythm problems. This involves assessment and management of patients with a variety of symptoms like palpitations, dizziness, faints, breathlessness and fatigue. He routinely performs catheter ablation for both simple and complex arrhythmias, using the latest 3D mapping technologies to enhance the chances of success. Dr Gupta’s particular passion lies in catheter ablation for Atrial Fibrillation, and he has earned repute locally and regionally for his expertise at treating these patients.&lt;/P&gt;
&lt;P&gt;Dr Gupta routinely implants implantable defibrillators, pacemakers, and cardiac resynchronisation devices.&lt;/P&gt;
&lt;P&gt;Research Interests:&lt;/P&gt;
&lt;P&gt;Dr Gupta holds an honorary clinical lecturer status at the University of Liverpool. He is investigating specific tools for measuring quality of life for patients with rhythm disturbances, and especially the magnitude and nature of impact of catheter ablation therapy on these measures. Dr Gupta is also trialling modifications in RF lesion set delivery for enhancing the results of catheter ablation for long standing persistent atrial fibrillation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mr Norman Briffa&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Consultant in Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Trust; Honorary Clinical Senior Lecturer, University of Sheffield.&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mr Briffa's specialty includes adult cardiac surgery and general thoracic surgery&lt;/P&gt;
&lt;P&gt;His other interests are arterial conduits in coronary surgery, off pump and minimally invasive cardiac surgery, aortic valve disease and stentless valves.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374002</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374002]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Genetics</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,ARRHYTHMIA,GENETICS,CAUSES AND RISK FACTORS,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert summary on Genetics by Dr Denise Williams&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Consultant Clinical Geneticist, &lt;BR&gt;Birmingham Women's Hospital&lt;BR&gt;&lt;BR&gt;Clinical Lead for NHS Evidence&amp;nbsp; - Genetics&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374002/nelhImp_0000_genetics.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;STRONG&gt;The genetics of atrial fibrillation&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Atrial fibrillation is the commonest type of arrhythmia and is frequently associated with hypertension, primary cardiac disease (including coronary artery disease, valvular abnormalities &amp;amp; congenital heart disease), hyperthyroidism and lung disease.&amp;nbsp; Other risk factors include advanced age, male sex and obesity.&amp;nbsp; So-called lone atrial fibrillation (LAF) is seen in the absence of structural heart disease and other predisposing factors and often presents at a younger age. 
&lt;P&gt;Atrial fibrillation is not traditionally considered a genetic condition, but over the last 10 years there has been increasing evidence that this arrhythmia, particularly lone AF, may have a substantial genetic basis.&amp;nbsp; Indeed in the last 12 months, 4 review articles have been published on the ‘Genetics of atrial fibrillation’ (1 – 4).&amp;nbsp; Each of these provides an excellent overview on the subject for the interested reader. &lt;/P&gt;
&lt;P&gt;A familial form of atrial fibrillation was in fact first recognised by Wolff in 1943 (5).&amp;nbsp; Since then families showing a clear autosomal dominant form of AF have been described by several authors (6 – 13), but they remain relatively rare.&amp;nbsp; Autosomal dominant atrial fibrillation is genetically heterogeneous.&amp;nbsp; To date mutations have been identified in a series of ion channel genes, KCNQ1 (chromosome 11p15.5), KCNE2 (chromosome 21q22.1) &amp;amp; KCNA5 (chromosome 12p13), as well as in two genes, atrial natriuretic peptide (chromosome 1p35-36) and lamin A/C (chromosome 1q21.2), not known to be associated with ion transport.&amp;nbsp; Mutations in these last two genes have only been reported in one family.&amp;nbsp; For the majority of families with a Mendelian form of AF, a molecular diagnosis remains elusive, although genetic studies suggest further genes at chromosome 6q14-16 and 10q22 -24.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;In addition to these clear familial forms of AF, it is now recognised that there is a significant genetic predisposition for more common forms of the condition.&amp;nbsp; In 2004, Fox et al (14) reported the results of a 19 year follow up study of more than 5000 individuals whose parents were enrolled in the original Framingham Heart Study.&amp;nbsp;&amp;nbsp;&amp;nbsp; Having a parent with AF approximately doubled the four year risk of developing AF, even after adjustment for known risk factors.&amp;nbsp; Further evidence of the heritability of AF was demonstrated by Arnar(15), Darbar (16) and Ellinor (17).&amp;nbsp; Following these reports, genome wide association studies (GWAS) have been employed by a number of research groups.&amp;nbsp; These techniques, now commonly used to study common diseases, examine variation across the human genome and are designed to identify whether a specific variation is more frequent in people with a particular disease as compared to the control population.&amp;nbsp; Two loci that were highly associated with atrial fibrillation in Icelanders were identified on chromosome 4q25 by Gudbjartsson and colleagues (18).&amp;nbsp; This study has subsequently been replicated in other populations (19) and the work expanded with common variants in the ZFHX3 gene on chromosome 16q22 (19,20) and in the KCNN3 on chromosome 1q21 (21) identified.&lt;/P&gt;
&lt;P&gt;Atrial fibrillation is undoubtedly heritable.&amp;nbsp; There are a few families where the phenotype and pattern of inheritance are clearly monogenic.&amp;nbsp; However, like many complex, but common diseases, AF is most commonly inherited as a polygenic or multifactorial trait.&amp;nbsp; The loci already identified explain less than 10% of the inherited contribution to AF, suggesting that there are major contributions still to be discovered.&amp;nbsp; Ultimately an understanding of how the genes interact with environmental factors to either increase or decrease susceptibility to AF should enable modifiable factors to be recognised.&amp;nbsp; In addition a greater understanding of how the genetic variants and mutations leads to disease should improve diagnosis and lead to more targeted treatments for this common arrhythmia.&amp;nbsp;&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;UL&gt;
&lt;LI&gt;Kaab S, Darbar D, Van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. European Heart Journal. 2009;30(7):813-9. &lt;BR&gt;&lt;STRONG&gt;Bottom-line Conclusion&lt;/STRONG&gt;: The non-coding SNPs rs2200733 and rs10033464 are strongly associated with AF in four cohorts of European descent. These results confirm the significant relations between AF and intergenic variants on chromosome 4. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19141561" target="_blank"&gt;Pubmed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Lin Z, Li Z, Yafei L, Xiangyu M. MinK gene G112A polymorphisms and atrial fibrillation: a Meta-analysis. Journal of Medical Colleges of PLA. 2009;24(4):198-207.&lt;BR&gt;&lt;STRONG&gt;Bottom-line Conclusion:&lt;/STRONG&gt; Gl12A polymorphisms in Mink gene may have an important effect on the pathogenesis of AF. This warrants further investigation in large multi-center studies with precise design. &lt;BR&gt;[&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B8JBP-4X9FCHK-2&amp;amp;_user=121707&amp;amp;_coverDate=08%2F31%2F2009&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_origin=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_searchStrId=1504410037&amp;amp;_rerunOrigin=google&amp;amp;_acct=C000009958&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=121707&amp;amp;md5=5c4138517bc4f54c01f8a78efddd3224&amp;amp;searchtype=a" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. Journal of General Internal Medicine. 2009;24(5):656-64. &lt;BR&gt;&lt;STRONG&gt;Bottom-line Conclusion:&lt;/STRONG&gt; We did not find sufficient evidence to support the use of pharmacogenetics to guide warfarin therapy. Additional clinical trials are needed to define the optimal approach to use warfarin pharmacogenetics in clinical practice. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669873/" target="_blank"&gt;Full-text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics. 2010;42(3):240-4. &lt;BR&gt;&lt;STRONG&gt;Bottom-line Conclusion:&lt;/STRONG&gt; we identified a new locus for lone AF at the calcium activated potassium channel gene, KCNN3. Future studies will seek to determine the mechanistic links between genetic variation at this locus and AF. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20173747" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/SPAN&gt;&lt;/UL&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional Expert references&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Genetics of familial atrial fibrillation.&amp;nbsp; Campuzano O, Brugada R.&amp;nbsp; Europace.&amp;nbsp; 2009 Oct; 11(10):1267-71.&lt;/LI&gt;
&lt;LI&gt;Impact of genetic discoveries on the classification of lone atrial fibrillation.&amp;nbsp; Roberts JD, Gollob MH.&amp;nbsp; J Am Coll Cardiol.&amp;nbsp; 2010 Feb 23; 55(8):705-12.&lt;/LI&gt;
&lt;LI&gt;Genetics of atrial fibrillation.&amp;nbsp; Lubitz SA, Yi BA, Ellinor PT.&amp;nbsp; Heart Fail Clin. 2010 Apr; 6(2):239-47.&lt;/LI&gt;
&lt;LI&gt;The genetics of atrial fibrillation.&amp;nbsp; Sabeh MK, MacRae CA.&amp;nbsp; Curr Opin Cardiol. 2010 May; 25(3): 186-191.&lt;/LI&gt;
&lt;LI&gt;Familial auricular fibrillation.&amp;nbsp; Wolff L.&amp;nbsp; New Eng J Med.&amp;nbsp; 1943; 229:&amp;nbsp; 396-398.&lt;/LI&gt;
&lt;LI&gt;Identification of a genetic locus for familial atrial fibrillation.&amp;nbsp; Brugada R, Tapscott T, Czernuszewicz GZ et al.&amp;nbsp; New Eng J Med.&amp;nbsp; 1997; 336:&amp;nbsp; 905-911.&lt;/LI&gt;
&lt;LI&gt;KCNQ1 gain-of-function mutation in familial atrial fibrillation.&amp;nbsp; Chen YH, Xu SJ, Bendahhou S et al.&amp;nbsp; Science.&amp;nbsp; 2003; 299: 251 – 254.&lt;/LI&gt;
&lt;LI&gt;Locus for atrial fibrillation maps to chromosome 6q14-16.&amp;nbsp; Ellinor PT, Shin JT, Moore RK et al.&amp;nbsp; Circulation.&amp;nbsp; 2003; 107: 2880-2883.&lt;/LI&gt;
&lt;LI&gt;Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation.&amp;nbsp; Yang Y, Xia M, Jin Q et al.&amp;nbsp; Am J Hum Genet.&amp;nbsp; 2004; 75:&amp;nbsp; 899-905.&lt;/LI&gt;
&lt;LI&gt;Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation.&amp;nbsp; Olson TM, Alekseev AE, Liu XK.&amp;nbsp; Hum Mol Genet.&amp;nbsp; 2006; 15:&amp;nbsp; 2185-2191.&lt;/LI&gt;
&lt;LI&gt;Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.&amp;nbsp; Hodgson-Zingman DM, Karst ML, Zingman LV et al.&amp;nbsp; New Eng J Med.&amp;nbsp; 2008; 359:&amp;nbsp; 158-165.&lt;/LI&gt;
&lt;LI&gt;Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation.&amp;nbsp; Yang Y, Li J, Lin X et al.&amp;nbsp; J Hum Genet.&amp;nbsp; 2009; 54:&amp;nbsp; 277-283.&lt;/LI&gt;
&lt;LI&gt;A novel mutation in LAMIN A/C is associated with isolated early-onset atrial fibrillation and progressive atrioventricular block followed by cardiomyopathy and sudden cardiac death.&amp;nbsp; Pan H, Richards, AA, Zhu X et al.&amp;nbsp; Heart Rhythm.&amp;nbsp; 2009 May; 6(5):&amp;nbsp; 707-710.&lt;/LI&gt;
&lt;LI&gt;Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring.&amp;nbsp; Fox CS, Parise H, D’Agostino RB et al.&amp;nbsp; JAMA.&amp;nbsp; 2004 June; 291(23): 2851 – 2855.&lt;/LI&gt;
&lt;LI&gt;Familial aggregation of atrial fibrillation in Iceland.&amp;nbsp; Arnar DO, Thorvaldsson S, Manolio TA et al.&amp;nbsp; Eur Heart J.&amp;nbsp; 2006 Mar; 27(6):&amp;nbsp; 708 – 712.&lt;/LI&gt;
&lt;LI&gt;Familial atrial fibrillation is a genetically heterogeneous disorder.&amp;nbsp; Darbar D, Herron KJ, Ballew JD et al.&amp;nbsp; Journal of the American College of Cardiology.&amp;nbsp; 2003; 41(12):&amp;nbsp; 2185 – 2192.&lt;/LI&gt;
&lt;LI&gt;Familial aggregation in lone atrial fibrillation.&amp;nbsp; Ellinor PT, Yoerger DM, Ruskin JN et al.&amp;nbsp; Hum Genet.&amp;nbsp; 2005 Nov; 118(2):&amp;nbsp; 179 – 184.&lt;/LI&gt;
&lt;LI&gt;Variants conferring risk of atrial fibrillation on chromosome 4q25.&amp;nbsp; Gudbjartsson DF, Arnar DO, Helgadottir A et al.&amp;nbsp; Nature.&amp;nbsp; 2007; 448:&amp;nbsp; 353 – 357.&lt;/LI&gt;
&lt;LI&gt;Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry.&amp;nbsp; Benjamin EJ, Rice KM, Arking DE et al.&amp;nbsp; Nature Genet.&amp;nbsp; 2009; 41:&amp;nbsp; 879 – 881.&lt;/LI&gt;
&lt;LI&gt;A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischaemic stroke.&amp;nbsp;&amp;nbsp; Gudbjartsson DF, Holm H, Gretarsdottir S et al.&amp;nbsp; Nature Genet.&amp;nbsp; 2009; 41:&amp;nbsp; 876 – 878.&lt;/LI&gt;
&lt;LI&gt;Common variants in KCNN£ are associated with lone atrial fibrillation.&amp;nbsp; Ellinor PT, Lunetta KL, Glazer NL et al.&amp;nbsp; Nature Genet.&amp;nbsp; 2010; 42:&amp;nbsp; 240 – 244. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Cochrane Protocols for Systematic Reviews&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;None identified.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Economic Evaluations&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.&amp;nbsp;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;American Journal of GeriatricPharmacotherapy&amp;nbsp;2009;&amp;nbsp;7(4):&amp;nbsp;197-203&lt;/SPAN&gt;[&lt;A href="nelh:364758:0" name=internalLink&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22009103743" target="_blank"&gt;abstract&lt;/A&gt;&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;British Cardiovascular Society [&lt;A href="nelh:187642:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;British Heart Foundation [&lt;A href="nelh:3560:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;NHS Improvement [&lt;A href="http://www.improvement.nhs.uk/" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Stroke Association [&lt;A href="nelh:284666:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt"&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE rules=rows border=1&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage8 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg" name=nelh_tempImage8&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg" name=nelh_tempImage1&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage10 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg" name=nelh_tempImage10&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>373641</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=373641]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Homepage</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PATIENT INFORMATION,PREVENTION,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,ARRYTHMIA,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;DIV&gt;Published on the &lt;STRONG&gt;7th&amp;nbsp;June 2010:&lt;/STRONG&gt; An update for health professionals and patients on significant advances in knowledge about atrial fibrillation since our &lt;A href="nelh:314789:1" name=internalLink&gt;last update in 2009&lt;/A&gt;. 
&lt;P&gt;&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV align=center&gt;
&lt;CENTER&gt;
&lt;TABLE border=0 cellSpacing=10 width="70%" valign="top"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0010_intro.jpg"&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0000_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0001_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;FONT color=#ffffff&gt;spacer&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=bottom width="20%" align=middle&gt;&lt;IMG style="WIDTH: 58px; HEIGHT: 53px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" height=71&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Medication&lt;FONT size=2 face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:373642:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Cardioversion&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=center width="17%" align=middle&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=46 height=37&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;BR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0002_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0009_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0004_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 54px; HEIGHT: 44px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt;&lt;BR&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:373649:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Preventing Stroke&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:374002:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Genetics&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Catheter ablation and devices&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD width="17%" align=middle padding:top="0"&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 47px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png" width=51 height=50&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0005_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0011_other2.jpg"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0012_feedback2.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Surgical Aspects&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:374014:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Miscellaneous&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Key Documents&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/CENTER&gt;&lt;/DIV&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374112</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374112]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Introduction</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,GENERAL  / OVERVIEWS,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;&lt;FONT size=3 face=Verdana&gt;Introduction&lt;/FONT&gt;&lt;BR&gt;&lt;BR&gt;Professor Tom Quinn.&amp;nbsp;&lt;BR&gt;Professor of Clinical Practice,&amp;nbsp;University of Surrey &lt;BR&gt;Clinical Lead for&amp;nbsp;NHS Evidence - Cardiovascular, Stroke and Vascular.&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374112/nelhImp_0000_intro.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%" name="internalLink" nelh:314789:1?&gt;Welcome to our second Evidence Update on atrial fibrillation (AF), building on the work we published last year. [&lt;A href="nelh:314789:0" name=internalLink&gt;Atrial Fibrillation Evidence Update 2009&lt;/A&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The importance of AF is reflected in the amount of effort devoted by our NICE to the subject, &lt;A href="http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords=Atrial+fibrillation&amp;amp;currentpage=&amp;amp;paginatedpage=&amp;amp;searchType=Guidance&amp;amp;sort=&amp;amp;pageSize=50&amp;amp;startYearMonth=&amp;amp;endYearMonth=&amp;amp;refId=&amp;amp;fromSearch=true" target="_blank"&gt;with some 21 outputs including formal guidelines published in 2006&lt;/A&gt;, and appraisals published or in hand.&amp;nbsp;All are accessible via link.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;To support the NHS in providing better care, our colleagues in the NHS Improvement - Heart team are leading a national programme of work on AF, and details can be found at &lt;A href="http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=SDwfTKWHaZA%3d&amp;amp;tabid=36" target="_blank"&gt;http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=SDwfTKWHaZA%3d&amp;amp;tabid=36&lt;/A&gt;&lt;BR&gt;and &lt;A href="http://www.improvement.nhs.uk/graspaf/" target="_blank"&gt;http://www.improvement.nhs.uk/graspaf/&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;I’m grateful to the two NHS Improvement – Heart national clinical leads (Dr Campbell Cowan and Dr Matt Fay) and other contributors who have provided expert summaries for us this year, and to the NHS Evidence- cardiovascular team here at the University of Surrey for their work in searching for the high quality evidence and producing what I hope will be an informative and useful Update for our readers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374114</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374114]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Key Documents</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Key Documents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;&lt;STRONG&gt;Key Documents&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Links to key guidance and organisations are listed here. To see all systematic reviews identified go to individual topic pages.&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;H3&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;&amp;nbsp;&lt;/H3&gt;&lt;FONT face=arial size=2&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=top&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374114/nelhImp_0000_feedback2.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H3 class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;Guidance&lt;/H3&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;D&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;epartment of Health -The Coronary Heart Disease National Service Framework: Building on excellence, maintaining progress - Progress report for 2008 [&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=310047&amp;amp;code=85748bf26b5853a3ad43359d37f8bdac" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;National Institute for Health and Clinical Excellence (NICE) - &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (2010) &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;[&lt;A href="http://www.nice.org.uk/IPG181" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;National Institute for Health and Clinical Excellence (NICE) - &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (2008) [&lt;A href="http://guidance.nice.org.uk/IPG294" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;National Institute for Health and Clinical Excellence (NICE) - &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (2010) [&lt;A href="http://guidance.nice.org.uk/IPG286" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;SPAN style="COLOR: black"&gt;&lt;o:p&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;National Institute for Health and Clinical Excellence (NICE) - &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;Atrial fibrillation – dronedarone&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;(2010) – &lt;SPAN style="COLOR: red"&gt;Expected date of publication&amp;nbsp;August 2010&lt;/SPAN&gt; [&lt;A href="http://guidance.nice.org.uk/TA/Wave19/57" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Clinical Knowledge Summaries&lt;EM&gt; -&lt;/EM&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; TEXT-DECORATION: none; text-underline: none; mso-bidi-font-weight: bold"&gt;Atrial fibrillation&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt; (2010) [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=323358&amp;amp;tabID=288" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Clinical Knowledge Summaries&lt;EM&gt; -&lt;/EM&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; TEXT-DECORATION: none; text-underline: none; mso-bidi-font-weight: bold"&gt;Atrial fibrillation: First or new presentation of atrial fibrillation&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;(2010)&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=343925&amp;amp;tabID=288" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Clinical Knowledge Summaries &lt;EM&gt;-&lt;/EM&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; TEXT-DECORATION: none; text-underline: none; mso-bidi-font-weight: bold"&gt;Atrial fibrillation: Paroxysmal atrial fibrillation&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;(2010) [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=323361&amp;amp;tabID=288" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;NHS&amp;nbsp;Improvement - Atrial fibrillation in primary care: making an impact on stroke prevention (2009) [&lt;A href="http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=%2bLIKN1gSgOA%3d&amp;amp;tabid=62" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-themecolor: text1"&gt;NHS&amp;nbsp;Improvement - Commissioning for Stroke Prevention in Primary Care -The Role of Atrial Fibrillation (2009)&lt;/SPAN&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=327084&amp;amp;tabID=289" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;NHS Improvement - Continuing to Improve Cardiac Services 2009/2010 [&lt;A href="http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=SDwfTKWHaZA%3d&amp;amp;tabid=36" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;NHS Improvement - Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) [&lt;A href="http://www.improvement.nhs.uk/graspaf/" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Links to Key Organisations&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;Arrhythmia Alliance[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=56410&amp;amp;tabID=292&amp;amp;catID=679" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;BR&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;Atrial Fibrillation Association [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=278780&amp;amp;tabID=292" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;British Cardiovascular Society [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3557&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;British Heart Foundation [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3560&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-weight: bold"&gt;NHS Improvement [&lt;A href="http://www.improvement.nhs.uk/" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;/SPAN&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-weight: bold"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;Stroke Association [&lt;A href="http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=269753&amp;amp;tabID=290&amp;amp;catID=13305" target="_blank"&gt;Weblink&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;A href="http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=269753&amp;amp;tabID=290&amp;amp;catID=13305" target="_blank"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;/SPAN&gt;&lt;/A&gt;&lt;SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE rules=rows border=1&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage8 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg" name=nelh_tempImage8&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg" name=nelh_tempImage1&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage10 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg" name=nelh_tempImage10&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" padding:right="0" cell&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" padding:right="0" cell&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>373640</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=373640]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Medication</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-ARRHYTHMIC DRUGS,ARRHYTHMIA,DISEASE MANAGEMENT,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Medication&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert Summary on Medication by Dr Dhiraj Gupta&lt;BR&gt;&lt;BR&gt;Consultant Cardiologist, &lt;BR&gt;Liverpool Heart and Chest Hospital NHS Trust&lt;/H2&gt;&lt;EM&gt;
&lt;P&gt;&lt;/EM&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0007_medication.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;FONT-FAMILY: 10pt? FONT-SIZE: Arial;&gt;
&lt;P&gt;&lt;STRONG&gt;Amiodarone for rhythm control&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="#doyle"&gt;Doyle et al&lt;/A&gt; examined the efficacy of amiodarone therapy for rhythm control in patients with persistent AF by carrying out a meta-analysis of the 12 randomised controlled trials&amp;nbsp;&amp;nbsp;studying over 5000 patients. They found that Amiodarone was twice as effective as placebo in maintaining sinus rhythm in this population (21% vs 9%). However 1 in 10 patients had to discontinue this agent on account of unacceptable side effects. Amiodarone therapay was not associated with an increase in hospitalizations or in long-term mortality. The results of this metaanalysis are compatible with current scientific opinion on Amiodarone: it is an effective agent but is often poorly tolerated by patients.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Antiarrhythmic Drugs for treatment of AF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;No systematic reviews or metanalyses exploring the use of other antiarrhythmic drugs in atrial fibrillation were identified during this period.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Statins for prevention of AF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#dawe"&gt;Dawe et al&lt;/A&gt; (2009) reviewed the question as to whether statins have a preventative role for AF by analysing the results of 24 studies that explored this link. Most of these studies were retrospective reviews of patient records, with the inherent limitations thereof. They found that there was no consensus amongst the studies, and so concluded that the role of Statin therapy for prevention of AF is uncertain.&lt;BR&gt;The same link was also explored in the review by &lt;A href="#abuissa"&gt;Abuissa et al&lt;/A&gt; (2009). They identified 6 observational and 3 randomised studies assessing the effect of Statin therapy on AF occurrence. While the observational studies suggested a 50% decreased risk of AF on statin therapy, the more scientifically robust randomised studies had conflicting results. As such, the jury is still out on this hypothesis, and prescription of statins for the sole purpose of AF prevention can not be recommended at this point in time.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Biphosphonates and AF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#mak"&gt;Mak-Cheung et al &lt;/A&gt;(2009) and &lt;A href="#loke"&gt;Loke et al&lt;/A&gt;(2009) sought to prove/ disprove the fear that Biphosphonate therapy for osteoporosis increases the risk of AF. Both of their metanalyses showed that there was no evidence of this increased risk.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A name=abuissa&gt;Abuissa H &lt;/A&gt;, O'Keefe JH, Bybee KA. Statins as antiarrhythmics: A systematic review part I: Effects on risk of atrial fibrillation. Clinical Cardiology. 2009 2009;32(10):544-8.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Published data suggests that statins may possess antiarrhythmic properties that reduce the propensity for atrial fibrillation. Most of this data is observational; more randomized, placebo-controlled trials are needed. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19911349" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Beri A, Sural N, Mahajan SB. Non-atheroprotective effects of statins: A systematic review. American Journal of Cardiovascular Drugs. 2009;9(6):361-70. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is no definite evidence for the use of statins in any condition besides hyperlipidemia and atherosclerosis.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19929034" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=dawe&gt;Dawe DE&lt;/A&gt;, Ariyarajah V, Khadem A. Is there a role for statins in atrial fibrillation? PACE - Pacing and Clinical Electrophysiology. 2009;32(8):1063-72 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; there is not yet sufficient evidence to recommend statins for the prevention of AF in patients who do not have an existing indication for these medications.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19659628" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=doyle&gt;Doyle JF&lt;/A&gt;, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis. Mayo Clinic Proceedings. 2009;84(3):234-42. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Amiodarone, as part of a strategy to achieve and maintain sinus rhythm, appears to be safe and effective in patients with persistent AF. However, some patients may not tolerate the adverse effects of this agent.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19252110" target="_blank"&gt;PubMed abstrac&lt;/A&gt;t] [&lt;A href="nelh:358843:0" name=internalLink&gt;DARE commentary&lt;/A&gt;] [&lt;A href="http://www.mayoclinicproceedings.com/content/84/3/234.full.pdf+html" target="_blank"&gt;Full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, et al. Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review. Journal of Thoracic and Cardiovascular Surgery. 2009;138(3):678-86.e1. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Preoperative statin therapy is associated with a reduction in the incidence of atrial fibrillation after cardiac surgery&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698856" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=loke&gt;Loke YK&lt;/A&gt;, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Safety. 2009;32(3):219-28. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; While there are some data linking bisphosphonates to serious atrial fibrillation, heterogeneity of the existing evidence, as well as paucity of information on some of the agents, precludes any definitive conclusions on the exact nature of the risk.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19338379" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=mak&gt;Mak A&lt;/A&gt;, Cheung MW, Ho RCM, Cheak AAC, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskeletal Disorders. 2009;10(1). &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Bisphosphonate use was not associated with a significantly higher risk of AF when RCTs and observational were collectively analyzed.&lt;BR&gt;[&lt;A href="http://www.biomedcentral.com/content/pdf/1471-2474-10-113.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2009 15;54(12):1089-95.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has fewer adverse effects. For every 1,000 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrences of AF in exchange for 9.6 fewer deaths and 62 fewer adverse events requiring discontinuation of drug. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19744618" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Sanchez-Guinones J, Marin F, Roldan V, Lip GYH. The impact of statin use on atrial fibrillation. Quarterly journal of Medicine. 2008 2008;101(11):845-61. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18725372" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;The data are insufficient to recommend the use of statins before EC. Finally, perioperative statin therapy may represent an important non-antiarrhythmic adjunctive therapeutic strategy for the prevention of postoperative AF.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols for Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ong MGY, Domingo GGG, Sarol JN. Perioperative intravenous magnesium for preventing atrial fibrillation following coronary artery bypass. The Cochrane library. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006518/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. [&lt;A href="nelh:362800:0" name=internalLink&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006518/frame.html" name=internalLink target="_blank"&gt;abstract&lt;/A&gt;&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.&amp;nbsp;&amp;nbsp; &lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;American Heart Journal&amp;nbsp;2009;&amp;nbsp;157(6):&amp;nbsp;1064-1073&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;[&lt;A href="nelh:362503:1" name=internalLink&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Appraised topic&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Parris R, Clarke S. BET 4: Intravenous diltiazem for the control of ventricular rate for patients with recent onset atrial fibrillation and left ventricular failure. Emergency Medicine Journal. 2009;26(8):617-8. &lt;BR&gt;Bottom-line conclusion: There is some low-quality evidence suggesting that diltiazem is beneficial when used for the acute treatment of atrial fibrillation and LVF. However, it should not be used in this way until further evidence is forthcoming.&lt;BR&gt;[&lt;A href="http://www.bestbets.org/bets/bet.php?id=420" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;National Institute for Health and Clinical Excellence (NICE) - Atrial fibrillation – dronedarone &lt;SUB&gt;Expected date of publication&amp;nbsp;August 2010&lt;/SUB&gt; [&lt;A href="http://guidance.nice.org.uk/TA/Wave19/57" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;CKS – Atrial Fibrillation Management (2010)&amp;nbsp;[&lt;A href="nelh:144065:0" name=internalLink&gt;full text&lt;/A&gt;] &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="nelh:3557:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation &lt;A href="nelh:3560:1" name=internalLink&gt;[weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;NHS Improvement [&lt;A href="nelh:101581:0" name=internalLink&gt;weblink]&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="nelh:284666:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374125</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374125]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Methods</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Methods&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methodology&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="WIDTH: 89px; HEIGHT: 77px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374125/nelhImp_0000_rubicks.gif" width=70 height=64&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Our literature search was designed to add to the body of knowledge from last year's&amp;nbsp;Atrial Fibrillation&amp;nbsp;Evidence Update. Searches were designed with a slight overlap period to ensure a good fit. &lt;/P&gt;
&lt;P&gt;We bought together a small panel of experts to support us by summarising key evidence and commenting on key developments in the field.&lt;/P&gt;
&lt;P&gt;We identified systematic reviews published between&amp;nbsp;&lt;SPAN style="FONT-FAMILY: Arial"&gt;November 18th 2008 – March 3&lt;SUP&gt;rd&lt;/SUP&gt; 2010 &lt;/SPAN&gt;and sifted them for relevance and quality. Material included in the last Evidence Update was excluded. Our reviewers were able to identify additional evidence relevant to any section. &lt;/P&gt;
&lt;P&gt;In addition to a wide range of databases, we hand searched other key resources for relevant guidance,&amp;nbsp;economic evaluations&amp;nbsp;and reports. &lt;/P&gt;
&lt;P&gt;Further details of the methods used to produce this Evidence Update can be &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=374125" target="_blank"&gt;viewed&amp;nbsp;here &lt;/A&gt;and are also attached below.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>373649</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=373649]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Prevention of Stroke</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,ARRHYTHMIA,PREVENTION,SECONDARY PREVENTION,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Prevention of Stroke&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert Summary on Prevention of Stroke by Dr Matthew Fay&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;General Practioner, Westcliffe Medical Practice, Shipley&lt;BR&gt;&lt;BR&gt;National Clinical Lead for the Stroke Improvement Programme&lt;/H2&gt;&lt;STRONG&gt;
&lt;H2&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373649/nelhImp_0000_stroke1.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;Preventing Stroke in Atrial Fibrillation : The Quality of Anticoagulation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The role of oral anti-coagulation in reduction of stroke risk in attributable to atrial fibrillation is well established. The main oral anticoagulant in common use is warfarin (Coumadin) which can prove to be problematic to control. In the &lt;A href="#active"&gt;ACTIVE W trial &lt;/A&gt;where warfarin was compared to combined anti-platelet therapy of aspirin and clopidogrel Warfarin was found to be superior. However with a population who spend less than 65% of their Time in Therapeutic Range (TTR) the advantage of anticoagulation therapy is reduced to the level seen in the anti-platelet group. What is our understanding of the quality of anticoagulation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Use of therapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#ogilvie"&gt;Ogilvie et al&lt;/A&gt;&amp;nbsp;under took a systematic review of the literature of stroke prevention in atrial fibrillation and found that 27 of the studies reviewed showed an under use of anti-coagulation therapy in patients at high risk of stroke. These studies showed that between 19-70% of people who had previously suffered a stroke were receiving therapy and of those with a CHADS2 of 2 or greater showed slightly improved uptake of therapy (39-70%). This under use of therapy was reflected in an increased stroke rate in the general practice and hospital setting compared to the stroke rate in people attending the anticoagulation clinics. Information regarding the quality of the anticoagulation (Time in Therapeutic Range) was not commented on&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Time in Therapeutic Range&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#Baker"&gt;Baker et al&lt;/A&gt;&amp;nbsp;looked at the Quality of Anticoagulation control in American anticoagulation clinics. Their meta-analysis included in excess of 22,000 patients and found that the population only spent 55% (95% CI 51-59%) of their Time in Therapeutic Range. This level of control was seen in the hospital based services with the community based clinic populations spending less time in the therapeutic range on average (48% with 95% CI 47-54%)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;New Therapeutic Agents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#rely"&gt;The RE-LY study &lt;/A&gt;, published in Autumn 2009, was constructed to demonstrated that the Direct Thrombin Inhibitor Dabigatran was non inferior to Warfarin. This used two doses of Dabigatran at 110mg bd and 150mg bd compared with INR controlled Warfarin. This showed that at the lower dose Dabigatran was as effective as dose controlled warfarin but with lower risk of bleeding and possibly superiority to Warfarin at the higher dose for the same risk. Dabigatran does not require the regular monitoring of Warfarin.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The uptake of oral anticoagulants remains low when considering their considerable benefit for patients in atrial fibrillation in reducing the risk of stroke. The reasons for this poor uptake must involve both patient and physician factors but these are poorly understood.&lt;/P&gt;
&lt;P&gt;However when therapy is used, the TTR is very variable and seems to generally below the standards required to maximise its benefit. This TTR factor should be considered by commissioning organisations when assessing the quality of the clinics providing oral anti-coagulation monitoring.&lt;/P&gt;
&lt;P&gt;With the advent of new oral anticoagulants which no longer require the intensive monitoring of warfarin the TTR becomes less relevant however the cost implications to health care need to be carefully assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews&lt;/P&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Madrid C, Sanz M. What influence do anticoagulants have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009 Sep;20 Suppl 4:96-106. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; OAT patients (INR 2-4) who do not discontinue the AC medication do not have a significantly higher risk of post-operative bleeding than non-OAT patients and they also do not have a higher risk of post-operative bleeding than OAT patients who discontinue the medication. In patients with OAT (INR 2-4) without discontinuation, topical haemostatic agents were effective in preventing post-operative bleeding. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19663955" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=Baker&gt;Baker&lt;/A&gt;, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in artial fibrillation patients in the United States. Journal of Managed Care Pharmacy. 2009;15(3):244-52. &lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In the United States, AF patients spend only about one-half the time within therapeutic INR. Anticoagulation clinic services are associated with somewhat better INR control compared with standard community care. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19326955" target="_blank"&gt;Abstract&lt;/A&gt;][&lt;A href="http://www.amcp.org/data/jmcp/244-252.pdf" target="_blank"&gt;Full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. Journal of General Internal Medicine. 2009;24(5):656-64. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; study did not find sufficient evidence to support the use of pharmacogenetics to guide warfarin therapy outside of clinical trials at this time. Small sample sizes and heterogeneity across the few available studies precluded definitive estimates of the relative effectiveness of this intervention.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669873/" target="_blank"&gt;Full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: A meta-analysis. Arthritis Research &amp;amp; Therapy. 2010;19. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Study did not find an association between bisphosphonate exposure and AF. This finding is consistent with the FDA's statement.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20170505" target="_blank"&gt;[PubMed Abstract&lt;/A&gt;] [&lt;A href="http://arthritis-research.com/content/pdf/ar2938.pdf" target="_blank"&gt;Full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=Ogilvie&gt;Ogilvie IM&lt;/A&gt;, Newton N, Welner SA, Lip GYH. Suboptimal oral anticoagulant treatment in patients with arial fbrillation at elevated risk for stroke: A systematic review. Journal of the American College of Cardiology. 2009;53(10):A376. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Low levels of OAC therapy, and variation in event rates across settings, were observed. This indicates the need for improved management of patients with AF to prevent stroke in clinical practice.&lt;BR&gt;[&lt;A href="http://content.onlinejacc.org/cgi/reprint/53/10_Suppl_A/A367.pdf" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols for systematic reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mead GE, Cordina J, Elder A, Flapan AD. Rhythm control versus rate control for atrial fibrillation/flutter. The Cochrane Library. &lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006699/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Expert references&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A name=rely&gt;Conolly SJ&lt;/A&gt;, Ezekowitz MZ, Salim Y, Dabigatran versus Warfarin in Patients with Atrial Fibrillation. 2009:361(12):1139-1151. [&lt;A href="http://content.nejm.org/cgi/reprint/361/12/1139.pdf" target="_blank"&gt;Full text&lt;/A&gt;] &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=active&gt;Conolly SJ&lt;/A&gt;, Pogue J, Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. 2009:360(20):2066-2078. [&lt;A href="http://content.nejm.org/cgi/reprint/360/20/2066.pdf" target="_blank"&gt;Full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. &lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;American Heart Journal&amp;nbsp;2009;&amp;nbsp;157(6):&amp;nbsp;1064-1073&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;BR&gt;[&lt;A href="nelh:362503:1" name=internalLink&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Atrial fibrillation in primary care: making an impact on stroke prevention. (2009)&lt;BR&gt;[&lt;A href="nelh:343925:1" name=internalLink&gt;full text]&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;NHS Improvement - Commissioning for Stroke Prevention in Primary Care -The Role of Atrial Fibrillation. (2009)&lt;BR&gt;[&lt;A href="http://www.improvement.nhs.uk/heart/Portals/0/documents2009/AF_Commissioning_Guide_v2.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="nelh:56410:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="nelh:278780:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="nelh:3557:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;A href="nelh:3557:1" name=internalLink&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="nelh:3560:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;NHS Improvement [&lt;A href="nelh:101581:1" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="nelh:187630:0" name=internalLink&gt;weblink&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>373878</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=373878]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Surgical Treatment</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,SURGICAL PROCEDURES,DISEASE MANAGEMENT,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Surgical Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;FONT size=2 face=arial&gt;
&lt;P&gt;&lt;STRONG&gt;Expert summary on surgical treatment by &lt;/STRONG&gt;&lt;STRONG&gt;Mr Norman Briffa&lt;BR&gt;&lt;BR&gt;Consultant in Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Trust; Honorary Clinical Senior Lecturer, University of Sheffield.&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373878/nelhImp_0000_surgeons.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;In &lt;A href="#Kumar"&gt;Kumar Das et al&lt;/A&gt; , 17 patients who underwent MAZE procedure concomitant with other cardiac surgical procedures were followed for a mean of 134 days.&amp;nbsp; Although it was not clear how many patients developed more than 1 type of arrthymia,&amp;nbsp; it was clear that 50% of patients developed at least 1 arrthymia (atrial fibrillation, ,atrial tachycardia, junctional tachycardia) at some point during their followup. The findings confirm what was already known and that&amp;nbsp; after a surgical MAZE procedure, anticoagulation should only be withdrawn after a decent period of time has elapsed sine surgery and after sinus rhythm is confirmed beyond any doubt. . 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;In &lt;A href="#Quen"&gt;Quenville et al&lt;/A&gt; this highly technical cost effectiveness study from McGill, the authors performed a literature search and met-analysis to generate the efficacy and safety raw material for a Markov decision analysis model to compare mitral valve surgery alone with mitral valve surgery plus an ablation Maze procedure.&amp;nbsp; The Markov decision analytic model used a time horizon of 15 years and included 4 mutually exclusive health states – free of AF, AF, stroke, and death. Patients were then assumed to move from a higher to a lower heath sate. They found 6 randomised controlled trials and the pooled AF risk at 1 year after mitral valve surgery alone was 71% (95%CI 64-78) and after the combined procedure 33% (95%CI 19 to 55). There was no difference in mortality or morbidity rates between the 2 surgical strategies. An ablation based Maze procedure at the time of mitral valve surgery had an incremental cost-effectiveness ration of $4,446 CAD per QALY. 58.1%, 73.9% and 89.3% of the simulations of the Maze strategy were cost-effective at willingness to pay $20,000, $50,000 and $100,000 per QALY gained respectively. The authors conclude that surgical ablation is cost-effective provided patients have a good long term prognosis. &lt;BR&gt;This paper has several flaws resulting from misguided assumptions – stroke risk of patients who remain in SR after a MAZE procedure is the same as a patient who has never been in atrial fibrillation, the 15 year outcomes of an ablative Maze are the same as those of the original cut and sew operation, and that survival after mitral valve procedures is uniform – there is a lot of data to suggest that patients undergoing mitral valve repair survive longer than those who undergo mitral valve replacement.&amp;nbsp; Despite these flaws this is a serious first attempt to look at the cost-effectiveness of&amp;nbsp; a new and what has become a common surgical procedure.&amp;nbsp; The AMAZE randomised controlled&amp;nbsp; trial comparing the 2 strategies in the UK and which is now recruiting,&amp;nbsp; will look at cost-effectiveness issues.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;In &lt;A href="#Lam"&gt;Lam et al&lt;/A&gt;, 4 institutions in Canada, USA and China presented their experience with minimally invasive surgical ablation of lone atrial fibrillation using bipolar radiofrequency. This is the largest series of this operation that has ever been published.&amp;nbsp; Follow-up period was not specified in the abstract. The mean operative time was over 3 hours and the mean hospital length if stay was 7.5 days. There were no deaths and at the time of follow-up (??) , sinus rhythm was present in 88% of patients with paroxysmal AF, 89% of patients with persistent and 71% of patients with longstanding persistent AF.&amp;nbsp; Even if the outcomes as far as rhythm&amp;nbsp; is concerned are accurate and durable (which I would think is unlikely) , they do come at a cost of long operations, long hospital stays and significant morbidity. Based on this abstract , the procedure is highly unlikely to be cost-effective &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="#Kong"&gt;Kong et al&lt;/A&gt;&amp;nbsp;undertook a meta-analysis to compare the efficacy of surgical Maze procedures performed concomitantly with referral cardiac surgery versus pharmacologic therapy for the treatment of AF. They identified 9&amp;nbsp; RCTs with 249 patients undergoing the Maze procedure and 213 underwent ‘referral’ surgery alone. At 12 months the OR for freedom from AF in the MAZE group was 5.22 (95%CI 1.7-15.88) . Only 2 of the studies looked at freedom from AF and freedom form antiarrthymic drugs and both studies, there was no difference between the 2 groups at 1 year. This meta-analysis also confirmed that there was no increase in mortality and/or morbidity between patients undergoing cardiac surgery alone and cardiac surgery with MAZE.&amp;nbsp; This paper does not significantly add to the body of knowledge that is already out there on the surgical MAZE procedure.&amp;nbsp; &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Systematic Reviews&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;UL&gt;
&lt;LI&gt;Baker WL, Anglade MW, Baker EL, White CM, Kluger J, Coleman CI. Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. European Journal of Cardio-Thoracic Surgery. 2009;35(3):521-7.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;NAC appears to be a promising but not proven strategy for reducing post-CTS complications. Currently, the most&lt;BR&gt;compelling data for using NAC in CTS patients is in post-CTS AF prevention.&lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=324269&amp;amp;tabID=289" target="_blank"&gt;Abstract&lt;/A&gt;][&lt;A href="http://ejcts.ctsnetjournals.org/cgi/reprint/35/3/521" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Elahi MM, Flatman S, Matata BM. Tracing the origins of postoperative atrial fibrillation: The concept of oxidative stress-mediated myocardial injury phenomenon. European Journal of Cardiovascular Prevention and Rehabilitation. 2008;15(6):735-41. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Inflammatory factors and oxidative stress play a major role in the pathogenesis of postoperative AF. This review provides an analysis of current evidence in support of efforts directed at antiinflammatory and antioxidant agents as interventions. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19020458" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=Kong&gt;Kong&lt;/A&gt; MH, Lopes RD, Piccini JP, Hasselblad V, Bahnson TD, Al-Khatib SM. Surgical maze procedure as a treatment for atrial fibrillation: A meta-analysis of randomized controlled trials. Journal of the American College of Cardiology. 2009;53(10):A118.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Large RCTs defining rates of freedom from AF without AADs postprocedure, are still needed to evaluate outcomes and determine the appropriate role for surgical Maze procedures in the management of AF.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20370795" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A systematic review. Journal of Critical Care. 2009;24(3):458-63. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Moderate-dosage corticosteroid (hydrocortisone) should be considered for the prevention of AF in high-risk patients undergoing cardiac surgery. Although the optimal dose, dosing interval, and duration of therapy is unclear, a single dose given at induction may be adequate. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19327322" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Murtuza B, Pepper JR, Stanbridge RD, Darzi A, Athanasiou T. Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Texas Heart Institute Journal. 2008;35(4):428-38. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; We did not find a significant difference between the incidence of AF after minimal-access AVR and the incidence of AF after conventional AVR.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19156237" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation a meta-analysis of randomized, controlled trials. Circulation: Arrhythmia and Electrophysiology. 2009;2(6):626-33. &lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Compared with a non-ablation treatment strategy, PVI results in dramatically increased freedom from AF at one year. While the procedure can be associated with major complications, the risk of these complications is comparable to other interventional procedures.&lt;BR&gt;[&lt;A href="http://circep.ahajournals.org/cgi/content/short/CIRCEP.109.856633v1" target="_blank"&gt;Fulltext&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=Quen&gt;Quenneville&lt;/A&gt; SP, Xie X, Brophy JM. The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery. International Journal of Technology Assessment in Health Care. 2009;25(4):485-96. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Maze surgical ablation procedure at the time of MV surgery is associated with a reduced postoperative AF risk. Our economic model further suggests that the surgical ablation strategy at the time of mitral valve surgery is likely a cost-effective intervention, provided patients have a good long-term postsurgical prognosis. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19818194" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Saso S, Vecht JA, Rao C, Protopapas A, Ashrafian&amp;nbsp;H, Leff D, et al. Statin therapy may influence the incidence of postoperative atrial fibrillation: What is the evidence? Texas Heart Institute Journal. 2009;36(6):521-9.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; statin administration results in a reduction in the incidence of atrial fibrillation in patients who undergo cardiac surgery.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20069076" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, et al. Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review. Journal of Thoracic and Cardiovascular Surgery. 2009;138(3):678-86.e1.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our meta-analysis provides evidence that preoperative statin therapy is associated with a reduction in the incidence of atrial fibrillation after cardiac surgery. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698856" target="_blank"&gt;PubMed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;Cochrane Protocols for Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hassantash SA, Kalantarian S, Bikdeli B, Sadeghian M, Kasraii F, Haghdoost A. Surgical ablation for atrial fibrillation. The Cochrane library.[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007318/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Ong MGY, Domingo GGG, Sarol JN. Perioperative intravenous magnesium for preventing atrial fibrillation following coronary artery bypass. The Cochrane library. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006518/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Dieleman JM, van Paassen J, van Dijk D, Arbous SM, Kalkman CJ, Vandenbroucke JP, van der Heijden GJ, Dekkers OM. Prophylactic corticosteroids for cardiopulmonary bypass in adults. The Cochrane Library. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005566/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;U&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/U&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Additional Expert &lt;/STRONG&gt;&lt;/U&gt;&lt;U&gt;&lt;STRONG&gt;References&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/U&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;A name=Kumar&gt;Das&lt;/A&gt; MK, Hillel Steiner, Chakka K, Antoun K. Atrial Tachycardia After Surgical MAZE Procedure: Is There a Need for Postoperative Anticoagulation?J. Am. Coll. Cardiol., March 10, 2009; 53: A106.&amp;nbsp;[&lt;A href="http://content.onlinejacc.org/cgi/reprint/53/10_Suppl_A/A100.pdf" target="_blank"&gt;abstract&lt;/A&gt;]&amp;nbsp;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Lam B, &lt;A name=Lam&gt;Beyer E&lt;/A&gt;,&amp;nbsp;Xu Meng, Lee R, Multicenter Results of Minimally Invasive Surgical Ablation of Lone Atrial Fibrillation by Bipolar Radiofrequency. J. Am. Coll. Cardiol., March 10, 2009; 53: 1020-36&amp;nbsp;[&lt;A href="http://jtcs.ctsnetjournals.org/cgi/content/abstract/137/3/521" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation. (2009)&lt;BR&gt;[&lt;A href="http://guidance.nice.org.uk/IPG294" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. (2009)&lt;BR&gt;[&lt;A href="http://guidance.nice.org.uk/IPG286" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. (2009)&lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/live/11216/47574/47574.pdf" target="_blank"&gt;full text&lt;/A&gt;].&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/NCASP/Heart%20Disease/NHS%20Information%20Centre%20SADS%20Information%20Leaflet%20V1.0.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Arrhythmia Alliance [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=56410&amp;amp;tabID=292&amp;amp;catID=679" target="_blank"&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Atrial Fibrillation Association [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=278780&amp;amp;tabID=292" target="_blank"&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;British Cardiovascular Society [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3557&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=3560&amp;amp;tabID=290&amp;amp;catID=679" target="_blank"&gt;weblink&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Stroke Association [&lt;A href="http://www.library.nhs.uk/STROKE/ViewResource.aspx?resID=269753&amp;amp;tabID=290&amp;amp;catID=13305" target="_blank"&gt;weblink&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374121</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=374121]]&gt;</url>
    <title>2010 Evidence Update on Atrial Fibrillation - Uncertainties</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Atrial Fibrillation - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;Below are a list of uncertainties from systematic reviews&amp;nbsp;identified in the course of this evidence update. These will be translated into PICO format (Patient, Intervention, Comparison, Outcome) for entry onto the DUETs (Database of Uncertainties about the Effects of Treatments)&amp;nbsp;database of uncertainties in due course. See &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;www.library.nhs.uk/duets/&lt;/A&gt;&amp;nbsp;for further information about the database.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=top&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID374121/nelhImp_0000_Uncertaintiespic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;Beri A, Sural N, Mahajan SB. Non-atheroprotective effects of statins: A systematic review. American Journal of Cardiovascular Drugs. 2009;9(6):361-70.&lt;BR&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;Uncertainty:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt; Pending large, well designed, randomized trials, we conclude that there is no definite evidence for the use of statins in any condition besides hyperlipidemia and atherosclerosis.[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19929034" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;Dawe DE, Ariyarajah V, Khadem A. Is there a role for statins in atrial fibrillation? PACE - Pacing and Clinical Electrophysiology. 2009;32(8):1063-72.&lt;BR&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;Uncertainty:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt; There is not yet sufficient evidence to recommend statins for the prevention of AF in patients who do not have an existing indication for these medications. Large randomized controlled trials are needed to help clarify the effect of statin use in patientswith existing AF and in those who have been cardioverted.&amp;nbsp; &lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19659628" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. Journal of General Internal Medicine. 2009;24(5):656-64.&lt;BR&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;Uncertainty:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt; No sufficient evidence to support the use of pharmacogenetics to guide warfarin therapy. Additional clinical trials are needed to define the optimal approach to use warfarin pharmacogenetics in clinical practice.&amp;nbsp;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669873/" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A systematic review. Journal of Critical Care. 2009;24(3):458-63&lt;BR&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;Uncertainty:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt; Additional studies are required to determine the optimal dosing strategy as well as the risk and benefits associated with this therapy. As elevated levels of CRP have been implicated in the neurocognitive decline after cardiac surgery, the impact of treatment with corticosteroids on this important complication requires investigation.&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19327322" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2009;20(2):138-44.&lt;BR&gt;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;Uncertainty:&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt; Even though the results of the systematic review favor ablation therapy, large, well-designed, multicenter clinical trials are needed to confirm the efficacy and safety of AF ablation in view of the significant limitations that we have mentioned above.&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=322436&amp;amp;tabID=289" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;&lt;SPAN style="FONT-FAMILY: 'AGaramond-Regular','serif'; mso-bidi-font-family: AGaramond-Regular"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 8pt; mso-themecolor: text1"&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-bidi-font-family: Arial"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373641:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373640:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Medication &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0002_cardioversion.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373642:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Cardioversion&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0003_stroke1.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373649:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Preventing Stroke&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0004_genetics.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374002:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Genetics&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0005_catheterablation.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374001:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Catheter Ablation Therapy&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage10 name=nelh_tempImage10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0006_surgeons.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:373878:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Surgical&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346202</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346202]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Access to Care</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Access to Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Access to&amp;nbsp;Care&lt;/STRONG&gt;&amp;nbsp;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;Dr Gill Furze&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Senior Research Fellow, British Heart Foundation Care and Education Research Group, Department of Health Sciences, University of York&lt;/FONT&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to Cardiac Rehabilitation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Since last year’s Evidence Update three papers detailing two systematic reviews which included aspects of access to rehabilitation were published. Both of these systematic reviews are of methods which have been suggested as increasing access to and uptake of cardiac rehabilitation.&lt;/P&gt;
&lt;P&gt;While the majority of cardiac rehabilitation in the UK is delivered via centre-based, group sessions, it has been suggested that access and uptake are improved if there is patient choice in method of delivery of programmes – particularly for the inclusion of home-based programmes. The review of home-based vs. centre-based rehabilitation included 12 studies with 1938 participants, most of which were low risk patients following MI or revascularisation. These CR formats were found to be equally effective in improving outcomes, and there was no difference in adherence (&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;Taylor et al. 2009&lt;/A&gt;, &lt;A href="http://www.bmj.com/cgi/reprint/340/jan19_4/b5631?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Dalal&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;fdate=1/1/2009&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Dalal et al. 2009&lt;/A&gt;). Both papers conclude that extending the option for patients to choose home-based CR programmes, such as the Heart Manual, may impact upon uptake.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;In an extension of home-based programmes, there has been a growing interest in delivery of rehabilitation programmes via telecommunication and information technologies (telerehabilitation) in order to increase access and uptake.&amp;nbsp; In a systematic review of telerehabilitation for people with physical disabilities (including heart disease), &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18720118" target="_blank"&gt;Kairy et al., (2009)&lt;/A&gt; reported on clinical processes including attendance and compliance. They included 22 studies in their review, four of which compared group-based CR with home-based telerehabilitation.&amp;nbsp; They found that, in these four studies, attendance and adherence was similar for both telerehabilitation and hospital-based programmes. One of the studies reported a cost-saving for telerehabilitation.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Dalal, HM, Zawada A, Jolly, K, Moxham T &amp;amp; Taylor, R. Home based verses centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. British Medical Journal&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: AdvPBEC7B4; mso-bidi-font-family: AdvPBEC7B4"&gt; 2010; 340:b5631&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: AdvPBEC7B5; mso-bidi-font-family: AdvPBEC7B5"&gt;. &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;[ &lt;A href="http://www.bmj.com/cgi/reprint/340/jan19_4/b5631?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Dalal&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;fdate=1/1/2009&amp;amp;resourcetype=HWCIT" target="_blank"&gt;full text&lt;/A&gt; ]&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Taylor RS, Dalal H, Jolly K, Moxham T, Zawada A. Home-based versus centre-based cardiac rehabilitation. &lt;SPAN style="mso-bidi-font-style: italic"&gt;Cochrane Database of Systematic Reviews &lt;/SPAN&gt;2010, Issue 1. Art. No.: CD007130.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;[ &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;full text&lt;/A&gt; ]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;STRONG&gt;Additional Reference Added by Reviewer&lt;/STRONG&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Kairy D, Lehoux P, Vincent C, Visintin M. A systematic review of clinical outcomes, clinical process, healthcare utilization and costs associated with telerehabilitation. Disability &amp;amp; Rehabilitation 2009; 31 (6): 427-447. [ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18720118" target="_blank"&gt;abstract&lt;/A&gt; ] &lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Davies P, Taylor F, Beswick A, Wise FH, Moxham T, Taylor RS. Promoting patient uptake and adherence in cardiac rehabilitation The Cochrane Library 2009 [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007131/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jolly K, Lip G Y, Taylor R S, Raftery J, Mant J, Lane D, Greenfield S, Stevens A. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation (Structured abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2009 [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100638/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Papadakis S, Reid RD, Coyle D, Beaton L, Angus D, Oldridge, N. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100341/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Zeidler J, Mittendorf T, Vahldiek G, Graf Von Der Schulenburg JM. Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases (Brief record) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100746/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Spronk S, Bosch JL, Ryjewsk C, Rosenblum J, Kaandorp CG,&amp;nbsp; White JV, Hunink MG. Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100291/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Huang Y, Zhang R, Culler DS, Kutner NG. Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22008102043/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Dendale P, Hansen D, Berger J, Lamotte M. Long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100809/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Cardiac Rehabilitation Services [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CardiacRehabilitationService.jsp" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) - Unstable Angina &amp;amp; NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction [&lt;A href="http://www.nice.org.uk/nicemedia/live/12949/47988/47988.pdf" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Department of Health - National Service Framework for Coronary Heart Disease, Chapter 7, Cardiac Rehabilitation [&lt;A href="http://www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/Coronaryheartdisease/Cardiacrehabilitation/index.htm" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Clinical Knowledge Summaries CKS - Evidence on Engagement in Cardiac Rehabilitation After Myocardial Infarction [&lt;A href="http://www.cks.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation/cardiac_rehabilitation_after_mi" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;British Heart Foundation - Cardiac Care and Education Research Group. National Audit of&amp;nbsp;Cardiac Rehabilitation (NACR)&amp;nbsp;– Annual Statistical Report 2009 [&lt;A href="http://www.cardiacrehabilitation.org.uk/docs/NACR_2009.pdf" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – The National Audit of Cardiac Rehabilitation - Annual Statistical Report&amp;nbsp;2009 Executive Summary [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=345425&amp;amp;tabID=290" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – UK Coronary Heart Disease Statistics 2009-2010 [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001141" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Heart&amp;nbsp;(Cardiac Rehabilitation pages) [&lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation&amp;nbsp; [&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – Cardiac Rehabilitation Information [&lt;A href="http://www.bhf.org.uk/living-with-a-heart-condition/recovery/cardiac-rehabilitation.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;American Heart Association - Cardiac Rehabilitation [&lt;A href="http://www.americanheart.org/presenter.jhtml?identifier=3047638" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology [&lt;A href="http://www.escardio.org/communities/EACPR/Pages/welcome.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices -Recovering from a Heart Attack [&lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices - Recovering from Heart Disease [&lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0001_accesstocaresmall.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45 height=100&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 51px; HEIGHT: 41px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129 height=98&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 51px; HEIGHT: 43px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46 height=97&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 49px; HEIGHT: 35px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 height=31&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 44px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=46 height=37&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 47px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346557</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346557]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Contributors</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=0 cellPadding=4 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="80%"&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3 face=arial&gt;&lt;STRONG&gt;Contributors&lt;/STRONG&gt; &lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=right&gt;&lt;IMG style="WIDTH: 140px; HEIGHT: 94px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305729/nelhImp_0008_contributors.gif" width=138 height=85&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="90%" padding="10"&gt;
&lt;TABLE border=1 width="90%" align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="35%"&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0013_tomquinn.gif"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="65%"&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Professor Tom Quinn&amp;nbsp; &lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;Tom Quinn is one of the UK's leading cardiovascular nurses and has made a significant contribution to practice, policy and research both nationally and internationally. &lt;BR&gt;He was the UK's first Professor of Cardiac Nursing (at Coventry University), and took up post as Professor of Clinical Practice at the University of Surrey in January 2009. He has published extensively on acute cardiac and stroke care and his current responsibilities include being clinical lead for the NHS Evidence cardiovascular, stroke and vascular collections, part of the National Institute for Health and Clinical Excellence. He has been chief or co-applicant on more than £3.5m successful grant applications in the past two years, involving research into emergency cardiac and stroke care, and is on the steering group for two major clinical trials. He continues to advise the Department of Health as a member of the Emergency Cardiac Care Board, is a member of the group developing the Stroke Specific Educational Framework sponsored by the Department of Health, and chairs the steering group for development of primary angioplasty for the NHS in Surrey. He is Honorary Clinical and Research Adviser to South East Coast Ambulance Service NHS Trust.&lt;BR&gt;Tom Quinn is a member of the advisory committee for the European Society of Cardiology (ESC) Council of Cardiovascular Nursing and Allied Health Professions, a member of the ESC Working Group on Acute Cardiac Care, and a former Chairman of the ESC Working Group on Cardiovascular Nursing. He became a Fellow of the ESC in the mid 1990s and was awarded Fellowship of the Royal College of Nursing for his 'outstanding contribution to cardiac care' in 2006.&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0014_gillfurze.gif"&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top&gt;&lt;FONT size=2 face=arial&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Dr Gill Furze&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;Gill Furze is a Senior Research Fellow with the British Heart Foundation Care and Education Research Group, based in the Department of Health Sciences at the University of York, UK. She is also a Scientific Officer and Council member for the British Association for Cardiac Rehabiltiation. Her background is in cardiac nursing, but her PhD is in psychology. Her research interests are on developing and testing cognitive behavioural self-management programmes and of the effect of people's beliefs about illness on coping and outcome, with particular reference to people with coronary heart disease.&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD&gt;&amp;nbsp;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Dr&amp;nbsp;Clare Hawley&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;Clare Hawley is a GP at The Surgery at Wheatbridge and is an Associate Specialist in Cardiology at Chesterfield Royal Hospital NHS Trust.&lt;BR&gt;She has worked in cardiac rehabilitation for the last 15 years supporting and developing the hospital and community based cardiac rehabilitation programmes locally. Dr Hawley is the lead clinician for cardiac rehabilitation within her local PCT and runs a refractory angina service in primary care in partnership with the National Refractory Angina Centre. She is also a GP tutor for Bradford University PG Diploma in Cardiology for Practitioners with Special Interest and is also part of a small team of trainers providing education to healthcare professionals on cardiovascular topics across the country.&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0015_sallysingh.gif"&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;Professor Sally Singh&amp;nbsp;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=Arial&gt;Sally Singh is based at Coventry University, in the Faculty of Health and Life Sciences and at the University Hospitals of Leicester NHS Trust.&amp;nbsp; For several years she has been involved in the development of Cardiac Rehabilitation and Pulmonary Services. Her research interests initially focused on the development of robust outcome measures to evaluate these complex interventions. More recently research activity has focused upon service delivery .The physiological and metabolic response to exercise in patients with chronic cardio-respiratory disease is also of interest to the research group and some recent publications have explored this. She contributed to the Cochrane Review of exercise based rehabilitation for heart failure.&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0016_davethompson.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Professor David Thompson&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;David Thompson is Professor of Cardiovascular Nursing at the University of Leicester.&amp;nbsp; Prior to this he was Professor and Director of the Nethersole School of Nursing at the Chinese University of Hong Kong, and Director of the Hong Kong Centre for Evidence-Based Nursing, from June 2002 to May 2007.&amp;nbsp; From April 1998 until May 2002 he was Foundation Professor of Nursing at the University of York. From 1994-1998 he was Professor of Nursing at the University of Hull and from 1998-2001 he was also the first Professor of Nursing Research at the Department of Health in the UK, a new post established on a part-time basis to advise the Director of Research and Development.&amp;nbsp; He is Visiting Professor at the University of London and the University of Queensland.&lt;BR&gt;&lt;BR&gt;He&amp;nbsp; has extensive clinical and research experience in the field of cardiac care and rehabilitation, has published 350 papers, 40 chapters and 15 books, been awarded research grants in excess of £3 million and served as a member of numerous expert committees and prestigious bodies, including the Department of Health, the Medical Research Council, the British Heart Foundation and the European Society of Cardiology.&amp;nbsp; He is editor of the European Journal of Cardiovascular Nursing.&lt;BR&gt;Professor Thompson has received a number of honours in recognition of his contributions to the art and science of nursing and cardiology, including being elected a Fellow of the Royal College of Nursing, in 1992, and a Fellow of the European Society of Cardiology, in 1998.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0010_NHSImprovementHeartsmall.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;NHS Improvement - Heart&lt;/P&gt;
&lt;P&gt;Delivering tomorrow's improvement agenda for the NHS&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.improvement.nhs.uk/heart/" target="_blank"&gt;http://www.improvement.nhs.uk/heart/&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0011_New_BACR_logosmall.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;The British Association for Cardiac Rehabilitation (BACR) aims to promote the practice and philosophy of cardiac rehabilitation&lt;BR&gt;&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346557/nelhImp_0017_accesstocaresmall.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&amp;lt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 45px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346206</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346206]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Exercise</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Exercise&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Exercise &lt;/STRONG&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;Professor Sally Singh&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Professor of Cardiac and Pulmonary Rehabilitation, Coventry University and Cardio-Respiratory Directorate, Glenfield Hospital, University Hospitals of Leicester NHS Trust.&lt;/FONT&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG style="WIDTH: 142px; HEIGHT: 109px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P&gt;The length of a rehabilitation programme is recommended to be at least 8 weeks long with 2 supervised sessions a week. The ultimate aim is for participants to achieve 5 bouts of exercise 5 times a week. Once the formal cardiac rehabilitation programme has been completed participants should be offered a community exercise (phase IV) programme to support a sustained lifestyle incorporating exercise. Indeed cardiac rehabilitation programmes for low risk patients can be offered in the community or home but high risk, the more complex patients and those requiring high intensity training should be supervised with a hospital environment with resuscitation equipment.&amp;nbsp;Tai Chi as a rehabilitative option has gained some popularity recently, a systematic review (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19471133" target="_blank"&gt;Yeh et al 2009&lt;/A&gt;), suggested that as a stand alone intervention there may be some benefit in reducing blood pressure and enhancing exercise performance. However most of the studies included were judged to be of poor methodological quality, so although the data is encouraging there is a need for further research.&lt;/P&gt;
&lt;P&gt;Recently there have been an interesting review exploring the correlates of a successful rehabilitation programme (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19293716" target="_blank"&gt;Petter et al 2009&lt;/A&gt;), the review acknowledges that although there are well documented benefits to rehabilitation the adherence to the programme is low. To understand what variables may influence adherence to rehabilitation is likely to support the development of rehabilitation programmes. Six variables seemed to consistently be related to exercise (self efficacy, health status, intention, perceived control, beliefs/benefits and previous exercise experience). Age, BMI, education level were not associated with exercise in any context.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Petter M, Blanchard C, Kemp KA, &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place w:st="on"&gt;&lt;st1:City w:st="on"&gt;Mazoff&lt;/st1:City&gt; &lt;st1:State w:st="on"&gt;AS&lt;/st1:State&gt;&lt;/st1:place&gt;, Ferrier SN. Correlates of exercise among coronary heart disease patients: Review, implications and future directions. European Journal of Cardiovascular Prevention and Rehabilitation 2009, 16 (5): 515-526. &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; mso-fareast-language: EN-GB"&gt;[ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19293716" target="_blank"&gt;abstract&lt;/A&gt; ]&lt;B style="mso-bidi-font-weight: normal"&gt; &lt;/B&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Yeh GY, Wang C, Wayne PM, Phillips R. Tai Chi exercise for patients with cardiovascular condtions and risk factors: A systematic review.&amp;nbsp;&lt;SPAN style="mso-bidi-font-weight: bold"&gt; &lt;/SPAN&gt;Journal of Cardiopulmonary Rehabilitation Prevention 2009; 29 (3):152-60. &lt;SPAN style="FONT-FAMILY: Arial"&gt;[ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19471133" target="_blank"&gt;abstract&lt;/A&gt; ]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt; &lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Additional References not used by the Expert Reviewer&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Roine E, Roine RP, Räsänen P, Vuori I, Sintonen H, Saarto T. Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: A systematic literature review. International Journal of Technology Assessment in Health Care 2009; 25 (4): 427-454&lt;SPAN class=src1&gt;. &lt;/SPAN&gt;[ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19845974" target="_blank"&gt;abstract&lt;/A&gt; ]&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;o:p&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Cardiac Rehabilitation Services [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CardiacRehabilitationService.jsp" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Department of Health - National Service Framework for Coronary Heart Disease, Chapter 7, Cardiac Rehabilitation [&lt;A href="http://www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/Coronaryheartdisease/Cardiacrehabilitation/index.htm" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;British Heart Foundation - Cardiac Care and Education Research Group. National Audit of&amp;nbsp;Cardiac Rehabilitation (NACR)&amp;nbsp;– Annual Statistical Report 2009 [&lt;A href="http://www.cardiacrehabilitation.org.uk/docs/NACR_2009.pdf" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – The National Audit of Cardiac Rehabilitation - Annual Statistical Report&amp;nbsp;2009 Executive Summary [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=345425&amp;amp;tabID=290" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – UK Coronary Heart Disease Statistics 2009-2010 [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001141" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Heart&amp;nbsp;(Cardiac Rehabilitation pages) [&lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation&amp;nbsp; [&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – Cardiac Rehabilitation Information [&lt;A href="http://www.bhf.org.uk/living-with-a-heart-condition/recovery/cardiac-rehabilitation.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation - Exercise and Training[&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;American Heart Association - Cardiac Rehabilitation [&lt;A href="http://www.americanheart.org/presenter.jhtml?identifier=3047638" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology [&lt;A href="http://www.escardio.org/communities/EACPR/Pages/welcome.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices -Recovering from a Heart Attack [&lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices - Recovering from Heart Disease [&lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD width="18%"&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346140</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346140]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Home page</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Home page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;DIV&gt;Published on the &lt;STRONG&gt;12th April&amp;nbsp;2010:&lt;/STRONG&gt; An update for health professionals and patients on significant advances in knowledge about cardiac rehabilitation since our last update in 2009. This&amp;nbsp;update was developed in collaboration with experts identified by&amp;nbsp;&lt;A href="http://www.improvement.nhs.uk/heart/" target="_blank"&gt;NHS Improvement&amp;nbsp;&lt;/A&gt; and the &lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;British&amp;nbsp;Association&amp;nbsp;for Cardiac Rehabilitation&lt;/A&gt;.&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV align=center&gt;
&lt;CENTER&gt;
&lt;TABLE border=0 cellSpacing=10 width="70%" valign="top"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;IMG style="WIDTH: 120px; HEIGHT: 94px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304763/nelhImp_0001_HFKNWwelcome.jpg" width=120 height=90&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0001_accesstocare.gif"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG style="WIDTH: 120px; HEIGHT: 94px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=140&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;FONT color=#ffffff&gt;spacer&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=bottom width="20%" align=middle&gt;&lt;IMG style="WIDTH: 58px; HEIGHT: 53px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" height=71&gt;&lt;BR&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Access to&amp;nbsp;Care&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Psychosocial Aspects&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=center width="17%" align=middle&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=46 height=37&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;BR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG style="WIDTH: 125px; HEIGHT: 94px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG style="WIDTH: 125px; HEIGHT: 94px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0013_HF2009monitor.jpg" width=146&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG style="WIDTH: 120px; HEIGHT: 94px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=89&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 54px; HEIGHT: 44px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt;&lt;BR&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Organisation of&amp;nbsp; Care &lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Key Documents&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD width="17%" align=middle padding:top="0"&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 47px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png" width=51 height=50&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Cardiovascular/ContactUs.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/CENTER&gt;&lt;/DIV&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346633</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346633]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Introduction</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID304763/nelhImp_0001_HFKNWwelcome.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P&gt;&lt;STRONG&gt;Professor Tom Quinn, Professor of Clinical Practice, University of Surrey &lt;/STRONG&gt;&lt;STRONG&gt;and Clinical Lead for the Cardiovascular, Stroke and Vascular Specialist Collections.&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Welcome to the 2010 Evidence Update on cardiac rehabilitation.&lt;/P&gt;
&lt;P&gt;For all the major improvements made in the care of cardiac patients, and the (almost) halving of mortality from CHD since publication of the National Service Framework a decade ago, cardiac rehabilitation (CR) remains, in the words of the British Heart Foundation, 'unfinished business'.&amp;nbsp; Indeed, the Department of Health is now 'urging' the NHS to focus on what happens after the patient leaves hospital, especially CR. The annual report of the National Audit of Cardiac Rehabilitation tells us that just over a third of patients who might benefit from CR are referred, and efforts continue to improve access, led by the NHS Improvement Programme and the British Association for Cardiac Rehabilitation.&lt;/P&gt;
&lt;P&gt;We present here key, high quality evidence on CR that has been published since our 2009 Evidence Update, with short summaries from our panel of experts. I am grateful to them, and to Dr Freda Mold and April Coombe&lt;?XML:NAMESPACE PREFIX = SKYPE /&gt;&lt;SKYPE:SPAN style="BACKGROUND-IMAGE: url(https://toolbaricons.s4benterprises.com/NameHighlighter/GIF/offline.gif) !important" id=skype_name_injection_1_5002 class=skype_name_highlight skypename="april.coombe" eventRemoved="event.cancelBubble = true; event.returnValue = false;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;SKYPE:SPAN style="BACKGROUND-IMAGE: url(https://toolbaricons.s4benterprises.com/NameHighlighter/GIF/arrow.gif) !important" id=skype_name_arrow_1_5002 class=skype_nh_arrow_hid skypename="april.coombe"&gt;&amp;nbsp;&lt;/SKYPE:SPAN&gt;&lt;/SKYPE:SPAN&gt; from&amp;nbsp;the NHS Evidence team for their input.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/A&gt;&lt;/A&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;I&lt;FONT size=2 face=arial&gt;ntroduction&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:315609:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:314838:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346434</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346434]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Key Documents</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Key Documents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;Key Documents&lt;/STRONG&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG style="WIDTH: 133px; HEIGHT: 91px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Cardiac Rehabilitation Services [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CardiacRehabilitationService.jsp" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) - Unstable Angina &amp;amp; NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction [&lt;A href="http://www.nice.org.uk/nicemedia/live/12949/47988/47988.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Department of Health - National Service Framework for Coronary Heart Disease, Chapter 7, Cardiac Rehabilitation [&lt;A href="http://www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/Coronaryheartdisease/Cardiacrehabilitation/index.htm" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Clinical Knowledge Summaries CKS - Evidence on Engagement in Cardiac Rehabilitation After Myocardial Infarction [&lt;A href="http://www.cks.nhs.uk/mi_secondary_prevention/evidence/supporting_evidence/rehabilitation/cardiac_rehabilitation_after_mi" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;British Heart Foundation - Cardiac Care and Education Research Group. National Audit of&amp;nbsp;Cardiac Rehabilitation (NACR) – Annual Statistical Report 2009&amp;nbsp;[&lt;A href="http://www.cardiacrehabilitation.org.uk/docs/NACR_2009.pdf" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – The National Audit of Cardiac Rehabilitation - Annual Statistical Report&amp;nbsp;2009 Executive Summary [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=345425&amp;amp;tabID=290" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – UK Coronary Heart Disease Statistics 2009-2010 [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001141" target="_blank"&gt;weblink&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Heart&amp;nbsp;(Cardiac Rehabilitation pages) &lt;STRONG&gt;[&lt;/STRONG&gt;&lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation&amp;nbsp; [&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – Cardiac Rehabilitation Information [&lt;A href="http://www.bhf.org.uk/living-with-a-heart-condition/recovery/cardiac-rehabilitation.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation - Exercise and Training [&lt;A href="http://www.bacrphaseiv.co.uk/" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;American Heart Association - Cardiac Rehabilitation [&lt;A href="http://www.americanheart.org/presenter.jhtml?identifier=3047638" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology [&lt;A href="http://www.escardio.org/communities/EACPR/Pages/welcome.aspx" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Choices -Recovering from a Heart Attack [&lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices - Recovering from Heart Disease [&lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lewin RJ, Coulton S, FrizelleDJ, Kaye G, Cox H.&amp;nbsp; A brief cognitive behavioural preimplantation and rehabilitation programme for patients receiving an implantable cardioverter-defibrillator improves physical health and reduces psychological morbidity and unplanned readmissions (Structured abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination&amp;nbsp;2009&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100637/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jolly K, Lip G Y, Taylor R S, Raftery J, Mant J, Lane D, Greenfield S, Stevens A. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation (Structured abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2009 [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100638/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papadakis S, Reid RD, Coyle D, Beaton L, Angus D, Oldridge, N. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100341/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zeidler J, Mittendorf T, Vahldiek G, Graf Von Der Schulenburg JM. Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases (Brief record) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100746/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Spronk S, Bosch JL, Ryjewsk C, Rosenblum J, Kaandorp CG,&amp;nbsp; White JV, Hunink MG. Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100291/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang Y, Zhang R, Culler DS, Kutner NG. Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22008102043/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dendale P, Hansen D, Berger J, Lamotte M. Long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100809/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt; and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoPlainText&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346634</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346634]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Methodology</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=0 cellPadding=4 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt; &lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=bottom align=middle&gt;&lt;IMG style="WIDTH: 98px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="90%"&gt;
&lt;P&gt;Our literature search was designed to add to the body of knowledge from last year's Cardiac Rehabilitation Evidence Update. Searches were designed with a slight overlap period to ensure a good fit. &lt;/P&gt;
&lt;P&gt;We bought together a small panal of experts to support us by summarising key evidence and commenting on key developments in the field.&lt;/P&gt;
&lt;P&gt;We identified systematic reviews published between February 2009 and March 2010 and sifted them for relevance and quality. Material included in the last Evidence Update was excluded, with exception made for reviews amended within the search period and a small number not previously considered by an expert reviewer. Our reviewers were able to identify additional evidence relevent to any section. &lt;/P&gt;
&lt;P&gt;In addition to a wide range of databases, we hand searched other key resources for relevant guidance, statistics and reports. Those sources can be seen in the Key Document section. We were able to include some evidence published after the main search period. &lt;/P&gt;
&lt;P&gt;Further details of the methods used to produce this Evidence Update can be viewed below together with the complete reference list. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 37px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44 height=37&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45 height=100&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346201</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346201]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Organisation of Care</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Organisation of Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Organisation of Care&lt;/STRONG&gt;&lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;Dr Clare Hawley&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;GP at&amp;nbsp;The Surgery, Wheatbridge &amp;amp; Associate Specialist in Cardiology at Chesterfield Royal Hospital NHS&amp;nbsp;Foundation Trust&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The 2009 Cardiac Rehabilitation Evidence Update included a section on Secondary Prevention. This years Evidence Update (2010) does not include this section, as no new systematic reviews&amp;nbsp;were identified on this topic&amp;nbsp;but&amp;nbsp;evidence which can be categorised as the 'organisation of care' was identified and is included below.&lt;/EM&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&amp;nbsp; 
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346201/nelhImp_0000_organisationofcare.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 12pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;FONT size=2 face=Arial&gt;3&lt;/FONT&gt;&amp;nbsp;&lt;/SPAN&gt;systematic reviews were identified&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407659" target="_blank"&gt;Neubeck et al (2009)&lt;/A&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; reviewed 11 trials with 3145 participants; patients received telehealth intervention using telephone or internet of varying duration and intensity. The participants were mostly young men, post myocardial infarction and without significant co-morbidities, for many the teleintervention was in addition to traditional CRP.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;There was no significant difference in all cause mortality but lipid profiles, systolic blood pressure, prevalence of smoking and uptake of physical activity was significantly better in those receiving teleintervention. &lt;U&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18720118" target="_blank"&gt;Kairy et al (2009)&lt;/A&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; reviewed 28 studies where telerehabilitation methods were used for patients with a wide range of chronic conditions. Four studies, including 268 participants, recruited patients during phase 3 CR post myocardial infarction or revascularisation surgery and compared traditional centre based exercise CRPs with home based exercise. Home based patients communicated with their healthcare provider during exercise sessions by telephone or video and had transtelephonic ECG monitoring; one study monitored 5 patients at once who could communicate with each other during their session. Results showed a non-inferiority to centre based exercise programmes in terms of cardiovascular outcomes and quality of life with potential cost saving benefits.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531070" target="_blank"&gt;Eshah et al&lt;/A&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531070" target="_blank"&gt; (2009)&lt;/A&gt; reviewed 13 studies, including 1566 participants, to determine effectiveness of a variety of CRPs. They identified poorer access in women unless participating in female only classes and found&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;older patients appear to do better in home based programmes. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;U&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;What these studies add&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;These studies support growing evidence that home based CR programmes are not inferior to centre based programmes in terms of improved secondary prevention, physical and psychological wellbeing. Home based programmes supported by telehealth interventions can provide an option on the menu of CR which patients find acceptable and may improve access for those who are otherwise hard to reach. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB&lt;SPAN style="mso-bidi-font-weight: bold"&gt;.&amp;nbsp;Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review.&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;European Journal of Cardiovascular Prevention and Rehabilitation 2009; 16 (3):281-9. [ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407659" target="_blank"&gt;abstract&lt;/A&gt; ]&amp;nbsp;&lt;/SPAN&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place w:st="on"&gt;&lt;st1:City w:st="on"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Eshah&lt;/SPAN&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt; &lt;st1:State w:st="on"&gt;NF&lt;/st1:State&gt;&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt; and Bond AE. Cardiac rehabilitation programme for coronary heart disease patientsL An integrative literature review. International Journal of Nursing Practice.&amp;nbsp;&lt;SPAN style="mso-bidi-font-style: italic"&gt; &lt;/SPAN&gt;2009; &lt;SPAN style="mso-bidi-font-weight: bold"&gt;15 (3)&lt;/SPAN&gt;:131–139. [ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531070" target="_blank"&gt;full text&lt;/A&gt; ] &lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Kairy D, Lehoux P, Vincent C, Visintin M. A systematic review of clinical outcomes, clinical process, healthcare utilization and costs associated with telerehabilitation. Disability &amp;amp; Rehabilitation 2009; 31 (6): 427-447. [ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18720118" target="_blank"&gt;abstract&lt;/A&gt; ] &lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jolly K, Lip G Y, Taylor R S, Raftery J, Mant J, Lane D, Greenfield S, Stevens A. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation (Structured abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2009 [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100638/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Papadakis S, Reid RD, Coyle D, Beaton L, Angus D, Oldridge, N. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100341/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Zeidler J, Mittendorf T, Vahldiek G, Graf Von Der Schulenburg JM. Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases (Brief record) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100746/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Spronk S, Bosch JL, Ryjewsk C, Rosenblum J, Kaandorp CG,&amp;nbsp; White JV, Hunink MG. Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100291/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Huang Y, Zhang R, Culler DS, Kutner NG. Costs and effectiveness of cardiac rehabilitation for dialysis patients following coronary bypass (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22008102043/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Dendale P, Hansen D, Berger J, Lamotte M. Long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention (Provisional abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination 2008&amp;nbsp;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100809/frame.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Cardiac Rehabilitation Services [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CardiacRehabilitationService.jsp" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) - Unstable Angina &amp;amp; NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction [&lt;A href="http://www.nice.org.uk/nicemedia/live/12949/47988/47988.pdf" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Department of Health - National Service Framework for Coronary Heart Disease, Chapter 7, Cardiac Rehabilitation [&lt;A href="http://www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/Coronaryheartdisease/Cardiacrehabilitation/index.htm" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;British Heart Foundation - Cardiac Care and Education Research Group. National Audit of&amp;nbsp;Cardiac Rehabilitation (NACR)&amp;nbsp;– Annual Statistical Report 2009 [&lt;A href="http://www.cardiacrehabilitation.org.uk/docs/NACR_2009.pdf" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – The National Audit of Cardiac Rehabilitation - Annual Statistical Report&amp;nbsp;2009 Executive Summary [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=345425&amp;amp;tabID=290" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – UK Coronary Heart Disease Statistics 2009-2010 [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001141" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Heart&amp;nbsp;(Cardiac Rehabilitation pages) [&lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation&amp;nbsp; [&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – Cardiac Rehabilitation Information [&lt;A href="http://www.bhf.org.uk/living-with-a-heart-condition/recovery/cardiac-rehabilitation.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;American Heart Association - Cardiac Rehabilitation [&lt;A href="http://www.americanheart.org/presenter.jhtml?identifier=3047638" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology [&lt;A href="http://www.escardio.org/communities/EACPR/Pages/welcome.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices -Recovering from a Heart Attack [&lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices - Recovering from Heart Disease [&lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:334323:0" name=internalLink&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346200</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346200]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Psychosocial Aspects</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Psychosocial Aspects&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;Psychosocial Aspects&lt;/STRONG&gt; &lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Professor David R Thompson&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Professor of Cardiovascular Nursing, University of Leicester&lt;/FONT&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG style="HEIGHT: 96px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=140&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Psychosocial Interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;The personality traits of anger and hostility have long been believed to be associated with increased risk of coronary heart disease (CHD) events in healthy people as well as those with existing CHD.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;A recent meta-analysis (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19281923" target="_blank"&gt;Chida &amp;amp; Steptoe 2009&lt;/A&gt;) examined this association focusing on prospective cohort studies.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;The authors examined anger and hostility as one construct, which is problematic, but found they are associated with CHD in both healthy and CHD populations.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Interestingly, the harmful effects of anger and hostility on CHD events in healthy people are greater in men than women. This suggests the need for the routine assessment of both and a holistic multidisciplinary approach to the prevention and treatment of them.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;Music has long been used to reduce anxiety and distress in patients in hospital but its efficacy for individuals with CHD is unclear.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;A recent meta-analysis of music for stress and anxiety reduction in CHD patients (&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006577/frame.html" target="_blank"&gt;Bradt &amp;amp; Dileo 2009&lt;/A&gt;) found that music listening has a moderate effect on anxiety, reducing heart and respiratory rates and blood pressure.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Studies that included two or more music sessions led to a small and consistent pain-reducing effect.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;However, the quality of the evidence is not strong and the clinical significance is unclear.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Most studies examined the effects of listening to pre-recorded music and more research is needed on the effects of music offered by a trained music therapist.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial" lang=EN-GB&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;Bradt J and Dileo C. Music for stress and anxiety reduction in coronary heart disease patients (Review). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006577. [ &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006577/frame.html" target="_blank"&gt;full text &lt;/A&gt;]&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. Journal of the &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place w:st="on"&gt;&lt;st1:PlaceName w:st="on"&gt;American&lt;/st1:PlaceName&gt; &lt;st1:PlaceType w:st="on"&gt;College&lt;/st1:PlaceType&gt;&lt;/st1:place&gt; of Cardiology. 2009 17; 53 (11): 936-46. [ &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19281923" target="_blank"&gt;abstract&lt;/A&gt; ]&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;&lt;STRONG&gt;Cochrane Protocols&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;Baumeister H, Hutter N, Bengel, J. Psychological and pharmacological interventions for depression in patients with coronary artery disease The Cochrane Library 2009 [&lt;A href="http://www2.cochrane.org/reviews/en/protocol_2CAA86BF82E26AA2019F167AA5505AF8.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; mso-ansi-language: EN-US"&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;Lewin RJ, Coulton S, FrizelleDJ, Kaye G, Cox H.&amp;nbsp; A brief cognitive behavioural preimplantation and rehabilitation programme for patients receiving an implantable cardioverter-defibrillator improves physical health and reduces psychological morbidity and unplanned readmissions (Structured abstract) NHS Economic Evaluation Database, Centre for Review &amp;amp; Dissemination&amp;nbsp;2009&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cleed/articles/NHSEED-22009100637/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Cardiac Rehabilitation Services [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cardiacrehabilitationservice/CardiacRehabilitationService.jsp" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) - Unstable Angina &amp;amp; NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction [&lt;A href="http://www.nice.org.uk/nicemedia/live/12949/47988/47988.pdf" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Department of Health - National Service Framework for Coronary Heart Disease, Chapter 7, Cardiac Rehabilitation [&lt;A href="http://www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/Coronaryheartdisease/Cardiacrehabilitation/index.htm" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;British Heart Foundation - Cardiac Care and Education Research Group. National Audit of&amp;nbsp;Cardiac Rehabilitation (NACR)&amp;nbsp;– Annual Statistical Report 2009 [&lt;A href="http://www.cardiacrehabilitation.org.uk/docs/NACR_2009.pdf" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – The National Audit of Cardiac Rehabilitation - Annual Statistical Report&amp;nbsp;2009 Executive Summary [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=345425&amp;amp;tabID=290" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – UK Coronary Heart Disease Statistics 2009-2010 [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001141" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement - Heart&amp;nbsp;(Cardiac Rehabilitation pages) [&lt;A href="http://www.improvement.nhs.uk/heart/?TabId=56" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Association for Cardiac Rehabilitation&amp;nbsp; [&lt;A href="http://www.bcs.com/pages/page_bacr.asp?PageID=314&amp;amp;NewsCatID=852" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;British Heart Foundation – Cardiac Rehabilitation Information [&lt;A href="http://www.bhf.org.uk/living-with-a-heart-condition/recovery/cardiac-rehabilitation.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;American Heart Association - Cardiac Rehabilitation [&lt;A href="http://www.americanheart.org/presenter.jhtml?identifier=3047638" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology [&lt;A href="http://www.escardio.org/communities/EACPR/Pages/welcome.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices -Recovering from a Heart Attack [&lt;A href="http://www.nhs.uk/Conditions/Heart-attack/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;NHS Choices - Recovering from Heart Disease [&lt;A href="http://www.nhs.uk/Conditions/Coronary-heart-disease/Pages/Recovery.aspx?url=Pages/What-is-it.aspx" target="_blank"&gt;weblink&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 9pt 0pt 0cm" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;UK Clinical Research Network &lt;/A&gt;and &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation&amp;nbsp; of Care&lt;/FONT&gt;&lt;/A&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346790</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=346790]]&gt;</url>
    <title>2010 Evidence Update on Cardiac Rehabilitation - Uncertainties</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,APR-JUNE 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Cardiac Rehabilitation - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;&lt;STRONG&gt;Uncertainties&lt;/STRONG&gt; &lt;/FONT&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=center align=middle&gt;&lt;IMG style="WIDTH: 136px; HEIGHT: 91px" id=nelh_tempImage1 name=nelh_tempImage1 alt="Duets uncertainties" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt;&lt;/TD&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="82%"&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;&lt;STRONG&gt;This systematic review has been identified as highlighting a treatment uncertainty. This review will also appear under other Evidence Update sections. eg. Psychosocial. In the coming weeks we will be working to&amp;nbsp;include this uncertainty into&amp;nbsp;the PICO (Patient-Intervention-Comparison-Outcome)&amp;nbsp;format for submission to DUETs (Database of Uncertainties&amp;nbsp;about the Effects of Treatments). See &lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;&lt;STRONG&gt;http://www.library.nhs.uk/duets/&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;for more information.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2 face=arial&gt;Bradt J and Dileo C. Music for stress and anxiety reduction in coronary heart disease patients. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006577. DOI: 10.1002/14651858.CD006577.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Results indicated that music listening has a moderate effect on anxiety in patients with coronary heart disease; however, results were inconstant across studies. The review did not find strong evidence for reduction of psychological distress. More research is needed to investigate the effects of music listening on depression, mood, myocardial oxygen demand and peripheral skin temperature, since only a small number of trials investigated the effects of music on these outcomes. Hence, the evidence is not clinically applicable at the time.&lt;BR&gt;Because of the lack of RCTs examining the effect of music interventions offered by a trained music therapist on patients with coronary heart disease, it is impossible to distinguish whether these interventions are more effective than only listening to pre-recorded music.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006577/frame.html" target="_blank"&gt;Link to full text here&amp;nbsp;&lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;Evidence&lt;BR&gt;Update&lt;BR&gt;&lt;A href="nelh:346140:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 37px" id=nelh_tempImage2 name=nelh_tempImage2 alt="Access to Care" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346202/nelhImp_0000_accesstocare.gif" width=44 height=37&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346202:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Access to&lt;BR&gt;Care&lt;/A&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0018_AEUPsychosocial.jpg" width=45 height=100&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346200:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Psychosocial&lt;BR&gt;Aspects&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 51px; HEIGHT: 41px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0020_AEUexercise.jpg" width=129 height=98&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;A href="nelh:346206:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Exercise&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 51px; HEIGHT: 43px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0019_HF2009monitor.jpg" width=46 height=97&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 49px; HEIGHT: 35px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 height=31&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346434:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 44px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346634:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=46 height=37&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;Contributors &lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR bgColor=#cccccc&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:346790:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334829</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334829]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Acute Coronary Syndromes</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CARDIOVASCULAR,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,CHEST PAIN (ISCHAEMIC),CHEST,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,JAN-MAR 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Acute Coronary Syndromes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;: A C U T E&amp;nbsp; C O R O N A R Y&amp;nbsp; S Y N D R O M E S&lt;BR&gt;Professor Steve Goodacre , Professor of Emergency Medicine, Medical Care Research Unit, Health Services Research, School of Health and Related Research (ScHARR),University of Sheffield&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/FONT&gt;&lt;/A&gt;&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;&lt;BR&gt;&lt;/EM&gt;&lt;/A&gt;&lt;/U&gt;&lt;EM&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0014_acs.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXPERT SUMMARY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=MImg&amp;amp;_imagekey=B6T18-4RS9SN5-1-9&amp;amp;_cdi=4884&amp;amp;_user=10&amp;amp;_pii=S073510970800226X&amp;amp;_orig=search&amp;amp;_coverDate=03%2F04%2F2008&amp;amp;_sk=999489990&amp;amp;view=c&amp;amp;wchp=dGLzVzz-zSkWb&amp;amp;md5=02a8704d09da6033cf60b4a781fd871f&amp;amp;ie=/sdarticle.pdf" target="_blank"&gt;Abbate et al&lt;/A&gt; undertook a systematic review and meta-analysis of ten trials comparing percutaneous coronary intervention (PCI) to medical therapy in 3560 patients who presented late (&amp;gt;12 hours) after acute myocardial infarction. PCI was associated with reduced mortality (6.3% versus 8.4%, odds ratio 0.49, 95% confidence interval (CI) 0.26 to 0.94, p = 0.030). The median time from infarction to randomisation was 12 days. A substantial proportion of patients with acute myocardial infarction present late, despite our best efforts using public education to reduce time delays before presentation. These findings suggest that such patients may still benefit from early PCI, although this is clearly not emergency PCI.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="#Qayyum"&gt;Qayyum et al &lt;/A&gt;systematically reviewed trials comparing routine and selective invasive strategies for acute coronary syndrome. They identified ten trials with a total of 10,648 patients that compared death or myocardial infarction outcomes in patients with non-ST elevation acute coronary syndrome between those receiving a routine invasive strategy (i.e. all patients receive coronary angiography and PCI if indicated) and those receiving a selective strategy (i.e. only patients with refractory or inducible ischaemia undergo angiography). There were no significant differences between the groups in the composite outcome of death or non fatal myocardial infarction (relative risk 0.90; 95% CI 0.74 to 1.08), death alone (relative risk 0.95; 95% CI 0.80 to 1.14) or non fatal myocardial infarction alone (relative risk 0.86; CI 0.68 to 1.08). The point estimates favoured the invasive strategy, so although the available evidence does not support a routine invasive strategy for patients with non ST-elevation acute coronary syndrome, the confidence interval does not rule out a potentially worthwhile effect. However, given the size of trial required to demonstrate what is likely to be a modest benefit, future research efforts may be better directly towards methods of identifying which patients should be selected for an invasive strategy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="#Sarkees"&gt;BMJ Clinical Evidence &lt;/A&gt;has published a series of systematic reviews evaluating the effectiveness and safety of interventions for acute coronary syndrome. They confirm that aspirin reduces the risk of death, myocardial infarction and stroke compared with placebo at doses up to 325 mg daily, but higher doses of aspirin are no more effective and increase the risk of complications. Adding clopidogrel to aspirin may reduce the risk of death or myocardial infarction, but may increase the risk of bleeding. Similarly, intravenous glycoprotein IIb/IIIa platelet receptor inhibitors further reduce the risk of death or myocardial infarction, but also increase the risk of bleeding. Adding heparin to aspirin reduces the risk of death or myocardial infarction up to one week but longer-term benefits are not clear. Low molecular weight heparin may reduce myocardial infarction and direct thrombin inhibitors (hirudin and bivalirudin) may reduce death or myocardial infarction compared to unfractionated heparin. Meanwhile, drugs that have negative effects include warfarin, that increases the risk of bleeding without producing benefit, and short-acting dihydropyridine calcium channel blockers, that may increase mortality in people with coronary heart disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Finally, &lt;A href="#con"&gt;O’Connor and Fraser &lt;/A&gt;undertook a systematic review to evaluate therapies for preventing and treating cardiogenic shock after acute myocardial infarction. They found that prehospital thrombolysis, transfer for emergency revascularisation (patients aged &amp;lt; 75 years) and thrombolysis for older patients (patients aged = 75 years) were effective in preventing and treating cardiogenic shock due to acute myocardial infarction. In hospital thrombolysis and intra-aortic balloon pump use in patients aged &amp;lt; 75 years and emergency revascularisation in older patients may be beneficial in patients with established cardiogenic shock, but the evidence is weak and limited to subgroup analyses and observational studies.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;SYSTEMATIC REVIEWS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=Abbate&gt;Abbate A &lt;/A&gt;, Biondi-Zoccai GG, Appleton DL, Erne P, Schoenenberger AW, Lipinski MJ, et al. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51(9):956-64. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Percutaneous coronary intervention of the IRA performed late (12 h to 60 days) after AMI is associated with significant improvements in cardiac function and survival.&lt;BR&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=MImg&amp;amp;_imagekey=B6T18-4RS9SN5-1-9&amp;amp;_cdi=4884&amp;amp;_user=10&amp;amp;_pii=S073510970800226X&amp;amp;_orig=search&amp;amp;_coverDate=03%2F04%2F2008&amp;amp;_sk=999489990&amp;amp;view=c&amp;amp;wchp=dGLzVzz-zSkWb&amp;amp;md5=02a8704d09da6033cf60b4a781fd871f&amp;amp;ie=/sdarticle.pdf" target="_blank"&gt;Link to full-text here&lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp;requires leaving this site)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=Qayyum&gt;Qayyum R&lt;/A&gt;, Adomaityte J. Non-ST-segment elevation ACS: Should all patients undergo cardiac catheterization? &lt;ABBR class=site-title title="Annals of Internal Medicine"&gt;&lt;ABBR class=site-title title="Annals of Internal Medicine"&gt;&lt;ABBR class=site-title title="Annals of Internal Medicine"&gt;&lt;ABBR class=site-title title="Annals of Internal Medicine"&gt;Ann Intern Med.&lt;/ABBR&gt;&lt;SPAN class=cit-print-date&gt; 2008 &lt;/SPAN&gt;&lt;SPAN class=cit-vol&gt;148&lt;SPAN class="cit-sep cit-sep-after-article-vol"&gt;:&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;SPAN class=cit-pages&gt;&lt;SPAN class=cit-first-page&gt;186&lt;/SPAN&gt;&lt;SPAN class=cit-sep&gt;-&lt;/SPAN&gt;&lt;SPAN class=cit-last-page&gt;196.&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/ABBR&gt;&lt;/ABBR&gt;&lt;/ABBR&gt;&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclussion&lt;/STRONG&gt;:This systematic review does not support a routine invasive strategy as clearly superior to a selective invasive strategy for managing patients with non–ST-segment elevation Acute Coronary Syndrome.&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.annals.org/content/148/3/186.full.pdf+html" target="_blank"&gt;Link to full-text here&lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp;requires leaving this site)&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=sarkees&gt;Sarkees ML&lt;/A&gt;, Bavry AA. Acute coronary syndrome (unstable angina and non-ST elevation MI). Clin Evid (Online). 2009;2009. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; In this systematic review we present information relating to the effectiveness and safety of the following interventions: aspirin, beta-blockers, calcium channel blockers, clopidogrel, direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors (oral or intravenous), heparin (low molecular weight, unfractionated), nitrates, routine early cardiac catheterisation and revascularisation, statins, and warfarin.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445778" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=Con&gt;O'Connor E&lt;/A&gt;, Fraser JF. How can we prevent and treat cardiogenic shock in patients who present to non-tertiary hospitals with myocardial infarction? A systematic review. Med J Aust. 2009;190(8):440-5. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; In regional centres, prevention of Cardiogenic Shock (CS)&amp;nbsp;is achieved with early fibrinolysis, preferably before hospital arrival. Patients of all ages should be considered for thrombolysis, early transfer for coronary revascularisation, and intra-aortic balloon pump insertion unless contraindicated. Glycoprotein inhibitors have no role in the management of CS in non-tertiary hospitals. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19374618" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; (Warning:&amp;nbsp;requires leaving this site)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COCHRANE PROTOCOLS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Briel Matthias. Statins for acute coronary syndrome. Cochrane Database of Systematic Reviews:&amp;nbsp;2008;Issue 1. &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006870/pdf_fs.html" target="_blank"&gt;http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006870/pdf_fs.html&lt;/A&gt; (Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Wu T, Chen X, Deng L. Beta-blockers for unstable angina. Cochrane Database of Systematic Reviews: 2008; Issue 2.&amp;nbsp; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007050/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007050/frame.html&lt;/A&gt;.&lt;BR&gt;(Warning:&amp;nbsp; requires leaving this site) &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER RELEVANT DOCUMENTS&lt;BR&gt;&lt;BR&gt;Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11661" target="_blank"&gt;NICE guideline in development Chest pain of recent onset: assessment and investigation of recent onset chest pain/discomfort of suspected cardiac origin&lt;/A&gt;&lt;BR&gt;Due to be published March 2010.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://guidance.nice.org.uk/CG/Wave14/24" target="_blank"&gt;Acute coronary syndromes: the management of unstable angina and non-ST segment elevation myocardial infarction&amp;nbsp;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Due to be published March 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black; mso-bidi-font-weight: bold"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;(2009 reviewed)&lt;A href="http://www.library.nhs.uk/emergency/ViewResource.aspx?resID=266673" target="_blank"&gt;&amp;nbsp;Emergency Care Specialist Collection Chest Pain &lt;/A&gt;:&amp;nbsp;Part of the Emergency Care’s National Knowledge Week&amp;nbsp;for foundation year doctors&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;For details of ongoing research visit the&amp;nbsp;UK Clinical Research Network at&amp;nbsp;&lt;/STRONG&gt;&lt;A href="http://www.ukcrn.org.uk/index.html%20and%20Current" target="_blank"&gt;&lt;STRONG&gt;http://www.ukcrn.org.uk/index.html&amp;nbsp;&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;and Current Controlled Trials at &lt;/STRONG&gt;&lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;STRONG&gt;http://www.controlled-trials.com/&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334823</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334823]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Angina</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,BETA BLOCKERS,CHEST PAIN,INTERVENTIONS / PROCEDURES,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,STABLE ANGINA,GENERAL/OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Angina&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;: A N G I N A &lt;BR&gt;Dr. Kathryn Griffith, General Practitioner, University Health Centre, York University, Heslington, York&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;U&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;&lt;U&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/U&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/U&gt;&amp;nbsp;&lt;BR&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334823/nelhImp_0000_anginapic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXPERT SUMMARY&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Medical management of chronic stable angina&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="#tool"&gt;O’Toole&lt;/A&gt; reviewed the evidence for the medical management of chronic stable angina which was defined as regular or predictable angina symptoms which have been present for over 2 months. This is associated with increased cardiovascular events and mortality, and amongst people not thought to need coronary revascularisation annual mortality is 1-2% and annual non-fatal MI rates are 2-3%. Studies included in the review included systematic reviews and RCT in any language, which were at least single blind and included at least 50 people of whom more than 80% were followed up for a minimum of 6 months. RCT compared single drug treatment with placebo, compared 2 active anginal drug classes or a single drug and a combination of agents. The classes included were beta-blockers, calcium channel blockers, long acting nitrate preparations, and potassium channel openers.&amp;nbsp; There appears to be limited evidence due to insufficient statistical power and short duration of some studies and there is an absence of RCT for comparison between study groups. It is not possible to demonstrate overall outcome benefit of any class of treatment over another, or combination therapy over single therapy. There is consensus that all 4 classes are effective in treating the symptoms of stable angina.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Transmyocardial laser revascularization ( TMLR) versus medical therapy for refractory angina&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="#Briones"&gt;Briones et al &lt;/A&gt;identified 152 unique references and included 20 papers published in peer reviewed journals, reporting on 7 studies for this systematic review.&amp;nbsp; In total 1137 participants were randomized and 559 allocated to TMLR. The intervention was performed by 3 different types of laser, however the operative technique was considered similar. There were differences in severity of angina between studies as assessed using the CCS score in 5 and NYHA scale in 2. Primary outcomes were measured at 1 year and included an exercise test in 3 and reduced angina class in 4 studies, where angina relief in all was defined as a reduction by at least 2 classes in score. The risk of bias was assessed because blinding is difficult in surgical studies, only 1 study performed blinded assessment of the primary outcome. All studies showed a significant reduction of at least 2 angina classes with TMLR with 43.8% in TMLR group and 14.77% in control.&amp;nbsp; Overall mortality rate at 1 year was 12.2% in the TMLR group and 11.9% in control with no statistical significant difference and no difference in the early mortality up to 30 days of intervention with 4.01% in TMLR group and 3.5% in control.&amp;nbsp; There was no statistically significant difference in exercise tolerance, frequency of angina or perceived quality of life. The authors conclude there is insufficient evidence that clinical benefits outweigh&amp;nbsp; potential risks, there are concerns related to lack of blinding and risk of bias. More research is recommended in combination with research on the mechanisms of action of the treatment.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Spinal cord stimulation ( SCS)&amp;nbsp; in the treatment of refractory angina&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="#Taylor"&gt;Taylor et al&lt;/A&gt; undertook a&amp;nbsp; systematic review and meta-analysis of the use of spinal cord stimulation (SCS) in the management of refractory angina. These patients suffer from disabling angina despite optimal medical therapy. Sixty seven papers were considered for inclusion and 11 publications across 7 RCT and 270 patients were included. Four compared active with inactive SCS ( SCS OFF), 2 compared SCS to alternative active treatments and 1 to a control group with no implantation . All were single centre European studies and 3 in the same centre. Complete blinding was considered difficult due to paraesthesia in area of pain if SCS is efficacious. There was improvement in exercise capacity and quality of life compared with a no stimulation control and similar outcomes when compared with CABG and TMLR. SCS was considered to be a safe and effective treatment for refractory angina however the trials were small and of variable quality. More research is needed before this is routine treatment including health care costs and study of the mechanism of action of SCS.&lt;BR&gt;&lt;BR&gt;In the systematic review of SCS in refractory angina by&lt;A href="#Bor"&gt; Bjoresson at al &lt;/A&gt;, 43 studies were graded and 8 studies of medium to high quality were included in the review. The patient population was 539 with some studies as small as 12 patients. There is strong evidence that SCS improves symptoms (decreased angina attacks), improves functional capacity (improved exercise times), and quality of life. There was limited evidence to suggest a lack of negative effect on mortality, little data comparing SCS with other forms of treatment and again problems with blinding and bias in these studies. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=tool&gt;O'Toole L &lt;/A&gt;. Angina (chronic stable). Clin Evid (Online). 2008;2008.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion&lt;/STRONG&gt;: In this systematic review we present information relating to the long-term effectiveness and safety of the following interventions: beta-blockers, calcium channel blockers, long-acting nitrates, potassium channel openers, combinations of these anti-anginal drug treatments and the use of these anti-anginal drug treatment as an adjunct to existing therapies. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445795" target="_blank"&gt;Link to PubMed abstract here&lt;BR&gt;&lt;/A&gt;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=Briones&gt;Briones E &lt;/A&gt;, Lacalle Juan R, Marin I. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database of Systematic Reviews 2009; (1)&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on the review of all available studies we can not conclude that the clinical benefits of Transmyocardial laser revascularization (TMLR) outweigh the potential risks. It is suggested that application of TMLR in clinical practice should be restricted to research or special situations.&lt;BR&gt;&lt;A href="nelh:304875:0" name=internalLink&gt;Link to abstract here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Taylor&gt;Taylor RS&lt;/A&gt;, De Vries J, Buchser E, Dejongste MJ. Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials. BMC Cardiovasc Disord. 2009;9:13. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; Spinal Cord Stimulation (SCS) appears to be an effective and safe treatment option in the management of refractory angina patients and of similar efficacy and safety to Percutaneous Myocardial Laser Revascularisation (PMR), a potential alternative treatment. Further high quality Randomised Controlled Trials and cost effectiveness evidence is needed before SCS can be accepted as a routine treatment for refractory angina. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667170/pdf/1471-2261-9-13.pdf" target="_blank"&gt;Link to&amp;nbsp;full-text&amp;nbsp;here.&lt;/A&gt; (Warning:&amp;nbsp;requires leaving this site)&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Bor&gt;Borjesson M &lt;/A&gt;, Andrell P, Lundberg D, Mannheimer C. Spinal cord stimulation in severe angina pectoris--a systematic review based on the Swedish Council on Technology assessment in health care report on long-standing pain. Pain. 2008 Dec;140(3):501-8. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is strong evidence that Spinal Cord Stimulation (SCS) gives rise to symptomatic benefits (decrease in anginal attacks) and improved quality of life in patients with severe angina pectoris. In addition, SCS does not seem to have any negative effects on mortality in these patients (limited scientific evidence). The complication rate was found to be acceptable. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19004553" target="_blank"&gt;Link to PubMed asbtract here.&lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COCHRANE PROTOCOLS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Amin F, Al Hajeri A, Civelek B, Fedorowicz Z, Manzer Bruce M. Enhanced external counterpulsation for chronic angina pectoris. Cochrane Database of Systematic Reviews&amp;nbsp;. 2008; (3)&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007219/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007219/frame.html&lt;/A&gt;. (Warning:&amp;nbsp; requires leaving this site) &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER RELEVANT DOCUMENTS&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11661" target="_blank"&gt;NICE guideline in development. Chest pain of recent onset: assessment and investigation of recent onset chest pain/discomfort of suspected cardiac origin. &lt;/A&gt;Due to be published March 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations:&lt;BR&gt;&lt;BR&gt;NHS EED (2008)&lt;/STRONG&gt; &lt;A href="nelh:316852:0" name=internalLink&gt;Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: the SPiRiT trial.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;For details of ongoing research visit UK Clinical Research Network at &lt;/STRONG&gt;&lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;&lt;STRONG&gt;http://www.ukcrn.org.uk/index.html&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt; and Current Controlled Trials at &lt;/STRONG&gt;&lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;STRONG&gt;http://www.controlled-trials.com/&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334816</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334816]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Diagnosis and Risk</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIAGNOSIS,CONDITIONS,CHEST PAIN,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,DIAGNOSIS,DIAGNOSIS,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,STABLE ANGINA,OTHER,JAN-MAR 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Diagnosis and Risk&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0 : D I A G N O S I S&amp;nbsp;&amp;nbsp; A N D&amp;nbsp;&amp;nbsp; R I S K&lt;BR&gt;Dr Sunil Nadar, Consultant Interventional Cardiologist, Heart of England NHS Trust, Birmingham&lt;BR&gt;&lt;BR&gt;&lt;/STRONGFONT color="#000000"&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/FONT&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/A&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334816/nelhImp_0000_Diagnosispic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXPERT SUMMARY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Patients presenting with chest pain to the emergency services is a common occurrence. Presenting ECG and estimation of plasma biomarkers play a significant role in identifying the patients with acute coronary syndromes and those at high risk. However, majority of patients have normal ECG and plasma biomarkers that are within normal limits. Identifying patients at risk from this subgroup of patients poses significant diagnostic problems.&amp;nbsp; Exercise testing is the next investigation in majority of these patients. However, often patients have to wait to get this test and end up occupying a bed till this is done. Non invasive testing such as multislice CT (MSCT)scanning has been investigated as an investigative tool to help identify patients that would need further testing such as angiography and also identify those who could be safely sent home with a diagnosis of non cardiac chest pain.&lt;/P&gt;
&lt;P&gt;&lt;A href="#Athappan"&gt;Athappan et al&lt;/A&gt; perfomed a meta analysis to find out the exact role of MSCT in the diagnosis of acute chest pains. 16 studies including 1119 patients were included in this meta analysis. The pooled sensitivity and specificity was 95.9% and 91.6% respectively for the diagnosis of acute coronary syndromes. They suggest that MSCT is an excellent tool to be used to help rapid triage of patients presenting with chest pains. &lt;/P&gt;
&lt;P&gt;&lt;A href="#Bamberg"&gt;Bamberg et al &lt;/A&gt;tried to find out which patients would benefit the most from CT angiography in the diagnosis of coronary artery disease. They evaluated 368 patients with acute chest pain and an inconclusive initial evaluation (nondiagnostic electrocardiograhic findings, negative cardiac biomarkers). They underwent contrast enhanced 64-slice coronary CTA as a part of an observational cohort study. The presence of significant coronary stenosis on CTA and the occurrence of ACS increased with age for both men and women (p &amp;lt;0.001). Cardiac CTA was highly sensitive and specific in women &amp;lt;65 years of age (sensitivity 100% and specificity &amp;gt;87%) and men &amp;lt;55 years of age (sensitivity 100% for men &amp;lt;45 years and 80% for men 45 to 54 years old; specificity &amp;gt;88.2%). Moreover, in these patients, coronary CTA led to restratification from low to high risk (for positive findings on CTA) or from low to very low risk (for negative findings on CTA). In contrast, a negative result on CTA did not result in restratification to a low-risk category in women &amp;gt;65 years and men &amp;gt;55 years old. They summarized that men &amp;lt;55 years and women &amp;lt;65 years might benefit more from cardiac CTA than older patients. Thus, age and gender might serve as simple criteria to appropriately select patients who would derive the greatest diagnostic benefit from coronary CTA in the setting of acute chest pain.&lt;/P&gt;
&lt;P&gt;The role of non invasive testing in diagnosing coronary stent thrombosis is not clear. &lt;A href="#Vanhoe"&gt;Vanhoenacker et al &lt;/A&gt;perfomed a structured review and meta analysis of published studies to look at the role of multidetector computed tomography angiography in diagnosing acute stent thrombosis. They included a total of 14 studies on this topic. Their conclusion was that this modality of imaging was not useful in diagnosisng stent thrombosis as it missed nearly 20% of such patients. Also these scans are not very accurate in imaging stents. Improvement in imaging techniques are required before these scans are used to diagnose stent thrombosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The role of coronary artery calcium scoring in the diagnosis, management and prognosis of stable&amp;nbsp; coronary artery disease is uncertain.&amp;nbsp; &lt;A href="#Sarwar"&gt;Sarwar et al &lt;/A&gt;&amp;nbsp; (J. Am. Coll. Cardiol. Img. 2009;2;675-688) performed a systematic review of the available literature to assess the prognostic and diagnostic value of the absence of coronary artery calcium in symptomatic and asymptomatic individuals. Pooling various studies together, they found that 0.5% of asymptomatic patients without coronary artery calcium had a cardiovascular event during a mean follow up period of 51 months. 1.8% of symptomatic individuals without coronary artery calcium had an even during follow up. Overall, the presence of any CAC had a pooled sensitivity and negative predictive value of 98% and 93%, respectively, for detection of significant coronary artery disease on invasive coronary angiography. Similarily only 6% of individuals without coronary artery calcium demonstrated signs of myocardial ischaemia when&amp;nbsp; undergoing myocardial perfusion. The&amp;nbsp; absence of CAC had a negative predictive value of 99% for ruling out acute coronary syndrome. They conclude that we conclude that the absence of CAC is associated with a very low risk of future cardiovascular events, with modest incremental value of other diagnostic tests in this very low-risk group.&lt;/P&gt;
&lt;P&gt;In summary, multislice CT scanning and CT angiography are very good non invasive methods of assessing coronary artery disease in the emergency room and help in rapid triage of patients. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=Athappan&gt;Athappan&lt;/A&gt; G, Habib M, Ponniah T, Jeyaseelan L. Multi-detector computerized tomography angiography for evaluation of acute chest pain - A meta analysis and systematic review of literature. Int J Cardiol. 2009 Jan 29. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion&lt;/STRONG&gt;: Multi-detector Computerized&amp;nbsp;Tomography Angiography (MDCTA)&amp;nbsp;has an excellent diagnostic accuracy in detection of significant coronary artery stenosis in patients with acute chest pain. This diagnostic accuracy of MDCTA has a potential for rapid triage of patients in the ED, with acute chest pain of low to intermediate risk of acute coronary syndrome, to rule out significant epicardial stenosis as the etiology of chest pain.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19185936" target="_blank"&gt;Link to PubMed abstract here.&amp;nbsp;&lt;/A&gt;(Warning:&amp;nbsp;requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Bamberg&gt;Bamberg F &lt;/A&gt;, Truong QA, Blankstein R, Nasir K, Lee H, Rogers IS, et al. Usefulness of age and gender in the early triage of patients with acute chest pain having cardiac computed tomographic angiography. Am J Cardiol. 2009;104(9):1165-70. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The present analysis provides initial evidence that men &amp;lt;55 years and women &amp;lt;65 years might benefit more from cardiac Computed Tomographic Angiography (CTA) than older patients. Thus, age and gender might serve as simple criteria to appropriately select patients who would derive the greatest diagnostic benefit from coronary CTA in the setting of acute chest pain.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19840556" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract here&lt;/A&gt;.(Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=Brown&gt;Brown G.&lt;/A&gt; Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2. Diagnostic utility of chest X ray for investigation of pulmonary embolism. Emerg Med J. 2009 Apr;26(4):289-90. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A chest X-ray alone is of little value in the diagnosis of pulmonary embolus. Its main value is in ruling out other causes of the presenting symptoms, or as part of a risk stratification strategy to inform a further investigative protocol. &lt;BR&gt;&lt;A href="http://www.bestbets.org/bets/bet.php?id=611" target="_blank"&gt;Link to full-text here. &lt;/A&gt;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Di Tanna GL, Berti E, Stivanello E, Cademartiri F, Achenbach S, Camerlingo MD, et al. Informative value of clinical research on multislice computed tomography in the diagnosis of coronary artery disease: a systematic review. Int J Cardiol. 2008;130(3):386-404.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; Multislice Computed Tomography (MSCT) is a promising technology for the assessment of coronary artery stenosis. However, the available literature is of limited value in providing guidance to support the development of policies for its appropriate utilization in clinical practice. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18760849" target="_blank"&gt;Link to full-text here.&amp;nbsp; &lt;/A&gt;(Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Inaba Y, Bergmann SR. Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a meta-analysis. J Nucl Cardiol. 2008;15(3):345-52. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion&lt;/STRONG&gt;: Imaging with BMIPP at rest exhibits a moderate sensitivity and high specificity to detect Coronary Artery Disease (CAD) in patients with a high prevalence of CAD. Thus, this tracer may be of great value for patients with acute chest pain and those with relative contraindications to exercise or pharmacologic stress myocardial perfusion imaging (MPI). &lt;BR&gt;&lt;A href="http://www.bimcmedicine.org/attachments/Inabas_Article.pdf" target="_blank"&gt;Link to&amp;nbsp;full-text here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;(Warning: Requires leaving this site)&lt;BR&gt;&lt;A href="nelh:331762:0" name=internalLink&gt;Link to DARE commentary on this Systematic Review here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Sarwar&gt;Sarwar A,&lt;/A&gt; Shaw LJ, Shapiro MD, Blankstein R, Hoffman U, Cury RC, et al. Diagnostic and Prognostic Value of Absence of Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2009;2(6):675-88. &lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; On the basis of our review of more than 85,000 patients, we conclude that the absence of Coronary Artery Calcification is associated with a very low risk of future cardiovascular events, with modest incremental value of other diagnostic tests in this very low-risk group.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19520336" target="_blank"&gt;Link to PubMed Abstract here. &lt;/A&gt;&amp;nbsp;(Warning:&amp;nbsp;requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Vanhoe&gt;Vanhoenacker PK&lt;/A&gt;, Decramer I, Bladt O, Sarno G, Van Hul E, Wijns W, et al. Multidetector computed tomography angiography for assessment of in-stent restenosis: meta-analysis of diagnostic performance. BMC Medical Imaging. 2008;8:14. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The sensitivity of&amp;nbsp;&amp;nbsp;Multidetector computed tomography angiography (MDTCA) for the detection of in-stent stenosis is insufficient to use this test to select patients for further invasive testing as with this strategy around 20% of the patients with in-stent stenosis would be missed. Further improvement of scanner technology is needed before it can be recommended as a triage instrument in practice. In addition, the number of non-assessable stents is also high. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533305/?tool=pubmed" target="_blank"&gt;Link to&amp;nbsp;full-text here.&lt;/A&gt; (Warning - requires leaving this site)&lt;BR&gt;&lt;A href="nelh:322388:0" name=internalLink&gt;Link to DARE commentary on this Systematic Review here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COCHRANE PROTOCOLS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;None identified&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER RELEVANT DOCUMENTS&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11661" target="_blank"&gt;NICE guideline in development Chest pain of recent onset: assessment and investigation of recent onset chest pain/discomfort of suspected cardiac origin&lt;/A&gt;. Due to be published in March 2010.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;NHS EED 2009: &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101518" target="_blank"&gt;Economic analysis including long-term risks and costs of alternative diagnostic strategies to evaluate patients with chest pain (provisional record only)&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;NHS EED 2009: &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22008101740" target="_blank"&gt;Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;For details of ongoing research visit UK Clinical Research Network at &lt;/STRONG&gt;&lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;&lt;STRONG&gt;http://www.ukcrn.org.uk/index.html&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;and Current Controlled Trials at &lt;/STRONG&gt;&lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;STRONG&gt;http://www.controlled-trials.com/&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>343153</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=343153]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Methodology</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,STABLE ANGINA,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;: M E T H O D O L O G Y &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go Back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/FONT&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/A&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343153/nelhImp_0000_rubicks.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;We brought together a small panel of experts&amp;nbsp;to support us in summarising the key evidence identified. The starting point for our literature search was&amp;nbsp; August 2008 which was 3 months before the end date of our last search. Please&amp;nbsp;download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=343153" target="_blank"&gt;complete search strategy &lt;/A&gt;for details of sources searched and search terms used. (Available as a word file.)&lt;/P&gt;
&lt;P&gt;In addition, other sources were hand-searched for relevant key documents (including guidance, statistics and reports). Sources hand-searched were: NICE, NHS Clinical Knowledge Summaries, NHS Institute for Innovation and Improvement, NHS Heart Improvement Programme, Department of Health, Information Centre for Health and Social Care, Healthcare Commission, National Co-ordinating Centre for Health Technology Assessments (HTA), European Society of Cardiology and other organisations such as the British Heart Foundation.&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>341682</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=341682]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Miscellaneous</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,CHEST PAIN (PLEURITIC),CHEST PAIN (ATYPICAL),STABLE ANGINA,OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Miscellaneous&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;: M I S C E L L A N E O U S&lt;BR&gt;Alison Pottle, Consultant Nurse in Cardiology, Royal Brompton and Harefield NHS Trust&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/FONT&gt;&lt;/A&gt;&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID341682/nelhImp_0000_otherpic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXPERT SUMMARY&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Three reviews were identified since the last summary in 2009. Two of these looked at management of pain. &lt;A href="#Vanti"&gt;Vanti &lt;/A&gt;evaluated the validity and reliability of manual assessment and treatment and the effectiveness of manual therapy for non-specific adult thoracic pain. The review suggested that manipulative treatment seemed to be clinically effective but was unable to establish whether manual treatment was more effective than non-treatment. &lt;/P&gt;
&lt;P&gt;&lt;A href="#Simpson"&gt;Simpson&lt;/A&gt; looked at the clinical and cost effectiveness of spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. They reviewed 11 RCTs in the clinical effectiveness review. Unfortunately the ischaemic pain trials had small sample sizes and were not adequately powered to detect clinically meaningful differences. It was also difficult to determine whether spinal cord stimulation represented value for money. The authors suggest that there is a need for further trials of subgroups of ischaemic pain.&lt;/P&gt;
&lt;P&gt;Finally, &lt;A href="#Pilgrim"&gt;Pilgrim&lt;/A&gt; carried out a systematic review of Takotsubo cardiomyopathy, or transient left ventricular apical ballooning syndrome. They examined 28 case series with between 5 and 88 patients each. The review provides a useful source of information about this rare condition which is observed in 0.7-2.5% of patients with suspected ACS. TLVAPS is predominately observed in postmenopausal women subsequent to a stressful event.&amp;nbsp; The authors acknowledge the limitations of their review. Most case studies reported only a small number of patients and some characteristics varied considerably among the studies which could lead to reporting bias and overestimation of uncharacteristic presentations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=Vanti&gt;Vanti C&lt;/A&gt;, Ferrari S, Morsillo F, Tosarelli D, Pillastrini P. Manual therapy for non-specific thoracic pain in adults: review of the literature. Journal of Back &amp;amp; Musculoskeletal Rehabilitation. 2008;21(3):143-52.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Procedures of physical examination did not show sufficient interexaminer reliability. Manipulative treatment seems to be clinically effective, but whether manual treatment is more effective than non-treatment, other treatments or placebo, cannot be established. &lt;BR&gt;&lt;A href="nelh:334129:0" name=internalLink&gt;Link to DARE commentary on this review here.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=Simpson&gt;Simpson EL&lt;/A&gt;, Duenas A, Holmes MW, Papaioannou D, Chilcott J. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation. Health Technol Assess. 2009 Mar;13(17):iii, ix-x, 1-154. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion&lt;/STRONG&gt;: The evidence suggested that Spinal Cord Stimulation (SCS)&amp;nbsp;was effective in reducing the chronic neuropathic pain of FBSS and CRPS type I. For ischaemic pain, there may need to be selection criteria developed for CLI, and SCS may have clinical benefit for refractory angina short-term. Further trials of other types of neuropathic pain or subgroups of ischaemic pain, may be useful.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19331797" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;. (Warning:&amp;nbsp; requires leaving this site)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=Pilgrim&gt;Pilgrim TM&lt;/A&gt;, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. Int J Cardiol. 2008;124(3):283-92. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Transient Left Ventricular Apical Ballooning Syndrome (TLVABS)&amp;nbsp;is a considerable differential diagnosis in Acute Coronary Syndromes, especially in postmenopausal women with a preceding stressful event. Data on longterm follow-up is pending and further studies will be necessary to clarify the etiology and reach consensus in acute and longterm management of TLVABS. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17651841" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; (Warning: Requires leaving this site)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kisely, S, et al. Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy.The Cochrane Library, 2010 ;&amp;nbsp;(1)*&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This review suggests a modest to moderate benefit for psychological interventions, particularly those using a cognitive-behavioural framework, which was largely restricted to the first three months after the intervention. Hypnotherapy is also a possible alternative. The evidence for brief interventions was less clear. Further Randomised Controlled Trials of psychological interventions for Non Specific Chest Pain with follow-up periods of at least 12 months are needed.&lt;BR&gt;&lt;A href="nelh:238311:0" name=internalLink&gt;Link to abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;COCHRANE PROTOCOLS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;None identified&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER RELEVANT DOCUMENTS&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Guidance:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11661" target="_blank"&gt;NICE guideline in development Chest pain of recent onset: assessment and investigation of recent onset chest pain/discomfort of suspected cardiac origin&lt;/A&gt;&lt;STRONG&gt; &lt;/STRONG&gt;(Due to be published in March 2010)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;NHS EED 2008: &lt;A href="nelh:319534:0" name=internalLink&gt;Cost effectiveness of chest pain unit care in the NHS&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;For details of ongoing research visit UK Clinical Research Network at &lt;/STRONG&gt;&lt;A href="http://www.ukcrn.org.uk/index.html" target="_blank"&gt;&lt;STRONG&gt;http://www.ukcrn.org.uk/index.html&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;and Current Controlled Trials at &lt;/STRONG&gt;&lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;&lt;STRONG&gt;http://www.controlled-trials.com/&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;* This review was published after the initial searches were&amp;nbsp;undertaken so&amp;nbsp;was not included in the expert review or&amp;nbsp;the search methodology documentation.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334827</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=334827]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Surgery / Interventions</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CHEST PAIN,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,STABLE ANGINA,OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Surgery / Interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0 : S U R G E R Y&amp;nbsp; / I N T E R V E N T I O N S&lt;BR&gt;Dr Sunil Nadar, Consultant Interventional Cardiologist, Heart of England NHS trust, Birmingham&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:334321:1" name=internalLink&gt;Go back to Contents Page of 2010 Chest Pain Evidence Update&amp;nbsp;&lt;BR&gt;&lt;/A&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;See full&amp;nbsp;list of contributors to the 2010&amp;nbsp;Chest Pain&amp;nbsp;update&amp;nbsp;here.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334827/nelhImp_0000_Surgerypic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXPERT SUMMARY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The role of surgery in ischaemic heart disease.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) offer two modalities in revascularisation in patients with coronary artery disease. There has been debate over the benefits of one procedure versus the other. Various trials often produce conflicting data. Here we look at meta analyses and pooled data from the different trials. &lt;/P&gt;
&lt;P&gt;&lt;A href="#Hlatky"&gt;Hlatky et al &lt;/A&gt;&amp;nbsp;(Lancet 2009; 373: 1190–97)&amp;nbsp; pooled individual data from ten randomised trials to compare the effectiveness of CABG with PCI in patients with multi-vessel coronary artery disease. The included 7812 patients from ten trials. In six of these trials PCI was done with balloon angioplasty and in the remaining 4 trials PCI was performed with bare metal stents. The medial follow up was for nearly 6 years. The mortality over this period was similar in CABG and the PCI groups. However in the diabetic subgroup, the mortality was significantly lower in the CABG group. There was no difference in the non diabetic group. The only other factor that appeared to affect outcome was age, where patients over the age of 65 appeared to do better with CABG. There was no effect of other parameters including number of vessels treated or other comorbidity. This study suggests that apart from diabetics and patients above the age of 65, CABG and PCI offer similar outcomes in terms of mortality and treatment of choice should therefore depend on patient choice and technical feasibility. It should also be borne in mind that these trials did not include trials with drug eluting stents (and in fact included trials with balloon angioplasty alone) and one might argue that had this been the case, the results might have been more in favour of PCI. Another factor that has been noted in the discussion in this study was that there were very few patients above the age of 75. &lt;/P&gt;
&lt;P&gt;&lt;A href="#Takagi"&gt;Takagi et al &lt;/A&gt;(Am J Cardiol 2008;101:1259 –1262) also performed a meta analysis to look at the long term effects of CABG versus PCI in multi-vessel disease. They only included studies with bare metal stents as the PCI procedure. They did not include studies where only balloon angioplasty was used. Their results were similar to that from the previous group, where they found no long term survival benefit with either strategy. However patients undergoing CABG appeared to have better symptom relief and freedom from repeat revascularization procedures. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Moving on from multi-vessel disease to single vessel disease, &lt;A href="#Kapoor"&gt;Kapoor et al &lt;/A&gt;(J. Am. Coll. Cardiol. Intv. 2008;1;483-491)&amp;nbsp; performed&amp;nbsp; a meta analysis of 9 studies comparing the role of CABG and PCI in treating isolated left anterior descending artery disease. Their analysis included more than 1200 patients. They concluded that patients undergoing CABG had better symptom relief and had fewer repeat revascularisation episodes. Here as well, of the 9 studies, 4 had used balloon angioplasty as the PCI procedure, another 4 had used bare metal stents and only one had used drug eluting stents. Among the surgical procedures performed, four trials had “off pump” bypass surgery performed. &lt;/P&gt;
&lt;P&gt;As mentioned earlier, some of the criticisms of the above studies was the fact that they did not include trials with drug eluting stents, but in fact included “out-dated” modes of treatment such as balloon angioplasty. Some argue that if studies which had used drug eluting stents were included there may have been a benefit demonstrated towards PCI rather than CABG. To review this effect, &lt;A href="#Trikalinos"&gt;Trikalinos et al &lt;/A&gt;(Lancet 2009; 373: 911–918.) did a systematic review of trials that had compared balloon angioplasty, bare metal stents and drug eluting stents to each other and versus medical therapy in the treatment of stable angina. They included 61 trials with 25,388 patients They investigated four of six possible comnsbinations between the four interventions mentioned above except for drug eluting stents verus medical therapy or balloon angioplasty. The found that improvements in technology did not produce detectable improvements in death or myocardial infarctions. They did however record significant reductions in the need for repeat revasularisations from balloon angioplasty to bare metal stents and similarly from bare metal stents to drug eluting stents. Using indirect comparisons, they therefore calculated a very significant reduction in need for revascularizations from balloon angioplasty to drug eluting stent use. &lt;/P&gt;
&lt;P&gt;In summary, coronary artery bypass grafting and percutaneous coronary intervention appear to offer similar reductions in mortality and myocardial infarctions, whether it is for isolated left anterior descending artery lesions or multivessel disease. However, bypass grafting appears to offer better symptom control and decreases the need for repeat revascularizations. These meta analyses give us similar results to the recently published &lt;A href="#ser"&gt;SYNTAX trial&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;SYSTEMATIC REVIEWS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=Hlatky&gt;Hlatky MA,&lt;/A&gt;, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190-7. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&amp;nbsp;&lt;/STRONG&gt; Long-term mortality is similar after Coronary Artery Bybass Graft&amp;nbsp;(CABG) and Percutaneous Coronary Interventions (PCI) in most patient subgroups with multivessel coronary artery disease, so choice of treatment should depend on patient preferences for other outcomes. CABG might be a better option for patients with diabetes and patients aged 65 years or older because we found mortality to be lower in these subgroups. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19303634" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.(Warning: requires leaving this site)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A name=Kapoor&gt;Kapoor JR&lt;/A&gt;, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv. 2008 Oct;1(5):483-91. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In patients with single-vessel, proximal Left Anterior Descending (LAD) disease, survival was similar in Coronary Artery Bypass Graft (CABG)-assigned and Percutaneous Coronary Interventions (PCI)-assigned patients; CABG was significantly more effective in relieving angina and led to fewer repeat revascularizations.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19463349" target="_blank"&gt;Link to PubMed abstract here. (Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:342900:0" name=internalLink&gt;Link to DARE commentary on this Systematic Review here.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=Takagi&gt;Takagi H &lt;/A&gt;, Kawai N, Umemoto T. Meta-analysis of four randomized controlled trials on long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with stenting for multivessel coronary artery disease. Am J Cardiol. 2008;101(9):1259-62. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;pooled analysis demonstrated no statistically significant differences in death, cardiac death, Q-wave myocardial infarction, cerebrovascular accidents, and angina pectoris between Percutaneous Coronary Interventions (PCI) with stenting and Coronary Artery Bypass Grafts (CABG). However, PCI with stenting was associated with a statistically significant increase in subsequent PCI, subsequent CABG, subsequent revascularization (PCI or CABG), and major adverse cardiovascular events relative to CABG.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18435954" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.(Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=Trikalinos&gt;Trikalinos TA &lt;/A&gt;, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-8. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Sequential innovations in the catheter-based treatment of non-acute coronary artery disease showed no evidence of an effect on death or myocardial infarction when compared with medical therapy. These results lend support to present recommendations to optimise medical therapy as an initial management strategy in patients with this disease.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19286090" target="_blank"&gt;Link to PubMed abstract here.(&lt;/A&gt;Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER REFERENCES&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A name=Ser&gt;Serruys P et al &lt;/A&gt;. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. NeJM. 2009 360:961-972&lt;BR&gt;&lt;A href="http://content.nejm.org/cgi/content/full/360/10/961" target="_blank"&gt;Link to&amp;nbsp;full-text here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COCHRANE PROTOCOLS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;None identified&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FURTHER RELEVANT DOCUMENTS&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Guidance:&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11661" target="_blank"&gt;NICE guideline in development Chest pain of recent onset: assessment and investigation of recent onset chest pain/discomfort of suspected cardiac origin.&lt;/A&gt; (Due to be published March 2010)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NICE Guidance May 2009 : &lt;A href="http://guidance.nice.org.uk/IPG302" target="_blank"&gt;Percutaneous laser revascularisation for refractory angina pectoris &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NICE Guidance May 2009 : &lt;A href="http://guidance.nice.org.uk/IPG301" target="_blank"&gt;Transmyocardial laser revascularisation for refractory angina pectoris&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;For details of ongoing research visit UK Clinical Research Network at &lt;A href="http://www.ukcrn.org.uk/index.htmland" target="_blank"&gt;http://www.ukcrn.org.uk/index.htmland&lt;/A&gt;&amp;nbsp; and Current Controlled Trials at &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;http://www.controlled-trials.com/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>341683</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=341683]]&gt;</url>
    <title>2010 Evidence Update on Chest Pain : Uncertainties</title>
    <publicationDate>2010-02-22T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,STABLE ANGINA,OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Chest Pain : Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;STRONG&gt;C H E S T&amp;nbsp; P A I N&amp;nbsp; 2 0 1 0&amp;nbsp;:&amp;nbsp; U N C E R T A I N T I E S&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:334321:0" name=internalLink&gt;Go back to&amp;nbsp;Chest Pain&amp;nbsp;Annual Evidence Update 2010 Contents Page&lt;/FONT&gt;&lt;/A&gt;&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;&lt;BR&gt;or go to another section within the update ...&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:334816:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0008_Diagnosis.gif"&gt;&lt;/A&gt;&lt;/EM&gt;&amp;nbsp;&lt;A href="nelh:334823:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0009_angina.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:334829:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0010_acs.gif"&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:334827:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage6 name=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0011_Surgery.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341682:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0012_Misc.gif"&gt;&lt;/A&gt;&amp;nbsp;&lt;A href="nelh:341683:0" name=internalLink&gt;&lt;IMG id=nelh_tempImage7 name=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID334829/nelhImp_0013_Uncertainties.gif"&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID341683/nelhImp_0000_Uncertaintiespic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS&lt;BR&gt;&lt;BR&gt;These Systematic Reviews have been identified as highlighting uncertainties. They also appear under other topic headings. eg. Angina, surgery. In the coming weeks we will be working to&amp;nbsp;rephrase these uncertainties into&amp;nbsp;the PICO (Patient-Intervention-Comparison-Outcome)&amp;nbsp;&amp;nbsp;format for submission to DUETs (Database of Uncertainties&amp;nbsp;about the &amp;nbsp;Effects of Treatments). See &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;http://www.library.nhs.uk/duets/&lt;/A&gt;&amp;nbsp;for more information.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Briones E, Lacalle Juan R, Marin I. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database of Systematic Reviews 2009; (1)&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on the review of all available studies we can not conclude that the clinical benefits of TMLR outweigh the potential risks. It is suggested that application of TMLR in clinical practice should be restricted to research or special situations.&lt;BR&gt;&lt;A href="nelh:304875:0" name=internalLink&gt;Link to abstract here.&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Di Tanna GL, Berti E, Stivanello E, Cademartiri F, Achenbach S, Camerlingo MD, et al. Informative value of clinical research on multislice computed tomography in the diagnosis of coronary artery disease: a systematic review. Int J Cardiol. 2008;130(3):386-404.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; MSCT is a promising technology for the assessment of coronary artery stenosis. However, the available literature is of limited value in providing guidance to support the development of policies for its appropriate utilization in clinical practice. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18760849" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; (Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Vanti C, Ferrari S, Morsillo F, Tosarelli D, Pillastrini P. Manual therapy for non-specific thoracic pain in adults: review of the literature. Journal of Back &amp;amp; Musculoskeletal Rehabilitation. 2008;21(3):143-52.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Procedures of physical examination did not show sufficient interexaminer reliability. Manipulative treatment seems to be clinically effective, but whether manual treatment is more effective than non-treatment, other treatments or placebo, cannot be established.&lt;BR&gt;&lt;A href="nelh:334129:0" name=internalLink&gt;Link to DARE commentary on this review here&amp;nbsp;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Hlatky MA,, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190-7. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; Long-term mortality is similar after CABG and PCI in most patient subgroups with multivessel coronary artery disease, so choice of treatment should depend on patient preferences for other outcomes. CABG might be a better option for patients with diabetes and patients aged 65 years or older because we found mortality to be lower in these subgroups. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19303634" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.(Warning: requires leaving this site)&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Simpson EL, Duenas A, Holmes MW, Papaioannou D, Chilcott J. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation. Health Technol Assess. 2009 Mar;13(17):iii, ix-x, 1-154.&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The evidence suggested that Spinal Cord Stimulation was effective in reducing the chronic neuropathic pain of FBSS and CRPS type I. For ischaemic pain, there may need to be selection criteria developed for CLI, and SCS may have clinical benefit for refractory angina short-term. Further trials of other types of neuropathic pain or subgroups of ischaemic pain, may be useful.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19331797" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;(Warning:&amp;nbsp; requires leaving this site)&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. Int J Cardiol. 2008;124(3):283-92.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Transient Left Ventrical Apical Ballooning Syndrome (TLVABS)&amp;nbsp;is a considerable differential diagnosis in Acute Coronary Syndrome, especially in postmenopausal women with a preceding stressful event. Data on longterm follow-up is pending and further studies will be necessary to clarify the etiology and reach consensus in acute and longterm management of TLVABS. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17651841" target="_blank"&gt;Link to PubMed abstract here &lt;/A&gt;(Warning: requires leaving this site).&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387547</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387547]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Contributors</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Contributors&lt;BR&gt;&lt;BR&gt;The following experts have assessed and summarised the evidence identified.&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387547/nelhImp_0000_contributorspic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Professor Andrew L Clark&lt;BR&gt;Consultant Cardiologist&lt;BR&gt;Castle Hill Hospital&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Andrew Clark was educated at Pembroke College, Cambridge, and trained in medicine at the Westminster Medical School. He trained in cardiology at Manchester Royal Infirmary, the National Heart and Lung Institute (London) and the Western Infirmary, Glasgow. &lt;BR&gt;He is a founder member of the British Society for Heart Failure, and is a member of the working groups for Heart Failure and Cardiac Rehabilitation and Exercise Physiology in the European Society of Cardiology. &lt;BR&gt;&lt;BR&gt;He is presently Reader and Honorary Consultant Cardiologist at Hull University and hospitals. He is responsible for running the echocardiography service in Hull, and he plays an active role in the day-to-day provision of cardiology services to the population of the East Riding of Yorkshire.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Professor Jonathan Mant&lt;BR&gt;Professor of Primary care&lt;BR&gt;General Practice and Primary Care Research Unit&lt;BR&gt;University of Cambridge&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Jonathan Mant is Professor of Primary Care Research at the University of Cambridge. He trained as a public health physician in the Oxford Region, and from 1992-97 was clinical lecturer in public health medicine at the University of Oxford. From 1997-2008 he was based in the Department of Primary Care &amp;amp; General Practice at the University of Birmingham, moving to Cambridge in October 2008.&amp;nbsp; He is an associate director of the Stroke Research Network with responsibility for primary and community care, and has chaired the guideline development groups for three NICE guidelines: heart failure; prevention and control of tuberculosis; and type 2 diabetes.&amp;nbsp; His current research focuses on stroke prevention and treatment in primary care settings.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Professor Tom Quinn&lt;BR&gt;Professor of Clinical Practice at the University of Surrey&lt;BR&gt;Clinical Lead for NHS Evidence - Cardiovascular, Stroke and Vascular&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Tom Quinn is one of the UK's leading cardiovascular nurses and has made a significant contribution to practice, policy and research both nationally and internationally. &lt;BR&gt;He was the UK's first Professor of Cardiac Nursing (at Coventry University), and took up post as Professor of Clinical Practice at the University of Surrey in January 2009. He has published extensively on acute cardiac and stroke care and his current responsibilities include being clinical lead for the NHS Evidence cardiovascular, stroke and vascular collections, part of the National Institute for Health and Clinical Excellence. He has been chief or co-applicant on more than £3.5m successful grant applications in the past two years, involving research into emergency cardiac and stroke care, and is on the steering group for two major clinical trials. He continues to advise the Department of Health as a member of the Emergency Cardiac Care Board, is a member of the group developing the Stroke Specific Educational Framework sponsored by the Department of Health, and chairs the steering group for development of primary angioplasty for the NHS in Surrey. He is Honorary Clinical and Research Adviser to South East Coast Ambulance Service NHS Trust.&lt;BR&gt;Tom Quinn is a member of the advisory committee for the European Society of Cardiology (ESC) Council of Cardiovascular Nursing and Allied Health Professions, a member of the ESC Working Group on Acute Cardiac Care, and a former Chairman of the ESC Working Group on Cardiovascular Nursing. He became a Fellow of the ESC in the mid 1990s and was awarded Fellowship of the Royal College of Nursing for his 'outstanding contribution to cardiac care' in 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ms Jillian P Riley&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Head of Post-Graduate Education (Nursing)&lt;BR&gt;Royal Brompton and Harefield NHS Foundation Trust&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Jillian Riley is course director for the MSc Cardio-respiratory Nursing at Imperial College and is Head of Postgraduate Education (Nursing and Allied Professions) at the Royal Brompton Hospital. She also works in Professor Martin Cowie’s Health Services Research Group evaluating the use of remote monitoring in patients' with chronic heart failure.&lt;BR&gt;Jill has served on a number of expert committees at the British Cardiovascular Society, the British Heart Foundation and the European Council of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology. Currently she sits on the board of the European Heart Failure Association of the ESC.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Klaus Witte &lt;BR&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Senior Lecturer and Honorary Consultant Cardiologist&lt;BR&gt;University of Leeds and Leeds General Infirmary&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Klaus Witte is a Senior Lecturer and Honorary Consultant Cardiologist at the University of Leeds and Leeds General Infirmary. He trained in medicine at Kings’ College Hospital and subsequently in cardiology at Cardiff, Hull and Leeds. He is a founder member of the British Society of Heart Failure, and a member of the European Heart Rhythm Association. His research interests include exercise physiology, micronutrient therapy for chronic disease, and device therapy for heart failure.&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Dr James Beattie&lt;BR&gt;Consultant Cardiologist&lt;BR&gt;Birmingham Heartland Hospital&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;After initial cardiology training in the University Department at Glasgow Royal Infirmary, he took up a research fellowship in heart failure at the University of California at Davis. He returned to the US as a research scientist at the Space Medicine Laboratory of the University of Texas Southwestern Medical School at Dallas. He was later appointed Lecturer in Cardiovascular Medicine at Birmingham University and has been a consultant since 1990.&lt;/P&gt;
&lt;P&gt;For the past 15 years he has had an interest in palliative care for heart failure. He is currently a national clinical lead for the Heart Improvement Programme and with Michael Connolly, co-authored a report ‘Supportive and Palliative Care for Advanced Heart Failure’ which was published by the DoH in December 2004. He is a member of the circulatory forum of the National Council for Palliative Care and has worked with the Liverpool Care Pathway group to improve end-of-life care for those with heart disease. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387452</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387452]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Devices</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Devices&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert summary on Devices by Dr Klaus Witte&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Senior Lecturer and Honorary Consultant Cardiologist&lt;BR&gt;University of Leeds and Leeds General Infirmary&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387452/nelhImp_0000_Surgerypic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;Devices in heart failure&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cardiac resynchronisation therapy (CRT) is a pacemaker-based treatment for chronic heart failure (CHF) that has been accepted into mainstream treatment algorithyms as a result of several large randomised placebo-controlled studies demonstrating reductions in all-cause mortality and sudden cardiac death. Smaller studies have also demonstrated improvements in symptoms, cardiac function and exercise capacity. A recent meta-analysis &lt;A href="#lemos"&gt;(Lemos et al 2009) &lt;/A&gt;of the five main studies, confirmed reductions in total mortality (Absolute Risk Reduction [ARR] 6%) and sudden death (ARR 1%) along with a reduction in hospitalisation for heart failure (ARR 9%). There was a non-significant reduction in death due to heart failure. This is possibly the result of relatively short follow-up durations of the studies included although many deaths will have occurred in the community where deciding whether the death was sudden or due to an acute deterioration in heart failure is difficult. The meta-analysis confirms that CRT is a powerful treatment for symptomatic heart failure with left ventricular dysfunction and conduction delay.&lt;/P&gt;
&lt;P&gt;Two studies have demonstrated benefits of CRT in patients with cardiac dysfunction but less severe symptoms on a composite endpoint of heart failure hospitalisation and death (&lt;A href="#moss"&gt;Moss et al 2009&lt;/A&gt;), and a composite heart failure severity score (&lt;A href="#linde"&gt;Linde et al 2008&lt;/A&gt;). A subsequent meta-analysis&lt;A href="#lubitz"&gt;(Lubitz et al 2010)&lt;/A&gt; of CRT in CHF patients with mild symptoms has combined the data from these two studies to show a reduction in heart failure events at one year. Longer-term follow-up of the REVERSE study &lt;A href="#longer"&gt;(Daubert et al 2009)&lt;/A&gt; has since demonstrated that CRT can delay in time to hospitalisation or death. It is increasingly recognised, as with medical therapy, that early device treatment might be associated with even greater benefits on important outcome variables but that the follow-up time required to show these benefits in less symptomatic patients might need to be longer.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Two&amp;nbsp;Systematic Reviews have been identified&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;A name=lemos&gt;Lemos Júnior HP&lt;/A&gt;, Atallah AN. Cardiac resynchronization therapy in patients with heart failure: systematic review. Sau Paulo Med J 2009;127:40-5 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Patients receiving CRT had a significantly lower risk of hospitalization due to heart failure, but death rates due to heart failure were similar.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19466294" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.scielo.br/pdf/spmj/v127n1/a09v1271.pdf" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=360918&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;] &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A name=Lubitz&gt;Lubitz SA&lt;/A&gt;, Leong-Sit P, Fine N, Kramer DB, Singh J, Ellinor PT. Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: systematic review and meta-analysis of randomized trials. Eur J Heart Fail 2010;4:360-6&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; CRT reduces heart failure events in patients with mild heart failure symptoms, left ventricular dysfunction, sinus rhythm, and prolonged QRS duration.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20335354" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=385609&amp;amp;tabID=289" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Additional Expert References&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;A name=moss&gt;Moss AJ&lt;/A&gt;, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators&amp;nbsp; Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; CRT combined with ICD decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex.&amp;nbsp; &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19723701" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;A name=linde&gt;Linde C&lt;/A&gt;, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial demonstrates that CRT, in combination with optimal medical therapy (+/-defibrillator), reduces the risk for heart failure hospitalization and improves ventricular structure and function.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19038680" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://content.onlinejacc.org/cgi/content/full/52/23/1834" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;A name=longer&gt;Daubert C&lt;/A&gt;, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Török T, Linde C; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009;54:1837-46&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; CRT prevents the progression of disease in patients with asymptomatic or mildly symptomatic LV dysfunction &lt;BR&gt;[&lt;A href="http://content.onlinejacc.org/cgi/content/full/54/20/1837" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19800193" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS. &lt;BR&gt;Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? International Journal of Cardiology 2009; 137 (3): 206-15.&lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=382214&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right cell padding:right="0"&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386580</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=386580]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Diagnosis</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,HEART FAILURE,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;H2&gt;Expert summary on Diagnosis by Professor Johnathan Mant&lt;/H2&gt; &lt;H2&gt;Professor of Primary Care Research&lt;BR&gt;University of Cambridge&lt;/H2&gt; &lt;H2&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt; &lt;TD vAlign=top align=middle&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0000_Diagnosispic.gif" name=nelh_tempImage1&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Diagnosis and risk stratification&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt; &lt;P&gt;NICE have recently updated their guideline on the management of chronic heart failure &lt;A href="#nice"&gt;(NICE 2010)&lt;/A&gt; This has taken account of the growing evidence base for the role of natriuretic peptides and the prognostic significance of very high natriuretic peptide levels in the diagnosis of heart failure (see previous updates in this series). Key changes from the 2003 NICE guideline with regard to diagnosis in people with suspected heart failure: &lt;/P&gt; &lt;UL&gt; &lt;LI&gt;ECG is removed from the diagnostic pathway (but remains an important investigation for people with heart failure)&lt;/LI&gt; &lt;LI&gt;People with a history of a previous myocardial infarction should be referred directly for echocardiography and specialist assessment&lt;/LI&gt; &lt;LI&gt;All other patients should have a natriuretic peptide test, and further referral (for echocardiography and specialist assessment) should depend upon the result of that test&lt;/LI&gt; &lt;LI&gt;People with very high natriuretic peptides should be referred urgently (within two weeks), and people with raised levels within six weeks&lt;/LI&gt; &lt;LI&gt;The referral is now for echocardiography and specialist assessment, rather than simply for echocardiography.&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;A systematic review raises some question marks over the evidence base for natriuretic peptide testing in people aged 75 or over &lt;A href="#Vaes"&gt;(Vaes et al 2009)&lt;/A&gt;. However, four of the five studies that were included in this review were screening studies in an unselected population, so are not directly applicable to assessment of the role of natriuretic peptides in symptomatic patients. The one study in symptomatic patients found high sensitivity for left ventricular systolic dysfunction (96%), but that it was not good at identifying people with preserved ejection fraction heart failure (HEFPEF). The review highlights the need for further research in this area. &lt;/P&gt;&lt;BR&gt; &lt;P&gt;&lt;STRONG&gt;Risk Stratification&lt;/STRONG&gt;&lt;/P&gt; &lt;P&gt;Natriuretic peptides have also been under the spotlight with regard to whether they have a role in guiding therapy in heart failure. It is known that high natriuretic peptide levels are associated with poor prognosis, and that therapy for heart failure reduces the peptide levels. Therefore, the question has been raised as to whether serial monitoring of natriuretic peptides could be used to guide treatment. &lt;A href="#por"&gt;(Proapakkham et al 2010)&lt;/A&gt; and &lt;A href="#felker"&gt;(Felker et al 2009)&lt;/A&gt; conducted meta analyses to explore the impact of natriuretic guided therapy on outcome in people with chronic heart failure. Both concluded that natriuretic guided therapy was associated with better survival, but that this effect was attenuated in people aged 75 or over. Patients on natriuretic guided therapy received more intensive medical therapy than people receiving usual care, and it is probably this that is driving the difference in mortality. It is not clear whether there is any advantage to using natriuretic peptide guided monitoring over other formal approaches to monitoring. Nevertheless, it seems likely that serial monitoring of natriuretic peptides is of value for some patients. NICE recommends it is considered in patients under specialist care for whom uptitration is problematic or who have been admitted to hospital. &lt;/P&gt; &lt;P&gt;Atrial fibrillation is commonly associated with heart failure, and is well recognised as being associated with worse outcome. There has been some debate whether this is greater in people with heart failure with preserved ejection fraction (HFPEF) as compared to people with left ventricular systolic dysfunction (LVSD). &lt;A href="#Mamas"&gt;(Mamas et al 2009)&lt;/A&gt; conducted a systematic review of randomised controlled trials and observational studies to investigate the association between atrial fibrillation, and found that the increased mortality associated with atrial fibrillation (40% increase in risk of death) applied to both people with LVSD and people with HEFPEF. There is considerable interest in the prognostic value of echocardiographic parameters (see previous updates). &lt;A href="#Rossi"&gt;(Rossi et al 2009)&lt;/A&gt;&amp;nbsp; for the MeRGE collaborators have found that left atrial area is a predictor of outcome in people with LVSD, and so can be added to the list of potentially useful parameters for giving prognostic information.&lt;/P&gt;&lt;BR&gt;&lt;BR&gt; &lt;P class=MsoNormal style="MARGIN: 0cm 0cm 10pt"&gt;&lt;STRONG&gt;Five Systematic Reviews were identified&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt; &lt;OL&gt; &lt;LI&gt; &lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt; &lt;P&gt;&lt;A name=Felker&gt;Felker&lt;/A&gt; GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. American Heart Journal 2009; 158 (3): 422-430.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Titration of therapy incorporating serial BNP or N-terminal pro-B-type natriuretic peptide levels is associated with a significant reduction in all-cause mortality compared to usual care in patients with chronic heart failure.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19699866" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=379066&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt; &lt;P&gt;&lt;A name=Mamas&gt;Mamas&lt;/A&gt; MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. European Journal of Heart Failure 2009; 11 (7): 676-683. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The presence of AF is associated with an adverse prognosis in CHF irrespective of LV systolic function. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19553398" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://eurjhf.oxfordjournals.org/content/11/7/676.full.pdf+html" target="_blank"&gt;full text &lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=359988&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt; &lt;P&gt;&lt;A name=por&gt;Porapakkham&lt;/A&gt; P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy. Archives of Internal Medicine 2010; 170(6): 507-514. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;B-type natriuretic peptide–guided therapy reduces all-cause mortality in patients with chronic HF compared with usual clinical care, especially in patients younger than 75 years. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20308637" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=361208&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt; &lt;P&gt;&lt;A name=Rossi&gt;Rossi&lt;/A&gt;&amp;nbsp;A, Temporelli PL, Quintana M, Dini FL, Ghio S, Hillis GS, Klein AL, Ajmone Marsan N, Prior DL, Yu CM, Poppe KK, Doughty RN, Whalley GA. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). European Journal of Heart Failure 2009; 11(10): 929-936. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Left atrial area is a powerful predictor of outcome among HF patients with predominantly impaired systolic function, and is independent of, and provides additional prognostic information beyond LV systolic and diastolic function. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19789395" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=360733&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none"&gt; &lt;P&gt;&lt;A name=Vaes&gt;Vaes&lt;/A&gt; B, de Ruijter W, Gussekloo J, Degryse J. The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review. Age &amp;amp; Ageing 2009; 38 (6): 655-662. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;we found limited evidence supporting the use of plasma natriuretic peptide measurement for diagnosis of cardiac dysfunction or heart failure in the elderly of 75 years and over in the general population.&lt;BR&gt;[&lt;A href="http://ageing.oxfordjournals.org/content/38/6/655.full?view=long&amp;amp;pmid=19717394" target="_blank"&gt;full text &lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19717394" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=360977&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt; &lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Expert References&lt;/STRONG&gt;&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;&lt;A name=NICE&gt;National&lt;/A&gt; Institute for Health and Clinical Excellence (NICE) – Chronic Heart Failure: management of chronic heart failure in adults in primary and secondary care. Clinical guideline 108, 2010. [&lt;A href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;European Society of Cardiology - Diagnosis and treatment of acute and chronic heart failure. [&lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/acute-chronic-heart-failure.aspx" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt;&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;British Heart Foundation - Inpatient cases by main diagnosis and ethnic group, women, National Health Service hospitals, 2007/08, England [&lt;A href="http://www.heartstats.org/documents/download.asp?nodeid=8826&amp;amp;libraryversionid=3144" target="_blank"&gt;table&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;/SPAN&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;/P&gt;&lt;/TD&gt; &lt;TD&gt; &lt;TABLE rules=rows border=1&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage2 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 name=nelh_tempImage2&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&amp;nbsp;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386325</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=386325]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Homepage</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PATIENT INFORMATION,PREVENTION,SURGERY,SURGERY,HEART,HEART FAILURE,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Homepage&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;DIV&gt;Published on the 4&lt;STRONG&gt;th&amp;nbsp;October 2010:&lt;/STRONG&gt; An update for health professionals and patients on significant advances in knowledge about&amp;nbsp;heart&amp;nbsp;failure&amp;nbsp;since our &lt;A href="nelh:325170:1" name=internalLink&gt;&lt;A href="nelh:314789:1" name=internalLink&gt;last update in 2009&lt;/A&gt;. &lt;/A&gt;
&lt;P&gt;&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV align=center&gt;
&lt;CENTER&gt;
&lt;TABLE border=0 cellSpacing=10 width="70%" valign="top"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width="17%"&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0010_intro.jpg"&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0000_Diagnosispic.gif"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0000_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;FONT color=#ffffff&gt;spacer&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=bottom width="20%" align=middle&gt;&lt;IMG style="WIDTH: 58px; HEIGHT: 53px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" height=71&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:387450:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Pharmacological Therapy&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=center width="17%" align=middle&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=46 height=37&gt;&lt;BR&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374119:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt; &lt;BR&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0005_organisationofcarestandard.gif"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0002_Surgerypic.gif"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0003_rehab.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 54px; HEIGHT: 44px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt;&lt;BR&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:1" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Organisation of Care&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Devices&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:387453:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Rehabilitation&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD width="17%" align=middle padding:top="0"&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 47px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png" width=51 height=50&gt;&lt;BR&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ContactUs.aspx" target="_blank"&gt;Feedback&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG style="WIDTH: 170px; HEIGHT: 111px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0004_palliative.gif" width=168 height=114&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386325/nelhImp_0006_psychologystandard.gif"&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%"&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373641/nelhImp_0012_feedback2.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:387454:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Palliative Care&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;STRONG&gt;Psychology&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD vAlign=top width="17%" align=middle&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;&lt;FONT size=2 face=Arial&gt;&lt;B&gt;Key Documents&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/TD&gt;
&lt;TD width="17%"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/CENTER&gt;&lt;/DIV&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387450</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387450]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Introduction</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;H2&gt;Professor Tom Quinn&lt;BR&gt;&lt;BR&gt;Professor of Clinical Practice, University of Surrey &lt;BR&gt;Clinical Lead for NHS Evidence - Cardiovascular, Stroke and Vascular&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387450/nelhImp_0000_intro.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;Around 900,000 in the UK people have heart failure, with others at risk because of myocardial ischaemia, infarction or hypertensive heart disease but who have yet to develop heart failure symptoms.&amp;nbsp; Although there have been recent improvements, patients with heart failure have a poor outlook, with 30-40% dying within a year of diagnosis. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;NICE published an updated clinical guideline earlier this year [&lt;A href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf" target="_blank"&gt;NICE Chronic Heart Failure guidance&amp;nbsp; - partial update 2010&lt;/A&gt;&lt;/A&gt;]. The NHS Evidence- cardiovascular team have once again worked with experts to identify and summarise key new evidence from systematic reviews published since our last Evidence Update [&lt;A href="nelh:325170:0" name=internalLink&gt;Heart Failure Evidence Update 2009&lt;/A&gt;]. I hope you find this&amp;nbsp; information useful. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;I am grateful to our Expert reviewers, and to the team here at the University of Surrey (April Coombe, Dr Freda Mold, Rusell Dube, Mandy Howell, Magda Robertson and Dr Elena O'Selmo) for their sterling work in pulling this together.&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387531</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387531]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Key Documents</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Key Documents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Key Documents&lt;BR&gt;&lt;BR&gt;Below is a list of key documents other than the systematic reviews identified.&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387531/nelhImp_0000_feedback2.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;Guidelines &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;American Heart Association - Medication Errors in Acute Cardiovascular and Stroke Patients. A Scientific Statement which includes Recommendations for Medication Safety in Acute Cardiovascular Care [&lt;A href="http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181d4b43e" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation - Diastolic heart failure (FF 2 Apr10). Factfile written for GPs summarising the condition, its diagnosis, treatment and prognosis [&lt;A href="http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001232" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Department of Health - End of life care strategy [&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_118810" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;European Society of Cardioloby - Cardiac Pacing and Cardiac Resynchronisation Therapy and Focussed Update CRT/HF [&lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/cardiac-pacing-and-cardiac-resynchronisation-therapy.aspx" target="_blank"&gt;weblink&lt;/A&gt;] [&lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-CRTHF-Update-FT.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;European Society of Cardiology - Diagnosis and treatment of acute and chronic heart failure [&lt;A href="http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/acute-chronic-heart-failure.aspx" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Chronic Heart Failure: management of chronic heart failure in adults in primary and secondary care. Clinical guideline 108, August 2010&amp;nbsp;[&lt;A href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – Guidance on the prevention of cardiovascular disease at the population level. Public Health Guidance PH25&amp;nbsp;[&lt;A href="http://guidance.nice.org.uk/PH25/Guidance/pdf/English" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence (NICE) – guidance and appraisals relating to heart failure [&lt;A href="http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords=heart+failure&amp;amp;currentpage=2&amp;amp;paginatedpage=1&amp;amp;searchType=All&amp;amp;sort=&amp;amp;pageSize=&amp;amp;startYearMonth=&amp;amp;endYearMonth=&amp;amp;refId=&amp;amp;fromSearch=true" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Clinical Knowledge Summaries CKS - Heart Failure&amp;nbsp;[&lt;A href="http://www.cks.nhs.uk/heart_failure_chronic" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Improvement – End of Life Care in Heart Failure – A Framework for Implementation&amp;nbsp;[&lt;A href="http://system.improvement.nhs.uk/ImprovementSystem/ViewDocument.aspx?path=Cardiac%2fNational%2fWebsite%2fHeart%2fHeart%20Failure%2fEOL_in_HF.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Institute for Innovation and Improvement – Focus On: Heart Failure. Note: access to the full-text is restricted to registered users with an NHS e-mail account [&lt;A href="http://www.institute.nhs.uk/option,com_joomcart/Itemid,194/main_page,document_product_info/cPath,71/products_id,547/Joomcartid,nkj18stvaq977lu5e0sm85pr23.html" target="_blank"&gt;weblink&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Audit and Statistics&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;American Heart Association - Heart Disease and Stroke Statistics — 2010 Update (At-A-Glance Version) [&lt;A href="http://americanheart.org/presenter.jhtml?identifier=3000090" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;American Heart Association - Heart Disease and Stroke Statistics — 2010 Update (All Charts) [&lt;A href="http://americanheart.org/presenter.jhtml?identifier=3018163" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation - Inpatient cases by main diagnosis and ethnic group, women, National Health Service hospitals, 2007/08, England [&lt;A href="http://www.heartstats.org/documents/download.asp?nodeid=8826&amp;amp;libraryversionid=3144" target="_blank"&gt;table&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation - Inpatient cases by main diagnosis and ethnic group, men, National Health Service hospitals, 2007/08, England [&lt;A href="http://www.heartstats.org/documents/download.asp?nodeid=8827&amp;amp;libraryversionid=3145" target="_blank"&gt;table&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Information Centre - National&amp;nbsp; Heart Failure Audit 2008/2009 [&lt;A href="http://www.heartstats.org/documents/download.asp?nodeid=8827&amp;amp;libraryversionid=3145" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Enca M-R, Susan B, Chris H, Carolyn D, Anthony M, Taggart David P. Stem cell therapy for ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews: Protocols 2009; Issue 3. [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007888/pdf_fs.html" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Harald B, Nico H, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews: Protocols 2009; Issue 4.&amp;nbsp;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008012/pdf_fs.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Madmani ME, Shahrour Y, Solaiman AY, Tamr Agha K, Essali A, Kadro W, Bowarshi K. Coenzyme Q10 for heart failure (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008684/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jolly K, Lip GY, Taylor RS, Raftery J, Mant J, Lane D, Greenfield S, Stevens A. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart 2009; 95 (1): 36-42.&lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=329110&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circulation: Cardiovascular Quality and Outcomes 2009; 2 (6): 566-73. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=379005&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Collins SP, Schauer DP, Gupta A, Brunner H, Storrow AB, Eckman MH. Cost-effectiveness analysis of ED decision making in patients with non-high-risk heart failure. American Journal of Emergency Medicine 2009; 27 (3): 293-302. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=366754&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Shelley E, Capewell S. Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010. Value in Health 2009; 12 (1): 10-5. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=316874&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Goeree R, Bowen JM, Blackhouse G, Lazzam C, Cohen E, Chiu M, Hopkins R, Tarride JE, Tu JV. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care 2009; 25 (2): 196-207.&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=367263&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor M, Scuffham PA, Chaplin S, Papo NL. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. Value in Health 2009; 12 (4): 459-65. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=329120&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tibaldi V, Isaia G, Scarafiotti C, Gariglio F, Zanocchi M, Bo M, Bergerone S, Ricuada NA. Hospital at home for elderly patients with accute decompensation of chronic heart failure: a prospective randomized controlled trial. Archives of Internal Medicine 2009; 169 (17): 1569-75. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=362958&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? International Journal of Cardiology 2009; 137 (3): 206-15. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=382214&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Giordano A, Scalvini S, Zanelli E, Corra U, Longobardi GL, Ricci VA, Baiardi P, Glisenti F. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure. International Journal of Cardiology 2009; 131 (2): 192-9. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=366500&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal 2009; 157 (5): 837-44, e3.&lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=329120&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dar O, Riley J, Chapman C, Dubrey SW, Morris S, Rosen SD, Roughton M, Cowie MR. A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study. European Journal of Heart Failure 2009; 11 (3): 319-25. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=364139&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Useful Websites&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Choices - Heart Failure [&lt;A href="http://www.nhs.uk/Pathways/Heartfailure/Pages/Symptoms.aspx" target="_blank"&gt;weblink&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;American Heart Association - Heart Failure [&lt;A href="http://americanheart.org/presenter.jhtml?identifier=3004550" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Heart Foundation [&lt;A href="http://www.bhf.org.uk/living_with_a_heart_condition/understanding_heart_conditions/types_of_heart_conditions/heart_failure.aspx" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;British Society for Heart Failure [&lt;A href="http://www.bsh.org.uk/" target="_blank"&gt;weblink&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Heart Failure Matters (European Society of Cardiology)&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.heartfailurematters.org/EN/Pages/index.aspx" target="_blank"&gt;weblink&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE rules=rows border=1&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage2 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 name=nelh_tempImage2&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387530</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387530]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Methodology</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Methodology&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Our literature search was designed to add to the body of knowledge from last year's&amp;nbsp;Heart&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Failure&amp;nbsp;Evidence Update...&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 110px; HEIGHT: 87px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387530/nelhImp_0000_rubicks.gif" width=93 height=76&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;Searches were designed with a slight overlap period to ensure a good fit.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;We brought together a small panel of experts to support us by summarising key evidence and commenting on key developments in the field.&lt;/P&gt;
&lt;P&gt;We identified systematic reviews published between&amp;nbsp;1st April&amp;nbsp;2009 and&amp;nbsp;30th June&amp;nbsp;2010 and sifted them for relevance and quality. Material included in the last Evidence Update was excluded. Our reviewers were able to identify additional evidence relevent to any section. &lt;/P&gt;
&lt;P&gt;In addition to a wide range of databases, we hand searched other key resources for relevant guidance, statistics and reports. Those sources can be seen in the &lt;A href="nelh:387531:1" name=internalLink&gt;Key Document &lt;/A&gt;section. We were able to include some evidence published after the main search period. &lt;/P&gt;
&lt;P&gt;Further details of the methods used to produce this Evidence Update can be viewed below together with the complete reference list. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386587</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=386587]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Organisation of Care</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Organisation of Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;H2&gt;Expert summary on&amp;nbsp;Organisation of Care&amp;nbsp;by Jillian Riley&lt;/H2&gt; &lt;H2&gt;Head of Post-Graduate Education (Nursing)&lt;BR&gt;Royal Brompton and Harefield NHS Foundation Trust&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt; &lt;TD vAlign=top align=middle&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386587/nelhImp_0000_organisationofcarestandard.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;P&gt;&lt;STRONG&gt;Organisation of Care in Heart Failure&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Recent interest has focused on the organisation of heart failure care to widen the access to structured monitoring and follow-up whilst developing sustainable models of care that address both economic issues and limited personnel resources. Much of this interest has centred on the development of care through remote patient monitoring (both through telephone support or telemonitoring). There is now a need to establish the benefit of these approaches more clearly and a number of systematic reviews have been published in the last year.&lt;/P&gt; &lt;P&gt;&lt;a href="#klersy"&gt;Klersy et al (2009)&lt;/a&gt; undertook a review of remote monitoring; using monitoring equipment placed in the patient’s home (external monitoring) and implantable monitoring devices (implanted in electronic devices such as cardiac pacemakers or implantable defibrillators). The authors report a reduction in mortality (RR 0.83; 95% CI 0.73 – 0.95), a reduction in all-cause hospital admission (RR 0.93; 95% CI 0.87 – 0.99) and in heart failure related hospital admission (RR 0.71; 95% CI 0.64 – 0.8) with telemonitoring. However both randomised and cohort studies were included in the review and the authors report that the results were greater in the cohort studies.&lt;/P&gt; &lt;P&gt;&lt;a href="#Polisena"&gt;Polisena et al (2010)&lt;/a&gt; undertook a systematic review of telemonitoring. Pooling the results of randomised trials and observational studies they report moderately larger effect sizes; telemonitoring reduced the risk of death (RR 0.64; 95% CI 0.48 – 0.85) when compared with usual care in patients recently discharged from hospital. They also reported that fewer patients were hospitalised (RR 0.77; 95% CI 0.65 – 0.9).&lt;/P&gt; &lt;P&gt;Following this &lt;a href="#inglis"&gt;Inglis  et al (2010)&lt;/a&gt; undertook a systematic review and meta-analysis of remote patient monitoring; through telephone support or telemonitoring. Telemonitoring related only to external monitoring equipment, and all studies were compared with usual care. Using the Cochrane methodology they combined the results from 25 published randomised studies and over 8000 patients to report a statistically significant reduction in mortality with telemonitoring (RR 0.66; 95% CI 0.54-0.81, p &lt; 0.0001) and a non-significant trend to a reduction in mortality with telephone support (RR 0.88, 95% CI 0.76-1.01, p = 0.08). They also report benefit in terms of hospital readmission (both all-cause and heart failure related), albeit with less impressive effect sizes. Cost effectiveness was one of the secondary outcomes in this review. Fewer studies reported on this outcome and the results varied according to both the intensity of the intervention and type of equipment used. Fewer studies also reported on some of their other secondary outcomes such as health-related quality of life or length of hospital stay, making it difficult to suggest the impact of telemonitoring on such outcomes.&lt;/P&gt; &lt;P&gt;Consistent with much of the evidence for the management of patients with heart failure, these studies largely recruited patients with left ventricular systolic dysfunction. &lt;/P&gt; &lt;P&gt;These reviews provide some evidence for the benefit of remote patient monitoring through a reduction in mortality and the number of patients hospitalised. As such they suggest that remote monitoring could be offered alongside the more traditional models of home and clinic visits. In this way the different approaches can be matched to the clinical circumstances and needs (both medical and social) of the patient. However telemonitoring changes the traditional organisation of healthcare and the speed with which it is adopted may be influenced by the way in which it ‘fits’ within existing organisational structures and professional practices and by the attitudes of both professionals and patients. Whilst these reviews suggest there is much benefit to be gained from using telemonitoring, it has yet to become part of mainstream care.&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Three Systematic Reviews have been identified&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt; &lt;OL&gt; &lt;LI&gt; &lt;DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;SPAN style="mso-bidi-font-weight: bold"&gt;&lt;a name="Inglis"&gt;Inglis&lt;/a&gt; SC, Clark RA, McAlister FA, Ball J, Lewinter C, Cullington D, Stewart S, Cleland JGF (2010) Structured telephone support or remote telemonitoring programmes for patients with chronic heart failure. (Review). Cochrane library 2010. Issue 8&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Structured telephone support and telemonitoring are effective in reducing the risk of all-cause mortality and CHF-related hospitalisations in patients with CHF; they improve quality of life, reduce costs, and evidence-based prescribing.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20687083" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007228/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;a name="Klersy"&gt;Klersy&lt;/a&gt;, C., A. De Silvestri, A., Gabutti, G., Regoli, F., Auricchio, A. A meta-analysis of remote monitoring of heart failure patients. Journal of the American College of Cardiology 2009; 54 (18):1683-1694.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; RPM confers a significant protective clinical effect in patients with chronic HF compared with usual care. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19850208" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=360846&amp;amp;code=463d065b02f0eb4980e51c48db9a4a8f" target="_blank"&gt;DARE commentary&lt;/A&gt;]&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt; &lt;LI&gt; &lt;DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;a name="polisena"&gt; Polisena&lt;/a&gt; J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, Scott RE. Home telemonitoring for congestive heart failure: a systematic review and meta-analysis. Journal of Telemedicine and Telecare. 2010; 16 (2):68-76.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Patient quality of life and satisfaction with home telemonitoring were similar or better than with usual care &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20008054" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp; &lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt; &lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Other Key Documents&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;&lt;STRONG&gt;Economic Evaluations&lt;/STRONG&gt; &lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Dar O, Riley J, Chapman C, Dubrey SW, Morris S, Rosen SD, Roughton M, Cowie MR. A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study. European Journal of Heart Failure 2009; 11 (3): 319-25.&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=364139&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&lt;/LI&gt; &lt;LI&gt;Giordano A, Scalvini S, Zanelli E, Corra U, Longobardi GL, Ricci VA, Baiardi P, Glisenti F. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure. International Journal of Cardiology 2009; 131 (2): 192-9.&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=366500&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt; &lt;LI&gt;Tibaldi V, Isaia G, Scarafiotti C, Gariglio F, Zanocchi M, Bo M, Bergerone S, Ricuada NA. Hospital at home for elderly patients with accute decompensation of chronic heart failure: a prospective randomized controlled trial. Archives of Internal Medicine 2009; 169 (17): 1569-75.&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=362958&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp; &lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt; &lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt; &lt;TD&gt; &lt;TABLE border=1 rules=rows&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387454</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387454]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Palliative Care</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Palliative Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;Expert summary on Palliative Care by James Beattie&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/STRONG&gt;&lt;FONT style="FONT-SIZE: 8pt" size=1&gt;&lt;STRONG&gt;&lt;FONT style="FONT-SIZE: 8pt" size=1&gt;Heart of England NHS Foundation Trust&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT style="FONT-SIZE: 8pt" size=1&gt;&lt;STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;&lt;/FONT&gt;
&lt;P&gt;The authors offer a review of the effects of advanced heart failure close to the end of life (Stage D) as perceived by patients and informal carers.&amp;nbsp; The primary purpose was to examine this from the social care perspective to inform the development of such care for affected individuals and their families.&lt;BR&gt;A systematic literature review of articles in English from 1990 yielded 15 full text articles later subjected to thematic analysis.&amp;nbsp; These included 9 based on one-to-one interviews with heart failure patients, 2 mixed methods studies combining survey data and interviews, and 4 studies including informal carers in the interview process.&lt;BR&gt;Broad topical domains were defined in challenges related to heart failure and also in coping with those challenges.&lt;BR&gt;Thematic analysis identified 5 challenges:&lt;BR&gt;&amp;nbsp;1. Working with the health care system - largely mediated by &amp;nbsp;communication issues and difficulties accessing social support. &lt;BR&gt;&amp;nbsp;2. Life disruption - loss of personal role and disturbance of &amp;nbsp;family relationships and activities.&lt;BR&gt;&amp;nbsp;3. Social isolation - loss of friends and social life with a &amp;nbsp;dependency on others to maintain limited social contact.&lt;BR&gt;&amp;nbsp;4. Effects of symptoms - sense of 'imprisonment' due to limiting &amp;nbsp;physical symptoms, anxiety / depression, and the effects of &amp;nbsp;comorbidities.&lt;BR&gt;&amp;nbsp;5. Living with uncertainty - difficulties dealing with prognostic &amp;nbsp;ambiguity and the possibility of dying.&lt;BR&gt;Coping with these challenges generated 3 broad areas of need:&lt;BR&gt;&amp;nbsp;1. Effective clinical management of the heart failure state.&lt;BR&gt;&amp;nbsp;2. Dealing with the dying process.&lt;BR&gt;&amp;nbsp;3. Provision of accessible social support.&lt;BR&gt;Implications for social work practice emerged in a realisation that despite difficulties in prognostication, the needs of those with heart failure were similar to those with other long term conditions.&amp;nbsp; Social workers may facilitate care coordination and provide linkage to physical or psychological care across a range of health care settings.&amp;nbsp; Social care support needs to be individualised highlighting the importance of good communication.&amp;nbsp; The need for further social care research specifically related to heart failure / end of life care was acknowledged, emphasising gaps in knowledge on the effects of racial and ethnic diversity and other potential cultural barriers to social care support.&lt;BR&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387454/nelhImp_0000_palliative.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&lt;STRONG&gt;One Systematic Review was identified&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;Hopp, F. P., Thornton, N., Martin, L. The lived experience of heart failure at the end of life: a systematic literature review. Health &amp;amp; Social Work 2010; 35 (2): 109-117.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Greater attention to these issues in the social work literature is needed, with a particular focus on the role of racial and ethnic diversity as they pertain to people with HF facing end-of-life issues. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20506865" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Improvement – End of Life Care in Heart Failure – A Framework for Implementation [&lt;A href="http://system.improvement.nhs.uk/ImprovementSystem/ViewDocument.aspx?path=Cardiac%2fNational%2fWebsite%2fHeart%2fHeart%20Failure%2fEOL_in_HF.pdf" target="_blank"&gt;full&amp;nbsp;text&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386591</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=386591]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Pharmacological Therapy</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,EMERGENCY CARE,CLINICAL LIBRARY,CARDIOVASCULAR,HEART FAILURE,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Pharmacological Therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Expert summary on Pharmacological Therapy&lt;/H2&gt;
&lt;H2&gt;Professor Andrew L Clark, MA, MD, FRCP&lt;BR&gt;&lt;BR&gt;Consultant Cardiologist, Castle Hill Hospital&lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386591/nelhImp_0000_medication.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2 align=left&gt;&lt;U&gt;Pharmacological therapy&amp;nbsp;in heart failure&lt;/U&gt;&lt;/H2&gt;&lt;STRONG&gt;
&lt;P align=left&gt;&lt;BR&gt;Renin-Angiotensin system antagonists&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;The longest-serving group of agents used to prevent disease progression and improve prognosis for patients with chronic heart failure is, of course, angiotensin converting enzyme inhibitors (ACEi). Work over many years has established that ACEi are effective in reducing the risk of future events in patients with ischaemic heart disease without heart failure, and even in some populations of high risk patients. &lt;/P&gt;
&lt;P&gt;The side-effects of ACEi, particularly the dry cough, makes angiotensin receptor blockers (ARB) appear attractive in comparison, but the evidence that ARBs are as effective as ACEi is not at all conclusive. Some authors are concerned in particular that ARBs may increase the risk of myocardial infarction. &lt;A href="#Strauss"&gt;(Strauss et al 2006) &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Baker and colleagues &lt;A href="#Baker"&gt;(Baker et al 2009) &lt;/A&gt;have reviewed the available evidence on the effect of ACEi and ARB on outcomes in patients with stable coronary disease but no heart failure. The conclusion is that the addition of an ACEi to standard therapy reduces the risk of adverse events by around 15%, but at a cost of an increase in the risk of syncope and cough. There is, however, no substantial evidence of benefit for ARBs in this clinical scenario. Difficulties in interpreting the data arise from the lack of substantial trials with ARBs, and the fact that relatively low doses of ARBs have been used in many clinical contexts. It is now becoming clear, for example, that high dose ARBs convey more benefit than low in patients with overt heart failure. &lt;A href="#Konstam"&gt;(Konstam et al 2009)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;A fascinating question with ACEi and ARB in heart failure is whether they are helpful in patients with a normal left systolic ventricular function, a condition going under many aliases such as “diastolic heart failure” and “Heart failure with Normal Ejection Fraction” (HeFNEF, my preferred term). Quite what the diagnosis of HeFNEF means, and whether patients with HeFNEF have heart failure as the condition is commonly understood, remains controversial. Shah et al &lt;A href="#Shah"&gt;(Shah et al 2010) &lt;/A&gt;have assessed the evidence from three major studies of inhibitors of the renin-angiotensin system in patients with HeFNEF with over 8 000 patients, and found no evidence of an effect on either mortality or heart failure hospitalisation. The reason is unclear, but is consistent with the view that HeFNEF may be a mistaken diagnosis.&lt;/P&gt;
&lt;P&gt;One of the major risk factors for heart failure is hypertension, and reducing blood pressure reduces the risk of developing heart failure. An obvious question is whether ACEi or ARB therapy is better than other agents in reducing the risk. Verdeccia et al &lt;A href="#Ver"&gt;(Verdeccia et al 2009)&lt;/A&gt;&amp;nbsp; found that “the risk of CHF decreased by 24% for each 5 mmHg reduction in systolic BP” and that ACEi or ARB therapy had no obvious benefit as compared with betablockers or diuretics. &lt;BR&gt;By contrast, however, calcium antagonists were associated with an increase in the risk of heart failure. Whether the increased risk is related to the fluid retention encouraged by calcium antagonists isn’t clear, but the findings are consistent with earlier papers suggesting that calcium antagonists may not be the best agents for treating hypertension.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Aldosterone antagonists&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Aldosterone antagonists are also helpful in heart failure, but the details of which patients should be treated are uncertain. McKenna&amp;nbsp;&lt;A href="#McKenna"&gt; (McKenna et al 2010)&lt;/A&gt; analysed the data available for patients with left ventricular systolic dysfunction following myocardial infarction, but is necessarily limited by the fact that only the EPHESUS trial&amp;nbsp;&lt;A href="#Pitt"&gt; (Pitt et al 2003)&lt;/A&gt; (with eplerenone) has included a large enough number of patients to give useful information on hard outcomes. &lt;/P&gt;
&lt;P&gt;The interest is provoked in part by cost. Eplerenone (expensive) has only been shown to work when initiated during a short window following acute myocardial infarction; spironolactone (cheap) has only been shown to confer benefit in patients with severely symptomatic chronic heart failure. It’s not clear that either agent can be used in other clinical scenarios, and these two meta-analyses do not really answer the question. Far more information will come from the results of clinical trials: the EMPHASIS-HF trial of eplerenone in mild heart failure has already been stopped early due to its beneficial effect, suggesting that the meta-analyses will need to be re-run shortly.&lt;A href="#Pfizer"&gt;(Pfizer 2010) &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Beta blockers&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;A major outstanding issue with betablocker therapy is whether there is any substantial difference between cardioselective and non-selective drugs. &lt;/A&gt;De Peuter &lt;A href="#Peuter"&gt;(de Peuter et al 2009)&lt;/A&gt;&amp;nbsp; has examined the available trials in both patients with heart failure and those with acute coronary syndrome and found some evidence that non-selective agents had a better effect on mortality in both conditions. &lt;/P&gt;
&lt;P&gt;However, the data are difficult to interpret: there are few trials directly comparing the two treatments, the agents used and the clinical scenarios investigated were very different and there was marked heterogeneity in the quality and size of the studies included. As far as heart failure patients are concerned, the best evidence continues to be the COMET study suggesting that the non-selective agent carvedilol was associated with better outcomes than the selective agent metoprolol. &lt;A href="#Poole"&gt;(Poole-Wilson et al 2003)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Statin therapy&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Should statins be prescribed for patients with chronic heart failure? Post hoc surveys of patients with heart failure suggest that those on statins have a better outcome than those who do not, but randomised studies have shown no convincing evidence of benefit. Lipinski and colleagues &lt;A href="#Lipinski"&gt;(Lipinski et al 2009)&lt;/A&gt;&amp;nbsp; managed to find studies containing 10 192 patients treated with different statins for different lengths of time. Whilst finding that there was no effect on mortality, they concluded that statin therapy did decrease risk of hospitalization for worsening HF during follow-up, and also claimed that&amp;nbsp; there was heterogeneity between statins: use of atorvastatin was associated with reduced mortality.&lt;/P&gt;
&lt;P&gt;It is difficult to support the results. The overwhelming majority of the power of the meta-analysis comes from the two neutral rosuvastatin studies with 9 585 (94%) of the patients. The atorvastatin trials were all very small with very small numbers of events. The effect on hospitalisation of statins is also highly debatable: cardiovascular hospitalisations were not affected whereas heart failure hositalisations were, an effect of doubtful significance. This latter effect was in any case also highly dependent upon the very small atorvastatin studies.&lt;/P&gt;
&lt;P&gt;It’s important to remember how dependent meta-analysis is on the quality of the studies included. The data here do not allow an adequate judgement to be made on the benefits of statins, and certainly not on the relative effect of statins, in people with heart failure. The best evidence comes from the two large randomised trials demonstrating no benefit, at least from rosuvastatin.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Treatment of anaemia&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Patients with chronic heart failure are commonly anaemic, a potential target for therapy. Three meta-analyses have examined the effects of erythropoiesis-stimulating agents for anaemia in patients with CHF. Both Tehrani &lt;A href="#Tehrani"&gt;(Tehrani et al 2009)&lt;/A&gt;&amp;nbsp; and van den Meer &lt;A href="#Meer"&gt;(van den Meer et al 2009)&lt;/A&gt;&amp;nbsp; included the same 7 studies in their analyses and reported a lower risk of hospitalisation in treated patients, improvements in exercise capacity and improvements in symptoms. In the Cochrane review &lt;A href="#Ngo"&gt;(Ngo et al 2010)&lt;/A&gt;,&amp;nbsp;&amp;nbsp; Ngo included a greater number of studies, but endorsed the general conclusion that treatment with erythropoiesis-stimulating agents improved exercise capacity and symptoms of patients with CHF and anaemia, and some clinical outcomes.&lt;/P&gt;
&lt;P&gt;There is not yet enough evidence for erythropoiesis-stimulating agents to enter routine practice. The individual studies have all been relatively small and underpowered. A complicating issue is that of iron replacement therapy: there has been inconsistent use of iron in the studies included in the meta-analyses, and there is good clinical trial evidence that iron alone might be helpful.&amp;nbsp; &lt;A href="#Anker"&gt;(Anker er all 2009 )&lt;/A&gt;As Ngo points out, “… well-designed studies with careful attention to dose, haemoglobin treatment target and associated iron therapy” are vital to understand how to treat anaemia in patients with CHF.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Acute heart failure&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Patients with acute (rather than chronic) heart failure are not often studied. Usually such patients present with acute pulmonary oedema and are treated with vasodilators and diuretics. Positive inotropic agents are used in different amounts in different countries, but with little definitive evidence that they are beneficial.&amp;nbsp; Dobutamine is most often used, but there is evidence it is associated with a worse prognosis.&lt;/P&gt;
&lt;P&gt;Levosimendan appears to offer advantages, and is the subject of Delaney’s meta-analysis &lt;A href="#Delaney"&gt;(Delaney et al 2010)&lt;/A&gt;.&amp;nbsp; One striking finding was that very few of the included studies were of high methodological quality. Whilst levosimendan use was associated with a lower mortality than dobutamine, it was no better than placebo. There was some improvement in haemodynamic variables compared to placebo, but the effect was not striking.&lt;/P&gt;
&lt;P&gt;Patients with acute heart failure remain an under-researched group and more evidence is need to improve their management.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Ten Systematic Reviews were identified&lt;/STRONG&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Baker&gt;Baker WL&lt;/A&gt; , Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009;151:861-71&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Adding an ACE inhibitor to standard medical therapy improves outcomes, including reduced risk for mortality and myocardial infarctions.&lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=331888&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;] [&lt;A href="http://www.annals.org/content/early/2009/10/19/0003-4819-151-12-200912150-00162.full" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20008762" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Shah&gt;Shah RV&lt;/A&gt;, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail 2010;16:260-7 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although RAS inhibition may be valuable in the management of comorbidities related to HF-PEF, RAS inhibition in HF-PEF is not associated with consistent reduction in HF hospitalization or mortality in this emerging cohort&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20206902" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;A name=Ver&gt;Verdecchia&lt;/A&gt; P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009;30:679-88 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; BP reduction is beneficial for the prevention of CHF. Over and beyond BP reduction, the protective effect of ACEIs and ARBs is greater than that of CCBs.&lt;BR&gt;[&lt;A href="http://eurheartj.oxfordjournals.org/content/30/6/679.full.pdf+html" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19168534" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=342950&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;A name=McKenna&gt;McKenna&lt;/A&gt; C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. Health Technol Assess 2010;14:1-162 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; It consistently emerged that, compared with usual care, use of an aldosterone antagonist appears to be a highly cost-effective strategy for the management of postMI HF patients in the NHS.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20492762" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=382714&amp;amp;tabID=289" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Peuter&gt;de Peuter &lt;/A&gt;OR, Lussana F, Peters RJ, Büller HR, Kamphuisen PW. A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med 2009;67:284-94&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Additional beta2-receptor blockade may be more effective than beta1-receptor blockade alone in preventing total mortality and vascular events in patients with ACS or, to a lesser extent, HF &lt;BR&gt;[&lt;A href="http://www.njmonline.nl/njm/getpdf.php?t=a&amp;amp;id=10000506" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Lipinski&gt;Lipinski&lt;/A&gt;&amp;nbsp; MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, Vetrovec GW. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-16&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; meta-analysis of randomized controlled trials demonstrated that statins are safe and improve LVEF and decrease hospitalization for worsening HF. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19962481" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=374667&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&lt;BR&gt;&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;A name=Tehrani&gt;Tehrani&lt;/A&gt;&amp;nbsp;F, Dhesi P, Daneshvar D, Phan A, Rafique A, Siegel RJ, Cercek B. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Cardiovasc Drugs Ther 2009;23:511-8 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;In patients with heart failure and anemia, erythropoiesis stimulating agent therapy appears to have a positive effect on several important cardiovascular parameters, compared to control therapy.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19862609" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=379333&amp;amp;tabID=289" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&lt;BR&gt;&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;A name=Meer&gt;van der Meer&lt;/A&gt; P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309-14 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In chronic HF, treatment with ESPs is not associated with a higher mortality rate or more adverse events, whereas a beneficial effect on HF hospitalisation is seen.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19168472" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=360439&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;]&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;A name=Ngo&gt;Ngo&lt;/A&gt;&amp;nbsp;K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010:CD007613. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Meta-analysis of small RCTs suggests that ESA treatment in patients with symptomatic CHF and mild anaemia (haemoglobin more than 10g/dL) can improve anaemia and exercise tolerance, reduce symptoms and have benefits on clinical outcomes.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20091643" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Delaney&gt;Delaney&lt;/A&gt;&amp;nbsp;A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol 2010;138:281-9 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Levosimendan improved haemodynamic parameters when compared with placebo, without showing evidence of survival benefit. Levosimendan improved both haemodynamics and survival when compared with dobutamine.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18817994" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Additional Expert References&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;A name=Strauss&gt;Strauss&lt;/A&gt;&amp;nbsp;MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54.&amp;nbsp; &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;The evidence is persuasive that the reduction in incidence of both MI and CV death seen with ACEIs is above that achieved by blood pressure lowering alone and is significantly greater than that achieved by ARBs in high-risk patients. &lt;BR&gt;[&lt;A href="http://circ.ahajournals.org/cgi/content/full/114/8/838" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16923768" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/LI&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A name=Konstam&gt;Konstam&lt;/A&gt; MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8 &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; These findings show the value of up-titrating ARB doses to confer clinical benefit. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19922995" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/LI&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A name=Pitt&gt;Pitt&lt;/A&gt;&amp;nbsp;B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12668699" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A name=Pfizer&gt;Pfizer.&lt;/A&gt; Pfizer announces EMPHASIS-HF trial to halt recruitment due to significant benefit observed in patients treated with Inspra (eplerenone) [press release]. May 27, 2010&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; The interim analysis showed that patients treated with INSPRA®(eplerenone), in addition to current standard of care,experienced a significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization.&lt;BR&gt;[&lt;A href="http://media.pfizer.com/files/news/press_releases/2010/inspra_emphasis_trial_052710.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A name=anker&gt;Anker &lt;/A&gt;SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19920054" target="_blank"&gt;PubMed abstract&lt;/A&gt;] &lt;BR&gt;&lt;/LI&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A name=Poole&gt;Poole-Wilson&lt;/A&gt;&amp;nbsp;PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our results suggest that carvedilol extends survival compared with metoprolol.&lt;BR&gt;[&lt;A href="http://www.iihe.org/fpres/JournalClub/Coregvslopressor.pdf" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12853193" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;STRONG&gt;Guidelines &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;American Heart Association - Medication Errors in Acute Cardiovascular and Stroke Patients. A Scientific Statement which includes Recommendations for Medication Safety in Acute Cardiovascular Care [&lt;A href="http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181d4b43e" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Protocols&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Enca M-R, Susan B, Chris H, Carolyn D, Anthony M, Taggart David P. Stem cell therapy for ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews: Protocols 2009; Issue 3. [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007888/pdf_fs.html" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Harald B, Nico H, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews: Protocols 2009; Issue 4.&amp;nbsp;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008012/pdf_fs.html" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Madmani ME, Shahrour Y, Solaiman AY, Tamr Agha K, Essali A, Kadro W, Bowarshi K. Coenzyme Q10 for heart failure (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008684/frame.html" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluations &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Shelley E, Capewell S. Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010. Value in Health 2009; 12 (1): 10-5. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/CARDIOVASCULAR/ViewResource.aspx?resID=316874&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Taylor M, Scuffham PA, Chaplin S, Papo NL. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. Value in Health 2009; 12 (4): 459-65. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=329120&amp;amp;code=1786a05df6aa813bf2c7049ac120e5ea" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387529</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387529]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Psychology</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Psychology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;There is no expert review on psychology and heart failure - instead significant new evidence is listed below&lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 147px; HEIGHT: 107px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387529/nelhImp_0000_psychology.gif" width=139 height=101&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;One&amp;nbsp;Systematic Review was identified&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kang-Yi, CD. and Gellis, ZD. A systematic review of community-based health interventions on depression for older adults with heart disease. Aging &amp;amp; Mental Health 2010; 14(1): 1-19.&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Mixed evidence for community-based heart disease interventions on depression outcomes was found. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kang-Yi%20CD%22%5BAuthor%5D" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=379381&amp;amp;tabID=289" target="_blank"&gt;DARE commentary&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;One&amp;nbsp;Cochrane Protocol was identified&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Harald B, Nico H, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews: Protocols 2009; Issue 4. [&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008012/pdf_fs.html" target="_blank"&gt;full text&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387453</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387453]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Rehabilitation</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Rehabilitation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=10 cellPadding=6 width="100%" align=center border=0&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;H2&gt;There is no expert summary for the Rehabilitation section. Instead a list of new evidence identified is included below.&lt;BR&gt;&lt;/H2&gt;&lt;/TD&gt; &lt;TD vAlign=top align=middle&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387453/nelhImp_0000_rehab.gif" name=nelh_tempImage6&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR vAlign=top&gt; &lt;TD width="89%"&gt; &lt;P&gt;&lt;STRONG&gt;Five&amp;nbsp;Systematic Reviews were identified&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt; &lt;OL&gt; &lt;LI&gt;Davies Ed, J., Moxham, T., Rees, K., Singh, S.,Coats Andrew, JS.,Ebrahim, S.,Lough, F., Taylor Rod, S. Exercise based rehabilitation for heart failure. Cochrane Database of Systematic Reviews 2010; DOI: 10.1002/14651858.CD003331.pub3. &lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Exercise training may offer important improvements in patients' health-related quality of life.&lt;BR&gt;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD003331/frame.html" target="_blank"&gt;full text&lt;/A&gt;] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20393935" target="_blank"&gt;PubMed abstract&lt;/A&gt;] [&lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=238205&amp;amp;code=0025532eaf47ea222d756baab954ce3a" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt; &lt;LI&gt;Eshah NF and Bond AE. Cardiac rehabilitation programme for coronary heart disease patients: An integrative literature review. International Journal of Nursing Practice 2009; 15 (3):131–139. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Cardiac rehabilitation programmes provided significant improvement in participants' quality of life, exercise capacity, lipid profile, body mass index, body weight, blood pressure, resting heart rate, survival rate, mortality rate and decreased myocardial infarction (MI) risk factors, although there was limited participation.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531070" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt; &lt;LI&gt;Hwang, R. and T. Marwick. Efficacy of home-based exercise programmes for people with chronic heart failure: a meta-analysis. European Journal of Cardiovascular Prevention and Rehabilitation 2009; 16 (5): 527-35. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Home-based exercise programmes have been shown to benefit people with heart failure in the short term.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20054288" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=382456&amp;amp;tabID=289" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt; &lt;LI&gt;Spruit, MA., Eterman, RM., Hellwig, VA., Janssen, PP., Wouters, EF., Uszko-Lencer, NH. Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. Heart 2009; 95 (17): 1399-1408. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The current peer-reviewed evidence seems inadequate to generally recommend incorporation of resistance training into exercise-based rehabilitation programmes for patients with CHF. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19342376" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19342376" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt; &lt;LI&gt;Taylor Rod S, Dalal H, Jolly K, Moxham T, Zawada A. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007130. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Home and centre based forms of cardiac rehabilitation seem to be equally effective in improving clinical and health related quality of life outcomes in patients with a low risk of further events after myocardial infarction or revascularisation.&lt;BR&gt;[&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007130/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20085991" target="_blank"&gt;PubMed abstract&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/OL&gt; &lt;P&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt; &lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;/P&gt; &lt;P&gt;&lt;U&gt;&lt;STRONG&gt;Other Key Documents&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;&lt;BR&gt;&lt;P&gt;&lt;STRONG&gt;Guidance and Policy&lt;/STRONG&gt;&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;·NHS Clinical Knowledge Summaries CKS - Heart Failure&lt;BR&gt;&amp;nbsp;[&lt;A href="http://www.cks.nhs.uk/heart_failure_chronic#" target="_blank"&gt;full text&lt;/A&gt;] &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;STRONG&gt;Economic Evaluations &lt;/STRONG&gt;&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Jolly K, Lip GY, Taylor RS, Raftery J, Mant J, Lane D, Greenfield S, Stevens A. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart 2009; 95 (1): 36-42. &lt;BR&gt;[&lt;A href="http://www.library.nhs.uk/Cardiovascular/ViewResource.aspx?resID=329110&amp;amp;tabID=289" target="_blank"&gt;NEED commentary&lt;/A&gt;]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;For details of ongoing research visit &lt;A href="http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_search" target="_blank"&gt;UK Clinical Research Network&lt;/A&gt;, &lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;Current Controlled Trials&lt;/A&gt;&amp;nbsp;and &lt;A href="http://apps.who.int/trialsearch/Default.aspx" target="_blank"&gt;WHO International Clincial Trials Registry Platform&lt;/A&gt;.&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt; &lt;TD&gt; &lt;TABLE rules=rows border=1&gt; &lt;TBODY&gt; &lt;TR vAlign=top&gt; &lt;TD align=right width="5%"&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif" name=nelh_tempImage0&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG" name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage2 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 name=nelh_tempImage2&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage5 style="WIDTH: 48px; HEIGHT: 39px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg" name=nelh_tempImage5&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 name=nelh_tempImage3&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 48px; HEIGHT: 39px" alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40 name=nelh_tempImage0&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage3 style="WIDTH: 47px; HEIGHT: 45px" src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg" name=nelh_tempImage3&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%"&gt;&lt;IMG id=nelh_tempImage4 height=39 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 name=nelh_tempImage4&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;/A&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;&lt;FONT face=arial size=2&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage1 style="WIDTH: 45px; HEIGHT: 34px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif" name=nelh_tempImage1&gt; &lt;/TD&gt; &lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD align=right width="5%" cell padding:right="0"&gt;&lt;IMG id=nelh_tempImage0 style="WIDTH: 45px; HEIGHT: 43px" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt; &lt;TD&gt;&lt;FONT face=Arial size=2&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT face=Arial size=2&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt; &lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387550</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=387550]]&gt;</url>
    <title>2010 Evidence Update on Heart Failure - Uncertainties</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,GENERAL  / OVERVIEWS,RECENT ADDITIONS,OCTOBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Evidence Update on Heart Failure - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE border=0 cellSpacing=10 cellPadding=6 width="100%" align=center&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;H2&gt;Uncertainties&lt;BR&gt;&lt;BR&gt;Below is a list of uncertainties from systematic reviews identified in the course of this evidence update. These will be translated into PICO format (Patient, Intervention, Comparison, Outcome) for entry onto the DUETs (Database of Uncertainties about the Effects of Treatments) database of uncertainties in due course. See &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;www.library.nhs.uk/duets/&lt;/A&gt; for further information about the database.&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=middle&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage8 name=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID387550/nelhImp_0000_Uncertaintiespic.gif"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="89%"&gt;
&lt;P&gt;&lt;STRONG&gt;One Systematic Review&amp;nbsp;identifying uncertainties in heart failure has been identified&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Spruit, MA., Eterman, RM., Hellwig, VA., Janssen, PP., Wouters, EF., Uszko-Lencer, NH. Effects of moderate-to-high intensity resistance training in patients with chronic heart failure. Heart 2009; 95 (17): 1399-1408. &lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The current peer-reviewed evidence seems inadequate to generally recommend incorporation of resistance training into exercise-based rehabilitation programmes for patients with CHF.&amp;nbsp; &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19342376" target="_blank"&gt;PubMed abstract &lt;/A&gt;]&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19342376" target="_blank"&gt;DARE provisional record&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;TABLE border=1 rules=rows&gt;
&lt;TBODY&gt;
&lt;TR vAlign=top&gt;
&lt;TD width="5%" align=right&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346634/nelhImp_0000_Home.gif"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;BR&gt;&lt;A href="nelh:373641:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:386325:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;HOME&lt;/FONT&gt;&lt;/FONT&gt; &lt;/A&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0017_SRIntrosmall.JPG"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346201:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346633:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374112:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387450:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Introduction&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0001_Diagnosispicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386580:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/FONT&gt;Diagnosis&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID373640/nelhImp_0001_medication.jpg"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386591:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Pharmacological&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0002_Surgerypicsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387452:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Devices&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0003_organisationofcaresmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:386587:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Organisation of Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0004_psychologysmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387529:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Psychology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0005_rehabsmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387453:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Rehabilitation&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID386580/nelhImp_0006_palliativesmall.gif" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387454:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Palliative Care&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 48px; HEIGHT: 39px" id=nelh_tempImage0 name=nelh_tempImage0 alt="Key Documents" src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID325170/nelhImp_0022_HF2009Keydocs.jpg" width=40&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374114:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387531:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Key&lt;BR&gt;Documents&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG style="WIDTH: 47px; HEIGHT: 45px" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0014_icon_rubikBIG.jpg"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:374125:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387530:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Methodology&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right&gt;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/stroke/contentID331186/nelhImp_0018_SR2009Contribute.JPG" width=48 height=39&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:346557:0" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;/A&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;A href="nelh:387547:1" name=internalLink&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;&lt;FONT size=2 face=arial&gt;Contributors&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 34px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID305805/nelhImp_0009_DUETs.gif"&gt; &lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:374121:0" name=internalLink&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:0" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/A&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="nelh:387550:1" name=internalLink&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;Uncertainties&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width="5%" align=right padding:right="0" cell&gt;&lt;IMG style="WIDTH: 45px; HEIGHT: 43px" id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID346140/nelhImp_0000_Feedback.png"&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;FONT size=2 face=Arial&gt;&lt;A href="http://www.library.nhs.uk/cardiovascular/contactus.aspx" target="_blank"&gt;&lt;FONT size=2 face=Arial&gt;Feedback&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P style="MARGIN-BOTTOM: 0cm"&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394521</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/122/16_suppl_2/S250]]&gt;</url>
    <title>2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations</title>
    <publicationDate>2010-10-19T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,CARDIOPULMONARY ARREST,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document summarizes the 2010 evidence evaluation of published science about the recognition and response to sudden life-threatening events, particularly sudden cardiac arrest and periarrest events in victims of all ages.&lt;/P&gt;
&lt;P&gt;More detailed information is available in other parts of this publication. See related links below.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101654</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/11/81/02/04118102.pdf]]&gt;</url>
    <title>A case management competences framework for the care of people with long term conditions</title>
    <publicationDate>2005-08-17T00:00:00</publicationDate>
    <publisher>NHS Modernisation Agency and Skills for Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,SERVICE MODELS,HEALTH MANAGEMENT,HEALTH SERVICE STAFF,NHS ACTIVITIES,EDUCATION / CPD,MANAGERS,NURSES,SERVICE DELIVERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The competence framework aims to draw together and present the range of knowledge, skills and performance associated with case management in the long term conditions field.&amp;nbsp; The competencies are grouped together in areas of practice associated with case management, known as practice domains.&amp;nbsp; Each domain relates to the comptencies required by a case manager or community matron.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended Audience:&lt;/STRONG&gt; PCT Chief Executives, NHS Trust Chief Executives, Foundation Trust Chief Executives, Directors of Nursing, Directors of HR, Allied Health Professionals, Directors of Social Services, Deans of Nursing in HEI's, Directors of Workforce Planning.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 17th August 2005.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392304</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.improvement.nhs.uk/heart/Portals/0/documents2010/Cardiac_Surgery_Commissioning_Guide.pdf]]&gt;</url>
    <title>A guide to commissioning cardiac surgical services</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,SURGICAL PROCEDURES,DISEASE MANAGEMENT,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;FONT color=#4f4f50 size=2 face=Frutiger-Light&gt;&lt;/P&gt;
&lt;P align=left&gt;This report aims to share the successes with the wider NHS providing a range of excellent examples of where local teams have delivered innovation in their service to improve the efficiency and experience for patients and staff.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Sections Include:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;Pre-admission provision.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Referral management services.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Scheduling.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Discharge and post operative care management.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>33420</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/CHD%20Final%20Report.pdf]]&gt;</url>
    <title>A multidisciplinary challenge : improving services for people with coronary heart disease</title>
    <publicationDate>2003-04-08T00:00:00</publicationDate>
    <publisher>NHS Modernisation Agency, National Coronary Heart Disease Collaborative</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE DELIVERY,NATIONAL SERVICE FRAMEWORKS,NHS ACTIVITIES,POLICY,SERVICE MODELS,NATIONAL SERVICE FRAMEWORK FOR CHD,CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;FONT size=1&gt;This document reviews current progress by the Coronary Heart Disease Collaborative* (CHDC) in supporting clinical teams to redesign services for patients with Coronary Heart Disease, in line with the aims of the National Service Framework (NSF). Published in April 2003.&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;* Since publication the Coronary Heart Diseases Collaborative's&amp;nbsp;work has been subsumed&amp;nbsp;into the NHS Heart Improvement Programme&amp;nbsp;which was launched in April 2005.&lt;/P&gt;
&lt;P&gt;This document is hosted by NHS Heart Improvement Programme.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103506</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon940.pdf]]&gt;</url>
    <title>A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.</title>
    <publicationDate>2005-10-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,ARRHYTHMIA,GENERAL,PREVENTION,SCREENING,ADULT,NOT ROUTINELY OFFERED,ATRIAL FIBRILLATION,STROKE,ISCHAEMIC STROKE,CAUSES / RISK FACTORS,PREVENTION,HAEMORRHAGIC STROKE,CAUSES / RISK FACTORS,PREVENTION,CAUSES / RISK FACTORS,CARDIAC CAUSES,PREVENTION,PRIMARY PREVENTION,MANAGEMENT ISSUES,ECONOMIC EVALUATIONS,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Authors conclusions:&lt;/STRONG&gt; "The prevalence of AF (atrial fibrillation) in this population was found to be 7.2%. The incidence ranged from 1.04 to 1.64% per annum. Within the trial, in terms of a screening programme, the only strategy that improved on routine practice was opportunistic screening, at a cost of £337 per additional case detected. Model-based analyses indicated that there was a probability of approximately 60% of annual opportunistic screening being cost effective, Use of CDSS (computerised decision support software) may be considered for analysis of ECGs for detection of AF." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Atrial fibrillation (AF) is a major risk factor for stroke. This review seeks to answer the question of whether screening for AF would be a useful policy and if so what would be the best method for screening. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A multicentred randomised controlled trial involving patients aged 65 years and over from 50 primary care centres across the West Midlands.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; &amp;nbsp;Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al... A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over.&amp;nbsp; Health Technology Assessment. Vol 9: No.40, 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2005.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187395</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon936.pdf]]&gt;</url>
    <title>A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost effectiveness and cost utility for these groups in a UK context</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;The aim of this study&amp;nbsp;is to review&amp;nbsp;the clinical effectiveness and cost effectiveness of implantable cardiac defibrillators (ICDs) compared with conventional therapy of patients at risk of sudden cardiac death (SCD) due to arrhythmias.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The study finds that better patient targeting and efforts to reduce the need for post implantation hospitalisation are required to improve the cost effectiveness of implantable cardioverter defibrillators.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Buxton S et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost effectiveness and cost utility for these groups in a UK context. Health Technology Assessment 2006;10(27).&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2006.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>280998</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2007/PwSI_Framework_Jan07_HIP018.pdf]]&gt;</url>
    <title>A skills based operational framework for practitioners with a special interest in cardiology</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,ARTERIOSCLEROSIS,SERVICE MODELS,PRIMARY PREVENTION,HYPERTENSION,CARDIAC REHABILITATION,SECONDARY PREVENTION,CORONARY HEART DISEASE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CARDIOPULMONARY ARREST,ARRHYTHMIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report is a&amp;nbsp;skills based operational framework for practitioners with a special interest in cardiology.&amp;nbsp; It was developed&amp;nbsp;by a&amp;nbsp;multidisciplinary working party convened by the NHS Heart Improvement Programme and endorsed by the Royal College of General Practitioners, Royal College of Physicians, Royal College of Nursing, British Cardiovascular Society, Primary Care Cardiovascular Society, the Heart Team, and the Skills for Health unit of the Department of Health.&lt;/P&gt;
&lt;P align=left&gt;The aim of the framework is: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To describe those elements of a cardiology service that local commissioners might wish to provide within the community&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To develop the outline educational requirements for practitioners wishing to train specifically for each element&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To develop the service requirements in a way that could support the planning processes that local commissioners might use&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To share current best practice with staff who wish to become practitioners with a special interest in cardiology, service commissioners and training course providers&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in January 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>151876</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/70/41/04137041.pdf]]&gt;</url>
    <title>A stronger local voice : a framework for creating a stronger local voice in the development of health and social care services</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PATIENT CHOICE,SERVICE MODELS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This document sets out the Government's plans for the future of patient and public involvement in health and social care.&amp;nbsp;&amp;nbsp;These plans aim to promote public involvement&amp;nbsp;and to build on the exisiting work of the community and voluntary sector.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392616</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1424.pdf]]&gt;</url>
    <title>A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure</title>
    <publicationDate>2010-05-31T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment Programme</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; Despite the challenges and difficulties that emerged in attempting to undertake a formalcomparison of the effectiveness and costeffectiveness of spironolactone and eplerenone, an important finding has consistently emerged. That is, the use of an aldosterone antagonist moregenerally appears to be a highly cost-effective strategy for the management of post MI HF patients in the UK NHS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Despite the challenges and difficulties that emerged in attempting to undertake a formal comparison of the effectiveness and cost effectiveness of spiA myocardial infarction (MI) occurs when an area of the myocardium is exposed to prolonged ischaemia, usually as a result of a failure of the blood supply from one or more coronary arteries;the affected myocardium necroses and heals leaving a non-contractile scar. Depending uponthe size of the infarcted area,&amp;nbsp;heart function can be impaired leading to varying degrees of contractilefunction known as ‘systolic dysfunction’.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;A broad range of studies were considered for inclusion in the assessment of cost-effectiveness,including economic evaluations conducted alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations that compared two or more options and considered both costs and consequences (including cost-effectiveness, cost–utility or cost–benefit analyses) were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Health Technology Assessment 2010; Vol. 14: No. 24&lt;I&gt;&lt;FONT lang=JA size=3 face=GillSansMT-Italic&gt;&lt;FONT lang=JA size=3 face=GillSansMT-Italic&gt;&lt;/P&gt;
&lt;P&gt;&lt;/I&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access :&amp;nbsp; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&amp;nbsp; Abstract and executive summary also &lt;BR&gt;available as HTML files. &lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3844</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/Docref.asp?d=15727]]&gt;</url>
    <title>A systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Clinical Excellence, NHS R&amp;D Health Technology Assessment Programme</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,PREVENTION,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This review is commissioned by National Institute for Clinical Excellence (NICE) to inform the guideline 'Orlistat for treatment of obesity in adults.'&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3751</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/pdf/sibutraminehtareport.pdf]]&gt;</url>
    <title>A systematic review of the clinical effectiveness and cost effectiveness of sibutramine in the management of obesity</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Clinical Excellence, NHS R&amp;D Health Technology Assessment Programme</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,CARDIOVASCULAR DISEASES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This review aims to systematically assess the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. It concludes that although many trials demonstrated statistically significant diferences between groups in terms of weight loss in favour of sibutramine, the differences may not always be of clinical significance. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270395</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.185734]]&gt;</url>
    <title>AACVPR / ACC / AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation / secondary prevention services</title>
    <publicationDate>2007-10-02T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERFORMANCE INDICATORS,CARDIAC REHABILITATION,SECONDARY PREVENTION,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this document is to provide&amp;nbsp;performance measures that cover&amp;nbsp;two specific aspects of cardiac rehabilitation (CR): referral of eligible patients to a&amp;nbsp;rehabilitation program and delivery of CR services through multidisciplinary&amp;nbsp;programs.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;The ultimate purpose of these performance measures is&amp;nbsp;to help improve the delivery of CR in order to reduce cardiovascular mortality and morbidity and optimize health in persons with cardiovascular disease. &lt;/P&gt;
&lt;P align=left&gt;The document is endorsed by&amp;nbsp;the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association and the Society of Thoracic Surgeons.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3697</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1022188973899unstable_may8.pdf]]&gt;</url>
    <title>ACC / AHA  2002 guideline update for the management of patients with unstable angina and non ST Segment elevation myocardial infarction</title>
    <publicationDate>2002-03-01T00:00:00</publicationDate>
    <publisher>American College of Cardiology, American Heart Association, European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,ELECTROCARDIOGRAM,CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The updated version of the ACC/AHA guidelines originally produced in 2000. The guidelines address the diagnosis and management of patients with unstable angina and the closely related condition non-ST-segment elevation myocardial infarction. Chapters included are: initial evaluation and management; hospital care; coronary revascularisation; hospital discharge and post-hospital discharge care; special groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5942</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1060182581039Echocleanfulltext.pdf]]&gt;</url>
    <title>ACC / AHA / ASE 2003 guideline update for the clinical application of echocardiography</title>
    <publicationDate>2003-05-01T00:00:00</publicationDate>
    <publisher>American College of Cardiology, American Society of Echocardiography, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ STROKE,HAEMORRHAGIC STROKE,ISCHAEMIC STROKE,DIAGNOSIS,DIAGNOSIS,CARDIOVASCULAR DISEASES,CONDITIONS,ECHOCARDIOGRAM,ARRHYTHMIA,HEART FAILURE,VALVE DISORDERS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,ECHOCARDIOGRAPHY,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Update of the 1997 Guidelines aimed at professionals.&amp;nbsp; Sections include the hierarchical levels of echocardiography, murmurs and valvular heart disease, pericardial disease, pulmonary and pulmonary vascular disease, arrhythmias and palpitation and the use of intraoperative transesophageal echocardiography.&amp;nbsp; There have been extensive revisions to the sections on ischemic heart disease, congestive heart failure, cardiomyopathy, assessment of left ventricular function, and screening and echocardiography in the critically ill.&amp;nbsp; Includes recommendations for the use of echocardiography in both adults and pediatric patients.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&amp;nbsp;Portable Document File&amp;nbsp;/ PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3707</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1061222494555RNIFullTextFinal.pdf]]&gt;</url>
    <title>ACC / AHA / ASNC guidelines for the clinical use of cardiac radionuclide imaging : a report of the American College of Cardiology / American Heart Association</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association, American Society of Nuclear Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,NUCLEAR CARDIOLOGY,DIAGNOSIS,CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document is a 2003 update of the 1995 guidelines and discusses the clinical use of cardiac radionuclide imaging.&amp;nbsp; It includes a brief description of nuclear cardiologic techniques, followed by a discussion of their usefulness in specific cardiovascular diseases. Utility is considered for 1) diagnosis, 2) severity of disease/risk assessment/prognosis, and 3) assessment of therapy. Recommendations are summarised in each section.&amp;nbsp; Tabular information, references and appendices are included.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Portable Document File /&amp;nbsp;PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177013</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-VASCD-FT.pdf]]&gt;</url>
    <title>ACC / AHA / ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : executive summary</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association, European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,EMERGENCY CARE,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,REVASCULARISATION,PREVENTION,ARRHYTHMIA,ANTI-ARRHYTHMIC DRUGS,BETA BLOCKERS,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,DISEASE MANAGEMENT,DIAGNOSIS,DEFIBRILLATION,ARRYTHMIA,CARDIOVASCULAR,VENTRICULAR,SURGERY,CARDIAC ARRHYTHMIAS,HEART,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines update and combine previously published recommendations on treating patients with ventricular arrhythmias. Sections are included on acute management of specific arrhythmias, ventricular arrhythmia and sudden cardiac death and ventricular arrhythmias associated with cardiomyopathies. Published in European Heart Journal 2006, 27:2099-2140.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270445</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/atrial-fibrillation.aspx]]&gt;</url>
    <title>ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation : full text</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology Foundation, American Heart Association, European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,ANTI-ARRHYTHMIC DRUGS,ARRHYTHMIA,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document is an updated version of the 2001 guidelines. Its aims are to present the epidemiology, prognosis, pathophysiological mechanisms, clinical evaluation, and management strategies of atrial fibrillation. Recommendations have been revised to incorporate results from major clinical trials since 2001. The text has been amended to reflect the implications for patient care, the prevention of thromboembolism, and methods available for use in selected patients to correct the arrhythmia and maintain normal sinus rhythm. Advances in catheter-based ablation technologies are also incorporated.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Original guidelines published in 2001. These updated guidelines published in the European Heart Journal (2006) 27, 1979-2030.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>28820</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1062186010820SVAFullTextGLfinal.pdf]]&gt;</url>
    <title>ACC / AHA / ESC guideline for the management of patients with supraventricular arrhythmias</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association, European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-ARRHYTHMIC DRUGS,ARRHYTHMIA,CLINICAL LIBRARY,ARRYTHMIA,CARDIOVASCULAR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These&amp;nbsp;2003 guidelines aimed at clinicians, discusses the management of patients with supraventricular arrhythmias.&amp;nbsp; Sections are included on public health considerations and epidemiology, general mechanisms of supraventricular arrhythmia, and clinical presentation, general evaluation and management of patients with supraventricular arrhythmia.&amp;nbsp; The managment&amp;nbsp;of each specific arrhythmias is discussed and the treatment algorithms presented.&amp;nbsp; Includes tabular information and references.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document&amp;nbsp;File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286812</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCUALTIONAHA.108.189742]]&gt;</url>
    <title>ACC / AHA / HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC / AHA / NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices)</title>
    <publicationDate>2008-05-27T00:00:00</publicationDate>
    <publisher>American College of Cardiology Foundation, American Heart Association,  Heart Rhythm Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,GENERAL/OTHER,APR-JUNE 08,ARRHYTHMIA,CONDITIONS,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Revision reflects the most relevant and significant advances in pacemaker and implantable cardiac devices therapy since 2002. &lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;To provide, wherever possible, evidence-based recommendations for device-based therapy of cardiac rhythm abnormalities.&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281530</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/117/8/1101]]&gt;</url>
    <title>ACC / AHA / Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter : a report of the American College of Cardiology / American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation)</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,DIAGNOSIS,PERFORMANCE INDICATORS,RISK ASSESSMENT,GENERAL,GENERAL/OTHER,CARDIOVASCULAR DISEASES,DIAGNOSIS,ARRHYTHMIA,MANAGEMENT ISSUES,CONDITIONS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;These performance measures have been developed to assist with the diagnosis and treatment of atrial fibrillation (AF) and atrial flutter. They specifically refer to adults with nonvalvular AF; they do not apply to patients with acute, reversible causes of AF or atrial flutter. Information is included on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Methodology&lt;BR&gt;
&lt;LI&gt;AF and atrial flutter performance measures&lt;BR&gt;
&lt;LI&gt;Discussion on risk stratification and potential measures for addressing disease management issues.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Includes tabular information and references.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268564</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1131740149971PCI_Final%20Final%20Clean%20Revision_AHA.pdf]]&gt;</url>
    <title>ACC / AHA / SCAI 2005 guideline update for percutaneous coronary intervention : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (ACC / AHA / SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,INTERVENTIONS / PROCEDURES,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,REPERFUSION,RESCUE PCI,CORONARY HEART DISEASE,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To update the 2001 guidelines due to the continual refinement and modification of the techniques of percuatneous coronary intervention (PCI). Recommendations are made to aid the appropriate application of PCI in general situations.&lt;/P&gt;
&lt;P align=left&gt;The guideline&amp;nbsp;contains changes in the recommendations, along with supporting text.&amp;nbsp;References that support either the 2001 recommendations that have changed or the new or revised recommendations are cited in parentheses at the end of each recommendation or comment.&lt;/P&gt;
&lt;P align=left&gt;Sections include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;outcomes&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;institutional and operator competency&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;clinical presentations&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;management of patients.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177688</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.acc.org/qualityandscience/clinical/guidelines/exercise/exercise_clean.pdf]]&gt;</url>
    <title>ACC / AHA 2002 guideline update for exercise testing</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EXERCISE TOLERANCE TESTS,CONDITIONS,CARDIOVASCULAR DISEASES,DIAGNOSIS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;The guidelines are designed to make recommendations regarding the appropriate use of exercise testing in the diagnosis and treatment of patients with known or suspected cardiovascular disease.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; The guidelines are intended to assist physicians in clinical decision making.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Methodology:&lt;/STRONG&gt; The committee reviewed and compiled pertinent published reports through a computerised search of the English language literature since 1975 and a manual search of final articles. Specific attention was devoted to identification and compilation of appropriate meta analyses.&lt;FONT face="Times New Roman" size=3&gt;&lt;/P&gt;&lt;/FONT&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; This report was&lt;STRONG&gt; &lt;/STRONG&gt;approved by the American College of Cardiology (ACC)&amp;nbsp;Board of Trustees in July 2002 and by the American Heart Association (AHA) Science Advisory and Coordinating Committee&amp;nbsp;in June 2002.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;References to previous version of the guideline:&lt;/STRONG&gt; These guidelines update the previous report of the ACC / AHA which was published in 1986: Schlant RC et al. Guidelines for exercise testing : a report of the ACC / AHA&amp;nbsp;Task Force on assessment of cardiovascular procedures.&amp;nbsp;Journal of the American College of&amp;nbsp;Cardiology 1986;8:725-38.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3698</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1044991838085StableAnginaNewFigs.pdf]]&gt;</url>
    <title>ACC / AHA 2002 guideline update for the management of patients with chronic stable angina</title>
    <publicationDate>2002-11-17T00:00:00</publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ REVASCULARISATION,SURGICAL PROCEDURES,GENERAL  / OVERVIEWS,STABLE ANGINA,CONDITIONS,DISEASE MANAGEMENT,CHEST PAIN,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines aim to address the diagnosis, risk stratification, treatment, and patient follow-up of adult patients with stable chest pain syndromes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 1999 updated 2002. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File&amp;nbsp;/ PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. 
&lt;P&gt;&lt;FONT face="Times New Roman" size=4&gt;&amp;nbsp; &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3613</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1091729475910CABG_Clean_Full_Text.pdf]]&gt;</url>
    <title>ACC / AHA 2004 guideline update for coronary artery bypass graft surgery</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CORONARY ARTERY BYPASS GRAFTS,DISEASE MANAGEMENT,SURGICAL PROCEDURES,REVASCULARISATION,ISCHAEMIC HEART DISEASE,HEART,SURGERY,SURGERY,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This 2004 report of the American College of Cardiology and American Heart Association Task Force on Practice Guidelines is a revision of the 1991 and 1999 guidelines for coronary artery bypass graft surgery. Sections include outcomes, comparison of medical therapies versus surgical revascularisation, comparison of bypass surgery with percutaneous revascularisation, management strategies, impact of evolving technology, institutional and operator competence, and cost effectiveness of bypass surgery.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 1991, updated 1999 and 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3933</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/112/12/e154.pdf]]&gt;</url>
    <title>ACC / AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines, International Society of Heart and Lung Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,DIAGNOSIS,SURGERY,SURGERY,HEART FAILURE,HEART,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To provided guidance on the diagnosis and management of heart failure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Target Audience:&lt;/STRONG&gt; American health care professionals involved in the care or patients with heart failure.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; First published in 1995, updated 2001 and 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143473</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cardiosource.com/guidelines/guidelines/valvular/3205P149.pdf]]&gt;</url>
    <title>ACC / AHA 2006 guidelines for the management of patients with valvular heart disease</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,VALVE DISORDERS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,GENERAL/OTHER,SURGERY,SURGERY,HEART,VALVULAR HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;To provide guidance on the management of patients with valvular heart disease.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; American health care professionals involved in the care of patients with valvular heart disease.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270404</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.181940]]&gt;</url>
    <title>ACC / AHA 2007 guidelines for the management of patients with unstable angina / non-ST-elevation myocardial infarction : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina / non-ST-elevation myocardial infarction)</title>
    <publicationDate>2007-08-14T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,ANTI-COAGULANTS,ANTI-HYPERTENSIVE DRUGS,ANTI-PLATELET DRUGS,BETA BLOCKERS,CALCIUM CHANNEL BLOCKERS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,GENERAL,LIPID-REGULATING DRUGS,INTERVENTIONS / PROCEDURES,NITRATES,SURGICAL PROCEDURES,ACE INHIBITORS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY ARTERY BYPASS GRAFTS,LOW MOLECULAR WEIGHT HEPARINS,REVASCULARISATION,WARFARIN,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,DIAGNOSIS,DISEASE MANAGEMENT,DIAGNOSIS,DISEASE MANAGEMENT,SECONDARY PREVENTION,SURGERY,SURGERY,HEART,ISCHAEMIC HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document aims to make recommendations regarding the diagnosis and treatment of patients with known or suspected&amp;nbsp;unstable angina / non-ST-elevation myocardial infarction.&lt;/P&gt;
&lt;P align=left&gt;The following information is provided:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;initial evaluation and management&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;early hospital care&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;coronary revascularisation&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;late hospital care, hospital discharge and post-hospital discharge&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;treatment of special groups:&lt;/DIV&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;women&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;people with diabetes mellitus&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;post-coronary artery bypass graft patients&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;older adults&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;people with chronic kidney disease&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;cocaine and methamphetamine users&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;people with variant angina&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;people with cardiovascular syndrome X&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;people with Takotsubo cardiomyopathy&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Healthcare providers must ensure the patient understands the treatment and lifestyle regimens through active participation and in order to improve adherence.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270357</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.185700]]&gt;</url>
    <title>ACC / AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : executive summary. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery)</title>
    <publicationDate>2007-10-23T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,RISK ASSESSMENT,SURGICAL PROCEDURES,GENERAL/OTHER,SURGERY,PERIOPERATIVE MANAGEMENT,TESTS &amp; RISK ASSESSMENT,COMPLICATIONS,OPTIMISING PATIENT HEALTH,CARDIOVASCULAR CONDITION,CARDIOVASCULAR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this document&amp;nbsp;is to provide a&amp;nbsp;framework for considering cardiac risk of noncardiac surgery in a variety of patient and surgical situations. &lt;/P&gt;
&lt;P align=left&gt;The writing committee that prepared these guidelines strove to incorporate what is currently known about perioperative risk and how this knowledge can be used in the individual patient. The tables and algorithms provide quick references for decision making.&amp;nbsp;The overriding theme of this document is that intervention is rarely necessary to simply lower the risk of surgery unless such intervention is indicated irrespective of the preoperative context. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 23 October 2007. These guidelines update those published in&amp;nbsp;2002.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp;Physicians and nonphysician caregivers who are involved in the preoperative, operative and postoperative care of patients undergoing noncardiac surgery. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299246</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.108.190690v1.pdf]]&gt;</url>
    <title>ACC / AHA 2008 guidelines for the management of adults with congenital heart disease :  a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease)</title>
    <publicationDate>2008-12-02T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,GENERAL / OVERVIEWS,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To provide whenever possible, evidence-based recommendations for the management of adults with congenital heart disease. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6045</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1044978004593ja20038940p.pdf]]&gt;</url>
    <title>ACC / AHA clinical competence statement on echocardiography</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,ECHOCARDIOGRAM,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement is aimed at professionals and is a revision of the 1990 ACP/ACC/AHA Clinical Competence in Adult Echocardiography.&amp;nbsp; The revised statement recognises the growths in technology and the increased complexity of echocardiography.&amp;nbsp; The minimum knowledge required for performance and interpretation of all modalities of echocardiography is discussed.&amp;nbsp; New applications of echocardiography in the operating room and the application of echocardiography in patients with complex coronary heart disease (CHD) is included.&amp;nbsp; In addition, the application of echocardiography using miniaturised hand-carried ultrasound instruments is also addressed.&amp;nbsp; Includes tabular information and references. Published in J Am Coll Cardiol 2003;41(4). 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. 
&lt;P&gt;&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102772</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1124919481602HFPerfMeasFinal2[1].pdf]]&gt;</url>
    <title>ACC / AHA clinical performance measures for adults with chronic heart failure</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PATIENT INFORMATION,DISEASE MANAGEMENT,ACE INHIBITORS,HEART FAILURE,WARFARIN,ANTI-COAGULANTS,ANTI-HYPERTENSIVE DRUGS,BETA BLOCKERS,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These American College of Cardiology/American Heart Association (ACC/AHA) performance measures are concerned with the diagnosis and treatment of heart failure (HF). They refer to both hospitalised adult patients (age 18 years or older) with a principal discharge diagnosis of HF and to adults with HF evaluated in the outpatient setting.&lt;/P&gt;
&lt;P&gt;Sections are included on initial laboratory tests, weight measurement, blood pressure measurement, assessment of activity level, patient education, beta blocker therapy, ACE inhibitor therapy and warfarin therapy.&lt;/P&gt;
&lt;P&gt;After a period of consultation and peer review the performance measures&amp;nbsp;were&amp;nbsp;adopted by the respective boards of the ACC and AHA in August 2005.&amp;nbsp; These measures will be reviewed for currency once a year and will be updated if necessary.&lt;/P&gt;
&lt;P&gt;Includes tabular information and references.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general publc. Portable Document File / PDF requiring Adobe Acrobat Reader. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>123925</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1135028673759PAD_Full%20Text.pdf]]&gt;</url>
    <title>ACC / AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic)</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RENOVASCULAR DISEASES,IN ADULTS,ANEURYSMS,ABDOMINAL AORTIC,PERIPHERAL ARTERIAL DISEASE,RENAL ARTERY STENOSIS,LIMB ISCHAEMIA,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,BLOOD VESSELS &amp; LYMPHATICS,SURGERY,SURGERY,ARTERIOSCLEROSIS,CAUSES &amp; RISK FACTORS,GENERAL / OVERVIEW,CAUSES AND RISK FACTORS,DIAGNOSIS,CARDIOVASCULAR DISEASES,REVASCULARISATION,DISEASE MANAGEMENT,CONDITIONS,ANTI-HYPERTENSIVE DRUGS,HYPERTENSION,LIPID-REGULATING DRUGS,SMOKING,EXERCISE TOLERANCE TESTS,SURGICAL PROCEDURES,CORONARY HEART DISEASE,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,DISEASE MANAGEMENT,CAUSES / RISK FACTORS,DIAGNOSIS,PERIPHERAL VASCULAR DISEASE,PERIPHERAL VASCULAR DISEASE,CAUSES &amp; RISK FACTORS,GENERAL,CONDITIONS,VASCULAR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines primarily address the diagnosis and management of atherosclerotic, aneurysmal and thromboembolic peripheral arterial disease (PAD).&amp;nbsp; The ultimate goal of the guideline is to improve the quality of life for people with PAD.&amp;nbsp; Chapters include lower extremity PAD; renal artery disease; mesenteric arterial disease; aneurysms of the abdominal aorta, its branch vessels, and the lower extremities.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A target=_blank readstep2.html? acrobat products www.adobe.com http:&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60174</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1090338315100STEMIFinalFinalforposting.pdf]]&gt;</url>
    <title>ACC / AHA guidelines for the management of patients with ST elevation myocardial infarction</title>
    <publicationDate>2004-08-04T00:00:00</publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,OTHER,CARDIOVASCULAR DISEASES,ARRHYTHMIA,CHEST PAIN,MANAGEMENT ISSUES,CONDITIONS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Revised version of the 1999 ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. &lt;BR&gt;Chapters include pathology; pre-hospital issues; Emergency Department management; hospital management; long term management. 
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; Executive summary and recommendations&amp;nbsp;published in Circulation 2004;110:588-636.&lt;FONT face="Times New Roman" size=4&gt; &lt;/FONT&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals.&amp;nbsp;&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 1999 updated 2004. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&lt;FONT face="Times New Roman" size=4&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282033</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1194979355638UA-NSTEMI.Text.Final.pdf]]&gt;</url>
    <title>ACC / AHA management of patients with unstable angina / non-ST elevation myocardial infarction : pocket guideline</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>American College of Cardiology Foundation, American Heart</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ REVASCULARISATION,CORONARY ARTERY BYPASS GRAFTS,SURGICAL PROCEDURES,ACUTE CORONARY SYNDROMES,GENERAL/OTHER,DIAGNOSIS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DIAGNOSIS,MYOCARDIAL INFARCTION,UNSTABLE ANGINA,CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;Based on the ACC/AHA 2007 guideline revision of management of patients with unstable angina/non–ST-elevation myocardial infarction, this pocket version provides concise guidance on the diagnosis and treatment of patients with known or suspected unstable angina/non-ST-elevation myocardial infarction.&lt;/P&gt;
&lt;P align=left&gt;The document is divided into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Initial evaluation and management&lt;BR&gt;
&lt;LI&gt;Early hospital care&lt;BR&gt;
&lt;LI&gt;Coronary revascularisation&lt;BR&gt;
&lt;LI&gt;Hospital discharge and post-hospital discharge care&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Publilshed in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268099</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.sdo.lshtm.ac.uk/files/adhoc/33-research-summary.pdf]]&gt;</url>
    <title>Access to health care research summary : improving care for patients with angina : how to help clinicians make the right decisions</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Health Research</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RISK ASSESSMENT,GENERAL,DIAGNOSIS,STABLE ANGINA,CARDIOVASCULAR DISEASES,DIAGNOSIS,MANAGEMENT ISSUES,CHEST PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&amp;nbsp; '&lt;/STRONG&gt;The new appropriateness ratings system that assesses the best testing options tailored for individual patients with angina is a promising computerised tool that may improve health and help save lives. It may also help to reduce any inequalities that exist around people’s access to tests for angina.'&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; This research summary published in August 2007 is aimed at health professionals and health service managers.&amp;nbsp; It is based on work undertaken by researchers at the Royal Free and University College London Medical School on behalf of the National Institute for Health Research Service Delivery Organisation Programme. Evidence was analysed relating to the piloting of a new ratings system that assesses the most appropriate testing options for individual patients with angina. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Original study:&lt;/STRONG&gt; Hemingway H ... et al. Evaluation of appropriateness methods to define and improve access across primary, secondary and tertiary care among people with angina. Report for the NIHR Service Delivery and Organisation Programme. London: NCCSDO, 2005.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access to review:&lt;/STRONG&gt; Summary only. Available to the general public.&amp;nbsp;Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access to original study:&lt;/STRONG&gt; NHS staff please contact your local library for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103107</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://content.onlinejacc.org/cgi/content/long/46/7/1378]]&gt;</url>
    <title>ACCF / AHA / AAP recommendations for training in pediatric cardiology</title>
    <publicationDate>2005-10-04T00:00:00</publicationDate>
    <publisher>American College of Cardiology Foundation, American Heart Association, American College of Physicians</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,SERVICE MODELS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,GENERAL  / OVERVIEWS,CHILD HEALTH,CARDIOLOGY,SPECIALTIES,CONGENITAL HEART DISEASE,GENERAL / OVERVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To address overall recommendations for training in pediatric cardiology and important subspecialities within the field of pediatric cardiology.&amp;nbsp; This document also aims to define a more comprehensive set of guidelines for pediatric fellowship training.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Target Audience:&lt;/STRONG&gt; American health care professionals involved in pediatric cardiology and Pediatric Cardiology Training Program Directors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; Published October 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File/ PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105665</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/downloadable/heart/1120163081544CT%20MR%20Clinical%20Competence%20Statement%20-%206-30-05.pdf]]&gt;</url>
    <title>ACCF / AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology Foundation, American Heart Association &amp; American College of Physicians</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CHEST X-RAY,GENERAL,CARDIOVASCULAR DISEASES,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To assist in the assessment of physicians' expertise in the ability to apply and interpret cardiovascular computed tomography (CCT) and cardiovascular magnetic resonance (CMR). This competence statement outlines the&amp;nbsp;minimum education, training, experience and cognitive skills necessary for the evaluation and interpretation of cardiac imaging.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; American health professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2005.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281392</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.189097]]&gt;</url>
    <title>ACCF / ASE / ACEP / AHA / ASNC / SCAI / SCCT / SCMR 2008 appropriateness criteria for stress echocardiography : a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,ECHOCARDIOGRAM,RISK ASSESSMENT,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The American College of Cardiology Foundation (ACCF) and the American Society of Echocardiography (ASE) together with key specialty and subspecialty societies, conducted an appropriateness review for stress echocardiography. The review assessed the risks and benefits of stress echocardiography for several indications or clinical scenarios. This report discusses the appropriateness of stress echocardiography based on these findings.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344319</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192230]]&gt;</url>
    <title>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HYPERTENSION,GENERAL  / OVERVIEWS,CONGENITAL HEART DISEASE,GENERAL / OVERVIEWS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Pulmonary hypertension (PH) is a complex, multidisciplinary&lt;SUP&gt; &lt;/SUP&gt;disorder. Recent advances have led to increased recognition&lt;SUP&gt; &lt;/SUP&gt;and new therapies. While some data exist to form treatment guidelines,&lt;SUP&gt; &lt;/SUP&gt;other areas have been inadequately explored.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; March 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344418</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/120/13/e100]]&gt;</url>
    <title>ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease</title>
    <publicationDate>2009-09-21T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,MANAGEMENT ISSUES,PREVENTION,GENERAL,GENERAL,PRIMARY PREVENTION,SERVICE MODELS,SECONDARY PREVENTION,GENERAL/OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To develop&lt;SUP&gt; &lt;/SUP&gt;recommendations for attaining and maintaining the cognitive&lt;SUP&gt; &lt;/SUP&gt;and technical skills necessary for the competent performance&lt;SUP&gt; &lt;/SUP&gt;of a specific cardiovascular service, procedure, or technology.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; September 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267814</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/115/19/2549]]&gt;</url>
    <title>Acute coronary care in the elderly part 1. Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology</title>
    <publicationDate>2007-05-15T00:00:00</publicationDate>
    <publisher>American Heart Association, Council on Clinical Cardiology, Society of Geriatric Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A scientific statement from the AHA Council on Clinical Cardiology in association with the Society of Geriatric Cardiology.&lt;/P&gt;
&lt;P align=left&gt;There is limited trial data to guide the care of older adults with acute coronary syndromes (ACS) and uncertainty about the benefits and risks of newer medications or invasive treatments in the older age groups.&lt;/P&gt;
&lt;P align=left&gt;The statement summarises the evidence on patient heterogeneity, clinical presentation and treatment of non-ST-segment-elevation ACS in relation to age and provides a framework for future work in the care of the elderly with acute cardiac disease.&lt;/P&gt;
&lt;P align=left&gt;Elderly patients should be enrolled in trials proportionate to their prevalence among the treated population.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267816</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/115/19/2570]]&gt;</url>
    <title>Acute coronary care in the elderly part II. ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association council on Clinical Cardiology</title>
    <publicationDate>2007-05-15T00:00:00</publicationDate>
    <publisher>American Heart Association, Council on Clinical Cardiology, Society of Geriatric Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A scientific statement from the AHA Council on Clinical Cardiology in collaboration with the Society of Geriatric Cardiology.&lt;/P&gt;
&lt;P align=left&gt;The statement summarises the evidence on presentation and treatment of ST-segment-elevation myocardial infarction in relation to age. It identifies areas in which evidence is sufficient to guide practice in the elderly and to highlight areas that warrant further study.&lt;/P&gt;
&lt;P align=left&gt;Treatment benefits should rise in elderly populations, but data to confirm the benefits are limited and the heterogeneity of older populations increases treatment-associated risks. Data support a benefit from reperfusion in the elderly up to 85 years of age, but the selection of reperfusion strategy is made more on availability, time from presentation, shock and comorbidity than on age.&lt;/P&gt;
&lt;P align=left&gt;Efforts should be made to enrol the elderly in trials in proportion to their prevalence among the treated population. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394579</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f9a223]]&gt;</url>
    <title>Acute Heart Failure Syndromes: Emergency Department Presentation, Treatment, and Disposition: Current Approaches and Future Aims</title>
    <publicationDate>2010-11-09T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To describe current standard practice for HF clinicians, to highlight the knowledge gaps that are present, and to serve as a call to action for Emergency Department based research as a future endeavor for those with a vested interest in AHFS care. It examines the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What Happens Currently in the ED: Diagnosis, Treatment, and Disposition? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Post-Emergency Department Course &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Integrated Care of the Heart Failure Team &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published Novemeber 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377809</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181e3b133]]&gt;</url>
    <title>ADA/AHA/ACCF Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes</title>
    <publicationDate>2010-05-03T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,PREVENTION,ANTI-PLATELET DRUGS,DIABETES MELLITUS,PRIMARY PREVENTION,ASPIRIN,STROKE,ISCHAEMIC STROKE,PREVENTION,HAEMORRHAGIC STROKE,PREVENTION,DISEASE MANAGEMENT,SECONDARY PREVENTION,ANTI-PLATELET DRUGS,ASPIRIN,VASCULAR,CONDITIONS,DISEASE MANAGEMENT,ANTI-PLATELET DRUGS,ASPIRIN,PREVENTION,PRIMARY PREVENTION,RECENT ADDITIONS,RECENT ADDITIONS,RECENT ADDITIONS,APR-JUN 10,APR-JUNE 10,APR-JUNE 10,JUNE 2010,JUNE 2010,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;To provide treatment guidance based on either a combination of age, sex, and other risk factors or on an estimate of absolute cardiovascular risk. All patients with diabetes do not have high cardiovascular risk, despite the assumptions of some previous guidelines.&lt;/P&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; May 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;Abstract only. Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;Full-text online access is available to NHS staff in England via ATHENS passwords.&amp;nbsp; To find out how to get an ATHENS password and access this resource and many others please refer to "Athens Registration" at &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126257</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/46/96/04134696.pdf]]&gt;</url>
    <title>Adult congenital heart disease : a commissioning guide for services for young people and grown ups with congenital heart disease</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,PERFORMANCE INDICATORS,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,COMMISSIONING,POPULATIONS SERVED,DISEASE/CONDITION GROUPS,CIRCULATION PROBLEMS,CHILDREN,YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide provides indicators of care for congential heart disease services in the areas of transition from child to adult services. It examines access to expertise, mulitidisciplinary working and special need.&amp;nbsp; It also suggests a direction to travel in local planning and provides some examples of good practice. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3776</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/104/13/1577]]&gt;</url>
    <title>AHA / ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease : 2001 update</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MYOCARDIAL INFARCTION,PREVENTION,ACUTE CORONARY SYNDROMES,PREVENTION,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report defines target cholesterol levels, expanded indications for drug treatment, and initiated therapy earlier for preventing heart attack and dealth in patients with atherosclerotic cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general pubic.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126282</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/113/19/2363]]&gt;</url>
    <title>AHA / ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease : 2006 update</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,PREVENTION,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Statement for the secondary prevention for patients with coronary and other atherosclerotic vascular disease from the AHA/ACC. The recommendations are based mainly on practice guidelines from the National Institutes for Health and the AHA/ACC.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; American health care professionals involved in the care of patients with coronary and other atherosclerotic vascular disease.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published 2001, updated 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250665</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cardiosource.com/guidelines/cvdinwomen.pdf]]&gt;</url>
    <title>AHA guideline evidence-based guidelines for cardiovascular disease prevention in women : update 2007</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,PRIMARY PREVENTION,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This 2007 update provides the most current clinical recommendations for the prevention of CVD in women &amp;gt;20 years of age and is based on a systematic search of the highest-quality science, interpreted by experts in the fields of cardiology, epidemiology, family medicine, gynecology, internal medicine, neurology, nursing, public health, statistics, and surgery. &lt;/P&gt;
&lt;P&gt;These guidelines cover the primary and secondary prevention of chronic atherosclerotic vascular diseases. More acute management of vascular disease in the periprocedural or immediate posthospital settings and of valvular heart disease is covered in other AHA guidelines.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published February 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393530</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f9a223]]&gt;</url>
    <title>AHA Scientific Statement on Acute Heart Failure Syndromes: Emergency Department Presentation, Treatment, and Disposition</title>
    <publicationDate>2010-11-11T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The purpose of this scientific statement,&amp;nbsp;is to describe current standard practice for HF clinicians, to highlight the knowledge gaps that are present, and to serve as a call to action for ED-based research as a future endeavor for those with a vested interest in AHFS care.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344455</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/121/6/833]]&gt;</url>
    <title>AHA/ACS/AUA Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,GENERAL,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Androgen-deprivation therapy (ADT) is a widely used treatment&lt;SUP&gt; &lt;/SUP&gt;for prostate cancer. Recently, several studies have reported&lt;SUP&gt; &lt;/SUP&gt;an association between ADT and an increased risk of cardiovascular&lt;SUP&gt; &lt;/SUP&gt;events, including myocardial infarction and cardiovascular mortality.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; February 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251552</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-HCM-FT.pdf]]&gt;</url>
    <title>American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>American College of Cardiology Foundation, European society of Cardiology</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,ACUTE CORONARY SYNDROMES,ANTI-ARRHYTHMIC DRUGS,CALCIUM CHANNEL BLOCKERS,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;To provide guidance on the current state of management of patients with hypertrophic cardiomyopathy.&amp;nbsp; Sections are included on:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Overview of the condition&lt;BR&gt;
&lt;LI&gt;Symptoms and pharmacological management&lt;BR&gt;
&lt;LI&gt;Treatment options for drug-refractory patients&lt;BR&gt;
&lt;LI&gt;Sudden cardiac death&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Published in European Heart Journal 2003;24:1965-1991.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&amp;nbsp; &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5940</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/107/12/1692]]&gt;</url>
    <title>American Heart Association / American College of Cardiology foundation guide to warfarin therapy</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology, American Heart Association Task Force on Practice Guidelines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ WARFARIN,HEPARIN,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,ANTI-COAGULANTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;AHA/ACC scientific statement&amp;nbsp;aimed at professionals.&amp;nbsp; Main sections covered are the pharmacology of warfarin, management of oral anticoagulant therapy and clinical applications of oral anticoagulant therapy.&amp;nbsp; Subsections include the antithrombotic effect of warfarin, patient self-management and primary prevention of ischemic coronary events.&amp;nbsp; Tabular information and references are included.&amp;nbsp; Published in Circulation 2003;107:1692.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3924</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/107/4/645]]&gt;</url>
    <title>American Heart Association guide for improving cardiovascular health at the community level</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline suggests a comprehensive approach to reducing the burden of cardiovascular disease (CVD) through improving the local policies and environment as a means to promote cardiovascular health. It recommends the population-based or public health approach to risk factor modification and emphasizes the social and environmental origins of the CVD epidemic. Published in Circulation 2003;107:645.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293709</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : August 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,GENERAL/OTHER,JUL-SEPT 08,CARDIOPULMONARY ARREST,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;* American Heart Association / American College of Cardiology Foundation / Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death : a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;*&lt;/STRONG&gt; Implementation and integration of prehospital ECGs into systems of care for acute coronary syndrome : a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research, Emergency Cardiovascular Care Committee, Council on Cardiovascular Nursing, and Council on Clinical Cardiology &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;* Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment : a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young and the Council for High Blood Pressure Research &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in August 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302258</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=3003999]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : December 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ISCHAEMIC STROKE,GENERAL / OVERVIEWS,HAEMORRHAGIC STROKE,STROKE,CAUSES AND RISK FACTORS,DIAGNOSIS,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE,DIABETES MELLITUS,MANAGEMENT ISSUES,GENERAL  / OVERVIEWS,STATISTICS,GENERAL,ARTERIOSCLEROSIS,GENERAL / OVERVIEW,STATISTICS,MANAGEMENT ISSUES,VASCULAR,CONDITIONS,PERIPHERAL VASCULAR DISEASE,PERIPHERAL VASCULAR DISEASE,GENERAL / OVERVIEWS,JAN-MAR 09,JAN-MAR 09,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Atherosclerotic Peripheral Vascular Disease Symposium II &lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Intensive glycemic control and the prevention of cardiovascular events : implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association &lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;Heart disease and stroke statistics 2009 update :&amp;nbsp; a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;2008 key data elements and definitions for cardiac imaging : a report of the American College of Cardiology / American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging) &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;2008 health policy statement on structured reporting in cardiovascular imaging&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307550</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : February 2009</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,NUCLEAR CARDIOLOGY,HEART FAILURE,JAN-MAR 09,GENERAL,ELECTROCARDIOGRAM,ECHOCARDIOGRAM,PREVENTION,CONDITIONS,CARDIOVASCULAR DISEASES,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis : a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research &lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;AHA / ACCF / HRS recommendations for the standardization and interpretation of the electrocardiogram &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ionizing radiation in cardiac imaging : a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention &lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305716</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : January 2009</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ STROKE,HAEMORRHAGIC STROKE,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,DIET,CORONARY HEART DISEASE,PREVENTION,PREVENTION,CAUSES AND RISK FACTORS,DIET,OVERWEIGHT AND OBESITY,ARTERIOSCLEROSIS,CAUSES &amp; RISK FACTORS,PREVENTION,GENERAL / OVERVIEWS,SUBARACHNOID HAEMORRHAGE,JAN-MAR 09,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Omega-6 fatty acids and risk for cardiovascular disease : a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guidelines for the management of aneurysmal subarachnoid hemorrhage : a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Progress and challenges in metabolic syndrome in children and adolescents : a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ACCF / SCAI / STS / AATS / AHA / ASNC 2009 appropriateness criteria for coronary revascularization : a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Partnering to reduce risks and improve cardiovascular outcomes : American Heart Association initiatives in action for consumers and patients &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305716</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : January 2009</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ STROKE,HAEMORRHAGIC STROKE,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,DIET,CORONARY HEART DISEASE,PREVENTION,PREVENTION,CAUSES AND RISK FACTORS,DIET,OVERWEIGHT AND OBESITY,ARTERIOSCLEROSIS,CAUSES &amp; RISK FACTORS,PREVENTION,GENERAL / OVERVIEWS,SUBARACHNOID HAEMORRHAGE,JAN-MAR 09,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Omega-6 fatty acids and risk for cardiovascular disease : a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guidelines for the management of aneurysmal subarachnoid hemorrhage : a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Progress and challenges in metabolic syndrome in children and adolescents : a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ACCF / SCAI / STS / AATS / AHA / ASNC 2009 appropriateness criteria for coronary revascularization : a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Partnering to reduce risks and improve cardiovascular outcomes : American Heart Association initiatives in action for consumers and patients &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377885</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : January 2009</title>
    <publicationDate>2010-06-15T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,JANUARY 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Regional Systems of Care for Out-of-Hospital Cardiac Arrest: A Policy Statement From the American Heart Association.&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Update on Cardiovascular Implantable Electronic Device Infections and Their Management: A Scientific Statement From the American Heart Association. &lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General Public&amp;nbsp;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377885</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : January 2009</title>
    <publicationDate>2010-06-15T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,JANUARY 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Regional Systems of Care for Out-of-Hospital Cardiac Arrest: A Policy Statement From the American Heart Association.&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Update on Cardiovascular Implantable Electronic Device Infections and Their Management: A Scientific Statement From the American Heart Association. &lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General Public&amp;nbsp;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291445</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : July 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ VALVE DISORDERS,DISEASE MANAGEMENT,PREVENTION,ARTERIOSCLEROSIS,PREVENTION,GENERAL/OTHER,JUL-SEPT 08,CARDIOVASCULAR DISEASES,PREVENTION,CONDITIONS,DISEASE MANAGEMENT,CORONARY HEART DISEASE,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;* Sleep apnea and cardiovascular disease : an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing Council &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;* ACC/AHA 2008 guideline update on valvular heart disease : focused update on infective endocarditis : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;* Management of stroke in infants and children : a scientific statement from a special writing group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;* Translating research into practice for healthcare providers : the American Heart Association's Strategy for building healthier lives, free of cardiovascular diseases and stroke &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;* The impact of prevention on reducing the burden of cardiovascular disease&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388620</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : July 2010</title>
    <publicationDate>2010-08-03T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,CHEST PAIN,GENERAL,HEART FAILURE,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Reduction in Adults &lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Published in August 2010.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291451</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=3062770]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : June 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE,GENERAL  / OVERVIEWS,ARTERIOSCLEROSIS,GENERAL / OVERVIEW,JUL-SEPT 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;* Population-based prevention of obesity : the need for comprehensive promotion of healthful eating, physical activity, and energy balance&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Noninvasive coronary artery imaging : magnetic resonance angiography and multidetector computed tomography angiography&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* State of the Science Conference : initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS : executive summary&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Effects of HIV infection and antiretroviral therapy on the heart and vasculature&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Screening and assessment of coronary heart disease in HIV-infected patients&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Development of appropriate coronary heart disease risk prediction models in HIV-infected patients&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* Prevention strategies for cardiovascular disease in HIV-infected patients&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;* Wallet Card, ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;* ACC/AHA pocket guideline based on the ACC/AHA/HRS 2008 guidelines "device-based therapy of cardiac rhythm abnormalities" &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377880</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : May 2010</title>
    <publicationDate>2010-06-15T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,ANTI-PLATELET DRUGS,DIABETES MELLITUS,GENERAL,PRIMARY PREVENTION,ASPIRIN,VASCULAR,CONDITIONS,CAUSES &amp; RISK FACTORS,GENERAL,RECENT ADDITIONS,RECENT ADDITIONS,APR-JUNE 10,APR-JUNE 10,JUNE 2010,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P align=left&gt;ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents &lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P align=left&gt;Particulate Matter Air Pollution and Cardiovascular Disease.&amp;nbsp;An Update to the Scientific Statement From the American Heart Association &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/NOBR&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2010.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299242</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : November 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,THROMBOLYTICS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,PERFORMANCE INDICATORS,INTERVENTIONS / PROCEDURES,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,GENERAL / OVERVIEWS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,OCT-DEC 08,REPERFUSION,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;ACC / AHA 2008 guidelines for the management of adults with congenital heart disease :&amp;nbsp; a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease) &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;ACC / AHA 2008 guidelines for the management of adults with congenital heart disease : executive summary : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease) &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;ACC / AHA 2008 performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction : a report of the American College of Cardiology / American Heart Association Task Force on Performance Measures (writing committee to develop performance measures for ST-elevation and non–ST-elevation myocardial infarction) &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;ACC / AHA 2008 statement on performance measurement and reperfusion therapy : a report of the ACC / AHA Task Force on Performance Measures (work group to address the challenges of performance measurement and reperfusion therapy) &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;ACC / AHA classification of care metrics : performance measures and quality metrics : a report of the American College of Cardiology / American Heart Association Task Force on Performance Measures &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in November 2008.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>297766</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=3062770]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : October 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,ANTI-PLATELET DRUGS,CARDIOPULMONARY ARREST,PERFORMANCE INDICATORS,ASPIRIN,GENERAL  / OVERVIEWS,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Post–cardiac arrest syndrome : epidemiology, pathophysiology, treatment, and prognostication : a consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Standards for measures used for public reporting of efficiency in health care : a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ACCF / ACG / AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use : a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295293</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=3062770]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : September 2008</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,SERVICE MODELS,VALVE DISORDERS,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;2008 Focused update incorporated into the ACC / AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease)&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;The American Heart Association's 2008 statement of principles for healthcare reform &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Depression and coronary heart disease - recommendations for screening, referral, and treatment : a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388619</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.americanheart.org/presenter.jhtml?identifier=9181]]&gt;</url>
    <title>American Heart Association practice guidelines and scientific statements : September 2010</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,SMOKING,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment. A Policy Statement From the American Heart Association.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Comprehensive Overview of Nursing and Interdisciplinary Rehabilitation Care of the Stroke Patient &lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83466</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://journals.elsevierhealth.com/periodicals/ymhj/current]]&gt;</url>
    <title>American Heart Journal : current issue</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Journal, Mosby</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;American Heart Journal: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not&lt;BR&gt;accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal&lt;BR&gt;articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Library.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3627</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://ajpheart.physiology.org/]]&gt;</url>
    <title>American Journal of Physiology : Heart and Circulation Physiology</title>
    <publicationDate></publicationDate>
    <publisher>American Physiological Society</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ UNSURE CARDEX,CARDIOVASCULAR DISEASES,RESOUCES THAT ARE HIDDEN BUT WE ARE HOLDING ONTO FOR NOW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;American Journal of Physiology : Heart and Circulatory Physiology publishes original investigations on the physiology of the heart, blood vessels, and lymphatics, including experimental and theoretical studies of cardiovascular function. Table of contents and abstracts available; full text documents at charge.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187384</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16904048]]&gt;</url>
    <title>An evaluation of the clinical and cost effectiveness of pulmonary artery catheters in patient management in intensive care : a systematic review and a randomised controlled trial</title>
    <publicationDate></publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,INTERVENTIONS / PROCEDURES,VALVE DISORDERS,DISEASE MANAGEMENT,INVASIVE HAEMODYNAMIC MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The aim of this review was to evaluate the clinical and cost effectiveness of managing adult critically ill patients in general intensive care, with or without pulmonary artery catheters (PACs).&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The study indicated that clinical management of critically ill patients with a pulmonary artery catheter, as currently practised in the UK, neither improves hospital survival for adult general intensive care patients, nor reduces length of stay in hospital.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Harvey S et al. An evaluation of the clinical and cost effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial. Health Technology Assessment 2006;10(29).&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394580</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f9b345]]&gt;</url>
    <title>Arteriotomy Closure Devices for Cardiovascular Procedures: AHA Scientific Statement</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,DISEASE MANAGEMENT,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To provide an overview of vascular access and patient risk for vascular complications, the available evidence for ACDs, recommendations for their use based on the available evidence, and the trials and end points needed to inform future clinical practice. The following topics are discussed:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Choice of Site and Arterial Access 
&lt;LI&gt;Femoral Access Complications With Manual Compression 
&lt;LI&gt;Patient Risk for Vascular Complications 
&lt;LI&gt;Closure Devices 
&lt;LI&gt;Recommendations Regarding ACD Use&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; October 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389097</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bhsoc.org/bhf_factfiles/BHS_Statement_on_Aspirin_January_2010.pdf]]&gt;</url>
    <title>Aspirin in primary prevention of cardiovascular disease</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>British Hypertension Society</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,ANTI-PLATELET DRUGS,ASPIRIN,SECONDARY PREVENTION,RECENT ADDITIONS,JANUARY 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a statement, from the BHS Working Party, on the use of Aspirin to prevent future cardiovascular events in those with a prior history of cardiovascular disease. It reaffirms the society’s earlier recommendations on aspirin use in the prevention of cardiovascular disease in hypertensive people. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp; &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268503</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.178458]]&gt;</url>
    <title>Assessment of coronary artery disease by cardiac computed tomography : a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology</title>
    <publicationDate>2006-10-17T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CORONARY HEART DISEASE,ELECTROCARDIOGRAM,DIAGNOSIS,ARTERIOSCLEROSIS,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&amp;nbsp;&lt;/STRONG&gt;This statement reviews the data for cardiac computed tomography (CT) in the imaging of coronary artery disease (CAD) and atherosclerosis.&lt;/P&gt;
&lt;P align=left&gt;The statement provides the following information:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Cardiac CT has undergone a rapid progression in imaging capabilities which has resulted in diagnostic capabilities sometimes&amp;nbsp;being ahead of critical evaluation of clinical application.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Cardiac CT has been demonstrated to provide quantitative measures of coronary artery calcified plaque (CACP) and noncalcified plaque (NCP). CACP indicates the presence of coronary atherosclerosis and&amp;nbsp;identifies individuals at risk of myocardial infarction (MI) and cardiovascular disease (CVD) death.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The use of cardiac CT angiography to assess lumen stenosis has the potential to alter the management of CAD significantly in symptomatic patients&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The assessment of progression of CACP and detection of nonobstructive NCP by cardiac CT angiography need further investigation.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>121165</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/08/09/81/04080981.pdf]]&gt;</url>
    <title>At least five a week : evidence on the impact of physical activity and its relationship to health</title>
    <publicationDate>2004-04-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ OBESITY,BLOOD PRESSURE,BIOLOGICAL COMPOSITION,OUTCOMES,CANCER,CIRCULATORY DISEASES,CARDIOVASCULAR DISEASES,HYPERTENSION,DIABETES,ENDOCRINE DISORDERS,MUSCULOSKELETAL DISORDERS,DEPRESSION,MENTAL &amp; BEHAVIOURAL DISORDERS,CARDIOVASCULAR DISEASES,PREVENTION,MANAGEMENT ISSUES,PHYSICAL ACTIVITY,NHS IMPROVEMENT,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,LIFESTYLE,PHYSICAL ACTIVITY,INDIVIDUAL BEHAVIOUR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents the evidence on the relationship between physical activity and health.&amp;nbsp; It is particularly aimed at public health and Primary Care Trusts (PCTs), and those concerned with formulating and implementing policies and programmes that utilise the promotion of physical activity, sport, exercise and active travel to achieve health gain.&amp;nbsp; The report sets out the latest research evidence of the benefits of physical activity for health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in April 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Full-text available in Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177190</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=15205&amp;Rendition=Web]]&gt;</url>
    <title>Atrial fibrillation - incidental / asymptomatic findings</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,ARRHYTHMIA,ECHOCARDIOGRAM,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for a patient presenting with atrial fibrillation.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156305</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=15205&amp;Rendition=Web]]&gt;</url>
    <title>Atrial fibrillation - prolonged QtC - incidental / asymptomatic finding</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for a patient presenting with prolonged QtC. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156306</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=15205&amp;Rendition=Web]]&gt;</url>
    <title>Atrial fibrillation - rationale for suggested pulse check for all individuals aged over 65 years</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,ARRHYTHMIA,ECHOCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the rationale for suggested pulse check for all individuals aged over 65 years. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182578</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=336576]]&gt;</url>
    <title>Atrial fibrillation : national clinical guideline for management in primary and secondary care</title>
    <publicationDate>2006-06-28T00:00:00</publicationDate>
    <publisher>Royal College of Physicians of London</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,ANTI-COAGULANTS,ARRHYTHMIA,ECHOCARDIOGRAM,ELECTROCARDIOGRAM,DIAGNOSIS,DISEASE MANAGEMENT,VASCULAR,DISEASE MANAGEMENT,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The guideline covers aspects of diagnosis and the management of atrial fibrillation (AF) in a number of different circumstances. It covers paroxysmal, persistent and permanent AF, considers AF developing after surgical procedures, and offers advice on haemodynamically unstable AF. Many of the recommendations relate to control of AF and the important decision of whether to attempt to restore sinus rhythm or concentrate on control of the heart rate. In a linked set of recommendations, the importance of considering anticoagulation in all these patients is emphasised.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315247</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=315247]]&gt;</url>
    <title>Atrial Fibrillation Annual Evidence Update 2009: Search Strategy</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - cardiovascular</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Atrial Fibrillation Annual Evidence Update 2009: Search Strategy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Click on the attached file to download the Atrial Fibrillation Annual Evidence Update 2008 search strategy.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Link &lt;A href="http://www.library.nhs.uk/cardiovascular/viewResource.aspx?resid=314789&amp;amp;code=23586c360c429153fd7ce2c41cedda09" target="_blank"&gt;here&lt;/A&gt; to the 2009 Annual Evidence Update on Atrial Fibrillation:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>343925</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=%2bLIKN1gSgOA%3d&amp;tabid=62]]&gt;</url>
    <title>Atrial fibrillation in primary care: making an impact on stroke prevention</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,ARRHYTHMIA,NHS IMPROVEMENT,GENERAL  / OVERVIEWS,STROKE,ISCHAEMIC STROKE,DISEASE MANAGEMENT,PREVENTION,HAEMORRHAGIC STROKE,PREVENTION,PREVENTION,GENERAL / OTHER,INNOVATION AND IMPROVEMENT,CHANGE MANAGEMENT,LEADING IMPROVEMENT,SAFER CARE,JAN-MAR 10,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;FONT face=Frutiger-Light color=#4f4f50 size=2&gt;&lt;/P&gt;
&lt;P align=left&gt;These national priority projects were established in 2007 in response to Chapter Eight of the National Framework for Coronary Heart Disease; Arrhythmias and Sudden Cardiac Death, published in March 2005, which set out the quality requirements for the prevention and treatment of patients with cardiac arrhythmias.&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>374030</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bacreducation.co.uk/]]&gt;</url>
    <title>BACR Education &amp; Training Website</title>
    <publicationDate></publicationDate>
    <publisher>British Association for Cardiac Rehabilitation (BACR)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,PREVENTION,CARDIAC REHABILITATION,RECENT ADDITIONS,APR-JUNE 10,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The BACR Exercise Instructor training is aimed at exercise professionals who are looking to develop their knowledge in safe and effective exercise programming for individuals with cardiac disease.]]&gt;</body>
  </document>
  <document>
    <id>287714</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bcs.com/documents/affiliates/bacr/BACR%20Standards%202007.pdf]]&gt;</url>
    <title>BACR standards and core components for cardiac rehabilitation 2007</title>
    <publicationDate></publicationDate>
    <publisher>British Association for Cardiac Rehabilitation (BACR)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,PREVENTION,CARDIAC REHABILITATION,SECONDARY PREVENTION,APR-JUNE 08,CARDIOVASCULAR DISEASES,PREVENTION,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,DISEASE MANAGEMENT,CONDITIONS,GENERAL,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Document defines minimum standards and core components for cardiac rehabilitation (CR) services. The minimum standards relate to the infrastructure to support CR and the contents of a programme are defined by the recommended core components.&amp;nbsp; Includes appendices.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;This resource has been listed in the ‘Cardiac Rehabilitation Annual Evidence Update 2008' and has been selected for inclusion in the CVDSL.&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70241</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/Extraforbando/Bias.pdf]]&gt;</url>
    <title>Bandolier guide to bias</title>
    <publicationDate>2001-12-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,ENT AND AUDIOLOGY,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,LITERATURE APPRAISAL,EVIDENCE BASED PRACTICE RESOURCES,LITERATURE APPRAISAL GUIDES,KIDNEY DISEASES,MALE UROGENITAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier reference guide concludes that the presence and existence of bias in so many forms makes it necessary to be vigilant when reading clinical trials. 
&lt;P&gt;An educational, reference tool designed for health professionals, which&amp;nbsp;can be used when examining a systematic review or a single clinical trial. 
&lt;P&gt;This guide includes: 
&lt;UL&gt;
&lt;LI&gt;a definition of bias 
&lt;LI&gt;different forms of bias (such as publication bias, validity, size of trial and data manipulation) 
&lt;LI&gt;ways of introducing or preventing bias (e.g. blinding and randomisation)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;Tables and graphs are used to illustrate points. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3596</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://springerlink.metapress.com/content/0300-8428/]]&gt;</url>
    <title>Basic research in cardiology : Official Journal of the German Cardiac Society</title>
    <publicationDate></publicationDate>
    <publisher>Springer-Verlag London Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This journal publishes original reports and review articles on all aspects related to the physiology and pathology of the structure and function of the heart and the cardiovascular system. Subjects covered include molecular and cellular biology, biochemistry, biophysics, pharmacology, physiology, pathology and clinical cardiology.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full-text online access requires subscription to the journal. NHS staff please &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343251</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/big-hips-thighs-bum-healthy-for-women.aspx]]&gt;</url>
    <title>Behind the Headlines - A big bottom 'is good for the heart'</title>
    <publicationDate>2010-01-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,JANUARY 2010,JAN-MAR 10,PREVENTION,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,GENERAL,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Having a big bottom is good for you,” according to The Sun. Several newspapers have reported similar stories based on a research article that suggests that it is better for body fat to be stored around the hips, thighs and bottom than around the waist.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having a big bottom is good for you,” according to &lt;EM&gt;The Sun.&lt;/EM&gt; Several newspapers have reported similar stories based on a research article that suggests that it is better for body fat to be stored around the hips, thighs and bottom than around the waist.&lt;/P&gt;
&lt;P&gt;The research article draws on various other studies to support its argument that the risks of cardiovascular and metabolic diseases are lower in people who store fat in their lower bodies. However, the purpose of the review was to use selected research to justify further research into this relatively unknown association, and not to look at all the research on the subject. As such, the piece may have omitted research contradicting the authors’ theory. Much further research is needed to understand how the chemicals&amp;nbsp;and hormones involved in fat storage have an effect on cardiovascular diseases.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a non-systematic, narrative review that highlighted selected research that supports the authors'&amp;nbsp;theory that the way in which different fat stores are regulated may have implications for disease.&lt;/P&gt;
&lt;P&gt;This type of review is useful for arguing that a particular theory may warrant further research by presenting areas where further study may prove beneficial. However, while this review suggests an association between gluteofemoral fat stores and decreased disease, this area would benefit from a systematic review assessing the full range of data available. While the theory presented is of interest, extensive research is needed to determine the mechanisms underlying this proposed effect.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01january/pages/big-hips-thighs-bum-healthy-for-women.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Manolopoulos KN, Karpe F and Frayn KN. &lt;A href="http://www.nature.com/ijo/journal/vaop/ncurrent/abs/ijo2009286a.html" target="_blank"&gt;Gluteofemoral body fat as a determinant of metabolic health&lt;/A&gt;. &lt;EM&gt;International Journal of Obesity&lt;/EM&gt;, [Advance online publication] January 12 2010 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380243</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/tea-and-coffee-good-for-heart.aspx]]&gt;</url>
    <title>Behind the headlines - A hearty cup of tea?</title>
    <publicationDate>2010-06-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE,CAUSES AND RISK FACTORS,GENERAL  / OVERVIEWS,RECENT ADDITIONS,JULY 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“People who drink several cups of tea or coffee a day could be at lower risk of heart disease,” reports the BBC. The news channel says drinking tea could cut the chances of a heart attack by up to a third.

The news is based on a Dutch study that followed 38,000 people for over a decade, looking at their risk of stroke, cardiovascular incidents and death. When examining the association between coffee consumption and events relating to heart disease, the study found that drinking moderate amounts of coffee (two to three cups a day) was better than a little or a lot. With tea, drinking more than six cups a day was linked to the lowest risk.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;“People who drink several cups of tea or coffee a day could be at lower risk of heart disease,” reports the BBC. The news channel says drinking tea could cut the chances of a heart attack by up to a third.&lt;/P&gt;
&lt;P&gt;The news is based on a Dutch study that followed 38,000 people for over a decade, looking at their risk of stroke, cardiovascular incidents and death. When examining the association between coffee consumption and events relating to heart disease, the study found that drinking moderate amounts of coffee (two to three cups a day) was better than a little or a lot. With tea, drinking more than six cups a day was linked to the lowest risk.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large cohort study with a long follow-up time has found an association between some levels of tea and coffee consumption and reduced risk of coronary heart disease events.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/06June/Pages/tea-and-coffee-good-for-heart.aspxhttp://" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;de Koning Gans JM, Uiterwaal CSPM ; van der Schouw YT et al. &lt;A href="http://atvb.ahajournals.org/cgi/content/abstract/ATVBAHA.109.201939" target="_blank"&gt;Tea and Coffee Consumption and Cardiovascular Morbidity and Mortality&lt;/A&gt;. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>391928</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/aircraft-noise-and-heart-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Aircraft noise and heart risk studied</title>
    <publicationDate>2010-10-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Living under a flight path ‘can increase your risk of heart attack’,” reported the Daily Mail. It said, “constant noise from roaring engines can increase the risk by at least 30%”. This Swiss study looked for an association between aeroplane noise, air pollution and the risk of death from heart attack.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Living under a flight path ‘can increase your risk of heart attack’,” reported the &lt;EM&gt;Daily Mail&lt;/EM&gt;. It said, “constant noise from roaring engines can increase the risk by at least 30%”. This Swiss study looked for an association between aeroplane noise, air pollution and the risk of death from heart attack.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers found that there was a small increased risk of heart attack in people who had been exposed to aeroplane noise of more than 60 decibels for 15 years. However, it should be emphasised that this result was of only borderline statistical significance. Aeroplane noise had no influence on the risk of dying from any other cause.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/10October/Pages/aircraft-noise-and-heart-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Huss, A, Spoerri A, Egger M, et al.&amp;nbsp;&lt;A href="http://journals.lww.com/epidem/Abstract/2010/11000/Aircraft_Noise,_Air_Pollution,_and_Mortality_From.13.aspx" target="_blank"&gt;Aircraft Noise, Air Pollution, and Mortality From Myocardial Infarction.&lt;/A&gt; Epidemiology 2010, 21: 829 - 836&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388070</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/dash-diet-reduce-heart-attack-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Balanced diet cuts heart risk</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,DIET,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,PREVENTION,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A diet combining fruit and vegetables with foods such as fish, poultry and nuts “can protect you against heart attack”, reported The Independent.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A diet combining fruit and vegetables with foods such as fish, poultry and nuts “can protect you against heart attack”, reported &lt;EM&gt;The Independent.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news is based on a well-conducted trial which tested the DASH diet, a diet high in fruit and vegetables but low in saturated fat that is recommended by the US government.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted trial benefits from its relatively large size, accurate provision of the three randomised diets and high study completion rates (95%). It also featured a reliable study outcome by using the average of a series of blood pressure measures, which is preferable to relying on a single blood pressure reading.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/dash-diet-reduce-heart-attack-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Chen ST, Maruthur NM, Appel LJ. &lt;A href="http://circoutcomes.ahajournals.org/cgi/content/abstract/CIRCOUTCOMES.109.930685" target="_blank"&gt;The Effect of Dietary Patterns on Estimated Coronary Heart Disease Risk: Results from the Dietary Approaches to Stop Hypertension (DASH) Trial&lt;/A&gt;. &lt;EM&gt;Circulation: Cardiovascular Quality and Outcomes&lt;/EM&gt;. August 31 2010 (published online before print) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380248</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Beetroot-juice-and-blood-pressure.aspx]]&gt;</url>
    <title>Behind the headlines - Beetroot juice for blood pressure</title>
    <publicationDate>2010-07-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,DIET,HYPERTENSION,CAUSES AND RISK FACTORS,STROKE,ISCHAEMIC STROKE,CAUSES / RISK FACTORS,PREVENTION,HAEMORRHAGIC STROKE,CAUSES / RISK FACTORS,PREVENTION,CAUSES / RISK FACTORS,DIET,PREVENTION,DIET,GENERAL / OTHER,RECENT ADDITIONS,RECENT ADDITIONS,JULY 2010,JULY 2010,JUL-SEPT 10,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Beetroot juice “could save your life” claimed the Daily Mail. It said that the juice contains nitrate, a chemical that reduces blood pressure and therefore cuts the risk of heart disease and stroke.

The research behind this story aimed to look at whether nitrates may be responsible for the blood pressure-lowering effects of beetroot juice. It found that drinking beetroot juice or taking nitrate capsules resulted in short-term reductions in blood pressure in healthy volunteers with normal blood pressure.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;Beetroot juice “could save your life” claimed the &lt;EM&gt;Daily Mail.&lt;/EM&gt; It said that the juice contains nitrate, a chemical that reduces blood pressure and therefore cuts the risk of heart disease and stroke.&lt;/P&gt;
&lt;P&gt;The research behind this story aimed to look at whether nitrates may be responsible for the blood pressure-lowering effects of beetroot juice. It found that drinking beetroot juice or taking nitrate capsules resulted in short-term reductions in blood pressure in healthy volunteers with normal blood pressure.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study has shown some reduction in blood pressure with beetroot juice. This finding needs cautious interpretation however, as the study has several features that limit the conclusions that can be drawn from it. These include the fact that it was in only a small number of people (nine who drank beetroot juice) and that all participants were healthy and had normal blood pressure. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Beetroot-juice-and-blood-pressure.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kapil V, Milsom AB, Okorie M, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://hyper.ahajournals.org/cgi/content/abstract/HYPERTENSIONAHA.110.153536v1" target="_blank"&gt;Inorganic Nitrate Supplementation Lowers Blood Pressure in Humans. Role for Nitrite-Derived NO.&lt;/A&gt; Hypertension 2010, published online June 28&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>393840</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/benefits-of-statins-explored.aspx]]&gt;</url>
    <title>Behind the Headlines - Benefits of statins explored</title>
    <publicationDate>2010-11-09T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,LIPID-REGULATING DRUGS,LIPIDS MANAGEMENT,STATINS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,STROKE,ISCHAEMIC STROKE,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,RECENT ADDITIONS,RECENT ADDITIONS,NOVEMBER 2010,NOVEMBER 2010,OCT-DEC 2010,OCT-DEC 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Thousands of deaths could be prevented a year if people at risk of heart attack or stroke are prescribed more powerful statins,” the Daily Mail reported. The newspaper said that intensive use of statins lowers cholesterol levels even further than standard therapy, cutting the risk of heart attack and stroke by a further 15%</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Thousands of deaths could be prevented a year if people at risk of heart attack or stroke are prescribed more powerful statins,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; reported. The newspaper said that intensive use of statins lowers cholesterol levels even further than standard therapy, cutting the risk of heart attack and stroke by a further 15%.&lt;/P&gt;
&lt;P&gt;The news report is based on a large meta-analysis of recent studies looking at the effectiveness of statins. A major strength is its size, involving data from 170,000 patients in 26 randomised trials, and this indicates that the results are probably reliable. It is important to point out that this research applies only to people at high risk of heart disease and stroke.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an important study. It shows that among high-risk patients, lowering LDL cholesterol with high dose statin therapy reduces the risk of adverse outcomes such as heart attack and stroke more than standard statin treatment. The reduction in risk is in direct relation to the reduction in cholesterol levels.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/benefits-of-statins-explored.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60310-8/abstract" target="_blank"&gt;Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.&lt;/A&gt;&amp;nbsp;The Lancet, Published Online November 9&lt;/P&gt;
&lt;P&gt;Cholesterol Treatment Trialists’ (CTT) Collaboration.&amp;nbsp;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/abstract" target="_blank"&gt;Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants n 26 randomised trials.&lt;/A&gt; The Lancet 2010, Published Online November 9&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392742</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/skipping-breakfas-heart-disease-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Breakfast and heart disease</title>
    <publicationDate>2010-11-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIET,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Skipping breakfast too often can put you at risk of heart disease,” the Daily Mail has reported. The newspaper says that this may be because people who skip breakfast are more likely to have poorer diets and take less exercise.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Skipping breakfast too often can put you at risk of heart disease,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; has reported. The newspaper says that this may be because people who skip breakfast are more likely to have poorer diets and take less exercise.&lt;/P&gt;
&lt;P&gt;Contrary to the newspaper headline, this study did not look at heart disease. Instead, it looked at the link between skipping breakfast as a child and as an adult, and certain risk factors that may be associated with heart disease, such as waist circumference and levels of cholesterol in the blood.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests a link between skipping breakfast and cardiometabolic risk factors, such as larger waist circumference and higher levels of cholesterol.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/skipping-breakfas-heart-disease-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Smith KJ, Gall SL, McNaughton SA &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.ajcn.org/cgi/content/abstract/ajcn.2010.30101v1" target="_blank"&gt;Skipping breakfast: longitudinal associations with cardiometabolic risk factors in the Childhood Determinants of Adult Health Study&lt;/A&gt;. &lt;EM&gt;American Journal of Clinical Nutrition&lt;/EM&gt;, [Published online ahead of print] October 6 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380249</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/television-predicts-heart-death-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Can the World Cup kill? Unlikely...</title>
    <publicationDate>2010-06-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,GENERAL,CAUSES AND RISK FACTORS,STROKE,ISCHAEMIC STROKE,CAUSES / RISK FACTORS,HAEMORRHAGIC STROKE,CAUSES / RISK FACTORS,CAUSES / RISK FACTORS,GENERAL,RECENT ADDITIONS,RECENT ADDITIONS,JULY 2010,JULY 2010,JUL-SEPT 10,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Watching the World Cup on TV could kill you,” according to the &lt;EM&gt;Daily Express.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news story is based on a study that followed over 13,000 adults (average age 61) for almost 10 years to see how their level of TV viewing was associated with their risk of death. After adjusting for various&amp;nbsp;lifestyle factors that could affect the relationship, the reseachers calculated that each extra hour&amp;nbsp;of TV&amp;nbsp;viewing a day raised the risk of dying from any cause by 4% and of death from cardiovascular disease by 6%. However, a further analysis suggests that greater body fat among those watching more TV may explain these increases.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large cohort study of over 13,000 people has found that greater TV viewing is associated with a slight increase in risk of death from any cause over an almost 10-year follow-up. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/television-predicts-heart-death-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wijndaele K, Brage S, Besson H &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://ije.oxfordjournals.org/cgi/content/abstract/dyq105" target="_blank"&gt;Television viewing time independently predicts all-cause and cardiovascular mortality: the EPIC Norfolk Study&lt;/A&gt;. &lt;EM&gt;International Journal of Epidemiology&lt;/EM&gt;, June 23 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>343876</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Coffee-and-blood-flow.aspx]]&gt;</url>
    <title>Behind the headlines - Coffee and blood flow</title>
    <publicationDate>2010-02-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,DIET,HEART FAILURE,CAUSES AND RISK FACTORS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A “single espresso a day ‘can damage the heart,’” The Daily Telegraph reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A&amp;nbsp;“single espresso a day ‘can damage the heart,’” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. It said a study has found that one cup is enough to reduce blood flow to the heart by 22% within an hour of being drunk.&lt;/P&gt;
&lt;P&gt;Though this research&amp;nbsp;found that a group of volunteers had raised blood pressure and slightly constricted arteries an hour after drinking caffeinated coffee,&amp;nbsp;the actual effect was modest and unlikely to have any adverse health effects. It is normal for&amp;nbsp;arteries to dilate and constrict throughout the day, with exercise for example.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study looked at how drinking a cup of caffeinated espresso affected arterial blood pressure and blood flow up to an hour afterwards. Although caffeinated espresso did appear to alter measurements of these compared to decaffeinated espresso, the researchers did not assess whether these changes persisted beyond an hour or how long it would take for blood pressure and blood flow to return to normal. The changes seen in systolic and diastolic blood pressure were only minimal, and it is unlikely that these small changes alone would have any health effects.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/02February/Pages/Coffee-and-blood-flow.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Buscemi S, Verga S, Batsis JA, et al.&amp;nbsp;&lt;A href="http://www.nature.com/ejcn/journal/vaop/ncurrent/abs/ejcn20109a.html" target="_blank"&gt;Acute effects of coffee on endothelial function in healthy subjects.&lt;/A&gt; European Journal of Clinical Nutrition advance online publication 2010. February 3&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>391850</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/CPR-technique-scrutinized.aspx]]&gt;</url>
    <title>Behind the Headlines - CPR technique scrutinised</title>
    <publicationDate>2010-10-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Several newspapers have today reported on resuscitation techniques after a new study analysed survival rates using the two main approaches. The Daily Telegraph suggested we should “skip the kiss” when giving the kiss of life, while BBC News emphasised that the study “backs chest compressions in resuscitation”.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;Several newspapers have today reported on resuscitation techniques after a new study analysed survival rates using the two main approaches. &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; suggested we should “skip the kiss” when giving the kiss of life, while BBC News emphasised that the study “backs chest compressions in resuscitation”.&lt;/P&gt;
&lt;P&gt;The new study, which does not constitute official guidance, examined a form of CPR (cardiopulmonary resuscitation) that uses chest compressions but not breathing into the mouth. This is known as 'compression-only CPR'. It compared this technique to the standard, 'mouth-to-mouth' CPR&amp;nbsp; in the specific setting of resuscitation for heart attacks outside of a hospital setting guided by emergency service personnel. Crucially, this means that the findings of this study only apply in these specific settings where bystanders are instructed by trained dispatchers in which technique to use.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an important study, and the researchers note that the best CPR technique for survival is a ‘controversial issue’ that has been discussed intensively over the past few years. They say that uninterrupted, high-quality chest compression is very important for successful CPR, and that these considerations were the reason why the 2005 resuscitation guidelines increased the recommended compressions-to-ventilations ratio (i.e. number of chest compressions in relation to number of rescue breaths) from 15:2 to 30:2.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/CPR-technique-scrutinized.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Hüpfl M, Selig HF, Nagele P &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61454-7/fulltext" target="_blank"&gt;Chest-compression-only versus standard cardiopulmonary resuscitation: a meta-analysis.&lt;/A&gt; &lt;EM&gt;The Lancet&lt;/EM&gt; 2010, Early Online Publication, October 15&lt;/P&gt;
&lt;P&gt;Nolan JP, Soar J. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61857-0/fulltext" target="_blank"&gt;Dispatcher-assisted bystander CPR: a KISS for a kiss.&lt;/A&gt; &lt;EM&gt;The Lancet&lt;/EM&gt; 2010, Early Online Publication, October 15&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345168</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Daily-aspirin.aspx]]&gt;</url>
    <title>Behind the Headlines - Daily aspirin not for the healthy</title>
    <publicationDate>2010-03-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES / RISK FACTORS,GENERAL,CAUSES / RISK FACTORS,GENERAL / OVERVIEWS,DISEASE MANAGEMENT,ANTI-PLATELET DRUGS,ASPIRIN,DISEASE MANAGEMENT,ANTI-PLATELET DRUGS,CONDITIONS,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,GENERAL,HEART FAILURE,CAUSES AND RISK FACTORS,ASPIRIN,ISCHAEMIC STROKE,CAUSES / RISK FACTORS,GENERAL / OVERVIEWS,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,STROKE,MARCH 2010,RECENT ADDITIONS,JAN-MAR 10,JAN-MAR 10,JAN-MAR 10,RECENT ADDITIONS,RECENT ADDITIONS,MARCH 2010,MARCH 2010,CAUSES &amp; RISK FACTORS,GENERAL,DISEASE MANAGEMENT,ASPIRIN,ANTI-PLATELET DRUGS,VASCULAR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Healthy people who take aspirin in the hope of preventing a heart attack or stroke are doing themselves more harm than good,” The Daily Telegraph reported. It said that healthy people who take a low dose of daily aspirin to reduce their risk of a heart attack are also increasing their likelihood of major internal bleeding.

The news is based on a study in almost 30,000 men and women aged between 50 and 75 without known heart disease. It found that taking 100mg aspirin daily almost doubled the risk of dangerous internal bleeding compared to dummy pills (placebo), while having no effect on heart attacks or strokes.
</description>
    <body>&lt;![CDATA[ &lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;
&lt;P&gt;“Healthy people who take aspirin in the hope of preventing a heart attack or stroke are doing themselves more harm than good,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. It said that healthy people who take a low dose of daily aspirin to reduce their risk of a heart attack are also increasing their likelihood of major internal bleeding.&lt;/P&gt;
&lt;P&gt;The news is based on a study in almost 30,000 men and women aged between 50 and 75 without known heart disease. It found that taking 100mg aspirin daily almost doubled the risk of dangerous internal bleeding compared to dummy pills (placebo), while having no effect on heart attacks or strokes.&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This trial has tried to answer an important question regarding who should be given aspirin to prevent a heart attack or stroke. It used a systematic method to screen people and followed a reasonably large group of patients for up to 10 years in some cases. The finding of “no statistical significance” can be an important result, and in this case suggests that any benefits from taking aspirin for this group of people are likely to be small. The risk of bleeding was also small and not technically of statistical significant.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/03March/Pages/Daily-aspirin.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Fowkes FGR, Price JF, Stewart MCW, et al.&amp;nbsp;&lt;A href="http://jama.ama-assn.org/cgi/content/short/303/9/841" target="_blank"&gt;Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index&lt;/A&gt;. JAMA 2010; 303: 841-848&lt;/P&gt;
&lt;P&gt;Editorial&lt;/P&gt;
&lt;P&gt;&lt;A href="http://jama.ama-assn.org/cgi/content/full/303/9/880" target="_blank"&gt;Berger JS. Aspirin as Preventive Therapy in Patients With Asymptomatic Vascular Disease.&lt;/A&gt;&amp;nbsp;JAMA 2010; 303: 880-882&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388480</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/Chilli-blood-pressure-link.aspx]]&gt;</url>
    <title>Behind the Headlines - Do chillies lower blood pressure?</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HYPERTENSION,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Curry could save your life,” reports the Daily Star. It said that “chilli-laden dishes such as vindaloo or phall might appear to cause the brave eater to tense up, but they make blood vessels relax”.This “lowers blood pressure, reducing the risk of deadly heart attacks”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Curry could save your life,” reports the &lt;EM&gt;Daily Star.&lt;/EM&gt; It said that “chilli-laden dishes such as vindaloo or phall might appear to cause the brave eater to tense up, but they make blood vessels relax”.This “lowers blood pressure, reducing the risk of deadly heart attacks”.&lt;/P&gt;
&lt;P&gt;Contrary to the impression created by this news, the study in question only looked at the effects of capsaicin (the chemical that makes chillies hot) on the blood vessels of rats and mice, not humans. No investigation was made of&amp;nbsp;humans eating chillies and their risk of high blood pressure, heart disease or death.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study found that in rats with high blood pressure eating a diet containing capsaicin over a period of months reduced their blood pressure. At this stage, it is not possible to say whether a similar effect would be seen in humans. The researchers report that another study has found that eating hot chillies causes a temporary increase in blood pressure in humans, but that the longer-term effects are not known. Until more research is done, people with high blood pressure should not try substituting their blood pressure medication with chillies.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/Chilli-blood-pressure-link.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yang D, Luo Z, Ma S &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.cell.com/cell-metabolism/abstract/S1550-4131(10)00228-7" target="_blank"&gt;Activation of TRPV1 by Dietary Capsaicin Improves Endothelium-Dependent Vasorelaxation and Prevents Hypertension.&lt;/A&gt; &lt;EM&gt;Cell Metabolism&lt;/EM&gt; 2010; 12; 130-141&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388081</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/chocolate-and-heart-failure-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Does chocolate cut heart risk?</title>
    <publicationDate>2010-08-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,DIET,HEART FAILURE,CAUSES AND RISK FACTORS,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Eating just two small bits of chocolate a week can cut the risk of heart failure by up to a third,” according to an article in&amp;nbsp;the &lt;EM&gt;Daily Express&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;The news story is based on a study of whether chocolate affects the risk of heart failure in elderly and middle-aged women. Women who ate moderate amounts of chocolate (one-to-two servings a week or one-to-three servings a month) were found to be at lower risk of heart failure. This association was not found in women who ate three or more servings a week.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has strengths in its large size and that it had a relatively long follow-up period. However, it has several limitations, some of which are noted by the researchers.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/chocolate-and-heart-failure-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mostofsky E, Levitan EB, Wolk A, et al. &lt;A href="http://circheartfailure.ahajournals.org/cgi/content/abstract/CIRCHEARTFAILURE.110.944025v1" target="_blank"&gt;Chocolate Intake and Incidence of Heart Failure: A Population-Based, Prospective Study of Middle-Aged and Elderly Women.&lt;/A&gt; Circulation: Heart failure 2010; Published online before print August 16&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>391871</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/drinking-tea-protect-the-heart.aspx]]&gt;</url>
    <title>Behind the Headlines - Does tea boost the heart?</title>
    <publicationDate>2010-10-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIET,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Two cups of tea a day cuts heart disease,” the Daily Express has reported. The newspaper says that tea contains “health boosting flavonoids” that can reduce the risk of heart disease by 11%.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Two cups of tea a day cuts heart disease,” the &lt;EM&gt;Daily Express&lt;/EM&gt; has reported. The newspaper says that tea contains “health boosting flavonoids” that can reduce the risk of heart disease by 11%.&lt;/P&gt;
&lt;P&gt;The news is based on a study examining a selection of research on the potential heart benefits of both green and black tea. It concludes that regular consumption of any type of tea is likely to reduce the risk of cardiovascular disease, probably due to levels of substances called flavonoids that are found in tea. The authors suggest that the reduction in risk is the result of actions such as preventing clogging of the arteries and improving body weight.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This review summarises a selection of the existing evidence on the associations between tea and aspects of cardiovascular health. It is not clear whether researchers included all the available evidence, how they selected their studies, or whether any other evidence came to similar conclusions.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/drinking-tea-protect-the-heart.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Hodgson JM, Croft KD &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T9P-511G1SP-4&amp;amp;_user=10&amp;amp;_coverDate=09/15/2010&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_origin=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_searchStrId=1497768483&amp;amp;_rerunOrigin=google&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=" target="_blank"&gt;Tea flavonoids and cardiovascular health&lt;/A&gt;. &lt;EM&gt;Molecular Aspects of Medicine&lt;/EM&gt;, [published online]. September 15 2010.&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388079</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/kidneys-from-heart-deaths-good-for-transplant.aspx]]&gt;</url>
    <title>Behind the Headlines - Donor kidneys from heart deaths 'usable'</title>
    <publicationDate>2010-08-19T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Hundreds of lives a year will be saved if the NHS embraces a transplant revolution involving patients receiving donated kidneys that were previously rejected as inadequate,” &lt;EM&gt;The Guardian&lt;/EM&gt; reported. It said that a new study has given kidneys from people who have died from major heart failure following severe brain injury a “clean bill of health for donation”.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-designed study was rigorously carried out and its findings have important implications for the future of kidney transplant service and the way kidneys are allocated.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/kidneys-from-heart-deaths-good-for-transplant.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Summers DM,&amp;nbsp; Johnson RJ, Allen J &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60827-6/fulltext" target="_blank"&gt;Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study.&lt;/A&gt; &lt;EM&gt;The Lancet 2010&lt;/EM&gt;, Early Online Publication, August 19 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388422</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/getting-flu-jab-cuts-heart-attack-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Flu jab may cut heart attacks</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The winter flu jab may prevent heart attacks,” reported &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; The newspaper said that having a seasonal flu jab may reduce the risk of a heart attack by one-fifth.&lt;/P&gt;
&lt;P&gt;The story is based on research that analysed data on 79,000 UK patients. The study compared rates of heart attacks in people given the flu vaccine with those in people who were not vaccinated. Researchers say that the flu vaccination was associated with a 19% lower rate of heart attacks, which may be due to the jab preventing chest infections that lead to heart attacks.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large, well-conducted study suggests that the annual flu vaccine may protect against heart attacks, even in people without known risk factors for heart disease. The researchers minimised the possibility of bias by including all cases of heart attack within a given time period, carefully matching them to controls and only including patients who had at least five years’ up-to-date information on the database. They also adjusted their findings for important confounders. Additionally, the size of this study means that its results are more likely to be reliable.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/getting-flu-jab-cuts-heart-attack-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Siriwardena AN, Gwini SM, Coupland CAC. &lt;A href="http://www.cmaj.ca/cgi/content/abstract/cmaj.091891v1" target="_blank"&gt;Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study&lt;/A&gt;. &lt;EM&gt;Canadian Medical Association Journal&lt;/EM&gt;, September 20 2010 (published online ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>343254</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/football-heart-health-get-fit.aspx]]&gt;</url>
    <title>Behind the Headlines - Football for fighting fat</title>
    <publicationDate>2010-02-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010,CARDIOVASCULAR DISEASES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Playing football is better for your health ‘than going for a run or lifting weights,’” according to The Daily Telegraph.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Playing football is better for your health ‘than going for a run or lifting weights,’” according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news is based on research that compared how football and running affected the health of people with slightly raised blood pressure. The study followed men for 12 weeks as they either played football or ran on a treadmill. The results show that regular sessions of either exercise were beneficial for fitness, weight loss and building muscle.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a very small study that showed that both football and running improved fitness over a 12-week period, by reducing body fat and improving lung function. However, while &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; suggested that the footballers saw their blood pressure fall by an average of twice as much as the runners, this is misleading. The researchers did not find a statistically significant difference in the blood pressure reduction seen between the groups.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Knoepfli-Lenzin C, Sennhauser C, Toigo M &lt;EM&gt;et al. &lt;/EM&gt;&lt;A href="http://www3.interscience.wiley.com/journal/123271536/abstract" target="_blank"&gt;Effects of a 12-week intervention period with football and running for habitually active men with mild hypertension&lt;/A&gt;. &lt;EM&gt;Scandinavian Journal of Medicine &amp;amp; Science in Sports.&lt;/EM&gt; [Published online] February 2 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>377893</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Gout-drug-for-treating-angina.aspx]]&gt;</url>
    <title>Behind the headlines - Gout drug relieves angina</title>
    <publicationDate>2010-06-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CHEST PAIN,DISEASE MANAGEMENT,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,DISEASE MANAGEMENT,STABLE ANGINA,GENERAL/OTHER,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A drug commonly used to treat gout can also relieve angina,” BBC News reported. It said that, although effective drugs for angina already exist, allopurinol could be a cheaper option.&lt;/P&gt;
&lt;P&gt;This study looked at the effects of allopurinol in 65 people with stable angina – a condition where chest pain or discomfort occurs during exercise or stress. It found that, after taking the drug for six weeks, participants could exercise for about 58 seconds longer on average and experienced chest pain about 38 seconds later than after six weeks of taking 'dummy’ pills. Based on this study, it is not possible to say how allopurinol compares to other anti-angina drugs.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study had a good design, and its results suggest that allopurinol may increase exercise tolerance in people with stable angina.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Gout-drug-for-treating-angina.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Noman A,&amp;nbsp; Ang DSC, Ogston S, et al.&amp;nbsp;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60391-1/fulltext" target="_blank"&gt;Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial&lt;/A&gt;. &lt;EM&gt;The Lancet&lt;/EM&gt; 2010; Early Online Publication, 8 June&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>344236</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Happy-people-healthy-hearts.aspx]]&gt;</url>
    <title>Behind the Headlines - Happy people, healthy hearts?</title>
    <publicationDate>2010-02-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,GENERAL,CAUSES AND RISK FACTORS,GENERAL  / OVERVIEWS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Being happy is a great way to keep your heart healthy,” reported the &lt;EM&gt;Daily Express&lt;/EM&gt;. The newspaper quoted doctors who said that&amp;nbsp;we should all have more fun to help avoid heart attacks. &lt;/P&gt;
&lt;P&gt;The 10-year study assessed a range of symptoms, such as depression, hostility and&amp;nbsp;anxiety, in almost 2,000 men and women. The participants were recorded in videotaped interviews and scored on their joy, happiness, excitement and contentment on a five-point happiness scale. For each point higher up the scale a person was placed, their risk of developing heart disease dropped by 22%.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study tested a theory that many people already accept without any strong evidence: that being happy is good for the heart. This research appears to show a link between happiness and heart disease, at least in the context of recorded interviews as an assessment of happiness.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02February/Pages/Happy-people-healthy-hearts.aspx" target="_blank"&gt;NHS Choices Commentary&lt;/A&gt; on this news item.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Davidson KW, Mostofsky E and Whang W.&amp;nbsp;&lt;A href="http://eurheartj.oxfordjournals.org/cgi/content/abstract/ehp603v1" target="_blank"&gt;Don't worry, be happy: positive affect and reduced 10-year incident coronary heart disease: The Canadian Nova Scotia Health Survey.&lt;/A&gt; &lt;EM&gt;European Heart Journal&lt;/EM&gt; February 17 2010 (advance access published online) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>377888</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Heart-attacks-fall-after-smoking-ban.aspx]]&gt;</url>
    <title>Behind the headlines - Heart attacks fall after smoking ban</title>
    <publicationDate>2010-06-09T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,SMOKING,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>"Heart attack hospital admissions have fallen since the smoking ban,” reported The Times. This news is based on a study on the rates of hospital admissions for heart attacks before and after the smoking ban was introduced in England on July 1 2007. Researchers estimated a 2.4% reduction in heart attack emergency admissions to hospital (or 1,200 fewer admissions) in the 12 months following the ban.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Heart attack hospital admissions have fallen since the smoking ban,” reported &lt;EM&gt;The Times&lt;/EM&gt;. This news is based on a study on the rates of hospital admissions for heart attacks before and after the smoking ban was introduced in England on July 1 2007. Researchers estimated a 2.4% reduction in heart attack emergency admissions to hospital (or 1,200 fewer admissions) in the 12 months following the ban.&lt;/P&gt;
&lt;P&gt;This well-conducted study shows a clear association between the smoking ban and a decreased rate of hospital admissions for heart attack. As the study did not look at smoking status or people’s exposure to second-hand smoke before the ban, it is not possible to say how much of the decline is due to less exposure to second-hand smoke and how much is due to people giving up smoking. Further research that assesses the ban’s long-term impact and its effect on other diseases is warranted.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study showed that the rates of hospital heart attacks have been falling since 2000, and that since the smoking ban the rates have fallen by an estimated additional 2.4%. The researchers suggest that this may be due to the general population being exposed to less second-hand smoke since the legislation came in.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Heart-attacks-fall-after-smoking-ban.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sims M, Maxwell R, Bauld L, Gilmore A.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/abstract/340/jun08_1/c2161" target="_blank"&gt;Short term impact of smoke-free legislation in England: retrospective analysis of hospital admissions for myocardial infarction&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010;340:c2161&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388073</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/ivabradine-pill-chronic-heart-failure.aspx]]&gt;</url>
    <title>Behind the Headlines - Heart failure pill performs in trial</title>
    <publicationDate>2010-08-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,GENERAL,HEART FAILURE,DISEASE MANAGEMENT,PREVENTION,GENERAL/OTHER,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The lives of 10,000 patients could be saved each year by a “breakthrough pill”, according to the Daily Express.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;The lives of 10,000 patients could be saved each year by a “breakthrough pill”, according to the &lt;EM&gt;Daily Express.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news story comes from a study that looked at whether a drug called ivabradine could help prevent deaths or hospital admissions due to chronic heart failure. This relatively common condition occurs when the heart is no longer able to pump enough blood to meet the demands of the body. The study found that over an average of 23 months, patients taking the drug experienced fewer cardiovascular deaths or hospital admissions with worsening heart failure than people taking an inactive placebo pill.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large, well-conducted study has demonstrated the role that heart rate reduction may have in improving outcomes of people with heart failure. It found that the drug ivabradine, which slows heart rate, significantly reduced cardiovascular deaths and hospital admissions due to heart failure when combined with standard treatments.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/ivabradine-pill-chronic-heart-failure.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Swedberg K, Komajda M, Böhm M &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61198-1/fulltext" target="_blank"&gt;Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study&lt;/A&gt;. &lt;EM&gt;The Lancet&lt;/EM&gt;,&amp;nbsp;August 29 2010 (early online publication) 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>373789</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/workplace-stress-raises-heart-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Heart risk for working women</title>
    <publicationDate>2010-05-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,APR-JUNE 10,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“High flying career women with stressful jobs face a higher risk of heart disease,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; has claimed.&lt;/P&gt;
&lt;P&gt;This news story is based on Danish research, which followed 12,000 female nurses aged over 45, and compared their work-related stress to their risk of heart disease over the next 15 years. The study focused on women because the bulk of previous studies on work stress and heart disease have concentrated on men, even though heart problems affect the sexes relatively equally.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This study followed a large cohort of Danish nurses and found an association between a perceived high work pressure and an increased risk of heart disease. The study was conducted well and made adjustments to account for other factors that could contribute to a risk for heart disease. There are some limitations, many of which the authors highlighted.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; NHS&lt;A href="http://www.nhs.uk/news/2010/05May/Pages/workplace-stress-raises-heart-risk.aspx" target="_blank"&gt; Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Allesøe K, Andersen Hundrup Y, Frølund Thomsen J, Osler M. &lt;A href="http://oem.bmj.com/content/67/5/291.extract" target="_blank"&gt;Psychosocial work environment and risk of ischaemic heart disease in women: the Danish Nurse Cohort Study.&lt;/A&gt; &lt;EM&gt;Occup Environ Med&lt;/EM&gt; 2009;67:318e322.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>387464</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/working-long-hours-fatal-heart-attack.aspx]]&gt;</url>
    <title>Behind the Headlines - Heart risk from working late?</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Men who work more than 45 hours a week are more than twice as likely to die from heart disease if they are unfit,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported.&lt;/P&gt;
&lt;P&gt;The news comes from a 30-year Danish study of 5,000 men, which looked at how their working hours and physical fitness related to their risk of dying of a heart attack. The research has a number of strengths, such as its unusually long length and its assessment of participants’ fitness and working hours at the start of the study, rather than estimating them during the past. Its limitations include the fact that the participants’ physical fitness and working hours were only measured once and may not have been representative of the men’s lives as a whole.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These findings suggest that long working hours may have the greatest effect on mortality risk in men who are physically unfit. &lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;NHS &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/working-long-hours-fatal-heart-attack.aspx" target="_blank"&gt;Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>343176</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Herbal-medicine-and-heart-drugs.aspx]]&gt;</url>
    <title>Behind the Headlines - Herbal medicines affect heart drugs</title>
    <publicationDate>2010-02-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,GENERAL/OTHER,FEBRUARY 2010,RECENT ADDITIONS,JAN-MAR 10,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Herbal remedies taken by millions of Britons can pose a serious risk to their health by interfering with medicines commonly prescribed for heart disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Herbal remedies taken by millions of Britons can pose a serious risk to their health by interfering with medicines commonly prescribed for heart disease,” reported &lt;EM&gt;The Times&lt;/EM&gt;. The newspaper story is based on a review of the available evidence on the potential harms and interactions of herbal products for people who have&amp;nbsp;heart disease.&lt;/P&gt;
&lt;P&gt;As the newspaper points out, it is already known that some complementary medicines can lessen the effectiveness of drugs. However, by restating the case and carrying out this review, these researchers are trying to alert those most at risk from these interactions. As this was not a systematic review, it is not possible to say how harmful these remedies are or estimate how often these adverse effects occur.&lt;/P&gt;
&lt;P&gt;Anybody considering taking complementary or alternative medicine alongside their own prescribed medication is advised to discuss this with a doctor, nurse or pharmacist first.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This review has looked at a serious topic using acceptable methods. There are several difficulties due to the fact they found little good quality research on the topic.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/cardex/See%20the%20entire%20NHS%20Choices%20commentary%20on%20this%20news%20item." target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tachjian A, Maria V, and Jahangir A.&amp;nbsp;&lt;A href="http://content.onlinejacc.org/cgi/content/abstract/55/6/515" target="_blank"&gt;Use of Herbal Products and Potential Interactions in Patients With Cardiovascular Diseases.&lt;/A&gt; &lt;EM&gt;Journal of the American College of Cardiology&lt;/EM&gt;, 2010; 55:515-525&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392051</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/testosterone-and-male-heart-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Hormone affects heart patients' risk</title>
    <publicationDate>2010-10-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENETICS,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A study has found that “men with higher testosterone levels are less likely to die of heart disease”, reports The Daily Telegraph.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;A study has found that “men with higher testosterone levels are less likely to die of heart disease”, reports &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;This seven-year study of 930 men with heart disease found that those who had low testosterone had a greater risk of dying from any cause and of dying from a vascular cause. This appears to be a reliable association, and one that is clearly worthy of further investigation.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study demonstrated that there was a relatively high prevalence of testosterone deficiency among 60-year old men with established coronary artery disease. This deficiency was associated with a greater risk of dying over a seven-year follow-up period.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/testosterone-and-male-heart-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Malkin CJ,&amp;nbsp; Pugh PJ,&amp;nbsp; Morris PD &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://heart.bmj.com/content/early/2010/09/28/hrt.2010.195412.abstract" target="_blank"&gt;Low serum testosterone and increased mortality in men with coronary heart disease.&lt;/A&gt; &lt;EM&gt;Heart&lt;/EM&gt; 2010, Published Online First October 19&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>343257</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Low-carb-diets-and-blood-pressure.aspx]]&gt;</url>
    <title>Behind the Headlines - Low-carb diets and blood pressure</title>
    <publicationDate>2010-01-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ JAN-MAR 10,RECENT ADDITIONS,JANUARY 2010,CONDITION MANAGEMENT,PREVENTION,OBESITY,CHRONIC COMPLICATIONS,CARDIOVASCULAR,DIET,OVERWEIGHT AND OBESITY,PREVENTION,CARDIOVASCULAR DISEASES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>"A low-carbohydrate diet like Atkins is better at cutting blood pressure than weight-loss pills," BBC News reported. It said a study has found that twice as many people on a low-carb diet had lowered blood pressure compared to those who were taking orlistat.</description>
    <body>&lt;![CDATA[ &lt;P&gt;"A low-carbohydrate diet like Atkins is better at cutting blood pressure than weight-loss pills," BBC News reported. It said a study has found that twice as many people on a low-carb diet had lowered blood pressure compared to those who were&amp;nbsp;taking orlistat.&lt;/P&gt;
&lt;P&gt;The main aim of this study was to&amp;nbsp;assess weight change from these diets, and it&amp;nbsp;found that both a&amp;nbsp;low-carb diet and a low-fat diet with orlistat had a similar effect. Although it found that the low-carb diet was associated with lowered blood pressure, it also found&amp;nbsp;the low-fat/orlistat diet was associated with better cholesterol levels. Also, many statistical tests were carried out, increasing the likelihood that these findings are due to chance alone. On balance, this is not strong evidence that low-carb diets lower blood pressure or are better in general.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a generally well-designed study. However, interpretations should be made with care.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Low-carb-diets-and-blood-pressure.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yancy Jr WS, Westman EC, McDuffie JR &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://archinte.ama-assn.org/cgi/content/short/170/2/136" target="_blank"&gt;A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss&lt;/A&gt;. &lt;EM&gt;Archives of Internal Medicine&lt;/EM&gt; 2010; 170: 136-145&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388077</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/migraines-and-heart-disease-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Migraine with aura and heart risk</title>
    <publicationDate>2010-08-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,GENERAL,CONGENITAL HEART DISEASE,CAUSES &amp; RISK FACTORS,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"People who suffer from a severe form of migraine are more likely to die of heart disease and strokes,” reported &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; It said that people who had migraine with aura were 28% more likely to die from coronary heart disease and 40% more likely to die of stroke.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a large, cohort study with a lengthy follow-up. There are several limitations that should be taken into account when interpreting this research.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/migraines-and-heart-disease-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Gudmundsson LS, Scher AI, Aspelund T, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/full/341/aug24_1/c3966" target="_blank"&gt;Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study.&lt;/A&gt; &lt;EM&gt;British Medical Journal&lt;/EM&gt; 2010, 341:c3966&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345778</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/new-statin-high-blood-pressure-cholesterol.aspx]]&gt;</url>
    <title>Behind the headlines - New cholesterol drug tested</title>
    <publicationDate>2010-03-11T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,DISEASE MANAGEMENT,SECONDARY PREVENTION,LIPID REGULATING DRUGS,STATINS,ISCHAEMIC STROKE,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,STROKE,CONDITIONS,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,STATINS,LIPID-REGULATING DRUGS,ACUTE CORONARY SYNDROMES,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,RECENT ADDITIONS,MARCH 2010,JAN-MAR 10,JAN-MAR 10,MARCH 2010,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A new drug “cuts heart attack and stroke risk without side effects”, according to the Daily Mail. The newspaper says that the eprotirome tablets could rapidly lower cholesterol in people that do not respond to conventional statin drugs.

This is an important and well-conducted trial that gave participants either eprotirome or a placebo alongside their prescribed statin drugs. After 12 weeks of treatment with eprotirome, which is designed to mimic a thyroid hormone, there was a significant reduction in LDL cholesterol. Greater reductions were seen with increasing doses of eprotirome. 
</description>
    <body>&lt;![CDATA[ &lt;P&gt;A new drug “cuts heart attack and stroke risk without side effects”, according to the &lt;EM&gt;Daily Mail.&lt;/EM&gt; The newspaper says that the eprotirome tablets could rapidly lower cholesterol in people that do not respond to conventional statin drugs.&lt;/P&gt;
&lt;P&gt;This is an important and well-conducted trial that gave participants either eprotirome or a placebo alongside their prescribed statin drugs. After 12 weeks of treatment with eprotirome, which is designed to mimic a thyroid hormone, there was a significant reduction in LDL cholesterol. Greater reductions were seen with increasing doses of eprotirome. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an important and well-conducted trial, which has demonstrated the potential of a drug, eprotirome, to lower cholesterol levels. However, conclusions about the effects of this drug should not be made too prematurely and much further research is needed&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/new-statin-high-blood-pressure-cholesterol.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>341803</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/omega-3-fish-oil-lower-heart-problems.aspx]]&gt;</url>
    <title>Behind the Headlines - Omega-3 tested on heart patients</title>
    <publicationDate>2010-01-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,CARDIOVASCULAR DISEASES,CONDITIONS,DIET,CORONARY HEART DISEASE,PREVENTION,COMPLEMENTARY AND ALTERNATIVE MEDICINE,CARDIOVASCULAR DISEASES,DIETARY AND NUTRITIONAL THERAPIES,CONDITIONS A-Z,CONDITIONS C,CORONARY HEART DISEASE,JAN-MAR 10,JANUARY 2010,RECENT ADDITIONS,JANUARY 2010,OMEGA-3 FATTY ACIDS,NUTRITIONAL SUPPLEMENTS,LIPIDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Fish oil may really be an ‘elixir of youth’ because of its effects on our biological ageing.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Fish oil may really be an ‘elixir of youth’ because of its effects on our biological ageing.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was an interesting preliminary study, which found that high omega-3 levels were associated with reduced telomere shortening over time in a population who had stable heart disease. However, interpretations should be made with care.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/omega-3-fish-oil-lower-heart-problems.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Links to the science&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Farzaneh-Far R, Lin J, Epel ES &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://jama.ama-assn.org/cgi/content/short/303/3/250?home" target="_blank"&gt;Association of Marine Omega-3 Fatty Acid Levels With Telomeric Aging in Patients With Coronary Heart Disease&lt;/A&gt;. &lt;EM&gt;JAMA&lt;/EM&gt;. 2010;303(3):250-257&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>375171</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/processed-meat-and-heart-disease-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Processed meat 'raises' heart risk</title>
    <publicationDate>2010-05-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,DIET,CAUSES AND RISK FACTORS,RECENT ADDITIONS,APR-JUNE 10,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“'Sausage not steak’ increases heart disease risk”, reported the BBC. It said that eating processed meat such as sausages increases the likelihood of heart disease, while red meat does not seem to be as harmful. The risk of diabetes is also reportedly raised, with 50g of processed meat a day increasing that risk.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“'Sausage not steak’ increases heart disease risk”, reported the BBC. It said that eating processed meat such as sausages increases the likelihood of heart disease, while red meat does not seem to be as harmful. The risk of diabetes is also reportedly raised, with 50g of processed meat a day increasing that risk.&lt;/P&gt;
&lt;P&gt;This news story is based on a review and analysis of 20 studies&amp;nbsp;on red or processed meat and the risk of coronary heart disease, stroke&amp;nbsp;and diabetes. As reported by the BBC, red meat did not appear to be associated with increased risk, but processed meat was linked.&lt;/P&gt;
&lt;P&gt;As it stands, this well-conducted study shows an association between eating processed meat and an increased risk of heart disease and diabetes. However, it is still not certain whether this increased risk is caused by particular components of processed meat, or if it is due to other dietary or lifestyle factors that are also associated with higher consumption of processed meats. Further research will need to address this question.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a large systematic review and meta-analysis, which found an association between processed meats and an increase in the risk of coronary heart disease and diabetes mellitus. Red meat itself did not appear to increase the risk of these illnesses.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/processed-meat-and-heart-disease-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Micha R, Wallace SK and Mozaffarian D. &lt;A href="http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.109.924977v1" shape=rect target="_blank"&gt;Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus.&lt;/A&gt; &lt;EM&gt;Circulation&lt;/EM&gt;. 2010 [Published online before print May 17, 2010]&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392734</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/scorpion-venom-heart-bypass-surgery.aspx]]&gt;</url>
    <title>Behind the Headlines – Scorpions provide heart op clue</title>
    <publicationDate>2010-10-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,SURGICAL PROCEDURES,CORONARY ARTERY BYPASS GRAFTS,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Scorpion venom “could prevent bypass failures”, according to the Daily Mail, which says the toxin can help keep veins clear after heart bypass surgery.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Scorpion venom “could prevent bypass failures”, according to the &lt;EM&gt;Daily Mail,&lt;/EM&gt; which says the toxin can help keep veins clear after heart bypass surgery. According to the newspaper, a study has found that ‘margatoxin’,&amp;nbsp;produced by&amp;nbsp;the Central American bark scorpion, could stop the scarring that can block grafted blood vessels after surgery.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This laboratory research has detailed the involvement of a particular potassium channel in the cell wall of smooth muscle cells in mouse and human blood vessels. These channels have been linked with migration and reproduction of the muscle cells, and are therefore implicated in the development of scar tissue in the cardiac vessels following surgery. The study investigated the effects of blocking the Kv1.3 channels with different substances. One of the two compounds studied here, margatoxin, is found in the venom of a scorpion. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/scorpion-venom-heart-bypass-surgery.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Cheong A, Li J, Sukumar P &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://cardiovascres.oxfordjournals.org/content/early/2010/09/29/cvr.cvq305.full.pdf+html?sid=" target="_blank"&gt;Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers&lt;/A&gt;. &lt;EM&gt;Cardiovascular Research&lt;/EM&gt; [Advance Access] published September 29, 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>377889</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Short-people-and-heart-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Short stature link to heart disease</title>
    <publicationDate>2010-06-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,GENETICS,GENERAL,CAUSES AND RISK FACTORS,GENERAL  / OVERVIEWS,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Short people are more likely to develop heart disease,” BBC News reported. It said that men under 5ft 4in (163cm)&amp;nbsp;and women under 5ft (152cm)&amp;nbsp;were 1.5 times more likely to develop and die from heart disease than tall adults.&lt;/P&gt;
&lt;P&gt;The news story is based on a large review of 52 studies in more than 3 million people. The review does suggest that there is a link between shorter height and risk of cardiovascular events. However, it is not clear why this is the case, or exactly how strong the link is.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study used the most appropriate design for summarising the available high quality research evidence on a question. It includes a large number of individuals and its findings are likely to be reasonably robust. The explanation for this link between height and cardiovascular risk is unclear, but it seems unlikely that short stature itself ‘causes’ this increase in risk, and more likely that it is another linked factor. The authors suggest that short individuals may have smaller coronary arteries and that this possibility needs looking into. As individuals cannot be randomised to being different heights, studies looking at this link can only observe what happens in the general population, and as such they are affected by the possibility of confounding.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Short-people-and-heart-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Paajanen TA, Oksala NKJ, Kuukasja¨rvi P, and Karhunen PJ.&amp;nbsp;&lt;A href="http://eurheartj.oxfordjournals.org/content/early/2010/06/04/eurheartj.ehq155.full" target="_blank"&gt;Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis.&lt;/A&gt; European Heart Journal 2010; First published online: June 8&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>344238</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/statins-high-cholesterol-diabetes.aspx]]&gt;</url>
    <title>Behind the Headlines - Small diabetes risk from statins</title>
    <publicationDate>2010-02-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,ISCHAEMIC STROKE,DIABETES MELLITUS,DISEASE MANAGEMENT,ANTI-PLATELET DRUGS,CAUSES / RISK FACTORS,CAUSES / RISK FACTORS,DISEASE MANAGEMENT,CAUSES / RISK FACTORS,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,VASCULAR,CONDITIONS,STATINS,LIPID-REGULATING DRUGS,CAUSES &amp; RISK FACTORS,DIABETES MELLITUS,DISEASE MANAGEMENT,FEBRUARY 2010,RECENT ADDITIONS,FEBRUARY 2010,RECENT ADDITIONS,JAN-MAR 10,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010,JAN-MAR 10,TYPE 2,DIABETES MELLITUS,LIPID-REGULATING DRUGS,STATINS,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,DIABETES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Statins raise your chance of diabetes,” said the Daily Mail, but apparently the benefits in terms of heart disease protection still outweigh the risks. Taking the cholesterol-lowering drugs reportedly increases the chance of developing type 2 diabetes by 9%.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Statins raise your chance of diabetes,” said the &lt;EM&gt;Daily Mail&lt;/EM&gt;, but apparently the benefits in terms of heart disease protection still outweigh the&amp;nbsp;risks. Taking the cholesterol-lowering drugs reportedly increases the&amp;nbsp;chance of developing type 2 diabetes&amp;nbsp;by 9%. &lt;/P&gt;
&lt;P&gt;This report is based on a well-conducted review investigating the association between statin treatment and risk of diabetes. The research combined the results on 91,140 people from 13 trials. It estimated that over four years the risk of diabetes was 9% greater in those using the drugs than in those using no treatment. However, the actual number of people who developed diabetes was small, with the researchers estimating that treating 255 people with statins for four years would result in one extra case of diabetes. As a result, the benefits of statin treatment in people at risk of cardiovascular disease still appear to outweigh any small increase in risk of diabetes. &lt;/P&gt;
&lt;P&gt;Statins raise your chance of diabetes,” said the &lt;EM&gt;Daily Mail&lt;/EM&gt;, but apparently the benefits in terms of heart disease protection still outweigh the&amp;nbsp;risks. Taking the cholesterol-lowering drugs reportedly increases the&amp;nbsp;chance of developing type 2 diabetes&amp;nbsp;by 9%. &lt;/P&gt;
&lt;P&gt;This report is based on a well-conducted review investigating the association between statin treatment and risk of diabetes. The research combined the results on 91,140 people from 13 trials. It estimated that over four years the risk of diabetes was 9% greater in those using the drugs than in those using no treatment. However, the actual number of people who developed diabetes was small, with the researchers estimating that treating 255 people with statins for four years would result in one extra case of diabetes. As a result, the benefits of statin treatment in people at risk of cardiovascular disease still appear to outweigh any small increase in risk of diabetes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This was a large and well-conducted review, which has found that the overall risk of diabetes is increased 9% by statin treatment. It should be noted that the risk of participants developing diabetes was relatively low to begin with. This means that even after the 9% increase associated with statins, the actual risk remained low.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/02February/Pages/statins-high-cholesterol-diabetes.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sattar N, Preiss D, Murray HM &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61965-6/fulltext" target="_blank"&gt;Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials&lt;/A&gt;. &lt;EM&gt;The Lancet,&lt;/EM&gt; [Early Online Publication], February 17&amp;nbsp;2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>375072</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/side-effects-of-statins-studied.aspx]]&gt;</url>
    <title>Behind the Headlines - Statin side-effects examined</title>
    <publicationDate>2010-05-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,LIPID-REGULATING DRUGS,STATINS,RECENT ADDITIONS,APR-JUNE 10,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“GPs should think more carefully about prescribing cholesterol-busting drugs,” reported BBC News, adding that some statin drugs raised the risk of adverse effects such as liver and kidney problems.

The research used medical records on over 2 million patients to assess side effects of cholesterol-lowering statin drugs. Clinical trials to approve a drug tend to look at side effects in a selected population over a relatively short time. This study monitored patients in general practice over a longer period of time, which allows rarer side effects to be revealed.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;“GPs should think more carefully about prescribing cholesterol-busting drugs,” reported BBC News, adding that some statin drugs raised the risk of adverse effects such as liver and kidney problems.&lt;/P&gt;
&lt;P&gt;The research used medical records on over 2 million patients to assess side effects of cholesterol-lowering statin drugs. Clinical trials to approve a drug tend to look at side effects in a selected population over a relatively short time. This study monitored patients in general practice over a longer period of time, which allows rarer side effects to be revealed.&lt;/P&gt;
&lt;P&gt;The study confirmed some side effects that are already known, such as an increased risk of muscle weakness, cataracts, acute kidney failure, and moderate or severe liver dysfunction. However, these problems were still estimated to be quite rare, with cataracts affecting less than 3% of statin users and other side effects less 1%. A greater number of patients benefited from taking statins to lower cholesterol, which in turn prevented heart attacks. This study provides invaluable numerical data for clinicians that will help them weigh up the risks and benefits of these drugs for each patient.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a large and well-conducted study that has shown that there was an increased risk of myopathy (muscle weakness), cataracts, kidney failure, and moderate or severe liver dysfunction associated with statin use. However, very few in the study population (non-users and users of statins) developed the conditions, suggesting that it is important for people considering these drugs to have an understanding of their individual chances of any side effect when compared to the potential benefit. The study did show that fluvastatin gave the highest risks for liver dysfunction and this may affect the choice of which statin to prescribe.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/side-effects-of-statins-studied.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hippisley-Cox J, and C Coupland. &lt;A href="http://www.bmj.com/cgi/content/abstract/340/may19_4/c2197?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=Hippisley-Cox&amp;amp;searchid=" target="_blank"date&amp;amp;resourcetype=HWCIT&amp;quot;'"&gt;Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010;340:c2197&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>341804</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Stress-and-heart-attacks.aspx]]&gt;</url>
    <title>Behind the Headlines - Stress and artery health studied</title>
    <publicationDate>2010-01-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES / RISK FACTORS,TRANSIENT ISCHAEMIC ATTACK,CAUSES / RISK FACTORS,GENERAL,CAUSES / RISK FACTORS,GENERAL,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,STROKE,ISCHAEMIC STROKE,CAUSES / RISK FACTORS,HAEMORRHAGIC STROKE,RECENT ADDITIONS,JANUARY 2010,JAN-MAR 10,JAN-MAR 10,RECENT ADDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Stress really does increase the risk of heart attacks and strokes.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Stress really does increase the risk of heart attacks and strokes,” reported the &lt;EM&gt;Daily Mail.&lt;/EM&gt; It said research has found that people who become stressed are more likely to suffer from hardened arteries.&lt;/P&gt;
&lt;P&gt;This study measured volunteers’ levels of cortisol, a stress hormone, while they carried out tests aimed at raising their stress levels.&amp;nbsp;It found that&amp;nbsp;people who had&amp;nbsp;increased cortisol levels were more likely to have high calcium deposits in the arteries,&amp;nbsp;a&amp;nbsp;marker of coronary heart disease.&lt;/P&gt;
&lt;P&gt;Although high calcium deposits may indicate heart disease, this study did not directly investigate if stress increases the risk of a heart attack or stroke. A single measure of stress taken at the same time as a measure of calcium build-up in the arteries cannot show whether a person’s lifetime stress habits have caused the build-up.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research found that people whose cortisol levels increased when given acute behavioural tasks were associated with high&amp;nbsp;CAC scores, an indicator of cardiovascular disease. However, the researchers were relatively cautious in the interpretation of their work, and highlighted the following limitations of their study.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01january/pages/stress-and-heart-attacks.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;H2&gt;Links to the headlines&lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.dailymail.co.uk/health/article-1244055/Stress-does-raise-risk-heart-attack-stroke.html" target="_blank"&gt;Stress 'does raise the risk of a heart attack and a stroke'&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;Daily Mail&lt;/EM&gt;, January 17 2010&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.telegraph.co.uk/health/healthnews/7011133/Stress-can-cause-heart-damage.html" target="_blank"&gt;Stress 'can cause heart damage'&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;The Daily Telegraph&lt;/EM&gt;, January 17 2010&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;H2&gt;Links to the science&lt;/H2&gt;
&lt;P&gt;Hamer M, O'Donnell K, Lahiri A and Steptoe A.&amp;nbsp;&lt;A href="http://eurheartj.oxfordjournals.org/cgi/content/abstract/ehp386" target="_blank"&gt;Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women&lt;/A&gt;. &lt;EM&gt;European Heart Journal&lt;/EM&gt;: Advance Access; Published online September 10 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388069</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/cortisol-stress-hormone-heart-attack.aspx]]&gt;</url>
    <title>Behind the headlines - Stress and heart attacks</title>
    <publicationDate>2010-09-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Stress increases the chances of dying from heart-related problems by five-fold,” according to The Daily Telegraph. The newspaper reported that a study of people aged over 65 found that those with high levels of stress hormones were five times more likely to die from cardiovascular causes, such as heart attacks and strokes, within the next six years.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Stress increases the chances of dying from heart-related problems by five-fold,” according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; The newspaper reported that a study of people aged over 65 found that those with high levels of stress hormones were five times more likely to die from cardiovascular causes, such as heart attacks and strokes, within the next six years.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that urinary cortisol levels in older adults may be related to risk of death from cardiovascular causes.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/cortisol-stress-hormone-heart-attack.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Vogelzangs N, Beekman ATF, Milaneschi Y &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://jcem.endojournals.org/cgi/content/abstract/jc.2010-0192v1" target="_blank"&gt;Urinary Cortisol and Six-Year Risk of All-Cause and Cardiovascular Mortality&lt;/A&gt;. &lt;EM&gt;Journal of Clinical Endocrinology &amp;amp; Metabolism&lt;/EM&gt;, August 25 2010 (published online) 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>377896</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/cholesterol-may-be-controlled-by-brain.aspx]]&gt;</url>
    <title>Behind the headlines - The brain may control cholesterol</title>
    <publicationDate>2010-06-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,DIET,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Cholesterol levels are controlled by a “hormone in the brain” the &lt;EM&gt;Daily Mail&lt;/EM&gt; has reported. It says the finding offers hope of new treatments to reduce levels of “the dangerous fat”.&lt;/P&gt;
&lt;P&gt;The &lt;EM&gt;Mail&lt;/EM&gt;’s story is based on animal research that appears to indicate that blood cholesterol levels are regulated remotely by the central nervous system. The researchers found that increasing levels of a hormone called ghrelin, which is thought to regulate energy intake, caused mice to develop higher levels of cholesterol. The finding that cholesterol can be regulated by the brain could be the basis for new drug treatments, they suggest.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an interesting laboratory study that showed that, in mice, levels of blood cholesterol can be increased by raising the levels of the hormone ghrelin and blocking the melanocortin receptor.&amp;nbsp;This suggests that the central nervous system has a role in the production of cholesterol.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/cholesterol-may-be-controlled-by-brain.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>287705</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nzgg.org.nz/guidelines/0001/cardiac_rehabilitation.pdf]]&gt;</url>
    <title>Best practice evidence-based guideline : cardiac rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>New Zealand Guidelines Group</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DISEASE MANAGEMENT,SECONDARY PREVENTION,CARDIAC REHABILITATION,APR-JUNE 08,CORONARY HEART DISEASE,GENERAL,CONDITIONS,DISEASE MANAGEMENT,PREVENTION,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To provide a summary of the most up to date (at the time of publishing) New Zealand and overseas evidence on cardiac rehabilitation and make recommendations based on the evidence, that will lead to best practice cardiac rehabilitation in New Zealand. &lt;/P&gt;
&lt;P align=left&gt;Sections are included on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Background information of cardiovascular disease and rehabilitation in New Zealand.&lt;BR&gt;
&lt;LI&gt;Lifestyle interventions&lt;BR&gt;
&lt;LI&gt;Pharmacotherapy&lt;BR&gt;
&lt;LI&gt;Rehabilitation programmes&lt;BR&gt;
&lt;LI&gt;Specific populations&lt;BR&gt;
&lt;LI&gt;Maori/Pacific perspectives&lt;BR&gt;
&lt;LI&gt;Audit, programme evaluation and patient satisfaction&lt;BR&gt;
&lt;LI&gt;Implementation&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2002.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;This resource has been listed in the 'Cardiac Rehabilitation Annual Evidence Update 2008' and has been selected for inclusion in the CVDSL.&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310401</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.stroke.org.uk/document.rm?id=1572]]&gt;</url>
    <title>Better coronary heart disease and stroke care : a consultation document</title>
    <publicationDate>2008-08-29T00:00:00</publicationDate>
    <publisher>NHS Scotland</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ STROKE,ISCHAEMIC STROKE,HAEMORRHAGIC STROKE,PREVENTION,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CORONARY HEART DISEASE,CONDITIONS,DISEASE MANAGEMENT,GENERAL/OTHER,ARTERIOSCLEROSIS,REHABILITATION,DISEASE MANAGEMENT,REHABILITATION,PREVENTION,GENERAL / OTHER,PREVENTION,JAN-MAR 09,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This consultation document examines coronary heart disease and stroke care in Scotland.&amp;nbsp; It discusses the action plan for health and wellbeing and confirms that both coronary heart disease and stroke remain clinical priorities in Scotland. It has a foreword by Nicola Sturgeon, Deputy First Minister and Cabinet Secretary for Health and Wellbeing.&lt;/P&gt;
&lt;P&gt;Includes sections on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where we are now 
&lt;LI&gt;Healthy lifestyles 
&lt;LI&gt;Tackling health inequalities 
&lt;LI&gt;Services for CHD 
&lt;LI&gt;Stroke services 
&lt;LI&gt;Improving the experience of care 
&lt;LI&gt;IT infrastructure 
&lt;LI&gt;Developing an action plan for Scotland&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published August 2008&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70838</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bmjlearning.com/planrecord/index.jsp]]&gt;</url>
    <title>BMJ learning</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This website is dedicated to learning for medical professionals. It offers a wide range of learning resources, commissioned by the BMJ Publishing Group. The learning resources deal with everyday issues in primary care and hospital medicine, all of which are evidence based and kept up to date. Currently there are over&amp;nbsp;140 learning modules. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Registration with BMJ Learning website is required. Available to the general public. 
&lt;P&gt;&lt;FONT face=Arial size=2&gt;&lt;STRONG&gt;This item has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Information last checked 16/4/08.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>63615</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bnf.org/bnf/extra/current/450017.htm]]&gt;</url>
    <title>Body mass index</title>
    <publicationDate></publicationDate>
    <publisher>British National Formulary</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GENERAL,OVERWEIGHT AND OBESITY,CARDIOVASCULAR DISEASES,DIAGNOSIS,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This tool allows you to quickly and accurately calculate body mass from a patient's weight (in kilograms) and height (in metres). 
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>63617</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bnf.org/bnf/extra/current/450018.htm]]&gt;</url>
    <title>Body surface area</title>
    <publicationDate></publicationDate>
    <publisher>British National Formulary</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,GENERAL,CARDIOVASCULAR DISEASES,DIAGNOSIS,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This tool allows you to calculate a patient's body surface area by using the Dubois formula.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>223933</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;ID=32006000215]]&gt;</url>
    <title>Botulinum toxin A in the treatment of upper and lower limb spasticity : a systematic review of randomized controlled trials</title>
    <publicationDate>2006-03-16T00:00:00</publicationDate>
    <publisher>Health Technology Assessment Database</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,DISEASE MANAGEMENT,ISCHAEMIC STROKE,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,STROKE,GENERAL/OTHER,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; BTX-A has a demonstrated effect on muscle tone. BTX-A reduced muscle tone in patients with stroke, cerebral palsy and multiple sclerosis.&lt;BR&gt;&lt;BR&gt;With regard to the effect of BTX-A on range of motion, many studies report increased range of motion, improved gait and improved function. Statistical significance is not always reached. The variability across studies may be due to the variety of disorders studied and their unique expression, and the differences in outcome measures and study design. Combining the results to improve clarity is sometimes impossible.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;With regard to the relative harm of BTX-A, few adverse events are reported in most trials and are often transient. Improved methods of reporting would allow for more robust conclusions about the relative safety of BTX-A.&lt;BR&gt;&lt;BR&gt;With regard to the long-term effects of BTX-A, patient-specific and goal-focused outcomes are needed to further define clinically meaningful improvements in therapeutic outcomes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;The aim of the work was to conduct a systematic review of the literature to determine if BTX-A is effective and safe compared with other therapies when it is used to reduce focal spasticity in patients with upper or lower limb spasticity. (NOTE: This Overview is based on Technology Report No. 51, 2005, commissioned by CCOHTA, written by Garces K, McCormick A, McGahan L, Skidmore B., titled Botulinum toxin A for upper and lower limb spasticity: a systematic review.) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Abstract available to the general public.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383412</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/link-between-heart-and-brain-examined.aspx]]&gt;</url>
    <title>Brain and heart link studied</title>
    <publicationDate>2010-08-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,GENERAL,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Keeping your heart fit and strong can slow down the ageing of your brain,” says BBC News, reporting that a poor cardiac output may age the brain by an average of nearly two years.&lt;/P&gt;
&lt;P&gt;The research behind this news looked at a measurement of heart blood flow called cardiac index, which indicates a person’s heart output rate for their size. In the examination of 1,500 volunteers, scientists found there was an association between a greater cardiac index and higher brain volume, irrespective of whether participants had clinical symptoms of cardiovascular disease. However, neither cardiac index nor brain volume appeared to be linked to brain functioning.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This relatively large cross-sectional study found an association between a low cardiac index and smaller brain volume. However, a low cardiac index, and the associated reduction in brain volume, did not seem to have a strong effect on brain function. Also, as a cross-sectional analysis thatonly examines factors at a single point in time, it cannot demonstrate causation between cardiac function and the physiological signs of brain ageing assessed here. &lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/link-between-heart-and-brain-examined.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Jefferson AL, Himali JJ, Beiser AS &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.109.905091v1" target="_blank"&gt;Cardiac Index Is Associated With Brain Aging. The Framingham Heart Study&lt;/A&gt;. &lt;EM&gt;Circulation&lt;/EM&gt;. 2010 [Published online before print] August 2 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>371724</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.health.org.uk/publications/research_reports/bridging_the_quality.html?dm_i=4Y2,42WJ,1TZOYQ,CNUZ,1]]&gt;</url>
    <title>Briding the quality gap: heart failure</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>The Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,HEART FAILURE,RECENT ADDITIONS,APRIL 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report provides a comprehensive review of the current quality of heart failure care, captures the international evidence on what works to improve care and assesses the cost-effectiveness of different interventions.]]&gt;</body>
  </document>
  <document>
    <id>124365</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=299608]]&gt;</url>
    <title>Brief interventions and referral for smoking cessation in primary care and other settings</title>
    <publicationDate>2006-03-29T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SMOKING,SMOKING CESSATION,RESPIRATORY,SMOKING,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Department of Health in collaboration with the National Institute for Health and Clinical Excellence have produced guidance on brief interventions and referrals to specialist services to help people who smoke to stop, in particular, pregnant women and disadvantaged groups.&amp;nbsp; Includes recommendations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383414</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/calcium-pills-and-heart-risk.aspx]]&gt;</url>
    <title>Calcium pills may raise heart risk</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CAUSES AND RISK FACTORS,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Calcium pills increase risk of heart attacks,” BBC News reported. It said a study has found that people taking the supplements are 30% more likely to have a heart attack.&lt;/P&gt;
&lt;P&gt;This research combined the results from 11 placebo-controlled trials of calcium supplementation. Researchers looked at the numbers of heart attacks and strokes in 11,921 participants over an average of four years. In total, 296 people had a heart attack, of whom 166 were taking calcium supplements compared&amp;nbsp;to 130 taking placebo.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted review has important findings. Calcium supplements are widely used among elderly people, particularly postmenopausal women, to try to reduce their risk of fractures due to loss of bone mineral density.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/calcium-pills-and-heart-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>287865</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://hyper.ahajournals.org/cgi/reprint/HYPERTENSIONAHA.107.189010]]&gt;</url>
    <title>Call to action on use and reimbursement for home blood pressure monitoring : a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,HYPERTENSION,GENERAL/OTHER,APR-JUNE 08,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement describes the important role for home blood pressure monitoring (HBPM), the proper technique and recommended equipment, the target goals for treatment, and the patient populations for which HBPM is especially useful. It states that&amp;nbsp;HBPM should become a routine component of blood pressure measurement in the majority of patients with known or suspected hypertension. It concludes that HBPM has the potential to improve the quality of care while reducing costs, and that costs incurred by patients and providers should be reimbursed. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in May 2008.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287867</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://hyper.ahajournals.org/cgi/reprint/HYPERTENSIONAHA.107.189011]]&gt;</url>
    <title>Call to action on use and reimbursement for home blood pressure monitoring : executive summary : a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,DISEASE MANAGEMENT,GENERAL/OTHER,APR-JUNE 08,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement describes the important role for home blood pressure monitoring (HBPM), the proper technique and recommended equipment, the target goals for treatment, and the patient populations for which HBPM is especially useful. It states that HBPM should become a routine component of blood pressure measurement in the majority of patients with known or suspected hypertension. It concludes that HBPM has the potential to improve the quality of care while reducing costs, and that costs incurred by patients and providers should be reimbursed. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2008.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3561</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.pulsus.com/CARDIOL/home.htm]]&gt;</url>
    <title>Canadian Journal of Cardiology</title>
    <publicationDate></publicationDate>
    <publisher>The Canadian Cardiovascular Society</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ UNSURE CARDEX,CARDIOVASCULAR DISEASES,RESOUCES THAT ARE HIDDEN BUT WE ARE HOLDING ONTO FOR NOW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Official Journal of the Canadian Cardiovascular Society. It publishes original reports, reviews, and case reports relating to cardiovascular medicine. Other topics covered include health systems, ethics, medical history and political issues affecting practice. Table of contents and abstracts available; full text documents at charge.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Registration with the Pulsus website is required. Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347027</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_114416.pdf]]&gt;</url>
    <title>Cardiac Imaging: A report from the National Imaging Board</title>
    <publicationDate>2010-03-24T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,GENERAL,RECENT ADDITIONS,MARCH 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"&gt;The report outlines many opportunities which can be used to transform cardiac services and support the QIPP (quality, innovation, productivity and prevention) agenda. It illustrates how the NHS can improve quality, safety and productivity while working across disciplines to deliver better care for cardiac patients. &lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287701</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.circ.ahajournals.org/cgi/content/full/111/3/369]]&gt;</url>
    <title>Cardiac rehabilitation and secondary prevention of coronary heart disease : an American Heart Association scientific statement from the Council on Clinical Cardiology (subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,DISEASE MANAGEMENT,PREVENTION,CARDIAC REHABILITATION,SECONDARY PREVENTION,APR-JUNE 08,CARDIOVASCULAR DISEASES,PREVENTION,DISEASE MANAGEMENT,CONDITIONS,GENERAL,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To update the 1994 American Heart Association scientific statement on cardiac rehabilitation. Statement provides a review of recommended components for an effective cardiac rehabilitation/secondary prevention program, ways to deliver these services with emphasis on exercise training, and recommended future research directions. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287701</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.circ.ahajournals.org/cgi/content/full/111/3/369]]&gt;</url>
    <title>Cardiac rehabilitation and secondary prevention of coronary heart disease : an American Heart Association scientific statement from the Council on Clinical Cardiology (subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,DISEASE MANAGEMENT,PREVENTION,CARDIAC REHABILITATION,SECONDARY PREVENTION,APR-JUNE 08,CARDIOVASCULAR DISEASES,PREVENTION,DISEASE MANAGEMENT,CONDITIONS,GENERAL,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To update the 1994 American Heart Association scientific statement on cardiac rehabilitation. Statement provides a review of recommended components for an effective cardiac rehabilitation/secondary prevention program, ways to deliver these services with emphasis on exercise training, and recommended future research directions. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289841</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.circ.ahajournals.org/cgi/content/full/111/3/369]]&gt;</url>
    <title>Cardiac rehabilitation and secondary prevention of coronary heart disease : an American Heart Association scientific statement from the Council on Clinical Cardiology (subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,DISEASE MANAGEMENT,PREVENTION,DISEASE MANAGEMENT,PREVENTION,ARTERIOSCLEROSIS,CARDIAC REHABILITATION,CARDIOVASCULAR DISEASES,PREVENTION,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement updates the 1994 American Heart Association scientific statement on cardiac rehabilitation. It provides a review of recommended components for an effective cardiac rehabilitation/secondary prevention program, alternative ways to deliver these services, recommended future research directions, and the rationale for each component of the rehabilitation/secondary prevention program, with emphasis on the exercise training component.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289841</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.circ.ahajournals.org/cgi/content/full/111/3/369]]&gt;</url>
    <title>Cardiac rehabilitation and secondary prevention of coronary heart disease : an American Heart Association scientific statement from the Council on Clinical Cardiology (subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,DISEASE MANAGEMENT,PREVENTION,DISEASE MANAGEMENT,PREVENTION,ARTERIOSCLEROSIS,CARDIAC REHABILITATION,CARDIOVASCULAR DISEASES,PREVENTION,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement updates the 1994 American Heart Association scientific statement on cardiac rehabilitation. It provides a review of recommended components for an effective cardiac rehabilitation/secondary prevention program, alternative ways to deliver these services, recommended future research directions, and the rationale for each component of the rehabilitation/secondary prevention program, with emphasis on the exercise training component.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287455</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=287455]]&gt;</url>
    <title>Cardiac Rehabilitation Annual Evidence Update 2008 : Search Strategy</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIAC REHABILITATION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Cardiac Rehabilitation Annual Evidence Update 2008 : Search Strategy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;A detailed search narrative of searches undertaken for the&amp;nbsp;June 2008 Cardiac Rehabilitation Annual Evidence Update.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word File.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>64539</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2003(6).pdf]]&gt;</url>
    <title>Cardiac resynchronisation for heart failure</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,HEART FAILURE,GENERAL/OTHER,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This study aims to assess the effects of cardiac resynchronisation (biventricular pacing) in people with chronic heart failure and no other indication for ventricular pacing, compared to other forms of therapy.&amp;nbsp; STEER: Succint and Timely Evaluated Evidence Reviews 2003;3:10 
&lt;P&gt;&lt;STRONG&gt;Access to abstract:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&lt;STRONG&gt;Access to original study:&lt;/STRONG&gt; Available to the general public at&amp;nbsp;&lt;A href="http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2003(6).pdf" target="_blank"&gt;http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2003(6).pdf&lt;/A&gt;&amp;nbsp;Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377908</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.resus.org.uk/pages/standard.pdf]]&gt;</url>
    <title>Cardiopulmonary resuscitation : standards for clinical practice and training</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Resuscitation Council (UK)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,INTERVENTIONS / PROCEDURES,APR-JUN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides guidelines for clinical practice and training for those with a responsibility for resuscitation services within healthcare institutions. The document builds on previous reports from the Royal College of Physicians, the Royal College of Anaesthetists, the British Medical Association, the Royal College of Nursing, and the Resuscitation Council (UK).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3789</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.resus.org.uk/pages/standard.pdf]]&gt;</url>
    <title>Cardiopulmonary resuscitation guidance for clinical practice and training in hospitals</title>
    <publicationDate></publicationDate>
    <publisher>Resuscitation Council (UK)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,CARDIOPULMONARY ARREST,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document aims to provide guidelines for resuscitation standards and training for those with responsibility for resuscitation services within hospitals. It outlines the requirements for hospital resuscitation teams, ‘Do Not Resuscitate’ (DNR) policy, post-resuscitation care, and audit and reporting standards.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3790</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.resus.org.uk/pages/cpatpc.htm]]&gt;</url>
    <title>Cardiopulmonary resuscitation guidance for clinical practice and training in primary care</title>
    <publicationDate></publicationDate>
    <publisher>Resuscitation Council (UK)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CONDITIONS,CARDIOPULMONARY ARREST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document aims to provide guidance about resuscitation standards and training for those working in the community as part of the Primary Health Care Team. It recommends that all Primary Health Care Team members who have contact with patients should be proficient in basic life support (BLS), while the majority of the team should be capable of using an automated external defibrillator (AED). Every healthcare practice should be equipped with an AED and appropriate arrangments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>123328</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.advisorybodies.doh.gov.uk/comeap/statementsreports/CardioDisease.pdf]]&gt;</url>
    <title>Cardiovascular disease and air pollution</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PREVENTION,CONDITIONS,GENERAL,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report explores the link between cardiovascular diseases and air pollutants, identifying areas for further research.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324782</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/abstract/120/1/86]]&gt;</url>
    <title>Cardiovascular evaluation and management of severely obese patients undergoing surgery</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,RISK ASSESSMENT,OVERWEIGHT AND OBESITY,JUL-SEP 09,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This scientific advisory was developed to provide recommendations for the preoperative cardiovascular evaluation, intraoperative and perioperative management, and postoperative cardiovascular care of the severely obese patient undergoing surgery. Whilst the cardiological discussion is relevant and useful, the section on anaesthetic technique is basic, and may not necessarily be relevant to UK practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Cardiologists, surgeons, anesthetists, and other healthcare professionals.&lt;STRONG&gt;&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published online June 15 2009 and later in &lt;EM&gt;Circulation&lt;/EM&gt;, July 7 2009, Vol 120(1), 86-95.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284187</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.189473]]&gt;</url>
    <title>Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs : a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing</title>
    <publicationDate>2008-05-06T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHILD HEALTH,ADOLESCENCE,CARDIOLOGY,COMMUNITY CHILD HEALTH,CONGENITAL HEART DISEASE,ATTENTION DEFICIT AND HYPERKINETIC DISORDERS,SPECIALTIES,CONGENITAL HEART DISEASE,GENERAL / OVERVIEWS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; Statement discusses the prevalence of attention deficit/hyperactivity disorder (ADHD) in children with heart disease. The use of stimulant medications and the need for cardiovascular monitoring is reviewed and recommendations on these are made.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 6th May 2008.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343992</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=343992]]&gt;</url>
    <title>Cardiovascular risk with oral antidiabetes drugs - Eyes on Evidence Commentary</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CURRENT AWARENESS - HOT OFF THE PRESS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Cardiovascular risk with oral antidiabetes drugs - Eyes on Evidence Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=0 cellPadding=0 width=415 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=20&gt;&lt;IMG height=16 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343992/nelhImp_0000_art_eye.gif" width=20 NOSEND="1"&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="FONT-SIZE: 14px; COLOR: #0179c1; FONT-FAMILY: Arial, Helvetica, sans-serif" vAlign=top align=left width=395&gt;&lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NSwxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NSwxMjcxODAzMDU=" target="_blank"&gt;&lt;FONT title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NSwxMjcxODAzMDU= color=#000000 size=3&gt;&lt;STRONG title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NSwxMjcxODAzMDU=&gt;New role for thiazolidinediones in diabetes?&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=395 height=4&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-TOP: #0179c1 1px solid" vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=395 height=5&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="FONT-SIZE: 12px; COLOR: #0179c1; FONT-FAMILY: Arial, Helvetica, sans-serif" vAlign=top align=left width=395&gt;
&lt;P&gt;&lt;FONT color=#000000 size=2&gt;&lt;FONT color=#000000 size=2&gt;&lt;FONT face="Arial Black"&gt;Overview:&lt;/FONT&gt; Type 2 diabetes is a progressive condition affecting glucose metabolism. People with diabetes are up to five times more likely to have cardiovascular disease than people without diabetes. Cardiovascular causes account for more than 65 per cent of deaths in people with diabetes.&lt;BR&gt;&lt;BR&gt;&lt;FONT face="Arial Black"&gt;Current treatment:&lt;/FONT&gt; Oral antidiabetes drugs are commonly used for glycaemic control, however, there are concerns that some may increase cardiovascular risk. &lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NiwxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NiwxMjcxODAzMDU=" target="_blank"&gt;&lt;FONT title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NiwxMjcxODAzMDU= color=#0000ff&gt;NICE recommends &lt;/FONT&gt;&lt;/A&gt;metformin &lt;IMG height=198 alt="Blood sugar monitor" hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343992/nelhImp_0001_EoEi10_HighBloodSugar.jpg" width=152 align=left vspace=10 border=0 NOSEND="1"&gt;and sulfonylureas as first and second line oral glucose-lowering therapy when indicated. Thiazolidinediones such as pioglitazone and rosiglitazone, are recommended in some patients instead of a sulfonylurea as second-line therapy to first-line metformin when blood glucose is not adequately controlled. It advises to not commence or continue a thiazolidinedione (pioglitazone, rosiglitazone) in people who have heart failure, or who are at higher risk of fracture.&lt;BR&gt;&lt;BR&gt;&lt;FONT face="Arial Black"&gt;New evidence:&lt;/FONT&gt;&amp;nbsp; Tzoulaki et al (&lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NywxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NywxMjcxODAzMDU=" target="_blank"&gt;&lt;FONT title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5NywxMjcxODAzMDU= color=#0000ff&gt;BMJ 2009;339(dec03_1):b4731&lt;/FONT&gt;&lt;/A&gt;) investigated the risk of incident myocardial infarction, congestive heart failure and all cause mortality associated with oral antidiabetes drugs. The results are based on a retrospective cohort study using the general practice research database, of 91,521 people aged between 35 and 90 with diabetes.&lt;BR&gt;The findings suggest a relatively unfavourable risk profile of sulfonylureas compared with metformin for all outcomes examined, highlighting the potential risk of sulfonylureas on cardiovascular complications and all case mortality.&lt;BR&gt;Pioglitazone was associated with reduced all cause mortality compared with metformin. The drug also was shown to have a favourable risk profile compared to rosiglitazone, which the authors conclude could have implications for prescribing within the thiazolidinedione group. The economic implications of prescribing this drug need to be examined before any guidance on its use is updated.&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT color=#000000 size=2&gt;&lt;FONT face="Arial Black"&gt;Commentary:&lt;/FONT&gt; "Sulfonylurea has been associated with hypoglycaemia and increased risks of cardiovascular disease and all cause mortality. The newer glucose-lowering agents do not &lt;IMG height=135 alt="A ball and stick model of pioglitazone " hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343992/nelhImp_0002_EoEi10_Pioglitazone.jpg" width=198 align=right vspace=10 border=0 NOSEND="1"&gt;seem to have some of these disadvantages.&lt;BR&gt;"This study sheds more light on these new drugs highlighting the benefits of pioglitazone which is shown to have a significantly lower risk of all cause mortality.&lt;BR&gt;"Pioglitazone is due to come off patent in around 12 month's time, after which it is likely to drop in price, making it a similar cost to sulfonylurea. When this happens national guidelines may come to reflect the value of using pioglitazone second to metformin.&lt;BR&gt;"This could mean that pioglitazone&amp;nbsp;may replace sulfonylurea as the preferred agent to be used as second line treatment to metformin.&lt;EM&gt; - Dr Roger Gadsby is the clinical lead for NHS Evidence – diabetes&lt;BR&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=395&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>125815</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/40/12/04134012.pdf]]&gt;</url>
    <title>Caring for people with long term conditions</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,SECONDARY PREVENTION,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document provides a framework for commissioners and providers of education and training for community matrons and case managers. It is designed to help ensure that education and training for practitioners enables them to provide more effective care for people with complex long term conditions.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; PCT CEs, NHS Trust CEs, SHA CEs, Care Trust CEs, Foundation Trust CEs, Directors of Nursing, Directors of HR, Allied Health Professionals, Directors of Social Services,Deans of Nursing in HEI’s, Directors of Workforce Planning.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published April 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>33971</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/20/2543]]&gt;</url>
    <title>Case definitions for acute coronary heart disease in epidemiology and clinical research studies : a statement from the American Heart Association et al.</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GENERAL,CONDITIONS,DIAGNOSIS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement proposes case definition standards for coronary heart disease (CHD). Sections are included on ischaemic CHD in developing countries and measuring population trends in ischaemic CHD.&amp;nbsp; Includes tabular information and references. Published in Circulation 2003;108:2543. 
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>77815</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.chestjournal.org/current.shtml#CARDIOLOGY]]&gt;</url>
    <title>Chest : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Chest, The American College of Chest Physicians</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Chest: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277016</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?pagename=CHESTPAIN]]&gt;</url>
    <title>Chest Pain Evidence Update: February 2007</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS,STABLE ANGINA,OTHER,CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2 face=ArialMT&gt;
&lt;P align=left&gt;A literature search was performed to find new systematic reviews and randomised controlled trials published on chest pain since the publication of the European Task force on the management of chest pain (Erhardt L et al, 2002). This evidence update on chest pain identifies new significant knowledge published since August 2001 (one year prior to the publication of the task force document).&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/FONT&gt;&lt;FONT size=2 face=ArialMT&gt;&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>223732</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004820/pdf_fs.html]]&gt;</url>
    <title>Chest pain observation units for patients with symptoms suggestive of acute cardiac ischaemia : protocol</title>
    <publicationDate>2004-07-19T00:00:00</publicationDate>
    <publisher>The Cochrane Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,OTHER,STABLE ANGINA,GENERAL/OTHER,MYOCARDIAL INFARCTION,UNSTABLE ANGINA,CONDITIONS,CHEST PAIN,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=AGaramond-Regular size=1&gt;
&lt;P align=left&gt;This is the protocol for a review.&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Chest pain accounts for 20-30% of all medical admissions in the US and in the UK. The diagnosis of an acute coronary syndrome&amp;nbsp;(a range of conditions&amp;nbsp;from unstable angina to myocardial infarction) remains a complex and difficult issue for emergency physicians.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; The primary objective of this study was to compare chest pain observation unit care with (routine) emergency care in terms of morbidity (myocardial infarction, acute heartfailure, urgent cardiac revascularisation) and mortality (from all causes and due to cardiovascular diseases) in adult patients presenting to the emergency department with chest pain.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&amp;nbsp;Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398535</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.arif.bham.ac.uk/c/chest-pain-services-south-asian-and-deprived-communities.shtml]]&gt;</url>
    <title>Chest Pain Services South Asian Communities Deprived Communities Chest Pain Assessment</title>
    <publicationDate>2010-03-30T00:00:00</publicationDate>
    <publisher>Aggressive Research Intelligence Facility</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CHEST PAIN,DIAGNOSIS,STABLE ANGINA,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; NICE are due to publish guidelines on the management of patients presenting with chest pain of cardiac origin. The guidelines have taken into account two studies that have examined whether patients from Asian origin have atypical chest pain, and whether this should be considered during patient assessment. &lt;BR&gt;&lt;BR&gt;Both studies found that Asian patients were younger and more likely to have diabetes. Weak evidence suggests that there were more Asian patients with atypical symptoms than Caucasians. This is also an area that needs further research.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General public.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;ARIF Disclaimer:&lt;/STRONG&gt; The information is only a very brief summary of that available at the time. It was primarily designed to give readers a starting point to consider research evidence in a particular area. Readers should not use the comments made in isolation and should read the literature suggested. Readers should also be aware that more appropriate evidence may have become available since the request was undertaken. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125843</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/43/68/04134368.pdf]]&gt;</url>
    <title>Choice at referral : guidance framework for 2006 / 7</title>
    <publicationDate>2006-04-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This document supplements exisiting guidance on choice at referral policy and implementation by setting out a framework to govern the extension of choice in 2006/7.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143470</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/55/42/04135542.pdf]]&gt;</url>
    <title>Choice matters : increasing choice improves patients' experience</title>
    <publicationDate>2006-05-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This document provides an update on patient choice within the NHS, since it was introduced at the start of 2006.&amp;nbsp; It focuses on the experiences of patients and NHS staff. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125814</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/44/73/04134473.pdf]]&gt;</url>
    <title>Choosing Health : Obesity Bulletin</title>
    <publicationDate>2006-05-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ BIOLOGICAL COMPOSITION,OBESITY,GUIDELINES,STRATEGY,DIET,OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY,PREVENTION,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,GOVERNMENT &amp; LAW,FRAMES OF REFERENCE,INFORMATION,GOVERNMENT,MANAGEMENT &amp; POLICY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The Obesity Bulletin provides an update on latest developments in the Obesity programme and highlights good practice.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3925</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4005803&amp;chk=F3lXOg]]&gt;</url>
    <title>Chronic disease management and self care</title>
    <publicationDate>2002-08-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,KEY POLICIES,DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,NATIONAL SERVICE FRAMEWORK FOR CHD,PPI IN PRACTICE,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Part of National Service Frameworks (NSFs)&amp;nbsp;: A Practical Aid To Implementation In Primary Care series. This document deals with cardiovascular disease, hypertension, diabetes and dementia are conditions that can be managed within the primary care setting. Disease registers (including call and recall systems), effective prescribing and medicines management, and the enabling of self-care and patient empowerment are all key to effective management within primary care. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/support/downloads/main.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3649</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/96/9/3243]]&gt;</url>
    <title>Cigarette smoking, cardiovascular disease, and stroke : a statement for healthcare professionals from the American Heart Association</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association. Task Force on Risk Reduction, Ockene IS, Miller NH</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,STROKE,ISCHAEMIC STROKE,PREVENTION,HAEMORRHAGIC STROKE,CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,SMOKING CESSATION,PREVENTION,LATER LIFE,STROKE,CAUSES AND PRIMARY PREVENTION,SMOKING CESSATION,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This advisory emphasises the value of smoking cessation intervention by healthcare professionals and outlines methods found to be of value. Issues explored include physician intervention, smoking cessation pharmacotherapy, organisation of primary and secondary care services. Published in Circulation 1997, 96(9), 3243-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83465</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/current.shtml]]&gt;</url>
    <title>Circulation : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Circulation, American Heart Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,STROKE,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Circulation : Current Issue&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70792</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/rapidaccess.shtml]]&gt;</url>
    <title>Circulation : rapid access articles</title>
    <publicationDate></publicationDate>
    <publisher>Circulation, American Heart Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,STROKE,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Circulation&amp;nbsp;: articles published ahead of print&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343962</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1349.pdf]]&gt;</url>
    <title>Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation</title>
    <publicationDate>2009-11-10T00:00:00</publicationDate>
    <publisher>Health Technology Assessment</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-HYPERTENSIVE DRUGS,ANTI-PLATELET DRUGS,HYPERTENSION,DISEASE MANAGEMENT,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;FONT color=#231f20 size=2 face=Humanist521BT-Roman&gt;&lt;/P&gt;
&lt;P align=left&gt;The review aims to investigate the clinical and costeffectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of adults with pulmonary arterial hypertension (PAH) within theirlicensed indications.&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89262</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/execsumm/summ838.htm]]&gt;</url>
    <title>Clinical effectiveness and cost effectiveness of clopidogrel and modified release dipyridamole in the secondary prevention of occlusive vascular events : a systematic review and economic evaluation</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,ANTI-PLATELET DRUGS,CORONARY HEART DISEASE,ASPIRIN,GENERAL  / OVERVIEWS,OTHER,SECONDARY PREVENTION,CLOPIDOGREL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Clopidogrel was marginally more effective than aspirin at reducing risk of ischaemic stroke, MI or vascular death in patients with atherosclerotic vascular disease, however it did not&amp;nbsp;statistically significantly reduce the risk of vascular death or death from any cause complared with aspirin.&amp;nbsp; There was no statistically significant difference in the number of bleeding complications experienced in the clopidogrel and aspirin groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A total of 2906 titles and abstracts were rigorously screened and 441 studies were assessed in detail.&amp;nbsp; Two RCTs were identified.&amp;nbsp; For the assessment of cost-effectiveness, eight reviews were identified.&amp;nbsp; The results were presented in structured tables and as a narrative summary.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In the CAPRIE trial the point estimate for the primary outcome, i.e. ischaemic stroke, myocardial infarction (MI), or vascular death, favoured cloidogrel over aspirin, but the boundaries of the confidence intervals raise the possibility that clopidogrel is not more beneficial than aspirin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technology Assessment. Vol 8 No. 38, 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published in October 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89232</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/execsumm/summ917.htm]]&gt;</url>
    <title>Clinical effectiveness and cost effectiveness of immediate angioplasty for acute myocardial infarction : systematic review and economic evaluation</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,INTERVENTIONS / PROCEDURES,THROMBOLYTICS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,REPERFUSION,RESCUE PCI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; If both immediate angioplasty and thrombolysis were routinely available, the economic analysis favours percutaneous coronary interventions&amp;nbsp;(PCI), given the assumptions of the model.&amp;nbsp; However, very few units in England could offer a routine immediate PCI service at present, and there would be considerable resource implications of setting up such services.&amp;nbsp; A gradual incremental approach based on clinical networks, with transfer to centres able to offer PCI, may be used.&amp;nbsp; In rural areas, one option may be to promote an increase in prehospital thrombolysis, with PCI for thrombolysis failures.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp;A comprehensive review of randomised control trials (RCTs) was used for efficacy, and a selection of observational studies used for effectiveness in routine practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The results were consistent in showing an advantage of immediate angioplasty over hospital thrombolysis.&amp;nbsp; The updated meta-analysis showed that mortality is reduced by about one third, from 7.6% to 4.99% in the first six months, and by about the same in studies up to 24 months.&amp;nbsp; Reinfarction is reduced by over half, from 7.6% to 3.1%.&amp;nbsp; Stroke is reduced by about two thirds from 2.3% with thrombolysis to 0.7% with percutaneous coronary intervention.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematice review and economic evaluation. Health Technology Assessment. Vol 9: No.17, 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published May 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>34498</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/109/4/551]]&gt;</url>
    <title>Clinical management of metabolic syndrome : report of the American Heart Association / National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIET,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report follows on from an earlier report which considered the definition of metabolic syndrome.&amp;nbsp; This&amp;nbsp;document considers the clinical management of metabolic syndrome in relation to the following issues: pathogenesis and presentation of the metabolic syndrome, management of underlying risk factors, management of metabolic risk factors and unresolved issues and research challenges.&amp;nbsp; Includes references.&amp;nbsp; Published in Circulation 2004;109:551-556. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89233</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/execsumm/summ840.htm]]&gt;</url>
    <title>Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non ST segment elevation acute coronary syndromes : a systematic review and economic evaluation</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-PLATELET DRUGS,ASPIRIN,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,CLOPIDOGREL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results of the CURE trial indicate that clopidogrel in combination with aspirin was significantly more effective than placebo combined with aspirin in a wide range of patients with acute coronary syndromes.&amp;nbsp; This benefit was largely related to a reduction in Q-wave myocardial infarction.&amp;nbsp;&amp;nbsp;There was no statistically significant benefit in relation to mortality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies were selected using rigorous criteria.&amp;nbsp; The quality of randomised controlled trials (RCTs) was assessed according to criteria based on NHS Centre for Reviews and Dissemination (CRD)&amp;nbsp;Report No. 4 and the quality of systematic reviews was assessed according to the guidelines of the Database of Reviews of Effect (DARE) criteria.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; One RCT (the CURE trial) was a randomised, double-blind, placebo controlled trial of high quality and showed that clopidogrel in addition to aspirin was significantly more effective than placebo plus aspirin in patients with non-ST-segment-elevation acute coronary syndromes for the composite outcomes of death from cardiovascular causes, non-fatal myocardial infarction or stroke over the 9 month treatment period.&amp;nbsp; However, clopidogrel was associated with a significantly higher number of episodes of both major and minor bleeding.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Main C, Palmer, S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technology Assessment. Vol 8: No. 40, 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398324</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.arif.bham.ac.uk/c/combined-use-aspirin-clopidogrel-warfarin.shtml]]&gt;</url>
    <title>Combined use of Aspirin, Clopidogrel and Warfarin Stents Percutaneous Coronary Intervention (PCI) Cardiovascular Disease</title>
    <publicationDate>2009-06-02T00:00:00</publicationDate>
    <publisher>Aggressive Research Intelligence Facility</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,ANTI-COAGULANTS,ANTI-PLATELET DRUGS,INTERVENTIONS / PROCEDURES,ASPIRIN,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,WARFARIN,CLOPIDOGREL,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The data from both the review and RCT suggest a trend toward increased bleeding in patients who take an antiplatelet combined with an anticoagulant. Therapeutic effects, regarding thrombus formation and cardiovascular events appears to be less studied, with mixed benefits reported. Expert opinion suggests that decisions to use aspirin, clopidogrel and warfarin, should take into account the risks and benefits for each patient. &lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published March 2009&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General Public.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;ARIF Disclaimer:&lt;/STRONG&gt; The information is only a very brief summary of that available at the time. It was primarily designed to give readers a starting point to consider research evidence in a particular area. Readers should not use the comments made in isolation and should read the literature suggested. Readers should also be aware that more appropriate evidence may have become available since the request was undertaken. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392198</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://system.improvement.nhs.uk/ImprovementSystem/ViewDocument.aspx?path=Cardiac%2fNational%2fWebsite%2fBulletins%2fHeart%2fbulletin_11jan2010%2f101209_CR%20Packs_Final.pdf]]&gt;</url>
    <title>Commissioning Pack for Cardiac Rehabilitation</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,CARDIAC REHABILITATION CENTRES,CLINICAL AUDIT AND GOVERNANCE,NHS IMPROVEMENT,CARDIAC REHABILITATION,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Commissioning Pack's will enable the effective commissioning of Cadiac Rehabilitation; ensuring the shape of CR services reflects best clinical evidence and use of CR resources are optimal. This will raise both quality and productivity of CR services and will help to meet the challenge of providing timely access to good quality, patient-centred CR.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177490</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;ID=12006008116]]&gt;</url>
    <title>Comparison of primary and facilitated percutaneous coronary interventions for ST elevation myocardial infarction : quantitative review of randomised trials</title>
    <publicationDate></publicationDate>
    <publisher>Database of Abstracts of Reviews of Effectiveness, Centre for Reviews and Dissemination</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,REVASCULARISATION,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; Facilitated percutaneous coronary intervention&amp;nbsp;(PCI) does not offer any additional benefits compared with primary percutaneous intervention in patients with ST - segment elevation myocardial infarction (STEMI). 
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; This is a 2006 DARE (Database of Abstracts of Reviews of Effects) structured abstract of a 2006 systematic review. The authors' objective was to compare facilitated regimens and primary approaches of percutaneous coronary intervention. 
&lt;P&gt;&lt;STRONG&gt;Quality Assessment:&lt;/STRONG&gt; 
&lt;UL&gt;
&lt;LI&gt;Publication bias was not explored 
&lt;LI&gt;Full details of the validity criteria were not provided 
&lt;LI&gt;Biases on&amp;nbsp;aspects of the review process could not be ruled out &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;However, despite the above mentioned comments DARE recognises,&amp;nbsp;' The conclusions are an accurate reflection of the evidence presented and&amp;nbsp;given the high incidence of adverse events the recommendations for practice are justified.'&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Original study:&lt;/STRONG&gt;&amp;nbsp;Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST- elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006;367:579-588.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access to review:&lt;/STRONG&gt;&amp;nbsp;Abstract only. Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262218</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ccad.org.uk/congenital]]&gt;</url>
    <title>Congenital heart disease website</title>
    <publicationDate></publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,STATISTICS,DISEASE MANAGEMENT,CONGENITAL HEART DISEASE,PATIENT INFORMATION,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;A website resource created by The Information Centre for Health and Social Care.&amp;nbsp;&amp;nbsp;Information&amp;nbsp;on every congenital heart disease centre in the UK, including the number and range of procedures they carry out and survival rates for the most common types of treatment is included.&lt;/P&gt;
&lt;P&gt;Contributors include the&amp;nbsp;Society for Cardiothoracic Surgery, The British Congenital Cardiac Association (BCCA) formerly the British Paediatric Cardiac Association. &lt;/P&gt;
&lt;P&gt;The website has been funded by the Healthcare Commission.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156339</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/113/14/1807]]&gt;</url>
    <title>Contemporary definitions and classification of the cardiomyopathies</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,GENERAL  / OVERVIEWS,PREVENTION,CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;This document proposes a new contemporary and rigorous classification of cardiomyopathies with definitions.&amp;nbsp; Of particular note, the present classification scheme recognises the rapid evolution of molecular genetics in cardiology, as well as the introduction of several recently described diseases, and is unique in that it incorporates ion channelopathies as a primary cardiomyopathy.&amp;nbsp; Published in Circulation,&amp;nbsp;2006, 113(14):1807-16.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published March 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371705</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=SDwfTKWHaZA%3d&amp;tabid=36]]&gt;</url>
    <title>Continuing to improve cardiac services</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,HEART FAILURE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,RECENT ADDITIONS,APRIL 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;FONT face=Arial&gt;Launched at the NHS Improvement National Heart Conference the Heart Improvement Programme National Project Summaries 2009/10 details the areas the Heart Improvement Programme has been working on during 2009/10 and briefly describes the various ideas that have been tested by commissioners and providers across &lt;?xml:namespace prefix = st1 /&gt;&lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;England&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;/FONT&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287617</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/115/20/2675]]&gt;</url>
    <title>Core components of cardiac rehabilitation / secondary prevention programs : 2007 update : a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,PREVENTION,CARDIAC REHABILITATION,SECONDARY PREVENTION,APR-JUNE 08,CORONARY HEART DISEASE,GENERAL,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;update 'Core components of cardiac rehabilitation/secondary prevention programs: a statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group', published in 2000.&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;present current information on the evaluation, interventions, and expected outcomes in each of the core components of cardiac rehabilitation/secondary prevention programs, in agreement with the 2006 update of the American Heart Association/American College of Cardiology Secondary Prevention Guidelines.&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304164</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ncepod.org.uk/2008cabg.htm]]&gt;</url>
    <title>Coronary Artery Bypass Grafts: The heart of the matter 2008</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>National Confidential Enquiry into Patient Outcome and Death</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,DISEASE MANAGEMENT,CORONARY ARTERY BYPASS GRAFTS,SURGICAL PROCEDURES,GENERAL/OTHER,JAN-MAR 09,CORONARY HEART DISEASE,CONDITIONS,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>
</description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This National Confidential Enquiry into Patient&amp;nbsp;Outcome and Death report analyses the care of a sample of patients who in the majority&amp;nbsp;did not survive to leave hospital following their operation. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3658</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon423.pdf]]&gt;</url>
    <title>Coronary artery stents in the treatment of ischaemic heart disease : a rapid and systematic review</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ARTERY BYPASS GRAFTS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The objective of this review is to address the effects and effectiveness of elective stent insertion versus percutaneous coronary angioplasty (PTCA) and coronary artery bypass (CABG) in subacute ischaemic heart disease and acute myocardial infarction. Published in Health Technology Assessment, 2000;4(23). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document Format / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89292</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon835.pdf]]&gt;</url>
    <title>Coronary artery stents: a rapid systematic review and economic evaluation</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ARTERY BYPASS GRAFTS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ACUTE CORONARY SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom -line conclusion:&lt;/STRONG&gt;&amp;nbsp; DES might be considered cost-effective if the additional cost (compared with ordinary stents) was substantially reduced, the outcome benefits from the use of DES were much improved, and/or its use targeted on the subgroups of patients with the highest risks of requiring reintervention.&amp;nbsp; Long-term clinical studies are needed that focus on significant outcomes such as mortality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Randomised controlled trials that include comparisons of percutaneous transluminal coronary angioplasty (PTCA) versus PCTA with stent, stent versus coronary artery bypass (CABG), and drug eluting stents (DES) versus non-DES in patients with CAD in native or graft vessels and those with stable angina or acute coronary syndromes (ACS) and unstable anginawere also included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Stents were found to be more effective than PTCA in preventing adverse events and revascularisations.&amp;nbsp; In multiple-vessel disease there was no evidence of a difference in mortality (at 1 year) between patients treated surgically and those receiving a stent.&amp;nbsp; A reduction in&amp;nbsp;event rate at 9 and 12 months was found in patients treated with DES.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Hill R, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technology Assessment. Vol 8 No. 35, 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3767</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/chdframework.pdf]]&gt;</url>
    <title>Coronary heart disease : guidance for implementing the preventive aspects of the NSF</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY,DIET,CARDIOVASCULAR DISEASES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance covers strategic development and interventions to promote CHD-related lifestyles. Sections include reducing smoking revalence, improving diet and nutrition, increasing physical activitiy, and reducing overweight and obesity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344579</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.chd-taskforce.com/chd_prevention_slidekits.html]]&gt;</url>
    <title>Coronary heart disease and stroke: risk factors and global risk</title>
    <publicationDate></publicationDate>
    <publisher>International Task Force For Prevention Of Coronary Heart Disease</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,RISK ASSESSMENT,GENERAL  / OVERVIEWS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Two scores for estimating the 10-year risk of developing a coronary event based on the latest and most comprehensive analysis of PROCAM are available. These are the PROCAM Quick Check and the PROCAM Health Check.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89173</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/27794/Discovery%20Interviews%20final%20report%2025%20April.pdf]]&gt;</url>
    <title>Coronary Heart Disease Collaborative : evaluation of discovery interviews final report</title>
    <publicationDate></publicationDate>
    <publisher>Coronary Heart Disease Collaborative</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ STROKE,SERVICE MODELS,PERFORMANCE INDICATORS,NHS IMPROVEMENT,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES,PATIENT AND PUBLIC INVOLVEMENT,INDIVIDUAL INVOLVEMENT,GETTING INFORMATION,PATIENT EXPERIENCE,PPI IN PRACTICE,TECHNIQUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Discovery interviews are based upon a philosophy that puts patients and carers at the centre, and values listening to their experiences as a way of gaining insight into their needs which is unavailable elsewhere.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The Discovery Interview process was piloted across 10 Coronary Heart Disease Collaborative (CHDC) sites in 2001 and susequently rolled out to a further 30 CHCD sites across England.&amp;nbsp; In 2004, an independent body was appointed to undertake an evaluation of the Discovery Interview approach, the results of which are outlined in this report.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Refocus support resources on "closing the loop", sharing stories and implementing service improvements. &lt;BR&gt;
&lt;LI&gt;Ensure that the Discovery Interviews are integrated with other aspects of patient and carer involvement and service improvement. &lt;BR&gt;
&lt;LI&gt;Ensure that Discovery Interviews do not take place until it is clear that the approach fits within the strategic vision of the organisation that is required to support it. &lt;BR&gt;
&lt;LI&gt;Ensure that while "on the ground" experiences of implementation are taken into account, the core methodology is adhered to. &lt;BR&gt;
&lt;LI&gt;Seek to gain a reassessment of the categorisation of Discovery Interviews as research.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in April 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;*Since publication the Coronary Heart Diseases Collaborative's&amp;nbsp;work has been subsumed&amp;nbsp;into the NHS Heart Improvement Programme&amp;nbsp;which was launched in April 2005.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3735</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4007849&amp;chk=KKNWbk]]&gt;</url>
    <title>Coronary heart disease information strategy</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Coronary Heart Disease Information Strategy outlines national and local activities supporting the delivery of integrated health care across health sectors. Priorities include electronic patient records, dataset and clinical audit database, rapid access chest pain clinics, practice-based registers, local implementation of Information for Health, and easy access to evidence base at the point of care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>88994</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/04017623_200904033853.pdf]]&gt;</url>
    <title>Coronary heart disease survey of patients 2004</title>
    <publicationDate></publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,NATIONAL SERVICE FRAMEWORK FOR CHD,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,PREVENTION,GENERAL,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Service Framework for Coronary Heart Disease survey of patients was carried out as part of a wider piece of work undertaken by the Healthcare Commission to look at how the National Service Framework for Coronary Heart Disease was being implemented.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;The survey took place during January and February 2004.&amp;nbsp; Approximately one third of acute and specialist trusts in England were sampled for the patient survey.&amp;nbsp; The sampled patients were sent a postal questionnaire and covering letters were sent to people who had not responded.&amp;nbsp; Questionnaires were sent to 5,185 patients and completed questionnaires were received from 3,784, a response rate of 75%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key findings:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Good progress has been made in a number of important areas, such as faster treatment for heart attack patients and reducing waiting times for revascularisation procedures. &lt;BR&gt;
&lt;LI&gt;Progress has been slower in arease such as prevention, treatment of heart failure and access to cardiac rehabilitation services. &lt;BR&gt;
&lt;LI&gt;Further work is needed in areas such as advice patients received when they were discharged, rehabilitation and links between GPs and hospitals.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260396</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074238]]&gt;</url>
    <title>Coronary heart disease ten years on - improving heart care</title>
    <publicationDate>2007-04-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ FOOD &amp; NUTRITION,NUTRITION,OUTCOMES,DETERMINANTS,CARDIOVASCULAR DISEASES,CIRCULATORY DISEASES,PROJECTS,PHYSICAL ACTIVITY,OVERWEIGHT AND OBESITY,PERFORMANCE INDICATORS,DIET,INTERVENTIONS / PROCEDURES,CORONARY HEART DISEASE,GENERAL,PREVENTION,CONDITIONS,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,PRIMARY PREVENTION,SERVICE MODELS,SMOKING CESSATION,STATISTICS,DEFIBRILLATION,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,PREVENTION,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,EATING HABITS,INDIVIDUAL BEHAVIOUR,SMOKING,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,CARE,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report sets out the progress made in coronary heart disease in the NHS over the last ten years.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212726</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063021]]&gt;</url>
    <title>Cost benefit analysis of health impact assessment : final report</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NHS IMPROVEMENT,CARDIOVASCULAR DISEASES,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The report provides the findings of the cost benefit evaluation of health impact assessment (HIA). The York Health Economics Consortium used qualitative and quantitative methods to assess the process, impact, outcomes, cost and benefits of 16 HIAs. The findings show the benefits outweigh the costs.&lt;/P&gt;
&lt;P align=left&gt;The&amp;nbsp;report&amp;nbsp;is now be subject to further consideration and the Department of Health welcomes comments from practitioners and stakeholders involved in health impact assessment.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302000</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/1539]]&gt;</url>
    <title>Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment Programme</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,ARRHYTHMIA,DISEASE MANAGEMENT,GENERAL/OTHER,ECONOMIC EVALUATIONS,OCT-DEC 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bottom –line conclusion:&lt;/STRONG&gt; The available evidence suggests that radio frequency catheter ablation (RFCA) is a relatively safe and efficacious procedure for the therapeutic treatment of AF and typical atrial flutter. There is some randomised evidence to suggest that RFCA is superior to AADs in patients with drug-refractory paroxysmal AF in terms of freedom from arrhythmia at 12 months. RFCA appears to be cost-effective if the observed quality of life benefits are assumed to continue over a patient’s lifetime. However, there remain uncertainties around longer-term effects of the intervention and the extent to which published effectiveness findings can be generalised to ‘typical’ UK practice.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic reviews of clinical studies and economic evaluations of catheter ablation for AF and typical atrial flutter were conducted. The quality of the included studies was assessed using standard methods. A decision model was developed to evaluate a strategy of RFCA compared with long-term antiarrhythmic drug (AAD) treatment alone in adults with paroxysmal AF. This was used to estimate the cost-effectiveness of RFCA in terms of cost per quality-adjusted life-year (QALY) under a range of assumptions. Decision uncertainty associated with this analysis was presented and used to inform future research priorities using the value of information analysis. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 4858 studies were retrieved for the review of clinical effectiveness. Of these, eight controlled studies and 53 case series of AF were included. Two controlled studies and 23 case series of typical atrial flutter were included. For atrial fibrillation, freedom from arrhythmia at 12 months in case series ranged from 28% to 85.3% with a weighted mean of 76%. Three RCTs suggested that RFCA is more effective than long-term AAD therapy in patients with drug-refractory paroxysmal AF. Single RCTs also suggested superiority of RFCA over electrical cardioversion followed by long-term AAD therapy and of RFCA plus AAD therapy over AAD maintenance therapy alone in drug-refractory patients. The available RCTs provided insufficient evidence to determine the effectiveness of RFCA beyond 12 months or in patients with persistent or permanent AF. Adverse events and complications were generally rare. Mortality rates were low in both RCTs and case series. Cardiac tamponade and pulmonary vein stenosis were the most frequently recorded complications. For atrial flutter, freedom from arrhythmia at 12 months in case series ranged from 85% to 92% with a weighted mean of 88%. Neither of the atrial flutter RCTs reported freedom from arrhythmia at 12 months. One RCT found a statistically significant benefit favouring ablation over AADs in terms of freedom from arrhythmia at a mean follow-up of 22 months. A second RCT reported a more modest effect favouring ablation in terms of freedom from atrial flutter at follow-up in older patients (mean age 78 years) after their first episode of flutter. In the atrial flutter case series, mortality was rare and the most frequent complications were atrioventricular block and haematomas. Complications in the RCTs were similar, except for those events likely to have been caused by AAD therapy (e.g. thyroid dysfunction). The review of cost-effectiveness evidence found one relevant study, which from a UK NHS perspective had a number of important limitations. The base-case analysis in the decision model demonstrated that if the quality of life benefits of RFCA are maintained over the remaining lifetime of the patient then the cost-effectiveness of RFCA appears clear. These findings were robust over a wide range of alternative assumptions, being between £7763 and £7910 per additional QALY with very little uncertainty. If the quality of life benefits of RFCA are assumed to be maintained for no more than 5 years, cost-effectiveness of RFCA is dependent on a number of factors. Estimates of cost-effectiveness that explored the influence of these factors ranged from £23,000 to £38,000 per QALY. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess 2008;12(34). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published November 2008&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.]]&gt;</body>
  </document>
  <document>
    <id>87372</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bentham.org/ccr/CurrentIssue.htm]]&gt;</url>
    <title>Current Cardiology Reviews : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Current Cardiology Reviews, Bentham Science Publishers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Current Cardiology Reviews: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389055</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ehnheart.org/euroheart/publications-wp-5-wp-6/publication/119-cvd-prevention-in-europe-the-unfinished-agenda.html]]&gt;</url>
    <title>CVD prevention in Europe - the unfinished agenda</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>European Heart Network</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,STATISTICS,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report deals with one of EuroHeart’s work packages – work package 5 - providing an overview of existing national strategies and actions in the fields of cardiovascular health promotion and/or disease prevention in 16 countries in Europe. Sections include: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction 
&lt;LI&gt;Background 
&lt;LI&gt;The EuroHeart mapping project 
&lt;LI&gt;Results 
&lt;LI&gt;General comments 
&lt;LI&gt;Essential elements in a comprehensive national strategy on cardiovascular diseases 
&lt;LI&gt;Conclusions 
&lt;LI&gt;Recommendations &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; This report is also available in Dutch, French, German, Greek, Hungarian, Italian, Slovak and Slovenian.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284858</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://d2b.acc.org/Menu/WhatisD2B/tabid/140/Default.aspx]]&gt;</url>
    <title>D2B - An Alliance for Quality</title>
    <publicationDate></publicationDate>
    <publisher>American College of Cardiology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;D2B - An Alliance for Quality is a new Guidelines Applied in Practice (GAP) program launched by the American College of Cardiology (ACC) to save time and save lives by reducing the door-to-balloon times in US hospitals performing primary percutaneous coronary intervention (PCI).&amp;nbsp; The website includes information on the program, participating hospitals, D2B implementation manual and presentations and slideshows.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Information last checked 15 october 2010.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343993</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=343993]]&gt;</url>
    <title>Debate continues over use of off-pump CABG - Eyes on Evidence Commentary</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,SURGICAL PROCEDURES,CORONARY ARTERY BYPASS GRAFTS,CURRENT AWARENESS - HOT OFF THE PRESS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Debate continues over use of off-pump CABG - Eyes on Evidence Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;TABLE cellSpacing=0 cellPadding=0 width=415 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=20&gt;&lt;IMG height=16 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343993/nelhImp_0000_art_eye.gif" width=20 NOSEND="1"&gt;&lt;/TD&gt;
&lt;TD vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="FONT-SIZE: 14px; COLOR: #0179c1; FONT-FAMILY: Arial, Helvetica, sans-serif" vAlign=top align=left width=395&gt;&lt;FONT size=3&gt;&lt;STRONG&gt;
&lt;P style="LINE-HEIGHT: 150%"&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'"&gt;&lt;FONT color=#000000 size=3&gt;&lt;U&gt;&lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OCwxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OCwxMjcxODAzMDU=" target="_blank"&gt;&lt;/A&gt;&lt;/U&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&amp;nbsp;&lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OSwxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OSwxMjcxODAzMDU=" target="_blank"&gt;&lt;FONT title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OSwxMjcxODAzMDU= color=#000000 size=3&gt;&lt;STRONG title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDI5OSwxMjcxODAzMDU=&gt;Debate continues over use of off-pump CABG&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD width=395 height=4&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-TOP: #0179c1 1px solid" vAlign=top align=left width=395&gt;
&lt;TABLE cellSpacing=0 cellPadding=0 width=395 border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=395 height=5&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="FONT-SIZE: 12px; COLOR: #0179c1; FONT-FAMILY: Arial, Helvetica, sans-serif" vAlign=top align=left width=395&gt;&lt;FONT color=#000000 size=2&gt;
&lt;P&gt;&lt;FONT color=#000000 size=2&gt;&lt;FONT face="Arial Black"&gt;Overview:&lt;/FONT&gt;&amp;nbsp; Coronary-artery bypass grafting (CABG) is open heart surgery to treat coronary artery disease using a blood vessel (a graft) taken from the chest wall, leg or arm to bypass a narrowed or &lt;IMG height=198 alt="Heart attack" hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343993/nelhImp_0001_EoE10HeartAttack.jpg" width=149 align=right vspace=10 border=0 NOSEND="1"&gt;blocked coronary artery. A CABG does not cure coronary artery disease so it is possible for blockages to recur in both the grafts and other blood vessels. However, it does improve symptoms such as angina.&lt;BR&gt;&lt;BR&gt;&lt;FONT face="Arial Black"&gt;Current treatment:&lt;/FONT&gt; Traditional CABG operations are performed 'on-pump' whereby the heart and lungs are connected to a bypass machine that takes over to add oxygen to the blood and maintain circulation. 'Off-pump' CABG is an alternative technique that doesn't require the patient to be connected to a heart-lung (bypass) machine.&lt;BR&gt;NICE states that current evidence on the safety and efficacy of off-pump coronary artery bypass appears adequate to support the use of this procedure, only when performed through a median sternotomy.&lt;BR&gt;&lt;BR&gt;&lt;FONT face="Arial Black"&gt;New evidence:&lt;/FONT&gt; The ROOBY study by Shroyer et al (&lt;A title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDMwMSwxMjcxODAzMDU= href="http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDMwMSwxMjcxODAzMDU=" target="_blank"&gt;&lt;FONT title=http://system.newzapp.co.uk/GLink.asp?LID=MzA2MDMwMSwxMjcxODAzMDU= color=#0000ff&gt;N Engl J Med. 2009 Nov 5;361(19):1827-37&lt;/FONT&gt;&lt;/A&gt;) compared outcomes for 2203 patients randomised to receive on-pump or off-pump CABG for urgent or elective procedures. A standard median sternomy was performed on all patients in the study. There was no difference between the two groups for the short-term (30-day) composite outcome of death or complications. However, the off-pump CABG group experienced poorer outcomes for the other composite primary endpoint at 1 year — the rate of death, repeat revascularisation procedure or nonfatal myocardial infarction was significantly higher in this population. Graft patency and the completed number of planned interventions were also lower in the off-pump CABG group.&lt;BR&gt;The findings support current treatment but further research is required.&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT color=#000000 size=2&gt;&lt;FONT face="Arial Black"&gt;Commentary:&lt;/FONT&gt; ""This important paper enhances knowledge of off pump CABG surgery. Large surgical randomized trials are unusual because of logistical difficulties and expense. &lt;BR&gt;&lt;IMG height=132 hspace=10 src="https://rmsadmin.library.nhs.uk/libraryImages/Cardiovascular%20Diseases/contentID343993/nelhImp_0002_EoEi10_StethoscopeWithHeart.jpg" width=198 align=left vspace=10 border=0 NOSEND="1"&gt;"However, I don't believe that off pump CABG can be discounted based on these findings. &lt;BR&gt;Substantial evidence, albeit retrospective, suggests that high risk patients suffer fewer deaths and complications after off pump surgery but patients with co-morbidities were largely excluded from this trial.&lt;BR&gt;"The significant difference between the number of grafts planned and the number of grafts completed in the off pump group suggests inexperience of surgeons. Surgeons were eligible if they had completed 20 prior off pump procedures. Because different coronary territories are not equally amenable to grafting, experience in one territory does not necessarily provide the experience and ability to treat triple vessel coronary disease. &lt;BR&gt;"Surgeon inexperience may also partially explain the inferior patency figures in grafts completed off pump. Postoperative coagulopathy may also have contributed to the increase in occluded grafts. New antiplatelet drugs such as clopidogrel, which are not routinely used in CABG surgery, may reverse the effect. &lt;BR&gt;"The CRISP trial, which has just opened recruitment, will compare outcomes after on pump and off pump CABG in high risk patients (ISRCTN29161170, MRC ref: G0700469). Trial organisers have taken steps to ensure that off pump operations are carried out by very experienced off pump surgeons."&amp;nbsp;&lt;EM&gt;- Joint analysis was provided by Professor Tom Quinn clinical lead for NHS Evidence - cardiovascular, stroke and vascular collections and Professor of Clinical Practice at the Faculty of Health and Medical Sciences, University of Surrey; Mr Norman Briffa, cardiothoracic surgeon from Sheffield and Professor Mike Larvin, Clinical Lead for NHS Evidence - Surgery&amp;nbsp;and Professor of Surgery at the University of Nottingham.&lt;/EM&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD vAlign=top align=left width=395&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>3791</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.resus.org.uk/pages/dnar.htm]]&gt;</url>
    <title>Decisions relating to cardiopulmonary resuscitation : a joint statement from the British Medical Association,  Resuscitation Council (UK) and the Royal College of Nursing</title>
    <publicationDate></publicationDate>
    <publisher>British Medical Association, Resuscitation Council (UK), Royal College of Nursing</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CARDIOPULMONARY ARREST,DISEASE MANAGEMENT,EMERGENCY CARE,CLINICAL LIBRARY,ORGANISATIONAL AND OTHER ISSUES,CARDIOVASCULAR,CONSENT,ETHICS AND STANDARDS,CARDIOPULMONARY ARREST,PALLIATIVE AND SUPPORTIVE CARE,CONDITIONS,CARDIOVASCULAR DISEASES,ETHICS &amp; LAW,WITHHOLDING &amp; WITHDRAWING TREATMENT,ADVANCED LIFE SUPPORT (ALS),BASIC LIFE SUPPORT (BLS),PROCEDURES,WITHOLDING / WITHDRAWING TREATMENT,CAPACITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The purpose of these guidelines is to outline legal and ethical standards for planning patient care and decision making in relation to cardiopulmonary resuscitation. The focus is on situations in which decisions are made in advance and form part of the patient’s care plan. Emergency situations where no advance decision has been made are also covered.]]&gt;</body>
  </document>
  <document>
    <id>34500</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/109/3/433]]&gt;</url>
    <title>Definition of metabolic syndrome : report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related to definition</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,DIABETES MELLITUS,DIET,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report considers the definition of metabolic syndrome from the following perspectives: major clinical outcomes, metabolic components, pathogenesis, clinical criteria for diagnosis, risk for clinical outcomes and therapeutic interventions.&amp;nbsp; Includes tabular information and references. Published in Circulation 2004;109:433-438. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3919</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4075279]]&gt;</url>
    <title>Delivering better heart services : progress report 2003</title>
    <publicationDate>2003-03-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,CORONARY HEART DISEASE,GENERAL  / OVERVIEWS,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Service Framework (NSF) for Coronary Heart Disease (CHD) sets 12 standards for improved prevention, diagnosis, treatment and rehabilitation and goals to secure fair access to high quality services. This document outlines the progress made in 3 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82462</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094550]]&gt;</url>
    <title>Delivering choosing health : making healthier choices easier</title>
    <publicationDate>2005-03-09T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,KEY POLICIES,PREVENTION,ALCOHOL DRINKING,DIET,GENERAL,GENERAL,HEALTH INEQUALITIES,DIET,OVERWEIGHT AND OBESITY,PRIMARY PREVENTION,SMOKING,SMOKING CESSATION,DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,DELIVERY OF CARE,OBESITY,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,OTHER LIFE STYLE,OTHER LIFE STYLE,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,COMMISSIONING,PUBLIC HEALTH,DETERMINANTS,OUTCOMES,INDIVIDUAL BEHAVIOUR,ALCOHOL CONSUMPTION,EATING HABITS,PHYSICAL ACTIVITY,SMOKING,TOBACCO USE,SOCIAL DETERMINANTS,LIFESTYLE,SOCIETY,MANAGEMENT &amp; INTERVENTIONS,SETTINGS,CANCER,CIRCULATORY DISEASES,LIVER DISORDERS,MENTAL &amp; BEHAVIOURAL DISORDERS,GEOGRAPHY,NATIONAL,GOVERNMENT &amp; LAW,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,GOVERNMENT,PUBLIC SERVICES,HEALTH SERVICES,FRAMES OF REFERENCE,POLICY,GOOD PRACTICE,GUIDELINES,CONDITION MANAGEMENT,PREVENTION,SCHOOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Delivering Choosing Health: making healthier choices easier outlines the commitments identified in the public health white paper. &lt;/P&gt;
&lt;P&gt;Choosing Health: making healthier choices easier will be delivered at national, regional and local level, across all sectors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document Format / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126258</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_100667]]&gt;</url>
    <title>Department of Health : Departmental Report 2009. The Health and Personal Social Services Programmes</title>
    <publicationDate>2009-06-11T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,PERFORMANCE INDICATORS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report provides both Parliament and the public with details of how the Department of Health has spent the resources that have been allocated to it. Future spending plans are also inlcuded. It also describes the departments policies and programmes and gives a breakdown of the spending within these programmes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3929</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4009037&amp;chk=XZox62]]&gt;</url>
    <title>Developing the information systems</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 1&lt;/FIRSTPAGE&gt;&lt;FIRSTPAGEID&gt;1&lt;/FIRSTPAGEID&gt;&lt;PAGE&gt;&lt;PAGEID&gt;1&lt;/PAGEID&gt;&lt;PAGESEQUENCE&gt;-1&lt;/PAGESEQUENCE&gt;&lt;PAGETITLE&gt;&lt;/PAGETITLE&gt;&lt;PAGEBODY&gt;&lt;P&gt;Part of National Service Frameworks (NSFs)&amp;nbsp;: A Practical Aid To Implementation In Primary Care series. This document explores information handling, systems, and registers at primary practice level in support of NSFs. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>61378</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Researchanddevelopment/A-Z/Cardiovasculardiseaseandstroke/DH_4015653]]&gt;</url>
    <title>DI5: What is the most cost effective anti thrombotic strategy to reduce mortality in heart failure?</title>
    <publicationDate>2002-10-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,ANTI-COAGULANTS,ANTI-PLATELET DRUGS,HEART FAILURE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors'&amp;nbsp;conclusion:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;It is technically feasible to conduct a study of patients with heart failure&amp;nbsp;&lt;STRONG&gt;with&lt;/STRONG&gt; a&amp;nbsp;placebo or "no treatment" arm (in which one-third of the patients would be randomised to no anti-thrombotic therapy) but that recruitment to such a study would be slow and costly.&amp;nbsp;This high cost&amp;nbsp;reflected the weight of peer pressure in favour of anti-thrombotic therapy in patients with heart failure and coronary disease. Although not the weight of evidence. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; This resource is an abstract of&amp;nbsp;a pilot study commissioned for the NHS R&amp;amp;D programme for cardiovascular disease presents the conclusion. For research methods refer to original study. 
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Athero-thrombotic events are common among patients with heart failure but there is no evidence that anti-thrombotic therapy is safe or effective in this clinical setting. A large trial comparing the effects of aspirin , warfarin and clopidogrel in three separate groups &lt;STRONG&gt;without &lt;/STRONG&gt;a placebo arm is now planned. 
&lt;P&gt;&lt;STRONG&gt;Original study:&lt;/STRONG&gt; The WASH study steering committee and investigators. The WASH Study (Warfarin/Aspirin Study in Heart Failure) rationale, design and end-points. European Journal of Heart Failure 1999;1:95-99 &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access to abstract:&lt;/STRONG&gt; Available to the general public. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access to original study on which review is based:&lt;/STRONG&gt; To access to the full-text of this article online requires subscription to the journal. NHS staff please &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt; &lt;BR&gt;
&lt;P class=MsoPlainText style="MARGIN: 3pt 0cm 0pt 7.1pt; tab-stops: 14.2pt"&gt;&lt;FONT face="Times New Roman" color=#000000 size=2&gt;&lt;/FONT&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3811</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/100/10/1134]]&gt;</url>
    <title>Diabetes and cardiovascular disease</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,CAUSES AND RISK FACTORS,CONDITIONS,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CORONARY HEART DISEASE,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement examines the cardiovascular complications of diabetes mellitus and considers opportunities for their prevention. These complications include coronary heart disease (CHD), stroke, peripheral arterial disease, nephropathy, retinopathy, and possibly neuropathy and cardiomyopathy. Published in Circulation 1999;100:1134-1146.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267824</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/103/2/335]]&gt;</url>
    <title>Diagnostic guidelines for Kawasaki disease</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Published 2001.&lt;/P&gt;
&lt;P align=left&gt;Accurate diagnosis and early therapeutic interventions can decrease the risk of developing coronary artery abnormalities.&lt;/P&gt;
&lt;P align=left&gt;This guide lists:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Principal clinical findings&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Other significant clinical and laboratory findings&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Selected reading&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267820</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.176158]]&gt;</url>
    <title>Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee</title>
    <publicationDate>2006-07-04T00:00:00</publicationDate>
    <publisher>American Heart Association Nutrition Committee</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,OUTCOMES,FOOD &amp; NUTRITION,NUTRITION,CIRCULATORY DISEASES,CARDIOVASCULAR DISEASES,PREVENTION,LIPIDS MANAGEMENT,DIET,PHYSICAL ACTIVITY,GENERAL,CARDIOVASCULAR DISEASES,PUBLIC HEALTH,PHYSICAL ACTIVITY,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,ALCOHOL CONSUMPTION,EATING HABITS,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; &amp;nbsp;A scientific statement from the American Heart Association Nutrition Committee.&lt;/P&gt;
&lt;P align=left&gt;Gives&amp;nbsp;recommendations to improve diet and lifestyle in order to reduce cardiovascular risk in the general population. Specific goals are listed with recommendations on how to achieve them.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277843</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1146.pdf]]&gt;</url>
    <title>Drug eluting stents : a systematic review and economic evaluation</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,ECONOMIC EVALUATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;FONT face=Humanist521BT-Bold size=2&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;The aim of this study&amp;nbsp;was to&amp;nbsp;assess the effectiveness and cost effectiveness of the use of drug eluting coronary artery stents in percutaneous coronary intervention (PCI) in patients with coronary artery disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt;&amp;nbsp;The use of&amp;nbsp;drug eluting stents&amp;nbsp;would be best targeted at the subgroups of patients with the highest risks of requiring reintervention, and could be considered cost effective in only a small percentage of such patients (HTA, 2007).&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5285</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon715.pdf]]&gt;</url>
    <title>Early thrombolysis for the treatment of acute myocardial infarction : a systematic review and economic evaluation</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,THROMBOLYTICS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,REPERFUSION,LUCY'S QUERIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This systematic review and economic evaluation examines the clinical and cost-effectiveness of available drugs for early thrombolysis in the treatment of acute myocardial infarction in hospital and pre-hospital settings. Chapters are included on background information on coronary heart disease and thrombolytic agents licensed for use, methods for reviewing clinical effectiveness and cost effectiveness and an economic evaluation of the results. The authors’ comment that no clear conclusion based on statistical comparison can be drawn regarding clinical effectiveness and that the decision regarding which agent to use is a balance of the risks and benefits related to mortality and stroke. The economic evaluation of the agents produces similar results and concludes that cost-effectiveness becomes largely determined by the acquisition costs of the drug. Streptokinase was therefore the most cost-effective drug. Health Technology Assessment 2003; Vol. 7: No 15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3573</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/collection/arrhythmias]]&gt;</url>
    <title>eBMJ collected resources : arrhythmias</title>
    <publicationDate></publicationDate>
    <publisher>British Medical Journal, BMJ Publishing Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,ARRHYTHMIA,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Collected resources on arrhythmias from the online British Medical Journal. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>35034</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/20/2575]]&gt;</url>
    <title>Education in resuscitation : an ILCOR symposium : Utstein Abbey: Stavanger, Norway: June 22-24, 2001</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,DEFIBRILLATION,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,CARDIOPULMONARY ARREST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement contains the discussions and recommendations of the International Liaison Committee on Resuscitation (ILCOR) Symposium 'Education in Resuscitation'.&amp;nbsp; Sections are included on general objectives in cardiopulmonary resuscitation (CPR) training, training laypersons in basic life support (BLS) and new technologies in training.&amp;nbsp; Includes assessment guidelines and references.&amp;nbsp; Full-text available.&amp;nbsp; Published in Circulation 2003;108:2575.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102763</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/project/1153.asp]]&gt;</url>
    <title>Effectiveness and cost effectiveness of alternative strategies for the initial medical management of presumed unstable angina : a decision model and systematic literature review</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ LOW MOLECULAR WEIGHT HEPARINS,HEPARIN,UNSTABLE ANGINA,ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,ANTI-COAGULANTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Effectiveness and cost effectiveness of alternative strategies for the initial medical management of presumed unstable angina : a decision model and systematic literature review&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Initial consideration of a number of new drug treatments for non-ST elevation Acute Coronary Syndrome (ACS) concluded that the most important uncertainties surrounded the use of glycoprotein IIb/IIIa antagonists (GPAs).&amp;nbsp; The systematic review and decision model clearly demonstrated that use of GPAs in all patients as part of initial medical management was more cost-effective than selective use associated with intervention, or no use at all.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp;Potential areas of uncertainty were identified by discussion with clinicians, and by identfying areas of disagreement in published guidelines.&amp;nbsp; A systematic literature review was limited to the most highly prioritised decision problems.&amp;nbsp; It focused on published&amp;nbsp;RCTs and full economic evaluations.&amp;nbsp; A two-part decision model was constructed that consisted of a short-term and long-term phase.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Results before sensitivity analysis suggested that strategy 1 (use of GPAs as part of initial management of all non-ST elevation ACS) was the optimal choice, with an incremental cost-effectiveness ratio (ICER) of £5738 per quality-adjusted life-year (QALY) compared with no use of GPAs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L Bowens A, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical model.&amp;nbsp; Health Technology Assessment. Vol 9: No.27, 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>93284</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.york.ac.uk/inst/crd/EHC/ehc84.pdf]]&gt;</url>
    <title>Effectiveness of antihypertensive drugs in black people</title>
    <publicationDate></publicationDate>
    <publisher>University of York, NHS Centre for Reviews and Dissemination</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,HYPERTENSION,ANTI-HYPERTENSIVE DRUGS,CAUSES AND RISK FACTORS,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CARDIOVASCULAR DISEASES,DISEASES AND CONDITIONS,ETHNICITY AND HEALTH,STROKE,CAUSES / RISK FACTORS,ISCHAEMIC STROKE,HAEMORRHAGIC STROKE,PREVENTION,HYPERTENSION,CAUSES / RISK FACTORS,CAUSES / RISK FACTORS,PREVENTION,HYPERTENSION MANAGEMENT,PREVENTION,ETHNIC GROUPS,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; There is insufficient evidence to conclude that any antihypertensive drug or drug combination is superior in reducing morbidity and mortality outcomes in hypertensive black people. The commonly used antihypertensive drugs differ in their efficacy to lower blood pressure levels in black people. In particular, the blood pressure lowering effects of ACE inhibitors for diastolic and beta-blockers for systolic blood pressure were not significantly different from placebo. Betablockers might even increase systolic blood pressure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; This issue of Effective Health Care summarises the available research evidence on the effects of commonly used antihypertensive drugs on blood pressure reduction and morbidity and mortality outcomes in black people.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; Published in 2004&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3897</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/effective_eating_elderly.pdf]]&gt;</url>
    <title>Effectiveness of interventions to promote healthy eating in elderly people living in the community : a review</title>
    <publicationDate>1998-06-01T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,FOOD &amp; NUTRITION,FOOD,NUTRITION,ADULTS,LOCAL COMMUNITIES,OLDER PEOPLE,CARDIOVASCULAR DISEASES,PREVENTION,DIET,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,EATING HABITS,ANALYSIS,METHODS,MONTHLY ADDITIONS,2008-JULY,ANALYSIS &amp; RESEARCH,POPULATIONS,COMMUNITIES,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Health Promotion Effectiveness Review : Summary Bulletin 08. The majority of health promotion studies targeting elderly people which were found by this review used nutrition interventions to reduce the risk of coronary heart disease, placing emphasis on reducing saturated fat intake, increasing fruit and vegetable consumption, and reducing salt intake. Overall, there is some evidence for the effectiveness of health promotion interventions to increase healthy eating in elderly people. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>87963</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://emj.bmjjournals.com/current.shtml]]&gt;</url>
    <title>Emergency Medicine Journal : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Emergency Medicine Journal, BMJ Publishing Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Emergency Medicine Journal: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301042</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nao.org.uk/publications/0708/end_of_life_care.aspx]]&gt;</url>
    <title>End of life care</title>
    <publicationDate>2008-11-26T00:00:00</publicationDate>
    <publisher>National Audit Office</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,HEART FAILURE,SERVICE MODELS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,EMERGENCY CARE,CLINICAL LIBRARY,ORGANISATIONAL AND OTHER ISSUES,GENERAL/OTHER,STROKE,ISCHAEMIC STROKE,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,DISEASE MANAGEMENT,REHABILITATION,PALLIATIVE CARE,MANAGEMENT ISSUES,PATIENT CHOICE,SERVICE MODELS,OCT-DEC 08,OCT-DEC 08,END OF LIFE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This report is an examination of the current provision of end of life care services and identifies the potential for improving their quality.&amp;nbsp; It also highlights the issues that will need to be addressed in the implementation of the Department of Health’s &lt;A href="nelh:291811:0" name=internalLink&gt;End of Life Care Strategy&lt;/A&gt;.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 26th November 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380723</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://system.improvement.nhs.uk/ImprovementSystem/ViewDocument.aspx?path=Cardiac%2fNational%2fWebsite%2fHeart%2fHeart%20Failure%2fEOL_in_HF.pdf]]&gt;</url>
    <title>End of life care in heart failure: A framework for implementation</title>
    <publicationDate>2010-07-05T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,HEART FAILURE,SERVICE MODELS,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,JULY 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This guide highlights how an end of life care service can best accommodate the specific needs of heart failure patients.&amp;nbsp;&lt;BR&gt;The frame work takes each step of the end of life pathway and suggests the heart failure specific care that a patient and their carers need and how it can be delivered in the community, in the hospice environment or in secondary care, allowing the patient and carer real choice in their preferred priority of care and so avoiding unnecessary and unwanted hospital admissions.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291811</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_086277]]&gt;</url>
    <title>End of life care strategy</title>
    <publicationDate>2008-07-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,HEART FAILURE,SERVICE MODELS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,EMERGENCY CARE,CLINICAL LIBRARY,ORGANISATIONAL AND OTHER ISSUES,GENERAL/OTHER,STROKE,ISCHAEMIC STROKE,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,DISEASE MANAGEMENT,REHABILITATION,PALLIATIVE CARE,MANAGEMENT ISSUES,PATIENT CHOICE,SERVICE MODELS,JUL-SEPT 08,JUL-SEPT 08,END OF LIFE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To provide people approaching the end of life with more choice about where they would like to live and die.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare Professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 16th July 2008&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398508</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.arif.bham.ac.uk/e/enhanced-external-counterpulsation.shtml]]&gt;</url>
    <title>Enhanced External Counterpulsation Angina Chronic Refractory</title>
    <publicationDate>2010-03-02T00:00:00</publicationDate>
    <publisher>Aggressive Research Intelligence Facility</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CHEST PAIN,HEART FAILURE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,DISEASE MANAGEMENT,STABLE ANGINA,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Overall, data from the review suggest that evidence on the effectiveness of EECP for chronic stable angina is sparse and weak.&amp;nbsp; It should be noted that there are potentially adverse events associated with EECP.&amp;nbsp; Decisions on the use of EECP would rely on firm evidence from further better quality RCTs regarding the effectiveness and adverse effects with EECP in this population.&amp;nbsp; NICE have published a draft scope for a clinical practice guideline on the management of stable angina; the anticipated publication date is July 2011.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2009&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General public&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;ARIF Disclaimer:&lt;/STRONG&gt; The information is only a very brief summary of that available at the time. It was primarily designed to give readers a starting point to consider research evidence in a particular area. Readers should not use the comments made in isolation and should read the literature suggested. Readers should also be aware that more appropriate evidence may have become available since the request was undertaken. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284178</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/117/17/2299]]&gt;</url>
    <title>Essential features of designating out-of-hospital cardiac arrest as a reportable event : a scientific statement from the American Heart Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, Perioperative, and Critical Care; Council on Cardiovascular Nursing; Council on Clinical Cardiology; and Quality of Care and Outcomes Research Interdisciplinary Working Group</title>
    <publicationDate>2008-04-14T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,ACUTE CORONARY SYNDROMES,GENERAL/OTHER,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CARDIOPULMONARY ARREST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; To provide a brief overview of strategies for managing out-of-hospital cardiac arrest in the United States.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Potential barriers to action on cardiac arrest include concerns about privacy, methodological challenges, and costs associated with designating cardiac arrest as a reportable event. The present statement should serve as a guide to policy makers as they work with agencies to develop and implement emergency cardiovascular care surveillance systems to help prevent heart disease and stroke.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in Circulation 2008;117:2299-2308.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>37281</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/portals/0/docs_2004/chd_network%20guide.pdf]]&gt;</url>
    <title>Establishing and developing cardiac networks</title>
    <publicationDate>2004-03-01T00:00:00</publicationDate>
    <publisher>NHS Modernisation Agency, National Coronary Heart Disease Collaborative</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,NETWORKS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document relates to the establishment of local cardiac networks. It covers such matters as funding, engaging stakeholders, creating a structure, skills development and patient involvement. A case study for the Peninsula Cardiac Managed Clinical Network is also provided.&amp;nbsp; This document is hosted by NHS Heart Improvement Programme. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. 
&lt;P&gt;&lt;STRONG&gt;This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library.&lt;/STRONG&gt; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258736</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-SCORE-FT.pdf]]&gt;</url>
    <title>Estimation of ten-year risk of fatal cardiovascular disease in Europe : the SCORE project</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,CAUSES AND RISK FACTORS,RISK ASSESSMENT,CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;The SCORE project was initiated to develop a risk scoring system for use in the clinical management of cardiovascular risk in European practice. This document discusses the methods and the results of the project.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in European Heart Journal 2003;24;987-1003.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388935</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heartstats.org/datapage.asp?id=8854]]&gt;</url>
    <title>Ethnic differences in cardiovascular disease 2010</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>British Heart Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,PREVENTION,ETHNIC GROUPS,RECENT ADDITIONS,APRIL 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Ethnic differences in cardiovascular disease in divided into three chapters:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chapter 1 provides an overview of incidence, prevalence, case-fatality and mortality rates by ethnic group 
&lt;LI&gt;Chapter 2 reports on access to treatment and rehabilitation by ethnic group, focusing on the experience of different ethnic groups in National Health Service hospitals 
&lt;LI&gt;Chapter 3 focuses on estimates of the prevalence of smoking, poor diet, physical inactivity, alcohol consumption, raised blood pressure, raised cholesterol, obesity and diabetes by ethnic group&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Access: Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp; &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5922</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.westhertshospitals.nhs.uk/WHC/archive/guidelines/01%20prevention/ESC%20Cardiovascular%20Prevention-EHJ%202003.pdf]]&gt;</url>
    <title>European guidelines on cardiovascular disease prevention in clinical practice</title>
    <publicationDate></publicationDate>
    <publisher>Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,GENERAL,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Third Joint Task Force provides a second revision of the joint European guidelines.&amp;nbsp; The guidelines give recommendations on how to decide the initiation of specific preventive action, how to assess the risk for development of CVD different multifactorial risk models, and the use of SCORE Models and Risk Charts.&amp;nbsp; Published in European Heart Journal 2003;24;1601-1610.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Registration required. Available to the general public. Portable Document File&amp;nbsp;/ PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Instructions for registration:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Click on the url which will take you to the 'log-in' page.&lt;BR&gt;
&lt;LI&gt;Follow the instructions on screen for registration.&lt;BR&gt;
&lt;LI&gt;Click on 'Full text' version of document.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>283042</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.westhertshospitals.nhs.uk/WHC/archive/guidelines/01%20prevention/ESC%20Cardiovascular%20Prevention-EHJ%202003.pdf]]&gt;</url>
    <title>European guidelines on cardiovascular disease prevention in clinical practice : full text : Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,MANAGEMENT ISSUES,PREVENTION,CORONARY HEART DISEASE,GENERAL,GENERAL,RISK ASSESSMENT,GENERAL  / OVERVIEWS,PREVENTION,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; To update the 2003 Third Joint Task Force guidelines on the prevention of cardiovascular disease (CVD). Updated guidelines include (taken directly from the text):&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Increased input from general practice and cardiovascular nursing&lt;BR&gt;
&lt;LI&gt;Increased emphasis on exercise, weight and lifestyle&lt;BR&gt;
&lt;LI&gt;More detailed discussion on the limitations of present systems of grading evidence&lt;BR&gt;
&lt;LI&gt;Re-defined priorities and objectives&lt;BR&gt;
&lt;LI&gt;Revised approach to risk in the young&lt;BR&gt;
&lt;LI&gt;Total events considered as well as mortality&lt;BR&gt;
&lt;LI&gt;More information from score on total events, diabetes,&amp;nbsp; high density lipoprotein (HDL) cholesterol and body mass index (BMI)&lt;BR&gt;
&lt;LI&gt;New sections on gender, heart rate, BMI/waist circumference, other manifestations of CVD and renal impairment&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp; Clinicians and other healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70793</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://eurjhf.oxfordjournals.org/papbyrecent.dtl]]&gt;</url>
    <title>European Heart Journal : Advance Access</title>
    <publicationDate></publicationDate>
    <publisher>European Heart Journal, Oxford Journals</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;European Heart Journal&amp;nbsp;: articles published ahead of print&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78263</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.eurheartj.oupjournals.org/current.dtl]]&gt;</url>
    <title>European Heart Journal : current issue</title>
    <publicationDate></publicationDate>
    <publisher>European Heart Journal, Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;European Heart Journal: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78264</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardiocontent.org/periodicals/ejcn/current]]&gt;</url>
    <title>European Journal Cardiovascular Nursing : current issue</title>
    <publicationDate></publicationDate>
    <publisher>European Journal Of Cardiovascular Nursing, Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;European Journal of Cardiovascular Nursing: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>77807</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://eurjhf.oxfordjournals.org/]]&gt;</url>
    <title>European Journal of Heart Failure : current issue</title>
    <publicationDate></publicationDate>
    <publisher>European Journal of Heart Failure, Oxford Journals</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;European Journal of Heart Failure : current issue&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111880</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.erc.edu/index.php/guidelines_download_2005/en/?]]&gt;</url>
    <title>European Resuscitation Council : Resuscitation Guidelines 2005</title>
    <publicationDate>2005-11-29T00:00:00</publicationDate>
    <publisher>European Resuscitation Council</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;These updated European resuscitation guidelines address the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Adult Basic Life Support and use of Automated External Defibrillators&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Electrical Therapies&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Adult Advanced Life Support&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Initial Management of Acute Coronary Syndromes&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Paediatric Life Support&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Cardiac Arrest in Special Circumstances&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The Ethics of Resuscitation and End of Life decisions&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Principles of Training in Resuscitation&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; European Healthcare professionals trained in resuscitation techniques.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Originally published 2000, updated November 2005.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>213001</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1048.pdf]]&gt;</url>
    <title>Evaluation of the ventricular assist device programme in the UK</title>
    <publicationDate>2006-11-30T00:00:00</publicationDate>
    <publisher>Health Technology Assessment Database</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,SURGICAL PROCEDURES,DISEASE MANAGEMENT,SECONDARY PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; 
&lt;P&gt;"Study found that while ventricular assist device (VAD) implantation can be justified for selected cases, there is currently no cost-effectiveness argument for widespread dissemination of the technology." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;"Medical management of patients with mild to moderate heart failure has substantially improved survival and quality of life in recent years owing to the increased use of angiotensin-converting enzyme inhibitors and b-blockers. For severe heart failure, transplantation is widely accepted as the most effective surgical treatment for suitable patients. However, heart transplantation is rationed by the availability of suitable donor hearts and there has been a steady decline in donor hearts over time.&lt;/P&gt;
&lt;P&gt;Ventricular assist devices (VADs) were first used to support transplant candidates with rapidly failing circulation who were considered unlikely to survive until a suitable organ could be found. This situation is described as bridge to transplantation (BTT).&lt;/P&gt;
&lt;P&gt;The National Specialist Commissioning Advisory Group (NSCAG) has agreed to support a new national service providing VAD therapy in three centres in the UK. A standard requirement of NSCAG is that such new services should be subject to an appropriate evaluation. Thus, this integrated but independently led health technology assessment was conducted, focusing on the clinical and cost-effectiveness of the use of VADs in the context of bridging to either transplantation or recovery in patients who are appropriate candidates for heart transplantation." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Setting&lt;BR&gt;NSCAG-funded VAD implantation was carried out at the Freeman, Harefield and Papworth transplant centres in the UK.&lt;/P&gt;
&lt;P&gt;Participants&lt;BR&gt;"The study involved 70 patients implanted with a VAD as a BTT between April 2002 and December 2004. The construction of a fair comparison group was not feasible. To provide bounds on effectiveness/cost-effectiveness of VADs three other groups were studied. The first and second groups consisted of non-VAD-supported transplant candidates (n = 250), listed at the three centres between April 2002 and December 2004. They were divided into an inotrope-dependent group (n = 71) and a non-inotrope-dependent group (n = 179). Although patients in the inotrope-dependent group were closest to the VAD group they were less sick. The final group comprised a hypothetical worst case scenario, which assumed that all VAD patients would die in the intensive care unit (ICU) within 1 month without VAD technology."&lt;/P&gt;
&lt;P&gt;Interventions&lt;BR&gt;"Patients were included who were implanted with a VAD designed for circulatory support for more than 30 days, with intention to BTT. A multistate model of VAD and transplant activity was constructed; this was populated by data from the&lt;STRONG&gt; &lt;/STRONG&gt;UK."&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sharples L, Buxton M, Caine N, Cafferty F, Demiris N, Dyer M, et al. Evaluation of the ventricular assist device programme in the UK. Health Technol Assess 2006;10(48).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access :&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; Abstract and executive summary also available as HTML files. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>34542</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/109/5/672]]&gt;</url>
    <title>Evidence based guidelines for cardiovascular disease prevention in women</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE,DIABETES MELLITUS,DIET,DIURETICS,BETA BLOCKERS,ANTI-COAGULANTS,PREVENTION,HYPERTENSION,PHYSICAL ACTIVITY,OVERWEIGHT AND OBESITY,LIPIDS MANAGEMENT,DIET,SMOKING,SMOKING CESSATION,PRIMARY PREVENTION,PREVENTION,HAEMORRHAGIC STROKE,ISCHAEMIC STROKE,STROKE,PREVENTION,OCT-DEC 08,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These&amp;nbsp;collaborative effort guidelines&amp;nbsp;provides evidence-based guidance on the prevention of cardiovascular diseases in adult women with a broad range of cardiovascular risk.&amp;nbsp; Includes tabular information, appendices and references.&amp;nbsp; Published in Circulation 2004;109:672-693. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>28919</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/107/24/3109]]&gt;</url>
    <title>Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease : a statement from The Council on Clinical Cardiology (subcommittee on exercise, rehabilitation, and prevention) and The Council on Nutrition, Physical Activity, and Metabolism (subcommittee on physical activity)</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIAC REHABILITATION,OUTCOMES,CARDIOVASCULAR DISEASES,CIRCULATORY DISEASES,POPULATION BASED &amp; PREVENTATIVE SERVICES,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,LIFESTYLE,SOCIAL DETERMINANTS,PHYSICAL ACTIVITY,INDIVIDUAL BEHAVIOUR,SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2&gt;
&lt;P&gt;This document is aimed at health professionals and summarises the evidence for the benefits of exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. The statement discusses the treatment for patients with diagnosed coronary artery disease (CAD) and considers the risks of physical activity. Concludes that additional studies are needed on the health benefits, the risks of exercise and the cost-effectiveness compared to other interventions for patients with CAD. Includes recommendations which are supported by summary articles and meta-analyses. Includes references.&amp;nbsp;Published in Circulation 2003;107:3109. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260271</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1110.pdf]]&gt;</url>
    <title>Exercise evaluation randomised trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only</title>
    <publicationDate>2007-04-24T00:00:00</publicationDate>
    <publisher>Health Technology Assessment Database</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,PHYSICAL ACTIVITY,PRIMARY PREVENTION,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; The results of this trial suggest that referral for tailored advice, supported by written materials, including details of locally available facilities, supplemented by detailed assessments may be effective in increasing physical activity. The inclusion of supervised exercise classes or walks as a formal component of the scheme may not be more effective than the provision of information about their availability. On cost-effectiveness grounds, assessment and advice alone from an exercise specialist may be appropriate to initiate action in the first instance. Subsidised schemes may be best concentrated on patients at higher absolute risk, or with specific conditions for which particular programmes may be beneficial. Walking appears to be as effective as leisure centre classes and is cheaper. Efforts should be directed towards maintenance of increased activity, with proven measures such as telephone support. Further research should include an updated meta-analysis of published exercise interventions using the standardised mean difference approach.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Physical activity is known to be beneficial in reducing the risk of cardiovascular disease, but there is a high prevalence of inactivity in the UK population. Primary care is an important setting for encouraging increased physical activity, but brief advice from GPs may not be effective in increasing physical activity levels. Exercise referral schemes, also known as exercise on prescription, have been developed to address this issue and are increasingly popular, but have not been rigorously evaluated.&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The study was a single-centre, parallel-group, randomised controlled trial, consisting of three arms, with the primary comparison at 6 months. The two structured exercise groups were followed for a further 6 months. Subjects in the control arm were rerandomised to one of the other trial arms and followed for a further year, although these data are not included in this report.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Isaacs AJ, Critchley JA, See Tai S, Buckingham K, Westley D, Harridge SDR, et al. Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only. Health Technol Assess 2007;11(10).&lt;BR&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Access :&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; Abstract and executive summary also available as HTML files. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3820</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4009671&amp;chk=0cMFrC]]&gt;</url>
    <title>Exercise referral systems : a national quality assurance framework</title>
    <publicationDate>2001-04-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES,PREVENTION,OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides guidelines for exercise referral systems. The Framework focuses primarily on the most common model of exercise, where the GP or practice nurse refers patients to facilities such as leisure centres of gyms for supervised exercise programmes. Guidance covers patient selection, evaluation and long-term follow up. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343991</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192521]]&gt;</url>
    <title>Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ FEBRUARY 2010,RECENT ADDITIONS,JAN-MAR 10,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,DIABETES MELLITUS,TYPE 2,DIABETES,PREVENTION,PHYSICAL ACTIVITY,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;To document the mechanisms whereby exercise is important in T2DM management, analyze the existing evidence regarding exercise interventions, andprovide practical guidelines about preparation for exercise training programs and safety issues, as well as specific exercise training guidelines that can be used to initiate anexercise program.&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251436</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-CVD-pregnancy-FT.pdf]]&gt;</url>
    <title>Expert consensus document on management of cardiovascular diseases during pregnancy</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ VALVE DISORDERS,HYPERTENSION,CONGENITAL HEART DISEASE,ARTERIOSCLEROSIS,ACUTE CORONARY SYNDROMES,GENERAL/OTHER,CARDIOVASCULAR DISEASES,ARRHYTHMIA,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; To provide guidance on the management of cardiovascular diseases during pregnancy. Sections are included on:&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Haemodynamic modifications during pregnancy&lt;BR&gt;
&lt;LI&gt;Congenitial heart disease&lt;BR&gt;
&lt;LI&gt;Marfan syndrome &lt;BR&gt;
&lt;LI&gt;Valvular heart disease&lt;BR&gt;
&lt;LI&gt;Coronary artery disease&lt;BR&gt;
&lt;LI&gt;Hypertensive disorders&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Cardiologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in European Heart Journal 2003;24;761-781.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&amp;nbsp; &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324702</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.sts.org/documents/pdf/expertconsensus/ExpertConsensus.pdf]]&gt;</url>
    <title>Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Society of Thoracic Surgeons</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,VALVE DISORDERS,INTERVENTIONS / PROCEDURES,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,JUL-SEP 09,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document reviews the natural history of aortic disease, indications for repair, outcomes after conventional open surgery, currently available devices, and insights from outcomes of randomized studies using stent-grafts for abdominal aortic aneurysm surgery, the latter having been treated for a longer time by stent-grafts; and offers suggestions for treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Cardiovascular surgeons.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in the Annals of Thoracic Surgery January 2008: Vol 85(1), Supplement 1: S1-S41.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>33959</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/knowledge/guidelines/antiplatelet_agents.htm?escid=272436]]&gt;</url>
    <title>Expert consensus document on the use of antiplatelet agents : the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ ASPIRIN,OTHER,CLOPIDOGREL,CARDIOVASCULAR DISEASES,ANTI-PLATELET DRUGS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides a guide to the administration of antiplatelet agents.&amp;nbsp; Includes tabular and graphical information, conclusions and references.&amp;nbsp;&amp;nbsp;&amp;nbsp; Published in Eur Heart J 2004;25:166-181. 
&lt;P&gt;&lt;STRONG&gt;This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library.&lt;/STRONG&gt; 
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&amp;nbsp; &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288017</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ncchta.org/fullmono/mon1221.pdf]]&gt;</url>
    <title>Ezetimibe for the treatment of hypercholesterolaemia : a systematic review and economic evaluation</title>
    <publicationDate>2008-05-28T00:00:00</publicationDate>
    <publisher>School of Health and Related Research, University of Sheffield.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STATINS,FIBRATES,DISEASE MANAGEMENT,LIPID-REGULATING DRUGS,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,ECONOMIC EVALUATIONS,APR-JUNE 08,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The aim of this study is&amp;nbsp;to review the evidence for the clinical and cost effectiveness of ezetimibe (in its licensed indication) as combination therapy or monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia in the UK.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp; Twelve electronic bibliographic databases covering the biomedical, scientific, and grey literature were searched from inception to June 2006 (supplemented by contact with experts in the field). Data relating to study design, baseline patient characteristics, clinical or surrogate outcomes, and adverse events were abstracted and methodological quality was assessed. In addition, results of eligible randomised controlled trials(RCTs) were statistically synthesised(metaanalysed) where appropriate. A new Markov model was developed, to assess the costs and health outcomes associated with ezetimibe treatment. Several treatment regimens were explored including: ezetimibe monotherapy versus no treatment for individuals in whom statin therapy is contraindicated or those who do not tolerate statins; ezetimibe plus a statin compared with the same statin; ezetimibe plus a statin compared with a switch to a more potent statin. The model utilised the established relationship linking changes in low-density lipoprotein cholesterol (LDL-c) and cardiovascular events to estimate the cardiovascular events avoided through lipid lowering therapies.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; No published clinical outcome trials (&amp;gt;12 weeks) examining the cardiovascular benefit of ezetimibe were identified. In the absence of clinical end point data from trials, 13 (of which five were multi-arm) Phase III multi-centre randomised controlled trials (of varying methodological quality) of short term duration (12–48 weeks) with surrogate end point data [such as LDL-c and total cholesterol (Total-c)] were included. Although all the included studies involved patients with primary hypercholesterolaemia (mean baseline LDL-c levels ranging from 3.36 to 6.50 mmol/l), the populations were not fully representative of the population specified in the inclusion criteria, that is, individuals whose lipids were not adequately controlled with current statin treatment or those who are intolerant of statins. The clinical evidence is derived from a population that required a washout or discontinuation of all ongoing lipid regulating drug therapy prior to randomisation and initiation of study treatments.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377869</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heartuk.org.uk/FHToolkit/]]&gt;</url>
    <title>FH GIT Toolkit</title>
    <publicationDate></publicationDate>
    <publisher>Heart UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,LIPIDS MANAGEMENT,CAUSES AND RISK FACTORS,ARTERIOSCLEROSIS,CAUSES &amp; RISK FACTORS,RECENT ADDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Heart UK toolkit for implementation of the NICE clinical guideline on the identification and management of familial hypercholesterolaemia.]]&gt;</body>
  </document>
  <document>
    <id>187529</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4138630]]&gt;</url>
    <title>Forecasting obesity to 2010</title>
    <publicationDate>2006-08-25T00:00:00</publicationDate>
    <publisher>National Centre for Social Research</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,PREVENTION,DIET,OVERWEIGHT AND OBESITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The focus of this report is to forecast the levels of obesity in England in 2010. The report is divided into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Section&amp;nbsp;one discusses the measures of obesity and non response weighting.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Section&amp;nbsp;two&amp;nbsp;provides the current picture of overweight and obesity prevalence among children and adults, using data from the Health Survey for England 2003 (HSE 2003). &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Section three&amp;nbsp;uses&amp;nbsp;data from the HSE to project&amp;nbsp;trends&amp;nbsp;of overweight and obesty to 2010.&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Section&amp;nbsp;four&amp;nbsp;estimates the number and proportion of adults and children, within different socio demographic groups, who may be obese in 2010.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; This report was first produced for the Department of Health in September 2005, and was revised in July 2006.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124369</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=299528]]&gt;</url>
    <title>Four commonly used methods to increase physical activity : brief interventions in primary care, exercise referral schemes, pedometers and community based exercise programmes for walking and cycling</title>
    <publicationDate>2006-03-29T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,INTERVENTIONS / PROCEDURES,PREVENTION,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The Department of Health in collaboration with the National Institute for Health and Clinical Excellence have produced guidance on four common methods used to increase the population's physical activity levels.&amp;nbsp; The four interventions considered are: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes.&amp;nbsp; Includes recommendations.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Medical and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3800</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nhlbi.nih.gov/about/framingham/]]&gt;</url>
    <title>Framingham heart studies</title>
    <publicationDate></publicationDate>
    <publisher>National Heart, Lung, Blood Institute</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RISK ASSESSMENT,MANAGEMENT ISSUES,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This web site gives the background information on the Framingham Heart Studies, including the CHD Risk Prediction Score Sheets.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212729</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=122790&amp;Rendition=Web]]&gt;</url>
    <title>General practitioner patient survey : your doctor, your experience, your say : guidance for strategic health authorities, primary care trusts and general practitioner practices</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,PATIENT CHOICE,SERVICE MODELS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This guidance explains what the GP patient survey is, why it is being conducted, how it works and roles / responsibilities. It aims to increase understanding and raise the survey’s profile, encouraging local discussion prior to the survey being sent to patients in January 2007. The survey is part of the ‘Improved Access Scheme’ directed to enhance services. It has been introduced in response to the view that patients want more say&amp;nbsp;about how their services are being provided. The results will be used to reward GPs offering good access to services. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3678</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4005148&amp;chk=HNOxVk]]&gt;</url>
    <title>Government response to the Health Select Committee's second report on the tobacco industry and the health risks of smoking</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLICATIONS,SMOKING,OUTCOMES,ECONOMICS,ECONOMICS,INDUSTRY,CANCER,CIRCULATORY DISEASES,TAXATION,STRATEGY,POLICY,PREVENTION,SMOKING CESSATION,CONDITIONS,CARDIOVASCULAR DISEASES,KEY POLICIES,PREVENTION,CORONARY HEART DISEASE,RESPIRATORY,DETERMINANTS,PUBLIC HEALTH,REPORTS,MANAGEMENT &amp; INTERVENTIONS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,LAW,GOVERNMENT,MANAGEMENT &amp; POLICY,GOVERNMENT &amp; LAW,NATIONAL,GEOGRAPHY,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper sets out the Government’s response to the Health Committee’s report on the Tobacco Industry and the Health Risks of Smoking and its overall strategy on promoting smoking cessation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This publication is out of print,&amp;nbsp; but it may be possible to order a photocopy from The Stationery Office.&lt;/P&gt;
&lt;P class="subContent first"&gt;&lt;A class=externalLink href="http://www.tso.co.uk/bookshop/bookstore.asp" target="_blank"&gt;The Stationery Office online bookshop &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124372</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/28/23/04132823.pdf]]&gt;</url>
    <title>Government response to the House of Commons Health Committee's first report of session 2005-2006 : smoking in public places</title>
    <publicationDate></publicationDate>
    <publisher>United Kingdom Parliament</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SMOKING,PUBLICATIONS,CAUSES OF HARM,ENVIRONMENTAL,GENERAL PUBLIC,POLICY,SMOKING,SMOKING CESSATION,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PREVENTION,RESPIRATORY,DETERMINANTS,REPORTS,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,SMOKING,TOBACCO USE,LIFESTYLE,SOCIAL DETERMINANTS,SOCIETY,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,GOVERNMENT,LAW,GOVERNMENT &amp; LAW,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This command paper sets out the Government's response to the recommendations in the report&amp;nbsp;"Smoking in Public Places".&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324436</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103184.pdf]]&gt;</url>
    <title>Guide to good practice in clinical perfusion</title>
    <publicationDate>2009-07-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,SURGICAL PROCEDURES,JUL-SEP 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Aims: The purpose of this document is to provide guidance on the systems and processes which need to be in place to assure safe, high quality perfusion services provided by the NHS and Independent sector to support cardiopulomonary bypass (CPB) and mechanical circulatory support during cardiac surgical procedures.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Trust Boards, Medicines Management Committees, Clinical Governance and Service Commissioners and&amp;nbsp;Practitioners.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;Abstract only. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268128</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-cardiac-pacing-ES.pdf]]&gt;</url>
    <title>Guidelines for cardiac pacing and cardiac resynchronization therapy : the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DEFIBRILLATION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,HEART FAILURE,INTERVENTIONS / PROCEDURES,GENERAL/OTHER,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines aim to provide an up to date specialist view of the areas of cardiac pacing and cardiac resynchronization therapy.&amp;nbsp; The document is divided into two sections. The first section includes information on permanent pacing in bradyarrhythmias, syncope and other specific conditions.&amp;nbsp; The second section refers to ventricular resynchronization as an adjunct therapy in patients with heart failure&lt;STRONG&gt;.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&amp;nbsp; &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378263</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://scst.org.uk/clin_guidance/Guidelines%20for%20Follow-Up%20of%20Implanted%20Devices%20for%20CRM%20Final%20version-October%202008.pdf]]&gt;</url>
    <title>Guidelines for follow up of implantable cardiac devices for cardiac rhythm management</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Society for Cardiological Science and Technology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=3&gt;
&lt;P align=justify&gt;The following guidelines for Cardiac Physiologist led clinics have been drawn up by HRUK and the Society for Cardiological Science and Technology (SCST), both of which are affiliated groups of the British Cardiovascular Society. &lt;/P&gt;
&lt;P&gt;These groups have been instrumental in guiding device follow up training since the previous policy conference conducted by the British Pacing and Electrophysiology Group (now HRUK). &lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>251356</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/percutaneous-coronary-interventions.aspx]]&gt;</url>
    <title>Guidelines for percutaneous coronary interventions</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-COAGULANTS,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,THROMBOLYTICS,CORONARY ARTERY BYPASS GRAFTS,HEPARIN,LOW MOLECULAR WEIGHT HEPARINS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,REVASCULARISATION,ACUTE CORONARY SYNDROMES,REPERFUSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; To provide practical recommendations on when to perform percutaneous coronary interventions (PCI). Sections are included on:&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Indications for PCI&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Adjunctive medications for PCI&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Adjunctive devices for PCI&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Drug-eluting stents&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Published in European Heart Journal 2005;26:804-847.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&amp;nbsp; &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343888</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-PH-FT.pdf]]&gt;</url>
    <title>Guidelines for the diagnosis and treatment of pulmonary hypertension</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,ANTI-COAGULANTS,CALCIUM CHANNEL BLOCKERS,DIURETICS,GENERAL,HYPERTENSION,SURGICAL PROCEDURES,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines are intended to provide clear and concise indications for the practical use of the new clinical classification of pulmonary arterial hypertension, in addition to a description of the new pathological classification and recent pathogenic insights.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Health Professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;New Publication 2009.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>35697</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-neonatal-FT.pdf]]&gt;</url>
    <title>Guidelines for the interpretation of the neonatal electrocardiogram</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEONATAL AND INFANT CARE,POSTNATAL CARE,NORMAL PREGNANCY,WOMEN'S HEALTH,GENERAL EXAMINATION AND SCREENING,CARDIOVASCULAR DISEASES,DIAGNOSIS,ELECTROCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines aim to: 
&lt;UL&gt;
&lt;LI&gt;Present adult cardiologists with a concensus document designed to provide guidelines for the interpretation of the neonatal electrocardiogram (ECG), focusing on the most clinically relevant abnormalities and on the ensuing management and referral options. 
&lt;LI&gt;Provide paediatricians and neonatologists with updated information of clinical relevance that can be detected from a neonatal ECG.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; These guidelines have been prepared for adult cardiologists, paediatricians and neonatologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&amp;nbsp;&lt;/STRONG&gt;Schwartz PJ... et al. Guidelines for the interpretation of the neonatal electrocardiogram. European Heart Journal: 2002 Sep, 23 (17), 1329-44. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267822</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/106/12/1572]]&gt;</url>
    <title>Guidelines for the reporting of renal artery revascularization in clinical trials</title>
    <publicationDate>2002-09-17T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,REVASCULARISATION,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,JUL-SEP 08,SURGICAL PROCEDURES,OTHER,DISEASE MANAGEMENT,VASCULAR,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,IN ADULTS,RENOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A scientific statement from the American Heart Association.&lt;/P&gt;
&lt;P align=left&gt;Well-designed and rigorously conducted trials are needed that compare percutaneous angioplasty, stenting and surgical revascularisation in the treatment of atherosclerotic renal artery stenosis.&lt;/P&gt;
&lt;P align=left&gt;The statement provides guidelines and definitions for the design, conduct, evaluation and reporting of renal artery revascularisation randomised controlled trials (RCT), plus areas&amp;nbsp;are identified where renal artery revascularisation investigations are&amp;nbsp;critically needed.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251408</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-syncope-FT.pdf]]&gt;</url>
    <title>Guidelines on management, diagnosis and treatment of syncope (new 2009 version)</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,DIAGNOSIS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,EXERCISE TOLERANCE TESTS,CONDITIONS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,ARRHYTHMIA,ECHOCARDIOGRAM,ELECTROCARDIOGRAM,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,DIAGNOSIS,SELECTED SYMPTOMS,CLINICAL LIBRARY,SYNCOPE,GENERAL/OTHER,OCT-DEC 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;To update the 2001 guidelines and to provide specific recommendations on the diagnostic evaluation and management of syncope. Sections are included on:&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Classification, epidemiology and prognosis&lt;BR&gt;
&lt;LI&gt;Diagnosis&lt;BR&gt;
&lt;LI&gt;Treatment&lt;BR&gt;
&lt;LI&gt;Special issues in evaluating patients with syncope&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60661</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-IE-FT.pdf]]&gt;</url>
    <title>Guidelines on prevention, diagnosis and treatment of infective endocarditis (new 2009 version)</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,SURGICAL PROCEDURES,CONDITIONS,ECHOCARDIOGRAM,EMERGENCY CARE,CLINICAL LIBRARY,ENDOCARDITIS,CARDIOVASCULAR,ACUTE CORONARY SYNDROMES,OCT-DEC 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines outline the prevention, diagnosis and treatment of endocarditis.&amp;nbsp; Sections are included on the management of complications and surgery for infective endocarditis.&amp;nbsp; Includes tabular information and references. Published in European Heart Journal 2004;25:267-276.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60044</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/pages/pericardial-diseases.aspx]]&gt;</url>
    <title>Guidelines on the diagnosis and management of pericardial diseases</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,EMERGENCY CARE,DIAGNOSIS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,ECHOCARDIOGRAM,ELECTROCARDIOGRAM,CONDITIONS,SURGICAL PROCEDURES,INTERVENTIONS / PROCEDURES,CARDIOVASCULAR,ACUTE CORONARY SYNDROMES,PERICARDIOSCENTESIS,PERICARDITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides guidance on the diagnosis and management of pericardial diseases.&amp;nbsp; Pericardial syndromes are discussed and specific forms of pericarditis considered.&amp;nbsp; Includes tabular information and references.&amp;nbsp; An executive summary and educational slides are also available.&amp;nbsp;Published in European Heart Journal 2004;25:587-610.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>155747</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-angina-FT.pdf]]&gt;</url>
    <title>Guidelines on the management of stable angina pectoris</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,GENERAL,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,DIAGNOSIS,CAUSES AND RISK FACTORS,CORONARY ARTERY BYPASS GRAFTS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,GENERAL  / OVERVIEWS,PREVENTION,REVASCULARISATION,SECONDARY PREVENTION,STABLE ANGINA,ECHOCARDIOGRAM,ELECTROCARDIOGRAM,CHEST PAIN,CONDITIONS,DIAGNOSIS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This document aims to present the pathophysiology, diagnosis, assessment, treatment and secondary prevention of angina pectoris. Includes conclusions and recommendations.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in European Heart Journal (2006) 27, 1341-1381.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3926</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4009175&amp;chk=U3etUC]]&gt;</url>
    <title>Health improvement and prevention</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,PREVENTION,CORONARY HEART DISEASE,DIET,PHYSICAL ACTIVITY,SMOKING CESSATION,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Part of National Service Frameworks (NSFs): A Practical Aid To Implementation In Primary Care series. This document provides a selection of interventions which have been shown to be effective in promoting healthy lifestyle. Actions on smoking reduction, healty eating, alcohol consumption, and mental health will help to address the objectives of the NHS Plan, NSFs for Coronary Heart Disease (CHD) and Older People. Primary practice needs to develop local health profiles and work closely with local communities. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document&amp;nbsp;File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187237</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_093465]]&gt;</url>
    <title>Health Profile of England 2008</title>
    <publicationDate>2006-10-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PERFORMANCE INDICATORS,SERVICE MODELS,STATISTICS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Health Profile of England provides a collection of national and regional data.&amp;nbsp;The focus of the profile is the six priority areas identified in Choosing health: Tackling health inequalities:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Reducing the number of people who smoke 
&lt;LI&gt;Reducing obesity and improving diet and nutrition 
&lt;LI&gt;Improving sexual health 
&lt;LI&gt;Improving mental health and wellbeing 
&lt;LI&gt;Reducing harm and encouraging sensible drinking.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Health Profile of England is aimed at public service professionals and officials within the local community - such as local councillors and primary care trust directors of public health. But the document will also be of interest to a much wider audience - anyone with an interest in the profile of health and health determinants in this country.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3898</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/healthpromo_older.pdf]]&gt;</url>
    <title>Health promotion in older people for the prevention of coronary heart disease and stroke</title>
    <publicationDate>1996-07-01T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ LIPIDS MANAGEMENT,HYPERTENSION,LATER LIFE,CAUSES AND PRIMARY PREVENTION,STROKE,SECONDARY PREVENTION,PREVENTION,ANTI-HYPERTENSIVE DRUGS,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Health Promotion Effectiveness Review : Summary Bulletin 01. This review studies various interventions in reducing blood pressure and lowering cholesterol in older people. It recommends that health promotion activities should be targeted much more closely at people at high risk of cardiovascular disease. Better integration of medical treatments provided by GPs and non-drug treatments provided by health promotion staff is also needed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3778</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH_4004550]]&gt;</url>
    <title>Healthy living centres</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>PATIENT GROUP DIRECTION</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PREVENTION,NHS IMPROVEMENT,HEALTH INEQUALITIES,HEALTH MANAGEMENT,POLICY,SERVICE SECTORS,INEQUALITIES,PUBLIC HEALTH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Healthy Living Centre initiative was set up in January 1999 by the New Opportunities Fund (NOF). Healthy Living Centres support national and local health strategies including Health Improvement Programmes and contribute to tackling inequalities in health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3635</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://heart.bmjjournals.com/]]&gt;</url>
    <title>Heart</title>
    <publicationDate></publicationDate>
    <publisher>British Cardiac Society, British Medical Journal</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ UNSURE CARDEX,CARDIOVASCULAR DISEASES,RESOUCES THAT ARE HIDDEN BUT WE ARE HOLDING ONTO FOR NOW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Heart (formerly the British Heart Journal) publishes research on the treatment and prevention of cardiovascular diseases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>77808</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://heart.bmj.com/onlinefirst.dtl]]&gt;</url>
    <title>Heart : articles in press</title>
    <publicationDate></publicationDate>
    <publisher>Heart, BMJ Publishing Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Heart: articles to be published in forthcoming issues of Heart&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>276790</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://heart.bmjjournals.com/current.shtml]]&gt;</url>
    <title>Heart : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Heart, BMJ Publishing Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Heart:&amp;nbsp;Current Issue&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not&lt;BR&gt;accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal&lt;BR&gt;articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Library.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5893</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4007734&amp;chk=6CM4Dv]]&gt;</url>
    <title>Heart choice initiative : trustees report July 2002 / July 2003</title>
    <publicationDate>2003-07-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,PATIENT CHOICE,SURGICAL PROCEDURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This reports on the results of the first year of The Patient Choice Initiative, which was introduced to address waiting times for cardiac surgery. The report&amp;nbsp;hails the role of Patient Care Advisors in reducing these waiting times.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277850</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/heart-disease]]&gt;</url>
    <title>Heart disease</title>
    <publicationDate></publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CONGENITAL HEART DISEASE,HEART FAILURE,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CARDIOPULMONARY ARREST,ARRHYTHMIA,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The Information Centre runs a programme of nine national heart disease audits. Each audit offers reliable information to help health professionals continually measure and improve care by comparing their work to specific standards and national trends.&lt;/P&gt;
&lt;P&gt;The following heart disease audits are being run: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;adult cardiac interventions&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;cardiac rhythm management &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;adult cardiac surgery service &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;ambulance outcomes &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;cardiac rehabilitation &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;congenital heart disease &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;heart failure&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;infarct angioplasty &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;myocardial infarction&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70070</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/09/89/19/04098919.pdf]]&gt;</url>
    <title>Heart disease and South Asians : delivering the National Service Framework for coronary heart disease</title>
    <publicationDate>2004-12-10T00:00:00</publicationDate>
    <publisher>British Heart Foundation, Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,PREVENTION,CORONARY HEART DISEASE,DIABETES MELLITUS,DIET,NHS IMPROVEMENT,HEALTH INEQUALITIES,OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY,SERVICE MODELS,SMOKING,SMOKING CESSATION,CAUSES AND RISK FACTORS,PREVENTION,CARDIAC REHABILITATION,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide aims to support service providers working with South Asian communities to deliver heart disease services to South Asian people.&amp;nbsp; Sections covered include: 
&lt;UL&gt;
&lt;LI&gt;Background information on heart disease and South Asians. &lt;BR&gt;
&lt;LI&gt;A&amp;nbsp;selection of best practice case studies illustrating where service providers are working together to improve services. &lt;BR&gt;
&lt;LI&gt;Details of other resources available, including further reading, weblinks and useful organisations. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Includes appendices.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File /&amp;nbsp;PDF &lt;BR&gt;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291757</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2008/HF_commissioning_guide.pdf]]&gt;</url>
    <title>Heart Failure : A quick guide to quality comissioning across the whole pathway of care</title>
    <publicationDate>2008-07-03T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,NHS IMPROVEMENT,HEART FAILURE,SERVICE MODELS,DISEASE MANAGEMENT,COMMISSIONING,DISEASE/CONDITION GROUPS,CIRCULATION PROBLEMS,JUL-SEPT 08,INNOVATION AND IMPROVEMENT,TOOLS AND TECHNIQUES,PATHWAY MAPPING,EVALUATION,OUTCOMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This practical guide sets out to help commissioners develop integrated heart failure services by highlighting evidence-based practice and measurable outcomes. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306339</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFAEU08INT]]&gt;</url>
    <title>Heart Failure National Annual Evidence Update : 6th - 12th  October 2008</title>
    <publicationDate></publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,HEART FAILURE,JAN-MAR 09,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This evidence update provides details of new systematic reviews and other key documents published since the Heart Failure National Knowledge Week of 2007. Information is arranged in the following sections: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction and background &lt;BR&gt;
&lt;LI&gt;Contributors &lt;BR&gt;
&lt;LI&gt;Diagnosis and risk stratification &lt;BR&gt;
&lt;LI&gt;Pharmacological therapy &lt;BR&gt;
&lt;LI&gt;Devices and interventions &lt;BR&gt;
&lt;LI&gt;Psychology &lt;BR&gt;
&lt;LI&gt;Rehabilitation &lt;BR&gt;
&lt;LI&gt;Palliative care &lt;BR&gt;
&lt;LI&gt;Organisation and monitoring &lt;BR&gt;
&lt;LI&gt;Other &lt;BR&gt;
&lt;LI&gt;Feedback&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277285</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFNKWHOME]]&gt;</url>
    <title>Heart Failure National Knowledge Week</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,INTERVENTIONS / PROCEDURES,GENERAL,HEART FAILURE,CAUSES AND RISK FACTORS,DIAGNOSIS,GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,GENERAL/OTHER,CARDIAC REHABILITATION,GENERAL,GENERAL,PREVENTION,MANAGEMENT ISSUES,CONDITIONS,DISEASE MANAGEMENT,DIAGNOSIS,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Heart failure National Knowledge Week provides information on the current state of knowledge in this field.&amp;nbsp; A summary of the evidence available has been prepared by the Cardiovascular Diseases Specialist Library. A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. Expert summaries based on the knowledge retrieved are presented on the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diagnosis and risk stratification&lt;BR&gt;
&lt;LI&gt;Pharmacological therapy&lt;BR&gt;
&lt;LI&gt;Devices and interventions&lt;BR&gt;
&lt;LI&gt;Psychology&lt;BR&gt;
&lt;LI&gt;Rehabilitation&lt;BR&gt;
&lt;LI&gt;Palliative care&lt;BR&gt;
&lt;LI&gt;Organisation and monitoring&lt;BR&gt;
&lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278086</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFKNWDEV]]&gt;</url>
    <title>Heart Failure National Knowledge Week : devices and interventions</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,DEFIBRILLATION,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge in the fields of 'devices and interventions'. A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277998</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?prv=y&amp;pagename=HFKNWDIAG]]&gt;</url>
    <title>Heart Failure National Knowledge Week : diagnosis and risk stratification</title>
    <publicationDate></publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,DIAGNOSIS,CARDIAC MARKERS,CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,ECHOCARDIOGRAM,ELECTROCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge in the fields of 'diagnosis and risk stratification'. A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication&amp;nbsp;history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278125</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFKNWORG]]&gt;</url>
    <title>Heart Failure National Knowledge Week : monitoring and organisation of care</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,HEART FAILURE,GENERAL  / OVERVIEWS,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge regarding 'monitoring and organisation of care'.&amp;nbsp; A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278119</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFKNWPAL]]&gt;</url>
    <title>Heart Failure National Knowledge Week : palliative care</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,HEART FAILURE,SERVICE MODELS,GENERAL/OTHER,CONDITIONS,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge regarding 'palliative care services'.&amp;nbsp; A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278075</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFKNWPHARM#ACE%20INHIBITORS%20and%20ARBs]]&gt;</url>
    <title>Heart Failure National Knowledge Week : pharmacological therapy</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ACE INHIBITORS,DISEASE MANAGEMENT,HEART FAILURE,POSITIVE INTOTROPIC DRUGS,GENERAL/OTHER,CONDITIONS,BETA BLOCKERS,CALCIUM CHANNEL BLOCKERS,ANTI-HYPERTENSIVE DRUGS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge in the field of 'pharmacological therapy'. A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.]]&gt;</body>
  </document>
  <document>
    <id>278107</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=KNWHFPSCY]]&gt;</url>
    <title>Heart Failure National Knowledge Week : psychology</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,HEART FAILURE,GENERAL/OTHER,CARDIAC REHABILITATION,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge regarding the 'psychological aspects of heart failure care'.&amp;nbsp; A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278114</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?&amp;pagename=HFKNWREHAB]]&gt;</url>
    <title>Heart Failure National Knowledge Week : rehabilitation</title>
    <publicationDate>2007-11-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,DISEASE MANAGEMENT,CARDIAC REHABILITATION,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the 'Heart Failure National Knowledge Week' provides information on the current state of knowledge regarding rehabilitation services.&amp;nbsp; A literature search was performed to identify new significant knowledge in the form of systematic reviews published since 2003. An expert summary based on the knowledge retrieved is presented here.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271295</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=271295]]&gt;</url>
    <title>Heart Failure National Knowledge Week 2007: Search Strategy</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Cardiovascular diseases specialist library</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,HEART FAILURE,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Heart Failure National Knowledge Week 2007: Search Strategy&lt;/pageTitle&gt;&lt;pageBody&gt;Available as a word file for downloading.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>288035</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/priority%5Fprojects/summary_documents/Cardiac_Diagnostics_Summary.pdf]]&gt;</url>
    <title>Heart Improvement : 18 weeks focus on cardiac diagnosis : national priority project</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,ELECTROCARDIOGRAM,GENERAL,NHS IMPROVEMENT,DIAGNOSIS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Focus on Cardiac Diagnostics is a national priority project of the Heart Improvement Programme focusing on reducing the waiting times for all non-invasive diagnostics and achieving the maximum wait of two weeks.&lt;BR&gt;The projects ran over the period June 2007 to March 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288034</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/priority%5Fprojects/summary_documents/18_weeks_pathways_summary.pdf]]&gt;</url>
    <title>Heart Improvement : 18 weeks whole pathway : national priority project</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,NHS IMPROVEMENT,GENERAL  / OVERVIEWS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The aim of the 18 Weeks Whole Pathway Project was to ensure that by 2008 no one waits more than 18 weeks from GP referral to hospital treatment. This project has reviewed, identified and supported the practical implementation of ways to reduce the waiting time from GP referral to definitive treatment, exploring in detail what really works. The project involves seven cardiac networks and some 25 NHS Trusts (including foundation trusts). The scope of the project covers the main 18 week bottlenecks / constraints including:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;• Outpatients (OPD)&lt;BR&gt;• Diagnostics&lt;BR&gt;• Secondary to tertiary care interface&lt;BR&gt;• Some sites taking a whole pathway approach.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The current projects are phased for completion from March 2008 onwards with work continuing with demonstration sites to ensure delivery solutions are implemented and that sustainability is in place. Consequently, this review only captures a proportion of the work to date. The resulting case studies and associated resources (process maps, policies, examples of questionnaires etc) will be available on the NHS Improvement website as the projects are validated.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288031</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/priority%5Fprojects/summary_documents/af_summary.pdf]]&gt;</url>
    <title>Heart Improvement : atrial fibrillation in primary care : national priority project</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,ARRHYTHMIA,NHS IMPROVEMENT,GENERAL  / OVERVIEWS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Atrial Fibrillation in Primary Care is a national priority project of the Heart Improvement Programme focusing on improving the identification and management of patients with atrial fibrillation (AF) in primary care.&lt;BR&gt;The time scale for the projects varies, with many projects still in the initial stages of collecting data.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288036</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/BNP/bnp_resource.pdf]]&gt;</url>
    <title>Heart Improvement : Brain - type Natriuretic Peptide</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This paper sets out a brief overview of information available around Brain-type Natriuretic Peptide (BNP) testing as a ‘rule-out’ measure for echocardiogram when suspecting a diagnosis of heart failure. It aims to draw together in one document:&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;• the strands of evidence around BNP&lt;BR&gt;• to give a snapshot of cardiac networks and trusts where activity has been&amp;nbsp;documented&lt;BR&gt;• to provide links to the relevant key documents&lt;BR&gt;• to provide links to research evidence&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288033</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/priority%5Fprojects/summary_documents/inpatients_summary.pdf]]&gt;</url>
    <title>Heart Improvement : making best use of inpatient beds : national priority project</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,NHS IMPROVEMENT,GENERAL  / OVERVIEWS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Making Best Use of Inpatient Beds is a national priority project of the Heart Improvement Programme focusing on a variety of approaches to reducing avoidable inpatient bed days. The project ran over the period June 2007 to March 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182575</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/endoflifecare/resource_kit.htm]]&gt;</url>
    <title>Heart improvement programme : supportive and palliative care in heart failure - a resource kit for cardiac networks</title>
    <publicationDate></publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,PALLIATIVE AND SUPPORTIVE CARE,CONDITIONS,CARDIOVASCULAR DISEASES,SYMPTOM MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This website is a resource kit for cardiac networks. The kit is divided into sections that reflect the sequence a network might follow to review and plan the provision of supportive and palliative care services for local heart failure patients. Within each section there is a description of the materials and a link to a range of resources e.g. word documents, portable document files, presentations and movie files.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324667</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.jhltonline.org/article/PIIS1053249806004578/fulltext]]&gt;</url>
    <title>Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices</title>
    <publicationDate>2006-09-14T00:00:00</publicationDate>
    <publisher>International Society for Heart and Lung Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,JUL-SEP 09,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;DIV id=abstractSummary&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Heart failure may be associated with an abnormal sequence of ventricular contractions, referred to as cardiac or ventricular dyssynchrony. This abnormality may be due to both disturbed electrical activation and regional abnormalities in contraction due to ischemia, myocardial scarring or replacement of myocardium by infiltrative diseases. This document considers the implementation and management of various therapies which address the condition.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp;Healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published online 16 June 2006 and later in the Journal of Heart and Lung Transplantation, 14 September 2006, Vol.25((9): 1043-1056.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;&lt;/DIV&gt;
&lt;P class=noWrap&gt;&lt;STRONG&gt;Publication Date:&lt;/STRONG&gt; 14 Sep 2006&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>281043</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2007/NHRD_booklet.pdf]]&gt;</url>
    <title>Heart rhythm management devices : guidance for commissioners</title>
    <publicationDate></publicationDate>
    <publisher>National Heart Rhythm Management Device Taskforce</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,SERVICE MODELS,DISEASE MANAGEMENT,DEFIBRILLATION,NATIONAL SERVICE FRAMEWORK FOR CHD,ARRHYTHMIA,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This guidance, derived from current national and international consensus guidelines, is offered specifically to assist commissioners responsible for the local provision of implantable cardiac devices and their supporting services to cardiac patients. Local commissioning decisions should be informed both by the current consensus guidelines and by the relative need of the local community as documented in the latest reports of the &lt;A href="http://www.devicesurvey.com/" target="_blank"&gt;Networks Devices Survey.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;The aims of the guidance are to summarise briefly the operational principles and evidence base for the use of&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;cardiac pacemakers&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;implantable cardioverter defibrillators&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;cardiac resynchronisation therapy&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;implantable loop recorders&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;remote monitoring systems&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;In addition, to indicate the health economics of commissioning the technology, manpower implications of providing target level commissioning&lt;BR&gt;and to provide summary key recommendations distilled from the above.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication&amp;nbsp;history information:&lt;/STRONG&gt; Published in October 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101875</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/documents/Helping%20Smokers%20Stop.doc]]&gt;</url>
    <title>Helping smokers to stop : advice for pharmacists in England</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Health and Clinical Excellence, Royal Pharmaceutical Society of Great Britain, Pharmacy Health Link 2005</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NHS IMPROVEMENT,SMOKING,SMOKING CESSATION,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,MANAGEMENT ISSUES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The purpose of this document is to provide pharmacists with the basic information needed to&amp;nbsp;support smokers in their efforts to stop.&amp;nbsp; It is divided into the following sections:&lt;/P&gt;
&lt;P align=left&gt;Section 1: 'Helping smokers to stop' covers:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Background information&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Giving brief advice&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Providing behavioural support&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Using nicotine replacement therapy and buproprion.&amp;nbsp; &lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Section 2: 'Useful information' covers:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Smoking patterns and prevalence&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Health risks and the benefits of stopping smoking&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Sources of further information.&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Includes references and bibliography.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Date of publication:&lt;/STRONG&gt; 2005.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Information last checked 21/4/08.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3805</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/104/4/499]]&gt;</url>
    <title>Hormone replacement therapy and cardiovascular disease</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,WOMEN'S HEALTH,MENOPAUSE,LONG TERM EFFECTS OF THE MENOPAUSE,CARDIOVASCULAR DISEASE,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A Scientific Statement of the American Heart Association. This document summarizes the currently available data concerning potential CVD benefits and risks associated with ERT/HRT and to provide updated clinical recommendations regarding its use in the secondary and primary prevention of CVD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105921</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.parliament.the-stationery-office.co.uk/pa/cm200304/cmselect/cmhealth/23/2302.htm]]&gt;</url>
    <title>House of Commons Health Select Committee Report on Obesity</title>
    <publicationDate></publicationDate>
    <publisher>United Kingdom Parliament</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ OBESITY,BIOLOGICAL COMPOSITION,CAUSES AND RISK FACTORS,CAUSES AND RISK FACTORS,CONDITIONS,CARDIOVASCULAR DISEASES,DIET,OVERWEIGHT AND OBESITY,DIET,PHYSICAL ACTIVITY,CORONARY HEART DISEASE,PREVENTION,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,GOVERNMENT &amp; LAW,GOVERNMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;House of Commons Health Select Committe Report on Obesity - Third Report of Session 2003-2004.&lt;/P&gt;
&lt;P&gt;Includes the following sections:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;1 Introduction &lt;BR&gt;&lt;/STRONG&gt;Scope and nature of our inquiry &lt;BR&gt;Defining obesity &lt;BR&gt;How prevalent is obesity?&lt;BR&gt;Obesity and health inequalities&lt;BR&gt;What are the potential health risks of obesity and what are the costs of these?&lt;BR&gt;What are the economic costs?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2 Causes&lt;BR&gt;&lt;/STRONG&gt;Gluttony or sloth? &lt;BR&gt;Nutritional causes&lt;BR&gt;Changing nutritional habits&lt;BR&gt;Information and choice &lt;BR&gt;Causes of obesity related to physical inactivity&lt;BR&gt;Changing lifestyles&lt;BR&gt;Children's activity levels&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3 Solutions&lt;/STRONG&gt; &lt;BR&gt;Nutritional solutions &lt;BR&gt;Information and choice&lt;BR&gt;Food advertising and promotion &lt;BR&gt;Food labelling&lt;BR&gt;Food composition &lt;BR&gt;Food pricing &lt;BR&gt;Food in schools &lt;BR&gt;Causes of obesity relating to physical inactivity: solutions &lt;BR&gt;Organised and recreational activity &lt;BR&gt;Active lifestyles &lt;BR&gt;The workplace &lt;BR&gt;Strategic direction &lt;BR&gt;The role of the NHS &lt;BR&gt;Prevention of obesity &lt;BR&gt;Treatment of obesity &lt;BR&gt;Prioritisation within the NHS&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;4 Conclusion&lt;/STRONG&gt; &lt;BR&gt;Conclusions and recommendations&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2004&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>51876</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/minap/HowHospitalsManageHeartAttacks12Nov2002.pdf]]&gt;</url>
    <title>How hospitals manage heart attacks : first public report of the Myocardial Infarction National Audit Project</title>
    <publicationDate></publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ THROMBOLYTICS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,REPERFUSION,ANTI-PLATELET DRUGS,BETA BLOCKERS,KEY POLICIES,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the&amp;nbsp;first Myocardial National Audit Project&amp;nbsp;(MINAP) report examining the performance of hospitals in England and their progress towards achievement of the National Service Framework (NSF) targets for Coronary Heart Disease (CHD). The report covers the period&amp;nbsp;for the first half of 2002&amp;nbsp;and includes a table showing hospitals and their achievements against the NSF targets for Door to Needle time and drug treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5874</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/minap/]]&gt;</url>
    <title>How hospitals manage heart attacks : second public report of the Myocardial Infarction National Audit Project</title>
    <publicationDate></publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ THROMBOLYTICS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,REPERFUSION,CARDIOVASCULAR DISEASES,KEY POLICIES,BETA BLOCKERS,ANTI-PLATELET DRUGS,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the second Myocardial National Audit Project (MINAP) report examining the performance of hospitals in England and their progress towards achievement of the National Service Framework (NSF) targets for Coronary Heart Disease(CHD). The report covers the period April 2002 to March 2003 and includes a table showing hospitals and their achievements against the NSF targets for Door to Needle time and drug treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389515</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/media/Documents/press-release-documents/public_report_2009.pdf]]&gt;</url>
    <title>How the NHS cares for people with heart attacks : ninth public report on the Myocardial Infarction National Audit Project (MINAP)</title>
    <publicationDate>2010-10-06T00:00:00</publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,SERVICE MODELS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,GENERAL/OTHER,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=1 face=DIN-Light&gt;&lt;FONT size=1 face=DIN-Light&gt;&lt;FONT size=1 face=DIN-Light&gt;&lt;FONT size=1 face=DIN-Light&gt;
&lt;P align=left&gt;This is the ninth annual MINAP Public Report. It presents analyses from all hospitals and ambulance services in England and Wales that provided care for patients with suspected heart attack from April 2009 to March 2010 (2009/10). It also presents some data from previous years.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&amp;nbsp; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>318622</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/media/Documents/press-release-documents/public_report_2009.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : eighth public report on the Myocardial Infarction National Audit Project (MINAP)</title>
    <publicationDate>2009-06-24T00:00:00</publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,MANAGEMENT ISSUES,ANTI-PLATELET DRUGS,BETA BLOCKERS,CLINICAL AUDIT AND GOVERNANCE,INTERVENTIONS / PROCEDURES,SERVICE MODELS,THROMBOLYTICS,EMERGENCY CARE,CLINICAL LIBRARY,ORGANISATIONAL AND OTHER ISSUES,CARDIOVASCULAR,ETHICS AND STANDARDS,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,AUDIT,APR-JUN 09,REPERFUSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This is the Eighth Public Report from the Myocardial Ischaemia National Audit Project (MINAP) on the treatment of heart attack patients. It presents analyses from all hospitals and ambulance services in England and Wales that provided care for patients with suspected heart attack from April 2008 to March 2009 (2008/9), and compares these with the previous year (2007/8). &lt;/P&gt;
&lt;P align=left&gt;The report shows that the&amp;nbsp;longest delay in the treatment of heart attack patients is usually not the delay in the arrival of the ambulance or giving thrombolytic treatment, but the delay in calling for professional help. The earlier the treatment can be given the better the outcomes for patients.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&lt;FONT size=3 face=Arial&gt;&amp;nbsp; &lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>148597</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/minap06/HowHospitalsManageHeartAttacksJune2006.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : fifth public report on the Myocardial Infarction National Audit Project (MINAP)</title>
    <publicationDate></publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,THROMBOLYTICS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,REPERFUSION,KEY POLICIES,ANTI-PLATELET DRUGS,BETA BLOCKERS,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This is the fifth Myocardial Infarction National Audit Project (MINAP) report on the treatment of heart attack patients.&amp;nbsp; It presents data from all hospitals in England and Wales that admit patients with suspected heart attack from April 2005 to March 2006 (2005/06) in comparison with data from the previous year (2004/05).&amp;nbsp; The report shows continuing improvement in the care of heart attack patients. &lt;/P&gt;
&lt;P align=left&gt;Key findings:&lt;/P&gt;
&lt;P align=left&gt;Patients receive thrombolytic treatment faster&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;83% of eligible patients in England received thrombolytic treatment within 30 minutes of arrival at hospital compared with 44% during early 2001. 
&lt;LI&gt;74% of eligible patients in Wales received thrombolytic treatment within 30 minutes of arrival at hospital, compared to 65% in 2003/4 when the Welsh hospitals were first included in the Public Report. 
&lt;LI&gt;58% of patients received thrombolytic treatment within 60 minutes of calling for professional help in England compared with only 22% in early 2001 (30% in Wales, compared to 22% in 2003/4).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;More ambulance personnel can diagnose heart attack and give thrombolytic treatment before the patient arrives at hospital &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;28 of the 31 ambulance services in England and the Welsh ambulance service can now give thrombolytic treatment to patients before they reach hospital (pre-hospital thrombolysis). 
&lt;LI&gt;In 2005/6, 2231 patients received pre-hospital thrombolytic treatment compared with 1374 patients in 2004/5. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;More patients are being treated by primary angioplasty.&amp;nbsp; More hospitals are now using angioplasty as an emergency treatment for heart attack &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In 2005/6, 1,647 patients were treated with primary angioplasty in preference to thrombolytic treatment, compared with 1,087 in 2004/5. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published June 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89366</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/minap05/HowHospitalsManageHeartAttacksJune2005.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : fourth public report of the Myocardial Infarction National Audit Project (MINAP)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ THROMBOLYTICS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,INTERVENTIONS / PROCEDURES,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,REPERFUSION,CONDITIONS,DISEASE MANAGEMENT,KEY POLICIES,ANTI-PLATELET DRUGS,BETA BLOCKERS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the fourth Myocardial Infarction National Audit Project (MINAP) report on the treatment of heart attack patients.&amp;nbsp; It presents data from all hospitals in England and Wales that admit patients with suspected heart attack from April 2004 to March 2005 (2004/05) in comparison with data from the previous year (2003/04).&amp;nbsp; The report shows continuing improvement in the care of heart attack patients.&lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Patients are receiving thrombolytic treatment faster (86% within 30 minutes of arrival at hospital) 
&lt;LI&gt;More ambulance personnel can diagnose heart attack and give thrombolytic treatment before the patient arrives at hospital (27 out of 31 ambulance services across England and Wales can now give pre-hospital thrombolysis) 
&lt;LI&gt;More patients are being treated by primary angioplasty (1,087 in 2004/05 compared to 390 in 2003/04) 
&lt;LI&gt;Prescription of secondary prevention medication continues to increase&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published June 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289546</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/clinical-standards/organisation/partnership/Documents/Minap-2008.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : seventh public report on the Myocardial Infarction National Audit Project (MINAP)</title>
    <publicationDate>2008-06-26T00:00:00</publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,THROMBOLYTICS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,INTERVENTIONS / PROCEDURES,SERVICE MODELS,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,JUL-SEPT 08,REPERFUSION,CONDITIONS,MANAGEMENT ISSUES,KEY POLICIES,ANTI-PLATELET DRUGS,BETA BLOCKERS,CLINICAL AUDIT AND GOVERNANCE,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This is the seventh Myocardial Infarction National Audit Project (MINAP) report on the treatment of heart attack patients. It presents data from all hospitals in England and Wales that admit patients with suspected heart attack from April 2007&amp;nbsp;to March 2008 (2007/8) in comparison with data from the previous year *2006/7). &lt;BR&gt;&lt;BR&gt;The report shows that more patients received thrombolytic treatment within 60 minutes of calling for help. More ambulance personnel can diagnose heart attack and give thrombolytic treatment before the patient arrives at hospital and more patients are being treated by primary angioplasty. Prescription of secondary prevention medication continues to exceed national standards and there is a falling mortality in heart&amp;nbsp;attack patients.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266236</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/contents/1236173e-ec7d-49be-ae16-322ed16f7de6.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : sixth public report of the Myocardial National Audit Project (MINAP)</title>
    <publicationDate></publicationDate>
    <publisher>Royal College of Physicians (London)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,THROMBOLYTICS,INTERVENTIONS / PROCEDURES,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,GENERAL / OVERVIEWS,REPERFUSION,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"The sixth public report from MINAP (the Myocardial Infarction National Audit Project) shows data from all hospitals and ambulance services in England and Wales that provided care for patients with suspected heart attack in 2006/7 in comparision with data from the previous year.&lt;/P&gt;
&lt;P&gt;The report shows that more patients received thrombolytic treatment within 60 minutes of calling for help. This saves lives and contributes to the overall decrease in deaths from heart attacks shown in this report. More ambulance personnel can diagnose heart attack and give thrombolytic treatment before the patient arrives at hospital and more patients are being treated by primary angioplasty"&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>51738</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/books/minap04/HowHospitalsManageHeartAttacksJune2004.pdf]]&gt;</url>
    <title>How the NHS manages heart attacks : third public report of the Myocardial Infarction National Audit Project</title>
    <publicationDate></publicationDate>
    <publisher>Myocardial Infarction National Audit Project Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR CHD,THROMBOLYTICS,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,REPERFUSION,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,KEY POLICIES,BETA BLOCKERS,ANTI-PLATELET DRUGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the&amp;nbsp;third Myocardial Infarction National Audit Project&amp;nbsp;( MINAP ) report examining the performance of hospitals in England and Wales&amp;nbsp;and their progress towards achievement of the National Service Framework (NSF) targets for Coronary Heart Disease (CHD). The report covers the period April 2003 to March 2004 and includes a table showing hospitals and their achievements against the NSF targets for Door to Needle time and drug treatments. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187531</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/80/35/04138035.pdf]]&gt;</url>
    <title>How to assess structured diabetes education : an improvement toolkit for commissioners and local diabetes communities</title>
    <publicationDate>2006-08-09T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,MANAGEMENT ISSUES,DIABETES MELLITUS,SERVICE MODELS,DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This toolkit has been developed to help local services to deliver high quality patient education to their diabetes community. It highlights best practice to enable local services to meet the recommendations outlined in the Diabetes National Service Framework and the National Institute for Clinical Excellence Health Technology Appraisal on patient education models.&amp;nbsp;The tools will enable those involved in delivering diabetes patient education to assess robustly their programmes, to enhance their skills and to continue to improve the educational support given to people with diabetes.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271339</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://eurheartj.oxfordjournals.org/cgi/reprint/28/20/2539]]&gt;</url>
    <title>How to diagnose diastolic heart failure : a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,BLOOD PRESSURE,ECHOCARDIOGRAM,GENERAL,HEART FAILURE,CARDIAC MARKERS,DIAGNOSIS,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This document updates the strategies for the diagnosis of heart failure with normal left ventricular ejection fraction (HFNEF). It provides guidance for individual patient management and states that the following three requirements need to be satisified to diagnose HFNEF:&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;(i) Signs or symptoms of congestive heart failure&lt;BR&gt;&lt;BR&gt;(ii) Normal or mildly abnormal systolic left ventricular (LV) funtion&lt;BR&gt;&lt;BR&gt;(iii) Evidence of diastolic LV dysfunction&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Document is also useful as a guide for patient selection of future clinical trials looking at treatments for HFNEF. Includes references.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Published in EHJ 2007;28(20):2539-2550.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281407</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188629]]&gt;</url>
    <title>Hyperglycemia and acute coronary syndrome : a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity and Metabolism</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; Hyperglycemia is common and associated with increased mortality rates in patients hospitalised with acute coronary syndromes (ACS). This statement aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;summarise the current state of knowledge regarding the link between elevated glucose and patient outcomes with acute coronary syndromes (ACS)&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;outline the most important knowledge gaps in this field&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;provide consensus recommendations for hyperglycemia management in patients with ACS on the basis of the available data.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3554</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://hyper.ahajournals.org/]]&gt;</url>
    <title>Hypertension : Journal of the American Heart Association</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the American Heart Association publishes research in the field of blood pressure regulation and the pathophysiological mechanisms underlying the hypertensive diseases. Table of contents and abstracts available; full text documents at charge.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59773</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=CG34]]&gt;</url>
    <title>Hypertension : management of hypertension in adults in primary care</title>
    <publicationDate>2004-08-25T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,DIAGNOSIS,HYPERTENSION,CONDITIONS,CARDIOVASCULAR DISEASES,ISCHAEMIC STROKE,HAEMORRHAGIC STROKE,PREVENTION,STROKE,PREVENTION,HYPERTENSION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;This site provides the clinical guidelines from the National Institute for Clinical Excellence&amp;nbsp;(NICE) on the management of hypertension in adults in primary care.&amp;nbsp;The&amp;nbsp; guidelines&amp;nbsp;include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;how doctors should find out whether someone has high blood pressure 
&lt;LI&gt;how doctors should assess someone's risk of developing problems with their heart or blood vessels, such as a heart attack or stroke (also called 'cardiovascular disease') 
&lt;LI&gt;how lifestyle factors such as smoking, diet and exercise can affect blood pressure 
&lt;LI&gt;the use of medicines to lower blood pressure 
&lt;LI&gt;how high blood pressure should be monitored (NICE)&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;NICE clinical guideline No.&amp;nbsp;34. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Supersedes clinical guideline No. 18.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document Format / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>63618</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bnf.org/bnf/extra/current/450020.htm]]&gt;</url>
    <title>Imperial-metric conversions</title>
    <publicationDate></publicationDate>
    <publisher>British National Formulary</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GENERAL,DIAGNOSIS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This tool allows you to convert volumes, lengths and weights from imperial to metric measurement. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3659</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon426.pdf]]&gt;</url>
    <title>Implantable cardioverter defibrillators : arrhythmias : a rapid and systematic review</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report studies the use of implantable cardioverter defibrillators (ICDs) in the management of risk factors leading to sudden cardiac death. Published in Health Technology Assessment, 2000, 4 (26). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document Format&amp;nbsp;/ PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324783</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bhf.org.uk/publications/view_publication.aspx?ps=1000155]]&gt;</url>
    <title>Implantable cardioverter defibrillators in patients who are reaching the end of life</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>British Heart Foundation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,DEFIBRILLATION,JUL-SEP 09,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; National guidelines in this area of care have not yet been developed. The aim of this document is to raise awareness of the potential dilemmas that devices such as ICDs introduce in advanced disease management, and to promote discussion about the possibility of deactivating the defibrillator function of the ICD in patients who are reaching the end of their life.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Health professionals involved in caring for dying patients with an active defibrillator device.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published July 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156310</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=16916&amp;Rendition=Web]]&gt;</url>
    <title>Implanted device lead extraction</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for&amp;nbsp;implanted device lead extraction.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268518</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.178777]]&gt;</url>
    <title>Indications for renal arteriography at the time of coronary arteriography : a science advisory from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Councils on Cardiovascular Radiology and Intervention on Kidneys in Cardiovascular Disease</title>
    <publicationDate>2006-10-24T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,ARTERIOSCLEROSIS,CORONARY HEART DISEASE,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CONDITIONS,DIAGNOSIS,CARDIOVASCULAR DISEASES,DIAGNOSIS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,RENOVASCULAR DISEASES,IN ADULTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN lang=EN-GB style="mso-ansi-language: EN-GB"&gt;The aim of this consensus document is to describe the rationale for patient &lt;/SPAN&gt;&lt;SPAN lang=EN-GB style="mso-ansi-language: EN-GB"&gt;selection for screening renal angiography at the time of cardiac catheterization.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;Atherosclerotic renal artery stenosis is commonly present in patients with clinically manifest atherosclerosis in other vascular beds and is independently associated with increased cardiovascular morbidity and mortality. Screening tests such as renal angiography should be selectively applied to patients at high risk for renal artery stenosis who are potential candidates for revascularisation. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>87957</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://internationaljournalofcardiology.com/inpress]]&gt;</url>
    <title>International Journal of Cardiology : articles in press</title>
    <publicationDate></publicationDate>
    <publisher>International Journal of Cardiology, Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;International Journal of Cardiology: articles in press&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>87952</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science/journal/01675273]]&gt;</url>
    <title>International Journal of Cardiology : current issue</title>
    <publicationDate></publicationDate>
    <publisher>International Journal of Cardiology, Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;International Journal of Cardiology: Current Issue&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384116</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181e8edf1]]&gt;</url>
    <title>Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults</title>
    <publicationDate>2010-07-12T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,PREVENTION,DIET,GENERAL,GENERAL,DIET,PHYSICAL ACTIVITY,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;To promote physical activity (PA) and healthy diets in all American&lt;SUP&gt; &lt;/SUP&gt;adults.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Pulbished July 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;Abstract only. Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;Full-text online access is available to NHS staff in England via ATHENS passwords.&amp;nbsp; To find out how to get an ATHENS password and access this resource and many others please refer to "Athens Registration" at &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291238</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/project/1659.asp]]&gt;</url>
    <title>Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation</title>
    <publicationDate>2008-07-29T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DISEASE MANAGEMENT,CORONARY ARTERY BYPASS GRAFTS,SURGICAL PROCEDURES,ECONOMIC EVALUATIONS,JUL-SEPT 08,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,BETA BLOCKERS,ANTI-ARRHYTHMIC DRUGS,PREVENTION,MANAGEMENT ISSUES,CORONARY HEART DISEASE,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Bottom line conclusion:&lt;/STRONG&gt; Prophylaxis is less likely to be a cost-effective option if it requires changes in admission routines that result in longer preoperative stays than would be the case without prophylaxis.&lt;/P&gt;
&lt;P align=left&gt;This systematic review aims to assess the clinical and cost-effectiveness of magnesium sulphate compared with sotalol, and to assess the clinical effectiveness of magnesium sulphate compared with placebo in the prevention of atrial fibrillation (AF) in patients who have had a coronary artery bypass graft (CABG).&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>31066</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/17/2154]]&gt;</url>
    <title>Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CHRONIC KIDNEY DISEASE,COMPLICATIONS OF KIDNEY DISEASE,CARDIOVASCULAR DISEASE,PREDISPOSING FACTORS,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,CONDITIONS,CORONARY HEART DISEASE,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This 2003 statement reviews chronic kidney disease (CKD) as a risk factor for the development of cardiovascular diseases (CVD).&amp;nbsp; The document&amp;nbsp;considers the definition of CKD and the stages of severity.&amp;nbsp; The spectrum of CVD in CKD and differences from the general population&amp;nbsp;are explored.&amp;nbsp; Arterial vascular disease and cardiomyopathy are discussed as the primary types of CVD and CVD risk factors in CKD are covered.&amp;nbsp; CVD in kidney failure, kidney transplant recipients, diabetic kidney disease and non-diabetic kidney disease&amp;nbsp;are also reviewed.&amp;nbsp; Includes studies, tabular information, summary and references. Published in Circulation 2003;108:2154. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82455</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/10/52/82/04105282.pdf]]&gt;</url>
    <title>Leading the way progress report 2005 : the coronary heart disease National Service Framework</title>
    <publicationDate>2005-03-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,MANAGEMENT ISSUES,ARRHYTHMIA,CHEST PAIN,CORONARY HEART DISEASE,HEART FAILURE,PATIENT CHOICE,SURGICAL PROCEDURES,GENERAL  / OVERVIEWS,REVASCULARISATION,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,STABLE ANGINA,CARDIAC REHABILITATION,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; The Coronary Heart Disease (CHD)&amp;nbsp;National Service Framework (NSF)&amp;nbsp;continues to deliver improvements in CHD services.&lt;/P&gt;
&lt;P&gt;This progress report is published to mark the fifth anniversary of the National Service Framework for Coronary Heart Disease. &lt;BR&gt;&lt;BR&gt;It&amp;nbsp;contains sections on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Prevention of heart disease;&lt;/STRONG&gt; including the Public Health White Paper, the reduction of key risk factors for CHD and preventing CHD in high risk patients.&lt;BR&gt;
&lt;LI&gt;&lt;STRONG&gt;Improving access and choice&lt;/STRONG&gt; for patients with CHD.&lt;BR&gt;
&lt;LI&gt;&lt;STRONG&gt;Delivery of care for people living with heart disease;&lt;/STRONG&gt; includes heart failure and mentions the new NSF chapter on arrhythmias and sudden cardiac death.&lt;BR&gt;
&lt;LI&gt;&lt;STRONG&gt;Continued implementation&lt;/STRONG&gt; of the NSF for CHD&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3869</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/Toolkit.pdf]]&gt;</url>
    <title>Learning from patients and carers experiences</title>
    <publicationDate></publicationDate>
    <publisher>NHS Modernisation Agency, National Coronary Heart Disease Collaborative</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,RESOUCES THAT ARE HIDDEN BUT WE ARE HOLDING ONTO FOR NOW]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;CHD Collaborative Toolkit. This document gives information on how to better understand patients' and carers' experiences through Discovery Interviews. &lt;/P&gt;
&lt;P&gt;This document is hosted by NHS Heart Improvement Programme.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Information last checked 21/4/08.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389058</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ehnheart.org/publications/heart-health-nutrition/publication/100--lifestyle-and-risk-of-heart-disease-among-children-and-adolescents.html]]&gt;</url>
    <title>Lifestyle and risk of heart disease among children and adolescents</title>
    <publicationDate>2006-01-16T00:00:00</publicationDate>
    <publisher>European Heart Network</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,GENERAL,GENERAL,CAUSES AND RISK FACTORS,ARTERIOSCLEROSIS,CAUSES &amp; RISK FACTORS,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report comprises a scientific review of the instruments used by professionals in the scientific community to influence the lifestyle of children and adolescents in order to reduce the risk of heart disease in adult life. The purpose of the report is to provide a basis for policymaking for children and adolescents with regard to diet, physical activity and smoking. Includes sections on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Atherosclerosis 
&lt;LI&gt;Correlation between lifestyle and risk factors and heart desease 
&lt;LI&gt;Diet 
&lt;LI&gt;Physical activity&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324784</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.jhltonline.org/article/PIIS1053249806004608/fulltext]]&gt;</url>
    <title>Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the care of cardiac transplant candidates</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>International Society for Heart and Lung Transplantation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,JUL-SEP 09,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document from the International Society for Heart and Lung Transplantation delivers the criteria for listing patients for heart transplantation, re-evaluating the listing criteria to provide succinct and clear guidance to transplant centres. These recommendations can be used to update listing and management policies for potential heart transplant recipients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Transplant surgeons.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in the Journal of Heart and Lung Transplantation, September 2006: Vol 25 (9), 1024-1042.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177581</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;ID=12005000531]]&gt;</url>
    <title>Low molecular weight heparin versus unfractionated heparin in percutaneous coronary intervention : a combined analysis</title>
    <publicationDate></publicationDate>
    <publisher>Database of Abstracts of Reviews of Effectiveness, Centre for Reviews and Dissemination</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,HEPARIN,LOW MOLECULAR WEIGHT HEPARINS,ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,ANTI-COAGULANTS,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; For people not&amp;nbsp;receiving anticoagulation, a single intravenous injection of low molecular weight heparin (LMWH) immediately before percutaneous coronary intervention (PCI) has the potential to be as safe and effective as unfractionated heparin (UFH). 
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; This is a 2006 DARE (Database of Abstracts of Reviews of Effects) structured abstract of a 2005 systematic review. The authors' objective was to assess the effects of intravenous&amp;nbsp;LMWH compared with&amp;nbsp;UFH in people undergoing percutaneous coronary intervention. 
&lt;P&gt;&lt;STRONG&gt;Quality Assessment:&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Database search was limited to MEDLINE 
&lt;LI&gt;Methods of the review e.g. study selection and&amp;nbsp;data extraction were not described and there was no mention of&amp;nbsp;quality assessment 
&lt;LI&gt;Insufficient&amp;nbsp;detail about the participants 
&lt;LI&gt;Unreliable evidence used from non&amp;nbsp;randomised controlled trials (RCTs) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;However, the authors' conclusions seem suitably cautious with reference to the above mentioned comments (DARE).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Original study:&lt;/STRONG&gt; Borentain M et al.&amp;nbsp; Low molecular weight heparin&amp;nbsp;versus unfractionated heparin in percutaneous coronary intervention : a combined analysis. Catheterization and Cardiovascular Interventions 2005;65(2): 212-21.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to review:&lt;/STRONG&gt; Abstract only. Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>87466</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/CHD%20Review%202005.pdf]]&gt;</url>
    <title>Making a difference : an overview of the work of the Coronary Heart Disease Collaborative</title>
    <publicationDate>2005-03-03T00:00:00</publicationDate>
    <publisher>Coronary Heart Disease Collaborative</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PERFORMANCE INDICATORS,SERVICE MODELS,NHS IMPROVEMENT,NATIONAL SERVICE FRAMEWORK FOR CHD,CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES,NETWORKS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document reviews the progress made by the CHD Collaborative *&amp;nbsp;since 2000. It examines the impact of the work from a national perspective and contains practical case studies from Collaborative programme teams, demonstrating how they have worked with local clinical teams to deliver real service improvement to patients.&lt;/P&gt;
&lt;P&gt;* Since publication the Coronary Heart Diseases Collaborative's&amp;nbsp;work has been subsumed&amp;nbsp;into the NHS Heart Improvement Programme&amp;nbsp;which was launched in April 2005.&lt;/P&gt;
&lt;P&gt;This document is hosted by NHS Heart Improvement Programme.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readermain.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125299</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/CHD/5453/28116/Making%20Moves%20April%202006%20HIP008.pdf]]&gt;</url>
    <title>Making moves : results of a data audit and review of service improvements in interhospital transfer arrangements for cardiac patients</title>
    <publicationDate></publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,SERVICE MODELS,GENERAL/OTHER,CARDIOVASCULAR DISEASES,CONDITIONS,DISEASE MANAGEMENT,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Results of a voluntary audit of interhospital transfers in inpatient cardiology undertaken in&amp;nbsp;October 2005. The document reviews the key findings from the audit and gives examples of good practice to address common issues.&amp;nbsp; Recommendations for improvements to the service are included.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156328</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=10791&amp;Rendition=Web]]&gt;</url>
    <title>Management after resuscitation from cardiac arrest</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,CARDIOPULMONARY ARREST,DIAGNOSIS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for a patient after resuscitation from cardiac arrest. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>32854</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/Documents/ACS/guidelines-NSTE-ACS-FT-2002.pdf]]&gt;</url>
    <title>Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation</title>
    <publicationDate></publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,RISK ASSESSMENT,POTASSIUM-CHANNEL ACTIVATORS,NITRATES,SURGICAL PROCEDURES,THROMBOLYTICS,CARDIAC MARKERS,CORONARY ARTERY BYPASS GRAFTS,MANAGEMENT ISSUES,ANTI-PLATELET DRUGS,ELECTROCARDIOGRAM,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY HEART DISEASE,CALCIUM CHANNEL BLOCKERS,BETA BLOCKERS,REVASCULARISATION,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES,CLINICAL LIBRARY,CARDIOVASCULAR,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,REPERFUSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is an updated version of the document published in 2000 and reflects the current knowledge for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.&amp;nbsp; Sections are included on pathophysiology, diagnosis, risk assessment, treatment options and management strategy.&amp;nbsp; Includes tabular information, summary statement and references. Published in Eur Heart J 2002;23:1809-40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282020</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188950]]&gt;</url>
    <title>Management of cocaine associated chest pain and myocardial infarction : a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,CHEST PAIN,GENERAL,DIAGNOSIS,DISEASE MANAGEMENT,EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,CARDIOVASCULAR,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,CHEST PAIN (ISCHAEMIC),CHEST,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DIAGNOSIS,DISEASE MANAGEMENT,OTHER,SECONDARY PREVENTION,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; To provide a critical review of the literature on cocaine associated chest pain and myocardial infarction (MI) and to give guidance for diagnostic and therapeutic interventions.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251530</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/guidelinesdocuments/guidelines-guch-ft.pdf]]&gt;</url>
    <title>Management of grown up congenital heart disease</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,SURGICAL PROCEDURES,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,GENERAL / OVERVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To provide guidance on the management of grown up congenital heart disease (GUCH) and to promote collaboration between the various professional groups involved in the care of adolescents and adults with GUCH. Sections are included on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Organisation of care&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Medical issues&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Surgical issues&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Psychosocial issues&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Management of common lesions&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp; Cardiologists, clinicians and other healthcare progessionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in European Heart Journal 2003;24:1035-1084.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&amp;nbsp;&amp;nbsp;&lt;/STRONG&gt;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; Guidelines Simulator is a spreadsheet requiring Microsoft Excel.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60167</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.manchesterheartcentre.org/aa/aa.php]]&gt;</url>
    <title>Managing cardiac rhythm disorders in the UK : the need for change</title>
    <publicationDate></publicationDate>
    <publisher>Arrhythmia Alliance</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NATIONAL SERVICE FRAMEWORK FOR CHD,CONDITIONS,MANAGEMENT ISSUES,KEY POLICIES,ARRHYTHMIA,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This consultation document has been published by the Arrhythmia Alliance in advance of the new chapter to be included in&amp;nbsp;the revised National Service Framework for Heart Disease, due&amp;nbsp;to be published in March,&amp;nbsp;2005. It aims to introduce the complex subject of arrhythmias and to provide data and opinion to inform discussion on the new chapter.&lt;/P&gt;
&lt;H2&gt;This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;&lt;FONT face=Arial size=2&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;FONT face=Arial size=2&gt;&lt;STRONG&gt;&lt;FONT face=Arial size=2&gt;&lt;BR&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78048</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Researchanddevelopment/A-Z/Cardiovasculardiseaseandstroke/DH_4002092]]&gt;</url>
    <title>MC10 : randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina : final results of the Southampton heart integrated care project (SHW)</title>
    <publicationDate>2002-09-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CHEST PAIN,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,STABLE ANGINA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Author's Conclusion:&lt;/STRONG&gt;&amp;nbsp;Although the programme was effective in promoting follow up in general practice, it did not improve health outcome. Simply co-ordinating and supporting existing NHS care is insufficient. Ischaemic heart disease is a chronic condition which requires the same systematic approach to secondary prevention applied in other chronic conditions such as diabetes mellitus. 
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To assess the effectiveness of a programme to co-ordinate and support follow up care in general practice after a hospital diagnosis of myocardial infarction or angina. 
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&amp;nbsp;A&amp;nbsp;programme to co-ordinate preventive care led by specialist liaison nurses which sought to improve communication between hospital and general practice and to encourage general practice nurses to provide structured follow up. 
&lt;P&gt;&lt;STRONG&gt;Outcome measures:&lt;/STRONG&gt;&amp;nbsp;Serum total cholesterol concentration, blood pressure, distance walked in six minutes, confirmed smoking cessation, and body mass index measured at&amp;nbsp;one year follow up. 
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 559 surviving patients at 1 year, 502 (90%) were followed up. There was no significant difference between the intervention and control groups in smoking (cotinine validated quit rate 19% v 20%), lipid concentrations (serum total cholesterol 5.80 v 5.93 mmol/l), blood pressure (diastolic pressure 84 v 85 mm Hg), or fitness (distance walked in six minutes 443 v 433 m). Body mass index was slightly lower in the intervention group (27.4 v 28.2; P = 0.08). 
&lt;P&gt;&lt;STRONG&gt;Original Study:&lt;/STRONG&gt; Jolly K ... et al&amp;nbsp;Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. &lt;SPAN title="BMJ (Clinical research ed.)" eventRemoved="AbbrLookUp(this, "&gt;BMJ&lt;/SPAN&gt; 1999;318:706-11 
&lt;P&gt;&lt;STRONG&gt;Access to abstract:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&lt;STRONG&gt;Access to original Study:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125733</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/44/72/04134472.pdf]]&gt;</url>
    <title>Measuring childhood obesity : guidance to primary care trusts on data handling</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ OBESITY,BIOLOGICAL COMPOSITION,CHILDREN,GUIDELINES,SPECIALTIES,OBESITY,CHILD HEALTH,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PREVENTION,OVERWEIGHT AND OBESITY,DIET,NUTRITION,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,INFORMATION,FRAMES OF REFERENCE,MEASUREMENT,METHODS,GROUPS,POPULATIONS,ANALYSIS &amp; RESEARCH,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Guidance to PCTs on how to measure childhood obesity.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287622</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/112/21/3354]]&gt;</url>
    <title>Medical director responsibilities for outpatient cardiac rehabilitation / secondary prevention programs : a scientific statement from the American Heart Association / American Association for Cardiovascular and Pulmonary Rehabilitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,PHYSICAL ACTIVITY,SECONDARY PREVENTION,CARDIAC REHABILITATION,APR-JUNE 08,CORONARY HEART DISEASE,GENERAL,GENERAL,CONDITIONS,DISEASE MANAGEMENT,PREVENTION,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To provide an overview of specific responsibilities for the medical director of an outpatient cardiac rehabilitation and secondary prevention program. The statement also provides guidance on linking the clinical aspects of physician involvement to the provision of services by program staff while maintaining compliance with regulatory requirements.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377831</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/121/14/1664]]&gt;</url>
    <title>Medication Errors in Acute Cardiovascular and Stroke Patients</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,ANTI-COAGULANTS,GENERAL/OTHER,STROKE,ISCHAEMIC STROKE,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,DISEASE MANAGEMENT,RECENT ADDITIONS,RECENT ADDITIONS,APR-JUN 10,APR-JUNE 10,JUNE 2010,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Medical errors are the eighth leading cause of death in the&lt;SUP&gt; &lt;/SUP&gt;United States and are estimated to account for somewhere between&lt;SUP&gt; &lt;/SUP&gt;44 000 and 98 000 deaths in the United States each year. An&lt;SUP&gt; &lt;/SUP&gt;exact number of deaths remains both uncertain and controversial,&lt;SUP&gt; &lt;/SUP&gt;with arguments that the actual figure may be lower or higher]]&gt;</body>
  </document>
  <document>
    <id>3911</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/smoking_cessation_targets_part1.pdf]]&gt;</url>
    <title>Meeting Department of Health Smoking Cessation Targets : recommendations for Primary Care Trusts</title>
    <publicationDate>2003-02-01T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PERFORMANCE &amp; ASSESSMENT FRAMEWORKS,SMOKING CESSATION,POPULATION BASED &amp; PREVENTATIVE SERVICES,QUALITY,SMOKING CESSATION,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PREVENTION,NHS IMPROVEMENT,DETERMINANTS,PUBLIC HEALTH,LIFESTYLE,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,FRAMEWORKS,HEALTH SERVICES,GOVERNMENT,SERVICES,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,GOVERNMENT &amp; LAW,PRIMARY CARE ORGANISATIONS,AREAS,PLACES,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This 2003&amp;nbsp;document aims to aid Primary Care Trusts (PCTs) in their continuing development of smoking cessation programmes in order to meet the targets set in the &lt;EM&gt;Priorities and Planning Framework&lt;/EM&gt; &lt;EM&gt;2003-2006&lt;/EM&gt; document. It looks at the structuring of smoking cessation treatment services, paying particular attention to local variables by presenting several case studies of smoking cessation programmes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File /&amp;nbsp;PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3916</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/smoking_cessation_targets_part2.pdf]]&gt;</url>
    <title>Meeting Department of Health Smoking Cessation Targets : recommendations for service providers</title>
    <publicationDate>2003-02-01T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ QUALITY,POPULATION BASED &amp; PREVENTATIVE SERVICES,SMOKING CESSATION,PERFORMANCE &amp; ASSESSMENT FRAMEWORKS,NHS IMPROVEMENT,PREVENTION,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES,SMOKING CESSATION,PUBLIC HEALTH,DETERMINANTS,INDIVIDUAL BEHAVIOUR,SMOKING,TOBACCO USE,MANAGEMENT &amp; INTERVENTIONS,GEOGRAPHY,NATIONAL,REGIONAL VARIATIONS,GOVERNMENT &amp; LAW,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,SERVICES,GOVERNMENT,HEALTH SERVICES,FRAMEWORKS,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This 2003 document provides information to co-ordinators, clinicians and counsellors to aid them in their continuing development of smoking cessation programmes in order to meet the targets set in the &lt;EM&gt;Priorities and Planning Framework 2003-2006&amp;nbsp;&lt;/EM&gt;document. The report covers the most common issues in a question-and-answer format. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250511</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6W9H-4KM446R-H&amp;_user=10&amp;_coverDate=08%2F31%2F2006&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=6820e8e59300601a5ef4304c08986f2b]]&gt;</url>
    <title>Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>American Heart Journal, Mosby</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,CARDIAC MARKERS,GENERAL,OTHER,UNSTABLE ANGINA,ACUTE CORONARY SYNDROMES,DIAGNOSIS,DIAGNOSIS,MYOCARDIAL INFARCTION,CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CHEST PAIN,ELECTROCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; A negative triple prediction test of a non diagnostic electrocardiogram, negative troponin and negative ischemia-modified albumin has a higher negative predictive value for excluding acute coronary syndromes in the emergency department. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Abstract only.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325126</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/news/newsitem050809.shtml]]&gt;</url>
    <title>Methods for the diagnosis of heart failure reviewed</title>
    <publicationDate>2009-08-05T00:00:00</publicationDate>
    <publisher>Health Technology Assessment</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,GENERAL,HEART FAILURE,DIAGNOSIS,JUL-SEP 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Heart failure is associated with significant morbidity, mortality, and healthcare expenditure. There is however, a good evidence base for interventions to improve prognosis although the diagnosis of heart failure in primary care is often inaccurate. Current NICE recommendations are that patients in whom heart failure is suspected should undergo ECG and/or BNP. If either of these is positive, they should then be referred for echocardiography as part of their diagnostic work-up&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371720</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NHS%20IC%20PCI%20AUDIT%202009%20INTERACTIVE.pdf]]&gt;</url>
    <title>National Audit of Angioplasty Procedures 2009</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>NHS Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,RECENT ADDITIONS,APRIL 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=FrutigerLTStd-Light size=2&gt;
&lt;P align=left&gt;This fourth report for the National Audit of Angioplasty Procedures presents key findings and recommendations from the audit. The audit provides a mechanism to collect procedure-specific data based on the current minimum British Cardiovascular Interventional Society dataset.&lt;/P&gt;
&lt;P align=left&gt;The main objective of this audit is to improve the care of patients who undergo Percutaneous Coronary Intervention (PCI) procedures in the UK.&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>283166</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/28010308-NationalAngioplastyAudit-FullReport.pdf]]&gt;</url>
    <title>National Coronary Angioplasty Audit 2007</title>
    <publicationDate></publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,APR-JUNE 08,REPERFUSION,RESCUE PCI,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This report presents the main findings from the National Coronary Angioplasty Audit. The main objective of this audit is to improve the care of patients who undergo Percutaneous Coronary Intervention (PCI) procedures in the UK. The audit provides a mechanism to collect procedure-specific data based on the current minimum British Cardiovascular Interventional Society dataset. This audit project is being delivered in collaboration with the British Cardiovascular Interventional Society (BCIS) and The NHS Information Centre for health and social care.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343918</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/7063_Angioplasty_Summary%20FINAL.pdf]]&gt;</url>
    <title>National Coronary Angioplasty Executive Summary Audit 2008</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,REPERFUSION,JAN-MAR 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;FONT face=Frutiger-Light size=3&gt;&lt;FONT face=Frutiger-Light size=3&gt;&lt;FONT face=Frutiger-Light size=3&gt;&lt;FONT face=Frutiger-Light size=3&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P align=left&gt;The audit described here allows clinicians to assess key aspects of the quality of their care when performing coronary angiogram and PCI. This is a United Kingdom wide audit performed by the Audit Lead of the British Cardiovascular Intervention Society (BCIS). &lt;FONT face=Frutiger-Light size=3&gt;&lt;FONT face=Frutiger-Light size=3&gt;&lt;/P&gt;
&lt;P align=left&gt;This audit has recently been enhanced by the Central Cardiac Audit Database (CCAD) which allows electronic transfer of much more detailed information. This data collection and analysis for centres in England and Wales has project management and specialist IT support provided by the National Clinical Audit Support Programme (NCASP), which is part of the NHS Information Centre for health and social care (The IC). This portion of the audit is funded by the Healthcare Quality Improvement Partnership (HQIP).&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177377</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcareworkforce.nhs.uk/]]&gt;</url>
    <title>National Health Service Healthcare Workforce Portal</title>
    <publicationDate></publicationDate>
    <publisher>National Health Service</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NHS Healthcare workforce portal provides one-stop access to NHS healthcare workforce planning information, knowledge, intelligence and practical tools.&amp;nbsp;&amp;nbsp;The portal&amp;nbsp;divides its resources into various sectors across the healthcare workforce to&amp;nbsp;help users&amp;nbsp;locate&amp;nbsp;information specific&amp;nbsp;to the individual&amp;nbsp;workforce. The sectors are as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Acute Care 
&lt;LI&gt;Education 
&lt;LI&gt;Mental Health 
&lt;LI&gt;Primary Care 
&lt;LI&gt;Social&amp;nbsp;Care 
&lt;LI&gt;Urgent and Emergency Care 
&lt;LI&gt;Child Health&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3918</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4129922]]&gt;</url>
    <title>National heart and lung transplant standards</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,SERVICE MODELS,SURGICAL PROCEDURES,HEALTH MANAGEMENT,NHS ACTIVITIES,COMMISSIONING,SERVICE DELIVERY,COMMISSIONING,SERVICE SECTORS,ACUTE SERVICES,DISEASE/CONDITION GROUPS,CIRCULATION PROBLEMS,RESPIRATORY PROBLEMS,SPECIALIST AND TERTIARY CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document sets out a framework of common standards for heart and lung transplant services for adults and children. It covers staffing levels and qualifications, retrieval arrangements, outcomes such as survival and rejection rates.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published in September 2002, updated in February 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284025</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/National%20Heart%20Failure%20Audit%20April%202007.pdf]]&gt;</url>
    <title>National Heart Failure Audit : initial report for the audit period ending April 2007</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,HEART FAILURE,SERVICE MODELS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This first report for the National Heart Failure Audit presents key findings and recommendations from the pilot phase undertaken between October 2006 and March 2007.&amp;nbsp;&amp;nbsp;It is&amp;nbsp;aimed at healthcare professionals, managers and clinical governance leads,&amp;nbsp;and it&amp;nbsp;describes how the audit has been modified to support a national roll-out. The report also&amp;nbsp;explains how participation will help providers and commissioners measure standards of care against evidence-based best practice and national standards, identify gaps in care and improve services.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343912</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NHS_National_Heart_Failure_Audit_09_INTERACTIVE.pdf]]&gt;</url>
    <title>National Heart Failure Audit 2008/09</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,HEART FAILURE,SERVICE MODELS,JAN-MAR 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;FONT face=FrutigerLTStd-Light size=2&gt;&lt;FONT face=FrutigerLTStd-Light size=2&gt;&lt;FONT face=FrutigerLTStd-Light size=2&gt;&lt;FONT face=FrutigerLTStd-Light size=2&gt;&lt;/P&gt;
&lt;P align=left&gt;The audit focuses on the care and treatment of all patients with an unscheduled admission to hospital with heart failure.The main purposes of the audit are to measure the quality of care and clinical outcomes, enabling comparisons between Trusts and bring about improvement where necessary.&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>280187</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083061]]&gt;</url>
    <title>National Infarct Angioplasty Project (NIAP) interim report</title>
    <publicationDate>2008-02-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ARTERIOSCLEROSIS,DISEASE MANAGEMENT,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,REPERFUSION,RESCUE PCI]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;National Infarct Angioplasty Project (NIAP) is a feasibility study looking at how far primary angioplasty can be rolled out as the main treatment for heart attack in place of clot-busting drugs. This interim report covers findings based on the first year of data from seven pilots and is being published for information.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279732</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2008/Networks_and_NIAP_Jan08.doc]]&gt;</url>
    <title>National infarct angioplasty project : review of cardiac networks</title>
    <publicationDate></publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,NETWORKS,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,NHS IMPROVEMENT,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ARTERIOSCLEROSIS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;SPAN style="mso-bidi-font-family: Arial" lang=EN-GB&gt;The NHS Heart Improvement Programme received a request from the Department of Health to gain a snapshot of reperfusion activity in all of the cardiac networks to provide additional information to support the findings of the National Infarct Angioplasty Audit.&amp;nbsp; &lt;/SPAN&gt;&lt;SPAN style="mso-bidi-font-family: Arial" lang=EN-GB&gt;Phase&amp;nbsp;1 was a survey of the 31 cardiac networks requesting information on the geographical coverage of the network, pre-hospital thrombolysis services, arrangements for ambulance transfers, hospital based reperfusion services, and future plans for changes to reperfusion services.&lt;/SPAN&gt;&lt;SPAN style="mso-bidi-font-family: Arial" lang=EN-GB&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="mso-bidi-font-family: Arial" lang=EN-GB&gt;Phase 2 focussed on the 04 December meeting with cardiac networks to discuss the findings of the survey and discuss in more detail the barriers to change of implementing a&amp;nbsp;primary percutaneous coronary intevention&amp;nbsp;(PPCI) service and learning and sharing experiences from networks across the country. The key findings are presented in this review.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN style="mso-bidi-font-family: Arial" lang=EN-GB&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in December 2007.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>283336</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nihr.ac.uk/about/Pages/default.aspx]]&gt;</url>
    <title>National Institute for Health Research</title>
    <publicationDate></publicationDate>
    <publisher>National Health Service</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ STROKE,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,NHS IMPROVEMENT,APR-JUN 08,APR-JUNE 08,NHS HEALTH IMPROVEMENT PROGRAMMES,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The National Institute&amp;nbsp;for Health Research (NIHR) has been established by the Department of Health to deliver the Government's research and development strategy 'Best Research for Best Health'. It will focus on meeting the needs of the research community, patients and the public.&amp;nbsp; The website includes sections on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Research&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Health research systems&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Health research infrastructure&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Patient and public awareness&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;News&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Information last checked 5 March 2010.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392192</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=lmrELs5M4Gs%3d&amp;tabid=36]]&gt;</url>
    <title>National roll-out of Primary PCI for patients with ST segment elevation myocardial infarction</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,NHS IMPROVEMENT,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;After randomised trials had established the potential superiority of primary PCI over thrombolysis for STEMI, the Department of Health and national societies (British Cardiovascular Society, British Cardiovascular Intervention Society) conducted a feasibility study (National Infarct Angioplasty Project, NIAP), and concluded in its final report (October 2008) that the roll out of PPCI was both desirable, feasible and cost effective.&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;FONT color=#444445 size=1 face=Frutiger-Light&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3603</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094275]]&gt;</url>
    <title>National Service Framework : coronary heart disease</title>
    <publicationDate>2000-03-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,CHEST PAIN,CORONARY HEART DISEASE,HEART FAILURE,SURGICAL PROCEDURES,DISEASE MANAGEMENT,REVASCULARISATION,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,STABLE ANGINA,CARDIAC REHABILITATION,GENERAL/OTHER,SURGERY,SURGERY,HEART,CARDIAC ARRHYTHMIAS,ISCHAEMIC HEART DISEASE,HEART FAILURE,REVASCULARISATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This site contains the full-text of the National Service Framework (NSF) for Coronary Heart Disease (CHD). This NSF sets national standards of care for preventing and treating coronary heart disease and recommends service models enabling the efficient delivery of those standards.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82452</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/10/52/80/04105280.pdf]]&gt;</url>
    <title>National Service Framework for coronary heart disease : chapter eight : arrhythmias and sudden cardiac death</title>
    <publicationDate>2005-03-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,ARRHYTHMIA,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Chapter Eight of the National Service Framework for Coronary Heart Disease sets out three quality requirements and 20 markers of good practice for the prevention and treatment of patients with cardiac arrhythmias and people who may be at risk of sudden cardiac death.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82464</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.chi.gov.uk/_db/_documents/04015185.pdf]]&gt;</url>
    <title>National Service Framework report : getting to the heart of it : coronary heart disease in England : a review</title>
    <publicationDate>2005-03-07T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,CHEST PAIN,CORONARY HEART DISEASE,HEART FAILURE,SURGICAL PROCEDURES,REVASCULARISATION,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,STABLE ANGINA,CARDIAC REHABILITATION,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A&amp;nbsp;review by the Healthcare Commission of progress towards the national standards for the treatment of Coronary Heart Disease. The document takes stock of what has already been achieved within the National Service Framework and determines what further work or help is needed to ensure continuous improvement in the provision of health services for patients and to reduce the level of heart disease in the community. &lt;/P&gt;
&lt;P&gt;The document includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Executive summary 
&lt;LI&gt;Progress against the standards 
&lt;LI&gt;Standards 1 and 2 Reducing heart disease in the population 
&lt;LI&gt;Standards 3 and 4 Preventing coronary heart disease in high risk patients 
&lt;LI&gt;Standards 5, 6 and 7 Heart attacks and other acute coronary syndromes 
&lt;LI&gt;Standard 8 Stable angina 
&lt;LI&gt;Standard 9 and 10 Revascularisation 
&lt;LI&gt;Standard 11 Heart failure 
&lt;LI&gt;Standard 12 Cardiac rehabilitation&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277034</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=10964&amp;Rendition=Web]]&gt;</url>
    <title>National Service Framework: Chapter 4 - Stable Angina</title>
    <publicationDate>2000-03-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,CHEST PAIN,GENERAL  / OVERVIEWS,NATIONAL SERVICE FRAMEWORK FOR CHD,STABLE ANGINA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Chapter 4 of the National Service Framework for Coronary Heart Disease covering stable angina.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3893</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4082776&amp;chk=9K%2Bu1n]]&gt;</url>
    <title>National Service Frameworks : a practical aid to implementation in primary care</title>
    <publicationDate>2002-08-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,PREVENTION,HEALTH INEQUALITIES,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A National Service Framework (NSF)&amp;nbsp;implementation guidance pack developed by the government and the Royal College of General Practitioners. Topics include information systems, health improvement and prevention, inequalities, partnership working, chronic disease management and self care, screening, organisational management, and funding. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258945</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/publications.cfm?search_string=National+target+indicators+for+acute+and+specialist+trusts+2007%2F2008&amp;widCall1=customDocManager.search_do_2&amp;tcl_id=2&amp;top_parent=4513&amp;tax_child=4618&amp;tax_grand_child=]]&gt;</url>
    <title>National target indicators for acute and specialist trusts 2007/2008</title>
    <publicationDate>2007-03-28T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,PERFORMANCE INDICATORS,PREVENTION,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;As part of their annual health check the Healthcare Commission will be using thirteen indicators to assess the performance of acute and specialist trusts&amp;nbsp;&amp;nbsp; against the new as described in National Standards, Local Action: Health and Social Care Standards and Planning Framework 2005/2006 – 2007/2008, published by the Department of Health in July 2004). These indicators include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Emergency bed days&amp;nbsp; 
&lt;LI&gt;Obesity: compliance with NICE guidance 43&amp;nbsp; 
&lt;LI&gt;Participation in audits&amp;nbsp; 
&lt;LI&gt;Waiting time for diagonistic tests&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;This document includes details of the rationale, the data source, the data period and the constructions for each indicator.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258948</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/PCT_-_NNT_200806264357.doc]]&gt;</url>
    <title>National target indicators for primary care trusts 2007/2008</title>
    <publicationDate>2007-03-28T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PERFORMANCE INDICATORS,OVERWEIGHT AND OBESITY,SMOKING CESSATION,LIPIDS MANAGEMENT,HYPERTENSION,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES,PREVENTION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;As part of their annual health check the Healthcare Commission will be using thirteen indicators to assess the performance of acute and specialist trusts&amp;nbsp;&amp;nbsp; against the new as described in National Standards, Local Action: Health and Social Care Standards and Planning Framework 2005/2006 – 2007/2008, published by the Department of Health in July 2004). These indicators include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Blood pressure 
&lt;LI&gt;Cardiovascular disease mortality&amp;nbsp; 
&lt;LI&gt;Childhood obesity: data quality&amp;nbsp; 
&lt;LI&gt;Cholesterol levels&amp;nbsp; 
&lt;LI&gt;Emergency bed days&amp;nbsp; 
&lt;LI&gt;Experience of patients&amp;nbsp; 
&lt;LI&gt;Four week smoking quitters&amp;nbsp; 
&lt;LI&gt;GP recording of body mass index (BMI) status&amp;nbsp; 
&lt;LI&gt;Smoking status among the population aged 16 and over&amp;nbsp; 
&lt;LI&gt;Waiting times for diagnostic tests&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These include details of the rationale, the data source, the data period and the constructions for each indicator.&lt;/P&gt;
&lt;P&gt;Information last accessed 16 April 2009.&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>229106</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.networks.nhs.uk/]]&gt;</url>
    <title>Networks by topic : cardiac</title>
    <publicationDate></publicationDate>
    <publisher>NHS Networks</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,NETWORKS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Networks is a means of promoting and connecting the many networks which exist throughout the NHS - and encouraging the formation of new ones.&amp;nbsp; NHS Networks' mission is to identify all the networks which exist and encourage the sharing of ideas between, as well as within, networks. This part of the website lists networks by topic.&amp;nbsp;A list of relevant networks dealing with cardiovascular diseases is listed under 'Cardiac'. Scroll down the alphabetical list of topics to access the networks.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268447</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://americanheart.org/downloadable/heart/1167841403445Pharm2611_Levine-PCI.pdf]]&gt;</url>
    <title>Newer pharmacotherapy in patients undergoing percutaneous coronary interventions : a guide for pharmacists and other healthcare professionals. Expert opinion from the American Heart Association's Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology and the American College of Clinical Pharmacy's Cardiology Practice Research Network</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DISEASE MANAGEMENT,THROMBOLYTICS,INTERVENTIONS / PROCEDURES,OTHER,CLOPIDOGREL,REPERFUSION,CORONARY HEART DISEASE,CARDIOVASCULAR DISEASES,ANTI-PLATELET DRUGS,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This guide&amp;nbsp;aims to review&amp;nbsp;the newer antiplatelet and antithrombin drugs that may be used during percutaneous coronary intervention (PCI) and provides recommendations regarding the proper administration of these agents.&lt;/P&gt;
&lt;P align=left&gt;Pharmacists and other health care professionals should play an integral role in collaboration with interventional cardiologists in development of hospital protocols, determination of appropriate agent selection, assessment of patient renal function and haematologic status, dosing and monitoring for adverse effects.&lt;/P&gt;
&lt;P&gt;The guide provides a summary of the changes between the 2001 PCI guideline revisions and the 2005 PCI guideline update. Revisions may be expected as new data emerge.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Pharmacists and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313443</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=313443]]&gt;</url>
    <title>NHS Evidence - cardiovascular collection development strategy</title>
    <publicationDate>2009-04-28T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular specialist collection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,APR-JUN 09]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NHS Evidence - cardiovascular collection development strategy&lt;/pageTitle&gt;&lt;pageBody&gt;See attached file.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389997</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//cardiovascular/ViewResource.aspx?resID=389997]]&gt;</url>
    <title>NHS Evidence - cardiovascular steering group</title>
    <publicationDate>2010-10-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - cardiovascular specialist collection</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,OCT-DEC 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NHS Evidence - cardiovascular steering group&lt;/pageTitle&gt;&lt;pageBody&gt;See attached file.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>236115</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/diabetes/]]&gt;</url>
    <title>NHS Evidence - diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ STROKE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,DIAGNOSIS,CAUSES AND RISK FACTORS,MANAGEMENT ISSUES,KEY POLICIES,PREVENTION,DIABETES MELLITUS,DIABETES MELLITUS,CAUSES / RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,JAN-MAR 09,PREVENTION,KEY POLICIES AND RELATED PUBLICATIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence - diabetes is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of diabetes including both clinical and organisational issues. Website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236125</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/emergency/]]&gt;</url>
    <title>NHS Evidence - emergency care</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,KEY POLICIES,GENERAL/OTHER,STROKE,DISEASE MANAGEMENT,EMERGENCY CARE,KEY POLICIES AND RELATED PUBLICATIONS,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence - emergency care collection is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;emergency healthcare&amp;nbsp;including both clinical and organisational issues. Website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>375210</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/ethnicity/]]&gt;</url>
    <title>NHS Evidence - ethnicity</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,MANAGEMENT ISSUES,GENETICS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Specialist Library for Ethnicity and Health (SLEH) became 'NHS Evidence - ethnicity and health' on the 1st April 2009 as part of a move of all the NHS Specialist Libraries into NHS Evidence, provided by NICE, with a single access portal.&amp;nbsp;]]&gt;</body>
  </document>
  <document>
    <id>236133</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/laterlife/]]&gt;</url>
    <title>NHS Evidence - later life</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES,STROKE,KEY POLICIES AND RELATED PUBLICATIONS,MANAGEMENT ISSUES,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The purpose of this site is to signpost&amp;nbsp;the best available evidence and other key documents&amp;nbsp;to support people who are making health care decisions related to later life.&amp;nbsp; It aims to meet the information needs of health care professionals who work with elderly people.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377872</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/screening/]]&gt;</url>
    <title>NHS Evidence - screening</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIAGNOSIS,APR-JUN 09,RECENT ADDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This specialist collection&amp;nbsp;undertakes to find, organise and provide access to the best available evidence on screening. We have concentrated initially on the NSC policies, programmes and reports, and the secondary evidence produced or licensed by the NHS - the Cochrane Library, Health Technology Assessment (HTA)&amp;nbsp;reports, NICE guidelines and&amp;nbsp;Centre for Reviews and Dissemination abstracts (DARE). We also include UK and international Health Technology Assessments contained in the Centre for Reviews and Dissemination HTA database, and economic evaluations from the NHS Economic Evaluation database.]]&gt;</body>
  </document>
  <document>
    <id>377870</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/Theatres/]]&gt;</url>
    <title>NHS Evidence - surgery, anaesthesia, perioperative and critical care</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,APR-JUN 09,RECENT ADDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Aims&lt;/P&gt;
&lt;LI&gt;To provide efficient access to current, quality assured, evidence based resources to support the team providing high quality perioperative and critical care 
&lt;LI&gt;To work with the&amp;nbsp;partner organisations&amp;nbsp;for NHS Evidence - surgery, anaesthesia, perioperative and critical care&amp;nbsp;through external reference panel meetings and topic advisor groups to ensure that&amp;nbsp;information needs are met for all those involved in perioperative and critical care 
&lt;LI&gt;To encourage communication and knowledge sharing within the perioperative and critical care community 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/LI&gt;]]&gt;</body>
  </document>
  <document>
    <id>282630</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefdentalofficerletters/DH_083679?IdcService=GET_FILE&amp;dID=162383&amp;Rendition=Web]]&gt;</url>
    <title>NICE guidance on antibiotic prophylaxis against infective endocarditis : chief dental officer letter</title>
    <publicationDate>2008-03-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,VALVE DISORDERS,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,GENERAL/OTHER,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This document is a letter from the chief dental officer&amp;nbsp;regarding the National Institute for Health and Clinical Excellence (NICE) response to conflicting advice in relation to antibiotic prophylaxis against infective endocarditis.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>290571</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.108.189695v1.pdf]]&gt;</url>
    <title>Noninvasive coronary artery imaging : magnetic resonance angiography and multidetector computed tomography angiography : a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention, and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ ARTERIOSCLEROSIS,DIAGNOSIS,DIAGNOSIS,GENERAL,JUL-SEPT 08,CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&amp;nbsp; &lt;/STRONG&gt;Statement discusses and summarises the use of magnetic resonance angiography (MRA) and multidetector computed tomographic angiography (CTA) for noninvasive coronary artery imaging.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in June 2008.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>31655</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/16/2015]]&gt;</url>
    <title>Nonvalvular cardiovascular device-related infections</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GENERAL/OTHER,INFECTIOUS DISEASES,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,PREVENTION,GENERAL,INFECTIONS,JAN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This review discusses the scope of infections associated with a range of cardiovascular prostheses and devices that are used to replace or assist damaged or dysfuntional tissues. The review is divided into two broad sections.&amp;nbsp; Section one investigates the general principles for the evaluation and management of infection that apply to all cardiovascular devices.&amp;nbsp; Infections are discussed in relation to clinical manifestations, microbiology, pathogenesis, diagnosis, treatment and prevention.&amp;nbsp; The second section examines intracardiac, arterial and venous devices.&amp;nbsp; Each device is reviewed and unique clinical features of infection described. Includes tabular information, diagrams, conclusions and references. Published in Circulation 2003;108:2015. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125727</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4134408&amp;chk=Sq/wNd]]&gt;</url>
    <title>Obesity care pathways and weight loss guide</title>
    <publicationDate>2006-05-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,PREVENTION,DIET,OVERWEIGHT AND OBESITY,PRIMARY PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Comprises materials for health professionals as well as providing information to give to patients.&amp;nbsp; Includes Obesity Care Pathways for adults and children along with a supporting booklet with detailed information for health professionals.&lt;/P&gt;
&lt;P&gt;Materials are available to download.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>235306</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063507]]&gt;</url>
    <title>Obesity guidance for healthy schools co-ordinators and their partners</title>
    <publicationDate>2007-01-11T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,MANAGEMENT ISSUES,PREVENTION,DIET,NHS IMPROVEMENT,DIET,OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This guidance is designed&amp;nbsp;to help Healthy Schools Co-ordinators and their partners provide support to primary and secondary schools in addressing the prevention issues around obesity. The guidance sets out approaches that work when tackling obesity and appropriate actions to consider.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Directors of Public Health, Directors of Nursing, Directors of Children's School Services, Healthy Schools Programme Co-ordinators, Primary Care Trust Obesity, Healthy Eating and Physical Acivity Leads, Partnership Development Managers, School Nurses, Primary Link Teachers, and School Travel Advisers.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;in January 2007. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3619</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.webarchive.org.uk/pan/11052/20050218/www.ohn.gov.uk/ohn/ohn.htm]]&gt;</url>
    <title>Our healthier nation website (archive copy only)</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HEALTH INEQUALITIES,NHS IMPROVEMENT,PREVENTION,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Our Healthier Nation (OHN) web site is a gateway to information on all aspects of Saving Lives: Our Healthier Nation, the government-wide health strategy for England, published in July 1999. It aims to help professionals who are working to improve health and reduce health inequalities, to access online information, research, networks and projects. This web site offers Our Healthier Nation in Practice Database (OHNiP) which provides information on a wide range of projects contributing to OHN in the UK.&lt;/P&gt;
&lt;P&gt;This website is no longer being actively updated and is for archive purposes only.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392293</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117675.pdf]]&gt;</url>
    <title>Overview of Commissioning Cardiac Rehabilitation Services</title>
    <publicationDate>2010-10-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,CARDIAC REHABILITATION CENTRES,CARDIAC REHABILITATION,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;FONT face=ArialMT&gt;&lt;FONT face=ArialMT&gt;This commissioning pack is a set of resources designed for commissioners to use when commissioning cardiac rehabilitation services for NHS patients. It brings together evidence-based guidance and the work of national clinical experts and commercial specialists to make it quicker and easier to realise the opportunities for improving patient outcomes and value for money.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; October 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177526</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;ID=12006008197]]&gt;</url>
    <title>Pacemaker and implantable cardioverter defibrillator (ICD) generator reliability : meta analysis of device registries</title>
    <publicationDate></publicationDate>
    <publisher>Database of Abstracts of Reviews of Effectiveness, Centre for Reviews and Dissemination</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ DEFIBRILLATION,INTERVENTIONS / PROCEDURES,GENERAL/OTHER,CONDITIONS,ARRHYTHMIA,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt;&amp;nbsp; The malfunction rate of pacemakers has remained low since technological advancements occurred in the 1980s.&amp;nbsp; The ICD malfunction rate has been substantially higher than the pacemaker rate since the late 1990s, although improvements were noted between 2003 and 2004. 
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; This is a 2006 DARE (Database of Abstracts of Reviews of Effects) structured abstract of a 2006 systematic review.&amp;nbsp;The author's objective was to determine annual rates and trends for malfunction in pacemakers and implantable cardioverter defibrillator (ICD) generators. 
&lt;P&gt;&lt;STRONG&gt;Quality Assessment:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Papers were restricted to English language, therfore&amp;nbsp;articles relevant to the topic area may have been missed, and language bias is a potential threat 
&lt;LI&gt;Publication bias was addressed, but the results were not reported. 
&lt;LI&gt;Only&amp;nbsp;brief criteria to assess the validity of the study 
&lt;LI&gt;There were no details of the study selection, validity assessment or data extraction processes and these potentially contribute major sources of bias to the review 
&lt;LI&gt;Some details of the small number of included registries were given, although the absence of data on the year of implant and details of specific device models limits the practical usefulness of the results 
&lt;LI&gt;It was unclear whether the method of data synthesis was appropriate, given the potential diversity of the models used 
&lt;LI&gt;Heterogeneity between registries was assessed, but reported only for pacemaker data 
&lt;LI&gt;The results of planned sensitivity analyses were not supplied &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Original study:&lt;/STRONG&gt; Maisel WH. Pacemaker and implantable cardioverter defibrillator (ICD) generator reliability: meta-analysis of device registries. Journal of the American Medical Association 2006;295(16):1929-34.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access to review:&lt;/STRONG&gt; Abstract only. Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156309</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=10472&amp;Rendition=Web]]&gt;</url>
    <title>Pacemaker follow-up</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for follow-up for a patient with a pacemaker.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377879</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/121/21/2331]]&gt;</url>
    <title>Particulate Matter Air Pollution and Cardiovascular Disease</title>
    <publicationDate>2010-05-10T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,GENERAL,RECENT ADDITIONS,APR-JUNE 10,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The primary objective of this scientific statement is to provide&lt;SUP&gt; &lt;/SUP&gt;a comprehensive updated evaluation of the evidence linking PM&lt;SUP&gt; &lt;/SUP&gt;exposure with CVDs. The focus of this review is explicitly on&lt;SUP&gt; &lt;/SUP&gt;PM because the majority of air pollution studies have centered&lt;SUP&gt; &lt;/SUP&gt;on its cardiovascular effects, and the strength of the evidence&lt;SUP&gt; &lt;/SUP&gt;makes it possible to provide consensus opinions and recommendations.]]&gt;</body>
  </document>
  <document>
    <id>236139</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/ppi/]]&gt;</url>
    <title>Patient and Public Involvement Specialist Library</title>
    <publicationDate></publicationDate>
    <publisher>National Library for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ STROKE,CARDIOVASCULAR DISEASES,KEY POLICIES,MANAGEMENT ISSUES,PATIENT CHOICE,JAN-MAR 09,KEY POLICIES AND RELATED PUBLICATIONS,MANAGEMENT ISSUES,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;The Patient and Public Involvement Specialist Library aims to support the implementation of patient, user, carer and public involvement in health&amp;nbsp;care by providing access, in one location, to&amp;nbsp;the best information which is available on the Web.&amp;nbsp;Website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281970</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188525]]&gt;</url>
    <title>Percutaneous and minimally invasive valve procedures : a scientific statement from the American Heart Association Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology, Functional Genomics and Translational Biology Interdisciplinary Working Group, and Quality of Care and Outcomes Research Interdisciplinary Working Group</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ SURGICAL PROCEDURES,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DISEASE MANAGEMENT,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,VALVE DISORDERS,GENERAL/OTHER,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This statement discusses the expected increase of valvular heart disease in the future and the anticipated broad transition of surgical therapy to minimally invasive therapy.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Less invasive and percutaneous valve therapies will probably have a major impact on the management of patients with valvular heart disease in the near future.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268566</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/111/7/940]]&gt;</url>
    <title>Percutaneous coronary intervention and adjunctive pharmacotherapy in women : a statement for healthcare professionals from the American Heart Association</title>
    <publicationDate>2005-02-22T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,ARTERIOSCLEROSIS,INTERVENTIONS / PROCEDURES,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DISEASE MANAGEMENT,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,UNSTABLE ANGINA,ACUTE CORONARY SYNDROMES,DISEASE MANAGEMENT,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&amp;nbsp;The aim of this document is to&amp;nbsp;review sex-specific data on the safety and efficacy of&amp;nbsp;coronary therapies in women.&lt;/P&gt;
&lt;P align=left&gt;The following information is provided:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Sex differences in outcomes of&amp;nbsp;percutaneous coronary intervention&amp;nbsp;(PCI)&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Outcomes in women by device, lesion type and clinical syndrome&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Treatment of acute coronary syndromes in women&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Interventional treatment of ST-elevation myocardial infarction (STEMI) in women&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Adjunctive pharmacotherapy in women undergoing PCI&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Opportunities for improving the evidence base and outcomes for women&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268520</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.177276]]&gt;</url>
    <title>Physiological assessment of coronary artery disease in the cardiac catheterization laboratory : a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology</title>
    <publicationDate>2006-09-19T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CONDITIONS,DIAGNOSIS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This consensus statement was designed to provide the background and evidence&amp;nbsp;for physiological measurements and to describe standard methods for data acquisition and interpretation. It aims to provide a logical approach to the use of coronary physiological measurements in the catheterisation laboratory to assist both clinicians and investigators in improving patient care.&lt;/P&gt;
&lt;P align=left&gt;With advances in technology, the physiological assessment of coronary artery disease in patients in the catheterisation laboratory has become increasingly important in both clinical and research applications. This assessment has evolved without standard nomenclature or techniques of data acquisition and measurement. Some questions regarding the interpretation, application and outcome related to the results also remain unanswered. &lt;/P&gt;
&lt;P align=left&gt;The most common uses and support data from many clinical studies for the physiological assessment of coronary artery disease in the cardiac catheterisation laboratory are reviewed.&lt;/P&gt;&lt;FONT face=Times-Roman size=2&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392302</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117668.pdf]]&gt;</url>
    <title>Planning a Cardiac Rehabilitation Service</title>
    <publicationDate>2010-10-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CARDIAC REHABILITATION CENTRES,CORONARY HEART DISEASE,SERVICE MODELS,ARTERIOSCLEROSIS,CARDIAC REHABILITATION,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This Commissioning Pack&amp;nbsp;is a&amp;nbsp;tool to help commissioners improve the quality of services for patients and minimises unwarranted variation in service delivery in Cardiac rehabilitation. It provides a tailored set of guidance, templates, tools and information to assist commissioners in commissioning healthcare services from existing providers or for use in new procurements.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and Managers.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; October 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268402</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/111/20/2699]]&gt;</url>
    <title>Practical implementation of the guidelines for unstable angina / non-ST-segment elevation myocardial infarction in the emergency department : a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Society of Chest Pain Centers</title>
    <publicationDate>2005-05-24T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,DIAGNOSIS,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,DIAGNOSIS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; The aim&lt;STRONG&gt; &lt;/STRONG&gt;of these guidelines is to provide an evidence based approach to the diagnosis and treatment of patients with unstable angina and non-ST-segment elevation myocardial infarction (UA / NSTEMI) in the emergency department, in hospital and after hospital discharge.&lt;/P&gt;
&lt;P align=left&gt;The document&amp;nbsp;recommends that adherence to the 2002 American College of Cardiology / American Heart Association UA / NSTEMI guidelines, through improved communication between emergency physicians and cardiologists and implementation of quality improvement initiatives, will improve outcomes and provide more consistent care for patients with acute coronary syndrome (ACS).&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78348</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.rpsgb.org.uk/pdfs/otcsimvastatinguid.pdf]]&gt;</url>
    <title>Practice guidance on : sale of over-the-counter simvastatin</title>
    <publicationDate></publicationDate>
    <publisher>Royal Pharmaceutical Society of Great Britain</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HYPERTENSION,LIPID-REGULATING DRUGS,SMOKING,SURGICAL PROCEDURES,CAUSES AND RISK FACTORS,CORONARY ARTERY BYPASS GRAFTS,DISEASE MANAGEMENT,STATINS,ACUTE CORONARY SYNDROMES,ETHNICITY AND HEALTH,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,CARDIOVASCULAR DISEASES,DISEASES AND CONDITIONS,CONDITIONS,CORONARY HEART DISEASE,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,DIET,GENETICS,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; Guidance is provided for pharmacists on how they can manage consultations for the sale of over-the-counter (OTC)&amp;nbsp;simvastatin.&amp;nbsp; This guideline, along with continuing professional development and staff training, aims to equip pharmacists with the knowledge to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Describe the group of people suitable for OTC simvastatin.&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;List the types of person for whom it would not be appropriate.&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;State the likely benefits and potential harms of treatment.&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Tailor the suggested algorithm for managing consultations within their pharmacy.&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Describe how assessment of an individual's risk is undertaken and what records should be kept.&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Describe what training or other developments are needed within their pharmacy before OTC can be sold appropriately.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Includes references and appendices.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp; This practice guideline has been prepared for pharmacists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published July 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;"This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library."&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250505</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.psy.psychiatryonline.org/cgi/content/full/44/3/222]]&gt;</url>
    <title>Predicting panic disorder among patients with chest pain: an analysis of the literature</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Psychosomatics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,GENERAL  / OVERVIEWS,OTHER,CARDIOVASCULAR DISEASES,CHEST PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Author's Conclusion: &lt;/STRONG&gt;Five variables appear to correlate with higher rates of panic disorder among&lt;SUP&gt; &lt;/SUP&gt;persons who present with chest pain: &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;absence of coronary&lt;SUP&gt; &lt;/SUP&gt;artery disease&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;atypical quality of chest pain&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;female&lt;SUP&gt; &lt;/SUP&gt;sex&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;younger age&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;a high level of self-reported anxiety&lt;/DIV&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=left&gt;Further studies of these and other variables associated with&lt;SUP&gt; &lt;/SUP&gt;panic disorder should aid in the detection of this disabling&lt;SUP&gt; &lt;/SUP&gt;but treatable cause of chest pain.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343894</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-perioperative-cardiac-care-FT.pdf]]&gt;</url>
    <title>Pre-operative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-Cardiac Surgery</title>
    <publicationDate>2009-08-27T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,RISK ASSESSMENT,SURGICAL PROCEDURES,GENERAL/OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #231f20; FONT-SIZE: 10pt"&gt;The present guidelines focus on the cardiological management ofpatients undergoing non-cardiac surgery, i.e. patients where heart disease is a potential source of complications during surgery.&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #231f20; FONT-SIZE: 10pt"&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;
&lt;UL&gt;
&lt;LI&gt;Pre-operative evaluation &lt;/LI&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;
&lt;LI&gt;Risk reduction strategies&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;/LI&gt;
&lt;LI&gt;Specific diseases&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;/LI&gt;
&lt;LI&gt;Perioperative monitoring&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;FONT color=#d8133f size=1 face=AdvOTb7819099&gt;&lt;/LI&gt;
&lt;LI&gt;Anaesthesia&lt;/LI&gt;&lt;/UL&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378320</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/cardiovascular_diseases/guidelines/Prevention_of_Cardiovascular_Disease/en/index.html]]&gt;</url>
    <title>Prevention of cardiovascular disease : guide for assessment and management of cardiovascular risk</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>World Health Organisation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,SECONDARY PREVENTION,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This publication provides guidance on reducing disability and premature deaths from coronary heart disease, cerebrovascular disease and peripheral vascular disease in people at high risk, who have not yet experienced a cardiovascular event. People with established cardiovascular disease are at very high risk of recurrent events and are not the subject of these guidelines. They have been addressed in previous WHO guidelines. The WHO/ISH risk prediction charts that accompany these guidelines allow treatment to be targeted according to simple predictions of absolute cardiovascular risk.&lt;/P&gt;
&lt;P&gt;Recommendations are made for management of major cardiovascular risk factors through changes in lifestyle and prophylactic drug therapies. The guidelines provide a framework for the development of national guidance on prevention of cardiovascular disease that takes into account the particular political, economic, social and medical circumstances.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378323</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/cardiovascular_diseases/guidelines/Pocket_GL_information/en/index.html]]&gt;</url>
    <title>Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>World Health Organisation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,PREVENTION,GENERAL/OTHER,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These pocket guidelines provide evidence-based guidance on how to reduce the incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people. They include; 1. People with risk factors who have not yet developed clinically manifest cardiovascular disease (primary prevention). 2. People with established CHD, CeVD or peripheral vascular disease (secondary prevention). &lt;/P&gt;
&lt;P&gt;The accompanying World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts enable the estimation of total cardiovascular risk of people in the first category. The evidence-based recommendations given in Part 1 of these guidelines, provide guidance on which specific preventive actions to initiate, and with what degree of intensity. People in the second category have high cardiovascular risk and need intensive lifestyle interventions and appropriate drug therapy as elaborated in Part II of these guidelines. Risk stratification using risk charts is not required for making treatment decisions in them. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282928</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188965v1]]&gt;</url>
    <title>Prevention of heart failure :  a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,CAUSES AND RISK FACTORS,GENERAL,HEART FAILURE,HYPERTENSION,PREVENTION,APR-JUNE 08,GENERAL,GENERAL,CONDITIONS,PREVENTION,DIAGNOSIS,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Statement discusses the increase in heart failure (HF) and the prevention of illnesses that lead to HF. Hypertension, coronary heart disease and chronic kidney disease are recognised illnesses that may lead to HF. &lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Future research should focus on obtaining a better knowledge of genetics and HF, especially both genetic risk factors for development of HF and genetic markers as tools to guide prevention. A national awareness campaign should be promoted to increase public awareness of HF and the importance of its prevention. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in April 2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299650</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/116/15/1736]]&gt;</url>
    <title>Prevention of infective endocarditis : guidelines from the American Heart Association : a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group</title>
    <publicationDate>2007-10-09T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,GENERAL/OTHER,OCT-DEC 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To update the recommendations by the American Heart Association for the prevention of infective endocarditis that were last published in 1997. The main changes in the updated recommendations (taken directly from the abstract) include the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Only an extremely small number of cases of infective endocarditis might be prevented by antibiotic prophylaxis for dental procedures even if such prophylactic therapy were 100% effective.&lt;/LI&gt;
&lt;LI&gt;Infective endocarditis prophylaxis for dental procedures is reasonable only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from infective endocarditis. &lt;/LI&gt;
&lt;LI&gt;For patients with these underlying cardiac conditions, prophylaxis is reasonable for all dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa. &lt;/LI&gt;
&lt;LI&gt;Prophylaxis is not recommended based solely on an increased lifetime risk of acquisition of infective endocarditis. &lt;/LI&gt;
&lt;LI&gt;Administration of antibiotics solely to prevent endocarditis is not recommended for patients who undergo a genitourinary or gastrointestinal tract procedure.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 9th October 2007&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268446</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/115/6/813]]&gt;</url>
    <title>Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents : a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians</title>
    <publicationDate>2007-02-13T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OTHER,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,PREVENTION,ORAL SURGERY,SPECIALIST DENTISTRY,ORAL HEALTH,CARDIOVASCULAR DISEASES,INTERVENTIONS / PROCEDURES,ANTI-PLATELET DRUGS,CORONARY HEART DISEASE,DISEASE MANAGEMENT,CONDITIONS,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DISEASE MANAGEMENT,ASPIRIN,SPECIAL CARE DENTISTRY,CARDIOVASCULAR CONDITIONS,CLOPIDOGREL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;SPAN lang=EN-GB style="mso-ansi-language: EN-GB"&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; The aim of this document is to emphasize the potential complications of&amp;nbsp;early discontinuation of thienopyridine therapy and to address potential strategies to &lt;/SPAN&gt;&lt;SPAN lang=EN-GB style="mso-ansi-language: EN-GB"&gt;minimize this occurrence.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;SPAN lang=EN-GB style="mso-ansi-language: EN-GB"&gt;Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. &lt;/SPAN&gt;This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and, if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high risk patients with drug-eluting stents.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343994</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192704]]&gt;</url>
    <title>Prevention of Torsade de Pointes in Hospital Settings</title>
    <publicationDate>2010-01-04T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,DISEASE MANAGEMENT,GENERAL/OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Aims:&amp;nbsp;To raise awareness among those who care for patients in hospital units about the risk, ECG monitoring, and management of drug-induced LQTS. Topics reviewed include the ECG characteristics of TdP and signs of impending arrhythmia, cellular mechanisms of acquired LQTS and current thinking about genetic susceptibility, drugs and drug combinations most likely to cause TdP, risk factors and exacerbating conditions, methods to monitor QT intervals in hospital settings, and immediate management of marked QT prolongation and TdP.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3695</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/97/18/1876]]&gt;</url>
    <title>Primary prevention of coronary heart disease : guidance from Framingham</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ LIPIDS MANAGEMENT,PRIMARY PREVENTION,PREVENTION,PREVENTION,CONDITIONS,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CORONARY HEART DISEASE,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A statement for health care professionals from the American Heart Association Task Force on Risk Reduction. This article explores the concept of risk factors in developing strategies for preventing coronary heart disease (CHD) and the mechanisms whereby various risk factors enhance the risk for CHD. Relative and absolute risks, and primary and secondary prevention measures, are defined and discussed. Some specific risk factors are discussed in more detail: age, cigarette smoking, hypertension, serum cholesterol, low HDL cholesterol, diabetes mellitus, the role of risk factors in women, and clustering of risk factors. Published in Circulation, 1998, 97: 1876-1887.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344295</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192628]]&gt;</url>
    <title>Promoting Self-Care in Persons With Heart Failure</title>
    <publicationDate>2009-08-31T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,DISEASE MANAGEMENT,GENERAL/OTHER,JUL-SEP 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To&amp;nbsp;highlight concepts and evidence&lt;SUP&gt; &lt;/SUP&gt;important to the understanding and promotion of self-care in&lt;SUP&gt; &lt;/SUP&gt;persons with HF. Specifically, the document describes what is&lt;SUP&gt; &lt;/SUP&gt;known about (1) the self-care behaviors required of HF patients,&lt;SUP&gt; &lt;/SUP&gt;(2) factors that make self-care challenging for patients, (3)&lt;SUP&gt; &lt;/SUP&gt;interventions that promote self-care, and (4) the effect of&lt;SUP&gt; &lt;/SUP&gt;self-care on HF outcomes. The review ends with evidence-based&lt;SUP&gt; &lt;/SUP&gt;recommendations for clinicians and direction for future research.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; August 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;Abstract only. Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;Full-text online access is available to NHS staff in England via ATHENS passwords.&amp;nbsp; To find out how to get an ATHENS password and access this resource and many others please refer to "Athens Registration" at &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282641</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_083707]]&gt;</url>
    <title>Proposed changes to the quality and outcomes framework for the financial year 2008 / 09</title>
    <publicationDate>2008-03-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PERFORMANCE INDICATORS,SERVICE MODELS,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This document has been sent to all general practitioners in England to inform of the amendments to the General Medical Services Statement of Financial Entitlements that will change the requirements for payments for taking part in the Quality and Outcomes Framework (QOF). Evidence based changes have been made to the management of atrial fibrillation.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89231</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/execsumm/summ841.shtml]]&gt;</url>
    <title>Provision, uptake and cost of cardiac rehabilitation programmes : improving services to under represented groups</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,CARDIAC REHABILITATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Provision of outpatient cardiac rehabilitation in the UK is low, well below the National Service Framework for Coronary Heart Disease goal of 85% of patients with acute myocardial infarction and following revascularisation being offered outpatient cardiac rehabilitation.&amp;nbsp; Little is known about the capacity of cardiac rehabilitation centres to increase this provision.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Analysis of hospital discharge statistics to ascertain the population need for outpatient&amp;nbsp;cardiac rehabilitation in the UK. 
&lt;LI&gt;Surveys of cardiac rehabilitation programmes to determine UK provision, uptake and audit activity. 
&lt;LI&gt;Systematic review of interventions to improve patient uptake, adherence and professional compliance in cardiac rehabilitation. 
&lt;LI&gt;Assessment of costs for improving uptake.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In England, Wales and Northern Ireland 146,000 patients discharged from hospital with a primary diagnosis of acute myocardial infarction, unstable angina or following revascularisation were potentially eligible for cardiac rehabilitation. 
&lt;LI&gt;In England, in 2000, 45-67% of these patients were referred, with 27-41% attending outpatient cardiac rehabilitation. 
&lt;LI&gt;Rates of referral were similar in Wales, but somewhat lower in Northern Ireland.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, et al.. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technology Assessment. Vol 8: No.41, 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &amp;nbsp;Published in October 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101885</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/docs/2nd_smoke_summary_EBsummary_word.doc]]&gt;</url>
    <title>Public health interventions for the prevention and reduction of exposure to second-hand smoke : a review of reviews</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SMOKING CESSATION,SMOKING,NHS IMPROVEMENT,PREVENTION,MANAGEMENT ISSUES,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This briefing presents an overview of the findings of public health interventions for the prevention and reduction of exposure to second-hand smoke.&amp;nbsp; The aims (reproduced from the briefing) are as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Identify all relevant systematic reviews, syntheses, meta-analyses and review-level papers on public health interventions relating to second-hand smoke (SHS).&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Review these papers and highlight 'what works' to prevent and reduce exposure to SHS for all population groups, but with particular reference to disadvantaged and vulnerable groups.&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Identify cost-effectiveness data for interventions that aim to prevent and reduce exposure to SHS.&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Identify findings that relate to inequalities in health for interventions that aim to prevent and reduce exposure to SHS.&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Highlight any gaps in the evidence and provide recommendations for future research.&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;Includes conclusion and references.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Date of publication:&lt;/STRONG&gt; 2005&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266084</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/Pushing_the_boundaries_Improving_services_for_patients_with_heart_failure_200707020413.pdf]]&gt;</url>
    <title>Pushing the boundaries: Improving Services for people with heart failure</title>
    <publicationDate>2007-07-06T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,DIAGNOSIS,HEART FAILURE,SERVICE MODELS,NATIONAL SERVICE FRAMEWORK FOR CHD,CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This service review carried out by the Healthcare Commission in 2005/2006 assessed the quality of healthcare for people with heart failure. &lt;/P&gt;
&lt;P align=left&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;"There is now better access to diagnostic services and key treatments, wider availability of specialist heart failure services and guidelines on services, more consideration of end-of-life needs and more comprehensive education and support arrangements. &lt;/DIV&gt;
&lt;LI&gt;However, commissioners and providers of services still need to work together in local communities to ensure that all patients with heart failure are identified, offered the full range of optimal medication and have access to specialists that is based on need rather than the care setting, type of ward or specialty of care. 
&lt;LI&gt;In addition, organisations need to improve the way they evaluate how they deliver care, based on the patient’s perspective, and they must establish robust clinical audit programmes."&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; July 2007&lt;/P&gt;
&lt;P&gt;Information last accessed: 7 April 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83477</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&amp;ID=32004000640]]&gt;</url>
    <title>Ranolazine for the treatment of stable angina</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Canadian Co-ordinating Office for Health Technology Assessment</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STABLE ANGINA,CARDIOVASCULAR DISEASES,CHEST PAIN,DISEASE MANAGEMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; Ranozaline has been investigated as monotherapy and as combination therapy in patients with stable angina. Both trials demonstrate significant anti-anginal efficacy, but several questions regarding the dose, target population, and safety remain unanswered. The lack of dose-response data and the evidence of a prolonged QTc interval with higher doses warrant further investigation. The ideal patient population must be defined as to whether ranolazine should be restricted to a particular group of patients. Ranolazine's tolerability and efficacy profile at therapeutic doses over the longer term requires further study, possibly with other anti-anginal agents.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; To summarise the available information on the use of ranolazine (trade name Ranexa, manufactured by CV Therapeutics, Inc.) for the treatment of stable angina.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to abstract:&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270391</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.186661]]&gt;</url>
    <title>Recommendations for implementation of community consultation and public disclosure under the Food and Drug Administration's 'Exception from informed consent requirements for emergency research': a special report from the American Heart Association Emergency Cardiovascular Care Committee and Council on Cardiopulmonary, Perioperative and Critical Care</title>
    <publicationDate>2007-10-16T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To provide&amp;nbsp;recommendations for obtaining research consent in emergency settings.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Obtaining informed consent from patients or surrogates in the emergency setting is difficult. Current regulations&amp;nbsp;allow studies to be performed with exception to informed consent, but ambiguities in implementing studies under current regulations can be onerous for institutional review boards and investigators and may discourage research to evaluate promising interventions (AHA, 2007).&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Endorsed by the American College of Emergency Physicians and the Society for Academic Emergency Medicine.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>33034</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/20/2550]]&gt;</url>
    <title>Recommendations for preparing children and adolescents for invasive cardiac procedures : a statement from the American Heart Association Pediatric Nursing Subcommittee of the Council on Cardiovascular Nursing in collaboration with the Council on Cardiovascular Diseases of the Young</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ADOLESCENCE,CHILD HEALTH,PUBLIC HEALTH,SURGICAL,GUIDELINES/EBM,CARDIOLOGY,CONGENITAL HEART DISEASE,SURGERY,SPECIALTIES,STAFF USE,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CONGENITAL HEART DISEASE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines provide recommendations for preparing children and adolescents for invasive cardiac procedures.&amp;nbsp;Evidence-based interventions are described and the resources needed to&amp;nbsp;implement them are identified. &amp;nbsp;Includes references and appendices.&amp;nbsp; Full-text available.&amp;nbsp; Published in Circulation 2003;108:2250.&amp;nbsp; Alternative spellings: paediatrics; adolescence.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3853</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://eurheartj.oupjournals.org/cgi/reprint/23/16/1253]]&gt;</url>
    <title>Recommendations on the management of the asymptomatic patient with valvular heart disease</title>
    <publicationDate>2002-05-22T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,ECHOCARDIOGRAM,VALVE DISORDERS,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report examines the problem of how to treat patients who have been diagnosed with various heart valve problems although their symptoms are considered atypical. The report attempts to draw together the existing evidence and provides some recommendations for the examination, care and treatment of such patients, stressing the importance of early intervention. Published in European Heart Journal 2002;23(16):1253-1266. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282095</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/116/21/2481]]&gt;</url>
    <title>Recommended guidelines for monitoring, reporting and conducting research on medical emergency team, outreach and rapid response systems : an Utstein-Style scientific statement : a scientific statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian Resuscitation Council, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, and the New Zealand Resuscitation Council); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiopulmonary, Perioperative, and Critical Care; and the Interdisciplinary Working Group on Quality of Care and Outcomes</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,MANAGEMENT ISSUES,CARDIOPULMONARY ARREST,CLINICAL AUDIT AND GOVERNANCE,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;"To create consensus-derived key data elements and definitions and to develop a standardised Utstein-style template for the reporting of data related to systems with response teams such as medical emergency teams (METs), rapid response teams (RRTs), and critical care outreach teams (CCOTs)." &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389100</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://scst.org.uk/clin_guidance/consensus%20guideline%20for%20recording%20a%2012%20lead%20ecg%20Rev%20072010b.pdf]]&gt;</url>
    <title>Recording a standard 12-lead electrocardiogram An approved methodology</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Society for Cardiological Science and Technology</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,ELECTROCARDIOGRAM,RECENT ADDITIONS,FEBRUARY 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;From introduction: This guideline has been developed by the Society for Cardiological Science and Technology and has been approved by the British Cardiovascular Society. The guideline is based on existing research and on the knowledge and experience of practitioners. Where research based evidence is not yet available consensus decisions have been made.&amp;nbsp; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review date February 2013.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281411</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.188486]]&gt;</url>
    <title>Reducing barriers for implementation of bystander initiated cardiopulmonary resuscitation : a scientific statement from the American Heart Association for healthcare providers, policymakers, and community leaders regarding the effectiveness of cardiopulmonary resuscitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,DEFIBRILLATION,GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Sudden cardiac arrest (SCA) is a leading cause of death in the United States and Canada. This statement provides recommendations to increase rates of bystander cardiopulmonary resuscitation (CPR). &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; "To maximize the chance of a successful resuscitation outcome, CPR must be started as soon as possible after a victim of sudden cardiac arrest collapses. Improved survival rates depend on a public trained and motivated to recognize the emergency, activate emergency medical services or the emergency response system, initiate high-quality CPR, and use an automated external defibrillator if available." &lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70243</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/documents/CHD_Briefing_nov_04.pdf]]&gt;</url>
    <title>Relative contributions of changes in risk factors and treatment to the reduction in coronary heart disease mortality</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,OUTCOMES,ENVIRONMENTAL,RISK FACTORS,CARDIOVASCULAR DISEASES,CIRCULATORY DISEASES,HEALTH PROTECTION,STRATEGY,PRIMARY CARE SERVICES,POPULATION BASED &amp; PREVENTATIVE SERVICES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,HYPERTENSION,DIET,DIABETES MELLITUS,CORONARY HEART DISEASE,OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY,INTERVENTIONS / PROCEDURES,DIET,ALCOHOL DRINKING,PREVENTION,CONDITIONS,SMOKING,PRIMARY PREVENTION,SMOKING CESSATION,SURGICAL PROCEDURES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,MEDICAL TREATMENT,SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This briefing paper looks at the contribution of changes in risk factors and improvement of medical interventions in the reduction of CHD mortality.&amp;nbsp; The paper concludes that both cardiological treatments and primary prevention play an important part in preventing CHD mortality.&amp;nbsp; However, only risk factor strategies have the potential to halve CHD deaths in the UK. 
&lt;P&gt;Researchers used a variety of methodologies based on available trial and epidemiological data to address this question.&amp;nbsp; 
&lt;P&gt;The key findings include: 
&lt;UL&gt;
&lt;LI&gt;In England and Wales, there were 68,230 fewer CHD deaths in 2000 compared with 1981. 
&lt;LI&gt;Approximately 42% of the mortality decrease was attributable to medical and surgical treatments.&amp;nbsp; However, about 58% of the decline in deaths was attributable to improvements in risk factors, particularly a fall in smoking prevalence. 
&lt;LI&gt;The UK decline in CHD mortality attributable to risk factor reduction was partly offset by the additional mortality caused by increases in obesity, diabetes and lack of physical activity.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2004. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&amp;nbsp; Full-text available in Portable Document File /&amp;nbsp;PDF&amp;nbsp;requiring&amp;nbsp;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282890</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://hyper.ahajournals.org/cgi/reprint/HYPERTENSIONAHA.108.189141v1]]&gt;</url>
    <title>Resistant hypertension : diagnosis, evaluation, and treatment : a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GENERAL,HYPERTENSION,CAUSES AND RISK FACTORS,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL/OTHER,APR-JUNE 08,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIAGNOSIS,CONDITIONS,DISEASE MANAGEMENT,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Clinical trials suggest that the prevalence of resistant hypertension is common and that it is likely to increase unless lifestyle factors contributing to treatment resistance are reversed. This statement discusses the diagnosis, evaluation and treatment of resistant hypertension.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;To improve the long-term management of resistant hypertension, it is essential to expand our understanding of the causes of the condition. This will then allow for more effective prevention and/or treatment of it.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;April&amp;nbsp;2008.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3670</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon210.pdf]]&gt;</url>
    <title>Resource allocation for chronic stable angina : a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions</title>
    <publicationDate>1998-12-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,BETA BLOCKERS,CALCIUM CHANNEL BLOCKERS,CHEST PAIN,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY ARTERY BYPASS GRAFTS,DISEASE MANAGEMENT,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,STABLE ANGINA,ECONOMIC EVALUATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper includes an assessment of medical therapy and of newer adjunctive technologies such as coronary stents. It also includes a broad assessment of patient benefits and a consideration of the cost and cost-effectiveness of such interventions. Published in NHS R&amp;amp;D Health Technology Assessment 1998, 2 (10). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>87960</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://resuscitationjournal.com/current]]&gt;</url>
    <title>Resuscitation : current issue</title>
    <publicationDate></publicationDate>
    <publisher>Resuscitation, Elsevier</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CURRENT AWARENESS - HOT OFF THE PRESS,LATEST ISSUES OF KEY JOURNALS,UNSURE CARDEX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Resuscitation: Current Issue&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.library.nhs.uk/mylibrary/default.aspx" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;All external links from "Hot Off the Press" service are provided for information only. A link does not imply endorsement of that site. We do not accept responsibility for the sites linked to, or the information displayed there. For further information on appraising current awareness journal articles visit the &lt;A href="http://www.library.nhs.uk/Cardiovascular/SearchResults.aspx?catID=8971&amp;amp;tabID=291" target="_blank"&gt;literature appraisal guides&lt;/A&gt; section of the Cardiovascular Diseases Specialist Collection.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5283</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4068251.pdf]]&gt;</url>
    <title>Review of early thrombolysis : faster and better treatment for heart attack patients</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,THROMBOLYTICS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,DISEASE MANAGEMENT,REPERFUSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2&gt;
&lt;P&gt;This review was commissioned in order to chart the progress of the delivery or NSF thrombolysis targets and to make recommendations based on the latest evidence, for the delivery of faster and better thrombolysis. The review pinpoints areas in which delays can be reduced in the heart attack patients care pathway such as improving communications, extending paramedic thrombolysis where appropriate and including all aspects of the care pathway in the MINAP database. The review details the action that needs to be taking. Among other things the authors suggest that local health communities must work closely with the CHD collaborative* to ensure the recommendations are implemented.&amp;nbsp;&amp;nbsp;&amp;nbsp; 
&lt;P&gt;* Since publication the Coronary Heart Diseases Collaborative's&amp;nbsp;work has been subsumed&amp;nbsp;into the NHS Heart Improvement Programme&amp;nbsp;which was launched in April 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156341</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/111/2/240]]&gt;</url>
    <title>Role of permanent  pacing to prevent atrial fibrillation : science advisory</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association Council on Clinical Cardiology and the Quality of Care and Outcomes Research Interdisciplinary Working Group, Heart Rhythm Society</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DISEASE MANAGEMENT,DEFIBRILLATION,INTERVENTIONS / PROCEDURES,ARRHYTHMIA,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This advisory document summarizes the current database on pacing modalities and algorithms used to prevent and terminate atrial fibrillation (AF). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; American health care professionals involved in the care of patients with atrial fibrillation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published 2005.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343989</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192576]]&gt;</url>
    <title>Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CONGENITAL HEART DISEASE,DISEASE MANAGEMENT,GENERAL / OVERVIEWS,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;&lt;FONT size=2 face=Times-Roman&gt;To address the state of evidence on the routine use of pulse oximetry in newborns to detect critical congenital heart disease (CCHD).&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P align=left&gt;Intended &lt;STRONG&gt;audience:&lt;/STRONG&gt; Clinicians and healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268439</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/102/12/1463]]&gt;</url>
    <title>Safety and utility of exercise testing in emergency room chest pain centers : an advisory from the Committee on Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology, American Heart Association</title>
    <publicationDate>2000-09-19T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,DIAGNOSIS,EXERCISE TOLERANCE TESTS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,DIAGNOSIS,STABLE ANGINA,OTHER,CARDIOVASCULAR DISEASES,DIAGNOSIS,CHEST PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The document summarises and interprets the evidence regarding the safety and utility of exercise testing in evaluating patients presenting with chest pain in the emergency department.&lt;/P&gt;
&lt;P align=left&gt;The studies summarised confirm the safety of symptom-limited treadmill exercise ECG testing after 8-12 hours of evaluation in patients with low to intermediate risk of an acute coronary ischaemic syndrome. Two well-designed studies demonstrate utility of exercise testing.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282023</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/116/24/2878]]&gt;</url>
    <title>Safety of magnetic resonance imaging in patients with cardiovascular devices : an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention : endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,DEFIBRILLATION,SURGICAL PROCEDURES,RISK ASSESSMENT,INTERVENTIONS / PROCEDURES,DIAGNOSIS,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,ECHOCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To summarise and clarify issues regarding the safety and magnetic imaging (MR) in patients with cardiovascular devices.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; "Safe MR imaging involves a careful initial patient screening, accurate determination of the cardiovascular (and other) device and its properties, a thoughtful analysis of the risks and benefits of performing the examination at that time and when indicated appropriate physician supervision."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282484</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/short/116/21/2501]]&gt;</url>
    <title>Scientific knowledge gaps and clinical research priorities for cardiopulmonary resuscitation and emergency cardiovascular care identified during the 2005 International Consensus Conference on E and CPR science with treatment recommendations : a consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian Resuscitation Council, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, and the New Zealand Resuscitation Council); the American Heart Association Emergency Cardiovascular Care Committee; the Stroke Council; and the Cardiovascular Nursing Council</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST,GENERAL,DIAGNOSIS,DISEASE MANAGEMENT,GENERAL  / OVERVIEWS,ACUTE CORONARY SYNDROMES,GENERAL/OTHER,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The 2005 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations (CoSTR) summarises the scientific evidence supporting all aspects of resuscitation. A new cycle of evidence evaluation has begun which is expected to be completed in 2010 with the publication of new and revised treatment recommendations. This statement identifies knowledge gaps and research priorities which can be incorporated into the 2010 evidence evaluation process. The following topics have been highlighted as research priorities:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Resuscitation of adults, children, and neonates&lt;BR&gt;
&lt;LI&gt;Acute coronary syndromes &lt;BR&gt;
&lt;LI&gt;Stroke &lt;BR&gt;
&lt;LI&gt;First aid&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007. Information last accessed 15&amp;nbsp;October 2010.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3928</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4006872&amp;chk=ZKO4gH]]&gt;</url>
    <title>Screening : case finding</title>
    <publicationDate>2002-08-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,CORONARY HEART DISEASE,PREVENTION,SCREENING,ADULT,IMPLEMENTATION,DIABETES,TYPE 2,CAUSES,CORONARY HEART DISEASE,NATIONAL SERVICE FRAMEWORK FOR CHD,MANAGEMENT,PRIMARY CARE,VASCULAR RISK]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Part of National Service Frameworks (NSFs): A Practical Aid To Implementation In Primary Care series. Screening, based around the main risk factors, plays an important part in the primary prevention of major diseases, including Coronary Heart Disease (CHD). This document recommends that any population approach for CHD, stroke and diabetes needs to apply consistency in the frequency of screening. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3657</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon429.pdf]]&gt;</url>
    <title>Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia : a systematic review and cost effectiveness analysis</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,LIPIDS MANAGEMENT,PREVENTION,VASCULAR,CONDITIONS,SCREENING,OTHER,JUL-SEP 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report evaluates whether screening for familial hypercholesterolaemia (FH) is appropriate, and assess the psychosocial effects of genetic and clinical screening for an asymptomatic treatable inherited condition. Published in Health Technology Assessment, 2000, 4 (29). Full-text available in Portable Document Format (PDF) requiring Adobe Acrobat Reader.]]&gt;</body>
  </document>
  <document>
    <id>236151</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/screening/]]&gt;</url>
    <title>Screening Specialist Library</title>
    <publicationDate></publicationDate>
    <publisher>National Library for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,STROKE,DIAGNOSIS,CARDIOVASCULAR DISEASES,KEY POLICIES,JAN-MAR 09,KEY POLICIES AND RELATED PUBLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Screening Specialist Library aims to to find, organise and provide access to the best available evidence on screening for health professionals.&amp;nbsp; The website includes knowledge updates, policies and reports and national screening programmes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3816</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/105/14/1735]]&gt;</url>
    <title>Secondary prevention of coronary heart disease in the elderly (with emphasis on patients &gt; or = 75 years of age)</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association. Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OVERWEIGHT AND OBESITY,PHYSICAL ACTIVITY,DISEASE MANAGEMENT,SECONDARY PREVENTION,CARDIAC REHABILITATION,PREVENTION,CONDITIONS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. This document covers the management of smoking cessaion, hypertension, lipid, diabetes, and obesity, psychosocial interventions, physical activity and cardiac rehabilition programme for the elderly. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122291</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/10/14/75/04101475.pdf]]&gt;</url>
    <title>Secondhand smoke : review of evidence since 1998</title>
    <publicationDate>2004-11-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DETERMINANTS,ENVIRONMENTAL,CAUSES OF HARM,SMOKING,SMOKING CESSATION,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PREVENTION,PUBLIC HEALTH,METHODS,ANALYSIS,ANALYSIS &amp; RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Authors' Conclusion:&lt;/STRONG&gt;&amp;nbsp;Knowledge of the hazardous nature of secondhand smoke has been consolidated over the last 5 years (from 1998 - 2004) and no infant, child or adult should be exposed to secondhand smoke.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212728</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063157]]&gt;</url>
    <title>Self care for people with long term conditions</title>
    <publicationDate>2006-11-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,PATIENT CHOICE,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,GENERAL/OTHER,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report identifies the benefits of self care to patients and&amp;nbsp;the National Health Service. In addition, the report provides details of the support patients need to self care, for example, information, skills, support networks and technology. Two case studies are included. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277824</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/Press_release_July_6th_2007_Progress_on_services_for_heart_failure.pdf]]&gt;</url>
    <title>Service review of heart failure</title>
    <publicationDate>2007-07-06T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,HEART FAILURE,CONDITIONS,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The Healthcare Commission carried out a service review in 2005 / 2006 to assess the quality of healthcare for people with heart failure,&amp;nbsp;looking at whether primary care trusts&amp;nbsp;and their associated secondary care trust were ensuring good outcomes for people with heart failure. The information provided includes: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;an introduction to the review &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;national findings &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;follow up &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;results of the review &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;benchmarking toolkit &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;background to the review&amp;nbsp;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;links to further information relating to other work being carried out to improve the care and treatment of people with heart failure&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;The full report, &lt;A href="http://www.cqc.org.uk/_db/_documents/Pushing_the_boundaries_Improving_services_for_patients_with_heart_failure_200707020413.pdf" target="_blank"&gt;Pushing the boundaries - improving services for people with heart failure&lt;/A&gt; and&amp;nbsp;links to other&amp;nbsp;Portable Document Files, requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;, are included. &amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279788</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2007/signposts_IHT.pdf]]&gt;</url>
    <title>Signposts to improving cardiac interhospital transfers</title>
    <publicationDate></publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This&amp;nbsp;document aims to outline the major challenges with regard to the mechanics of transferring patients from one hospital site to another from booking the transfer to repatriation. It&amp;nbsp;also provides signposts to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&amp;nbsp;potential solutions&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&amp;nbsp;examples of good practice from the cardiac networks and ambulance trusts&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&amp;nbsp;links to useful documents&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&amp;nbsp;access to service improvement tools and techniques to facilitate&amp;nbsp;the process&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&amp;nbsp;useful contacts and sources of information&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Throughout the document&amp;nbsp;there are&amp;nbsp;hyperlinks to supporting&amp;nbsp;information and learning which can be accessed by clicking on the highlighted blue text. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp;All those involved in the management of the&amp;nbsp;inter hospital transfer&amp;nbsp;pathway, for both the non elective and emergency transfer, from commissioners, managers, and clinicians within primary care trusts, NHS trusts, cardiac networks and the ambulance services.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; Published in September 2007.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3677</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.archive.official-documents.co.uk/document/cm41/4177/4177.htm]]&gt;</url>
    <title>Smoking kills : a white paper on tobacco</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,CANCER,POLICY,STRATEGY,POPULATION BASED &amp; PREVENTATIVE SERVICES,SMOKING CESSATION,CORONARY HEART DISEASE,PREVENTION,KEY POLICIES,CARDIOVASCULAR DISEASES,CONDITIONS,SMOKING CESSATION,PREVENTION,PUBLIC HEALTH,DETERMINANTS,INDIVIDUAL BEHAVIOUR,SMOKING,TOBACCO USE,SOCIAL DETERMINANTS,LIFESTYLE,SOCIETY,SOCIOECONOMIC FACTORS,MANAGEMENT &amp; INTERVENTIONS,GEOGRAPHY,NATIONAL,GOVERNMENT &amp; LAW,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,SERVICES,GOVERNMENT,LAW,PUBLIC SERVICES,HEALTH SERVICES,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper, published in December 1998, introduces a comprehensive strategy that committed the UK Government to introduce a ban on tobacco advertising, to launch a major education campaign, to develop NHS smoking cessation services, to support the licensed hospitality industry’s Public Places Charter on smoking, to support consultation on stronger measures on smoking in the workplace, and to lead tobacco control measures at a European and global level.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212307</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/State_of_Healthcare_2006_English_tagged_200701023846.pdf]]&gt;</url>
    <title>State of healthcare 2006</title>
    <publicationDate>2006-10-30T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PERFORMANCE INDICATORS,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report assess the performance of healthcare organisations in relation to standards set by the government.&amp;nbsp; The report includes a review of performance in meeting the minimum standards for the independent sector in England.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Information last accessed 16 April 2009.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389099</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bhsoc.org/pdfs/Angiotensin%20Receptor%20Blockers%20and%20the%20risk%20of%20cancer13%20July%2010.pdf]]&gt;</url>
    <title>Statement on the use of ARBs and the risk of cancer</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>British Hypertension Society</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,HEART FAILURE,HYPERTENSION,DISEASE MANAGEMENT,DISEASE MANAGEMENT,RECENT ADDITIONS,JULY 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is statement, on the use of angiotensin receptor blockers (ARBs) and the risk of cancer, was made in response to a publication reporting that ARBs may be associated with a modestly increased risk of incident cancer. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79486</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/107/20/2595]]&gt;</url>
    <title>Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation</title>
    <publicationDate>2003-05-12T00:00:00</publicationDate>
    <publisher>Circulation, American Heart Association</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,ARRHYTHMIA,CARDIOPULMONARY ARREST,GENERAL  / OVERVIEWS,GENERAL  / OVERVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom -line conclusion:&lt;/STRONG&gt;&amp;nbsp; Slowed or delayed myocardial activation is a common feature in patients with noncoronary heart disease with a history of ventricular activation, and its assessment may allow the prospective prediction of&amp;nbsp;ventricular activation&amp;nbsp;risk in these patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Slowed or delayed myocardial activation and dispersed refractoriness predispose to reentrant excitation that may lead to ventricular fibrillation (VF). Increased ventricular electrogram duration in response to extrastimuli and increased S1S2 coupling intervals at which electrogram duration starts to increase (S1S2delay) are seen both in hypertrophic cardiomyopathy (HCM) in those at risk of VF and in patients with Idiopathic VF (IVF). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp; Ventricular Electrogram Duration (VED)&amp;nbsp;and S1S2delay have been measured using paced electrogram fractionation analysis in 266 patients with noncoronary heart disease. Of these, one group of 61 patients had a history of VF and included 21 HCM, 17 IVF, 13 long-QT syndrome (LQTS), 5 dilated cardiomyopathy (DCM), and 5 others. These were compared with 205 patients with similar diseases with no VF history (non-VF group) and a control group (n=12) without heart disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Results from HCM VF patients (VED, 19±3.3 ms; S1S2delay, 350±9.7 ms) differed sharply from observations in HCM non-VF patients (VED, 7.3±1.35 ms; S1S2delay, 312±6.7 ms; P&amp;lt;0.001). DCM VF patients had longer delays (VED, 14.3±5.9; S1S2delay, 344±11.2) than DCM non-VF patients (VED, 5.8±1.87 ms; S1S2delay, 311±5.7 ms; P&amp;lt;0.001), with major differences also seen comparing LQTS VF (VED, 12.4±5.3 ms; S1S2delay, 343±13.8 ms) and LQTS non-VF patients (VED, 11.0±2.7 ms; S1S2delay, 320±5.4 ms; P&amp;lt;0.001). IVF patients had both severely abnormal and normal areas of myocardium. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This item is a Recommended Read and has been selected for inclusion in the library by&amp;nbsp;Dr Tim Bowker,&amp;nbsp; British Heart Foundation associate and&amp;nbsp;member of external reference group&amp;nbsp;for the&amp;nbsp;Cardiovascular Diseases Specialist Collection.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79468</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://qjmed.oupjournals.org/cgi/reprint/96/4/269]]&gt;</url>
    <title>Sudden, unexpected cardiac or unexplained death in England : a national survey</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>Quarterly Journal of Medicine, Oxford University Press</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GENERAL  / OVERVIEWS,CARDIOVASCULAR DISEASES,ARRHYTHMIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom -line conclusion:&lt;/STRONG&gt; In 4.1% of sudden unexpected deaths under 65 years, no cause was found. Until it becomes accepted practice to identify these cases by a name, such as Sudden Adult Death Syndrome (SADS), it will not be possible to study their aetiology systematically. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Background:&lt;/B&gt;&amp;nbsp;The aim of this survey was to estimate the frequency of sudden unexpected cardiac or unexplained death in England.&amp;nbsp; Post-mortem examinations of adults who were&lt;SUP&gt; &lt;/SUP&gt;apparently healthy but died suddenly and unexpectedly sometimes&lt;SUP&gt; &lt;/SUP&gt;reveal no morphological abnormalities to explain their deaths.&lt;SUP&gt; &lt;/SUP&gt;The frequency of such unexplained deaths in relation to other&lt;SUP&gt; &lt;/SUP&gt;causes of sudden cardiac death is not known.&lt;SUP&gt; &lt;/SUP&gt;
&lt;P&gt;&lt;B&gt;Methods:&lt;/B&gt;&amp;nbsp;Consecutive White Caucasians, aged 16–64&lt;SUP&gt; &lt;/SUP&gt;years, with no medical history of cardiac disease, seen alive&lt;SUP&gt; &lt;/SUP&gt;within 12 h of death, on whom autopsy found either a cardiac&lt;SUP&gt; &lt;/SUP&gt;or no identifiable cause of death, were included. The coroner's&lt;SUP&gt; &lt;/SUP&gt;officer sent a copy of the post-mortem report and a completed&lt;SUP&gt; &lt;/SUP&gt;case registration form to the investigators, with tissue samples.&lt;SUP&gt; &lt;/SUP&gt;
&lt;P&gt;&lt;B&gt;Results:&lt;/B&gt;&amp;nbsp;Sixty-seven (81%) coroners participated, each&lt;SUP&gt; &lt;/SUP&gt;maintaining prospective surveillance for 4 months. Of 692 ascertained&lt;SUP&gt; &lt;/SUP&gt;cases, case registration forms were received for 650 (94%),&lt;SUP&gt; &lt;/SUP&gt;post-mortem reports for 682 (99%), blood samples for 569 (82%),&lt;SUP&gt; &lt;/SUP&gt;myocardial slices for 517 (75%) and whole hearts for 47 (7%).&lt;SUP&gt; &lt;/SUP&gt;In cases with myocardial tissue, death was ascribed to ischaemic&lt;SUP&gt; &lt;/SUP&gt;heart disease in 465 (82.4%). In 43.1% the ischaemia was acute,&lt;SUP&gt; &lt;/SUP&gt;in 19.1% there was myocardial scarring but no acute ischaemia,&lt;SUP&gt; &lt;/SUP&gt;and 20.2% had coronary atheroma only. Death was due to left&lt;SUP&gt; &lt;/SUP&gt;ventricular hypertrophy in 32 (5.7%), to other cardiac causes&lt;SUP&gt; &lt;/SUP&gt;in 30 (5.3%) and in 23 (4.1%) there was no clear cause. Those&lt;SUP&gt; &lt;/SUP&gt;with cardiac causes were 81% male, median ages 55.9 (male) and&lt;SUP&gt; &lt;/SUP&gt;56.6 (female) years. The 23 unexplained deaths were 57% female,&lt;SUP&gt; &lt;/SUP&gt;median ages 40.5 (male) and 54.9 (female) years. The estimated&lt;SUP&gt; &lt;/SUP&gt;annual frequency of sudden unexpected death due to cardiac or&lt;SUP&gt; &lt;/SUP&gt;unidentified causes, in English adults of were 57% female,&lt;SUP&gt; &lt;/SUP&gt;median ages 40.5 (male) and 54.9 (female) years. The estimated&lt;SUP&gt; &lt;/SUP&gt;annual frequency of sudden unexpected death due to cardiac or&lt;SUP&gt; &lt;/SUP&gt;unidentified causes, in English adults of&amp;nbsp; employment age, was&lt;SUP&gt; &lt;/SUP&gt;11/100 000 (3481 annual deaths).&lt;SUP&gt; &lt;/SUP&gt;employment age, was&lt;SUP&gt; &lt;/SUP&gt;11/100 000 (3481 annual deaths).&lt;SUP&gt;&amp;nbsp;&lt;/SUP&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This item is a Recommended Read and has been selected for inclusion in the library by&amp;nbsp;Dr Tim Bowker,&amp;nbsp; British Heart Foundation associate and&amp;nbsp;member of external reference group&amp;nbsp;for the&amp;nbsp;Cardiovascular Diseases Specialist Library.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125842</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4134006&amp;chk=4LNCmR]]&gt;</url>
    <title>Supporting self care - a practical option : diagnostic, monitoring and assistive tools, devices, technologies and equipment to support self care</title>
    <publicationDate>2006-04-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,PREVENTION,DIABETES MELLITUS,GENERAL,DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PATIENT AND PUBLIC INVOLVEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,PPI IN PRACTICE,SECONDARY PREVENTION,GENERAL/OTHER,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report on a review of research on self care tools, devices and technologies.&amp;nbsp; The full report is divided into three parts in cascading levels of details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Part I gives a quick overview of self care devices and their implementation issues. 
&lt;LI&gt;Part II gives some details on the devices and some details on their research. 
&lt;LI&gt;Part III gives additional information on the devices where available and additional research references for those who want more information. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78319</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/Palliative%20Care%20Framework.pdf]]&gt;</url>
    <title>Supportive and palliative care for advanced heart failure</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>NHS Modernisation Agency, National Coronary Heart Disease Collaborative</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,HEART FAILURE,SERVICE MODELS,DISEASE MANAGEMENT,PALLIATIVE AND SUPPORTIVE CARE,CONDITIONS,CARDIOVASCULAR DISEASES,SYMPTOM MANAGEMENT,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines aim to build on the National Institute of Clinical Excellence (NICE) guidelines on palliative and supportive care for cancer sufferers and apply to service design for supportive and palliative care in heart failure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended Audience:&lt;/STRONG&gt; Service improvement managers and NHS teams involved in planning and providing care for heart failure patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 1st December 2004. * Since publication the Coronary Heart Diseases Collaborative's&amp;nbsp;work has been subsumed&amp;nbsp;into the NHS Heart Improvement Programme&amp;nbsp;which was launched in April 2005.&amp;nbsp; This document is hosted by NHS Heart Improvement Programme.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"&gt;&lt;FONT color=#0099cc&gt;Adobe Acrobat Reader&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;. &lt;/SPAN&gt;&lt;/P&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Collection.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/H2&gt;]]&gt;</body>
  </document>
  <document>
    <id>213164</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/endoflifecare/]]&gt;</url>
    <title>Supportive and palliative care in heart failure resource kit for cardiac networks</title>
    <publicationDate></publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,DISEASE MANAGEMENT,PATIENT INFORMATION,GENERAL  / OVERVIEWS,SUPPORT GROUPS,SYMPTOM MANAGEMENT,CONDITIONS,PALLIATIVE AND SUPPORTIVE CARE,CARDIOVASCULAR DISEASES,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,NETWORKS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This resource kit is designed&amp;nbsp;to help cardiac networks address&amp;nbsp;inequalities in the care of patients with heart failure and their informal carers. It contains a wealth of practical tips, case studies and support materials, drawn from experiences and from the range of agencies working in this field.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177038</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=25265&amp;Rendition=Web]]&gt;</url>
    <title>Supraventricular tachycardia (SVT) - page 2 surgical strategies</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,SURGICAL PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes surgical strategies for patients presenting with supraventricular tachycardia. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177039</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=25265&amp;Rendition=Web]]&gt;</url>
    <title>Supraventricular tachycardia (SVT) - page 3 drug therapy strategies</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,ARRHYTHMIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes drug therapy strategies&amp;nbsp;for patients presenting with supraventricular tachycardia. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177040</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=25265&amp;Rendition=Web]]&gt;</url>
    <title>Supraventricular tachycardia (SVT) - page 4 ablation strategies</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes ablation&amp;nbsp;strategies for patients presenting with supraventricular tachycardia. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177037</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=25265&amp;Rendition=Web]]&gt;</url>
    <title>Supraventricular tachycardia (SVT) care pathway</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for interventions for a patient presenting with supraventricular tachycardia.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236141</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/theatres/]]&gt;</url>
    <title>Surgery, Theatres &amp; Anaesthesia Specialist Library</title>
    <publicationDate></publicationDate>
    <publisher>National Library for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES,KEY POLICIES,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,STROKE,DISEASE MANAGEMENT,SURGICAL INTERVENTIONS,KEY POLICIES AND RELATED PUBLICATIONS,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The Surgery, Theatres &amp;amp; Anaesthesia &lt;SPAN class=noWrap&gt;Specialist Library&lt;/SPAN&gt; aims to provide the latest quality assured evidence-based quidance and useful websites for all theatre staff supporting the patient through perioperative care.&amp;nbsp; Website includes 'What's New', guest editorials and forthcoming events.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156308</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=16516&amp;Rendition=Web]]&gt;</url>
    <title>Surgical care pathway</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,SURGICAL PROCEDURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of surgical intervention.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392602</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1431.pdf]]&gt;</url>
    <title>Systematic review and cost effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment Programme</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-ARRHYTHMIC DRUGS,ARRHYTHMIA,DISEASE MANAGEMENT,RECENT ADDITIONS,NOVEMBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; The current lack of published evidence would appear to justify not supporting the general use of a PiP strategy in patients with PAF. Further evidence on the clinical effectiveness of PiP and its preference by patients may lead to this technology being implemented in the knowledge that it will not incur net additional cost to the NHS. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Atrial fibrillation (AF) is a tachyarrhythmia characterised by unco-ordinated atrial activation with consequent deterioration of impairment of atrial function and a rapid, irregular heartbeat. AF is characterised on the electrocardiogram (ECG) by the absence of consistent ‘P’ waves and the presence of irregular rough fibrillation or ‘f ’ waves and irregular QRS complexes. The patient may experience palpitations, chest pain, dizziness or, in severe cases, loss of consciousness. In some cases, patients with AF may present without any symptoms. An AF attack may be self-terminating or require clinical intervention (for example, pharmacological or medical cardioversion). 
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Electronic searches were conducted to identify clinical effectiveness and cost-effectiveness evidence describing the use of a PiP strategy for the treatment of PAF published since the release of the Royal College of Physicians’ national guidelines on AF in June 2006.3&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Health Technology Assessment 2010; Vol. 14: No. 31&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access :&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; Abstract and executive summary also available as HTML files. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>33976</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon802.pdf]]&gt;</url>
    <title>Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,CHEST PAIN,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,ELECTROCARDIOGRAM,SERVICE MODELS,THROMBOLYTICS,CARDIAC MARKERS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,STABLE ANGINA,REPERFUSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This systematic review assesses a range of methods used in the diagnosis and early management of acute coronary syndrome (ACS), suspected acute myocardial infarction (MI) and exertional angina.&amp;nbsp; Includes discussion, conclusions, references and appendices.&amp;nbsp; Published in Health Technology Assessment 2004;8:2. 
&lt;P&gt;&lt;STRONG&gt;This item is a Recommended Read and has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases Specialist Library.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286802</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1217.pdf]]&gt;</url>
    <title>Systematic review of the clinical effectiveness and cost effectiveness of 64 slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Health Technology Assessment</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,CORONARY HEART DISEASE,ELECTROCARDIOGRAM,INTERVENTIONS / PROCEDURES,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION,DIAGNOSIS,DISEASE MANAGEMENT,ARTERIOSCLEROSIS,DIAGNOSIS,DISEASE MANAGEMENT,APR-JUNE 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This review aims to assess the clinical effectiveness and cost effectiveness, in different patient groups, of the use of 64 slice or higher CT angiography, instead of invasive coronary angiography, for diagnosing people with suspected coronary artery disease (CAD) and assessing people with CAD.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260742</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/Tackling_Child_Obesity_-_First_Steps.pdf]]&gt;</url>
    <title>Tackling child obesity - first steps</title>
    <publicationDate>2006-02-27T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,PRIMARY PREVENTION,OVERWEIGHT AND OBESITY,PREVENTION,MANAGEMENT ISSUES,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This is a joint report produced by the Healthcare Commission and the National Audit Office.&amp;nbsp; The report aims to identify the barriers to creating a successful delivery chain and how these can be addressed in services for treating childhood obesity.&lt;/P&gt;
&lt;P align=left&gt;Information last accessed 16 April 2009.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282628</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH_083471]]&gt;</url>
    <title>Tackling health inequalities : 2007 status report on the programme for action</title>
    <publicationDate>2008-03-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ECONOMIC DEVELOPMENT,ECONOMICS,DETERMINANTS,FEMALE,MALE,SOCIAL SUPPORT,APR-JUNE 08,STATISTICS,CARDIOVASCULAR DISEASES,CLINICAL AUDIT AND GOVERNANCE,MANAGEMENT ISSUES,NHS IMPROVEMENT,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,SOCIETY,LIFESTYLE,GOVERNMENT &amp; LAW,HEALTH EQUITY AUDIT,METHODS,GOVERNMENT,DECISION MAKING,MANAGEMENT &amp; POLICY,POPULATIONS,ANALYSIS &amp; RESEARCH,GENDER,COMMUNITIES,HOUSEHOLDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;This&amp;nbsp;status report provides a review of developments against the data since the publication of the Programme for Action in 2003. It considers progress against the Public Service Agreement (PSA) target, the national headline indicators and against government commitments. The report highlights the challenging nature of the health inequalities PSA target for 2010. Data relating to coronary heart disease is provided.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>35906</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://eurheartj.oxfordjournals.org/content/22/16/1374.long]]&gt;</url>
    <title>Task force on sudden cardiac death of the European Society of Cardiology</title>
    <publicationDate></publicationDate>
    <publisher>European Heart Journal, Oxford Journals</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,CARDIOPULMONARY ARREST,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report details the findings of the Task Force on Sudden Cardiac Death of the European, Society of Cardiology. Prevention, risk factors and rescuscitation are all dealt with in detail. Published in Eur Heart J,2001; 22: 1374-1450.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3843</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-chest-pain-FT.pdf]]&gt;</url>
    <title>Task force on the management of chest pain</title>
    <publicationDate>2002-08-01T00:00:00</publicationDate>
    <publisher>European Society of Cardiology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,CARDIOVASCULAR DISEASES,CONDITIONS,DIAGNOSIS,DISEASE MANAGEMENT,CHEST PAIN,EMERGENCY CARE,SELECTED SYMPTOMS,CHEST PAIN (ISCHAEMIC),CHEST,CHEST PAIN (PLEURITIC),CHEST PAIN (ATYPICAL),OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document gives recommendations on the following areas: diagnostic tests for chest pain, fast track via patients, general practitioners, dispatch centre and ambulance, and quality indicators in the management of chest pain. Published in European Heart Journal 2002;23(15);1153-1176. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384098</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181ec61df]]&gt;</url>
    <title>Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>Amercian College of Cardiology, American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,MANAGEMENT ISSUES,CHEST PAIN,SERVICE MODELS,DIAGNOSIS,DIAGNOSIS,STABLE ANGINA,OTHER,RECENT ADDITIONS,AUGUST 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To help the clinician to&amp;nbsp;distinguish between those who&lt;SUP&gt; &lt;/SUP&gt;require urgent treatment of a serious problem and those with&lt;SUP&gt; &lt;/SUP&gt;more benign entities who do not require admission.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;Abstract only. Full-text online access to this article requires subscription to the journal. &lt;A href="http://www.nelh.nhs.uk/librarian/regional.asp" target="_blank"&gt;NHS staff please contact your local library for further assistance.&lt;/A&gt;&amp;nbsp;&amp;nbsp;Full-text online access is available to NHS staff in England via ATHENS passwords.&amp;nbsp; To find out how to get an ATHENS password and access this resource and many others please refer to "Athens Registration" at &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;. &lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316419</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192518]]&gt;</url>
    <title>The American Heart Association's princliples for comparative effectiveness in research: A policy statement from the American Heart Association</title>
    <publicationDate>2009-05-13T00:00:00</publicationDate>
    <publisher>American Heart Association/ American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures.  Committee on Radionuclide Imaging, American Society of Nuclear Cardiology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ APR-JUN 09,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The American Heart Association's princliples for comparative effectiveness in research: A policy statement from the American Heart Association&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;This policy statement from the American Heart Association examines the principles of comparative effectiveness research.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Includes sections on:&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Conducting and interpreting comparative effectiveness research according to fundamental scientific principles.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Defining value for patients through comparative effectiveness research.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Applying comparative effectiveness research to patient treatment decisions&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI style="LINE-HEIGHT: normal; MARGIN: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"&gt;Funding and oversight of comparative effectiveness research.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Publication history: Published May 2009.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>378329</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html]]&gt;</url>
    <title>The atlas of heart disease and stroke</title>
    <publicationDate></publicationDate>
    <publisher>World Health Organisation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,CORONARY HEART DISEASE,GENERAL  / OVERVIEWS,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The atlas addresses the global epidemic of heart disease and stroke in a clear and accessible format. This highly valuable reference material has been designed for use by policy makers, national and international organizations, health professionals and the general public. This picturesque atlas is in six parts: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cardiovascular disease&lt;/LI&gt;
&lt;LI&gt;Risk factors&lt;/LI&gt;
&lt;LI&gt;The burden&lt;/LI&gt;
&lt;LI&gt;Action&lt;/LI&gt;
&lt;LI&gt;The future and the past&lt;/LI&gt;
&lt;LI&gt;World tables&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>103163</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/project/1377.asp]]&gt;</url>
    <title>The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review</title>
    <publicationDate></publicationDate>
    <publisher>Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DEFIBRILLATION,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The use of implantable cardioverter defibrillators (ICDs) in the UK is increasing, but the technology is still under-utilised compared with other developed countries.&amp;nbsp; Extending the current indications to patients with prior myocardial infarction and depressed heart function would impact on cost and service provision.&amp;nbsp; Further research is needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic review of the literature was undertaken.&amp;nbsp; RCTs were assessed using the Jadad criteria, and of selected systematic reviews using criteria developed by the NHS Centre for Reviews and Dissemination.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The evidence suggests that ICDs reduce mortality in patients with previous ventricular arrest or symptomatic sustained ventricular&amp;nbsp;arrhythmia but have reduced left ventricular function due to coronary artery disease with asymptomatic non-sustained ventricular arrhythmia and sustained tachycardia that could be induced electrophysiologically, and in some patients with severe left ventricular dysfunction after myocardial infarction.&amp;nbsp; Studies show that ICDs improve survival compared with drug treatment, but with considerably increased cost.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bryant J, Brodin H, Loveman E, Payne E, Clegg A.&amp;nbsp; The clinical and cost-effectiveness of implantable cardioverter difibrillators: a systematic review.&amp;nbsp; Health Technology Assessment. Vol 9: No 36, 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111680</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/pdfexecs/summ945.pdf]]&gt;</url>
    <title>The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure : a systematic review and economic evaluation</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,HEART FAILURE,INTERVENTIONS / PROCEDURES,DISEASE MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; "Although the review showed that left ventricular assist devices (LVADs) are clinically effective as a bridge to heart transplantation (BTT) with end-stage heart failure (ESHF), the economic evaluation indicated that they are not cost-effective. With the limited and declining availability of donor hearts for transplantation, it appears that the future of the technology is in its use as an long-term chronic support (LTCS). Further research is needed to examine the clinical effectiveness of LVADs for people with ESHF, assessing patient survival, functional ability, quality of life and adverse events. Evaluations of the clinical effectiveness of LVADs should include economic evaluations, as well as data on quality of life, utilities, resources and costs. A systematic review of the epidemiology of ESHF should be undertaken to assess its potential impact." 
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;This review aims to assess the clinical and cost-effectiveness of left ventricular assist devices (LVADs) as a bridge to heart transplantation (BTT), as a bridge to myocardial recovery (BTR) or as a long-term chronic support (LTCS) for people with end-stage heart failure (ESHF). 
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;Systematic review and economic evaluation. 
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Clegg&amp;nbsp;AJ, Scott&amp;nbsp;DA, Loveman&amp;nbsp;E, Colquitt&amp;nbsp;J, Hutchinson&amp;nbsp;J, Royle&amp;nbsp;P, &lt;I&gt;et al&lt;/I&gt;. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technology Assessment. Vol 9: No.45, 2005&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;November 2005. 
&lt;P&gt;&lt;STRONG&gt;Access :&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;A href="http://www.ncchta.org/minisumm/min945.htm" target="_blank"&gt;Abstract &lt;/A&gt;and &lt;A href="http://www.ncchta.org/execsumm/summ945.htm" target="_blank"&gt;executive summary &lt;/A&gt;also available as HTML files. 
&lt;P&gt;&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>280129</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_083057.pdf]]&gt;</url>
    <title>The coronary heart disease national service framework : Building for the future / progress report for 2007</title>
    <publicationDate>2008-02-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,MANAGEMENT ISSUES,ARRHYTHMIA,CARDIOPULMONARY ARREST,CHEST PAIN,CLINICAL AUDIT AND GOVERNANCE,CORONARY HEART DISEASE,HEART FAILURE,VALVE DISORDERS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DIAGNOSIS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DISEASE MANAGEMENT,ARTERIOSCLEROSIS,DIAGNOSIS,DISEASE MANAGEMENT,NATIONAL SERVICE FRAMEWORK FOR CHD,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,MYOCARDIAL INFARCTION,DIAGNOSIS,DISEASE MANAGEMENT,DIAGNOSIS,DISEASE MANAGEMENT,STABLE ANGINA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This is the seventh progress report on the Coronary Heart Disease National Service Framework (CHD NSF), highlighting the progress made since it was first published in March 2000.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; This report supersedes &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4116526" target="_blank"&gt;Shaping the future.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310047</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_096555]]&gt;</url>
    <title>The coronary heart disease national service framework : building on excellence, maintaining progress - progress report for 2008</title>
    <publicationDate>2009-03-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GENERAL/OTHER,NATIONAL SERVICE FRAMEWORK FOR CHD,OUTCOMES,CIRCULATORY DISEASES,CARDIOVASCULAR DISEASES,NATIONAL SERVICE FRAMEWORKS,DISEASE MANAGEMENT,CARDIOVASCULAR DISEASES,GENERAL,CORONARY HEART DISEASE,CONDITIONS,KEY POLICIES,PREVENTION,GENERAL  / OVERVIEWS,PUBLIC HEALTH,MANAGEMENT &amp; POLICY,FRAMEWORKS,2009 MARCH,JAN-MAR 09,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;report is the eighth annual progress report on coronary heart disease and&amp;nbsp;demonstrates work that has been achieved during 2008 towards the Coronary Heart Disease National Service Framework.&amp;nbsp; The report is aimed at health professionals and has a foreword by the Secretary of State for Health and an introduction by the National Director for Heart Disease and Stroke.&lt;/P&gt;
&lt;P&gt;Includes sections on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Progress and successes in 2008 
&lt;LI&gt;Working with NHS Improvement 
&lt;LI&gt;Vascular checks programme 
&lt;LI&gt;2010 and beyond&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 20 March 2009&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224406</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063168]]&gt;</url>
    <title>The coronary heart disease national service framework : Shaping the future progress report</title>
    <publicationDate>2007-01-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CONDITIONS,KEY POLICIES,MANAGEMENT ISSUES,CORONARY HEART DISEASE,SERVICE MODELS,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Progress report detailing the progress which has been made in implementing the Coronary Heart Disease National Service Framework in the six years since its publication.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3794</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/pdfexecs/summ607.pdf]]&gt;</url>
    <title>The cost effectiveness of magnetic resonance angiography : carotid artery stenosis and peripheral vascular disease</title>
    <publicationDate>2002-04-18T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,CORONARY ANGIOGRAPHY &amp; CARDIAC CATHETERISATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This review aims to synthesise published evidence about the diagnostic performance of magnetic resonance angiography (MRA), compared with DSA, in carotid artery disease and in peripheral vascular disease at surgical decision thresholds, and to model its cost effectiveness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111248</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[https://www.nice.org.uk/nicemedia/pdf/DCPAssessmentReportForPublicConsultation.pdf]]&gt;</url>
    <title>The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome : systematic review and economic evaluation</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,DISEASE MANAGEMENT,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; "Dual-chamber pacing results in small but potentially important benefits in populations with&amp;nbsp;sick sinus syndrome (SSS)&amp;nbsp;and/or atrioventricular block (AVB) compared with ventricular pacemakers. There is no evidence of superiority in terms of mortality in the medium term (up to 5 years), which increases the importance of intermediate outcomes such as&amp;nbsp;atrial&amp;nbsp;fibrillation (AF) and of impacts on quality of life through, for example, pacemaker syndrome. 
&lt;P&gt;As well as the potential avoidance of a small number of important cardiovascular disease consequences, pacemaker syndrome is a crucial factor in determining cost-effectiveness. However, difficulties in standardising diagnosis and measurement of severity make it difficult to quantify precisely its impact.&amp;nbsp;&amp;nbsp; 
&lt;P&gt;At 5 years, dual-champer pacing in SSS and AVB is likely to yield additional quality-adjusted life-years (QALY)s at a cost of less than £10,000, although there is some uncertainty around this estimate, particularly&amp;nbsp;with regard to pacemaker syndrome. More conservative assumptions suggest that the cost-effectiveness ratio may be around £30,000 per QALY. 
&lt;P&gt;The evidence base comparing dual-chamber with single atrial pacing is much smaller and less robust. A single, small, parallel pilot RCT is available and informs the cost-effectiveness analysis. This suggests that atrial pacing is likely to be cost-effective compared with dual-chamber pacing. 
&lt;P&gt;Dual-chamber pacing is in common usage in the UK. Recipients are more likely to be younger. Insufficient evidence is currently available to inform policy on specific groups who may benefit most from pacing with dual-chamber devices, although overall the assessment is that&amp;nbsp;the technology is likely to yield benefits at a level that is generally considered acceptable value for money compared with ventricular devices.&amp;nbsp;"&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Bradycardia is abnormally slow heart rate. SSS is when the heart's natural pacemaker, the sinoatrial node, fails to initiate cardiac contractions. AVB is a defective conduction of the atrioventricular conduction system. This systematic review aims to assess the effectiveness and cost-effectiveness of dual-chamber pacemakers versus single chamber atrial or single-chamber ventricular pacemakers in the treatment of bradycaris&amp;nbsp;due to SSS or AVB.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systematic review (SR)&amp;nbsp;of randomised controlled trials (RCTs)&amp;nbsp;of the&amp;nbsp;effectiveness of dual-chamber pacemakers in the relevant populations&amp;nbsp;compared to ventricular or atrial devices.&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Citation:&lt;/STRONG&gt; Castelnuovo, E, Stein, K, Garside R, Payne E. The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. Health Technology Assessment ; Vol 9: No. 43, 2005. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2005. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>148523</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/01/85/78/04018578.pdf]]&gt;</url>
    <title>The expert patient : a new approach to chronic disease management for the 21st century</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,NHS IMPROVEMENT,GENERAL/OTHER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report looks at expert patient programmes. It recommends a programme of action over a six year period to introduce lay-led self-management training programmes for patients with chronic illness within the NHS in England.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212999</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063812]]&gt;</url>
    <title>The general practice physical activity questionnaire report.</title>
    <publicationDate>2006-10-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,PREVENTION,PHYSICAL ACTIVITY,PRIMARY PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report outlines details about the General Practice Physical Activity Questionnaire. It provides details about when the questionnaire should be used and with whom.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251544</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_073044]]&gt;</url>
    <title>The healthy living social marketing initiative : a review of the evidence</title>
    <publicationDate>2007-03-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ OBESITY,BIOLOGICAL COMPOSITION,OUTCOMES,GENERAL PUBLIC,LOW BIRTH WEIGHT,PREGNANCY &amp; CHILDBIRTH DISORDERS,GENITOURINARY DISEASES,SEXUALLY TRANSMITTED INFECTIONS,DIABETES,ENDOCRINE DISORDERS,HIV INFECTION,COMMUNICABLE DISEASES,CANCER,CIRCULATORY DISEASES,POPULATION BASED &amp; PREVENTATIVE SERVICES,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES,PRIMARY PREVENTION,DIET,OVERWEIGHT AND OBESITY,GENERAL,DIET,GENERAL,PREVENTION,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIETY,LIFESTYLE,SOCIAL DETERMINANTS,INDIVIDUAL BEHAVIOUR,ACTIVITIES,ALCOHOL CONSUMPTION,EATING HABITS,PHYSICAL ACTIVITY,SEXUAL HEALTH,SUBSTANCE MISUSE,TOBACCO USE,SMOKING,RESEARCH,SERVICES,POPULATIONS,ANALYSIS &amp; RESEARCH,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This report is part of the healthy living social marketing initiative that underpins the Government’s approach to tackling obesity. The report tackles&amp;nbsp;various issues&amp;nbsp;around obesity&amp;nbsp;including: what in people’s&amp;nbsp; behaviours place them at risk of unhealthy weight gain, what drives their current behaviours, how might they be motivated to change, who might be able to influence them and what might act as barriers to change.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345394</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001019]]&gt;</url>
    <title>The national audit of cardiac rehabilitation - annual statistical report 2009</title>
    <publicationDate>2009-08-24T00:00:00</publicationDate>
    <publisher>British Heart Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,PREVENTION,HEALTH INEQUALITIES,PERFORMANCE INDICATORS,STATISTICS,CARDIAC REHABILITATION,JAN-MAR 10,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The annual audit from the BHF to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Show locally and nationally what cardiac rehabilitation services are achieving and where those services are not fully developed&lt;/LI&gt;
&lt;LI&gt;Identify problems of inequitable provision for particular sections of the population&lt;/LI&gt;
&lt;LI&gt;Describe the typical benefits that a patient should expect&lt;/LI&gt;
&lt;LI&gt;Find out which ways of delivering cardiac rehabilitation are most effective&lt;/LI&gt;
&lt;LI&gt;Make local information available to providers, cardiac patients and the general public.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>345425</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.bhf.org.uk/publications/view_publication.aspx?ps=1001020]]&gt;</url>
    <title>The national audit of cardiac rehabilitation 2009 - executive summary</title>
    <publicationDate>2009-08-24T00:00:00</publicationDate>
    <publisher>British Heart Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,CARDIAC REHABILITATION,JAN-MAR 10,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Summary of findings from the 2009 National Audit of Cardiac Rehabilitation.&lt;/P&gt;
&lt;DIV class=extendedInformation&gt;
&lt;P&gt;&lt;STRONG&gt;Resource Code:&lt;/STRONG&gt; Z327&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Documetn File / PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>282869</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084011]]&gt;</url>
    <title>The national education and competence framework for advanced critical care practitioners</title>
    <publicationDate>2008-04-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,SERVICE MODELS,STROKE,MANAGEMENT ISSUES,SERVICE MODELS,APR-JUNE 08,APR-JUN 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This document describes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;the role of an advanced critical care practitioner &lt;/DIV&gt;
&lt;LI&gt;how the role should function within the critical care team 
&lt;LI&gt;the benefits of introducing the role in clinical practice&amp;nbsp; 
&lt;LI&gt;a&amp;nbsp;national framework of education and competence for the role within recognised standards of practice&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This document has been compiled in conjunction with representatives from The British Association of Critical Care Nurses, The Intensive Care Society, The Intercollegiate Board for Training in Intensive Care Medicine and The Royal College of Nursing Critical Care Forum.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>35554</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/07/71/58/04077158.pdf]]&gt;</url>
    <title>The National Service Framework for coronary heart disease : winning the war on heart disease</title>
    <publicationDate>2004-03-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,KEY POLICIES,CORONARY HEART DISEASE,NATIONAL SERVICE FRAMEWORK FOR CHD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report marking the four-year anniversary of the publication of the coronary heart disease national service framework. Much progress has been made in the treatment of coronary heart disease, with deaths from cardiovascular diseases having fallen by more than 23% between 1995/1997 and 2000/02. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250500</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ajemjournal.com/article/PIIS0735675705000525/abstract]]&gt;</url>
    <title>The prehospital 12-lead electrocardiogram's effect on time to initiation of reperfusion therapy: a systematic review and meta-analysis of existing literature</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>The American Journal of Emergency Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,DISEASE MANAGEMENT,OTHER,MYOCARDIAL INFARCTION,DIAGNOSIS,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DIAGNOSIS,ACUTE CORONARY SYNDROMES,UNSTABLE ANGINA,CARDIOVASCULAR DISEASES,DIAGNOSIS,CONDITIONS,CHEST PAIN,ELECTROCARDIOGRAM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=ja50-ce-simple-para&gt;&lt;STRONG&gt;Authors' Conclusions:&lt;/STRONG&gt; This systematic search revealed a relatively low quality and quantity of research on the prehospital ECG although a meta-analysis of studies found revealed a difference of 24.7 (95% confidence interval, 16.7-32.7) minutes when comparing patients that had a prehospital ECG to those that did not.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Abstract only. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284190</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/116/19/2216]]&gt;</url>
    <title>The role of endomyocardial biopsy in the management of cardiovascular disease : a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology</title>
    <publicationDate>2007-11-06T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DIAGNOSIS,DISEASE MANAGEMENT,CONDITIONS,GENERAL,HEART FAILURE,INTERVENTIONS / PROCEDURES,DIAGNOSIS,DISEASE MANAGEMENT,JUL-SEPT 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This statement aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Review the published literature on the role of endomyocardial biopsy (EMB) in cardiovascular diseases and summarise the information&lt;BR&gt;
&lt;LI&gt;Make recommendations for clinical practice.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians and other healthcare professionals.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94218</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/reprint/289.19.2560v1.pdf]]&gt;</url>
    <title>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</title>
    <publicationDate>2003-05-21T00:00:00</publicationDate>
    <publisher>National Heart, Lung and Blood Institute, National Institutes of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,CAUSES AND RISK FACTORS,GENERAL  / OVERVIEWS,DISEASE MANAGEMENT,HYPERTENSION,PREVENTION,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,DIAGNOSIS,CAUSES AND RISK FACTORS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This report aims to provide a clear and concise guideline on high blood pressure prevention, detection, evaluation and&amp;nbsp;treatment, and to simplify the classification of blood pressure.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published on 23rd May 2003.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236127</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/ethnicity/]]&gt;</url>
    <title>The Specialist Library for Ethnicity and Health</title>
    <publicationDate></publicationDate>
    <publisher>National Library for Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ STROKE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,KEY POLICIES,CONDITIONS,MANAGEMENT ISSUES,DISEASE MANAGEMENT,CAUSES / RISK FACTORS,JAN-MAR 09,KEY POLICIES AND RELATED PUBLICATIONS,MANAGEMENT ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Specialist Library for Ethnicity and Health provides&amp;nbsp;the best currently available evidence about the specific needs of health care for minority ethnic groups.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;Website includes resources on: &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="mso-spacerun: yes"&gt;Diseases and Conditions&lt;BR&gt;&lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="mso-spacerun: yes"&gt;Service Delivery&lt;BR&gt;&lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="mso-spacerun: yes"&gt;Cultural Competence&lt;BR&gt;&lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="mso-spacerun: yes"&gt;Management and Policy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>28913</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/1/118]]&gt;</url>
    <title>Therapeutic hypothermia after cardiac arrest : an advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation</title>
    <publicationDate></publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GENERAL/OTHER,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,CARDIOPULMONARY ARREST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement aimed at clinicians discusses the use of therapeutic hypothermia after cardiac arrest.&amp;nbsp; Recent clinical studies on the subject are highlighted.&amp;nbsp; Document also contains sections on cooling techniques and monitoring and the use of therapeutic hypothermia in children.&amp;nbsp; Includes references. Published in Circulation. 2003;108:118-21. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>34273</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/108/23/2941#FIG1]]&gt;</url>
    <title>Thiazolidinedione use, fluid retention, and congestive heart failure : a consensus statement from the American Heart Association and American Diabetes Association</title>
    <publicationDate></publicationDate>
    <publisher>Circulation, American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ HEART FAILURE,GENERAL/OTHER,CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DISEASE MANAGEMENT,CONDITIONS,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document is a&amp;nbsp;summary of the American Diabetes Association and the American Heart Association's findings on the use of thiazolidinediones&amp;nbsp;(TZDs) 'in patients with pre-existing heart disease and in those who develop edema or unexpected weight gain during the course of TZD therapy'.&amp;nbsp; Includes recommendations and references. Published in Circulation 2003;108:2941. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392196</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.improvement.nhs.uk/documents/Transforming_Cardiac_Rehab.pdf]]&gt;</url>
    <title>Transforming cardiac rehabilitation: celebrating achievements and sharing the learning from the national projects</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,MANAGEMENT ISSUES,CLINICAL AUDIT AND GOVERNANCE,NHS IMPROVEMENT,CARDIAC REHABILITATION,RECENT ADDITIONS,OCTOBER 2010,OCT-DEC 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To celebrate Achievements and Sharing Learning from the National Priority Projects aims to extract the key learning points from the Project and share them with a wider, national audience.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; August 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371733</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://stroke.ahajournals.org/cgi/reprint/STR.0b013e3181d2da7d]]&gt;</url>
    <title>Translating evidence into practice</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,PERFORMANCE INDICATORS,SERVICE MODELS,RECENT ADDITIONS,APRIL 2010,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;FONT face=Times-Roman size=2&gt;This article documents the milestones encountered in this decade long journey from 1998 to the present and attempts to capture the critical success factors that enabled the ASA to play such a prominent leadership role in the fight against stroke.&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT face=Times-Roman size=2&gt;The present report is organized according to 4 basic domains of translating evidence into practice: (1) generating basic science knowledge, (2) disseminating scientific findings, (3) convening experts for consensus, and (4) implementing guidelines into practice.&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143261</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/60/11/04136011.pdf]]&gt;</url>
    <title>Turning the corner : improving diabetes care</title>
    <publicationDate>2006-06-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIABETES MELLITUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This is the third report on the implementation of the Diabetes National Service Framework (NSF).&amp;nbsp; This report highlights the progress since the NSF delivery strategy was introduced.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>283386</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.crncc.nihr.ac.uk/]]&gt;</url>
    <title>UK Clinical Research Network</title>
    <publicationDate></publicationDate>
    <publisher>UK Clinical Research Network</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,NETWORKS,STROKE,MANAGEMENT ISSUES,NETWORKS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The UK Clinical Research Network supports clinical research and facilitates the conduct of trials and other studies across the UK. The website has the following sections:&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Research networks&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Clinical research&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Patient and public&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Industry&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Training&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;News&lt;BR&gt;&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Events&lt;BR&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>235700</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://ukpmc.ac.uk/]]&gt;</url>
    <title>UK PUBMED Central</title>
    <publicationDate></publicationDate>
    <publisher>UKPMC Funders Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ UNSURE CARDEX,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;A free digital archive of biomedical and life sciences journal literature, UK PubMed Central (UKPMC) provides free-to-access online digital archive of full-text, peer-reviewed research publications. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>272106</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.187397]]&gt;</url>
    <title>Universal definition of myocardial infarction</title>
    <publicationDate>2007-11-27T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GENERAL / OVERVIEWS,MYOCARDIAL INFARCTION,ACUTE CORONARY SYNDROMES,CARDIOVASCULAR DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To update the 2000 consensus document on the definition of myocardial infarction in order to refine the ESC / ACC criteria for&amp;nbsp;diagnosis from various perspectives. With this&amp;nbsp;aim in mind, the working groups were composed of experts within the field of biomarkers, ECG, imaging, interventions, clinical investigations, global perspectives and implications.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344290</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/121/3/458]]&gt;</url>
    <title>Update on Cardiovascular Implantable Electronic Device Infections and Their Management</title>
    <publicationDate>2010-01-14T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,PREVENTION,GENERAL,GENERAL/OTHER,JAN-MAR 10,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;Aims: To Update&amp;nbsp;Cardiovascular Implantable Electronic Device Infections and Their Management since the 2003 publication. Despite improvements in cardiovascular implantable electronic device (CIED) design, application of timely infection control practices, and administration of antibiotic prophylaxis at the time of device placement, CIED infections continue to occur and can be life-threatening.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; 14 January 2010&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>28896</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/107/25/3250]]&gt;</url>
    <title>Use of automated external defibrillators for children : an update : an advisory statement from the Pediatric Advanced Life Support Task Force, International Liaison Committee on Resuscitation</title>
    <publicationDate>2003-07-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,INTERVENTIONS / PROCEDURES,DEFIBRILLATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This statement, aimed at clinicians, extends and simplifies the 2000 International Liaison Committee on Resuscitation (ILCOR) recommendations on the use of automated external defibrillators (AEDs) in children.&amp;nbsp; The statement&amp;nbsp;discusses the&amp;nbsp;development of AEDs&amp;nbsp;and the safety of using AEDs in young children.&amp;nbsp; Includes references.&amp;nbsp; Published in Circulation. 2003;107:3250. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156311</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=12773&amp;Rendition=Web]]&gt;</url>
    <title>Ventricular tachycardia (VT) care pathway</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ARRHYTHMIA,INTERVENTIONS / PROCEDURES,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Developed and approved by the Department of Health Expert Reference Group on Cardiac Arrhythmias &amp;amp; Sudden Cardiac Death (NSF Chapter 8), this pathway describes the process of care for a patient presenting with Ventricular tachycardia (VT).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212634</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/serviceimprovement/1338/4668/web_referral_system_IHT_sep06_hip016.pdf]]&gt;</url>
    <title>Web based referral systems for interhospital transfers : a review and comparison of systems in English cardiac networks</title>
    <publicationDate>2006-09-30T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NHS IMPROVEMENT,ACUTE CORONARY SYNDROMES,MANAGEMENT ISSUES,NETWORKS,CLINICAL AUDIT AND GOVERNANCE,CONDITIONS,CARDIOVASCULAR DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This&amp;nbsp;report provides details of the web based cardiac patient transfer systems used within seven networks of England.&amp;nbsp;Each network provides background information to the implementation of the transfer system, and costing and infrastructure data. The appendices contain a useful quick comparative guide to the various features of the systems.&lt;/P&gt;
&lt;P align=left&gt;'The information provided in the report is purely to give an overview of the attributes of the existing systems. Networks or other organisations considering working with any of these providers should satisfy themselves that any system they are considering meets their local needs'&amp;nbsp; (Heart Improvement Programme, 2006). However, the Programme is sponsoring further work to agree a core common data set extract for these systems.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268435</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.escardio.org/guidelines-surveys/esc-guidelines/implementation/Pages/diabetes-esceasd-june07.aspx]]&gt;</url>
    <title>Webcast on diabetes and cardiovascular diseases</title>
    <publicationDate></publicationDate>
    <publisher>European society of Cardiology, European Association for the Study of Diabetes</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CONDITIONS,CAUSES &amp; RISK FACTORS,PERIPHERAL VASCULAR DISEASE,PERIPHERAL VASCULAR DISEASE,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,MANAGEMENT ISSUES,CONDITIONS,SURGICAL PROCEDURES,CAUSES AND RISK FACTORS,CORONARY ARTERY BYPASS GRAFTS,INTERVENTIONS / PROCEDURES,DIABETES MELLITUS,GENERAL,HYPERTENSION,HEART FAILURE,REVASCULARISATION,PERCUTANEOUS TRANSLUMINAL CORONARY INTERVENTIONS,ACUTE CORONARY SYNDROMES,ECONOMIC EVALUATIONS,VASCULAR,DIABETES MELLITUS,CAUSES / RISK FACTORS,JUL-SEP 08]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This page provides links to the presentations delivered at the Implementation Meeting for the European Society of Cardiology and the European Association for the Study of Diabetes Guidelines on 'Diabetes, Pre-diabetes and Cardiovascular Diseases' which was held on the 29-30th June 2007.&amp;nbsp; The available presentations are as follows:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Definition and classification of diabetes and pre-diabetic glucose abnormalities&amp;nbsp; &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Epidemiology of diabetes, impaired glucose homeostasis and cardiovascular risk &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Identification of subjects at high risk for cardiovascular disease or diabetes &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Pathophysiological aspects on the relation between hyperglycemia and cardiovascular disease&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Treatment to reduce cardiovascular risk: Hypertension and dyslipidaemia&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Management of cardiovascular diseases: Acute coronary syndromes &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Management of cardiovascular diseases: Coronary interventions&amp;nbsp; &lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Management of cardiovascular diseases: Peripheral and cerebrovascular disease&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Guideline distribution and adherence in a general perspective&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Intensive care&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Heart failure&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;Health economics and diabetes &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Disclaimer:&lt;/STRONG&gt; The Cardiovascular Diseases Specialist Library does not accept responsibility for the content or quality of the webcasts. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;This item has been selected for inclusion in the library by Professor Tom Quinn, Clinical Advisor to the Cardiovascular Diseases /Stroke Specialist Libraries.&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Information last checked 24/4/08.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70239</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/What_is_critical_appraisal.pdf]]&gt;</url>
    <title>What is critical appraisal?</title>
    <publicationDate>2000-07-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,ENT AND AUDIOLOGY,LITERATURE APPRAISAL GUIDES,EVIDENCE BASED PRACTICE RESOURCES,LITERATURE APPRAISAL,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,MALE UROGENITAL DISORDERS,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This essay published by Bandolier highlights the importance of critical appraisal in the process of evidence-based practice.&amp;nbsp; Critical appraisal is defined as " systematically finding, appraising and acting on evidence of effectiveness." 
&lt;P&gt;The paper includes: 
&lt;UL&gt;
&lt;LI&gt;an explanation of&amp;nbsp;the pros and cons of critical appraisal in practice 
&lt;LI&gt;how to appraise systematic reviews and randomised controlled trials 
&lt;LI&gt;example questions to help users with the critical appraisal process&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Full-text available in Portable Document File / PDF&amp;nbsp;requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>3656</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon319.pdf]]&gt;</url>
    <title>What role for statins? :  a review and economic model</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>National Co-ordinating Centre for Health Technology Assessment, Wessex Institute for Health Research and Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,PREVENTION,CORONARY HEART DISEASE,LIPID-REGULATING DRUGS,LIPIDS MANAGEMENT,DIET,PREVENTION,STATINS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report studies the effectiveness of low fat diets, statins, and non-cholesterol lowering drug treatments in reducing coronary heart disease. Published in Health Technology Assessment, 1999, 3 (19). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378326</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/cardiovascular_diseases/guidelines/Chart_predictions/en/index.html]]&gt;</url>
    <title>WHO/ISH cardiovascular risk prediction charts</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>World Health Organisation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CONDITIONS,ANTI-HYPERTENSIVE DRUGS,ANTI-PLATELET DRUGS,CORONARY HEART DISEASE,LIPID-REGULATING DRUGS,ASPIRIN,CAUSES AND RISK FACTORS,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ WHO/ISH risk prediction charts The WHO/ISH risk prediction charts indicate 10-year risk of a fatal or nonfatal major cardiovascular event (myocardial infarction or stroke), according to age, sex, blood pressure, smoking status, total blood cholesterol and presence or absence of diabetes mellitus for 14 WHO epidemiological sub-regions. There are two sets of charts. One set (14 charts) can be used in settings where blood cholesterol can be measured. The other set (14 charts) is for settings in which blood cholesterol cannot be measured. Both sets are available in colour and shades of black on a compact disc. Each chart can only be used in countries of the specific WHO epidemiological sub-region. The charts provide approximate estimates of CVD risk in people who do not have established coronary heart disease, stroke or other atherosclerotic disease. They are useful as tools to help identify those at high cardiovascular risk, and to motivate patients, particularly to change behaviour and, when appropriate, to take antihypertensive, lipid-lowering drugs and aspirin.]]&gt;</body>
  </document>
  <document>
    <id>268386</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/reprint/103/3/472]]&gt;</url>
    <title>Wine and your heart : a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association</title>
    <publicationDate>2001-01-23T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ FOOD &amp; NUTRITION,BEVERAGES,DETERMINANTS,OUTCOMES,CIRCULATORY DISEASES,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE,DIET,PREVENTION,CONDITIONS,PREVENTION,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,ALCOHOL CONSUMPTION,EATING HABITS,2008-JULY,MONTHLY ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; The aim of this document is to summarise the current literature on wine intake and cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;The&amp;nbsp;information is divided as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The biological basis for a protective effect of alcohol and red wine 
&lt;LI&gt;Does red wine decrease atherosclerotic cardiovascular disease because it is an antioxidant? 
&lt;LI&gt;How does alcohol ingestion change lipoproteins? 
&lt;LI&gt;Do wine and other alcoholic beverages have significant antithrombotic actions? 
&lt;LI&gt;Adverse effects of alcohol ingestion are there downsides to moderate alcohol consumption? Hypertension / stroke 
&lt;LI&gt;What conclusions can we make about a protective effect of wine against heart disease?&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; ' Moderate intake of alcoholic beverages (1 to 2 drinks per day) is associated with a reduced risk of coronary heart disease (CHD) in populations. There is no evidence that wine is more beneficial than other forms of alcohol, although further research is needed regarding the potential protective non-lipoprotein-altering effects of substances unique to wine'.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>51630</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://circ.ahajournals.org/cgi/content/full/109/6/805?ck=nck]]&gt;</url>
    <title>Women's ischemic syndrome evaluation : current status and future research directions : report of the National Heart, Lung and Blood Institute workshop : October 2-4, 2002 : executive summary</title>
    <publicationDate></publicationDate>
    <publisher>National Heart, Lung and Blood Institute, American College of Cardiology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ ARTERIOSCLEROSIS,ACUTE CORONARY SYNDROMES,MYOCARDIAL INFARCTION,PREVENTION,CONDITIONS,CARDIOVASCULAR DISEASES,CORONARY HEART DISEASE,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a summary of the findings of the Women's Ischemic Syndrome Evaluation (WISE) workshop which met to review the results of the WISE study and other studies of ischemic heart disease.&amp;nbsp; The objectives of the workshop are reviewed and areas for future research considered.&amp;nbsp; Includes references.&amp;nbsp; Published in Circulation 2004;109:805-807.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277617</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.heart.nhs.uk/heart/Portals/0/docs_2008/working_in_primary_care_v2.pdf]]&gt;</url>
    <title>Working with primary care : a resource for cardiac networks</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>NHS Improvement</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ SERVICE MODELS,DISEASE MANAGEMENT,PREVENTION,CARDIOVASCULAR DISEASES,MANAGEMENT ISSUES,NETWORKS,CONDITIONS,CORONARY HEART DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;This&amp;nbsp;document was developed in response to the&amp;nbsp;concerns that&amp;nbsp;cardiac networks have experienced in engaging with their colleagues in primary care. Although many individual projects have successfully managed to bridge the divide between primary and secondary / tertiary services, winning widespread primary care involvement remains a challenge for many networks. Recognising that primary care is the key to achieving whole system change, the national Heart Improvement Programme team have responded to these requests by devising the Working with primary care resource pack. The purpose is to assist networks to work more effectively with the primary care sector, by providing a range of resources to improve mutual understanding between primary care and cardiac networks, to ensure the successful delivery of the&amp;nbsp;cardiovascular diseases&amp;nbsp;agenda.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378317</id>
    <name>&lt;![CDATA[ Cardiovascular Diseases]]&gt;</name>
    <rootDirectory>/cardiovascular</rootDirectory>
    <url>&lt;![CDATA[http://www.ktl.fi/monica/]]&gt;</url>
    <title>World Health Organization - MONICA Project</title>
    <publicationDate></publicationDate>
    <publisher>World Health Organisation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,CONDITIONS,MANAGEMENT ISSUES,CORONARY HEART DISEASE,RISK ASSESSMENT,STATISTICS,APR-JUNE 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The MONICA (Multinational &lt;STRONG&gt;MONI&lt;/STRONG&gt;toring of trends and determinants in &lt;STRONG&gt;CA&lt;/STRONG&gt;rdiovascular disease) Project was established in the early 1980s in many Centres around the world to monitor trends in cardiovascular diseases, and to relate these to risk factor changes in the population over a ten year period. It was set up to explain the diverse trends in cardiovascular disease mortality which were observed from the 1970s onwards. There were total of 32 MONICA Collaborating Centres in 21 countries. The total population age 25-64 years monitored was ten million men and women. The ten year data collection was completed in the late 1990s, and the main results were published in the following years. The data are still being used for analysis.]]&gt;</body>
  </document>
</documents>